0001641172-25-001600.txt : 20250331 0001641172-25-001600.hdr.sgml : 20250331 20250331140625 ACCESSION NUMBER: 0001641172-25-001600 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250331 DATE AS OF CHANGE: 20250331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protagenic Therapeutics, Inc.\new CENTRAL INDEX KEY: 0001022899 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 061390025 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12555 FILM NUMBER: 25791549 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 994-8200 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: Atrinsic, Inc. DATE OF NAME CHANGE: 20090630 FORMER COMPANY: FORMER CONFORMED NAME: NEW MOTION, INC. DATE OF NAME CHANGE: 20070504 FORMER COMPANY: FORMER CONFORMED NAME: MPLC, Inc. DATE OF NAME CHANGE: 20050608 10-K 1 form10-k.htm
false FY 0001022899 Protagenic Therapeutics, Inc.\new 0001022899 2024-01-01 2024-12-31 0001022899 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001022899 PTIX:CommonStockPurchaseWarrantMember 2024-01-01 2024-12-31 0001022899 2024-06-30 0001022899 2025-03-31 0001022899 2024-12-31 0001022899 2023-12-31 0001022899 us-gaap:NonrelatedPartyMember 2024-12-31 0001022899 us-gaap:NonrelatedPartyMember 2023-12-31 0001022899 us-gaap:RelatedPartyMember 2024-12-31 0001022899 us-gaap:RelatedPartyMember 2023-12-31 0001022899 us-gaap:PreferredStockMember 2024-12-31 0001022899 us-gaap:PreferredStockMember 2023-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2024-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2023-12-31 0001022899 us-gaap:PreferredStockMember 2024-12-31 0001022899 us-gaap:PreferredStockMember 2023-12-31 0001022899 2023-01-01 2023-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001022899 us-gaap:CommonStockMember 2022-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001022899 us-gaap:RetainedEarningsMember 2022-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001022899 2022-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001022899 us-gaap:CommonStockMember 2023-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001022899 us-gaap:RetainedEarningsMember 2023-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001022899 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001022899 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001022899 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001022899 us-gaap:CommonStockMember 2024-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001022899 us-gaap:RetainedEarningsMember 2024-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001022899 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001022899 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001022899 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001022899 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001022899 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001022899 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001022899 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001022899 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001022899 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001022899 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001022899 us-gaap:PrivatePlacementMember 2024-10-29 2024-10-29 0001022899 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-10-29 0001022899 PTIX:SeriesACommonStockWarrantsMember 2024-10-29 2024-10-29 0001022899 PTIX:SeriesACommonStockWarrantsMember 2024-10-29 0001022899 PTIX:SeriesBCommonStockWarrantsMember 2024-10-29 2024-10-29 0001022899 PTIX:SeriesBCommonStockWarrantsMember 2024-10-29 0001022899 PTIX:PlacementAgentWarrantsMember 2024-10-29 0001022899 2024-10-29 2024-10-29 0001022899 PTIX:SeriesACommonStockPurchaseWarrantsMember 2024-10-29 2024-10-29 0001022899 PTIX:SeriesBCommonStockPurchaseWarrantsMember 2024-10-29 2024-10-29 0001022899 PTIX:PlacementAgentWarrantsMember 2024-10-29 2024-10-29 0001022899 PTIX:TwoThousandSixteenPlanMember 2024-01-01 2024-12-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2023-01-01 2023-12-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2022-01-01 2022-12-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2024-12-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2023-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001022899 PTIX:EmployeesMember 2024-01-01 2024-12-31 0001022899 PTIX:EmployeesMember 2023-01-01 2023-12-31 0001022899 PTIX:NonEmployeesMember 2024-01-01 2024-12-31 0001022899 PTIX:NonEmployeesMember 2023-01-01 2023-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2024-12-31 0001022899 PTIX:EmployeesMember 2024-12-31 0001022899 PTIX:NonEmployeesMember 2024-12-31 0001022899 us-gaap:CommonStockMember PTIX:EmployeesAndConsultantsMember 2024-01-08 2024-01-08 0001022899 us-gaap:CommonStockMember PTIX:ConsultingAgreementMember 2024-02-12 2024-02-12 0001022899 us-gaap:CommonStockMember PTIX:ConsultingAgreementMember 2024-02-12 0001022899 us-gaap:CommonStockMember PTIX:OfficersBoardOfDirectorsAndConsultantsMember 2024-03-25 2024-03-25 0001022899 us-gaap:CommonStockMember PTIX:OfficersBoardOfDirectorsAndConsultantsMember srt:MinimumMember 2024-03-25 2024-03-25 0001022899 us-gaap:CommonStockMember PTIX:OfficersBoardOfDirectorsAndConsultantsMember srt:MaximumMember 2024-03-25 2024-03-25 0001022899 us-gaap:WarrantMember 2024-12-31 0001022899 srt:MinimumMember 2024-12-31 0001022899 srt:MaximumMember 2024-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2023-12-31 0001022899 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001022899 us-gaap:WarrantMember srt:MinimumMember 2024-01-01 2024-12-31 0001022899 us-gaap:WarrantMember srt:MaximumMember 2024-01-01 2024-12-31 0001022899 us-gaap:WarrantMember 2023-12-31 0001022899 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001022899 PTIX:ResearchAgreementsMember 2024-01-01 2024-12-31 0001022899 PTIX:ResearchAgreementsMember 2023-01-01 2023-12-31 0001022899 us-gaap:LicensingAgreementsMember 2024-12-31 0001022899 2024-07-24 0001022899 PTIX:AgenusIncMember 2024-01-01 2024-12-31 0001022899 PTIX:AgenusIncMember 2023-01-01 2023-12-31 0001022899 PTIX:AgenusIncMember 2024-12-31 0001022899 PTIX:AgenusIncMember 2023-12-31 0001022899 PTIX:CTCNorthGmbHMember 2022-12-31 0001022899 PTIX:CTCNorthGmbHMember 2024-01-01 2024-12-31 0001022899 PTIX:CTCNorthGmbHMember 2023-01-01 2023-12-31 0001022899 PTIX:CTCNorthGmbHMember 2024-12-31 0001022899 PTIX:CTCNorthGmbHMember 2023-12-31 0001022899 PTIX:FederalMember 2024-12-31 0001022899 PTIX:LossesIncurredAfter2017Member 2024-12-31 0001022899 PTIX:LossesIncurredPriorTo2018Member 2024-12-31 0001022899 PTIX:StateAndLocalMember 2024-12-31 0001022899 PTIX:StateAndLocalMember 2023-12-31 0001022899 country:CA 2024-12-31 0001022899 country:CA 2023-12-31 0001022899 PTIX:TwoThousandSixEquityIncentivePlanMember srt:MinimumMember us-gaap:SubsequentEventMember 2025-02-21 2025-02-21 0001022899 PTIX:TwoThousandSixEquityIncentivePlanMember srt:MaximumMember us-gaap:SubsequentEventMember 2025-02-21 2025-02-21 0001022899 PTIX:TwoThousandSixteenEquityIncentivePlanMember srt:MinimumMember us-gaap:SubsequentEventMember 2025-02-21 2025-02-21 0001022899 PTIX:TwoThousandSixteenEquityIncentivePlanMember srt:MaximumMember us-gaap:SubsequentEventMember 2025-02-21 2025-02-21 0001022899 us-gaap:SubsequentEventMember 2025-02-21 2025-02-21 0001022899 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-03-05 2025-03-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure PTIX:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For fiscal year ended: December 31, 2024

 

OR

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________ to _______________

 

Commission file number: 001-12555

 

Protagenic Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

 

Delaware   06-1390025
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

149 Fifth Avenue    
New York, New York   10010
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (212) 994-8200

 

Securities registered under Section 12(b) of the Exchange Act:

 

Title of each class   Name of exchange on which registered
Common Stock, par value $0.0001, PTIX   Nasdaq Capital Market
Common Stock Purchase Warrant, PTIXW   Nasdaq Capital Market

 

Securities registered under Section 12(g) of the Exchange Act:

 

Common Stock, $0.0001 par value

(Title of class)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated file, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐ Accelerated filer ☐
  Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ☐ No ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. Yes ☐ No ☒

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on June 30, 2024, based on a closing price as reported on the Nasdaq Capital Market of $0.905 was approximately $4,042,876.

 

As of March 31, 2025, there were 7,525,681 shares of the registrant’s common stock, par value $0.0001, issued and outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

 

 

 

 

 

PROTAGENIC THERAPEUTICS, INC.

ANNUAL REPORT ON FORM 10-K

FOR THE YEAR ENDED DECEMBER 31, 2024

TABLE OF CONTENTS

 

  PART I 6
Item 1 Business 6
Item 1A Risk Factors 19
Item 1B Unresolved Staff Comments 41
Item 1C Cybersecurity 41
Item 2 Properties 41
Item 3 Legal Proceedings 41
Item 4 Mine Safety Disclosures 41
     
  PART II 42
Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 42
Item 6 [Reserved] 42
Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations 42
Item 7A Quantitative and Qualitative Disclosures About Market Risk 45
Item 8 Financial Statements and Supplementary Data 45
Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 45
Item 9A Controls and Procedures 46
Item 9B Other Information 47
Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 47
     
  PART III 48
Item 10 Directors, Executive Officers and Corporate Governance 48
Item 11 Executive Compensation 53
Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 55
Item 13 Certain Relationships and Related Transactions, and Director Independence 65
Item 14 Principal Accountant Fees and Services 67
     
  PART IV 68
Item 15 Exhibits and Financial Statement Schedules 68
  SIGNATURES 70

 

2
 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This report on Form 10-K contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause our actual results to differ materially from those projected, anticipated or implied in the forward-looking statements. As a result, you should not place undue reliance on any forward-looking statements. Except to the limited extent required by applicable law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Risk Factors Summary

 

Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should consider carefully the risks and uncertainties described under “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K as part of your evaluation of the risks associated with an investment in our securities.

 

Risks Related to Our Financial Condition and Capital Requirements

 

  ● The Company’s financial statements have been prepared on a going concern basis, and do not include adjustments that might be necessary if the Company is unable to continue as a going concern.
     
  ● If we continue to incur operating losses and fail to obtain the capital necessary to fund our operations, we will be unable to advance our development programs, complete our clinical trials, or bring products to market, or may be forced to reduce or cease operations entirely. In addition, any capital obtained by us may be obtained on terms that are unfavorable to us, our investors, or both.
     
  ● Unstable market and economic conditions may have serious adverse consequences on our ability to raise funds, which may cause us to cease or delay our operations.

 

3
 

 

Risks Related to Clinical Development and Regulatory Approval

 

  ● Our results to date provide no basis for predicting whether any of our product candidates will be safe or effective, or receive regulatory approval.
     
  ● We may not be able to initiate and complete preclinical studies and clinical trials for our product candidates which could adversely affect our business.
     
  ● If we experience delays or difficulties in the enrollment of subjects to our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented, which could materially affect our financial condition.
     
  ● If the market opportunities for our current and potential future drug candidates are smaller than we believe they are, our ability to generate product revenues will be adversely affected and our business may suffer.

 

Risks Related to Our Reliance on Third Parties

 

  ● We have no experience in sales, marketing and distribution and may have to enter into agreements with third parties to perform these functions, which could prevent us from successfully commercializing our product candidates.
     
  ● Data provided by collaborators and other parties upon which we rely have not been independently verified and could turn out to be inaccurate, misleading, or incomplete.
     
  ● We rely on third parties to conduct our non-clinical studies and our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize our current product candidates or any future products, on a timely basis or at all, and our financial condition will be adversely affected.

 

Risks Related to Commercialization of Our Product Candidates

 

  ● We have no experience as a company in commercializing any product. If we fail to obtain commercial expertise, upon product approval by regulatory agencies, our product launch and revenues could be delayed.
     
  ● We may not be able to gain market acceptance of our product candidates, which would prevent us from becoming profitable.
     
  ● We may not be able to manufacture our product candidates in clinical or commercial quantities, which would prevent us from commercializing our product candidates.
     
  ● Disputes under key agreements or conflicts of interest with our scientific advisors or clinical investigators could delay or prevent development or commercialization of our product candidates.

 

Risks Related to Our Intellectual Property

 

  ● We may not be able to maintain our exclusive worldwide license to use and develop PT00114 which could materially affect our business plan.

 

Risks Related to Our Business Operations and Industry

 

  ● If we are not able to retain our current senior management team and our scientific advisors or continue to attract and retain qualified scientific, technical and business personnel, our business will suffer.
     
  ● We may encounter difficulties in managing our growth, which could adversely affect our operations.
     
  ● Healthcare reform measures could adversely affect our business.

 

4
 

 

  ● Our business and operations are vulnerable to computer system failures, cyber-attacks or deficiencies in our cyber-security, which could increase our expenses, divert the attention of our management and key personnel away from our business operations and adversely affect our results of operations.
     
  ● Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business.
     
  ● If we, our CROs or our IT vendors experience security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of personal data, we may face costs, significant liabilities, harm to our brand and business disruption.
     
  ● If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.

 

Risks Associated to our Common Stock

 

  ● If we fail to comply with the continued minimum closing bid requirements of Nasdaq or other requirements for continued listing, including stockholder equity requirements, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted. On January 30, 2025, the Company participated in a Nasdaq delisting appeal panel, in an effort to keep its Nasdaq listing. On February 19, 2025, the Company received a hearing panel decision from Nasdaq (Nasdaq Listing Qualifications Hearings Docket No. NQ 7072C-25) indicating that its provisional plan for regaining compliance with the Nasdaq listing requirements had been accepted, and that the Company has until April 28, 2025 to demonstrate compliance with its minimum bid price and its shareholder equity.
     
  ● Our common stock is a “Penny Stock” subject to specific rules governing its sale to investors that could impact its liquidity.
     
  ● The market price of our common stock may be volatile, which could lead to losses by investors and costly securities litigation.
     
  ● If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or detect fraud. Consequently, investors could lose confidence in our financial reporting and this may decrease the trading price of our stock.
     
  ● Investors may experience dilution of their ownership interests because of the future issuance of additional shares of our common stock.
     
  ● Our common stock is controlled by insiders.
     
  ● We do not intend to pay dividends for the foreseeable future and may never pay dividends.
     
  ● Our certificate of incorporation allows for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our common stock.

 

5
 

 

PART I

 

Item 1. Business.

 

Overview

 

Protagenic Therapeutic, Inc. (together with its subsidiary, “Protagenic,” the “Company,” “we,” “our” or “us”) are a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Our proprietary, patent-protected, first-in-class lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (“TCAP”), an endogenous brain signaling peptide that can dampen overactive stress responses. Our preclinical models have demonstrated efficacy of PT00114 in animal models of depression, anxiety, substance abuse & addiction, and PTSD.

 

PT00114 leverages a completely novel mechanism of action. Protagenic owns exclusive, worldwide rights to PT00114 through its license agreement with the University of Toronto and has an exclusive right to license additional intellectual property generated by Dr. David Lovejoy’s lab at University of Toronto. Additionally, the company is engaged in the research & development of follow-on compounds in the TCAP family. Extensive publications in peer-reviewed scientific journals underline the central role stress plays in the onset and proliferation of neuropsychiatric disorders like depression, anxiety, substance abuse & addiction, and PTSD. The mechanism of action of TCAP suggests that it counterbalances stress overdrive at the cellular level within the brain’s stress response cascade. TCAP works to alleviate the harmful behavioral, biochemical, and physiological effects of these disorders, while simultaneously restoring brain health. This mechanism has been corroborated in preclinical animal models of the psychiatric disorders listed above. We completed our preclinical experiments required for to begin a clinical trial in the first half of 2023. We commenced our first human trial, seeking to prove the safety and efficacy of PT00114, on September 26, 2023. We announced the complete results of the single-dose portion of the Phase I trial, on May 22, 2024. We anticipate that we will be able to announce the complete results of the multiple-dose portion of the Phase I trial in the second quarter of 2025. We anticipate that we will be able to announce our first set of Phase II (efficacy) results in the first quarter of 2026.

 

As Protagenic transitions into a clinical-stage company, we aim to complete certain key strategic and tactical milestones over the coming two years;

 

  ● Rapidly advance our lead product candidate, PT00114, through clinical trials in treatment resistant depression, substance use disorder, generalized anxiety disorder, and/or post-traumatic stress disorder
     
  ● Develop additional product candidates from the TCAP family to build out a broad pipeline of assets with differentiated features using our unique expertise with this mechanism
     
  ● Explore efficacy in additional stress-related neuropsychiatric and mood disorders beyond initially targeted indications
     
  ● Facilitate long-term growth by building a nimble R&D, operational, clinical and commercial team
     
  ● Proactively assess strategic partnership opportunities including in important international markets

 

Continue with our strategy of strengthening our IP position in this important novel field of neuropsychiatry

 

IND Submission

 

We currently anticipate re-submitting an investigational new drug (IND) application in advance of initiating the Phase IIa portion of our present clinical study, to ascertain whether this portion of the study may be conducted in the United States. The Phase I/IIa study, to evaluate the safety, tolerability, and early activity of PT100114 (TCAP) in healthy volunteers and patients with psychiatric illnesses, commenced in the third quarter of 2023. The IND enabling studies, including the preclinical efficacy data generated, as well as the GLP toxicology study, and a summary of the Phase I clinical trial plan, were among the components of this regulatory submission.

 

Clinical Development

 

The clinical development program will be led by Dr. Maurizio Fava, MD, PhD, a world-leader in psychiatric disorders, the Psychiatrist-in-Chief of the Massachusetts General Hospital and Slater Family Professor of Psychiatry at Harvard Medical School. Dr. Fava was co-principal investigator of STAR*D, the largest research study ever conducted in depression, has coauthored more than 800 medical journal publications, and is one of the top enrolling psychiatry clinicians in the US. Protagenic’s Phase I/II clinical study was designed by Dr. Fava, who will be the trial’s principal investigator.

 

6
 

 

We will launch our clinical program with a basket trial designed first to evaluate the safety of TCAP in a small cohort of healthy volunteers, immediately followed by the evaluation of safety, pharmacological and clinical activity in cohorts of patients with stress-related neuropsychiatric disorders including, but not limited to depression, addiction, anxiety, and Post-Traumatic Stress Disorder (PTSD). We will be using this study for both safety and preliminary efficacy to prioritize indications for later phase development that would ultimately support a New Drug Application (NDA) and registration. The four indications were chosen for multiple reasons, including the mechanism of TCAP in reducing biological stress signals, preclinical evidence of efficacy in animal models of these disorders and the high unmet need in these patient populations, which creates significant market opportunity. We believe the basket trial structure offers the most efficient use of capital in early-stage development and will give us insights into which indication we should focus on in advanced clinical trials. Healthy volunteers will be the first cohort and subsequent parallel cohorts will include patients with:

 

  ● Major Depressive Disorder (MDD) who have suboptimal response to or poorly tolerated two prior SSRIs / SNRIs
     
  ● Generalized Anxiety Disorder (GAD) who have suboptimal response to or poorly tolerated two prior SSRIs /SNRIs
     
  ● Opioid Use Disorder (OUD) who are on treatment with Suboxone and have suboptimal response
     
  ● Post-Traumatic Stress Disorder (PTSD) who have suboptimal response to or intolerance of sertraline and paroxetine

 

The trial will use a classic sequential dose escalation design using cohort replication with initial doses estimated from non-clinical data. The study will assess dose ranging through standard and small cohorts with a rules-based approach for dose, safety, efficacy, and biomarkers. Trial participants will have a maximal 28-day exposure. As this will be the first in human study of TCAP, safety and adverse events will be the primary endpoint. Key secondary endpoints were chosen to ascertain efficacy in individual conditions and compare drug impact across disparate diseases. All disease cohorts will be measured for Strengths and Difficulties Questionnaire (SDQ), which is a validated broad self-rated outcome measure that has outperformed the clinician-rated Montgomery–Åsberg Depression Rating Scale (MADRS) scale in previous trials. Patients will also be assessed for stress biomarkers via pre- and post-treatment systemic cortisol levels and skin conductance. Each disease cohort (anxiety, depression, PTSD and addiction) will also have disease specific assessments.

 

Furthermore, although patient populations and their responses to CNS agents can be highly variable in clinical studies, we attempt to mitigate this by stratifying the initial series of cohorts to select for and control for corticosterone levels to enable the broadest window of effect detection. Preclinical studies of TCAP demonstrate that its beneficial actions are most easily observed in stressed animals, which show elevations of plasma corticosterone levels at baseline before TCAP treatment. Anxious or depressed patients have elevated corticosterone levels, providing an opportunity to identify patients more likely to benefit pharmacologically and potentially clinically. This also provides a useful translational bridge between preclinical behavioral models and human clinical studies and enables flexibility in evaluating routes of administration.

 

Market for Stress-Related Neuropsychiatric Disorders: Depression, Addiction, Anxiety, and PTSD

 

Humans living in our modern world, in both developed and developing nations, are being exposed to a multitude of life stressors that are progressively taking a toll on our mental health. The recent COVID-19 has exacerbated both near-term and long-term global impacts of stress-induced disorders on modern society. Stress-related mental, mood and behavioral disorders include, but are not limited to: treatment resistant depression (TRD), which is a subgroup of major depressive disorder (MDD); addiction or substance use disorder (SUD); and anxiety, including generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD). These disorders are a leading cause of disability worldwide and also a major contributor to suicide. Yet, a majority of these patients are inadequately served by current therapeutic options, which can have limited efficacy, significant side effects and high treatment burden. We believe these stress-related disorders are suitable indications for the use of Protagenic Therapeutics neuropeptide-based drug candidates.

 

7
 

 

Major depressive disorder (MDD) is highly prevalent and disabling. The lifetime prevalence is approximately 12% with a past year prevalence of 7.8% of adults in the United States in 2019, translating to over 19 million adults each year. The World Health Organization estimates 264 million people globally suffer from depression, which ranks depression as one of the highest causes of disability and mortality in the world. Stress plays a significant role in this illness and affects as many as half of people diagnosed with depression. MDD is characterized by multiple symptoms, potentially including depressed mood, loss of interest or pleasure, change in appetite or weight, sleep disturbance, fatigue or loss of energy, neurocognitive dysfunction, psychomotor agitation or retardation, feelings of worthlessness or excessive guilt, and suicidal ideation and behavior. MDD is highly treatment resistant, with 45-50% of patients who receive initial treatment for MDD not achieving long term remission, generally referred to as Treatment Resistant Depression (TRD). Patients suffering with TRD are at greater risk of hospitalization for their psychiatric illness and are more likely to abuse drugs and alcohol. These patients have a lower long-term quality of life and are at increased risk of attempting suicide. MDD is also highly recurrent and the estimated rate of recurrence over two years is over 40%, which rises to 75% after two episodes within five years.

 

Treatment guidelines recommend the combination of pharmacotherapy plus psychotherapy, but pharmacotherapy alone and psychotherapy alone are frequently used. For initial pharmacotherapy with antidepressants, selective serotonin reuptake inhibitors (SSRIs) are recommended. However, several classes of antidepressants are available, including serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, and serotonin modulators, with efficacy generally comparable across and within classes. Drug choice is based on multiple factors, including side effect profile, comorbid illnesses, concurrent medications, patient preference, and cost. Physicians typically cycle through multiple generics if the initial response is suboptimal or patients experience AEs. Efficacy of therapy is challenged by non-compliance during the weeks to months required to achieve therapeutic benefit in combination with daily dosing requirements. However, SSRIs can produce significant quality of life side effects that interfere with medication adherence, including sexual dysfunction, gastrointestinal nausea and diarrhea, insomnia and weight gain. As a last resort, this disease is currently managed by invasive treatment, primarily electroconvulsive therapy (ECT). However, the side effects and high cost prevent widespread adoption. Several drugs that have launched in recent years validate the market for branded agents in this field, in spite of their marginal improvements in safety or efficacy.

 

Generalized anxiety disorder (GAD) is one of the most common mental disorders in both community and clinical settings. In the United States, the estimated lifetime prevalence of GAD is 5.7%, corresponding to 18 million and 9 million individuals, respectively. GAD is characterized by excessive and persistent worrying that causes significant distress or impairment on most days and is hard to control. Other symptoms can include apprehensiveness, irritability, increased fatigue and muscular tension. GAD is also associated with increased rates of substance abuse, posttraumatic stress disorder, and obsessive-compulsive disorder. GAD is a potentially chronic illness, with symptom severity fluctuating over time. A 12-year study of treated patients showed approximately 60% of patients had symptoms resolve, but around one-half of those subsequently relapsed.

 

Pharmacotherapy for GAD is primarily selective-serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), which are mildly efficacious. Clinical trials for different SSRIs and SNRIs have shown approximately the same effectiveness, with response rates of approximately 60- 70% for the drug and 40% for placebo. However, SSRIs can produce significant quality of life side effects that interfere with medication adherence, including sexual dysfunction, gastrointestinal nausea and diarrhea, insomnia and weight gain. Thus, choice of agent is often dependent on the patient’s side effect profile for individual drugs. Benzodiazepines are efficacious and can reduce emotional and somatic symptoms within hours. However, concerns about dependence risk has contributed to a decline in their use. Buspirone has similar efficacy to benzodiazepines without the risk of dependence but has a time to onset of approximately four weeks. As the majority of these agents are now available as generics, the worldwide market for GAD therapies was expected to reach $1.8 billion in 2023 and with an anticipated forecasted value of $4.3 billion by 2033 (https://www.futuremarketinsights.com/reports/generalized-anxiety-disorder-treatment-market).

 

8
 

 

Post-traumatic stress disorder (PTSD) is one of the most common psychiatric disorders, with an estimated past-year and lifetime prevalence of 4.7% and 6.1%, translating to 11.5M adults in the US each year. PTSD develops in some patients following exposure to a traumatic event involving actual or threatened injury to themselves or others, such as war, natural disasters, rape or assault. Symptoms can be severe, chronic and disabling, which can include intrusive thoughts, nightmares and flashbacks of past traumatic events, avoidance of reminders of trauma, hypervigilance, and sleep disturbance, all of which lead to significant occupational and social impairment. Currently, PTSD is treated with psychotherapy and/or pharmacotherapy, with psychotherapy as the recommended primary intervention. Logistics and cost often limit access to psychotherapy, which results in many patients needing to rely on pharmacotherapy. Guidelines for pharmacotherapy recommend first-line treatment with sertraline and paroxetine, selective serotonin reuptake inhibitors (SSRI) antidepressants, as these are the only approved medications for PTSD. However, these only treat one aspect of symptomology and efficacy is limited, with fewer than 30% of patients experiencing remission. The side effect profile of these agents results in significant rates of discontinuation, particularly the severe effects such as suicidality and sexual dysfunction. Serotonin-norepinephrine reuptake inhibitors (SNRI) and second-generation antipsychotics are used off-label in some patients, but efficacy is sporadic, and side-effects can make these undesirable therapeutic options. As all of these options are currently generic, branded commercial sales for PTSD is almost non-existent. Given the size of the potential addressable population and limited therapeutic options available, a therapy with a superior therapeutic index could achieve significant market penetration and sales.

 

Substance use disorders (SUDs) are highly prevalent. According to the 2020 National Survey on Drug Use and Health (NSDUH), 40.3 million Americans, aged 12 or older, had a substance use disorder (SUD) in the past year. The majority of SUDs involve alcohol use disorder (14 million), followed by illicit drug use disorder (8 million). Illicit drug use and nonmedical use of medications alone or in combination with alcohol are associated with a substantial proportion of emergency department visits in the United States. Pharmacologic options to treat SUDs typically have limited efficacy, high treatment burden, with suboptimal side-effect profiles, ultimately leading to limited uptake and high remaining unmet medical need. 40- 60% of patients who receive SUD care experience chronic or relapsing disease course.

 

The incidence of opioid use disorder (OUD) and overdose deaths have reached epidemic proportions. Opioid use disorder is typically a chronic, relapsing illness, associated with significantly increased rates of morbidity and mortality. Opioid use disorder can be related to misuse of pharmaceutical opioids, heroin, or other opioids such as fentanyl and its analogues. In 2021, 3.3% of those 12 or older in the US were estimated to have used heroin at some point in their lives, translating 9.2 million people (https://www.samhsa.gov/data/sites/default/files/reports/rpt39443/2021NSDUHFFRRev010323.pdf)., Worldwide, an estimated 60 million people engaged in non-medical opioid use in 2021 (https://www.unodc.org/res/WDR-2023/WDR23_Exsum_fin_DP.pdf, https://www.unodc.org/res/wdr2022/MS/WDR22_Booklet_3.pdf ). Correspondingly, overdose deaths involving opioids in the US increased from an estimated 70,029 in 2020 to 80,816 in 2021, representing a 15% increase.

 

Unmet needs are particularly high in OUD. First-line treatment for most patients is medication-assisted treatment, consisting of pharmacotherapy with an opioid agonist or antagonist in combination with psychotherapy. Pharmacotherapy can include an opioid agonist (methadone or buprenorphine) and/or an opioid antagonist (e.g. naltrexone). Guidelines for mild opioid use disorder suggest first-line treatment with long-acting injectable naltrexone (e.g. Vivitrol) administered monthly. Guidelines for moderate to severe opioid use disorder suggest initial use of buprenorphine (e.g. Suboxone) due to the higher risk of lethal overdose with methadone. Treatment can allow patients to return to a productive lifestyle but has low success rates and can be extremely burdensome. These therapies require patients remain on maintenance treatment with an opioid agonist for many years as they are physically dependent upon the medications. A minority may be tapered off after a few years, with the taper itself taking several months to years.

 

The worldwide market for OUD therapies was valued at $3.5 billion in 2023 (https://www.thebusinessresearchcompany.com/report/opioid-use-disorder-oud-global-market-report#:~:text=It%20is%20distributed%20by%20hospital,and%20stores%2C%20and%20online%20pharmacies.&text=The%20opioid%20use%20disorder%20(OUD)%20market%20size%20has%20grown%20rapidly,(CAGR)%20of%2011.3%25. ) and projected to reach $8.4 billion by 2033 (https://www.futuremarketinsights.com/reports/opioid-use-disorder-treatment-market ).

 

The treatment burden and side effect profile of these therapies is substantial. Buprenorphine is classified as a schedule III controlled substance in the United States, with use limited to certified and specially trained physicians. Side effects include sedation, headache, nausea, constipation, insomnia, and sweating. Death is possible if buprenorphine is taken in combination with other substances, especially benzodiazepines and alcohol. Methadone is highly regulated in the United States, where it is classified as a schedule II drug. Only licensed opioid treatment programs or inpatient hospital units are permitted to dispense. Typical side effects of methadone include constipation, drowsiness, sweating, peripheral edema, reduced libido, and erectile dysfunction, with some patients experiencing severe adverse effects including cardiac arrhythmias, hyperalgesia, and overdose.

 

9
 

 

Alcohol use disorder (AUD) is extraordinarily prevalent. Approximately 30% of adults in the United States use alcohol in an unhealthy manner and may need some form of intervention. The 2019 United States National Survey on Drug Use and Health estimated that of Americans over the age of 12 in the past 30 days, 24% reported binge drinking (five or more drinks on one occasion) and 6% reported heavy drinking (five or more drinks on each of five or more days). The National Institute on Alcohol Abuse and Alcoholism (NIAAA) reports 28% of US adults exceed thresholds for risky use alcohol consumption, with 19% exceeding the daily limit and 9% exceeding both the daily and weekly limits. Rates of diagnosable AUD by DSM-5 criteria from the third National Epidemiologic Survey on Alcohol and Related Conditions showed that 29% had met criteria for an alcohol use disorder in their lifetime and 14% met criteria for a current alcohol use disorder. Worldwide, the World Health Organization estimates that 5% of adults (>283 million people) had alcohol use disorder within the prior 12 months.

 

AUD is responsible for significant mortality and morbidity. Excessive alcohol consumption is the third leading preventable cause of death in the United States directly causing approximately 85,000 deaths per year, roughly 10% of deaths among working age adults. Nearly 5% of all deaths worldwide (approximately three million each year) have been attributed to alcohol use with 5% of those specifically due to AUD. The economic cost of excessive alcohol use in the United States is estimated to be $249 billion in 20101 by the CDC. Therapeutic unmet needs are significant for AUD and the condition is frequently untreated. Psychosocial interventions can be effective for treatment but up to 70% of individuals return to heavy drinking. For patients who met DSM-IV criteria for alcohol abuse, 46% were in remission, 24% continued to meet abuse criteria, and 30% met criteria for alcohol dependence in the future. For patients who met DSM-IV criteria for alcohol dependence, 39% were in remission, 15% met criteria for abuse only, and 46% continued to meet dependence criteria.

 

Several medications can be used to treat AUD, which can lead to reduced heavy drinking and increased days of abstinence. For most patients treated with moderate to severe alcohol use disorder, guidelines recommend first-line treatment with naltrexone (e.g. Vivitrol), an opioid antagonist. Vivitrol is an extended-release injectable naltrexone that allows for once monthly dosing that was approved in 2006. Vivitrol is priced at $~1,738/month (https://www.drugs.com/price-guide/vivitrol ) and 2023 worldwide sales have grown to $400.4 million (https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-reports-financial-results-fourth-quarter-and-year-3). The manufacturer projects Vivitrol sales will increase to $410 – 430 million in 2024 (https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-reports-financial-results-fourth-quarter-and-year-3), with patent expiry in 2029 (https://www.fdanews.com/articles/192221-alkermes-grants-amneal-generic-rights-for-vivitrol). Acamprosate (e.g. Campral) is recommended for those in whom naltrexone is contraindicated, such as those taking opioids or with acute hepatitis. Campral (Acamprosate) was approved by the FDA in 2004 and reached peak worldwide sales of $87M in 2008. Acamprosate is currently only available as generic in the US, but is still sold as branded Campral ex-US. Given the overall prevalence of AUD, these relatively low sales numbers indicate the vast majority of patients with AUD are not treated with pharmacotherapy.

 

Teneurin Carboxy-terminal Associated Peptide (TCAP) as a Therapy

 

Our approach to treating stress-related neuropsychiatric and mood disorders is based on research into brain mechanisms conducted over the last 15 years in the laboratory of the company’s scientific founder, Dr. David Lovejoy, from the University of Toronto. TCAP was discovered in a genome-wide search for proteins related to corticotropin releasing factor (CRF), an endogenous brain peptide known to be the central mechanism coupling external stress to psychological, behavioral, and endocrine responses. Dr. Lovejoy and his colleagues discovered and characterized Teneurin Carboxy-terminal Associated Peptide (TCAP); their further work revealed that TCAP is of ancient evolutionary origin and plays a central role in maintaining healthy brain structure and function in the face of the negative effects of stress. Although four TCAP peptides were discovered, only TCAP-1 is expressed independent of a larger Teneurin protein and is the primary focus of our development (PT00114).

 

 

1 As of March 2023, these are the most recent data released by the CDC.

 

10
 

 

TCAP reverses the impact of stress on the Hypothalamic-Pituitary-Adrenal (HPA) axis, the endocrine and behavioral control system which connects environmental stress to behavioral responses via brain levels of Corticotropin Releasing Factor (CRF) and blood levels of the stress hormone cortisol. Stress elevates CRF, which in turn elevates cortisol levels. Studies have demonstrated that TCAP counteracts the effects of either endogenous or pharmacologically-administered CRF via a non-CRF receptor pathway in the brain, that is believed to be evolved over millions of years as a homeostasis-related pathway. There has been strong interest in the pharmaceutical industry for decades to develop drug candidates that block the negative effects of CRF by attempting to directly antagonize the CRF receptor, however clinical results to date with prior CRF receptor antagonists have been disappointing. Because TCAP counteracts the action of CRF by activating separate receptors instead of directly blocking CRF receptors, we believe it is a superior approach to alleviating stress-related neuropsychiatric disorders; TCAP-1 acts by binding to Latrophilin-1 and Latrophilin-3, G-protein-coupled receptors (GPCRs) expressed on nerve cells in the extended amygdala, the region of the brain involved in memory, emotion, and fear. TCAP acts through these receptors to block the effects of CRF and potentially other stress mediators such as Arginine-Vasopressin (AVP). Due to differences in the mechanism of action, TCAP is expected to be efficacious in clinical settings in which earlier studies with CRF receptor antagonists were not. We believe this novel mechanism of action can provide an attractive therapeutic profile for patients who are not fully responsive to currently available therapies.

 

 

Two key effects of TCAP may contribute to its pharmacological activity in reversing or preventing stress-induced behavioral distortions. In settings of stress and depression, the activity of specific neural circuits can be diminished compared to the levels of activity observed in healthy brain tissue. After administration, TCAP crosses the blood brain barrier and concentrates in regions of the brain associated with the regulation of mood disorders. Administered TCAP can lead to increases in activity in some of the neuronal circuitry implicated in depression, demonstrated by increases in the utilization of glucose, a surrogate for cell activity. The fact that the pharmacological effects of TCAP persist after the drug has been cleared aligns with findings that TCAP applied to neurons in culture stabilizes dendritic spines, structures that sprout from the surface of neurons and can form synapses with other neurons to create functional circuitry. Stress and the associated rise in CRF have been reported to cause loss of synapses in animal models. The fact that the pharmacological actions of TCAP persist for weeks are consistent with its producing lasting changes in neuronal function by changing patterns of gene expression and thus creating relatively stable changes in neuronal function. In a number of these models, a single subcutaneous dose of TCAP will prevent the behavioral consequences of stress encountered three weeks later. This is especially notable since the administered dose of TCAP is eliminated from the plasma within hours of administration.

 

Our lead compound is a 41-residue peptide synthetic TCAP-1, which we have designated PT00114. In addition, we have a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally. This affords a range of target product profiles and opportunities for lifecycle management.

 

11
 

 

While many of the initial studies of TCAP had been generated in the lab of Dr. David Lovejoy, we have designed several preclinical studies over the last four years to validate the safety and efficacy of PT00114, for which we hired multiple independent contract research organizations (CROs) to conduct these studies. In preclinical rodent models, administration of PT00114 results in reproducible, dose-dependent reversal of a range of stress-induced behavioral distortions, including depression, stress-exacerbated anxiety, excessive startle, drug seeking, and opioid withdrawal. Stress-induced anxiety was measured by an elevated plus maze, an open field with stressed animals, and acoustic startle in CRF-treated animals. Depression was measured by tail suspension and forced swim. Stress-induced changes in tube-restrained rodents were used as a well-validated model for sub-acute stress. Notably, PT00114 was found to be pharmacologically active in stressed rodents but relatively inactive in non-stressed rodents.

 

In studies conducted with Charles River Laboratories in Kuopio, Finland, PT00114 showed beneficial effects in Chronic Social Defeat, a murine model of stress-induced behavioral dysfunction that has features of depression. In this model, male mice are placed in cages along with older, dominant male mice. This results in progressively more “resigned” behaviors in the mice experiencing this domineering exposure. This results in a series of behaviors in the cowed mice, termed Chronic Social Defeat. PT00114 reverses many of the component behaviors typically measured in this model, suggesting that it reverses the negative effects of stress in the “defeated” animals.

 

PT00114 demonstrated efficacy in a variable chronic stress model that has features of anxiety and PTSD. In an open field assessment, mice or rats are stressed by being placed in a tube for several hours, then placed in an open box where their movement is observed for 20 minutes. Control animals exhibit stress response behavior by not moving around much and staying near the edges of the box. Animal receiving PT00114 at the end of the stress condition moved around the open field. Animals receiving multiple administrations of a control small molecule CRH antagonist did not venture into the open field, indicating they were stressed. These results are also reflected in blood cortisol levels, where control mice had increased cortisol levels, which were reduced by treatment with PT00114, but not by the small molecule CRF antagonist.

 

 

12
 

 

 

Stress plays a central role in a broad range of addictions, including alcohol and opioids. The ability of PT00114 to blunt excessive stress may be able to provide non-dependence forming treatment of addictions. A series of studies conducted at Porsolt Laboratories in Lavel France support the potential utility of PT00114 as a treatment to help people defeat opioid addiction. In rats addicted to opioids, administering CRF models environmental stress, causing them to frantically seek opioids. PT00114 reduces the opioid seeking behavior in response to CRF administration. Further studies conducted by Porsolt following EMEA guidelines demonstrated that on its own, PT00114 was not addictive and rats did not develop dependence to the peptide after chronic administration.

 

PT00114 has also demonstrated pre-clinical efficacy in a murine model of opioid withdrawal called the Saleens test. In this test, mice are addicted to opioids and the animals are then administered the opioid antagonist naloxone, which immediately blocks opioid action and triggers profound stress and opioid withdrawal. This manifests as a behavioral stress response with the mice jumping up to six inches into the air over 70 times in a 20-minute observation period. Administering PT00114 at three different time points within the experiment – before the naloxone-driven withdrawal, before the period of opioid addiction, or up to three weeks before the induced withdrawal – results in a reproducible, dose-dependent restoration to non-stressed behavior and reduced jumping. Significantly, this is not accompanied by any evidence of sedation or reduced activity. This effect appears independent of the opioid used as PT00114 ameliorates this withdrawal-triggered jumping stress behavior in mice experiencing withdrawal from both fentanyl and morphine.

 

Preclinical Safety and Toxicology

 

Preclinical safety data for PT00114 demonstrates a robust profile in both rats and non-human primates. As the mechanism is unique and TCAP is a part of healthy brain signaling, we believe PT00114 will have a differentiated side effect profile relative to existing antidepressant and antipsychotic agents. A key aspect of the TCAP mechanism is that it does not completely block the perception of and responses to stress; it rather protects against stress overload. Some perception of environmental stress and a proportionate response to that stress is adaptive behavior and it is not desirable to completely block stress responses. Unlike benzodiazepines that can cause sedation and are prone to dependence, TCAP prevents the maladaptive response to environmental stress without sedation and without developing dependence.

 

We have completed non-GLP Dose-Range-Finding (DRF) toxicology studies of PT00114 administered subcutaneously daily for five days in rats and non-human primates. The doses tested were substantially above the anticipated clinical doses and were well tolerated and safe, with no dose-limiting toxicities observed at doses at least 50-fold higher than anticipated clinical exposures. No major changes in hematology or clinical chemistries were seen, including prolactin levels or testosterone levels, changes in which may impact libido. Distinct from SSRI’s, there was no impact on ambulation, sedation or weight gain. Importantly, further studies conducted following EMEA guidelines, demonstrated that on its own PT00114 was not addictive and rats did not develop dependence to the peptide after chronic administration. The in life 28-day GLP toxicology testing in both the rats and non-human primate have been completed. There have been no changes in clinical chemistries or pathology that would prompt a stop in the program and the therapeutic margin if large. The final audited reports are currently being compiled.

 

13
 

 

Process Development and Manufacturing

 

We currently do not own any manufacturing facilities and rely on 3rd party contract manufacturers for synthesis of PT00114. We have sufficient PT00114 synthesized under current Good Manufacturing Practices (“cGMP”) conditions to complete GLP toxicology studies and Phase 1 human clinical trials. This material is currently undergoing requisite stability and accelerated stability testing. PT00114 is highly soluble and has shown excellent preliminary stability in several storage conditions, with the material being stable for at least 12 months.

 

The initial dosage form developed will be a subcutaneous injection. Because PT00114 is also amenable to other routes of administration including sublingually or intra-nasally, we will be doing preliminary process work to develop these formulations, and anticipate using one of these dosage forms in later stage clinical studies.

 

Technology License Agreement

 

On July 31, 2005, the Company had entered into a Technology License Agreement (“License Agreement”) with the University of Toronto (the “University” or “UT”) pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the “Technologies”). The Technology License Agreement was amended on February 18, 2015. Unless earlier terminated, the term of this License Agreement shall terminate on the expiration or invalidity of the last issued Patent in the License Agreement

 

Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University 10% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. The Company had no sales revenue for the year ended December 31, 2024 and therefore was not subject to paying any royalties.

 

In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at 3% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or Dr. David Lovejoy at the University, and/or the University, as the case may be. The Company has agreed to pay all out-of-pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to the University under the License Agreement and amendment.

 

The patent applications were made in the name of Dr. Lovejoy and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the six intellectual patent properties.

 

14
 

 

Sales and Marketing

 

We currently have no sales, marketing or distribution capabilities. In order to commercially market PT00114 and any product candidates we develop in the future, we would either need to develop an internal sales team and marketing department or collaborate with third parties who have sales and marketing capabilities. As we commenced clinical trials in the third quarter of 2023, we expect to seek a Market Access expert or consultancy to better understand clinician and payor dynamics in the therapeutic areas we are focused on, so that, as we begin later stage studies, we are working on a deeper commercial assessment in parallel. We have done some high-level benchmarking of pricing based on the current landscape of approved and available therapies for psychiatric disorders we are targeting, both in the generics and on-patent realms.

 

Competition

 

The pharmaceutical and biotechnology industries are highly competitive and characterized by rapidly evolving technology and intense research and development efforts. We expect to compete with companies, including major international pharmaceutical companies and other institutions that have substantially greater financial, research and development, marketing and sales capabilities and have substantially greater experience in undertaking preclinical and clinical testing of products, obtaining regulatory approvals and marketing and selling biopharmaceutical products. We will face competition based on, among other things, product efficacy and safety, the timing and scope of regulatory approvals, product ease of use and price.

 

Despite a large patient population and current treatments that leave much room for improvement, the developmental pipelines are sparse and few novel candidates are in development. The serendipitous discoveries of current drug classes, side effects and lack of efficacy have led to shrinkage or extinction of many pharma or small biotech neuroscience research programs.

 

Set forth below is a discussion of competitive factors for each of the current drug classes commercially available for TRD, and the competitive advantages that we believe PT00114 may offer. The basis for our beliefs regarding the competitive advantages that PT00114 may offer over its competitors is our own pre-clinical animal studies. We acknowledge that these beliefs and conclusions about competitive advantages must be regarded as theoretical until such time as we have human clinical data that supports and re-affirms the results seen in the pre-clinical animal studies.

 

Opioid receptor modulators

 

Opioid receptor modulators have the potential to be therapeutic drugs for TRD but have a high likelihood of abuse and thus regulatory restrictions. We believe that our competitive advantage is that PT00114 targets a different receptor system therefore it is not likely to have a clinical overlap with opioid receptor modulators.

 

Atypical Antipsychotics with antidepressant effects (dopamine receptor modulators)

 

Brexpiprazole (Rexulti from Otsuka) is a dopamine (D2 receptor) partial stimulator (agonist) approved as an oral adjunctive TRD therapy. Its side effects include suicidal risk, weight gain and restlessness. Cariprazine (Vraylar from AbbVie) is an oral dopamine D2 and D3 receptor antagonist approved for schizophrenia and bipolar disorder in development for TRD. The most common side effects reported were extrapyramidal symptoms, the urge to move (akathisia), indigestion (dyspepsia), vomiting, drowsiness (somnolence) and restlessness. We believe that our competitive advantage is that PT00114, due to its low toxicity profile, will be clinically preferable to these antipsychotic drugs.

 

Ketamine and Esketamine

 

Ketamine and Esketamine (Spratavo nasal spray from Johnson & Johnson) the S(+) enantiomer of the drug ketamine act primarily as a non-competitive NMDA receptor antagonist, but is also a dopamine reuptake inhibitor. Although ketamine is used off-label and Esketamine was recently approved for TRD, limitations and concerns around use limit uptake in a broader population. We believe that our competitive advantage is that the toxicity profile is likely to be less favorable when compared with PT00114.

 

15
 

 

GABA receptor modulators

 

GABA receptors, when bound by inhibitory neurotransmitters found throughout the brain, act as a brake on nerve activity. Sage Therapeutics is developing multiple compounds that target this mechanism and more candidates are expected to come from this therapeutic class that may present a competitive challenge for PT00114.

 

NMDA receptor modulators

 

The N-methyl-D-aspartate (or “NMDA”) receptor is a molecule that appears on the surface of neurons. When “activated” by a drug that binds with it, the NMDA receptor is a potential natural way to counteract TRD. More candidates are expected to come from this therapeutic class that may present a competitive challenge for PT00114.

 

PT00114’s Competitive Advantages

 

Our preclinical data and the corroborated mechanism of action of PT00114 indicates its advantages as compared to current approved therapies:

 

  ● PT00114 has a rapid onset of action in animal anxiety and depression models as compared with other TRD drugs
     
  ● PT00114’s effects are long-lasting and potent (single 1-10 nmole/kg dose lasts up to one week for glucose/insulin blood-based biomarkers)

 

  ● PT00114 is rapidly cleared (its “half-life” is 5-10min if given intravenously (IV), 20-30 minutes if given subcutaneously (SC)
     
  ● PT00114 naturally crosses the blood brain barrier
     
  ● PT00114 is an L-isomer, a naturally modified peptide, therefore liver toxicities typically associated with other psychiatric therapies are not anticipated
     
  ● PT00114 is stable when lyophilized form, making it delivery in an oral or nasal formulation feasible
     
  ● PT00114 will be manufactured by standard solid phase chemistry, which is less expensive than manufacturing processes required by other TRD drugs
     
    Studies have demonstrated that the compound does not caused dependency following multiple administrations

 

Intellectual Property

 

We believe that patents, trademarks, copyrights and other proprietary rights are important to our business. We also rely on trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. We seek to protect our intellectual property rights by a variety of means, including obtaining patents, maintaining trade secrets and proprietary know-how, and technological innovation to operate without infringing on the proprietary rights of others and to prevent others from infringing on our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, actively seeking patent protection in the United States and foreign countries.

 

As of December 31, 2024, we have four patents issued by the Governments of the United States, Canada, and European Union (validated in Germany, France and Great Britain) on our original platform technology, all of which have expired aside from the one granted in the United States. The patent applications were made in the name of Dr. David A. Lovejoy and inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement with UT. We have eight further issued patents and five pending patent applications in related technology that the company has rights in or own.

 

16
 

 

Our success will depend in part on our ability to maintain our proprietary position through effective patent claims and their enforcement against our competitors. Although we believe our patent applications provide a competitive advantage, the patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. We do not know whether any of our patent applications will result in the issuance of any patents. Those patents that may be issued in the future or those acquired by us may be challenged, invalidated or circumvented, and the rights granted under any issued patent may not provide us with proprietary protection or competitive advantages against competitors with similar technology. In particular, we do not know if competitors will be able to design variations on our treatment methods to circumvent our current and anticipated patent claims. Furthermore, competitors may independently develop similar technologies or duplicate any technology developed by us. Because of the extensive time required for the development, testing and regulatory review of a potential product, it is possible that, before any of our products can be commercialized or marketed, any related patent claim may expire or remain in force for only a short period following commercialization, thereby reducing the advantage of the patent.

 

We also rely upon trade secrets, confidentiality agreements, proprietary know-how and continuing technological innovation to remain competitive, especially where we do not believe patent protection is appropriate or obtainable. We continue to seek ways to protect our proprietary technology and trade secrets, including entering into confidentiality or license agreements with our employees and consultants, and controlling access to and distribution of our technologies and other proprietary information. While we use these and other reasonable security measures to protect our trade secrets, our employees or consultants may unintentionally or willfully disclose our proprietary information to competitors.

 

Our commercial success will depend in part on our ability to operate without infringing upon the patents and proprietary rights of third parties. It is uncertain whether the issuance of any third-party patents would require us to alter our products or technology, obtain licenses or cease certain activities. Our failure to obtain a license to technology that we may require to discover, develop or commercialize our future products may have a material adverse impact on us. One or more third-party patents or patent applications may conflict with patent applications to which we have rights. Any such conflict may substantially reduce the coverage of any rights that may issue from the patent applications to which we have rights. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine priority of invention.

 

We may collaborate in the future with other entities on research, development and commercialization activities. Disputes may arise about inventorship and corresponding rights in know-how and inventions resulting from the joint creation or use of intellectual property by us and our subsidiaries, collaborators, partners, licensors and consultants. As a result, we may not be able to maintain our proprietary position.

 

As of December 31, 2024, we own or have rights in the following intellectual property:

 

TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND METHODS AND USES THEREOF*
COUNTRY  FILED   SERIAL#   ISSUED   PATENT#   STATUS 
UNITED STATES   11/01/2004    10/510,959   01/03/2012    8,088,889    ISSUED 

 

A METHOD FOR REGULATING NEURITE GROWTH*
COUNTRY  FILED   SERIAL#   ISSUED   PATENT#   STATUS 
UNITED STATES   06/19/2012 (Continuation)    13/527,414   08/01/2017    9,718,857    ISSUED 

 

A METHOD FOR MODULATING INSULIN-INDEPENDENT GLUCOSE TRANSPORT USING TENEURIN C-TERMINAL ASSOCIATED PEPTIDE (TCAP)*
COUNTRY  FILED   SERIAL#   ISSUED   PATENT#   STATUS 
CANADA   07/21/2015    2,955,410    02/20/2024    2,955,410    ISSUED 
GREAT BRITAIN   07/21/2015    1702638.6    07/21/2020    2543996    ISSUED 
UNITED STATES   07/21/2015 (PCT)/ 01/17/2017(371c)    15/326,735   04/14/2020    10,617,736    ISSUED 

 

17
 

 

COMPOSITIONS, METHODS AND USES FOR ENHANCING MUSCLE FUNCTION*
COUNTRY  FILED   SERIAL#   ISSUED   PATENT#   STATUS 
US   09/26/2017(PCT) / 03/25/2019(371c)    16/336,334   09/20/2022    11,446,355    ISSUED 
CA   09/26/2017    3,038,169              PENDING 

 

COMPOSITIONS, METHODS AND USES FOR TREATING POST-TRAUMATIC STRESS DISORDER *
COUNTRY  FILED   SERIAL#   ISSUED   PATENT#   STATUS 
UNITED STATES   10/12/2018(PCT) /04/10/2020(371c)    11,426,444    08/30/2022    11,426,444    ISSUED 
CANADA   04/14/2020    3,079,724              PENDING 

 

COMPOSITIONS, METHODS AND USES OF A TENEURIN C-TERMINAL ASSOCIATED PEPTIDE-1 (TCAP-1) FOR TREATING OPIOID ADDICTION
COUNTRY  FILED   SERIAL#   ISSUED   PATENT#   STATUS 
CANADA   3/13/2019    3,093,841              PENDING 
UNITED STATES   3/13/2019(PCT) / 9/11/2010 (371c)    16/980,176             PENDING 
EUROPE(UPC + Switzerland, Spain, Great Britain and Ireland)   3/13/2019    19712494.4    02-08-2023    3765056    ISSUED 
HONG KONG (Extended EP Application. Registration for Grant filed Feb. 1, 2024))   3/13/2019    62021035260.0              PENDING 

 

In the future we may file additional patent applications based on proprietary formulations and novel compounds in the TCAP family.

 

Properties

 

The Company does not currently own any real property. The Company leases office space for its principal executive office located at 149 Fifth Avenue, Suite 500, New York, New York 10010.

 

Legal Proceedings

 

From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

 

Subsidiary

 

PTI Canada was incorporated in 2006 in the Province on Ontario, Canada. PTI Canada is a wholly-owned subsidiary of Protagenic. It provides operational support and assistance for the implementation of corporate and operational activities conducted in Canada. It also oversees and supports research and development activities conducted under auspices of UT. PTI Canada has three directors: Garo H. Armen (Chairman), Alexander K. Arrow and Vigen Nazarian. PTI Canada also has one part-time consultant, Robert Ziroyan. PTI Canada also benefits through tax incentive programs provided by the governments of Canada and the Province of Ontario. We derived credits from Canadian research and development tax credits for the years ended December 31, 2024 and 2023 of $0 and $0, respectively.

 

Employees

 

We currently have one full time and two part-time employees. We also engage consultants and temporary employees from time to time to provide services that relate to our research and development activities as well as for general administrative and accounting services. We believe that our current personnel are capable of meeting our operating requirements in the near term. We expect that as our business grows we may hire additional personnel to handle the increased demands on our operations, preclinical and clinical activities.

 

18
 

 

Corporate and Available Information

 

Our principal offices are located at 149 Fifth Avenue, New York, New York 10010. Our web address is www.protagenic.com.

 

We make available, free of charge through our website, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file or furnish such materials to the Securities and Exchange Commission, or SEC. In addition, you may read and copy any materials we file with the SEC at its Public Reference Room at 100 F Street, NE, Washington, DC 20549, on official business days during the hours of 10:00 am to 3:00 pm. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site, www.sec.gov that contains reports, proxy and information statements, and other information that we file electronically with the SEC. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.

 

Item 1A. Risk Factors.

 

An investment in our common stock is speculative and illiquid and involves a high degree of risk including the risk of a loss of your entire investment. You should carefully consider the risks and uncertainties described below and the other information contained in this report before purchasing shares of our common stock. The risks set forth below are not the only ones facing us. Additional risks and uncertainties may exist that could also adversely affect our business, operations and prospects. If any of the following risks actually materialize, our business, financial condition, prospects and/or operations could suffer. In such event, the value of our common stock could decline, and you could lose all or a substantial portion of the money that you pay for our common stock.

 

Risks Related to Our Financial Condition and Capital Requirements

 

The Company’s financial statements have been prepared on a going concern basis, and do not include adjustments that might be necessary if the Company is unable to continue as a going concern.

 

The Company’s consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2024, the Company had incurred significant operating losses since inception, and continues to generate losses from operations, and has an accumulated deficit of $36,350,247. Based on its cash resources as of December 31, 2024, the Company has sufficient resources to fund its operations until the end of the third quarter of 2025. The consolidated financial statements included in this report do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

We have a history of losses and expect that losses may continue in the future.

 

We have generated net losses since we began operations, including $5,525,344 and $5,000,497 for the years ended December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $36,303,216. We have no approved products and have generated no product revenue. We expect that product development, preclinical and clinical programs will increase losses significantly over the next five years. In order to achieve profitability, we will need to generate significant revenue. We cannot be certain that we will generate sufficient revenue to achieve profitability. We anticipate that we will continue to generate operating losses and negative cash flow from operations and our current cash position is sufficient to fund our current business plan until the third quarter of 2025. We cannot be certain that we will ever achieve, or if achieved, maintain profitability. If our revenue grows at a slower rate than we anticipate or if our product development, marketing and operating expenses exceed our expectations or cannot be adjusted accordingly, our business, results of operation and financial condition will be materially adversely affected, and we may be unable to continue operations.

 

19
 

 

We will not be able to generate product revenue unless and until one of our product candidates successfully completes clinical trials and receives regulatory approval. As our most advanced product candidates are at an early proof-of-concept stage, we do not expect to receive revenue from any product candidate for the foreseeable future. We may seek to obtain revenue from collaboration or licensing agreements with third parties. We currently have no such agreements which will provide us with material, ongoing future revenue and we may never enter into any such agreements. Even if we eventually generate revenues, we may never be profitable, and if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.

 

We need to obtain financing in order to continue our operations.

 

On a prospective basis, we will require both short-term financing for operations and long-term capital to fund our expected growth. We have no existing bank lines of credit and have not established any definitive sources for additional financing. Additional financing may not be available to us, or if available, then it may not be available upon terms and conditions acceptable to us. If adequate funds are not available, then we may be required to delay, reduce or eliminate product development or clinical programs. Our inability to take advantage of opportunities in the industry because of capital constraints may have a material adverse effect on our business and our prospects. If we fail to obtain the capital necessary to fund our operations, we will be unable to advance our development programs and complete our clinical trials.

 

In addition, our research and development expenses could exceed our current expectations. This could occur for many reasons, including:

 

  ● some or all of our product candidates fail in clinical or preclinical studies and we are forced to seek additional product candidates;
     
  ● our product candidates require more extensive clinical or preclinical testing than we currently expect;
     
  ● we advance more of our product candidates than expected into costly later stage clinical trials;
     
  ● we advance more preclinical product candidates than expected into early stage clinical trials;
     
  ● we are required, or consider it advisable, to acquire or license rights from one or more third parties; or
     
  ● we determine to acquire or license rights to additional product candidates or new technologies.

 

While we expect to seek additional funding through public or private financings, we may not be able to obtain financing on acceptable terms, or at all. In addition, the terms of our financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. These arrangements would generally require us to relinquish rights to some of our technologies, product candidates or products, and we may not be able to enter into such agreements, on acceptable terms, if at all. If we are unable to obtain additional funding on a timely basis, we may be required to curtail or terminate some or all of our development programs, including some or all of our product candidates.

 

If we continue to incur operating losses and fail to obtain the capital necessary to fund our operations, we will be unable to advance our development programs, complete our clinical trials, or bring products to market, or may be forced to reduce or cease operations entirely. In addition, any capital obtained by us may be obtained on terms that are unfavorable to us, our investors, or both.

 

Developing a new drug and conducting clinical trials and the regulatory review processes involves substantial costs. We have projected cash requirements for the near term based on a variety of assumptions, but some or all of such assumptions are likely to be incorrect and/or incomplete, possibly materially in an adverse direction. Our actual cash needs may deviate materially from those projections, changes in market conditions or other factors may increase our cash requirements, or we may not be successful even in raising the amount of cash we currently project will be required for the near term. We will need to raise additional capital in the future; the amount of additional capital needed will vary as a result of a number of factors, including without limitation the following:

 

  ● receiving less funding than we require;

 

20
 

 

  ● higher than expected costs to manufacture our product candidates;
     
  ● higher than expected costs for preclinical testing;
     
  ● an increase in the number, size, duration, and/or complexity of our clinical trials;
     
  ● slower than expected progress in developing PT00114, or other product candidates, including without limitation, additional costs caused by program delays;
     
  ● higher than expected costs associated with attempting to obtain regulatory approvals, including without limitation additional costs caused by additional regulatory requirements or larger clinical trial requirements;
     
  ● higher than expected personnel, consulting or other costs, such as adding personnel or industry expert consultants or pursuing the licensing/acquisition of additional assets; and
     
  ● higher than expected costs to protect our intellectual property portfolio or otherwise pursue our intellectual property strategy.

 

When we attempt to raise additional financing, there can be no assurance that we will be able to secure such additional financing in sufficient quantities or at all. We may be unable to raise additional capital for reasons including, without limitation, our operational and/or financial performance, investor confidence in us and the biopharmaceutical industry, credit availability from banks and other financial institutions, the status of current projects, and our prospects for obtaining any necessary regulatory approvals. Potential investors’ capital investments may have shifted to other opportunities with perceived greater returns and/or lower risk thereby reducing capital available to us, if available at all.

 

In addition, any additional financing might not be available, and even if available, may not be available on terms favorable to us or our then-existing investors. We will seek to raise funds through public or private equity offerings, debt financings, corporate collaboration or licensing arrangements, mergers, acquisitions, sales of intellectual property, or other financing vehicles or arrangements. To the extent that we raise additional capital by issuing equity securities or other securities, our then-existing investors will experience dilution. If we raise funds through debt financings or bank loans, we may become subject to restrictive covenants, our assets may be pledged as collateral for the debt, and the interests of our then-existing investors would be subordinated to the debt holders or banks. In addition, our use of and ability to exploit assets pledged as collateral for debt or loans may be restricted or forfeited. To the extent that we raise additional funds through collaboration or licensing arrangements, we may be required to relinquish significant rights (including without limitation intellectual property rights) to our technologies or product candidates, or grant licenses on terms that are not favorable to us. If we are not able to raise needed funding under acceptable terms or at all, then we will have to reduce expenses, including the possible options of curtailing operations, abandoning opportunities, licensing or selling off assets, reducing costs to a point where clinical development or other progress is impaired, or ceasing operations entirely.

 

We have a limited operating history, expect to incur significant operating losses, and have a high risk of never being profitable.

 

We commenced operations in February 2016 through a reverse merger and have a limited operating history of less than five years. Therefore, there is limited historical financial or operational information upon which to evaluate our performance. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations. Many if not most companies in our industry at our stage of development never become profitable and are acquired or go out of business before successfully developing any product that generates revenue from commercial sales or enables profitability.

 

21
 

 

As of December 31, 2024, we have incurred an accumulated deficit of $36,279,932. We expect to continue to incur substantial operating losses over the next several years for the clinical development of our current and future licensed or purchased product candidates.

 

The amount of future losses and when, if ever, we will become profitable are uncertain. We do not have any products that have generated any revenues from commercial sales, and do not expect to generate revenues from the commercial sale of products in the near future, if ever. Our ability to generate revenue and achieve profitability will depend on, among other things, successful completion of the development of our product candidates; obtaining necessary regulatory approvals from the FDA and international regulatory agencies; establishing manufacturing, sales, and marketing arrangements with third parties; obtaining adequate reimbursement by third-party payers; and raising sufficient funds to finance our activities. If we are unsuccessful at some or all of these undertakings, our business, financial condition, and results of operations are expected to be materially and adversely affected.

 

As a recently established public reporting company, we are subject to SEC reporting and other requirements, which will lead to increased operating costs in order to meet these requirements.

 

Unstable market and economic conditions may have serious adverse consequences on our ability to raise funds, which may cause us to cease or delay our operations.

 

From time to time, global and domestic credit and financial markets have experienced extreme disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. Our financing strategy will be adversely affected by any such economic downturn, volatile business environment and continued unpredictable and unstable market conditions. If the equity and credit markets deteriorate, it may make a debt or equity financing more difficult to complete, costlier, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms will have a material adverse effect on our business strategy and financial performance, and could require us to cease or delay our operations.

 

Risks Related to Clinical Development and Regulatory Approval

 

Our results to date provide no basis for predicting whether any of our product candidates will be safe or effective, or receive regulatory approval.

 

The Company’s proprietary portfolio of five new neuropeptide hormones are in various stages of research and preclinical evaluation and their risk of failure is high. It is impossible to predict when or if any of our neuropeptide hormones will prove effective or safe in humans or will receive regulatory approval. These compounds may not demonstrate in patients the chemical and pharmacological properties ascribed to them in laboratory studies, and they may interact with human biological systems or other drugs in unforeseen, ineffective or harmful ways. If we are unable to discover or successfully develop drugs that are effective and safe in humans, we will not have a viable business.

 

We may not be able to initiate and complete preclinical studies and clinical trials for our product candidates which could adversely affect our business.

 

We must successfully initiate and complete extensive preclinical studies and clinical trials for our product candidates before we can receive regulatory approval. Preclinical studies and clinical trials are expensive and will take several years to complete and may not yield results that support further clinical development or product approvals. Conducting clinical studies for any of our drug candidates for approval in the United States requires filing an IND and reaching agreement with the FDA on clinical protocols, finding appropriate clinical sites and clinical investigators, securing approvals for such studies from the independent review board at each such site, manufacturing clinical quantities of drug candidates, supplying drug product to clinical sites and enrolling sufficient numbers of participants. We cannot guarantee that we will be able to successfully accomplish all of the activities necessary to initiate and complete clinical trials.

 

As a result, our preclinical studies and clinical trials may be extended, delayed or terminated, and we may be unable to obtain regulatory approvals or successfully commercialize our products.

 

22
 

 

The drug development and approval process is uncertain, time-consuming and expensive.

 

The process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive and uncertain. It also can vary substantially based on the type, complexity, and novelty of the product. We must provide the FDA and foreign regulatory authorities with preclinical and clinical data demonstrating that our products are safe and effective before they can be approved for commercial sale. Clinical development, including preclinical testing, is a long, expensive and uncertain process. It may take us several years to complete our testing, and failure can occur at any stage of testing. Any preclinical or clinical test may fail to produce results satisfactory to the FDA. Preclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent regulatory approval. Negative or inconclusive results from a preclinical study or clinical trial, adverse medical events during a clinical trial or safety issues resulting from products of the same class of drug could cause a preclinical study or clinical trial to be repeated or a program to be terminated, even if other studies or trials relating to the program are successful.

 

The regulatory approval process is costly and lengthy and we may not be able to successfully obtain all required regulatory approvals.

 

The preclinical development, clinical trials, manufacturing, marketing and labeling of pharmaceuticals are all subject to extensive regulation by numerous governmental authorities and agencies in the United States and other countries. We must obtain regulatory approval for each of our product candidates before marketing or selling any of them. It is not possible to predict how long the approval processes of the FDA or any other applicable federal or foreign regulatory authority or agency for any of our products will take or whether any such approvals ultimately will be granted. The FDA and foreign regulatory agencies have substantial discretion in the drug approval process, and positive results in preclinical testing or early phases of clinical studies offer no assurance of success in later phases of the approval process. Generally, preclinical and clinical testing of products can take many years and require the expenditure of substantial resources, and the data obtained from these tests and trials can be susceptible to varying interpretations that could delay, limit or prevent regulatory approval. If we encounter significant delays in the regulatory process that result in excessive costs, this may prevent us from continuing to develop our product candidates. Any delay in obtaining, or failure to obtain, approvals could adversely affect the marketing of our products and our ability to generate product revenue. The risks associated with the approval process include:

 

  ● failure of our product candidates to meet a regulatory agency’s requirements for safety, efficacy and quality;
     
  ● limitation on the indicated uses for which a product may be marketed;
     
  ● unforeseen safety issues or side effects; and
     
  ● governmental or regulatory delays and changes in regulatory requirements and guidelines.

 

Even if we receive regulatory approvals for marketing our product candidates, if we fail to comply with continuing regulatory requirements, we could lose our regulatory approvals, and our business would be adversely affected.

 

The FDA continues to review products even after they receive initial approval. If we receive approval to commercialize any product candidates, the manufacturing, marketing and sale of these drugs will be subject to continuing regulation, including compliance with quality systems regulations, good manufacturing practices, adverse event requirements, and prohibitions on promoting a product for unapproved uses. Enforcement actions resulting from our failure to comply with government and regulatory requirements could result in fines, suspension of approvals, withdrawal of approvals, product recalls, product seizures, mandatory operating restrictions, criminal prosecution, civil penalties and other actions that could impair the manufacturing, marketing and sale of our potential products and our ability to conduct our business.

 

23
 

 

Even if we are able to obtain regulatory approvals for any of our product candidates, if they exhibit harmful side effects after approval, our regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims.

 

Even if we receive regulatory approval for our product candidates, we will have tested them in only a small number of patients during our clinical trials. If our applications for marketing are approved and more patients begin to use our product, new risks and side effects associated with our products may be discovered. As a result, regulatory authorities may revoke their approvals; we may be required to conduct additional clinical trials, make changes in labeling of our product, reformulate our product or make changes and obtain new approvals for our and our suppliers’ manufacturing facilities. We might have to withdraw or recall our products from the marketplace. We may also experience a significant drop in the potential sales of our product if and when regulatory approvals for such product are obtained, experience harm to our reputation in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent any sales of our approved product or substantially increase the costs and expenses of commercializing and marketing our product.

 

If we experience delays or difficulties in the enrollment of subjects to our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented, which could materially affect our financial condition.

 

Identifying, screening and enrolling patients to participate in clinical trials of our product candidates is critical to our success, and we may not be able to identify, recruit, enroll and dose a sufficient number of patients with the required or desired characteristics to complete our clinical trials in a timely manner. The timing of our clinical trials depends on our ability to recruit patients to participate as well as to subsequently dose these patients and complete required follow-up periods.

 

In addition, we may experience enrollment delays related to increased or unforeseen regulatory, legal and logistical requirements at certain clinical trial sites. These delays could be caused by reviews by regulatory authorities and contractual discussions with individual clinical trial sites. Any delays in enrolling and/or dosing patients in our planned clinical trials could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or in termination of the clinical trials altogether.

 

Patient enrollment may be affected if our competitors have ongoing clinical trials with products for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in our competitors’ clinical trials. Patient enrollment may also be affected by other factors, including:

 

  ● coordination with clinical research organizations to enroll and administer the clinical trials;
     
  ● coordination and recruitment of collaborators and investigators at individual sites;
     
  ● size of the patient population and process for identifying patients;
     
  ● design of the clinical trial protocol;
     
  ● eligibility and exclusion criteria;
     
  ● perceived risks and benefits of the product candidates under study;
     
  ● availability of competing commercially available therapies and other competing products’ clinical trials;
     
  ● time of year in which the trials are initiated or conducted;
     
  ● severity of the diseases under investigation;
     
  ● ability to obtain and maintain subject consents;
     
  ● ability to enroll and treat patients in a timely manner;
     
  ● risk that enrolled subjects will drop out before completion of the trials;
     
  ● proximity and availability of clinical trial sites for prospective patients;

 

24
 

 

  ● ability to monitor subjects adequately during and after treatment; and
     
  ● patient referral practices of physicians.

 

Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which could materially affect our financial condition.

 

New federal laws or regulations on drug importation could make lower cost versions of our future products available, which could adversely affect our revenues, if any.

 

The prices of some drugs are lower in other countries than in the United States because of government regulation and market conditions. Under current law, importation of drugs into the United States is generally not permitted unless the drugs are approved in the United States and the entity that holds that approval consents to the importation. Various proposals have been advanced to permit the importation of drugs from other countries to provide lower cost alternatives to the products available in the United States. In addition, the MMA requires the Secretary of Health and Human Services to promulgate regulations for drug re-importation from Canada into the United States under some circumstances, including when the drugs are sold at a lower price than in the United States.

 

If the laws or regulations are changed to permit the importation of drugs into the United States in circumstances that are currently not permitted, such a change could have an adverse effect on our business by making available lower priced alternatives to our future products.

 

Failure to obtain regulatory and pricing approvals in foreign jurisdictions could delay or prevent commercialization of our products abroad.

 

If we succeed in developing any products, we intend to market them in the European Union and other foreign jurisdictions. In order to do so, we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval abroad may differ from that required to obtain FDA approval. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and additional risks associated with requirements particular to those foreign jurisdictions where we will seek regulatory approval of our products. We may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. We and our collaborators may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market outside the United States. The failure to obtain these approvals could materially adversely affect our business, financial condition and results of operations.

 

It is uncertain whether product liability insurance will be adequate to address product liability claims, or that insurance against such claims will be affordable or available on acceptable terms in the future.

 

Clinical research involves the testing of new drugs on human volunteers pursuant to a clinical trial protocol. Such testing involves a risk of liability for personal injury to or death of patients due to, among other causes, adverse side effects, improper administration of the new drug, or improper volunteer behavior. Claims may arise from patients, clinical trial volunteers, consumers, physicians, hospitals, companies, institutions, researchers, or others using, selling, or buying our products, as well as from governmental bodies. In addition, product liability and related risks are likely to increase over time, in particular upon the commercialization or marketing of any products by us or parties with which we enter into development, marketing, or distribution collaborations. Although we are contracting for general liability insurance in connection with our ongoing business, there can be no assurance that the amount and scope of such insurance coverage will be appropriate and sufficient in the event any claims arise, that we will be able to secure additional coverage should we attempt to do so, or that our insurers would not contest or refuse any attempt by us to collect on such insurance policies. Furthermore, there can be no assurance that suitable product liability insurance (at the clinical stage and/or commercial stage) will continue to be available on terms acceptable to us or at all, or that, if obtained, the insurance coverage will be appropriate and sufficient to cover any potential claims or liabilities.

 

25
 

 

If the market opportunities for our current and potential future drug candidates are smaller than we believe they are, our ability to generate product revenues will be adversely affected and our business may suffer.

 

Our understanding of the number of people who suffer from stress-related indications, including, but not limited to: treatment resistant depression (“TRD”), which is a subgroup of major depressive disorder (“MDD”); addiction, recidivism, or substance use disorder (“SUD”); anxiety, including generalized anxiety disorder (“GAD”), and post-traumatic stress disorder (“PTSD”) is based upon estimates. These estimates may prove to be incorrect, and new studies may demonstrate or suggest a lower estimated incidence or prevalence of this condition. The number of patients in the U.S. or elsewhere may turn out to be lower than expected, may not be otherwise amenable to PT00114 treatment, or treatment-amenable patients may become increasingly difficult to identify and access, all of which would adversely affect our business prospects and financial condition.

 

Risks Related to Our Reliance on Third Parties

 

We may not be able to obtain and maintain the third party relationships that are necessary to develop, commercialize and manufacture some or all of our product candidates.

 

We expect to depend on collaborators, partners, licensees, clinical research organizations, manufacturers and other third parties to support our discovery efforts, to formulate product candidates, to conduct clinical trials for some or all of our product candidates, to manufacture clinical and commercial scale quantities of our product candidates and products and to market, sell, and distribute any products we successfully develop.

 

We cannot guarantee that we will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, manufacturers and other third parties on favorable terms, if at all. If we are unable to obtain or maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize our product candidates, which will in turn adversely affect our business.

 

We expect to expend substantial management time and effort to enter into relationships with third parties and, if we successfully enter into such relationships, to manage these relationships. In addition, substantial amounts of our expenditures will be paid to third parties in these relationships. However, we cannot control the amount or timing of resources our contract partners will devote to our research and development programs, product candidates or potential product candidates, and we cannot guarantee that these parties will fulfill their obligations to us under these arrangements in a timely fashion, if at all.

 

We have no experience in sales, marketing and distribution and may have to enter into agreements with third parties to perform these functions, which could prevent us from successfully commercializing our product candidates.

 

We currently have no sales, marketing or distribution capabilities. To commercialize our product candidates, we must either develop our own sales, marketing and distribution capabilities, which will be expensive and time consuming, or make arrangements with third parties to perform these services for us. If we decide to market any of our products on our own, we will have to commit significant resources to developing a marketing and sales force and supporting distribution capabilities. If we decide to enter into arrangements with third parties for performance of these services, we may find that they are not available on terms acceptable to us, or at all. If we are not able to establish and maintain successful arrangements with third parties or build our own sales and marketing infrastructure, we may not be able to commercialize our product candidates which would adversely affect our business and financial condition.

 

Data provided by collaborators and other parties upon which we rely have not been independently verified and could turn out to be inaccurate, misleading, or incomplete.

 

We rely on third-party vendors, scientists, and collaborators to provide us with significant data and other information related to our projects, clinical trials, and business. We do not independently verify or audit all of such data (including possibly material portions thereof). As a result, such data may be inaccurate, misleading, or incomplete.

 

26
 

 

In certain cases, we may need to rely on a single supplier for a particular manufacturing material or service, and any interruption in or termination of service by such supplier could delay or disrupt the commercialization of our products.

 

We rely on third-party suppliers for the materials used to manufacture our compounds. Some of these materials may at times only be available from one supplier. Any interruption in or termination of service by such single source suppliers could result in a delay or disruption in manufacturing until we locate an alternative source of supply. There can be no assurance that we would be successful in locating an alternative source of supply or in negotiating acceptable terms with such prospective supplier.

 

We rely on third parties to conduct our non-clinical studies and our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize our current product candidates or any future products, on a timely basis or at all, and our financial condition will be adversely affected.

 

We do not have the ability to independently conduct non-clinical studies and clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, collaborative partners and other third parties, such as contract research organizations or clinical research organizations, to conduct non-clinical studies and clinical trials on our product candidates. The third parties with whom we contract for execution of our non-clinical studies and clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we have limited ability to control the amount or timing of resources that they devote to our programs.

 

Although we rely on third parties to conduct our non-clinical studies and clinical trials, we remain responsible for ensuring that each of our non-clinical studies and clinical trials is conducted in accordance with its investigational plan and protocol. Moreover, the FDA, EMA and other foreign regulatory authorities require us to comply with regulations and standards, including some regulations commonly referred to as good clinical practices (“GCPs”), for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials.

 

In addition, the execution of non-clinical studies and clinical trials, and the subsequent compilation and analyses of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. Moreover, these third parties may also have relationships with other commercial entities, some of which may compete with us. Under certain circumstances, these third parties may be able to terminate their agreements with us upon short notice. If the third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated. If any of the foregoing were to occur, we may not be able to obtain, on a timely basis or at all, regulatory approval for or to commercialize the product candidate being tested in such trials, and as a result, our financial condition will be adversely affected.

 

Risks Related to Commercialization of Our Product Candidates

 

We have no experience as a company in commercializing any product. If we fail to obtain commercial expertise, upon product approval by regulatory agencies, our product launch and revenues could be delayed.

 

As a company, we have never obtained regulatory approval for, or commercialized, any product. Accordingly, we have not yet begun to build out any sales or marketing capabilities. If we are unable to establish, or contract for, effective sales and marketing capabilities, or if we are unable to enter into agreements with third parties to commercialize our product candidates on favorable terms or on any reasonable terms at all, we may not be able to effectively generate product revenues once our product candidates are approved for marketing. If we fail to obtain commercial expertise or capabilities, upon drug approval, our product launch and subsequent revenues could be delayed and /or fail to reach their commercial potential.

 

27
 

 

We may not be able to gain market acceptance of our product candidates, which would prevent us from becoming profitable.

 

We cannot be certain that any of our product candidates will gain market acceptance among physicians, patients, healthcare payers, pharmaceutical companies or others. Demonstrating the safety and efficacy of our product candidates and obtaining regulatory approvals will not guarantee future revenue. Sales of medical products largely depend on the reimbursement of patients’ medical expenses by government healthcare programs and private health insurers. Governments and private insurers closely examine medical products to determine whether they should be covered by reimbursement and if so, the level of reimbursement that will apply. We cannot be certain that third party payers will sufficiently reimburse sales of our products, or enable us to sell our products at profitable prices. Similar concerns could also limit the reimbursement amounts that health insurers or government agencies in other countries are prepared to pay for our products. In many countries where we plan to market our products, including Europe and Canada, the pricing of prescription drugs is controlled by the government or regulatory agencies. Regulatory agencies in these countries could determine that the pricing for our products should be based on prices of other commercially available drugs for the same disease, rather than allowing us to market our products at a premium as new drugs. Sales of medical products also depend on physicians’ willingness to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost-effective. We cannot predict whether physicians, other healthcare providers, government agencies or private insurers will determine that our products are safe, therapeutically effective and cost effective relative to competing treatments.

 

We may not be able to manufacture our product candidates in clinical or commercial quantities, which would prevent us from commercializing our product candidates.

 

To date, our product candidates have been manufactured in small quantities by us and third party manufacturers for preclinical studies. If any of our product candidates is approved by the FDA or other regulatory agencies for commercial sale, we will need to manufacture it in larger quantities and we intend to use third party manufacturers for commercial quantities. Our third party manufacturers may not be able to successfully increase the manufacturing capacity for any of our product candidates in a timely or efficient manner, or at all. If we are unable to successfully increase the manufacturing capacity for a product candidate, the regulatory approval or commercial launch of that product candidate may be delayed or there may be a shortage in the supply of the product candidate. Our failure or the failure of our third party manufacturers to comply with the FDA’s good manufacturing practices and to pass inspections of the manufacturing facilities by the FDA or other regulatory agencies could seriously harm our business.

 

Our products may not be accepted for reimbursement or properly reimbursed by third-party payers.

 

The successful commercialization of any products we might develop will depend substantially on whether the costs of our products and related treatments are reimbursed at acceptable levels by government authorities, private healthcare insurers, and other third-party payers, such as health maintenance organizations. Reimbursement rates may vary, depending upon the third-party payer, the type of insurance plan, and other similar or dissimilar factors. If our products do not achieve adequate reimbursement, then the number of physician prescriptions of our products may not be sufficient to make our products profitable.

 

Comparative effectiveness research demonstrating benefits of a competitor’s product could adversely affect the sales of our product candidates. If third-party payers do not consider our products to be cost-effective compared to other available therapies, they may not cover our products as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.

 

Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in the product development of that product. In addition, in the U.S. there is a growing emphasis on comparative effectiveness research, both by private payers and by government agencies. To the extent other drugs or therapies are found to be more effective than our products, payers may elect to cover such therapies in lieu of our products or reimburse our products at a lower rate.

 

28
 

 

New federal legislation may increase the pressure to reduce prices of pharmaceutical products paid for by Medicare, which could adversely affect our revenues, if any.

 

The Medicare Prescription Drug Improvement and Modernization Act of 2003, or MMA, expanded Medicare coverage for drug purchases by the elderly and disabled beginning in 2006. The new legislation uses formularies, preferred drug lists and similar mechanisms that may limit the number of drugs that will be covered in any therapeutic class or reduce the reimbursement for some of the drugs in a class. More recently, the Patient Protection and Affordable Care Act of 2010 also contained certain provisions with the potential to affect pricing of pharmaceutical products.

 

As a result of the expansion of legislation, including recent healthcare insurance legislation, and the expansion of federal coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These cost reduction initiatives could decrease the coverage and price that we receive for our products in the future and could seriously harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement systems, and any limits on or reductions in reimbursement that occur in the Medicare program may result in similar limits on or reductions in payments from private payers.

 

Disputes under key agreements or conflicts of interest with our scientific advisors or clinical investigators could delay or prevent development or commercialization of our product candidates.

 

Any agreements we have or may enter into with third parties, such as collaboration, license, formulation supplier, manufacturing, clinical research organization or clinical trial agreements, may give rise to disputes regarding the rights and obligations of the parties. Disagreements could develop over rights to ownership or use of intellectual property, the scope and direction of research and development, the approach for regulatory approvals or commercialization strategy. We intend to conduct research programs in a range of therapeutic areas, but our pursuit of these opportunities could result in conflicts with the other parties to these agreements who may be developing or selling pharmaceuticals or conducting other activities in these same therapeutic areas. Any disputes or commercial conflicts could lead to the termination of our agreements, delay progress of our product development programs, compromise our ability to renew agreements or obtain future agreements, lead to the loss of intellectual property rights or result in costly litigation.

 

We collaborate with outside scientific advisors and collaborators at academic and other institutions that assist us in our research and development efforts. Our scientific advisors are not our employees and may have other commitments that limit their availability to us. If a conflict of interest between their work for us and their work for another entity arises, we may lose their services.

 

Our competitors and potential competitors may develop products and technologies that make ours less attractive or obsolete.

 

Many companies, universities, and research organizations developing competing product candidates have greater resources and significantly greater experience in financial, research and development, manufacturing, marketing, sales, distribution, and technical regulatory matters than we have. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Our competitors could commence and complete clinical testing of their product candidates, obtain regulatory approvals, and begin commercial-scale manufacturing of their products faster than we are able to for our products. They could develop products that would render our product candidates, and those of our collaborators, obsolete and noncompetitive. If we are unable to compete effectively against these companies, then we may not be able to commercialize our product candidates or achieve a competitive position in the market. This would adversely affect our ability to generate revenues.

 

Competition in the biotechnology and pharmaceutical industries may result in competing products, superior marketing of other products and lower revenues or profits for us.

 

There are many companies that are seeking to develop products and therapies for the treatment of mood, anxiety and neurodegenerative disorders. Many of our competitors have substantially greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly greater experience than we do in undertaking preclinical testing and human clinical studies of new pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA approval for superior products.

 

29
 

 

Other risks and uncertainties include:

 

  ● our ability to successfully complete preclinical and clinical development of our products and services
     
  ● our ability to manufacture sufficient amounts of products for development and commercialization activities
     
  ● our ability to obtain, maintain and successfully enforce adequate patent and other proprietary rights protection of our products and services
     
  ● the scope, validity and enforceability of patents and other proprietary rights held by third parties and their impact on our ability to commercialize our products and services
     
  ● the accuracy of our estimates of the size and characteristics of the markets to be addressed by our products and services, including growth projections
     
  ● market acceptance of our products and services
     
  ● our ability to identify new patients for our products and services
     
  ● the accuracy of our information regarding the products and resources of our competitors and potential competitors
     
  ● the content and timing of submissions to and decisions made by the US Food and Drug Administration (FDA) and other regulatory agencies
     
  ● our ability to obtain reimbursement for our products and services from third-party payors, and the extent of such coverage
     
  ● our ability to establish and maintain strategic license, collaboration and distribution arrangements
     
  ● the continued funding of our collaborations and joint ventures, if any are ultimately established
     
  ● the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of operation of our subsidiaries and our customers, suppliers, distributors, couriers, collaborative partners, licensees and clinical trial sites.

 

Positive or timely results from preclinical studies and early clinical trials do not ensure positive or timely results in late-stage clinical trials or product approval by the FDA or any other regulatory authority. Product candidates that show positive preclinical or early clinical results often fail in later stage clinical trials. Data obtained from preclinical and clinical activities is susceptible to varying interpretations, which could delay, limit, or prevent regulatory approvals.

 

We have limited experience in conducting the clinical trials required to obtain regulatory approval. We may not be able to conduct clinical trials at preferred sites, enlist clinical investigators, enroll sufficient numbers of participants, or begin or successfully complete clinical trials in a timely fashion, if at all. Any failure to perform may delay or terminate the trials. Our current clinical trials may be insufficient to demonstrate that our potential products will be active, safe, or effective. Additional clinical trials may be required if clinical trial results are negative or inconclusive, which will require us to incur additional costs and significant delays. If we do not receive the necessary regulatory approvals, we will not be able to generate product revenues and may not become profitable.

 

30
 

 

Risks Related to Our Intellectual Property

 

We may not be able to maintain our exclusive worldwide license to use and develop PT00114 which could materially affect our business plan.

 

On July 21, 2005, we entered into the License Agreement with University of Toronto, or UT, pursuant to which UT agreed to license to us patent rights and other intellectual property related to PT00114, among other things. The Technology License Agreement was amended on February 18, 2015. Unless earlier terminated, the term of this agreement shall terminate on the expiration or invalidity of the last issued Patent in the Agreement

 

Pursuant to the License Agreement, we obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement. In the event we fail to provide UT with semi-annual reports on our progress or fail to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, UT may convert our exclusive license into a non-exclusive one. In such a case, we would lose our competitive advantage in the development of treatments based on PT00114.

 

We have to sustain and further build our intellectual property rights.

 

If we fail to sustain and further build our intellectual property rights, competitors will be able to take advantage of our research and development efforts to develop competing products. If we are not able to protect our proprietary technology, trade secrets, and know-how, our competitors may use our inventions to develop competing products. Protagenic has obtained worldwide exclusive rights to PT00114 and related technology that was developed at UT. As of December 31, 2024, we have four patents issued by the Governments of the United States, Canada, European Union (validated in Germany, France and Great Britain) and Australia on our original platform technology, all of which have expired aside from the one in the United States. The patent applications were made in the name of Dr. David A. Lovejoy and inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement with UT. We have eight issued patents (Canada, Great Britain, Europe (GPC and additionally validated in Switzerland, Great Britain, Ireland and Spain) and the United States and five pending patent applications in related technology that the company has rights in or own.

 

However, our patents and patent applications, even if granted, may not protect us against our competitors. Our patent positions, and those of other pharmaceutical and biotechnology companies, are generally uncertain and involve complex legal, scientific and factual questions. The standards which the United States Patent and Trademark Office uses to grant patents, and the standards which courts use to interpret patents, are not always applied predictably or uniformly and can change, particularly as new technologies develop. Consequently, the level of protection, if any, that will be provided by our patents if we attempt to enforce them, and they are challenged, is uncertain. In addition, the type and extent of patent claims that will be issued to us in the future is uncertain. Any patents that are issued may not contain claims that permit us to stop competitors from using similar technology.

 

In addition to our patentable technology, we also rely on unpatented technology, trade secrets, and confidential information. We may not be able to effectively protect our rights to this technology or information. Other parties may independently develop substantially equivalent information and techniques or otherwise gain access to or disclose our technology. We generally require each of our employees, consultants, collaborators, and certain contractors to execute a confidentiality agreement at the commencement of an employment, consulting, collaborative, or contractual relationship with us. However, these agreements may not provide effective protection of our technology or information or, in the event of unauthorized use or disclosure, they may not provide adequate remedies.

 

Our patent position is generally uncertain and involves complex legal and factual questions. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and other biotechnology companies have encountered significant problems in protecting and defending their proprietary rights in foreign jurisdictions. Whether filed in the United States or abroad, our patent applications may be challenged or may fail to result in issued patents. In addition, any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing or commercializing competing products. Furthermore, others may independently develop or commercialize similar or alternative technologies or drugs, or design around our patents. Our patents may be challenged, invalidated or fail to provide us with any competitive advantages. We may not have the funds available to protect our patents or other technology; such protection is costly and can result in further litigation expenses.

 

31
 

 

If we do not obtain or we are unable to maintain adequate patent or trade secret protection for our products in the United States, competitors could duplicate them without repeating the extensive testing that we will be required to undertake to obtain approval of the products by the FDA. Regardless of any patent protection, under the current statutory framework the FDA is prohibited by law from approving any generic version of any of our products for three years after it has approved our product. Upon the expiration of that period, or if that time period is altered, the FDA could approve a generic version of our product unless we have patent protection sufficient for us to block that generic version. Without sufficient patent protection, the applicant for a generic version of our product would be required only to conduct a relatively inexpensive study to show that its product is bioequivalent to our product and may not have to repeat the studies that we will need to conduct to demonstrate that the product is safe and effective. In the absence of adequate patent protection in other countries, competitors may similarly be able to obtain regulatory approval in those countries of products that duplicate our products.

 

We have to comply with our obligations in our intellectual property licenses with third parties.

 

If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business. We are a party to the License Agreement with UT under which we receive the right to practice and use important third party patent rights. We may enter into additional licenses in the future. Our existing licenses impose, and we expect future licenses will impose, various diligences, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, the licensor may have the right to terminate the license, in which event we might not be able to market any product that is covered by the licensed patents.

 

We may need to resort to litigation to enforce or defend our intellectual property rights, including any patents issued to us. If a competitor or collaborator files a patent application claiming technology also invented by us, in order to protect our rights, we may have to participate in an expensive and time consuming interference proceeding before the United States Patent and Trademark Office. We cannot guarantee that our product candidates will be free of claims by third parties alleging that we have infringed their intellectual property rights. Third parties may assert that we are employing their proprietary technologies without authorization and they may resort to litigation to attempt to enforce their rights. Third parties may have or obtain patents in the future and claim that the use of our technology or any of our product candidates infringes their patents. We may not be able to develop or commercialize combination product candidates because of patent protection others have. Our business will be harmed if we cannot obtain a necessary or desirable license, can obtain such a license only on terms we consider to be unattractive or unacceptable, or if we are unable to redesign our product candidates or processes to avoid actual or potential patent or other intellectual property infringement. Obtaining, protecting and defending patent and other intellectual property rights can be expensive and may require us to incur substantial costs, including the diversion of management and technical personnel. An unfavorable ruling in patent or intellectual property litigation could subject us to significant liabilities to third parties, require us to cease developing, manufacturing or selling the affected products or using the affected processes, require us to license the disputed rights from third parties, or result in awards of substantial damages against us.

 

There can be no assurance that we would prevail in any intellectual property infringement action, will be able to obtain a license to any third party intellectual property on commercially reasonable terms, successfully develop non-infringing alternatives on a timely basis, or license non-infringing alternatives, if any exist, on commercially reasonable terms. Any significant intellectual property impediment to our ability to develop and commercialize our products could seriously harm our business and prospects.

 

Patent litigation or other litigation in connection with our intellectual property rights may lead to publicity that may harm our reputation and the value of our common stock may decline.

 

During the course of any patent litigation, there may be public announcements of the results of hearings, motions, and other interim proceedings or developments in the litigation. If securities analysts or investors regard these announcements as negative, the value of our common stock may decline. General proclamations or statements by key public figures may also have a negative impact on the perceived value of our intellectual property.

 

32
 

 

Protecting and defending against intellectual property claims may have a material adverse effect on our business.

 

From time to time, we may receive notice that others have infringed on our proprietary rights or that we have infringed on the intellectual property rights of others. There can be no assurance that infringement or invalidity claims will not materially adversely affect our business, financial condition or results of operations. Regardless of the validity or the success of the assertion of claims, we could incur significant costs and diversion of resources in protecting or defending against claims, which could have a material adverse effect on our business, financial condition or results of operations. We may not have the funds or resources available to protect our intellectual property.

 

Intellectual property disputes could require us to spend time and money to address such disputes and could limit our intellectual property rights.

 

The biopharmaceutical industry has been characterized by extensive litigation regarding patents and other intellectual property rights, and companies have employed intellectual property litigation and USPTO post-grant proceedings to gain a competitive advantage. We may become subject to infringement claims or litigation arising out of patents and pending applications of our competitors, or additional interference proceedings declared by the USPTO to determine the priority and patentability of inventions. The defense and prosecution of intellectual property suits, USPTO proceedings, and related legal and administrative proceedings are costly and time-consuming to pursue, and their outcome is uncertain. Litigation may be necessary to enforce our issued patents, to protect our trade secrets and know-how, or to determine the enforceability, scope, and validity of the proprietary rights of others. An adverse determination in litigation or USPTO post-grant and interference proceedings to which we may become a party could subject us to significant liabilities, require us to obtain licenses from third parties, or restrict or prevent us from selling our products in certain markets. Even if a given patent or intellectual property dispute were settled through licensing or similar arrangements, our costs associated with such arrangements may be substantial and could include the payment by us of large fixed payments and ongoing royalties. Furthermore, the necessary licenses may not be available on satisfactory terms or at all. Even where we have meritorious claims or defenses, the costs of litigation may prevent us from pursuing these claims or defenses and/or may require extensive financial and personnel resources to pursue these claims or defenses. In addition, it is possible there may be defects of form in our current and future patents that could result in our inability to defend the intended claims. Intellectual property disputes arising from the aforementioned factors, or other factors, may materially harm our business.

 

We may not be able to enforce our intellectual property rights throughout the world.

 

The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S. Companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit.

 

Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market PT00114 or any future products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the U.S. and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our products and technology.

 

33
 

 

Changes to the patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

 

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently implementing wide ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the United States Patent and Trademark Office (“USPTO”), as well as other jurisdictions around the world, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

 

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

 

The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.

 

If we fail to comply with our obligations under any license, collaboration or other intellectual property-related agreements, we may be required to pay damages and could lose intellectual property rights that may be necessary for developing, commercializing and protecting our current or future technologies or drug candidates or we could lose certain rights to grant sublicenses.

 

Any license, collaboration or other intellectual property-related agreements impose, and any future license, collaboration or other intellectual property-related agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license. In spite of our best efforts, any of our future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technologies covered by these license agreements. Any license agreements we enter into may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

 

We may seek to obtain licenses from licensors in the future, however, we may be unable to obtain any such licenses at a reasonable cost or on reasonable terms, if at all. In addition, if any of our future licensors terminate any such license agreements, such license termination could result in our inability to develop, manufacture and sell products that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Any of these events could have a material adverse effect on our competitive position, business, financial condition, results of operations, and ability to achieve profitability.

 

Furthermore, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain, enforce and defend patents we may in-license, or lose rights to licensed patents or patent applications, our license rights may be reduced or eliminated. In such circumstances, our right to develop and commercialize any of our products or drug candidates that is the subject of such licensed rights could be materially adversely affected. In certain circumstances, our licensed patent rights are subject to our reimbursing our licensors for their patent prosecution and maintenance costs.

 

34
 

 

Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor’s intellectual property rights and the amount of any damages or future royalty obligations that would result, if any such claims were successful, would depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, due to such obligations, we may be unable to achieve or maintain profitability.

 

Risks Related to Our Business Operations and Industry

 

If we are not able to retain our current senior management team and our scientific advisors or continue to attract and retain qualified scientific, technical and business personnel, our business will suffer.

 

We are dependent on the members of our management team and our scientific advisors for our business success. An important element of our strategy is to take advantage of the research and development expertise of our current management and to utilize the unique expertise of our scientific advisors. We do not have any employment agreements with our executive officers. The loss of any one of our executive officers or key scientific consultants, including, in particular, Garo Armen, Ph.D., Chairman of the Board, and Dr. David A. Lovejoy, our Chief Scientific Advisor, could result in a significant loss in the knowledge and experience that we, as an organization, possess and could cause significant delays, or outright failure, in the development and further commercialization of our product candidates.

 

To grow, we will eventually need to hire a significant number of qualified commercial, scientific and administrative personnel. However, there is intense competition for human resources, including management in the technical fields in which we operate, and we may not be able to attract and retain qualified personnel necessary for the successful development and commercialization of our product candidates. Our inability to attract new employees or to retain existing employees could limit our growth and harm our business.

 

We may encounter difficulties in managing our growth, which could adversely affect our operations.

 

Our ability to manage our operations and growth effectively depends upon the continual improvement of our procedures, reporting systems, and operational, financial, and management controls. We may not be able to implement improvements in an efficient or timely manner and may discover deficiencies in existing systems and controls. If we do not meet these challenges, we may be unable to take advantage of market opportunities, execute our business strategies or respond to competitive pressures which in turn may slow our growth or give rise to inefficiencies that would increase our losses.

 

We may acquire additional technology and complementary businesses in the future. Acquisitions involve many risks, any one of which could materially harm our business, including the diversion of management’s attention from core business concerns, failure to exploit acquired technologies, or the loss of key employees from either our business or the acquired business.

 

Healthcare reform measures could adversely affect our business.

 

The efforts of governmental and third-party payers to contain or reduce the costs of healthcare may adversely affect the business and financial condition of pharmaceutical companies. In the United States and in foreign jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals aimed at changing the healthcare system. For example, in some countries other than the United States, pricing of prescription drugs is subject to government control, and we expect proposals to implement similar controls in the United States to continue. The pendency or approval of such proposals could result in a decrease in our common stock value or limit our ability to raise capital or to enter into collaborations or license rights to our products.

 

35
 

 

Our business and operations are vulnerable to computer system failures, cyber-attacks or deficiencies in our cyber-security, which could increase our expenses, divert the attention of our management and key personnel away from our business operations and adversely affect our results of operations.

 

Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are to damage from: computer viruses; malware; natural disasters; terrorism; war; telecommunication and electrical failures; cyber-attacks or cyber-intrusions over the Internet; attachments to emails; persons inside our organization; or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, and damage to our reputation, and the further development of our product candidates could be delayed. We could be forced to expend significant resources in response to a cyber security breach, including repairing system damage, increasing cyber security protection costs by deploying additional personnel and protection technologies, paying regulatory fines and resolving legal claims and regulatory actions, all of which would increase our expenses, divert the attention of our management and key personnel away from our business operations and adversely affect our results of operations.

 

Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business.

 

We and our current and any of our future collaborators may be subject to federal, state and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the U.S., numerous federal and state laws and regulations, including federal health information privacy laws (e.g., the Health Insurance Portability and Accountability Act (“HIPAA”), as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”)), state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, as amended by HITECH, or other privacy and data security laws. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.

 

International data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation (“GDPR”) may also apply to health-related and other personal information obtained outside of the U.S. The GDPR went into effect on May 25, 2018. The GDPR introduced new data protection requirements in the EU, as well as potential fines for non-compliant companies of up to the greater of €20 million or 4% of annual global revenue. The regulation imposes numerous new requirements for the collection, use, storage and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information (e.g., the right to access, correct and delete their data). In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Further, the United Kingdom’s vote in favor of exiting the EU, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated.

 

36
 

 

In addition, California recently enacted the California Consumer Privacy Act (“CCPA”), which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA will require covered companies to provide new disclosure to consumers about such companies’ data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with additional causes of action. The CCPA goes into effect on January 1, 2020, and the California Attorney General may bring enforcement actions for violations beginning July 1, 2020. The CCPA was amended on September 23, 2018, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.

 

Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business.

 

If we, our CROs or our IT vendors experience security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of personal data, we may face costs, significant liabilities, harm to our brand and business disruption.

 

In connection with our drug research and development efforts, we or our CROs may collect and use a variety of personal data, such as names, mailing addresses, email addresses, phone numbers and clinical trial information. Although we have extensive measures in place to prevent the sharing and loss of patient data in our clinical trial processes associated with our developed technologies and drug candidates, any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients’ personal data could result in significant liability under state (e.g., state breach notification laws), federal (e.g., HIPAA, as amended by HITECH), and international laws (e.g., the GDPR). Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients’ personal data may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business. We may also rely on third-party IT vendors to host or otherwise process some of our data and that of users, and any failure by such IT vendor to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business.

 

If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.

 

Our research and development and drug candidates and future commercial manufacturing may involve the use of hazardous materials and various chemicals. We currently do not maintain a research laboratory, but we engage third-party research organizations and manufacturers to conduct our preclinical studies, clinical trials and manufacturing. These third-party laboratories and manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We must rely on the third parties’ procedures for storing, handling and disposing of these materials in their facilities to comply with the relevant guidelines of the states in which they operate and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that their safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, this could result in significant delays in our development. We are also subject to numerous environmental, health and workplace safety laws and regulations. Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, this insurance may not provide adequate coverage against potential liabilities. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.

 

37
 

 

Risks Associated to our Common Stock

 

If we fail to comply with the continued minimum closing bid requirements of Nasdaq by April 28, 2025 or other requirements for continued listing, including stockholder equity requirements, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.

 

Our common stock is listed for trading on Nasdaq. We must satisfy Nasdaq’s continued listing requirements, including, among other things, a minimum closing bid price requirement of $1.00 per share for 30 consecutive business days. If a company’s common stock trades for 30 consecutive business days below the $1.00 minimum closing bid price requirement, Nasdaq will send a deficiency notice, advising that such company has been afforded a “compliance period” of 180 calendar days to regain compliance with the applicable requirements. Thereafter, if such a company does not regain compliance with the bid price requirement, a second 180-day compliance period may be available, provided (i) it meets the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on Nasdaq, including stockholder equity requirements, which we may be unable to satisfy (except for the bid price requirement), and (ii) it provides written notice to Nasdaq of its intention to cure this deficiency during the second compliance period by effecting a reverse stock split, if necessary. In the event the company does not regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180 calendar day period, and if it appears to the Staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Nasdaq Staff”) that the company will not be able to cure the deficiency, or if the company is not otherwise eligible, the Nasdaq Staff will provide the company with written notification that its securities are subject to delisting from Nasdaq. At that time, the company may appeal the delisting determination to a hearings panel.

 

On July 24, 2024, the Company received a deficiency letter (the “Notification Letter”) from the Nasdaq Listing Qualifications (“Nasdaq”) stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notification Letter states that the Company has 180 calendar days, or until January 20, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s closing bid price of the Company’s common stock must have a closing bid price of at least $1.00 for a minimum of ten consecutive business days.

  

On January 22, 2025, Nasdaq provided a notice to the Company that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as the Company does not comply with the requirements for initial listing on The Nasdaq Capital Market. This notification is part of the ongoing discussions with the Nasdaq Hearings Panel (the “Panel”) regarding the Company’s listing status, and the Company included this matter in its presentation to the Panel on January 30, 2025.   

 

On February 19, 2025, the Company received a hearing panel decision from Nasdaq (Nasdaq Listing Qualifications Hearings Docket No. NQ 7072C-25) indicating that its provisional plan for regaining compliance with the Nasdaq listing requirements had been accepted. For continued listing on the Nasdaq Capital Market, the Company has until April 28, 2025 to: (1) demonstrate compliance with Nasdaq Rules 5550(a)(2) and 5550(b)(2), (2) file a public disclosure describing any transactions undertaken by the Company to increase its equity and provide and indication of its equity following those transactions, and (3) provide the Panel with an update on its fundraising plans and updated income projections for the next 12 months.

 

If we fail to comply with the continued minimum closing bid requirements of Nasdaq or other requirements for continued listing, including stockholder equity requirements, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.

 

Our common stock is a “Penny Stock” subject to specific rules governing its sale to investors that could impact its liquidity.

 

The SEC has adopted Rule 15g-9 which establishes the definition of a “penny stock,” for the purposes relevant to our common stock, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require that a broker or dealer approve a person’s account for transactions in penny stocks; and the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

 

In order to approve a person’s account for transactions in penny stocks, the broker or dealer must obtain financial information and investment experience objectives of the person; and make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

 

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form sets forth the basis on which the broker or dealer made the suitability determination, and states that the broker or dealer received a signed, written agreement from the investor prior to the transaction.

 

Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors sell shares of our common stock.

 

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

 

The market price of our common stock may be volatile, and you could lose all or part of your investment.

 

The market price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control.

 

The market price of our common stock may fluctuate substantially and will depend on a number of factors many of which are beyond our control and may not be related to our operating performance. These fluctuations could cause you to lose all or part of your investment in our common stock since you might be unable to sell your shares at or above the price you pay for the shares. Factors that could cause fluctuations in the market price of our common stock include, but are not necessarily limited to, the following:

 

  ● price and volume fluctuations in the overall stock market from time to time;
  ● volatility in the market prices and trading volumes of pharmaceutical and biotechnology stocks;
  ● changes in operating performance and stock market valuations of other pharmaceutical and biotechnology companies generally, or those in our industry in particular;
  ● sales of shares of our common stock by us or our stockholders;
  ● failure of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow our company, or our failure to meet these estimates or the expectations of investors;
  ● the financial projections we may provide to the public, any changes in those projections or our failure to meet those projections;
  ● announcements by us or our competitors of new products or services;
  ● the public’s reaction to our press releases, other public announcements and filings with the SEC;
  ● rumors and market speculation involving us or other companies in our industry;
  ● actual or anticipated changes in our operating results or fluctuations in our operating results;
  ● actual or anticipated developments in our business, our competitors’ businesses or the competitive landscape generally;
  ● litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;

 

38
 

 

  ● developments or disputes concerning our intellectual property or other proprietary rights;
  ● announced or completed acquisitions of businesses or technologies by us or our competitors;
  ● new laws or regulations or new interpretations of existing laws or regulations applicable to our business;
  ● changes in accounting standards, policies, guidelines, interpretations or principles;
  ● any significant change in our management; and
  ● general economic conditions and slow or negative growth of our markets.

 

In addition, in the past, following periods of volatility in the overall market and the market price of a particular company’s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.

 

Compliance with the reporting requirements of federal securities laws can be expensive.

 

We are a public reporting company in the United States, and accordingly, subject to the information and reporting requirements of the Exchange Act and other federal securities laws, and certain compliance obligations of the Sarbanes-Oxley Act. The costs of preparing and filing annual and quarterly reports and other information with the SEC and furnishing audited reports to stockholders are substantial.

 

Applicable regulatory requirements, including those contained in and issued under the Sarbanes-Oxley Act of 2002, may make it difficult for us to retain or attract qualified officers and directors, which could adversely affect the management of its business and its ability to obtain or retain listing of our common stock.

 

We may be unable to attract and retain those qualified officers, directors and members of board committees required to provide for effective management because of the rules and regulations that govern publicly held companies, including, but not limited to, certifications by principal executive officers. The enactment of the Sarbanes-Oxley Act has resulted in the issuance of a series of related rules and regulations and the strengthening of existing rules and regulations by the SEC, as well as the adoption of new and more stringent rules by the stock exchanges. The perceived increased personal risk associated with these changes may deter qualified individuals from accepting roles as directors and executive officers.

 

Further, some of these changes heighten the requirements for board or committee membership, particularly with respect to an individual’s independence from the corporation and level of experience in finance and accounting matters. We may have difficulty attracting and retaining directors with the requisite qualifications. If we are unable to attract and retain qualified officers and directors, the management of our business and our ability to obtain or retain listing of our shares of common stock on any stock exchange (assuming we elect to seek and are successful in obtaining such listing) could be adversely affected.

 

If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or detect fraud. Consequently, investors could lose confidence in our financial reporting and this may decrease the trading price of our stock.

 

We must maintain effective internal controls to provide reliable financial reports and detect fraud. We have been assessing our internal controls to identify areas that need improvement and will continue to monitor internal controls to improve them. Failure to implement these changes to our internal controls or any others that it identifies as necessary to maintain an effective system of internal controls could harm our operating results and cause investors to lose confidence in our reported financial information. Any such loss of confidence would have a negative effect on the trading price of our stock.

 

Management has concluded that, during the year-ended December 31, 2024, our internal controls and procedures were not effective to detect the inappropriate application of U.S. GAAP. Management identified the following material weaknesses set forth below in our internal control over financial reporting.

 

  1. We lack the necessary corporate accounting resources to maintain adequate segregation of duties; and
  2. We did not perform an effective risk assessment or monitor internal controls over financial reporting.

 

39
 

 

The price of our common stock may become volatile, which could lead to losses by investors and costly securities litigation.

 

The trading price of our common stock is likely to be highly volatile and could fluctuate in response to factors such as:

 

  ● actual or anticipated variations in our operating results;
  ● announcements of developments by us or our competitors;
  ● the timing of IDE and/or NDA approval, the completion and/or results of our clinical trials;
  ● regulatory actions regarding our products;
  ● announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
  ● adoption of new accounting standards affecting our industry;
  ● additions or departures of key personnel;
  ● introduction of new products by us or our competitors;
  ● sales of our common stock or other securities in the open market; and
  ● other events or factors, many of which are beyond our control.

 

The stock market is subject to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been initiated against such a company. Litigation initiated against us, whether or not successful, could result in substantial costs and diversion of our management’s attention and resources, which could harm our business and financial condition.

 

Investors may experience dilution of their ownership interests because of the future issuance of additional shares of our common stock.

 

In the future, we may issue additional authorized but previously unissued equity securities, resulting in the dilution of the ownership interests of our present stockholders. We may also issue additional shares of our common stock or other securities that are convertible into or exercisable for our common stock in connection with hiring or retaining employees, future acquisitions, future sales of our securities for capital raising purposes, or for other business purposes and some of these issuances may be at a price (or exercise prices) below the price at which shares of our common stock is currently quoted on the NASDAQ Capital Market. The future issuance of any such additional shares of common stock may create downward pressure on the trading price of our common stock.

 

Our common stock is controlled by insiders

 

Our officers and directors beneficially own approximately 35% of our outstanding shares of common stock. Such concentrated control of our common stock may adversely affect the price of our common stock. Investors who acquire our common stock may have no effective voice in the management of our operations. Sales by our insiders or affiliates, along with any other market transactions, could affect the market price of our common stock.

 

We do not intend to pay dividends for the foreseeable future and may never pay dividends.

 

We have paid no dividends on our common stock to date and it is not anticipated that any dividends will be paid to holders of our common stock in the foreseeable future. While our future dividend policy will be based on the operating results and capital needs of our business, it is currently anticipated that any earnings will be retained to finance our future expansion and for the implementation of our business plan. As an investor, you should take note of the fact that a lack of a dividend can further affect the market value of our stock, and could significantly affect the value of any investment.

 

There can be no assurance that we will ever provide liquidity to our investors through a sale of our Company.

 

While acquisitions of pharmaceutical companies like ours are not uncommon, potential investors are cautioned that no assurances can be given that any form of merger, combination, or sale of our Company will take place or that any merger, combination, or sale, even if consummated, would provide liquidity or a profit for our investors. You should not invest in our Company with the expectation that we will be able to sell the business in order to provide liquidity or a profit for our investors.

 

40
 

 

Our certificate of incorporation allows for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our common stock.

 

Our board of directors has the authority to issue shares of our preferred stock, with such relative rights and preferences as the board of directors may determine, without further stockholder approval. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders special and unique rights, including without limitation, a preferred right to our assets upon liquidation, a right to receive dividend payments before dividends are distributed to the holders of common stock and the right to convert into our common stock at a price more favorable then the price at which you acquired our common stock. The issuance of any preferred stock could decrease the value of your common stock and relative voting power of our common stock or result in dilution to our existing stockholders.

 

In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of the voting rights on our common stock, from engaging in certain business combinations with us for a prescribed period of time.

 

Item 1B. Unresolved Staff Comments.

 

Not applicable.

 

Item 1C. Cybersecurity.

 

Risk Management and Strategy

 

We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. We design and assess our program based on ISO 27002 standards. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the ISO 27002 as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business. We engage external resources that contribute to, and provide independent evaluation of, our existing cybersecurity practices and organizational risk assessment systems. We use established processes designed to identify, assess, and manage third-party service provider risks when third parties handle, possess, process, and store the Company’s material information. Our cybersecurity risk management program includes (i) a policy designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment; (ii) the use of external service providers to manage, assess, test and otherwise assist with aspects of our security controls; and (iii) a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents. We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. However, there can be no assurance that our cybersecurity prevention and mitigation efforts will always be successful, and it is possible that cybersecurity threats could have a material adverse effect on our business, operations, or financial condition in the future.

 

Governance

 

Our board of directors administers its cybersecurity risk oversight function through its audit committee. The audit committee is responsible for overseeing our policies, practices and assessments with respect to cybersecurity, and provides periodic updates to our board of directors. The audit committee receives periodic updates from management and our external third party information technology consultant regarding the effectiveness of the systems and processes we have implemented designed to safeguard our information assets and operational integrity from cyber threats, protect employee information from unauthorized access or attack, as well as secure our networks and systems, and regarding other cybersecurity matters, including the results from cybersecurity systems testing and any recent cybersecurity incidents and related responses. Our audit committee is also notified between such updates as soon as practicable regarding significant new cybersecurity threats or incidents. The audit committee also receives a report on cybersecurity matters and related risk exposures periodically from our Chief Financial Officer.

 

Item 2. Properties.

 

The Company does not currently own any real property. The Company leases office space for its principal executive office located at 149 Fifth Avenue, Suite 500, New York, New York 10010.

 

Item 3. Legal Proceedings.

 

From time to time we may be named in claims arising in the ordinary course of business. As of December 31, 2024, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business, financial condition, and results of operations.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

41
 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market Information

 

Our common stock is currently available for trading in the over-the-counter market and is quoted on the Nasdaq Capital Market under the symbol “PTIX.” There has been very limited market for our common stock and trading volume has been negligible. There is no guarantee that an active trading market will develop in our common stock. The following table sets forth, for the periods indicated and as reported on the Nasdaq Capital Market, the high and low bid prices for our common stock. Such quotations reflect inter-dealer prices, without retail mark-up, markdown or commission and may not necessarily represent actual transactions.

 

   High   Low 
         
2023(1)          
First Quarter (1)  $2.36   $1.38 
Second Quarter (1)  $2.21   $1.67 
Third Quarter (1)  $2.19   $1.74 
Fourth Quarter (1)  $1.79   $0.74 
           
2024(1)          
First Quarter (1)  $1.82   $0.76 
Second Quarter (1)  $1.80   $0.90 
Third Quarter (1)  $1.03   $0.53 
Fourth Quarter (1)  $0.80   $0.47 

 

(1) The high and low bid prices for this quarter were reported by the Nasdaq Capital Market.

 

Holders

 

As of April 1, 2025, there are approximately 3,000 record holders of our common stock and zero holders of our Series B Preferred Stock.

 

Dividend Policy

 

We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant.

 

Reverse Stock Split

 

On March 22, 2023, the Company effectuated a 1 for 4 reverse stock split (the “Reverse Split”). The Company’s stock began trading on a split-adjusted basis effective on the Nasdaq Stock Market on March 22, 2023. There was no change to the number of authorized shares of the Company’s common stock. All share and per share information in these financial statements are adjusted to reflect the Reverse Split.

 

Recent Sales of Unregistered Securities

 

None

 

Item 6. [Reserved]

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included at the end of this report. This discussion and other parts of this report contain forward-looking statements that involve risks and uncertainties such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the “Risk factors” section of this report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

 

42
 

 

The discussion and analysis of our financial condition and results of operations are based on Protagenic’s financial statements, which Protagenic has prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires Protagenic to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, Protagenic evaluates such estimates and judgments, including those described in greater detail below. Protagenic bases its estimates on historical experience and on various other factors that Protagenic believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

We expect to continue to incur significant expenses and minimal positive net cash flows from operations or negative net cash flows from operations for the foreseeable future, and those expenses and losses may fluctuate significantly from quarter-to-quarter and year-to-year. We anticipate that our expenses will fluctuate substantially as we:

 

  ● continue our ongoing preclinical studies, clinical trials and our product development activities for our pipeline of product candidates;
     
  ● seek regulatory approvals for any product candidates that successfully complete clinical trials;
     
  ● continue research and preclinical development and initiate clinical trials of our other product candidates;
     
  ● seek to discover and develop additional product candidates either internally or in partnership with other pharmaceutical companies;
     
  ● adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products;
     
  ● maintain, expand and protect our intellectual property portfolio; and
     
  ● incur additional legal, accounting and other expenses in operating as a public company.

 

Recent Events

 

Nasdaq Hearings Panel

 

On July 24, 2024, the Company received a deficiency letter (the “Notification Letter”) from the Nasdaq Listing Qualifications (“Nasdaq”) stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notification Letter states that the Company has 180 calendar days, or until January 20, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s closing bid price of the Company’s common stock must have a closing bid price of at least $1.00 for a minimum of ten consecutive business days.

  

On January 22, 2025, Nasdaq provided a notice to the Company that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as the Company does not comply with the requirements for initial listing on The Nasdaq Capital Market. This notification is part of the ongoing discussions with the Nasdaq Hearings Panel (the “Panel”) regarding the Company’s listing status, and the Company included this matter in its presentation to the Panel on January 30, 2025.   

 

On February 19, 2025, the Company received a hearing panel decision from Nasdaq (Nasdaq Listing Qualifications Hearings Docket No. NQ 7072C-25) indicating that its provisional plan for regaining compliance with the Nasdaq listing requirements had been accepted. For continued listing on the Nasdaq Capital Market, the Company has until April 28, 2025 to: (1) demonstrate compliance with Nasdaq Rules 5550(a)(2) and 5550(b)(2), (2) file a public disclosure describing any transactions undertaken by the Company to increase its equity and provide and indication of its equity following those transactions, and (3) provide the Panel with an update on its fundraising plans and updated income projections for the next 12 months.

 

Results of Operations

 

We are a development stage company currently performing clinical trials to obtain Food and Drug Administration (“FDA”) approval and commercialization of our product.

 

During the year ended December 31, 2024, we incurred a loss from operations of $5,700,950 as compared to $4,526,974 for the year ended December 31, 2023. The increase in the loss is due to an increase in research and development expense of $781,381 from $3,063,603 for the year ended December 31, 2023 to $3,844,984 for the year ended December 31, 2024, and an increase in general and administrative expenses of $551,502 from $1,207,107 for the year ended December 31, 2023 to $1,758,609 for the year ended December 31, 2024 offset by a decrease in research and development expenses from related parties of $158,907 from $256,264 for the year ended December 31, 2023 to $97,357 for the year ended December 31, 2024. The increase in research and development expense is due to additional cost related to the Company’s continued research and development efforts. The increase in general and administrative expenses was due to increased stock compensation expense in the current year.

 

Liquidity and Capital Resources

 

Since our inception, we have incurred significant operating losses. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all. To date, we have primarily financed our operations through the public offering of our equity securities and the private placement of our convertible securities.

 

43
 

 

In June 2024, the SEC declared effective a shelf registration statement filed by us. This shelf registration statement allows us to issue any combination of our common stock, preferred stock, debt securities, warrants, or units from time to time for an aggregate initial offering price of up to $100.0 million. In July 2021, we entered into an At Market Issuance Agreement, or the ATM Agreement, with B. Riley Securities, Inc. and EF Hutton, division of Benchmark Investments, LLC, or the Sales Agents, under which we may issue and sell from time to time up to $10.0 million of our common stock through or to the Sales Agents, as agent or principal. Any sale of shares of our common stock under the Sales Agreement will be made under our shelf registration statement on Form S-3. Sales of our common stock under the Sales Agreement are made at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. The Company has sold approximately 800,000 shares under the ATM Agreement. Also, as the price of our stock has declined, the value of stock that can be sold under the ATM facility has declined. As of December 31, 2024, approximately $0.2 million of our common stock remained available for sale under the Sales Agreement.  

 

Operating activities used $4,216,517 and $3,703,776 in cash for the years ended December 31, 2024 and 2023, respectively. The use of cash in operating activities during the year ended December 31, 2024, primarily comprised of $5,525,344 net loss, $923,139 in stock compensation expense, a decrease in prepaid expenses and other current assets of $99,627, and a $463,127 increase of accounts payable and accrued expenses, which included payments to legal and accounting professionals, payments to consultants, and other administrative expenses.

 

Investing activities provided $2,802,880 and $4,775,482 by cash for the years ended December 31, 2024 and 2023, respectively. The cash provided by investing activities during the year ended December 31, 2024 consisted of $3,100,000 from the sale of marketable securities and partly offset by $297,120 in the purchase of marketable securities.

 

Financing activities provided $1,963,546 and $0 by cash for the years ended December 31, 2024 and 2023, respectively. The cash provided by financing activities during the year ended December 31, 2024 consisted of $1,963,546 from the issuance of shares and warrants for cash.

 

We continually project anticipated cash requirements, predominantly from the ongoing funding requirements of our neuropeptide drug development program. The majority of these expenses relate to paying external vendors such as Contract Research Organizations (CROs) and peptide synthesizer companies. They could also include business combinations, capital expenditures, and new drug development working capital requirements. As of December 31, 2024, we had cash of $1,838,469 and working capital of $940,108.

 

We anticipate that losses will continue for the foreseeable future. Based on our current operating plans, we believe that our cash resources will be sufficient to fund its operations until approximately the end of the third quarter of 2025. In order to continue our operations beyond our forecasted runway we will need to raise additional capital, and we have no committed sources of additional capital at this time. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of our expenses could vary materially and adversely as a result of a number of factors. We have based our estimates on assumptions that may prove to be wrong, and our expenses could prove to be significantly higher than we currently anticipate. Management does not know whether additional financing will be on terms favorable or acceptable to us when needed, if at all. If adequate additional funds are not available when required, or if we are unsuccessful in entering into partnership agreements for further development of our product candidates, management may need to curtail its development efforts and planned operations.

 

Plan of Operations

 

Business Overview

 

The Company is in its developmental stage, with encouraging but not conclusive evidence that its lead drug candidate, PT00014, may be effective as an anti-anxiety and/or anti-depression drug. It is focused on confirming the efficacy of this drug candidate, along with performing the other preclinical steps needed to progress along the pathway to bring this drug candidate into human clinical trials and eventually, to the global market to provide a new pharmaceutical for patients suffering from anxiety or treatment-resistant depression.

 

44
 

 

If we are able to successfully develop our drug, PT00114, and obtain FDA approval, we could then begin marketing and selling it in the United States and generate revenue. FDA approval to begin commercial sales is the singular gating item that will allow us to begin generating sales revenue in the U.S., so it will have an enormous impact on our business plan and our financial condition. It is anticipated that the sale of our drug will allow the Company to generate enough sales revenue to support all of our operations and to generate a profit. However, given the stage of development, even if FDA Approval is obtained, we do not anticipate generating any revenue from sales prior to 2027. On May 22, 2024, we announced the results of the single dose portion of the Phase I study for PT00114.

 

Development Milestones Currently Anticipated

 

Recent communications with the U.S. FDA have resulted in following revised guidance for clinical timelines.

 

  ● The Company in the process of refiling its IND application for PT00114 addressing the questions raised by regulators.
     
  ● Anticipate Q2 2025 Commence multiple dose portion of Phase I study for PT00114
     
  ● Anticipate Q2 2025 Public availability of results from multiple dose portion of Phase I study for PT00114
     
  ● Anticipate Q3 2025 : Initiation of Phase IIa study for PT00114

 

Human Resources (current state of employees)

 

The Company has two part-time employees: Garo H. Armen, PhD, the Executive Chairman, and Alexander K. Arrow, MD, the Chief Financial Officer, and one full-time employee, Lauren Mueller, PhD, a Senior Research Scientist. The Company also has six paid consultants: Andrew Slee, PhD, Chief Operating Officer, Robert S. Stein, MD, PhD, Chief Medical Officer, Dalia Barsyte, PhD, Scientific Advisor, David Lovejoy, PhD, Scientific Advisor, and Zack Armen, Strategic Advisor.

 

Off Balance Sheet Arrangements

 

We have no material off-balance sheet arrangements that are likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital resources, or capital expenditures.

 

Critical accounting policies and estimates

 

Our discussion and analysis of financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The notes to the consolidated financial statements contained in this Annual Report describe our accounting policies used in the preparation of the consolidated financial statements.    None of those policies are deemed to be critical accounting policies nor critical accounting estimates. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We continually evaluate our critical accounting policies and estimates.

 

Recently Issued Accounting Pronouncements

 

None

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 8. Financial Statements and Supplementary Data.

 

See pages F-1 through F-20 following the Exhibit Index of this Annual Report on Form 10-K.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None.

 

45
 

 

Item 9A. Controls and Procedures.

 

Assessment of the Effectiveness of Internal Controls over Financial Reporting

 

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework published in 2013. Based on its evaluation, our management concluded that our internal control over financial reporting was not effective as of the end of the period covered by this Annual Report on Form 10-K.

 

(a) Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Internal control over financial reporting includes those policies and procedures that:

 

(i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

 

(ii) provide reasonable assurance that the transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with the authorization of management and/or our Board of Directors; and

 

(iii) provide reasonable assurance regarding the prevention or timely detection of any unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

 

Due to its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate due to changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

As of December 31, 2024, management has completed a proper evaluation, risk assessment and monitoring of the Company’s internal controls over financial reporting based on the 2013 Committee of Sponsoring Organizations (COSO) framework. Management concluded that, during the period covered by this report, our internal controls and procedures were not effective to detect the inappropriate application of GAAP. Management identified the following material weaknesses and concluded that the internal controls over financial reporting were not effective.

 

  1. We lack the necessary corporate accounting resources to maintain adequate segregation of duties. We currently rely heavily on our Executive Chairman, for almost every key financial duty and he has access to materially all of our financial information. Such a lack of segregation of duties is typical in a company with limited resources. Although the Company’s Executive Chairman and Board of Directors review the financial statements and would most likely discover any misappropriation of funds, this cannot be assured by the existing system.
     
  2. Limited level of multiple reviews in connection with the financial reporting process.

 

This annual report does not include an attestation report by our independent registered public accounting firm regarding internal control over financial reporting. As we are neither a large accelerated filer nor an accelerated filer, our management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit us to provide only management’s report in this annual report.

 

46
 

 

(b) Evaluation of Disclosure Controls and Procedures

 

Pursuant to Rule 13a–15(b) under the Exchange Act, the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Board of Directors, the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a–15(e) under the Exchange Act) as of the end of the period covered by this Report. Based upon that evaluation, the Company’s management concluded that the Company’s disclosure controls and procedures were not effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management to allow timely decisions regarding required disclosure due to the following:

 

  1. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.
     
  2. Limited level of multiple reviews among those tasked with preparing the financial statements.

 

During the quarter ended December 31, 2024, the Company analyzed and documented   accounting policies and procedures. In addition, management implemented certain policies and procedures but concluded that material weaknesses still exist and that such controls are not effective under the COSO framework. These material weaknesses could result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.

 

Remediation Plan

 

To address the material weakness described above, we have engaged an independent third party to enhance our segregation of duties.

 

Since we remain a small Company, with limited segregation of duties, the third party has identified certain areas where we can layer in added controls and procedures. Management intends to implement such controls and procedures in the future.

 

Limitations on the Effectiveness of Controls. Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected.

 

(c) Changes in Internal Control over Financial Reporting

 

Other than as discussed above, there were no changes in our internal controls over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the quarter ended December 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information.

 

None

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

 

[Not applicable].

 

47
 

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance.

 

Executive Officers and Directors

 

The following sets forth certain information with respect to our executive officers and directors.

 

Name   Age   Position(s)
Garo H. Armen   72   Executive Chairman of the Board of Directors
Alexander K. Arrow   54   Chief Financial Officer
Robert B. Stein   74   Director, Chief Medical Officer
Andrew Slee   75   Chief Operating Officer
Khalil Barrage   60   Director
Timothy Wright   67   Director
Brian Corvese   67   Director
Jennifer Buell   50   Director

 

Garo H. Armen, PhD, Executive Chairman, is one of our founders and joined us in September 2004. Dr. Armen is Chairman and Chief Executive Officer of Agenus Inc., a biotechnology company he co-founded in 1994. From mid-2002 through 2004, he also served as Chairman of the Board of directors of the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Prior to Agenus Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies, and was the architect of the widely publicized creation of the Immunex Lederle oncology business in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and sustainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY.

 

Alexander K. Arrow, M.D., CFA, Chief Financial Officer. Dr. Arrow became our Chief Financial Officer in February 2016. Dr. Arrow is the Chief Executive Officer of Corramedical, Inc., a medical device manufacturer whose mission is to provide physicians with the tools needed to make use of all the cellular resources they extract from their patients. He was previously the CFO of Carlsmed, Inc., a spinal implant manufacturer providing 3-D printed personalized spinal implants to spine surgeons. He serves on the Board of Directors of Insightful Instruments, Inc., a developmental stage ophthalmology tool company. He previously served on the Boards of Paragonix Technologies, which developed and sold the leading solid organ transportation device and was acquired in September 2024 by Getinge AB for $469 million, and Neumedicines, Inc., a company developing protein therapeutics in Oncology, Hematology and Immunology, and as a director and as Chairman of the Audit and Compensation Committees of Biolase, Inc. (NASDAQ: BIOL) from 2010 through 2014, as well as the President and Chief Operating Officer. Biolase, Inc. was the leading manufacturer of dental lasers. Before Biolase, he was the Chief Medical and Strategic Officer of Circuit Therapeutics, Inc., in the field of optogenetics. From 2007 through 2012, Dr. Arrow was the Chief Financial Officer of Arstasis, Inc., a cardiology device manufacturer. From 2002 to 2007, he headed medical technology equity research at the global investment bank Lazard Capital markets, LLC. Dr. Arrow spent two years 1999-2001 as Chief Financial Officer of the Patent & License Exchange, and three years as the life sciences research analyst at Wedbush Morgan Securities. He received his CFA in 1999. He was awarded an M.D. from Harvard Medical School in 1996 and a B.A. in Biophysics, magna cum laude, from Cornell University in 1992.

 

48
 

 

Robert B. Stein, MD, PhD., Director, Chief Medical Officer, joined us effective the closing of the Merger in February, 2016. Dr. Robert B. Stein retired as President of R&D at Agenus Inc. in April 2017. He continues as Senior Advisor, R&D for both Agenus, Inc. and its cell therapy partially-owned subsidiary MiNK Therapeutics (Nasdaq: INKT). Dr. Robert B. Stein lead Agenus’ Research, Preclinical Development and Translational Medicine functions. He helps shape clinical development strategy for vaccines and adjuvants. Additionally, he lead integration of the 4-Antibody, PhosImmune, and Xoma Pilot Plant acquisitions, which includes the company’s fully human antibody drug discovery and optimization technology platform, and portfolio of immune checkpoint antibody programs. Over his 35 years of experience in the biopharmaceutical industry he played a pivotal role in bringing to the market Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta® and Eliquis®. Prior to joining Agenus, he held executive management positions at Ligand Pharmaceuticals, DuPont Merck, Incyte Pharmaceuticals, Roche Palo Alto and KineMed. Dr. Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology & Pharmacology from Duke University. Dr. Stein filed a personal voluntary bankruptcy petition under Chapter 7 in August of 2012 and the bankruptcy was discharged in May 2013.

 

Andrew Slee, PhD, Chief Operating Officer. Dr. Andy Slee joined us in April 2016. During his 37-year pharmaceutical career, Mr. Slee has taken several drugs from inception through all their pre-clinical and early clinical testing. During the past 37 years, he has worked for Preclinical CROs, immune-oncology companies and natural product companies focusing on anti-infectives, cancer, CNS, diabetes and inflammatory diseases. Spreading his influence beyond a single company, he created and ran his own Contract Research Organization (CRO), VivoSource Laboratories, which for ten years from 2003 to 2013 provided preclinical proof of concept catering to biopharmaceutical companies. For the 18 years before that, Mr. Slee shepherded multiple pharma targets in several therapeutic areas from inception onward at DuPont Pharmaceuticals. He is a graduate of Syracuse University and Leeds University.

 

Khalil Barrage, Director, joined us in July, 2007. Mr. Khalil Barrage has served as a Managing Director of The Invus Group, LLC since 2003, in charge of the Public Equities Group that he set up in September 2003. Invus manages over $3B of capital, with a primary focus is on private equity investments, biotechnology and health care. In addition, Invus manages a fund-of-funds liquid alternative investment and, most recently, the newly established public equities portfolio activity. Mr. Barrage is a value investor. He started his career in 1988 with The Olayan Group, a multibillion private group. He was in charge of the group’s US public equities portfolio, overseeing more than $2 billion of assets. Mr. Barrage holds a BA from American University of Beirut.

 

Brian J. Corvese, Director, joined us on July 28, 2017, filling the open board seat vacated by Gregory H. Ekizian. Since 1999, Mr. Corvese has been the President and Founder of Vencor Capital (“Vencor”), a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to working at Vencor, Mr. Corvese worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management (“Chancellor”), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert (“Drexel”) as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the board of directors of Agenus Inc. and the National Telecommunications Corporation, based in Cairo, Egypt. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School. With over 30 years of experience in the financial industry, Mr. Corvese brings substantial financial expertise to our Board.

 

Timothy Wright, Director, joined us on November 23, 2022, filling the open board seat vacated by Joshua Silverman. Mr. Wright was the Chief Executive Officer of MiMedX Group, Inc., a position he held from May 2019 through September 2022. MiMedX is an advanced wound care and emerging therapeutic biologics company. He is currently the senior advisor to the Wake Forest Institute of Regenerative Medicine and a Director of BIORG , a human organoid development company. Mr. Wright also currently serves on the board of directors of Agenus Inc., which he has served on since 2006. Mr. Wright also serves as a Partner at Signal Hill Advisors, LLC, a position he has held since February 2011. In addition, Mr. Wright serves as Chairman of The Ohio State University Comprehensive Cancer Center Drug Development Institute and Director of the Ohio State University Innovation Foundation. Mr. Wright previously held several executive roles at Covidien (now Medtronic), Teva Pharmaceuticals Industries Ltd., DuPont Merck, Elan Bio-Pharmaceuticals, M2Gen Corp. and Curaxis Pharmaceuticals Corporation. As our Lead Director, Mr. Wright brings 32 years of experience on boards of companies in North America, Europe, Asia and Japan.

 

Jennifer Buell, PhD, Director, joined our board in July 2020. Dr. Buell is the President and Chief Operating Officer of Agenus, Inc., where she has previously served as served as the Head of Global R&D operations, Head of Research, and Chief Communications and External Affairs Officer. She is also the president of Agenus’ cell therapy partially-owned subsidiary MiNK Therapeutics, Inc, (Nasdaq: INKT). With 20 years of biopharmaceutical R&D experience, Dr. Buell has extensive knowledge in advancing discovery candidates through development and experience communicating with external stakeholders including regulators, investors, and collaborators. She has a proven record of success in R&D leadership, most recently at Agenus, where she led high performing teams in advancing candidates into the clinic and delivered on key alliance collaborations. Prior to joining Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and later was responsible for Program and Alliance Management at Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government sponsored clinical programs. Dr. Buell obtained her PhD in Cellular, Biochemical, and Molecular Biochemistry with an MS in Biostatistics from Tufts University in Boston.

 

49
 

 

Consultants and Advisors

 

David A. Lovejoy, PhD, Scientific Advisor, is one of our founders and joined us in September 2004. He holds a PhD in Neuroendocrinology from the University of Victoria (Victoria, BC) and spent three years at the Clayton Foundation Laboratories for Peptide Biology at the Salk Institute (San Diego, CA) as a postdoctoral fellow. Dr. Lovejoy took his first academic appointment at the University of Manchester (Manchester, UK), one of the United Kingdom’s top-ranking research universities. He joined the University of Toronto (Toronto, Ontario) in 2000 and is currently Professor of Neuroendocrinology in the Department of Cell and Systems Biology at the University of Toronto. He is the author of more than 210 scientific publications including three books in the field and an Associate Editor for a scientific journal and is inventor or co-inventor on all of our intellectual property.

 

Dalia Barsyte PhD, Scientific Advisor. Dr. Dalia Barsyte received her PhD in molecular and cellular biology from the University of Manchester, UK. She did the postdoctoral training at the University of Manchester and Ontario Cancer Institute, and currently is a scientist at the University of Toronto, Structural Genomics Consortium, where she has been employed since 2009. Dr. Barsyte is an inventor on one of the key Protagenic patents and author of over 50 scientific publications in oncology and neuroscience. Dr. Barsyte’s scientific interests include exploring chemical biology in therapeutic target validation through peptide or small molecule chemical probe compounds as well as novel in vitro models of disease based on patient derived cell culture.

 

Zack Armen, Strategic Advisor. Mr. Armen became involved with Protagenic in Fall 2018, and brings experience in strategic finance and life sciences venture investing to the company through roles at Goldman Sachs, Flagship Pioneering, CiBO Technologies, and his current role as Director of Corporate Development at Valo Health.

 

Mark Berg, Strategic Consultant. Mr. Berg became a strategic consultant to Protagenic in January 2022. He brings several decades of perspective regarding publicly-traded biotechnology companies’ perceptions by investors.

 

Director Independence

 

Each of Messrs. Corvese, Wright, and Barrage are “independent” members of our board of directors as “independence” is defined in Nasdaq Marketplace Rule 5605(a)(2).

 

Family Relationships

 

There are no family relationships between or among the directors, executive officers or persons nominated or chosen by our stockholders or us to become directors or executive officers. There is one family relationship between Strategic Advisor Zack Armen and our Executive Chairman, Garo Armen (Garo Armen is Zack Armen’s father).

 

50
 

 

Involvement in Certain Legal Proceedings

 

To our knowledge, during the past ten years, none of our directors, executive officers, promoters, control persons, or nominees has:

 

been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);

 

except as set forth above with respect to Dr. Stein, had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time; been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;

 

been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

 

been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

Code of Business Conduct and Ethics

 

On February 24, 2017, we adopted a written Code of Business Conduct and Ethics. Guidelines on Significant Governance Issues, and Process for Security Holder Communications with Directors, each of which is filed as an exhibit to this annual report.

 

Board Committees

 

Our board of directors has established five standing committees: an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee, a Science Committee and a Clinical and Regulatory Committee. Each of these committees will operate under a charter that has been approved by our board of directors.

 

Audit Committee. The Audit Committee will oversee and monitor our financial reporting process and internal control system, review and evaluate the audit performed by our registered independent public accountants and reports to the Board any substantive issues found during the audit. The Audit Committee will be directly responsible for the appointment, compensation and oversight of the work of our registered independent public accountants. The Audit Committee will review and approve all transactions with affiliated parties. The Audit Committee shall be comprised on two or more independent directors who shall be appointed annually and subject to removal by the Board at any time. Each member of the Audit Committee shall meet the independence requirements of The NASDAQ Stock Market, LLC, and SEC regulations, as well as any other applicable requirements. Messrs. Corvese (Committee Chairperson), Wright, and Barrage comprise the Audit Committee, each of whom meets the independence requirements. In addition, the Board also designated Brian Corvese as an “audit committee financial expert,” as that term is defined by the NSADAQ Listing Rules and SEC regulations.

 

51
 

 

Compensation Committee. The Compensation Committee will provide advice and make recommendations to the board in the areas of employee salaries, benefit programs and director compensation. The Compensation Committee will also review the compensation of our President, Chief Executive Officer, and other officers and make recommendations in that regard to the board as a whole. The Compensation Committee shall be comprised on three or more directors who shall be appointed annually and subject to removal by the Board at any time. The Compensation Committee must have at least two members, and must consist solely of independent directors. Messrs. Barrage, Corvese, and Wright comprise the Compensation Committee and are all independent.

 

Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee will nominate individuals to be elected to the full board by our stockholders. The Nominating and Corporate Governance Committee will determine the slate of director nominees for election to the Board, to identify and recommend candidates to fill vacancies occurring between annual stockholder meetings, to review the Company’s policies and programs that relate to matters of corporate responsibility, including public issues of significance to the Company and its stockholders. The Nominating and Corporate Governance Committee shall be comprised on two or more directors who shall be appointed annually and subject to removal by the Board at any time. Each member of the Nominating and Corporate Governance Committee may or may not meet the independence requirements of The NASDAQ Stock Market, LLC and SEC regulations. Messrs. Wright (Committee Chairperson), and Mr. Corvese comprise the Nominating and Corporate Governance Committee.

 

Science Committee. The Science Committee will meet regularly to review the strategic direction being taken by Management with respect to developing the Company’s scientific assets. A key function of the Science Committee is to ensure that the Company is targeting disease indications for its drug candidates that take full advantage of the drug candidates’ potential, within the constraints of the working capital available to the Company. This process is expected to continually necessitate difficult choices concerning how many disease targets to pursue. The Science Committee will be directly responsible for the appointment, compensation and oversight of the Company’s top scientific staff. The Science Committee will review and approve all major contractual agreements with contract research organizations. Each member of the Science Committee may or may not meet the independence requirements of The NASDAQ Stock Market, LLC and SEC regulations Drs. Stein (Committee Chairperson), Buell, and Armen comprise the Science Committee.

 

Clinical and Regulatory Committee: The Clinical and Regulatory committee will meet at least once per year to review progress of the clinical trial programs of the Company. The Clinical and Regulatory committee was created in July 2020 and Dr. Jennifer Buell was appointed as its chair. Each member of the Clinical and Regulatory Committee may or may not meet the independence requirements of The NASDAQ Stock Market, LLC and SEC regulations. Drs. Buell (Chair), Armen, and Stein comprise the Clinical and Regulatory Committee.

 

Limitation of Directors Liability and Indemnification

 

The Delaware General Corporation Law authorizes corporations to limit or eliminate, subject to certain conditions, the personal liability of directors to corporations and their stockholders for monetary damages for breach of their fiduciary duties. Our certificate of incorporation limits the liability of our directors to the fullest extent permitted by Delaware law.

 

We have director and officer liability insurance to cover liabilities our directors and officers may incur in connection with their services to us, including matters arising under the Securities Act. Our certificate of incorporation and bylaws also provide that we will indemnify our directors and officers who, by reason of the fact that he or she is one of our officers or directors of our company, is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative related to their board role with the company.

 

We have entered into indemnification agreements with each of our directors and executive officers. It is anticipated that future directors and officers will enter into an Indemnification Agreement with us in substantially similar form. The Indemnification Agreement provides, among other things, that we will indemnify and hold harmless each person subject to an Indemnification Agreement (each, an “Indemnified Party”) to the fullest extent permitted by applicable law from and against all losses, costs, liabilities, judgments, penalties, fines, expenses and other matters that may result or arise in connection with such Indemnified Party serving in his or her capacity as a director of ours or serving at our direction as a director, officer, employee, fiduciary or agent of another entity. The Indemnification Agreement further provides that, upon an Indemnified Party’s request, we will advance expenses to the Indemnified Party to the fullest extent permitted by applicable law. Pursuant to the Indemnification Agreement, an Indemnified Party is presumed to be entitled to indemnification and we have the burden of proving otherwise. The Indemnification Agreement also requires us to maintain in full force and effect directors’ liability insurance on the terms described in the Indemnification Agreement. If indemnification under the Indemnification Agreement is unavailable to an Indemnified Party for any reason, we, in lieu of indemnifying the Indemnified Party, will contribute to any amounts incurred by the Indemnified Party in connection with any claim relating to an indemnifiable event in such proportion as is deemed fair and reasonable in light of all of the circumstances to reflect the relative benefits received or relative fault of the parties in connection with such event.

 

52
 

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

There is no pending litigation or proceeding involving any of our directors, officers, employees or agents in which indemnification will be required or permitted. We are not aware of any threatened litigation or proceeding that may result in a claim for such indemnification.

 

Item 11. Executive Compensation.

 

The following table sets forth information regarding each element of compensation that we paid or awarded to our named executive officers and for fiscal years ended December 31, 2024 and 2023.

 

Summary Compensation Table

 

Name and Principal Position  Year   Salary  

Bonus

($)

  

Stock Awards

($)

  

Option Awards

($)

  

Non-Equity Incentive Plan Compensation

($)

  

Non-

Qualified

Deferred

Compensation

Earnings

($)

  

All Other Compensation

($)

  

Total

Compensation

($)

 
                                     
Garo H. Armen,  2024    0    0    0   $108,684    0    0    0   $108,684 
Chairman  2023    0    0    0   $0    0    0    0   $0 
                                             
Alexander K. Arrow,  2024   $150,000   $0   $0   $32,605   $0   $0    0   $182,605 
Chief Financial Officer  2023   $150,000   $0   $0   $0   $0   $0    0   $150,000 

 

Employment Arrangements with Officers and Directors

 

Dr. Alexander Arrow, our Chief Financial Officer, receives base compensation of $150,000 per year for his part-time work for us, an increase from the $125,000 he received until July 1, 2021, except for an 18-month period from February 2019 through August 2020 during which he received zero cash salary and three grants totaling 88,541 options in lieu of cash salary. From 2016 through 2024, cumulatively, Dr. Arrow received 25,000 options under the 2006 Plan and grants totaling 272,291 incentive options in the aggregate under the 2016 plan with exercise prices of $1.74 and $7.00 per share. The terms of Dr. Arrow’s option grants include full vesting acceleration upon a change of control.

 

53
 

 

Consulting Agreements

 

Andrew Slee, PhD, Chief Operating Officer. In December 2020, we entered into a consulting agreement with Dr. Slee to act as our Chief Operating Officer. We granted Dr. Slee (i) 25,000 options on April 15, 2016, at an exercise price of $5.00 per option, (ii) 18,750 options on October 16, 2017, at an exercise price of $7.00 per option, (iii) 18,750 options on July 18, 2020, at an exercise price of $7.00 per option, (iv) 37,500 options on February 13, 2020, at an exercise price of $7.00 per option, (v) 12,500 options on February 25, 2021, at an exercise price of $22.40, (vi) 5,000 options on January 8, 2024, at an exercise price of $0.84. and (vii) 100,000 options on March 25, 2024, at an exercise price of $1.75.

 

Dalia Barsyte PhD, Scientific Advisor. Our subsidiary, Protagenic Therapeutics Canada (2006) Inc., entered into a consulting agreement with Dr. Dalia Barsyte. Dr. Barsyte is responsible for overseeing i) design and development of ELISA assays for measuring TCAP, ii) evaluation of TCAP exposure biomarker assay, iii) development of pipeline peptides, iv) development of clinically compatible formulations for TCAP, as well as all of the bench research and development of formulation and extraction methods. Her consulting agreement is effective through December 2017. She is compensated at the rate of up to $3,000 (Canadian) per month, if she works at least 20 hours on behalf of the Company. As well, we have granted Dr. Barsyte 2,500 shares of our common stock and ten-year options to purchase 37,500 shares of our common stock. Options to purchase 25,000 shares of common stock, at an exercise price of $4.00 per share, have fully vested; the options to purchase the remaining 12,500 shares of common stock, at an exercise price of $5.00 per share, vested in March 2016. On October 16, 2017, we granted Dr. Barsyte another ten-year option to purchase 5,000 shares of our common stock at an exercise price of $7.00 per share. On February 13, 2020, we granted Dr. Barsyte ten-year option to purchase 2,500 shares of our common stock at an exercise price of $7.00 per share.

 

Robert B. Stein, PhD, MD, Director, Chief Medical Officer. We entered into a consulting agreement with Dr. Stein effective January 2015, and amended and restated this consulting agreement in December 2020 to appoint Dr. Stein as our Chief Medical Officer. Dr. Stein is responsible for providing us with technical and advisory services related to our research and development efforts. On January 23, 2015, we granted Dr. Stein ten-year options to purchase 50,000 shares of our common stock, at an exercise price of $5.00 per share (the “January Options”). The January Options are fully vested. We granted Dr. Stein (i) 10,000 options on April 15, 2016, at an exercise price of $5.00 per option, (ii) 50,000 options on October 16, 2017, at an exercise price of $7.00 per option, (iii) 37,500 options on February 13, 2020, at an exercise price of $5.00 per option, (iv) 12,500 options on February 25, 2021, at an exercise price of $22.40 per option, and (v) 75,000 options on March 25, 2024, at an exercise price of $1.74 per option.

 

Jennifer Buell, PhD, Clinical and Regulatory Development Advisor. We entered into a consulting agreement with Dr. Buell effective February 2021, providing for her to do three things: (1) advise the Company’s clinical and regulatory development plan to support the Company’s lead product candidate, PT00114, in support of an IND application to the U.S. Food and Drug Administration and demonstration of safety and clinical activity in early phase clinical trials, (2) develop a panel of experts to prepare a clinical development plan and operational plan that would enable the evaluation of safety and clinical activity of the companies lead therapeutic, PT00114, and (3) determine the fastest development pathway of PT00114 in four key indications as defined by the Company Management. We granted Dr. Buell 50,000 nonstatutory stock options (“NSOs”) on February 25, 2021 at an exercise price of $22.40 per share, 36,250 options on July 18, 2020 at an exercise price of $7.00 per share, and 75,000 options on March 25, 2024, at an exercise price of $1.74 per option.

 

Mark Berg, Strategic Advisor. We entered into a consulting agreement with Mr. Berg effective January 2022, providing for him to provide strategic consulting services to the company, none of which involves direct contact with investors. We granted Mr. Berg 12,500 nonstatutory stock options (“NSOs”) on January 26, 2022 at an exercise price of $4.84 per share.

 

Director Compensation

 

Going forward, on April 15 of each fiscal year, we plan to grant each non-employee director an option under the 2016 Plan to purchase 10,000 shares of common stock, as well as an option to purchase 1,250 shares for each committee which they chair. No additional options shall be granted for serving on a committee without being its chair. All options will be granted at fair market value, as defined in the 2016 Plan, on the date of grant, and will vest over a three-year period in equal monthly installments. Vesting will accelerate in certain circumstances, such as a change of control of the Company, and unvested options will terminate upon the cessation of an individual’s service to us as a director.

 

54
 

 

Non-employee directors may be reimbursed for their reasonable expenses in attending Board and committee meetings.

 

We entered into an amended and restated consulting agreement during fiscal year 2020 with Robert B. Stein, PhD, MD, under which we issued 137,500 options on February 13, 2020, at an exercise price of $5.00 per option. During fiscal year 2021 with Robert B. Stein, PhD, MD, under which we issued 12,500 options on February 20, 2021, at an exercise price of $22.40 per option.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

Equity Compensation Plans

 

Equity Compensation Plan Information

 

Plan category 

(a)

No. of securities

to be issued upon exercise of outstanding options, warrants and rights

  

(b)

Weighted-average exercise price of outstanding options, warrants and rights

  

(c)

No. of securities remaining available for future issuance under equity compensation plans (excluding securities reflected

in column (a)

 
Equity compensation plans approved by security holders   1,953,491   $5.36    1,822,579 
                
Equity compensation plans not approved by security holders   0    0    0 
                
Total   1,953,491   $5.36    1,822,579 

 

2006 Employee, Director and Consultant Stock Plan

 

On June 17, 2016, our stockholders adopted our 2016 Equity Compensation Plan and, as a result, we terminated the 2006 Plan. We will not grant any further awards under the 2006 Plan. All outstanding grants under the 2006 Plan will continue in effect in accordance with the terms of the particular grant and the 2006 Plan.

 

The following description of the pertinent terms of the 2006 Plan is a summary and is qualified in its entirety by the full text of the 2006 Plan.

 

Administration. The administrator (the “Administrator”) of the 2006 Plan is the Board of Directors, except to the extent the Board of Directors delegates its authority to the Compensation committee (the “Committee”) of the Board, in which case the Committee shall be the Administrator.

 

Terms and Conditions of Options. Options granted under the 2006 Plan may be either “incentive stock options” that are intended to meet the requirements of Section 422 of the Code or “nonqualified stock options” that do not meet the requirements of Section 422 of the Code. The Administrator will determine the exercise price of options granted under the 2006 Plan. The exercise price of stock options may not be less than the fair market value per share of our common stock on the date of grant (or 110% of fair market value in the case of incentive stock options granted to a ten-percent stockholder).

 

If on the date of grant the common stock is listed on a stock exchange or national market system, the fair market value will generally be the closing sale price on the date of grant. If the common stock is not traded on a stock exchange or national market system on the date of grant, the fair market value will generally be the mean between the bid and the asked price for the common stock at the close of trading in the over-the-counter market for the trading day on which common stock was traded immediately preceding the applicable date. If no such prices are available, the fair market value shall be determined in good faith by the Administrator.

 

55
 

 

No option intended to qualify as an ISO may be exercisable for more than ten years from the date of grant (five years in the case of an incentive stock option granted to a ten-percent stockholder). Options granted under the 2006 Plan will be exercisable at such time or times as the Administrator prescribes at the time of grant. No employee may receive incentive stock options that first become exercisable in any calendar year in an amount exceeding $100,000.

 

Generally, the exercise price of an option may be paid (a) in cash or by certified bank check, (b) at the discretion of the Administrator, through delivery of shares of our common stock held for at least six months having a fair market value equal to the purchase price, (c) at the discretion of the Administrator, by delivery of the grantee’s personal note, for full, partial or no recourse, bearing interest payable not less than annually at market rate on the date of exercise and at no less than 100% of the applicable Federal rate, as defined in Section 1274(d) of the Code, with or without the pledge of such shares as collateral, or (d) at the discretion of the Administrator, in accordance with a cashless exercise program established with a securities brokerage firm, and approved by the Administrator, or (e) at the discretion of the Administrator, by any combination of the above methods.

 

No option may be transferred other than by will or by the laws of descent and distribution, and during a recipient’s lifetime an option may be exercised only by the recipient. The Administrator will determine the extent to which a holder of a stock option may exercise the option following termination of service with us.

 

The Administrator will determine the extent to which a holder of a stock option may exercise the option following termination of service with us.

 

Effect of Certain Corporate Transactions. If the Company is to be consolidated with or acquired by another entity in a merger, sale of all or substantially all of the Company’s assets other than a transaction to merely change the state of incorporation (a “Corporate Transaction”), the Administrator or the board of directors of any entity assuming the obligations of the Company hereunder (the “Successor Board”), shall, as to outstanding options, either (i) make appropriate provision for the continuation of such options by substituting on an equitable basis for the Shares then subject to such options; or (ii) upon written notice to the participants, provide that all options must be exercised (either to the extent then exercisable or, at the discretion of the Administrator, all options being made fully or partially exercisable), within a specified number of days of the date of such notice, at the end of which period the options shall terminate; or (iii) terminate all options in exchange for a cash payment equal to the excess of the fair market value of the shares of common stock subject to such options (either to the extent then exercisable or, at the discretion of the Administrator, all options being made fully or partially exercisable) over the exercise price thereof.

 

Tax Withholding. As and when appropriate, we shall have the right to require each optionee purchasing shares of common stock and each grantee receiving an award of shares of common stock under the 2006 Plan to pay any federal, state or local taxes required by law to be withheld.

 

2016 Equity Compensation Plan

 

The following description of the principal terms of the 2016 Plan is a summary and is qualified in its entirety by the full text of the 2016 Plan.

 

Administration. The 2016 Plan is administered by the Compensation Committee of our Board of Directors, provided that the entire Board of Directors may act in lieu of the Compensation Committee on any matter, subject to certain requirements set forth in the 2016 Plan. The Compensation Committee may grant options to purchase shares of our common stock, stock appreciation rights, stock units, restricted shares of our common stock, performance shares, performance units, incentive bonus awards, other cash-based awards and other stock-based awards. The Compensation Committee also has broad authority to determine the terms and conditions of each option or other kind of award, and adopt, amend and rescind rules and regulations for the administration of the 2016 Plan. Subject to applicable law, the Compensation Committee may authorize one or more reporting persons (as defined in the 2016 Plan) or other officers to make awards (other than awards to reporting persons, or other officers whom the Compensation Committee has specifically authorized to make awards). No awards may be granted under the 2016 Plan on or after the ten-year anniversary of the adoption of the 2016 Plan by our Board of Directors, but awards granted prior to such tenth anniversary may extend beyond that date.

 

56
 

 

Eligibility. Awards may be granted under the 2016 Plan to any person who is an employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary, or any person who is determined by the Compensation Committee to be a prospective employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary.

 

Shares Subject to the 2016 Plan. The aggregate number of shares of common stock proposed to be available for issuance in connection with options and awards granted under the 2016 Plan is 750,000 shares. Incentive Stock Options may, but need not be, granted with respect to all of the shares available for issuance under the 2016 Plan; provided, however, that the maximum aggregate number of shares of common stock which may be issued in respect of Incentive Stock Options (after giving effect to any increases pursuant to the “evergreen” provisions of the 2016 Plan discussed below) shall not exceed 1,500,000 shares, subject to adjustment in the event of stock, splits and similar transactions. If any award granted under the 2016 Plan payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan.

 

In addition, the 2016 Plan contains an “evergreen” provision allowing for an annual increase in the number of shares of our common stock available for issuance under the 2016 Plan on January 1 of each year during the period beginning January 1, 2017, and ending on (and including) January 1, 2026. The annual increase in the number of shares shall be equal to (i) five point five percent (5.5%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, or (ii) with respect to shares of common stock which may be issued under the 2016 Plan other than in respect to Incentive Stock Options, the difference between (x) eighteen percent (18%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, and (y) the total number of shares of common stock reserved under the 2016 Plan on December 31st of such preceding calendar year (including shares subject to outstanding awards, issued pursuant to awards or available for future awards) if such amount is greater than the amount determined in (i) immediately above; provided, however, that our Board may act prior to the first day of any calendar year to provide that there shall be no increase such calendar year, or that the increase shall be a lesser number of shares of common stock than would otherwise occur. On January 1, 2017, 2019, and 2020, each year 141,095 shares of common stock were added to the 2016 Plan pursuant to this evergreen provision. On January 1, 2021, 142,457 shares of common stock were added to the 2016 Plan pursuant to this evergreen provision. On January 1, 2022, 184,260 additional shares of common stock are available for issuance under the 2016 Plan as a result of operation of the evergreen provision: (a) 141,070 shares resulting from operation of the evergreen provision in 2019, which were never previously registered and (b) 43,191 shares resulting from operation of the evergreen provision in 2022. On January 1, 2023, 184,594 additional shares of common stock are available for issuance under the 2016 Plan as a result of operation of the evergreen provision resulting from operation of the evergreen provision in 2022. On January 1, 2024, 196,857 additional shares of common stock are available for issuance under the 2016 Plan as a result of operation of the evergreen provision resulting from operation of the evergreen provision in 2022.

 

Terms and Conditions of Options. Options granted under the 2016 Plan may be either “incentive stock options” that are intended to meet the requirements of Section 422 of the Code or “nonqualified stock options” that do not meet the requirements of Section 422 of the Code. The Compensation Committee will determine the exercise price of options granted under the 2016 Plan. The exercise price of stock options may not be less than the fair market value, on the date of grant, per share of our common stock issuable upon exercise of the option (or 110% of fair market value in the case of incentive options granted to a ten-percent stockholder).

 

57
 

 

If on the date of grant the common stock is listed on a stock exchange or national market system, the fair market value shall generally be the closing sale price as of such date, or if there were no trades recorded on such date, then the most recent date preceding such date on which trades were recorded. If on the date of grant the common stock is traded in an over-the-counter market, the fair market will generally be the average of the closing bid and asked prices for the shares of common stock as of such date, or, if there are no closing bid and asked prices for the shares of common stock on such date, then the average of the bid and asked prices for the shares of common stock on the most recent date preceding such date on which such closing bid and asked prices are available. If the common stock is not listed on a national securities exchange or national market system or traded in an over-the-counter market, the fair market value shall be determined by the Compensation Committee in a manner consistent with Section 409A of the Code. Notwithstanding the foregoing, if on the date of grant the common stock is listed on a stock exchange or is quoted on a national market system, or is traded in an over-the-counter market, then solely for purposes of determining the exercise price of any grant of a stock option or the base price of any grant of a stock appreciation right, the Compensation Committee may, in its discretion, base fair market value on the last sale before or the first sale after the grant, the closing price on the trading day before or the trading day of the grant, the arithmetic mean of the high and low prices on the trading day before or the trading day of the grant, or any other reasonable method using actual transactions of the common stock as reported by the exchange or market on which the common stock is traded. In addition, the determination of fair market value also may be made using any other method permitted under Treasury Regulation section 1.409A-1(b)(5)(iv).

 

No option may be exercisable for more than ten years from the date of grant (five years in the case of an incentive stock option granted to a ten-percent stockholder). Options granted under the 2016 Plan will be exercisable at such time or times as the Compensation Committee prescribes at the time of grant. No employee may receive incentive stock options that first become exercisable in any calendar year in an amount exceeding $100,000. The Compensation Committee may, in its discretion, permit a holder of a nonqualified stock option to exercise the option before it has otherwise become exercisable, in which case the shares of our common stock issued to the recipient will continue to be subject to the vesting requirements that applied to the option before exercise.

 

Generally, the option price may be paid in cash or by bank check, or such other means as the Compensation Committee may accept. As set forth in an award agreement or otherwise determined by the Compensation Committee, in its sole discretion, at or after grant, payment in full or part of the exercise price of an option may be made (a) in the form of shares of common stock that have been held by the participant for such period as the Compensation Committee may deem appropriate for accounting purposes or otherwise, valued at the fair market value of such shares on the date of exercise; (ii) by surrendering to the Company shares of common stock otherwise receivable on exercise of the option; (iii) by a cashless exercise program implemented by the Compensation Committee in connection with the 2016 Plan; and/or (iv) by such other method as may be approved by the Compensation Committee and set forth in an award agreement.

 

No option may be transferred other than by will or by the laws of descent and distribution, and during a recipient’s lifetime an option may be exercised only by the recipient or the recipient’s guardian or legal representative. However, the Compensation Committee may permit the transfer of a nonqualified stock option, share-settled stock appreciation right, restricted stock award, performance share or share-settled other stock-based award either (a) by instrument to the participant’s immediate family (as defined in the 2016 Plan), (b) by instrument to an inter vivos or testamentary trust (or other entity) in which the award is to be passed to the participant’s designated beneficiaries, or (c) by gift to charitable institutions. The Compensation Committee will determine the extent to which a holder of a stock option may exercise the option following termination of service.

 

Stock Appreciation Rights. The Compensation Committee may grant stock appreciation rights independent of or in connection with an option. The Compensation Committee will determine the terms applicable to stock appreciation rights. The base price of a stock appreciation right will be determined by the Compensation Committee, but will not be less than 100% of the fair market value of a share of our common stock with respect to the date of grant of such stock appreciation right. The maximum term of any SAR granted under the 2016 Plan is ten years from the date of grant. Generally, each SAR stock appreciation right will entitle a participant upon exercise to an amount equal to:

 

  ● the excess of the fair market value of a share of common stock on the date of exercise of the stock appreciation right over the base price of such stock appreciation right, multiplied by
     
  ● the number of shares as to which such stock appreciation right is exercised.

 

Payment may be made in shares of our common stock, in cash, or partly in common stock and partly in cash, all as determined by the Compensation Committee.

 

58
 

 

Restricted Stock and Stock Units. The Compensation Committee may award restricted common stock and/or stock units under the 2016 Plan. Restricted stock awards consist of shares of stock that are transferred to a participant subject to restrictions that may result in forfeiture if specified conditions are not satisfied. Stock units confer the right to receive shares of our common stock, cash, or a combination of shares and cash, at a future date upon or following the attainment of certain conditions specified by the Compensation Committee. The Compensation Committee will determine the restrictions and conditions applicable to each award of restricted stock or stock units, which may include performance-based conditions. Dividends with respect to restricted stock may be paid to the holder of the shares as and when dividends are paid to stockholders or at the times of vesting or other payment of the restricted stock award. Stock unit awards may be granted with dividend equivalent rights, which may be accumulated and may be deemed reinvested in additional stock units, as determined by the Compensation Committee in its discretion. If any dividend equivalents are paid while a stock unit award is subject to restrictions, the dividend equivalents shall be subject to the same restrictions on transferability as the underlying stock units, unless otherwise set forth in an award agreement. Unless the Compensation Committee determines otherwise, holders of restricted stock will have the right to vote the shares.

 

Performance Shares and Performance Units. The Compensation Committee may award performance shares and/or performance units under the 2016 Plan. Performance shares and performance units are awards which are earned during a specified performance period subject to the attainment of performance criteria, as established by the Compensation Committee. The Compensation Committee will determine the restrictions and conditions applicable to each award of performance shares and performance units.

 

Incentive Bonus Awards. The Compensation Committee may award Incentive Bonus Awards under the 2016 Plan. Incentive Bonus Awards may be based upon the attainment of specified levels of Company or subsidiary performance as measured by pre-established, objective performance criteria determined at the discretion of the Compensation Committee. Incentive Bonus Awards will be paid in cash or common stock, as set forth in an award agreement.

 

Other Stock-Based and Cash-Based Awards. The Compensation Committee may award other types of equity-based or cash-based awards under the 2016 Plan, including the grant or offer for sale of unrestricted shares of our common stock and payment in cash or otherwise of amounts based on the value of shares of common stock.

 

Section 162(m) Compliance. If stock or cash-based awards are intended to satisfy the conditions for deductibility under Section 162(m) of the Code as “performance-based compensation,” the performance criteria will be selected from among the following, which may be applied to our Company as a whole, any subsidiary or any division or operating unit thereof: (a) pre-tax income; (b) after-tax income; (c) net income; (d) operating income or profit; (e) cash flow, free cash flow, cash flow return on investment, net cash provided by operations, or cash flow in excess of cost of capital; (f) earnings per share; (g) return on equity; (h) return on sales or revenues; (i) return on invested capital or assets; (j) cash, funds or earnings available for distribution; (k) appreciation in the fair market value of the common stock; (l) operating expenses; (m) implementation or completion of critical projects or processes; (n) return on investment; (o) total return to stockholders; (p) dividends paid; (q) net earnings growth; (r) related return ratios; (s) increase in revenues; (t) the Company’s published ranking against its peer group of pharmaceutical companies based on total stockholder return; (u) net earnings; (v) changes (or the absence of changes) in the per share or aggregate market price of the common stock; (w) number of securities sold; (x) earnings before or after any one or more of the following items: interest, taxes, depreciation or amortization, as reflected in the Company’s financial reports for the applicable period; (y) total revenue growth; (z) economic value created; (aa) operating margin or profit margin; (bb) share price or total stockholder return; (cc) cost targets, reductions and savings, productivity and efficiencies; (dd) strategic business criteria, consisting of one or more objectives based on meeting objectively determinable criteria: specified market penetration, geographic business expansion, progress with research and development activities, investor satisfaction, employee satisfaction, human resources management, supervision of litigation, information technology, and goals relating to acquisitions, divestitures, joint ventures and similar transactions, and budget comparisons; (ee) objectively determinable personal or professional objectives, including any of the following performance goals: the implementation of policies and plans, the negotiation of transactions, the development of long term business goals, formation of joint ventures, research or development collaborations, and the completion of other corporate transactions, and (ff) any combination of, or a specified increase or improvement in, any of the foregoing.

 

59
 

 

At the end of the performance period established in connection with any award, the Compensation Committee will determine the extent to which the performance goal or goals established for such award have been attained, and shall determine, on that basis, the number of performance shares or performance units included in such award that have been earned and as to which payment will be made. The Compensation Committee will certify in writing the extent to which it has determined that the performance goal or goals established by it for such award have been attained.

 

With respect to awards intended to be performance-based compensation under Section 162(m) of the Code, no participant of the 2016 Plan may receive in any one fiscal year (a) options or stock appreciation rights relating to more than 250,000 shares of our common stock, and (b) stock units, restricted shares, performance shares, performance units or other stock-based awards that are denominated in shares of common stock relating to more than 250,000 shares of our common stock in the aggregate. The maximum dollar value payable to any participant for a fiscal year of the Company with respect to stock units, performance units or incentive bonus awards or other stock-based awards that may be settled in cash or other property (other than common stock) is $1,500,000.

 

Effect of Certain Corporate Transactions. The Compensation Committee may, at the time of the grant of an award, provide for the effect of a change in control (as defined in the 2016 Plan) on any award, including (i) accelerating or extending the time periods for exercising, vesting in, or realizing gain from any award, (ii) eliminating or modifying the performance or other conditions of an award, (iii) providing for the cash settlement of an award for an equivalent cash value, as determined by the Compensation Committee, or (iv) such other modification or adjustment to an award as the Compensation Committee deems appropriate to maintain and protect the rights and interests of participants upon or following a change in control. The Compensation Committee may, in its discretion and without the need for the consent of any recipient of an award, also take one or more of the following actions contingent upon the occurrence of a change in control: (a) cause any or all outstanding options and stock appreciation rights to become immediately exercisable, in whole or in part; (b) cause any other awards to become non-forfeitable, in whole or in part; (c) cancel any option or stock appreciation right in exchange for a substitute option; (d) cancel any award of restricted stock, stock units, performance shares or performance units in exchange for a similar award of the capital stock of any successor corporation; (e) redeem any restricted stock, stock unit, performance share or performance unit for cash and/or other substitute consideration with a value equal to the fair market value of an unrestricted share of our common stock on the date of the change in control; (f) cancel any option or stock appreciation right in exchange for cash and/or other substitute consideration based on the value of our common stock on the date of the change in control, and cancel any option or stock appreciation right without any payment if its exercise price exceeds the value of our common stock on the date of the change in control; (g) cancel any stock unit or performance unit held by a participant affected by the change in control in exchange for cash and/or other substitute consideration with a value equal to the fair market value per share of common stock on the date of the change in control, or (h) make such other modifications, adjustments or amendments to outstanding awards as the Compensation Committee deems necessary or appropriate.

 

Amendment, Termination. The 2016 Plan will remain in effect until March 2026, or, if earlier, when awards have been granted covering all available shares under the 2016 Plan or the 2016 Plan is otherwise terminated by the Board. The Board may amend the terms of awards in any manner not inconsistent with the 2016 Plan, provided that no amendment shall adversely affect the rights of a participant with respect to an outstanding award without the participant’s consent. In addition, our Board of Directors may at any time amend, suspend, or terminate the 2016 Plan, provided that (i) no such amendment, suspension or termination shall materially and adversely affect the rights of any participant under any outstanding award without the consent of such participant and (ii) to the extent necessary and desirable to comply with any applicable law, regulation, or stock exchange rule, the 2016 Plan requires us to obtain stockholder consent. Stockholder approval is required for any plan amendment that increases the number of shares of common stock available for issuance under the 2016 Plan or changes the persons or classes of persons eligible to receive awards.

 

Tax Withholding. The Company has the power and right to deduct or withhold, or require a participant to remit to the Company, the minimum statutory amount to satisfy federal, state, and local taxes, domestic or foreign, required by law or regulations to be withheld.

 

60
 

 

Recoupment Policy. Awards granted under the 2016 Plan will be subject to any provisions of applicable law providing for the recoupment or clawback of incentive compensation, such as provisions imposed pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act; the terms of any Company recoupment, clawback or similar policy in effect at the time of grant of the award; and any recoupment, clawback or similar provisions that may be included in the applicable award agreement.

 

Federal Income Tax Consequences. The following is a brief summary of the U.S. federal income tax consequences applicable to awards granted under the 2016 Plan based on the federal income tax laws in effect on the date of this report. This summary is not intended to be exhaustive and does not address all matters relevant to a particular participant based on his or her specific circumstances. The summary expressly does not discuss the income tax laws of any state, municipality, or non-U.S. taxing jurisdiction, or the gift, estate, excise (including the rules applicable to deferred compensation under Code Section 409A), or other tax laws other than federal income tax law. The following is not intended or written to be used, and cannot be used, for the purposes of avoiding taxpayer penalties. Because individual circumstances may vary, the Company advises all participants to consult their own tax advisor concerning the tax implications of awards granted under the 2016 Plan.

 

A recipient of a stock option or stock appreciation right will not have taxable income upon the grant of the stock option or stock appreciation right. For non-statutory stock options and stock appreciation rights, the participant will recognize ordinary income upon exercise in an amount equal to the difference between the fair market value of the shares and the exercise price on the date of exercise. Any gain or loss recognized upon any later disposition of the shares generally will be a capital gain or loss.

 

The acquisition of shares upon exercise of an incentive stock option will not result in any taxable income to the participant, except, possibly, for purposes of the alternative minimum tax. The gain or loss recognized by the participant on a later sale or other disposition of such shares will either be long-term capital gain or loss or ordinary income, depending upon whether the participant holds the shares for the legally-required period (two years from the date of grant and one year from the date of exercise). If the shares are not held for the legally-required period, the participant will recognize ordinary income equal to the lesser of (i) the difference between the fair market value of the shares on the date of exercise and the exercise price, or (ii) the difference between the sales price and the exercise price, and the balance of the gain, if any, will be afforded capital gain treatment.

 

For awards of stock grants, the participant will not have taxable income upon the receipt of the award (unless the participant elects to be taxed at the time of the stock is granted rather than when it becomes vested). The stock grants will generally be subject to tax upon vesting as ordinary income equal to the fair market value of the shares at the time of vesting less the amount paid for such shares (if any).

 

A participant is not deemed to receive any taxable income at the time an award of restricted stock units is granted. When vested restricted stock units (and dividend equivalents, if any) are settled and distributed, the participant will recognize ordinary income equal to the amount of cash and/or the fair market value of shares received less the amount paid for such restricted stock units (if any).

 

If the participant is an employee or former employee, the amount a participant recognizes as ordinary income in connection with any award is subject to withholding taxes (not applicable to incentive stock options) and the Company is allowed a tax deduction equal to the amount of ordinary income recognized by the participant. In addition, Code Section 162(m) contains special rules regarding the federal income tax deductibility of compensation paid to the Company’s chief executive officer and to certain of the Company’s other executive officers. The general rule is that annual compensation paid to any of these specified executives will be deductible only to the extent that it does not exceed $1,000,000. However, the Company can preserve the deductibility of certain compensation in excess of $1,000,000 if such compensation qualifies as “performance-based compensation” by complying with certain conditions imposed by the Code Section 162(m) rules (including the establishment of a maximum number of shares with respect to which awards may be granted to any one employee during one fiscal year).

 

61
 

 

Option Grants and Stock Awards

 

As of December 31, 2024, we had outstanding stock options to purchase 1,953,491 shares at an average exercise price of approximately $5.36 per share. Included in the total outstanding stock options were 0 stock options granted under the 2006 Plan in 2023 and 0 nonqualified stock options granted under the 2016 Plan in 2023 to our executive officers.

 

All awards to be made under the 2016 Plan are discretionary, subject to the terms of the 2016 Plan. Therefore, the benefits and amounts that will be received or allocated under the 2016 Plan are generally not determinable at this time. The equity grant program for our non-employee directors is described under the Compensation of Directors section in this proxy statement. The following table summarizes these 2016 awards to our named executive officers, all executive officers and the non-executive officer employees and consultants.

 

Outstanding Equity Awards at Fiscal Year End

 

The following table summarizes the equity awards made to our named executive officers that were outstanding at December 31, 2024.

 

Name 

No. of Securities

Underlying Unexercised Options (#) Exercisable

  

No. of Securities

Underlying Unexercised Options (#) Unexercisable

  

Option

Exercise Price

  

Option

Expiration Date

 
Garo H. Armen (1)   125,000    -   $5.00    April 15, 2026 
                     
Garo H. Armen (2)   62,500    -   $7.00    October 16, 2027 
                     
Garo H. Armen (3)   75,000    -   $7.00    February 13, 2030 
                     
Garo H. Armen (4)   62,500    187,500   $1.74    March 25, 2034 
                     
Alexander K. Arrow (5)   25,000    -   $5.00    February 12, 2026 
                     
Alexander K. Arrow (6)   35,000    -   $5.00    April 15, 2026 
                     
Alexander K. Arrow (7)   18,750    -   $7.00    October 16, 2027 
                     
Alexander K. Arrow (8)   10,417    -   $4.00    February 1, 2029 
                     
Alexander K. Arrow (9)   30,000    -   $7.00    February 13, 2030 
                     
Alexander K. Arrow (10)   46,874    -   $7.00    February 13, 2030 
                     
Alexander K. Arrow (11)   31,250    -   $7.00    July 18, 2030 
                     
Alexander K. Arrow (12)   25,000    75,000   $1.74    March 25, 2034 
                     
Andrew Slee (13)   25,000    -   $5.00    April 15, 2026 
                     
Andrew Slee (14)   18,750    -   $7.00    October 16, 2027 
                     
Andrew Slee (15)   37,500    -   $7.00    February 13, 2030 
                     
Andrew Slee (16)   18,750    -   $7.00    July 18, 2030 
                     
Andrew Slee (17)   11,979    521   $22.40    February 25, 2031 
                     
Andrew Slee (18)   1,250    3,750   $0.84    January 8, 2034 
                     
Andrew Slee (19)   18,750    81,250   $1.74    March 25, 2034 
                     
Robert B. Stein (20)   50,000    -   $5.00    January 22, 2030 
                     
Robert B. Stein (21)   10,000    -   $5.00    April 15, 2026 
                     
Robert B. Stein (22)   50,000    -   $7.00    October 16, 2027 
                     
Robert B. Stein (23)   37,500    -   $7.00    February 13, 2030 
                     
Robert B. Stein (24)   11,979    521   $22.40    February 25, 2031 
                     
Robert B. Stein (25)   18,750    56,250   $1.75    March 25, 2034 

 

(1) Dr. Armen was granted a 125,000 share option grant on April 15, 2016
   
(2) Dr. Armen was granted a 62,500 share option grant on October 16, 2017.

 

62
 

 

(3) Dr. Armen was granted a 75,000 share option grant on February 13, 2020.
   
(4) Dr. Armen was granted a 250,000 share option grant on March 25, 2024.
   
(5) Dr. Arrow was granted a 25,000 share option grant on February 12, 2016,
   
(6) Dr. Arrow was granted a 35,000 share option grant on April 15, 2016.
   
(7) Dr. Arrow was granted a 18,750 share option grant on October 16, 2017.
   
(8) Dr. Arrow was granted a 10,417 share option grant on February 1, 2019.
   
(9) Dr. Arrow was granted a 30,000 share option grant on February 13, 2020.
   
(10) Dr. Arrow was granted a 46,874 share option grant on February 13, 2020.
   
(11) Dr. Arrow was granted a 31,250 share option grant on July 18, 2020.
   
(12) Dr. Arrow was granted a 100,000 share option grant on March 25, 2026.
   
(13) Dr. Slee was granted a 25,000 shares option grant on April 15, 2016.
   
(14) Dr. Slee was granted a 18,750 shares option grant on October 16, 2017.
   
(15) Dr. Slee was granted a 37,500 shares option grant on February 13, 2020.
   
(16) Dr. Slee was granted a 18,750 shares option grant on July 18, 2020.
   
(17) Dr. Slee was granted a 12,500 shares option grant on February 25, 2021.
   
(18) Dr. Slee was granted a 5,000 shares option grant on January 8, 2024.
   
(19) Dr. Slee was granted a 100,000 shares option grant on March 25, 2024.
   
(20) Dr. Stein was granted a 50,000 shares option grant on January 22, 2015.
   
(21) Dr. Stein was granted a 10,000 shares option grant on April 15, 2016.
   
(22) Dr. Stein was granted a 50,000 shares option grant on October 16, 2017.
   
(23) Dr. Stein was granted a 37,500 shares option grant on February 13, 2020.
   
(24) Dr. Stein was granted a 12,500 shares option grant on February 25, 2021.
   
(25) Dr. Stein was granted a 75,000 shares option grant on March 25, 2024.

 

For Drs. Armen and Arrow, following a qualified Change of Control, a resignation for Good Reason, or an involuntary termination other than For Cause, 100% of the executives’ then-unvested options shall become immediately vested.

 

63
 

 

Security Ownership of Certain Beneficial Owners and Management

 

The following table sets forth information regarding the beneficial ownership of the Common Stock as of March 31, 2025, unless otherwise indicated, by (1) each person known by the Company to be the beneficial owner of more than 5% of the outstanding shares of common stock, (2) each director of the Company, (3) the Company’s current executive officers, and (4) all current directors and executive officers of the Company as a group. The persons and entities named in the table have sole voting and investment power with respect to all such shares owned by them, unless otherwise indicated.

 

Name and address of Beneficial Owner* 

Amount and Nature

of Beneficial

Ownership

   Percent of Class 
         
Garo H. Armen(1)   1,098,211(2)   14%
           
Robert B. Stein(1)   189,167(3)   3%
           
Khalil Barrage(1)   209,005(4)   3%
           
Alexander K. Arrow(1)   281,995(5)   4%
           
Brian J. Corvese(1)   79,271(6)   1%
           
David A. Lovejoy   144,275(7)   3%
           
Jennifer S. Buell(1)   115,417(8)   2%
           
Andrew Slee(1)   143,177(9)   2%
           
Pete Shaver   390,526(10)   5%
           
All directors and executive officers as a group (8 persons)   2,116,242(11)   25%

 

* Address for each party listed in the above table is c/o Protagenic Therapeutics, Inc., 149 Fifth Avenue, Suite 500, New York, NY 10010.

 

(1) Executive officer and/or director.

 

(2) Includes 738,489 shares of common stock. Also includes options to purchase 359,722 shares of common stock at an exercise price of $1.74, $5.00 or $7.00 per share. Does not include options to purchase 152,778 shares that are not exercisable within 60 days of the date of this report.

 

(3) Represents options to purchase 189,167 shares of common stock at an exercise price of $1.74, $5.00, $7.00, or $22.40 per share. Does not include options to purchase 45,833 shares that are not exercisable within 60 days of the date of this report.

 

(4) Includes 150,880 shares of common stock and options to purchase 58,125shares of common stock at an exercise price of $1.74, or $14.60 per share. Does not include options to purchase 9,375 shares that are not exercisable within 60 days of the date of this report.

 

(5) Includes 45,815 shares of common stock and Includes options to purchase 236,180 shares of common stock at an exercise price of $1.74, $4.00, $5.00 or $7.00 per share. Does not include options to purchase 61,111 shares that are not exercisable within 60 days of the date of this report.

 

(6) Includes options to purchase 79,271 shares of common stock at an exercise price of $7.00 per share. Does not include options to purchase 18,229 shares that are not exercisable within 60 days of the date of this report.

 

(7) Includes 37,200 shares of common stock and options to purchase 107,075 shares of common stock in the aggregate with an exercise price ranging from $4.00, $5.00, or $7.00 per share.

 

(8) Includes options to purchase 115,417 shares of common stock at an exercise price of $1.74, $7.00 or $22.40 per share. Does not include options to purchase 45,833 shares of common stock that are not exercisable within 60 days of the date of this report.

 

64
 

 

(9) Includes options to purchase 143,177 shares of common stock at an exercise price of $1.74, $5.00, $7.00, or $22.40 per share. Does not include options to purchase 74,323 shares of common stock that are not exercisable within 60 days of the date of this report.

 

(10) Includes 390,526 shares of common stock.

 

(11) Includes options to purchase 1,181,058 shares of common stock.

 

Options Repricing

 

On February 21, 2025, the Company held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on February 21, 2025. At the Company’s Annual Meeting, the Company’s stockholders approved the proposal to approve the repricing of certain outstanding stock options granted (the “Option Grants”) under the Company’s 2006 and 2016 Equity Incentive Plans (the “Plans”) to allow the Board of Directors (the “Board”) to reprice the exercise price of outstanding stock options under the Plans. Pursuant to that authority, on February 21, 2025, the Board repriced the Option Grants. The repriced Option Grants under the 2006 Equity Incentive Plan had original exercise prices ranging from $4.00 to $5.00 per share, and the repriced Option Grants under the 2016 Equity Incentive Plan had original exercise prices ranging from $1.74 to $19.92 per share. All of the Option Grants under the Plans were repriced to have an exercise price of $0.2655 per share, which was the closing price of the Company’s common stock on February 21, 2025.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

Certain Relationships and Related Party Transactions

 

Other than compensation arrangements for our named executive officers and directors, we describe below each transaction or series of similar transactions, since January 1, 2016, to which we were a party or will be a party, in which:

 

● the amounts involved exceeded or will exceed $120,000; and
   
● any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.

 

Compensation arrangements for our named executive officers and directors are described in Item 11, Executive Compensation.

 

Our principal offices are located at 149 Fifth Avenue, Suite 500, New York, New York 10010, in a conference room of Agenus, Inc. We utilize our principal office for quarterly board meetings and our annual shareholder meeting at no cost. Our personnel and consultants all work remotely, the Company’s basic science laboratory work is conducted in the Lovejoy Lab at the University of Toronto, and its preclinical efficacy work is conducted at CROs. Hence the Company does not have the need for a day-to-day physical office location other than a mailing address and conference room facility for meetings. For that reason, the Agenus conference room suits its purposes without imposing any inconveniences upon Agenus. Dr. Armen, our Executive Chairman, is also the Chairman and Chief Executive Officer of Agenus Inc.

 

2019-2020 Convertible Note Offering

 

Garo H. Armen and Khalil Barrage invested $200,000 and $200,000, respectively, in the Convertible Note Offering on the same terms as all other Investors. These options were converted as of December 31, 2023.

 

Zack Armen

 

During the latter part of 2018 and the first quarter of 2019, Zack Armen, the son of our Executive Chairman, Garo H. Armen, Ph.D., assisted us in the development of slide deck presentations and summaries, video editing, and forecasting and market size projections that were incorporated into presentations to investors and others. We have included these presentations in various Current Reports on Form 8-K which we filed with the Securities and Exchange Commission. On June 17, 2019, the Compensation and Audit Committees of the Board authorized the issuance to Mr. Zack Armen of 6,250 stock options under the 2016 Plan in consideration for his services. These options vested in their entirety on issuance, have a ten-year term and are exercisable at a price of $7.00 per share. On February 21, 2020 Mr. Zack Armen was also issued an additional 12,500 stock options that vest over 48 months and are exercisable at a price of $7.00 per share. On July 18, 2020 Mr. Zack Armen was also issued an additional 7,500 stock options that vest over 48 months and are exercisable at a price of $7.00 per share. On February 25, 2021, 2020 Mr. Zack Armen was also issued an additional 12,500 stock options that vest over 48 months and are exercisable at a price of $22.40 per share. On March 25, 2024 Mr. Zack Armen was also issued an additional 10,000 stock options that vest over 48 months and are exercisable at a price of $1.74 per share.

 

65
 

 

Policies and Procedures for Related Party Transactions

 

We have adopted a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock, any members of the immediate family of any of the foregoing persons and any firms, corporations or other entities in which any of the foregoing persons is employed or is a partner or principal or in a similar position or in which such person has a 5% or greater beneficial ownership interest, which we refer to collectively as related parties, are not permitted to enter into a transaction with us without the prior consent of our Board of Directors acting through the audit committee or, in certain circumstances, the chairman of the audit committee. Any request for us to enter into a transaction with a related party, in which the amount involved exceeds $100,000 and such related party would have a direct or indirect interest must first be presented to our audit committee, or in certain circumstances the chairman of our audit committee, for review, consideration and approval. In approving or rejecting any such proposal, our audit committee, or the chairman of our audit committee, is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances, the extent of the benefits to us, the availability of other sources of comparable products or services and the extent of the related party’s interest in the transaction.

 

Director Independence

 

We are not currently listed on any national securities exchange or in an inter-dealer quotation system that has a requirement that the Board of Directors be independent. However, in evaluating the independence of our members and the composition of the committees of our Board of Directors, our Board utilizes the definition of “independence” as that term is defined by applicable listing standards of the NASDAQ Stock Market and SEC rules, including the rules relating to the independence standards of an audit committee and the non-employee director definition of Rule 16b-3 promulgated under the Exchange Act.

 

Our Board of Directors expects to continue to evaluate its independence standards and whether and to what extent the composition of the Board and its committees meets those standards. We ultimately intend to appoint such persons to our Board and committees of our Board as are expected to be required to meet the corporate governance requirements imposed by a national securities exchange. Therefore, we intend that a majority of our directors will be independent directors of which at least one director will qualify as an “audit committee financial expert,” within the meaning of Item 407(d)(5) of Regulation S-K, as promulgated by the SEC.

 

We believe that Messrs. Barrage, Corvese, Wright, and Dr. Buell are each an “independent” director as that term is defined by the NASDAQ Stock Market, Inc. Marketplace Rules and SEC Regulations. In addition, the Board also designated Brian Corvese as an “audit committee financial expert,” as that term is defined by the NASDAQ Listing Rules and SEC regulations.

 

With regard to Mr. Wright’s independent status, the Board considered the fact that he is a current CEO of a publicly-traded biopharmaceutical company (MiMedX Group, Inc.) and that he is as a Partner at an investment firm (Signal Hill Advisors, LLC). He also serves on the Board of Directors of Agenus, Inc., a publicly-traded company for which Dr. Armen is the Chaiman and CEO.

 

With regard to Mr. Corvese’s independent status, the Board considered the fact that he has no business relationship with the Company.

 

With regard to Mr. Barrage’s independent status, the Board considered the fact that he has no business relationship with the Company.

 

With regard to Dr. Buell’s independent status, the Board considered the fact that she has no business relationship with the Company except her consulting role assisting with clinical trial design and that she reports to Dr. Armen in the course of her primary roles, as president of Agenus, Inc and MiNK Therapeutics, Inc, and is therefore not considered “independent.”.

 

Dr. Stein, a member of the Science and Clinical & Regulatory Committees, serves as our Chief Medical Officer, and is therefore not considered “independent.”

 

66
 

 

Dr. Armen, a member of the Science and Clinical & Regulatory Committees, serves as our Executive Chairman, and is therefore not considered “independent.”

 

Our principal offices are located at 149 Fifth Avenue, Suite 500, New York, New York 10010, in a conference room of Agenus, Inc. We utilize our principal office for quarterly board meetings and our annual shareholder meeting on a month to month basis at a nominal value. Dr. Armen, our Executive Chairman, is also the Chairman and Chief Executive Officer of Agenus Inc.

 

Item 14. Principal Accounting Fees and Services.

 

The following table sets forth the fees for services provided and reasonably expected to be billed by Malone Bailey LLP. The following is a summary of the fees billed to the Company for professional services rendered for the fiscal years ended December 31, 2024 and 2023.

 

   Fiscal Year 2024   Fiscal Year 2023 
Audit fees  $165,829   $100,000 
Audit-related fees  $-   $- 
Tax Fees  $-   $- 
All other fees  $-   $- 
           
Total  $165,829   $100,000 

 

Audit Fees: For the fiscal years ended December 31, 2024 and 2023, the aggregate audit fees billed by our independent auditors were for professional services rendered for audits and quarterly reviews of our consolidated financial statements, and assistance with reviews of registration statements and documents filed with the SEC.

 

Audit-Related Fees: Audit-related fees are for assurance and other activities not explicitly related to the audit of our financial statements.

 

Tax Fees: For the fiscal years ended December 31, 2024 and 2023, there were no tax fees, respectively.

 

All Other Fees: For the fiscal years ended December 31, 2024 and 2023, there were no other fees, respectively

 

Audit Committee Pre-Approval Policies and Procedures. The Audit Committee oversees and monitors our financial reporting process and internal control system, reviews and evaluates the audit performed by our registered independent public accountants and reports to the Board any substantive issues found during the audit. The Audit Committee is directly responsible for the appointment, compensation and oversight of the work of our registered independent public accountants. The Audit Committee convenes on a quarterly basis to approve each quarterly filing, and an annual basis to review the engagement of the Company’s external auditor.

 

The Audit Committee has considered whether the provision of Audit-Related Fees, Tax Fees, and all other fees as described above is compatible with maintaining MaloneBailey, LLP’s independence and has determined that such services for fiscal years 2024 and 2023, respectively, were compatible. All such services were approved by the Audit Committee pursuant to Rule 2-01 of Regulation S-X under the Exchange Act to the extent that rule was applicable.

 

67
 

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules.

 

(a) List of Documents filed as part of this Report

 

(1) Consolidated Financial Statements

 

The F-1 through F-20 following the Exhibit List as required by Part II, Item 8 “Financial Statements and Supplementary Data” of this Form 10-K.

 

(2) Financial Statement Schedules.

 

Schedules are omitted because they are either not required, not applicable, or the information is otherwise included.

 

(3) Exhibits

 

The Company has filed with this report or incorporated by reference herein certain exhibits as specified below pursuant to Rule 12b-32 under the Exchange Act. See Exhibit Index following the signature page to this report for a complete list of documents filed with this report.

 

Exhibit

No.

   Description
     
3.1   Third Amended and Restated Certificate of Incorporation of Protagenic Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to Company’s Current Report on Form 8-K, as filed with the SEC on June 20, 2016).
     
3.2   Certificate of Designations, Powers, Preferences and Other Rights of Preferred Stock and Qualifications, Limitations and Restrictions Thereof of Series B Convertible Preferred Stock of Atrinsic, Inc. (Incorporated by reference to Exhibit 3.1 to Company’s Current Report on Form 8-K, as filed with the SEC on February 5, 2016.)
     
3.3   Second Amended and Restated Bylaws Protagenic Therapeutics, Inc., (Incorporated by reference to Exhibit 3.1 to Company’s Current Report on Form 8-K, as filed with the SEC on June 1, 2018).
     
4.1   Description of Securities (Incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K, as filed with the SEC on April 1, 2024)
     
4.2   Form of Warrant of Protagenic Therapeutics, Inc. (Incorporated by reference to Exhibit 4.1 to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)
     
4.3(i)   Warrant of Protagenic Therapeutics, Inc. issued to Garo H. Armen on May 17, 2011. (Incorporated by reference to Exhibit 4.3(i) to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)
     
4.3(ii)   Warrant of Protagenic Therapeutics, Inc. issued to Garo H. Armen on February 18, 2013 (Incorporated by reference to Exhibit 4.3(ii) to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)
     
4.4(i)   Warrant of Protagenic Therapeutics, Inc. issued to Gregory H. Ekizian on July 7, 2011. (Incorporated by reference to Exhibit 4.4(i) to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)
     
4.4(ii)   Warrant of Protagenic Therapeutics, Inc. issued to PENSCO Trust Company, FBO Gregory H. Ekizian on February 18, 2013. (Incorporated by reference to Exhibit 4.4(ii) to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)
     
4.5   Form of Placement Agent Warrant (Incorporated by reference to Exhibit 4.5 to Company’s Current Report on Form 8-K, as filed with the SEC on April 18, 2016).
     
10.1   Employment Agreement, effective January 1, 2014 between Protagenic Therapeutics Canada (2006) Inc. and Dr. Robert Ziroyan (Incorporated by reference to Exhibit 10.12 to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)**
     
10.2   Consulting Agreement, effective December 18, 2020, between Protagenic Therapeutics Inc. and Dr. Andrew Slee. (Incorporated by reference to Exhibit 10.2 to Company’s Annual Report on Form 10-K, as filed with the SEC on March 25, 2021.)* **
     
10.3   Consulting Agreement, as amended, between Protagenic Therapeutics Canada (2006) Inc. and Dr. Dalia Barsyte (Incorporated by reference to Exhibit 10.13 to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)**
     
10.4   Amended and Restated Consulting Agreement, effective December 18, 2020, between Protagenic Therapeutics Inc. and Dr. Robert B. Stein. (Incorporated by reference to Exhibit 10.4 to Company’s Annual Report on Form 10-K, as filed with the SEC on March 25, 2021.)* **

 

10.5   Protagenic Therapeutics, Inc. 2006 Employee, Director and Consultant Stock Plan (Incorporated by reference to Exhibit 10.16 to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)**
     
10.6   Form of Nonqualified Stock Option Award Agreement under the 2006 Employee, Director and Consultant Stock Plan. (Incorporated by reference to Exhibit 10.17 to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.) **
     
10.7(i)   Technology License Agreement, effective July 21, 2005, between The University of Toronto Innovations Foundation and Protagenic Therapeutics, Inc. (Incorporated by reference to Exhibit 10.19(i) to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)

 

68
 

 

10.7(ii)   First Amendment to Technology License Agreement, effective February 18, 2015, between the Governing Council of the University of Toronto and Protagenic Therapeutics, Inc. (Incorporated by reference to Exhibit 10.19(ii) to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)
     
10.8(i)   Sponsored Research Agreement, effective April 1, 2014, between the Governing Council of the University of Toronto and Protagenic Therapeutics Canada (2006), Inc., Protagenic Therapeutics, Inc. (Incorporated by reference to Exhibit 10.20(i) to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)
     
10.8(ii)   Amendment to the Sponsored Research Agreement, effective April 1, 2015, between the Governing Council of the University of Toronto and Protagenic Therapeutics Canada (2006), Inc., Protagenic Therapeutics, Inc. (Incorporated by reference to Exhibit 10.20(ii) to Company’s Current Report on Form 8-K, as filed with the SEC on February 12, 2016.)
     
10.9   Protagenic Therapeutics, Inc. 2016 Equity Compensation Plan. (Incorporated by reference to Exhibit 10.1 to Company’s Current Report on Form 8-K, as filed with the SEC on June 20, 2016.)**
     
10.10   Form of Incentive Stock Option Agreement under the Protagenic Therapeutics, Inc. 2016 Equity Compensation Plan. (Incorporated by reference to Exhibit 10.2 to Company’s Current Report on Form 8-K, as filed with the SEC on June 20, 2016.) **
     
10.11   Form of Nonqualified Stock Option Grant Agreement under the Protagenic Therapeutics, Inc. 2016 Equity Compensation Plan. (Incorporated by reference to Exhibit 10.3 to Company’s Current Report on Form 8-K, as filed with the SEC on June 20, 2016.) **
     
10.12   Form of Convertible Note Purchase Agreement (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on November 21, 2019)
     
10.13   Form of Convertible Promissory Note (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, as filed with the SEC on November 21, 2019)
     
10.14   Form of Guaranty (Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, as filed with the SEC on November 21, 2019)
     
14.1   Protagenic Therapeutics, Inc. Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 to the Current Report on Form 10-K, as filed with the SEC on April 18, 2017).
     
14.2   Protagenic Therapeutics, Inc. Guideline on Significant Corporate Governance Issues (incorporated by reference to Exhibit 14.2 to the Current Report on Form 10-K, as filed with the SEC on April 18, 2017).
     
14.3   Protagenic Therapeutics, Inc. Process for Security Holder Communications with Directors (incorporated by reference to Exhibit 14.3 to the Current Report on Form 10-K, as filed with the SEC on April 18, 2017).
     
19.1*   Protagenic Therapeutics, Inc. Insider Trading Policy
     
21.1   Subsidiaries (Incorporated by reference to Exhibit 21.1 to the Company’s Annual Report on Form 10-K, as filed with the SEC on April 1, 2024)
     
23.1   Consent of Malone Bailey, LLP, independent registered public accounting firm
     
31.1*   Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)
     
31.2*   Certification of Chief Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b)
     
32.1*   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002
     
97   Protagenic Therapeutics, Inc. Policy on Recovery of Erroneously Awarded Compensation (Incorporated by reference to Exhibit 97 to the Company’s Annual Report on Form 10-K, as filed with the SEC on April 1, 2024)
     
99.1   Audit Committee Charter adopted by Board of Directors of Protagenic Therapeutics, Inc. on March 7, 2017 (Incorporated by reference to Exhibit 99.1 to the Company’s Annual Report on Form 10-K, as filed with the SEC on April 1, 2024).
     
99.2   Compensation Committee Charter adopted by Board of Directors of Protagenic Therapeutics, Inc. on March 7, 2017 (Incorporated by reference to Exhibit 99.2 to the Company’s Annual Report on Form 10-K, as filed with the SEC on April 1, 2024).
     
99.3   Governance and Nominating Committee Charter adopted by Board of Directors of Protagenic Therapeutics, Inc. on March 7, 2017 (Incorporated by reference to Exhibit 99.3 to the Company’s Annual Report on Form 10-K, as filed with the SEC on April 1, 2024).
     
99.4   Science Committee Charter adopted by the Board of Directors of Protagenic Therapeutics, Inc. (Incorporated by reference to Exhibit 99.1 to the Company’s Annual Report on Form 10-K, as filed with the SEC on April 29, 2020)
     
[100.1]   [XBRL-related documents]
     
[101.1]   [Interactive Data Files]
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith
** Designates management contracts and compensation plans
† Furnished herewith

 

69
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

      PROTAGENIC THERAPEUTICS, INC.
         
Date: March 31, 2025   By: /s/ Garo H. Armen
        Garo H. Armen
        Chairman (Principal Executive Officer and Duly Authorized Officer)
         
Date: March 31, 2025   By: /s/ Alexander K. Arrow
        Alexander K. Arrow
        Chief Financial Officer (Principal Financial Officer)

 

70
 

 

PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY

 

CONSOLIDATED FINANCIAL STATEMENTS

 

FOR THE YEARS ENDED

 

DECEMBER 31, 2024 AND 2023

 

  Page
Report of Independent Registered Public Accounting Firm (PCAOB ID 206) F-2
   
Consolidated Balance Sheets F-3
   
Consolidated Statements of Operations and Comprehensive Loss F-4
   
Consolidated Statements of Changes in Stockholders’ Equity F-5
   
Consolidated Statements of Cash Flows F-6
   
Notes to Consolidated Financial Statements F-7

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Stockholders and Board of Directors of

Protagenic Therapeutics, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Protagenic Therapeutics, Inc. and its subsidiary (collectively, the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern Matter

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has negative cash flows from operations that raises substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 

/s/ MaloneBailey, LLP  
www.malonebailey.com  
We have served as the Company’s auditor since 2017.  
Houston, Texas  
March 31, 2025  

 

F-2

 

 

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS

 

   December 31, 2024   December 31, 2023 
ASSETS          
           
CURRENT ASSETS          
           
Cash  $1,838,469   $1,287,893 
Marketable securities   -    2,768,119 
Prepaid expenses   44,398    144,025 
           
TOTAL CURRENT ASSETS   1,882,867    4,200,037 
           
Equipment - net   73,046    123,332 
           
TOTAL ASSETS  $1,955,913   $4,323,369 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
CURRENT LIABILITIES          
           
Accounts payable and accrued expenses  $902,884   $439,757 
Accounts payable and accrued expenses - related party   39,875    215,495 
           
TOTAL CURRENT LIABILITIES   942,759    655,252 
           
TOTAL LIABILITIES   942,759    655,252 
           
STOCKHOLDERS’ EQUITY          
Preferred stock, $0.000001 par value; 20,000,000 shares authorized; none shares issued and outstanding in the following classes:   -     -  
Preferred stock; par value $0.000001; 2,000,000 shares authorized; none issued and outstanding   -    - 
Series B convertible preferred stock, $0.000001 par value;18,000,000 shares authorized; 0 and 0 shares issued and outstanding at December 31, 2024, and December 31, 2023   -    - 
Common stock, $.0001 par value, 100,000,000 shares authorized, 7,241,443 and 4,435,132 shares issued and outstanding at December 31, 2024, and December 31, 2023   725    444 
Additional paid-in-capital   37,445,495    34,559,091 
Accumulated deficit   (36,303,216)   (30,777,872)
Accumulated other comprehensive loss   (129,850)   (113,546)
           
TOTAL STOCKHOLDERS’ EQUITY   1,013,154    3,668,117 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $1,955,913   $4,323,369 

 

See accompanying notes to the consolidated financial statements

 

F-3

 

 

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

   2024   2023 
   For the years ended December 31, 
   2024   2023 
OPERATING AND ADMINISTRATIVE EXPENSES          
Research and development  $3,844,984   $3,063,603 
Research and development – related party   97,357    256,264 
General and administrative   1,758,609    1,207,107 
           
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES   5,700,950    4,526,974 
           
LOSS FROM OPERATIONS   (5,700,950)   (4,526,974)
           
OTHER INCOME          
           
Interest income   43,465    264,476 
Interest expense   -    (107,682)
Realized loss on marketable securities   51,732    (630,317)
Gain on settlement of accounts payable and accrued liabilities with Related parties   80,409    - 
TOTAL OTHER INCOME   175,606    (473,523)
           
LOSS BEFORE TAX   (5,525,344)   (5,000,497)
           
INCOME TAX EXPENSE   -    - 
           
NET LOSS  $(5,525,344)  $(5,000,497)
           
COMPREHENSIVE LOSS          
           
Other Comprehensive Loss - net of tax          
Net unrealized gain (loss) on marketable securities   26,587    16,848 
Reclassification of realized losses on debt securities   (43,434)   489,120 
Foreign exchange translation income (loss)   543    57,393 
           
TOTAL COMPREHENSIVE LOSS  $(5,541,648)  $(4,437,136)
           
Net loss per common share - Basic and Diluted  $(1.13)  $(1.15)
           
Weighted average common shares - Basic and Diluted   4,899,953    4,344,580 

 

See accompanying notes to the consolidated financial statements

 

F-4

 

 

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGE IN STOCKHOLDERS’ EQUITY

For the Year Ended December 31, 2024 and 2023

 

   Shares   Amount   Shares   Amount   Capital   (Deficit)   Loss   Equity 
   Series B
Convertible
Preferred Stock		   Common Stock   Additional
Paid-in-		   Accumulated   Accumulated
Other
Comprehensive		   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   (Deficit)   Loss   Equity 
                                 
BALANCE -December 31, 2022   -   $-    4,321,315   $434   $33,371,406   $(25,777,375)  $(676,907)  $6,917,558 
                                         
Foreign currency translation gain   -    -    -    -    -    -    57,393    57,393 
Unrealized gain on marketable securities   -    -    -    -    -    -    16,848    16,848 
Reclassification of realized losses on debt securities   -    -    -    -    -    -    489,120    489,120 
Stock compensation - stock options   -    -    -    -    666,828    -    -    666,828 
Conversion of notes and interest   -    -    104,173    10    520,857    -    -    520,867 
Rounding from reverse split   -    -    9,644    -    -    -    -    - 
                                         
Net loss   -    -    -    -    -    (5,000,497)   -    (5,000,497)
                                         
BALANCE -December 31, 2023   -   $-    4,435,132   $444   $34,559,091   $(30,777,872)  $(113,546)  $3,668,117 
Foreign currency translation gain   -    -    -    -    -    -    543    543 
Unrealized gain on marketable securities   -    -    -    -    -    -    26,587    26,587 
 Reclassification of realized losses on debt securities   -    -    -    -    -    -    (43,434)   (43,434)
Stock compensation - stock options   -    -    -    -    923,139    -    -    923,139 
Stock issued for cash   -    -    858,016    86    1,963,460    -    -    1,963,546 
Stock and warrants issued at offering   -    -    1,948,295    195    (195)   -    -    - 
                                         
Net loss   -    -    -    -    -    (5,525,344)   -    (5,525,344)
                                         
BALANCE -December 31, 2024   -   $-    7,241,443   $725   $37,445,495   $(36,303,216)  $(129,850)  $1,013,154 

 

See accompanying notes to the consolidated financial statements

 

F-5

 

 

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   2024   2023 
   For the year ended December 31, 
   2024   2023 
         
CASH FLOWS FROM OPERATING ACTIVITIES          
Net Loss  $(5,525,344)  $(5,000,497)
Adjustments to reconcile net loss to net cash used in operating activities          
Depreciation expense   50,286    28,218 
Stock-based compensation   923,139    666,828 
Realized (gain) loss on sale of marketable securities   (51,732)   630,317 
Amortization of debt discount   -    85,770 
Gain on settlement of accounts payable and accrued liabilities   with related parties   (80,409)   - 
Changes in operating assets and liabilities          
Prepaid expenses   99,627    (87,086)
Accounts payable and accrued expenses   463,127    (183,832)
Accounts payable and accrued expenses – related party   (95,211)   156,506 
           
NET CASH USED IN OPERATING ACTIVITIES   (4,216,517)   (3,703,776)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
           
Proceeds from sale of marketable securities   3,100,000    7,689,507 
Purchase of marketable securities   (297,120)   (2,764,250)
Purchase of fixed assets   -    (149,775)
           
NET CASH PROVIDED BY INVESTING ACTIVITIES   2,802,880    4,775,482 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
           
Issuance of shares and warrants from offering, net of offering costs   1,963,546    - 
           
NET CASH PROVIDED BY FINANCING ACTIVITIES   1,963,546    - 
           
Effect of exchange rate changes on cash   667    998 
           
NET CHANGE IN CASH   550,576    1,072,704 
           
CASH, BEGINNING OF THE PERIOD   1,287,893    215,189 
           
CASH, END OF THE PERIOD  $1,838,469   $1,287,893 
           
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION          
Cash paid for interest expense  $-   $- 
Cash paid for income taxes  $-   $- 
           
NONCASH FINANCING AND INVESTING TRANSACTIONS          
Shares issued for conversion of notes and interest  $-   $520,867 
Unrealized gain or loss on marketable securities  $26,587   $16,848 

 

See accompanying notes to the consolidated financial statements

 

F-6

 

 

PROTAGENIC THERAPEUTICS, INC. & SUBSIDIARY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024

 

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

 

Company Background

 

Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), formerly known as Atrinsic, Inc., is a Delaware corporation with one subsidiary named Protagenic Therapeutics Canada (2006) Inc. (“PTI Canada”), a corporation formed in 2006 under the laws of the Province of Ontario, Canada.

 

We are a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.

 

NOTE 2 – LIQUIDITY AND GOING CONCERN

 

As shown in the accompanying consolidated financial statements, the Company has incurred significant recurring losses resulting in an accumulated deficit. The Company anticipates further losses in the development of its business. The Company also had negative cash flows used in operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

Based on its cash resources and positive working capital as of December 31 2024, the Company does not have sufficient resources to fund its operations past twelve months from the date these consolidated financial statements are available to be issued. The positive working capital as of December 31, 2024 was due to funds raised by the Company from its equity offering during the year ended December 31, 2021. Absent generation of sufficient revenue from the execution of the Company’s business plan, the Company will need to obtain debt or equity financing by the third quarter of 2025   . Because the Company has insufficient resources on hand to fund operations through the next twelve months from the date these consolidated financial statements are available to be issued, the Company believes that there is substantial doubt in its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued..   These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”).

Reclassification

 

Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation. These reclassifications relate to presenting “Research and development with related parties” as a separate line item in the Company’s Consolidated Statements of Operations and Comprehensive Loss.

 

F-7

 

 

Principles of consolidation

 

The consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated.

 

Use of estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the consolidated financial statements include valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.

 

Concentrations of Credit Risk

 

The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. As of December 31, 2024, the Company has bank balances that exceed the federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2024 and December 31, 2023 the Company did not have any cash equivalents. As of December 31, 2024 and December 31, 2023, the Company had cash of $1,838,469 and $1,287,893, respectively.  

 

Marketable Securities

 

The Company accounts for marketable debt securities, the only type of securities it owns, in accordance with the FASB Accounting Standards Codification 320, Investments – Debt and Equity Securities (“ASC 320”).

 

Pursuant to ASC 320-10-35-1, investments in debt securities that are classified as available for sale shall be measured subsequently at fair value in the consolidated balance sheets at each balance sheet date. Unrealized holding gains and losses for available-for-sale securities (including those classified as current assets) shall be excluded from earnings and reported in other comprehensive income until realized.

 

During the year ended December 31, 2024 the Company purchased $297,120 and sold $3,100,000 in marketable securities with a realized gain of $51,732 and an unrealized gain of $26,587. As of December 31, 2024 and December 31, 2023, the Company owned marketable securities with a total fair value of $0 and $2,768,119, respectively.

 

Equipment

 

Equipment is stated at cost less accumulated depreciation. Cost includes expenditures for computer equipment and lab equipment. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of equipment is depreciated using the straight-line method over the estimated useful lives of the related assets which is three years. Depreciation expense was $50,286 and $28,218 for the years ended December 31, 2024 and 2023, respectively.

 

Fair Value Measurements

 

ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

 

F-8

 

 

The three levels are described below:

 

Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;

 

Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;

 

Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.

 

The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short-term maturity of those instruments.

 

Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.

 

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2024.

 

   Carrying      Fair Value Measurement Using 
   Value       Level 1     Level 2     Level 3   Total 
Marketable securities  $—   $—   $—   $—   $— 

 

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2023.

 

   Carrying      Fair Value Measurement Using 
   Value       Level 1     Level 2     Level 3   Total 
Marketable securities  $2,768,119   $2,768,119   $—   $—   $2,768,119 

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported.

 

If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.

 

F-9

 

 

Basic and Diluted Net (Loss) per Common Share

 

Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the consolidated statements of operations and comprehensive loss.

 

  

Potentially Outstanding

Dilutive Common Shares

 
  

For the

Year Ended

December 31, 2024

  

For the

Year Ended

December 31, 2023

 
           
Conversion Feature Shares          
           
Stock Options   1,953,491    1,357,466 
           
Warrants   4,968,645    942,566 
           
Total potentially outstanding dilutive common shares   6,922,136    2,300,032 

 

Research and Development

 

Research and development expenses are charged to operations as incurred.

 

Foreign Currency Translation

 

The Company follows ASC 830, Foreign Currency Matters (“ASC 830”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. ASC 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to ASC 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.

 

The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the consolidated statements of operations and comprehensive loss.

 

Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.

 

F-10

 

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The adoption of this ASU did not have a material effect on the Company’s financial statements.

 

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The purpose of the amendment is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is to be applied retrospectively to all prior periods presented in the financial statements. The Company adopted this ASU and has updated its disclosure with segment reporting information.

 

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” to improve disclosures about the nature of expenses in commonly presented financial statement captions. ASU 2024-03 is effective for all public business entities for annual reporting periods beginning after December 15, 2026, on either a prospective or retrospective basis. Early adoption permitted. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements and related disclosures.

 

NOTE 4 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses, including related party balances, consist of the following at:

 

   December 31, 2024   December 31, 2023 
         
Accounting  $55,340   $36,750 
Research and development   666,002    498,366 
Legal   118,455    6,334 
Other   102,962    113,802 
Total  $942,759   $655,252 

 

NOTE 5 - STOCKHOLDERS’ EQUITY

 

Common Stock

 

During the year ended December 31, 2024, the Company issued 2,806,311 shares of common stock for cash.

 

During the year ended December 31, 2023, the Company issued 104,173 shares of common stock for the conversion of notes and interest and 9,644 shares of common stock for rounding of shares related to the Reverse Split.

 

Securities Purchase Agreement

 

On October 29, 2024, Protagenic Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue to the Purchasers in a private placement, 1,948,295 shares of the Company’s common stock (the “Shares”), par value $0.0001 per share (“Common Stock”), series A common stock purchase warrants (the “Series A Common Stock Warrants”) to purchase an aggregate of 1,948,295 shares of Common Stock (the “Series A Common Stock Warrant Shares”) with an exercise price of $0.64 per share (subject to adjustment as described therein), which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date (as defined in the Purchase Agreement), and series B common stock purchase warrants (the “Series B Common Stock Warrants”) to purchase an aggregate of 1,948,295 shares of Common Stock (the “Series B Common Stock Warrant Shares”) with an exercise price of $0.64 per share (subject to adjustment as described therein), which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. As used herein, the Series A Common Stock Warrants and the Series B Common Stock Warrants are sometimes referred to collectively as the “Common Stock Warrants”. Such private placement is referred to herein as the “Transaction.” The purchase price of each Share and associated Common Stock Warrants was $0.64 ($0.89 in the case of insiders).

 

F-11

 

 

Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”), acted as sole placement agent for the Transaction. The Company issued to Brookline or its designees warrants (the “Placement Agent Warrants”) to purchase up to 129,489 shares of Common Stock at an exercise price equal to $0.64 per share. The Placement Agent Warrants are exercisable immediately upon issuance and on or before the Termination Date (as defined in the Placement Agent Warrants).

 

The Purchase Agreement closed on November 4, 2024. The Company sold (a) 1,948,295 shares of Common Stock, (b) series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of Common Stock, (c) series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of Common Stock and (d) placement agent warrants to purchase an aggregate of 129,489 shares of Common Stock. The gross proceeds from the Transaction were approximately $1.9 million, before deducting fees and other offering expenses payable by the Company.

 

Stock-Based Compensation

 

The Company adopted an Employee, Director and Consultant Stock Plan on June 17, 2016 (the “2016 Plan”). Pursuant to the 2016 Plan, the Company’s Compensation Committee may grant awards to any employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary. Due to an annual “evergreen” provision in the 2016 Plan, the number of shares reserved for future grants was increased by 196,857, 186,594 and 184,260 in 2024, 2023 and 2022, respectively. As a result of these increases, as of December 31, 2024 and December 31, 2023, the aggregate number of shares of common stock available for awards under the 2016 Plan was 873,763 shares and 1,279,181 shares, respectively. Options issued under the 2016 Plan are exercisable for up to ten years from the date of issuance.

 

There were 1,953,491options outstanding as of December 31, 2024. During the year ended December 31, 2024, the Company issued 742,150 options, respectively. During the year ended December 31, 2023, the Company issued no options.

 

There were 1,357,466 options outstanding as of December 31, 2023.

 

The fair value of each stock option granted during the year ended December 31, 2024 was estimated using the Black-Scholes assumptions and or factors as follows:

 

Exercise price  $0.84-$5.00 
Expected dividend yield   0%
Risk free interest rate   4.01%-4.25%
Expected life in years   10 
Expected volatility   213-215%

 

The following is an analysis of the stock option grant activity under the Plan:

 

   Number  

Weighted Average

Exercise Price

  

Weighted Average

Remaining Life

 
Stock Options               
Outstanding December 31, 2023   1,357,466   $7.39    4.49 
Granted   742,150    1.73    9.23 
Expired   (146,125)   5.85    - 
Exercised   -    -    - 
Outstanding December 31, 2024   1,953,491   $5.36    5.77 

 

F-12

 

 

A summary of the status of the Company’s nonvested options as of December 31, 2024, and changes during the year ended December 31, 2024 is presented below:

 

Nonvested Options  Options  

Weighted-Average

Exercise Price

 
Nonvested at December 31, 2023   49,832   $14.72 
Granted   742,150    1.73 
Vested   (233,324)   4.14 
Forfeited   -    - 
Nonvested at December 31, 2024   558,658   $1.89 

 

As of December 31, 2024, the Company had 1,953,491 shares issuable under options outstanding at a weighted average exercise price of $5.36 and an intrinsic value of $0.

 

The Company recognized compensation expense related to options issued of $923,139 and $666,828 for the years ended December 31, 2024 and 2023, respectively, in which $431,884 and $206,104 is included in general and administrative expenses and $491,255 and $460,724 in research and development expenses, respectively. For the year ended December 31, 2024 and 2023, $186,031 and $6,852 of the stock compensation was related to employees and $737,108   and $659,976 was related to non-employees, respectively.

 

As of December 31, 2024, the unamortized stock option expense was $1,012,825 with $530,456 being related to employees and $482,369 being related to non-employees. As of December 31, 2024, the weighted average remaining vesting period for the unamortized stock compensation to be recognized is 2.83 years.

 

On January 8, 2024, the Company issued 20,750 options to purchase the Company’s common stock to consultants and employees. These options have an exercise price of $0.84 and expire in 10 years from issuance. These options vest over 48 months.

 

On February 12, 2024, the Company entered into a consulting agreement. As part of this agreement the Company agrees to pay $5,000 per month and issue 4,400 options to purchase the Company’s common stock. These options have an exercise price of $5.00 and expire in 10 years from issuance. These options vest over three months.

 

On March 25, 2024, the Company issued 717,000 options to purchase the Company’s common stock to officers, board of directors and consultants. These options have an exercise price of $1.74 and expire in 10 years from issuance. These options vest between 24 and 48 months with 160,000 options to vest upon achievement of certain performance conditions.

 

Warrants:

 

The fair value of each warrant granted during the year ended December 31, 2024 was estimated using the Black-Scholes assumptions and or factors as follows:

 

Exercise price  $0.64 
Expected dividend yield   0%
Risk free interest rate   4.31%-4.45%
Expected life in years   5-1.50 
Expected volatility   242-271%

 

F-13

 

 

A summary of warrant issuances are as follows:

 

   Number  

Weighted Average

Exercise Price

  

Weighted Average

Remaining Life

 
Warrants               
                
Outstanding December 31, 2023   942,566   $19.47    2.31 
Granted   4,206,079    0.64    3.30 
Expired   -    -    - 
Exercised   -    -    - 
Outstanding December 31, 2024   4,986,645   $4.21    2.92 

 

As of December 31, 2024, the Company had 4,968,645 shares issuable under warrants outstanding at a weighted average exercise price of $4.21 and an intrinsic value of $0.

 

The Company recognized compensation expense related to warrants issued of $0 and $0 during the year ended December 31, 2024 and 2023, respectively.

 

NOTE 6 - COLLABORATIVE AGREEMENTS

 

The Company and the University of Toronto (the “University”) entered into an agreement effective April 1, 2014 (the “New Research Agreement”) for the performance of a research project titled “Teneurin C-terminal Associated Peptide (“TCAP”) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “New Project”). The New Project is to perform research related to work done by Dr. David A. Lovejoy, a professor at the University and stockholder of the Company, in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, Dr. Lovejoy entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 30, 2016. In February 2017, the New Research Agreement was extended to December 31, 2017. The extension allowed for further development of the technologies and use of their applications. On April 10, 2018, the agreement was amended and the research agreement has been further extended to September 30, 2024. On December 20, 2024, the agreement was amended and the research agreement has been further extended to the entire lifetime of the last issued patent covered by the license.

 

The sponsorship research and development expenses pertaining to the Research Agreements were $0 and $0 for the year ended December 31, 2024 and 2023, respectively.

 

NOTE 7 - COMMITMENTS AND CONTINGENCIES

 

Licensing Agreements

 

On July 31, 2005, the Company had entered into a Technology License Agreement (“License Agreement”) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the “Technologies”). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date.

 

Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University 10% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. The Company had no sales revenue for the year ended December 31, 2024 and 2023 and therefore was not subject to paying any royalties.

 

F-14

 

 

In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at 3% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or Dr. Lovejoy, and/or the University, as the case may be. The Company has agreed to pay all out-of-pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to the University under the License Agreement and amendment.

 

The patent applications were made in the name of Dr. Lovejoy and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the five intellectual patent properties.

 

Legal Proceedings

 

From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

 

Notice of Delisting

 

On July 24, 2024, the Company received a deficiency letter (the “Notification Letter”) from the Nasdaq Listing Qualifications (“Nasdaq”) stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notification Letter states that the Company has 180 calendar days, or until January 20, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s closing bid price of the Company’s common stock must have a closing bid price of at least $1.00 for a minimum of ten consecutive business days.

  

On January 22, 2025, Nasdaq provided a notice to the Company that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as the Company does not comply with the requirements for initial listing on The Nasdaq Capital Market. This notification is part of the ongoing discussions with the Nasdaq Hearings Panel (the “Panel”) regarding the Company’s listing status, and the Company included this matter in its presentation to the Panel on January 30, 2025.   

 

On February 19, 2025, the Company received a hearing panel decision from Nasdaq (Nasdaq Listing Qualifications Hearings Docket No. NQ 7072C-25) indicating that its provisional plan for regaining compliance with the Nasdaq listing requirements had been accepted. For continued listing on the Nasdaq Capital Market, the Company has until April 28, 2025 to: (1) demonstrate compliance with Nasdaq Rules 5550(a)(2) and 5550(b)(2), (2) file a public disclosure describing any transactions undertaken by the Company to increase its equity and provide and indication of its equity following those transactions, and (3) provide the Panel with an update on its fundraising plans and updated income projections for the next 12 months.

 

F-15

 

 

NOTE 8 – RELATED PARTY TRANSACTIONS

 

The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen. The Company does not pay any rent for the use of this space. This space is used for quarterly board meetings and our annual shareholder meeting.

 

During the year ended December 31, 2021, the Company engaged Agenus Inc., a related party, to perform research and development services. Agenus Inc. is a related party due to the Company’s Director and Chairman of the Board being the CEO and Chairman of the Board for Agenus Inc. The Company incurred $97,357 and $149,509 in expenses related to these services during the year ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and December 31, 2023, the outstanding balance owed to Agenus Inc. is $39,875 and $150,296, respectively.

 

During the year ended December 31, 2022, the Company engaged CTC North, GmbH (“CTC”) to perform research and development services. CTC is a related party due to the Company’s Director and Chairman of the Board being the CEO and Chairman of the Board for Agenus Inc, CTC’s parent company. The total commitment for this agreement is $1.3 million. The Company incurred $0 and $106,755 in expenses related to these services during the year ended December 31, 2024 and 2023, respectively. During the year ended December 31, 2024, the Company wrote off the remaining accounts payable balance of $80,409 as CTC is no longer in business. As of December 31, 2024 and December 31, 2023, there is $0 and $80,409 owed to CTC in connection with this agreement, respectively.

 

NOTE 9 – SEGMENT REPORTING

 

The Company operates in one operating segment, and therefore one reportable segment, and is focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The Company’s business activities are managed on a consolidated basis through the development and potential commercialization of pharmaceutical products, which are aimed at the global market in the event that products are successful in receiving regulatory approvals. Our determination that we operate as a single operating segment is consistent with the financial information regularly reviewed by the chief operating decision makers for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. Our chief operating decision makers is the Chief Executive Officer and Chief Financial Officer.

 

The accounting policies for our single operating segment are the same as those described in the summary of significant accounting policies. Our single operating segment incurs expenses from the development of therapeutics. The Company has not yet generated revenue in its operating history.

For the segment, the chief operating decision makers use net loss, that also is reported on the consolidated statements of operations as consolidated net loss, to allocate resources. The chief operating decision maker also uses consolidated net loss, along with non-financial inputs and qualitative information, to evaluate our performance, establish compensation, monitor budget versus actual results, and decide the allocation of funds in our various research activities.

 

NOTE 10 – INCOME TAXES

 

The components of loss before income taxes are as follows:

 

   2024   2023 
Domestic   (5,526,365)   (4,998,066)
Foreign   1,021    (2,431)
Loss before income taxes   (5,525,344)   (5,000,497)

 

F-16

 

 

The Company had no income tax expense due to operating losses incurred for the years ended December 31, 2024 and 2023.

 

For the years ended December 31, 2024 and 2023, a reconciliation of the Company’s effective tax rate to the statutory U.S. Federal rate is as follows:

 

   2024   2023 
Income taxes at Federal statutory rate   (21.0)%   (21.0)%
State income taxes, net of Federal income tax effect   (8.9)%   (8.9)%
Perm difference   0.0%   0.0%
Foreign tax rate differential   0.0)%   (0.1)%
Change in valuation allowance   29.9%   30.0%
Other   0.0%   0.0%
Income tax provision   0.0%   0.0%

 

The tax effects of temporary differences that give rise to the Company’s deferred tax assets and liabilities are as follows:

 

   2024   2023 
U.S. net operating loss carryforwards   6,305,000    4,940,000 
Stock compensation   2,408,000    2,131,000 
 Deferred tax assets, gross   8,713,000    7,071,000 
Valuation allowance   (8,713,000)   (7,071,000)
Net deferred tax assets   -    - 

 

As of December 31, 2024 the Company had federal net operating loss carryforwards (“NOL”) of approximately $19.7 million. The 2017 Tax Cuts and Jobs Act (“TCJA”) will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss carryover or 80% of a corporation’s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended). Also, there will be no carryback for losses incurred after 2017. Losses incurred prior to 2018 will generally be deductible to the extent of the lesser of a corporation’s net operating loss carryover or 100% of a corporation’s taxable income and be available for twenty years from the period the loss was generated. The federal net operating losses generated prior to 2018 of $0.1 million will expire at various dates through 2037. As of December 31, 2024 and 2023, the Company had state and local net operating loss carryforwards of approximately $18.5 million and $14.0 million, respectively, to reduce future state tax liabilities also through 2035.

 

As of December 31, 2024 and 2023, the Company had Canadian NOL of approximately $1.4 million and $1.4 million respectively. The Canadian losses expire in stages beginning in 2026. As of December 31, 2024 and 2023, the Company also has unclaimed Canadian federal scientific research and development investment tax credits, which are available to reduce future federal taxes payable of approximately $0 and $0 respectively.

 

As a result of losses and uncertainty of future profit, the net deferred tax asset has been fully reserved. The net change in the valuation allowance during the years ended December 31, 2024 and 2023 was an increase of $0.5 million and $1.5 million, respectively.

 

Foreign earnings are assumed to be permanently reinvested. U.S. Federal income taxes have not been provided on undistributed earnings of our foreign subsidiary.

 

The Company recognizes interest and penalties related to uncertain tax positions in selling, general and administrative expenses. The Company has not identified any uncertain tax positions requiring a reserve as of December 31, 2024 and 2023.

 

The Company is required to file U.S. federal and state income tax returns. These returns are subject to audit by tax authorities beginning with the year ended December 31, 2018.

 

NOTE 11 – SUBSEQUENT EVENTS

 

On February 21, 2025, the Company held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on February 21, 2025. At the Company’s Annual Meeting, the Company’s stockholders approved the proposal to approve the repricing of certain outstanding stock options granted (the “Option Grants”) under the Company’s 2006 and 2016 Equity Incentive Plans (the “Plans”) to allow the Board of Directors (the “Board”) to reprice the exercise price of outstanding stock options under the Plans. Pursuant to that authority, on February 21, 2025, the Board repriced the Option Grants. The repriced Option Grants under the 2006 Equity Incentive Plan had original exercise prices ranging from $4.00 to $5.00 per share, and the repriced Option Grants under the 2016 Equity Incentive Plan had original exercise prices ranging from $1.74 to $19.92 per share. All of the Option Grants under the Plans were repriced to have an exercise price of $0.2655 per share, which was the closing price of the Company’s common stock on February 21, 2025.

 

On March 5, 2025, the Company issued 284,238 shares of its common stock for proceeds of $102,534.

 

F-17

 

 EX-19.1 2 ex19-1.htm

 

Exhibit 19.1

 

MEMORANDUM

 

TO:Protagenic Therapeutics, Inc. Directors, Officers and Employees
  
FROM:Garo Armen, Ph.D., Executive Chairman
  
DATE:May 26, 2021
  
RE:Insider Trading Policy
  

 

Enclosed is a copy of the Insider Trading Policy (the “Policy”) for Protagenic Therapeutics, Inc. and its subsidiaries (collectively, the “Company”).

 

As described in the Policy, violations of the insider trading laws can result in significant civil and criminal liability. Accordingly, please take the time to read the materials provided, and then sign and return a copy of this memorandum.

 

Certification

 

The undersigned hereby certifies that he or she has read, understands and agrees to comply with the Company’s Insider Trading Policy, a copy of which was distributed with this memorandum.

 

Date:     Signature:  
         
      Name:  
      (please print)

 

 

 

 

Protagenic Therapeutics, Inc.

 

POLICY PROHIBITING INSIDER TRADING

 

This Insider Trading Policy (the “Policy”) of Protagenic Therapeutics, Inc., and its subsidiaries (collectively, the “Company”), provides guidelines to all directors, officers and employees of the Company (collectively, sometimes referred to herein as “Company Personnel”) with respect to transactions in the Company’s securities and in the securities of any Company Partner (as defined herein).

 

Purpose

 

This Policy pertains to the disclosure of Material Nonpublic Information (as defined herein) regarding the Company or Company Partner and to trading in securities of the Company or the securities of a Company Partner while in possession of such Material Nonpublic Information. It is intended to ensure that all Company Personnel comply with all applicable laws and regulations concerning securities trading, commonly known as “insider trading”. Insider trading and stock tipping, as discussed below, are criminal offenses subject to severe criminal and civil consequences. Any violation of this Policy could subject Company Personnel to disciplinary action by the Company, up to and including termination. Appropriate judgment should be exercised in connection with all securities trading. Specific questions regarding this Policy or applicable law should be directed to the Company’s Chief Financial Officer.

 

Scope of Policy

 

Transactions Affected

 

This Policy applies to all purchases and sales of the Company’s securities by Company Personnel, including common stock, options for common stock and any other securities the Company may issue from time to time, as well as derivative securities relating to the Company’s securities whether or not issued by the Company, such as exchange-traded options. This Policy also applies to certain elections made pursuant to an employee benefit plan (a “Plan”) (i) an election to increase or decrease the percentage of periodic contributions that will be allocated to a Company share fund, (ii) an election to make an intra-plan transfer of an existing account balance into or out of a Company share fund, (iii) an election to borrow money against a Plan account if the loan will result in a liquidation of some or all of a Company share fund balance, and (d) an election to pre-pay a Plan loan if the pre-payment will result in allocation of loan proceeds to a Company share fund. Finally, this Policy also applies to purchases and sales of securities of other companies by Company Personnel at any time such Company Personnel are aware of Material Nonpublic Information about those companies that Company Personnel become aware of as a result of business dealings between the Company and such other companies (each such other company referred to herein as a “Company Partner”).

 

1

 

 

Persons Affected

 

All Company Personnel who receive or have access to Material Nonpublic Information regarding the Company or any Company Partner (“insider employees”) are subject to this Policy. Any employee can be an insider employee from time to time and would at those times be subject to this Policy. This group of people, members of their immediate families, and members of their households are sometimes referred to collectively in this Policy as “Insiders.” As used herein, the term “family” includes any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, a trust in which these persons have more than fifty percent of the beneficial interest, a foundation in which these persons (or the Insider) control the management of assets, and any other entity in which these persons (or the Insider) own more than fifty percent of the voting interests.

 

Statement of Policy

 

It is the policy of the Company to oppose the unauthorized disclosure of any Material Nonpublic Information acquired in the workplace and the misuse of such information in securities trading.

 

Trading on Material Nonpublic Information

 

No Insider shall engage in any transaction involving a purchase or sale of the Company’s securities or the securities of a Company Partner during any period commencing with the date that he or she possesses Material Nonpublic Information regarding the Company or a Company Partner, and ending at the close of business on the second Trading Day following the date of public disclosure of that information or at such time as such information is no longer material. As used in this Policy, the term “Trading Day” means a day on which the national stock exchanges and the Nasdaq Stock Market are open for trading.

 

Tipping

 

No Insider shall disclose (“tip”) Material Nonpublic Information to any person (including family members) where such information may be used by such person to his or her profit by trading in the securities of the Company or the securities of a Company Partner. Nor shall an Insider make recommendations or express opinions on the basis of Material Nonpublic Information as to trading in the Company’s securities or the securities of a Company Partner.

 

Confidentiality of Material Nonpublic Information

 

Material Nonpublic Information relating to the Company or a Company Partner is the property of the Company and the unauthorized disclosure of such information is forbidden. In addition, there are legal requirements governing the timing and nature of the Company’s disclosure of certain information to the public. Violation of these rules could result in substantial liability for the individual, the Company and its management. For this reason, the Company permits only specifically designated representatives to discuss the Company or a Company Partner with the news media, securities analysts and investors, and only in accordance with the Company’s communications policy.

 

2

 

 

Potential Criminal and Civil Liability and/or Disciplinary Action

 

Liability for Individuals

 

The consequences of and the penalties for insider trading can be severe. Under applicable U.S. law, individuals who trade on inside information (or tip information to others who trade) can be liable for sanctions that include:

 

(i) a civil penalty of up to three times the profit gained or loss avoided;

 

(ii) a criminal fine (no matter how small the profit) of up to $5 million; and

 

(iii) a jail term of up to 20 years.

 

Liability for the Company and Supervisory Personnel

 

For a company (as well as possibly any supervisory person) that fails to take appropriate steps to prevent insider trading, penalties can consist of:

 

(i) a civil penalty of the greater of (a) $1 million, and (b) three times the profit gained or loss avoided by the person as a result of the violation; and

 

(ii) a criminal fine of up to $25 million.

 

The consequences of and penalties for insider trading for the Company and for those directors, officers and employees that are subject to the securities laws in jurisdictions outside the U.S. can also be severe. You are required to comply fully with the securities laws in any jurisdiction to which you are subject. If you have any questions about the securities laws that apply to you, please contact the Company’s Chief financial Officer.

 

Company Disciplinary Actions

 

Employees of the Company who violate this Policy will also be subject to disciplinary action by the Company, which may include termination of employment, regardless of whether the employee’s non-compliance results in a violation of law.

 

3

 

 

Definition of Material Nonpublic Information

 

Material Information

 

The SEC and U.S. courts say that information is “material” if there is a substantial likelihood that a reasonable investor would consider the information important in making an investment decision regarding the purchase or sale of a company’s securities, or if the information would significantly alter the total mix of information already known about a company. Put simply, if the information could reasonably be expected to affect the price of a company’s securities, including the price of the Company’s securities or the securities of a Company Partner, it should be considered material. While it impossible to define all categories of material information, some categories of information are so particularly sensitive that, as a general rule, they should always be considered material. Examples of such information may include:

 

●Financial information, including revenue results, contracting activity or other revenue projections.
   
●News about a major contract award or cancellation of an existing contract.
   
●Financial projections, forecasts or budgets.
   
●Mergers, joint ventures, partnerships, collaborations, acquisitions, dispositions, tender offers, acquisition or sale of a business segment or unit, or other significant changes in assets.
   
●New products or discoveries related to the Company’s technology.
   
●Results of the Company’s or a Company Partner’s research and development activities, preclinical testing or clinical trials.
   
●Changes in senior management or other major personnel changes.
   
●Changes in dividend policy, declaration of a stock split or the offering of additional securities.
   
●Financial liquidity problems.
   
●Changes in pricing or discount policies.
   
●Significant legal exposure due to actual, pending or threatened litigation.
   
●Changes in the Company’s auditors or a notification from its auditors that the Company may no longer rely on the auditors’ audit report.
   
●Major events regarding the Company’s securities.
   
●Significant write-offs.
   
●Impending bankruptcy.
   
●Gain or loss of a significant customer or supplier.
   
●Notice of issuance of patents.

 

Both positive and negative information can be material. U.S. Federal and stock market investigators will scrutinize a questionable trade after the fact with the benefit of hindsight.

 

4

 

 

You should be aware that knowledge of a rumor that is affecting the Company’s stock price may be considered material, even if the rumor is false. In addition to the examples cited above, numerous other types of information have been found to be material based on the specific facts and circumstances of each case. Unfortunately, there are many examples of individuals found to have unlawfully traded while aware of various forms of Material Nonpublic Information.

 

A director, officer or employee may incur personal liability if he or she buys, sells, or makes certain other transfers, including gifts or donations, of any Company securities during a period when the director, officer or employee is aware of Material Nonpublic Information about the Company. It is possible that directors, officers, or employees of the Company by virtue of their position and access to certain material information, may, under U.S. laws, be presumed to know such information before it is released to the public

 

Nonpublic Information

 

“Nonpublic Information” is information that is not generally known or available to the public. The Company considers information to be available to the public only when:

 

●it has been released to the public by the Company through appropriate channels (for example, by means of a filing with the SEC, a press release or a statement from a senior officer widely disseminated through the national media or wire services), and
   
●enough time has elapsed to permit the investment market to absorb and evaluate the information. As a general rule, information should be considered nonpublic until two (2) Trading Days after public disclosure.

 

Guidelines with Respect to Trading in Company Securities

 

There are procedures that directors, officers and insider employees may follow to reduce the likelihood that they will be viewed as engaged in insider trading. Executive officers and directors are required to comply with these procedures at all times. Other employees may be informed by the Company’s Chief Financial Officer that they are required to comply with these procedures on a permanent or temporary basis, either because of their position with the Company or because of their involvement with a project that results in knowledge of Material Nonpublic Information about the Company or a Company Partner.

 

Temporary Suspension.

 

From time to time, the Company may recommend that directors, officers and insider employees suspend trading because of developments known to the Company, which have not yet been disclosed to the public. In such event, such persons are advised not to engage in any transaction involving the purchase or sale of the Company’s securities during such period and should not disclose to others the fact of such suspension of trading. Moreover, whether or not the Company has recommended a suspension of trading, anyone possessing Material Nonpublic Information about the Company or a Company Partner should not trade in the Company’s securities or the securities of a Company Partner until at least two Trading Days after such information has been made public.

 

5

 

 

Trading Window Periods.

 

In an effort to reduce the risk that an insider trading violation will occur, all Insiders of the Company are prohibited from engaging in any securities transaction in violation of the securities laws of the U.S. or any other jurisdiction. Specifically, unless such trade is conducted pursuant to a Rule 10b5-1 plan, Insiders are prohibited from conducting transactions involving the purchase or sale of the Company’s securities other than:

 

(i) during specified trading windows, (each a “Trading Window”) which begin at the open of the market on the third full Trading Day following the public disclosure of the financial results for a particular fiscal quarter or year-end and continuing until the close of the market on March 31, June 15, September 15 and December 15, respectively;

 

(ii) when they are not aware of Material, Nonpublic Information about the Company; and

 

(iii) after pre-clearance of the transaction is granted by the Company’s Chief Financial Officer.

 

The Company’s Chief Financial Officer has discretion to determine the length of each Trading Window, which discretion is exercised in consultation with other members of senior management. The Company’s Chief Financial Officer also has the discretion to shorten or lengthen a Trading Window, close or reopen the Trading Window for particular Insiders or employees, or to, close or open a Trading Window if the Company’s Chief Financial Officer determines, in consultation with other members of senior management, that doing so is reasonable or advisable in the circumstances.

 

For greater clarity, as described above, even during the Trading Window period, all securities transactions by Insiders must be approved in advance by the Company’s Chief Financial Officer. Unless such trade is conducted pursuant to a Rule 10b5-1 plan, other employees who have access to Material Nonpublic Information and whether or not they have been identified as Insider employees cannot engage in a securities transaction while they are aware of Material Nonpublic Information. Any employee who is are aware of Material Nonpublic Information or who has been designated as an Insider must have all securities transactions approved in advance by Company’s Chief Financial Officer. After pre-clearance is granted by the Company’s Chief Financial Officer, you should make your trade as soon as possible but no later than two (2) Business Days after pre-clearance has been granted. Should you, at any time prior to effecting your trade, become aware of any Material Nonpublic Information or believe that you have become aware of information that may constitute Material Nonpublic Information prior to trading (after pre-clearance has been granted), you must not trade and must notify the Company’s Chief Financial Officer as soon as possible regarding this information. The pre-clearance process must be undertaken again in light of this new information before you may make the requested trade. For the purpose of this Policy, the term “Business Day” shall mean any day that is not a Saturday, Sunday or any other day on which banks are required or authorized by law to be closed in New York, New York or Copenhagen, Denmark.

 

6

 

 

Employees who are not Insiders, and who do not have access to Material Nonpublic Information, are not restricted to the Trading Window periods for conducting transactions involving the purchase or sale of the Company’s securities, and do not need to go through the pre-clearance process. Notwithstanding the foregoing, no Insider, other employee or other person may engage in any securities transaction if they are, or believe they may be, in possession of Material Nonpublic Information. The restrictions in this Policy apply equally to Insiders, other employees and members of their families and members of their household.

 

In addition, you should not discuss your personal trading decisions, including but not limited to your entry into a trading plan, discussed below, with others within the Company, except as necessary to satisfy the requirements of this Policy, or if required to satisfy regulatory requirements. If pre-clearance to trade is denied, you must keep the fact of such denial and the reasons therefor confidential.

 

It should be emphasized that trading in the Company’s securities or the securities of a Company Partner even in a Trading Window should not be considered a “safe harbor,” and all Insiders and other employees should use good judgment at all times. As noted above, no Insider, other employee or other person may engage in any securities transaction if they are, or believe they may be, in possession of Material Nonpublic Information.

 

Trading Plan Satisfying Requirements of SEC Rule 10b5-1

 

Under Rule 10b5-1, Insiders and employees can establish an affirmative defense to an illegal insider-trading charge when their trades are made pursuant to a pre-existing written trading plan meeting the elements set forth below. The Company allows Insiders and other employees to establish written trading plans satisfying the requirements of SEC Rule 10b5-1. These plans allow you to plan future trades (sales or purchases) at a time when you do not possess Material Nonpublic Information and then have those trades executed later, even during times when you may possess Material Nonpublic Information about the Company, but requires that you maintain no control over trades once the Rule 10b5-1 plan takes effect. However, you may enter into written trading plans only when you are not aware of Material Nonpublic Information and after you have received pre-clearance from the Company’s Chief financial Officer. Insiders may only enter into trading plans during an open Trading Window period. There are limitations on your ability to amend, terminate and/or suspend trading under such plans.

 

If you decide to enter into a trading plan, establishment of a plan will impact the requirements under this Policy in the following ways:

 

●Your plan must be approved the Company’s Chief Financial Officer before it is implemented;

 

●You must, in all cases, abide by the terms of your established trading plan as long as it remains in effect;

 

7

 

 

●After the written trading plan has been approved by the Company’s Chief Financial Officer, and is in effect, you must wait 30 days before you can execute a trade under your plan (unless otherwise agreed to by the Company’s Chief Financial Officer), but you will not be required to pre-clear trades under the plan prior to their execution;

 

●Directors Executive Officers must report each trade under such plan immediately after it is made, or a process should be established whereby your broker reports such trades to Company’s Chief Financial Officer;

 

●You may make additional trades under this Policy outside of your trading plan, and you must satisfy the requirements of this Policy in connection with such trades, including having such trades pre-cleared by the Company’s Chief Financial Officer, and for Insiders, restricting these trades to the established Trading Window periods; provided, however, that purchases made outside of the plan may not operate as a hedge against the actual or anticipated trading established under the plan, and the pre-clearance process will include inquiry to confirm that hedging is not occurring or will not reasonably occur;

 

●The Company retains the right to require the inclusion of additional provisions or changes in your trading plan in order to ensure that your plan complies with applicable law, rules or regulations, whether before or after the date of initial approval of such plan by the Company’s Chief Financial Officer; and

 

●The Company will monitor your compliance with the terms of your trading plan and the trading plan policies. The Company also retains the right to request documents and other information from you, your broker, any administrator or agent of the Company, or others to confirm your compliance with the requirements of this Policy, as well as your compliance with all applicable laws in connection with the establishment and ongoing use of a trading plan. In entering into an approved plan, you are deemed to have agreed to provide this information to the Company at our request, and to our ability to access this information without your subsequent consent or knowledge.

 

In the event of a claim against you, even if your trading plan has been approved by the Company, you must still prove that you complied with the requirements of Rule 10b5-1. Also, compliance with Rule 10b5-1 does not prevent someone from bringing a claim, nor do they prevent the media or an analyst from reporting any sales or purchases you make, and as a result, there is still reputational risk for you and the Company associated with trading under these plans.

 

In addition, the affirmative defense of trading under an automatic trading plan is not available where the trading plan was entered into as part of a plan or scheme to evade applicable securities laws. As with other rules under the securities laws, judgments about a person’s good faith and overall compliance with the legislation will be made viewing circumstances in hindsight.

 

8

 

 

You must remember: any trades outside of the trading plan by you or any member of your family or household must continue to be made only after pre-clearance and in accordance with the other provisions of this Policy.

 

Prohibited Transactions

 

The Company considers it improper and inappropriate for any director, officer or other employee of the Company to engage in short-term or speculative transactions in the Company’s securities. Therefore, it is the Company’s policy that directors, officers and other employees may not engage in any of the following transactions:

 

●Short-term Trading. A director’s, officer’s and/or employee’s short-term trading of the Company’s securities may be distracting to the employee and may unduly focus the employee on the Company’s short-term stock market performance instead of the Company’s long-term business objectives. For these reasons, no director, officer or employee of the Company who purchases Company securities in the open market may sell any Company securities of the same class during the six months following the purchase.

 

●Short Sales. Short sales of the Company’s securities evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market that the seller has no confidence in the Company or its short-term prospects. In addition, short sales may reduce the seller’s incentive to improve the Company’s performance. For these reasons, short sales of the Company’s securities are prohibited by this Policy.

 

●Hedging Transactions. Certain forms of hedging or monetization transactions, such as forward sale contracts, allow a director or an employee to lock in much of the value of his or her securities holdings, often in exchange for all or part of the potential for upside appreciation in the securities. These transactions allow the director or employee to continue to own the covered securities, but without the full risks and rewards of ownership. When that occurs, the director or employee may no longer have the same objectives as the Company’s other shareholders. Therefore, all directors, officers and employees are prohibited from engaging in any such transactions.

 

●Margin Accounts and Pledges. Securities held in a margin account may be sold by the broker without the customer’s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of Material Nonpublic Information or otherwise is not permitted to trade in the Company’s securities, directors, officers and employees are prohibited from holding the Company’s securities in a margin account or pledging Company securities as collateral for a loan. The Company will allow an exception to this prohibition where the person wishing to pledge Company securities as collateral can demonstrate his or her financial capacity to repay the loan without resort to pledged securities. Such person must first submit a request for approval to the General Counsel’s office at least two weeks prior to the proposed execution of documents evidencing the proposed pledge.

 

9

 

 

●Other Transactions. The Company cannot possibly cover all potential transactions, trades, or types of products that may be developed in the future under this policy; accordingly, the Company reserves the right from time to time to review and consider whether to include additional transactions, types of products, and/or certain trading arrangements as prohibited under this Policy. During review of the terms of any such transaction or product, or the facts and circumstances surrounding the proposed transaction, that is undertaken as part of the pre-clearance process, the Company may determine that the transaction, product, or trade is not appropriate, and the Company may refuse to clear such transaction to proceed

 

Individual Responsibility

 

Every officer, director and insider employee of the Company has the individual responsibility to comply with this Policy against insider trading, regardless of such person’s position with the Company. The guidelines set forth in this Policy are guidelines only, and appropriate judgment should be exercised in connection with any trade in the Company’s securities or the securities of a Company Partner.

 

In the absence of a pre-established Rule 10b5-1 Trading Plan, an Insider may, from time to time, have to forego a proposed transaction in the Company’s securities (such as a sale of the Company’s securities in order to raise funds to pay personal tax obligations or other emergency expenditures) even if he or she planned to make the transaction before learning of the Material Nonpublic Information and even though the Insider believes he or she may suffer an economic loss or forego anticipated profit by waiting. Transactions that may be necessary or justifiable for independent reasons are not excepted from this Policy. The securities laws do not recognize such mitigating circumstances and, in any event, even the appearance of improper transaction must be avoided to preserve the Company’s reputation for adhering to the highest standards of conduct.

 

EXCEPTION FOR CERTAIN TRANSACTIONS

 

This Policy does not apply to all transactions involving the Company’s securities. The following exceptions are intended to facilitate several common types of transactions:

 

● Warrant Exercises. This Policy does not apply to the mere exercise of a warrant for cash under the Company’s Warrant Pans. However, this Policy does apply to:

 

(i) Any sale of shares as part of a broker-assisted “cashless” exercise of a warrant (i.e., any market sale for the purpose of generating the cash needed to pay the exercise price of a warrant); and

 

(ii) Any sale of Company shares received upon exercise of a warrant.

 

10

 

 

● Net Settlement upon Vesting of Restricted Shares. This Policy does not apply to a surrender of shares to the Company or the retention and withholding from delivery to the applicable officer, director or employee of shares by the Company (i.e., a so-called “net settlement”) upon vesting of restricted shares in satisfaction of any tax withholding obligations in a manner permitted by the applicable equity award agreement or the Company plan pursuant to which the restricted share was granted.

 

● Employee Stock Purchase Plan. This Policy does not apply to (i) an employee’s election to participate in, or increase his or her participation in, the Company’s employee share purchase plan, (ii) purchases of Company shares in the plan resulting from periodic contributions of money to the plan pursuant to the elections made at the time of enrollment in the plan, or (iii) purchases of Company shares resulting from lump sum contributions to the plan, provided that the participant elected to participate by lump-sum payment at the beginning of the applicable enrollment period. However, this Policy does apply to a participant’s sale.

 

Post-Termination Transactions

 

This Policy continues to apply after termination of a person’s relationship with the Company. If a director, officer or employee is in possession of Material Nonpublic Information when he or she terminates service or employment with the Company, such individual may not trade in the Company’s securities until that information has become public or is no longer material.

 

Company Assistance

 

An Insider’s and employee’s compliance with this Policy is of the utmost importance for the Insider, the employee and the Company. This Policy is not intended to address all conceivable questions about compliance with the securities laws. An Insider or employee should not try to resolve uncertainties he or she encounters as the rules relating to insider trading are often complex, not always intuitive and carry severe consequences. Questions concerning compliance with the securities laws and this policy should be addressed to the Company’s Chief Financial Officer.

 

Adopted by the Board of Directors on May 26, 2021.

 

11

 

 EX-23.1 3 ex23-1.htm

 

Exhibit 23.1

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements on Form S-1 (File No. 333-283949) and Form S-3 (File No. 333-280244) of our report dated March 31, 2025 with respect to the audited consolidated financial statements of Protagenic Therapeutics, Inc. appearing in this Annual Report on Form 10-K.

 

/s/ MaloneBailey, LLP

www.malonebailey.com

Houston, Texas

March 31, 2025

 

 

 

 

 

 EX-31.1 4 ex31-1.htm

 

Exhibit 31.1

 

 

CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE

 

SECURITIES EXCHANGE ACT OF 1934

 

 

I, Garo H. Armen, PhD, certify that:

 

1. I have reviewed this annual report on Form 10-K of Protagenic Therapeutics, Inc..

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

March 31, 2025   /s/ Garo H. Armen
  Name: Garo H. Armen, Ph.D.
  Title: Executive Chairman

 

 

 

 EX-31.2 5 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE

 

SECURITIES EXCHANGE ACT OF 1934

 

I, Alexander K. Arrow, MD, certify that:

 

1. I have reviewed this annual report on Form 10-K of Protagenic Therapeutics, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

March 31, 2025   /s/ Alexander K. Arrow
  Name: Alexander K. Arrow, MD
  Title: Chief Financial Officer

 

 

 

 EX-32.1 6 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES OXLEY ACT OF 2002

 

In connection with the annual Report of Protagenic Therapeutics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Garo H. Armen, Executive Chairman, and Alexander K. Arrow, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

March 31, 2025 By: /s/ Garo H. Armen
    Garo H. Armen, PhD
    Executive Chairman
    (Principal Executive Officer)
     
March 31, 2025 By: /s/ Alexander K. Arrow
    Alexander K. Arrow, MD, CFA
    Chief Financial Officer
    (Principal Financial Officer)

 

 

 

 

 GRAPHIC 7 ex23-1_001.jpg begin 644 ex23-1_001.jpg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end GRAPHIC 8 ex23-1_002.jpg begin 644 ex23-1_002.jpg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form10-k_001.jpg begin 644 form10-k_001.jpg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form10-k_002.jpg begin 644 form10-k_002.jpg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form10-k_003.jpg begin 644 form10-k_003.jpg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end GRAPHIC 12 form10-k_004.jpg begin 644 form10-k_004.jpg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�?&$^A+HWVF\BUE;IX)?*\KRO(?9+O1OF5=WR[ME 'I%A<22LX9 MMW^]5O>_]U?^^JS]*W;GVM5_;+_ST7_OF@!=[_W5_P"^J-[_ -U?^^JPX9KZ M;Q'=0>?%]BBMHI5B\KY][,_\>[_8_P#'JW-DG]Y?^^: #>_]U?\ OJC>_P#= M7_OJDVR_\]%_[YI=DG]Y?^^: #>_]U?^^J-[_P!U?^^J-DG]Y?\ OFDVR_\ M/1?^^: %WO\ W5_[ZHWO_=7_ +ZHV2?WE_[YHV2?WE_[YH -[_W5_P"^JKZ) M_P @FU_W*L;)/[R_]\U7T3_D$VO^Y0 Z/_CXE_W4JY5./_CXE_W4JY0 4444 M %%%% '#>.=$7Q)HVL:4SJGVR+RMS[OE_P"^:\XL_AIXA>]NXKGXBWTS_?BM M[3=;^1M1%^XK_P#CGW?GKUV_A9[R7"L?FKS_ %[X+:'XAU:]U"\6YW7DOFSQ M)MV,_E)%_<^;Y8DKJB9'/P_"7Q57WCB[AN(IV_X]]WSQ>;NV;V?Y=Z; M/D3Y?D_WM_KXO(EMV^T-O1%5]VQ?[JUV:0R M[)?E:K KT4_R)/[KT>1)_=>@@97">(?B%?>%=2U9;G19]5LK54>#^SXOWNWR MMS[]S[?]GY*[[R)/[KT_9.G\+4 >3I\=?M.I?9H/">KOL^1G=E3Y]B.B)_>^ M^_\ WQ4D?QNWS>1_PAVM_:/(6X9/W6SYOX-^_P";Y/\ OG[M>J;)_P#IK1LG M_P"FM!9SW@SQ)+XMT/\ M"73Y=-?SY8OL\S;W^5]J/\ \#7YJVZF\F5_O*U, M\B3^Z]! RIK;_6I3/(D_NO4L4,OFI\K4 VO5EBMY4MU5TWRN_W/XFV(GS- M7L*0RI]U6HV3_P#36@#'\)Z\WB?2[>^:QGTUWEV-;W'WUK)^(WBRY\&Z?:7D M%C]O26=HI43>S_=;9L5/O?-M_P!W[U=:D,OFIN5OO4NR5&?:K4 >/:5\9M8O M[_3+/_A'VF^V-9NMVD4J1+$RH]QN^_L9/-55^;Y_F_N5[#_R[_\ J-D_P#T MUIWDR^1]UOO4%F+XGU*YT3PUJNH6=LMY=6MM++!;O_RU=4^1*H^ _%$_C#P_ M_:%SI\FE3)CR)/[KT =!IO_ !Y15;JIIHV6456ZXI'0%%%% M !1110! W^OB_P"!5/4#?Z^+_@53T %%<7\0/&UMX$T1-4O8);BW^V6MJ_E, MB[?/N$B1OF9?NL]<=X0_: TWQ9XMTWP^FF7=I+J2WA@NII8GM[AX)71TB>)V MW?<9O]V@#KM$A4?$CQ5*&;=]EL%_UK?]-?X:[%T7:WSM_P!]5YYHFNZ'_P + M0\5J+RV^U)!9Q/\ WUV^;\M=A_;ND.=JW5MN_AH Q=0U.QT^\LH+K;]HG;;; M+Y6Y]W^S7#6WQI\!W5E_:3W/DVZ2Q637$NGRIL:5]J1?,G^\W^[\U=MJNH:/ M9W^GQZA"?&%GI,^F7T=Y#=7W]GV:?8W^6XV.WW M=GR_<^_]VJ.I?&OP'H%U-!?7WV2XBE>!D>QEW[M^UT3Y/F^9&9MG^]4T/BKX M;?V79>5>:7#I^C6?]KVJ(NQ+6W5WB^T)_L[MZU60_"F_U'^S,>'9;JRN6B6U MN&3=%*[[GV(W]YO[O^U5@7'^,WPR\WR&\5>'][?)L=D_^(K!UWXN_"F\MFT? M4Y=/O]*U2[^SW#RV:O:-*VS_ %O^^[JG^]\M79K_ .$G]N1:;+%X=^U7D32J MWE)Y4JKO39O^[N^1_D_V*9-I?PKDNGL19Z)-<7\%K_HT47F^:C;VMW15_B^^ M^_[WR;_X: --_BIX"T>TT=8-0MGM;V+9IWV2U9TE\ITB2*+Y?F;>Z(J5IW_C M?PII7]JSRW5M]HT3ROMR6]MON+#S?N;D5-R[ZYR#1/A=X5\/Z5HT[Z6^F6#3 MV]G'?7+77V=T7S951W9MK*OS?WEKJ+/PWX3\3V#ZG;:;97EIJGV>Z:[2+_CZ M:+_5.[_>W)_#_=H [/2D^9]U:'DK_??_ +ZK'MK^VLV=KR6*'=]W?5C^WM(_ MY^[>@"*V1?\ A*M0^=O^/.W_ (O]N6M?8/[[?]]5RMMKVD?\)1J#?:X/^/.# M_P!#EK8_M[2/^?NWH T/)7^^_P#WU1Y*_P!]_P#OJL_^WM(_Y^[>C^WM(_Y^ M[>@#2V#^^W_?5-\E?[[_ /?59_\ ;VD?\_=O1_;VD?\ /W;T :'DK_??_OJG M;!_?;_OJLW^WM(_Y^[>L2P\3VDGB#4(I=2MGM8HHGB3RMK)NW?Q?\!H ZW8/ M[[?]]55T3_D$VO\ N57_ +>TC_G[MZET'']DVNW[NR@"6/\ X^)?]U*N53C_ M ./B7_=2KE !1110 4444 JIO?^]5B_\ ^/\ E_WJKUU0,@WO M_>J9'^27_=J&IH?N2_-L^6K((=[_ -ZC>_\ >J;8O_/5:-B_\]5H AWO_>KA M];^,>D>'M>N]*OH+M+BWE1'V)OW[DW1?]]KO_P"_3UWVQ?\ GJM5IM-L[G?Y MD4$V_;NWQ;ON_<_[XH \ZA^.NE363O\ 8[M+M;7[1]D?Y/[^_P#]D_[[K8T3 MXM:#XAET2*TGN7;67G2SWP.GF^4FY_\ @.UDKJWT?3W9-UM:/M;GI MI5C#LVP6R;&=UV1?=H S/"OB3_A)]&74%@:V1I98D3S5E1]K[-ZNOWE>M7>_ M]ZFV>FVFFP)!9Q06=NOW8;>+8G_?"U8V+_SU6@"'>_\ >J:%_P!ZE&Q?^>JT MZ%%\U?WJT 5][_WJX>;XHQ6?B"TTB72+M'GU-]*6X\U73=\FQ_\ Q_=L_AKO MMB_\]5JC#HFGVUT]S%;6D-PS.[3) J/O;[[[Z +<+_O4_P!ZA]VZGPHOFI^] M7[U#HN[_ %JT 87ACQ;8^+8M0EL?/VV5Y+92^:NSYE_]EK=W_P"C_P# JAAL MX+;=Y7EP[VWML79N;^_5C8OD?ZU?O4 5WFV([?W5WUG^'O$,'B?0[75;3S$M M[I=RI+\CK\^WYZT_)5UVM*O_ 'S3(;."VB2*#RH8E78J0KL1: )D?Y)?]VH= M[_WJL(B[9?WJTW8O_/5: (=[_P!ZC>_]ZIMB_P#/5:-B_P#/5: -W3?^/**K M=5--_P"/**K=<4CH"BBB@ HHHH @;_7Q?\"J>H&_U\7_ *IZ ,76-!TWQ#9 M_9-3T^#4[7VE M?_EDU8,/P8\(6ZM%%H,*;EM8B_FR[U2"7=;HK[MRHC_,J?=K;M/%VLW]A;W, M7AK]U/$DL>Z^B7[WW:O'7O$/_0KO_P"!\5'*5*I*<8QE+X3F8?@=X.A?5FB\ M/VD,NJ6LMG?2Q,ZRSQ2ONE1GW;OGJ*3]GSP)->S7C^%;1[N5M[W&Y]^[_OO_ M &GKJ=*\0WM[JPT^^TS^S9_(^T(#.LJNN_:WW?\ >6NEWO\ W5_[ZH)/#H?V M4O 7_"+OH=SIL]]$'9X+NYG_ 'MJS)Y7[K^[\CO\O^V_]ZNKB^"_AN*71+F7 M3_M.H:-!%:V>H2RNMQ$J?=^=&7_+5Z-O?^ZO_?5&]_[J_P#?5 'G,GP7\)2V M]Q"_A^#R9[^74I8O,?9+=2ILEE?Y_F9E^6NIT?PQ!H.EVFFZ?;+;65K%Y4$2 M-]Q:W=[_ -U?^^J-[_W5_P"^J *]A;R6[/N7[U6/.;_GDU&]_P"ZO_?5&]_[ MJ_\ ?5 &/;2-_P )7J'[IO\ CS@_]#EK8\YO^>35CVWF?\)5J'RK_P >=O\ MQ?[34;W_NK_WU1O?^ZO\ WU0 >?[K5C6#;?%.L?>_P"/>U_]JU\Y?%G] MH'Q9X1\=ZGI5@UHEE9O$%WP;V^:)6^]O_P!JN+A_:>\R;M/W-%$K?Z- M_O\ ^W7FRQ]*$I0/M<-P?F6+H0Q%+EY9?WC[:\UO[E5M%&=*M?\ <%>)_LZ_ M%;7/B#=:K%J[0NEJL3Q>4NW[V^O:M'&-+M3_ +-=E&M"M#FB?+XW!5K% M_P#\?\O^]7">*?#7B/5/$-O?:1K[Z7;P6R+]F5ODEEW-OW)]W[K?W?X4KJ@9 M'9U-'_JI?]VN<\'VVO6VERKXCO(+R]\]]KVZ;$\K^"NCAV[9=R[_ ):L@AKS M>YF\?Z?/J:Q-/?NZSIIW[B!$W;]J>:^SY%1=C_[7SUZ7NB_YY_\ C]&^+^[_ M ./4%GG/AZY^(,UKJ=UJ\$%M_HOE06\*J[I*L2?O4VI\R[]_R/\ WT^YLJOK M>I>/4BTR73X)W2?3HGO$^QQ>;:R_\M77=]]G_N?PUZCNB_YY_P#C],WQ?W?_ M !Z@#SRXUCX@Q,D<&BZ?-^XBW2NW_+7RMS_=;^_\M4KOQ)\1'>)?[!6V1?D9 MXO[S)M1_O_=W/N;^[L_VZ]3WI_SR_P#'J8[Q)]Z+9_OM0!Y)8>,/'MAXAM/# MU]I&_P U;]UU/RM_FJN_[/\ =^5-_P GWZ?I6M_%*S74Q?:-;:E,C6_V/[D2 M.C2R^;OVO]Z*+;_O?+_?KUA)HIE?REWINV-L:C=%_P \_P#Q^@#G_#=SJMSJ MGB#[;+%+B!8G\K9\[HR?>5W^[_%71VW^M2C=%_P \_P#Q^G0O%YJ? MNO\ QZ@"O7 V=]XO/BI()XKS^RGU-MLK6:[/LOE? M?_C]&Z+_ )Y_^/T ,A_UJ_[U#_?I\+Q>:G[K^+^]0[Q;W_=?^/4 <]X7O-7O M(M0_M2".)HKR5;5UC>+S8/X6VN__ #=_%]ZM[_EW_X%3]Z?\\O_ !ZG;XO( M_P!5_'_>H JS;DB=E^_M^6LSPK>:G?\ A^RGUFV6SU)U_?Q(NW:W^Y6WNB_Y MY_\ C]&]/^>7_CU !'_JI?\ =J&K"/%LE_=_^/4W=%_SS_\ 'Z""&BIMT7_/ M/_Q^C=%_SS_\?H W=-_X\HJMU4TW_CRBJW7%(Z HHHH **** (&_U\7_ *I MZ@;_ %\7_ JGH **Y?Q5XMT_P9I(U/5YGMK'SXH&E6)FV/+*L2;MO\.YT^:N M2\,_'?P?XVUN+1M*U&YFU"?T59/^%D M^*F61?*^RV'R;?XOWO\ %73:HC-I5W\V[]P_\/\ LUR^B^1_PLOQ5(TOS_9; M!=GF?]=?X:[#?'_SU'_?V@#R'0GTATTV^G\8*BK;02K92W2LD%PL2)\JM\J? MQ?+_ 'FK$3P;HZ2I.OQ$\FXB=7@F5T1HO];\GW_^FK_^.?>VU[SOC_YZC_O[ M1OC_ .>H_P"_M '">$O[,_X2#3;32+Y;^TT[2OLOFK+YO\:;-[?WODKO=LO_ M #T7_OFF[X_^>H_[^TF8?^>B_P#?R@";;)_?'_?--V2?WE_[YIF^/_GJ/^_M M&^/_ )ZC_O[0 [;+_P ]%_[YI=DG]Y?^^:9OC_YZC_O[1OC_ .>H_P"_M $N MV3^^/^^:9ME_YZ+_ -\TW?'_ ,]1_P!_:^'_ -K3]O[7OV>/B]<>#M*\)Z;K M=I%8V]U]KN+R5'WR[OE^6@#[-MED_P"$JU#Y_P#ESM_X?]N6MC;)_?'_ 'S7 MY7I_P5D\7)?RWW_" :-OGB2+9]NG_AWM_P"SU[M^QY^WAKG[2WQ-N_"NJ^&- M-T2WM].EO?M-I>2N^]71-GS?[] 'VOME_P">B_\ ?-+LD_O+_P!\U'F'_GHO M_?REWQ_\]1_W]H ?LD_O+_WS3-LO_/1?^^*-\?\ SU'_ ']IN^+_ )Z_^1: M/AO]H#_DKOB#_?B_]$+7FT/_ "$+K_<);*CRR[FWM_?:O@\7_ !Y']8Y#'_A,H?X8GT;^Q[_R%_$6UO\ EE!_[/7T MQHG_ "#K?_D?%!1110 4444 WRHNS[U(#E=,^#-]IL3Q0>)[FR5W7=#8JT46W^/ MY-_WG^3<_P#>I\WPHUS;;K%XON9D@\J6)+O>_P"]5T?Y_G^97=-_]ZNKA^*_ MA6YMWG7Q'9;4B\U][;'1?]M*9-\5_#EM>7%M=:U!;/;Q>;YTWR(Z?[']ZF!Q M-A\(M>\/>(-'ETKQ'+-HB:FVH7EC-*R;MR(CI\OWOFWM_O/6AH/PENM"74(X M-5B1KJV>WM;CR'\W3OO;/(;=_M[FW?Q5UT/Q%TJYUE]*@GN;G4(I_L[116KO M\RHCN_\ N[73Y_\ ;HO/B1H=A!;W+:FLUO.TJ+<6Z^:FZ)-SIO7^*@"CX>\' MW.E:];ZA>7T%^T&E1:;]I\IUN)77[\LK_P 6[_QVNNMO]:E4='UZ+7K&*^M) M)6MY-W^NBV.K*VUT=&^ZV]:TX9I?-3YJ *]>=/\ "B>Z\:66N?VA!##9ZM+J M2V\43?/N1/O[OXODKTO[1)_>KGO^%A:8^I16/GS_ &B6^;35WVKI^_5-[I_W MS_'00;T/^M7_ 'J'^_4L-S+YJ?-_%37FEW_>H Y_PKX>N?#RZFMWJLNJO>7T MMTKRKL\I&_Y9??\ NI6[_P N_P#P*JFE>(;;6XI9=/OHKR**=K>5XOX95?:Z M?\ :M#SI?(^]_%0!5F3?$Z_WUV5F>%='G\/>'-/T^YO&O[B"+8UP^[Y_^^JV M'N61'9F^Y5?3=;@UBPM[ZQN5N;2==\4R?<9: +"?H AHJ;[1)_>H^T2?WJ -W3?^/**K=5--??9Q5;KBD= 4444 %%%% $#?Z^+ M_@5>/?M2WVH:#\'-:\0Z?K.I:)=Z-%]MB?3[E+?S6^[LE=D;Y?F_V?\ >KV% MO]?%_P "KRG]H+P['??#G5-02WU?4-1TM?M=K#HFHM97#-]U_F^96^7=\CHZ M_+]V@"E\,M$@^+/P \,P>+FDUK[5!%+=.]]O\V6*7>CM+$_S_,B?Q5N>&_@I MX*\&:M%K&CZ)!::A:EO*N(6=G^?_ 'F^;Y795_N*VU:YW]F'Q3KOBKX1=M>X4 ><:)H>D?\+*\58TJV^T M-:V3--]F7Y]WF_Q[:['^R],_Z!L'_@+_ /8USVB2L?B1XJ3RW9/LM@WF_+M_ MY:_+78^3 M4 9_]CZ?_P ^$'_@+1_9>F?] V#_ ,!?_L:T/.;_ )Y-1YS?\\FH S_[+TS_ M *!L'_@+_P#8T?V/I_\ SX0?^ M:'G-_SR:CSF_YY-0!G_V7IG_0-@_\!?\ M[&OR"_X*=PP6W[4EVD$:PK_8]E\B+L_OU^QOG-_SR:OQW_X*@_\ )UE[_P!@ M>S_]!>@#Y-?_ %2?[U?8O_!+"V@N?VCM36>%9E_L"?Y'7?\ \M8J^.G_ -4G M^]7V1_P2F_Y.3U/_ + %Q_Z-BH _5_\ LK3?^@9;?^ W_P!A3_[+TS_H&P?^ M O\ ]C5/7M5OK"&R^QQ0N\]U%;M]H;[JM_NUN>O^?%%-MB@V[XMW]^OIS0/^09!_N5\T M_L>_\A?Q%\O_ "R@_P#9J^F-$_Y!]O\ [E?58#_=HGX!QC_R-ZO_ &[_ .DD ML?\ Q\2_[J5_O57\E_\ M9_[ZJ6__ ./^7_>JO75 R'^2_P#L_P#?52I"VQ_N_P#?55Z*L@?Y+_[/_?58 M^H^"=*U6_P#MEY8QW,K^4[([?NI6B?=$SI]UF2M6B@#$F\ :/>7$TMS:_;/- MN?MLL5Q.TL3R[$7=L;Y?NJM5YOAIH#6=E:+8_9;6SBEB@M[>=XDB1G65MJJ_ MWMZJV[_9KHZ* .,UOX*>%=;T5M-ETJ.&W=D?]TR_PN[?Q;U_C?\ [[JOK?P' M\+^(=)LK.\MIWELEV17WG[[AOG=OG=OO;W?=_O;/[E=W1068_P#P@>E?VRFK M^0W]J_+_ *7]I?S=J_P??^[_ +%5_P#A6.@IIT.GII_DV44\MPMO%.ZIYLO^ MM9OG^;?O;_OJN@HH(*^E:+!HEA#8V!M,_M'[6T4DUQ]J^V_O;EV3S_N;]F^MBB@":&%O-3[OWO[ MU#PMO_A_[ZJ&B@"OIN@P:5]H^S1;'NI?M$KO+O=GK0\EO*_A^]_>JO10 ][9 MG5U;[CKL^]531]!@T'3K?3[&)8;6!=BINWU8HH L)"VV7[O_ 'U47DO_ +/_ M 'U3X_\ 52_[M<3XG\0^)='\6Z/!8Z4NI:%=,J7,L*MYL#;]N_\ NT =GY+_ M .S_ -]4>2_^S_WU7F5SXY\8I=+%!X59XHKE]TS[D\V)=_\ WSO^3;6KX \5 M:_KU_J=KK6BR6"0;98+AXF3=N_@_WOX_DH+/6--&RRBJW533?^/**K=<4C4* M*** "BBB@"!O]?%_P*N+^+7AOP_XH^&?B/1?%5[_ &;X=NK5DO[OSU@\J+[S M-O;Y5KM&_P!?%_P*O+_VE?*/P(\=^;9VVJQ?V9+OM+Z?RH7_ -Y]Z;?^^UH MZ+X8^'-&\'^ -%T;P_=M?Z/90>5:W D5]R;O[R_+7:UY/^S;M'P0\(FV@AMX MOL.Y8X7WI]]OXO-E^;^_\[?-78Z7X]\.:]<_9-,U[3=0ODW?Z-:7D4LOR_>^ M56H S]$\[_A9/BH;(_)^RV'S;OFW?O:['>_]U?\ OJN.T2%A\2/%4OF.B?9; M!?*^7;_RU^:NQ\EO^>K4 &]_[J_]]4;W_NK_ -]4>2W_ #U:CR6_YZM0 ;W_ M +J_]]4;W_NK_P!]4>2W_/5J/);_ )ZM0 ;W_NK_ -]4;W_NK_WU1Y+?\]6H M\EO^>K4 &]_[J_\ ?5&]_P"ZO_?5'DM_SU:CR6_YZM0 ;W_NK_WU7X[_ /!4 M#=_PU9>[NG]CV?\ Z"]?L1Y+?\]6K\=_^"H/_)UE[\W_ #![+_V>@#Y-?_5) M_O5]C_\ !*;=_P -)ZGM_P"@!&_C18VWAS3(O[* MN?D@3^)?[M><1?PU1T'_ ) >G_\ 7!*^5GCZG+\1XZQ=3GL>?_&75XM<^)6L M7L4;0I+Y7R/_ -1_97# M\O\ A*H2_NQ/HW]CW']L^(MO3RH/_9Z^F-$_Y!]O_N5\S_L>_P#(7\1?-_RR M@_\ 9J^F-$_Y!]O_ +E?99=_NT3\"XQ_Y&]7_MW\B6/_ (^)?]U*N53C_P"/ MB7_=2KE>F?%!1110 4444 <]?>5]LEWJWWO[U08C_NO_ -]4Z_\ ^/\ E_WJ MKUU0,B;$?]U_^^J$2)U?Y6^7_:J&IH_]5+_NU9 8C_NO_P!]48C_ +K_ /?5 M0T4 38C_ +K_ /?5&(_[K_\ ?50UY_XA^&^M:EKUWJ&F>*KG2K>XEBE6WB7[ MO_/PF_\ V]D7_C_]^@#T;$?]U_\ OJC$?]U_^^J\G3X3:]#:_8U\7RO9>1]G M:*5'^[\^SY]_S;&;[E;6@^#/%&E2Z(UYXQN=22SEN'OEF7_C_5ON)_LJG_LU M!9WV(_[K_P#?5&(_[K_]]5SG@CP]/X9\/)8WDD,MQY\MQ*UHK)%N9]_RJWW5 M_P!FMV@@FQ'_ '7_ .^J$2)WV[6_[ZJ&IK;_ %J4%AB/^Z__ 'U1B/\ NO\ M]]54N8?.M98OE^=73YZ\G3X+:O\ 85@;7K3S5LXK3S4@E_A6)?XG_A\K*55^^ZNBT$%C$?]V7_ M +ZH_=[=VUO^^JXGX>^#]:\)?;O[7\0?VZDZQ)!OB9/(V_PUV?\ R[_\"H ? MB/\ NO\ ]]48C_NO_P!]54O$::UN(HO*\UHG1?-7>F[_ &_]FLSP?H,OASPO MI^FSSQW%Q!%MEEB5D5GW;OE5ONK_ +/\- '0)Y6V7Y6_[ZIN^+^ZW_?5$?\ MJI?]VH: )M\?]R7_ +ZHWQ_W)?\ OJN1B\'W2?$*X\1M?+]G:#REM]K;_N(N MS?\ =V_+N_WFKJ* .CL-OV.*K=5--_X\HJMUQ2.@**** "BBB@"!O]?%_P " MKR7]IB2?_A0WC26VM?MEQ%ISRK;_ &=Y?,V_-]Q65O\ OGYEKUIO]?%_P*O( M?VHM'TW5?@EXD;5^;>RB6]7=+.B>;$ZNG^H='^]0!=_9UF6[^"GA::*RMM-B M>V9TBM()8HOOM\Z)*SR_-][YVW?-46B?!+0_#_Q&M_%UM=7::FOVII]B1+]J M:=]W[UT3M4 >;:#HFFI\2_%7[V?[0T%F^W[=+_%YO\.^NS_L>Q_YZS_^!DO_ M ,77/:+,J?$7Q5%M;=]EL&W;6V?\M?XJ['SE_N/_ -\T 9_]CV/_ #UG_P# MR7_XNC^Q+'_GK/\ ^!DO_P 76AYR_P!Q_P#OFG;Q_<;_ +YH S?['L?^>L__ M (&2_P#Q=']CV/\ SUG_ / R7_XNM#SE_N/_ -\T>Q_YZ MS_\ @9+_ /%T?V)8_P#/6?\ \#)?_BZT/.7^X_\ WS3MX_N-_P!\T 9O]B6/ M_/6?_P #)?\ XNOR!_X*;V\=O^U)=+&S!?['L^'E9_[_ />K]D-X_N-_WS7X MZ_\ !4'_ ).LO?\ L#V?_H+T ?)K_P"J3_>K["_X)9V\=S^T=J:R!BO]@7'W M)63_ ):Q?W:^/=_[K9_'7U/_ ,$X_B%H/PW^.NH:KXCU-=*LGT26W65XG;Y_ M-B^3Y$JHQE.7+ B4HPCS3/UD\0:1:HNF[9)_^/Z#_E\E_P#BJO:QI%HFDWK+ M)/N6"3_E\E_N_P"]7E6M_M6_"VY6P\KQ= ^V\B=O]%G^[_WQ5J\_:E^%^I6< MMI;>+('N+A6BC3[-/\S-\J_P5=7"8GDE>$ON.26-PW\\3S[[\6W^^M,L[.*P MMT@@79$GR*F[?4R)L3:U%?FL_B/(7QGC_CS_ )&K4/\ @/\ Z E($M[O_A();1Y?-_<):1;4\K;]]_]IZZ&%&=9=O\ M=JR!/.?_ &?^^:Y>'XB:+(UVGFSP_8UE:?S;-T\I(OONWR_=_A_VJZG[/)_= MKF;_ .&FBZDUQY]C)LNM_GHEU*B3[GW;)45_F^:@L?;?$?0+R6[2+4%?[+:_ M:I?W'_++8C[T^7YOE=?^^Z9>?$O0[-E66[^9K6*]1$@W[XI?N;?]I_[M.TKX M9Z!H-C<6FGZ1';1-]YT_UJ_)M^67[R_+45_\+M%U*#3X+FVNYDTZ)8K/_3)= M\'^VC[_O?[?WJ@"])XXT"*+S)=Z[/F_P!I'K'_ .%)Z'%XJAURVCN; M-U6Z\VTBE;RKAY_]:[?[VZIW^"_A5ENU.C#9=?9Q.GGR_O?(=VB;[_\ "[LW M_?']V@#H[#Q!:ZG>:A:P/_I%@RI.CP;-F[YD_P!Y:TX9F\U/N_\ ?-9FC>&K M;0Y=0DM5F\V_G^U3M+.TNZ7_ (%]W_+3+:^6YNI9Y;==D7R,\7^M^;_8KHO)D_NUS5G\,=#L+U;F"QE25;G[;L\^ M79YOSLC[=_\ "SM_WU0!TT,S>:GW?O?W:9-<[-[-MV+_ +-/AAE\U/E_BIES M9M,LL3*R(ZNGR-M?_ON@"EI7B?3]>25M,OK:_6+9N\K^#=6EYS?9_P"'[W]V MN:\*_#K1_!373Z/8M;/=;//=YVE>7;_?W?Q5TODR_9_N_P 5 $3W+(KO_<_N M+531]>M]?TZ*^LVWV\N[9OBV/\K;'1D_WEJQTFTTRQBD2TM8O*B1Y7=U7_ 'VH T$F;;+]W_OFF><_^S_WS3TA MEVS?+3?(D_NO0!SEM\1=%O/$+Z'!?+-J:RM$T*1?=941G^?_ (&M=%YS_P"S M_P!\US5M\,=#L-2>^MM-:VF>Z^WLD4K>4\^S;YKIOV[JZ;[/)_=H W=-.^RB MJW5/34V646[K5RN*1J%%%% !1110! W^OB_X%7CG[4/B%_"_P9UN0+/,MTT5 MFS(LKNC2ML5MJQ2[TW[-R[-NW?7L;?Z^+_@5>7?M :?_ ,)#\,=7\-VJ6USK M&O1-9:?:WH6MW9WJ6O[V*^ MB>)U?>W\#11;$_NIL7:NQ:]5KRG]GY[V/X3^%UOY8Y[V.!X9'AN7N$WI*RMF M5G?<_P GS?.WS;]ORUZM0!Q&B3/_ ,+(\5+Y+,GV6P;S=R_]-?EKL?.;_GDU M34>7_OF@ \YO^>34 M>7_OF@ \YO^>34>_Y& M'2?^ORW_ /0DK]6QG^[U?\/_ +:?E,/CB?:\W^M;_>IM.F_UK?[U-K^5<1_& M9]]1/'_'G_(U:A_P'_T!*YS^-*Z/QY_R-6H?\!_] 2N<_C2L#^V\@_Y%5#_# M$^BOV/?^0OXB^7_EE!_[-7TQHG_(/M_]ROF?]CW/]K^(MO\ SR@_]GKZ8T3_ M )!]O_N5]M@/]VB?@?&/_(WJ_P#;OY$L?_'Q+_NI5RJ+K:PUCS?&T[ZA>Q*D%Q_!$RN^SY&_V'3?LV_JO75 R/- MX?AUXNACB5/'5VFVY25]C-\\6^5V3YM^W[\2_P"[%70> _#WB;0?MW]O>(%U MY)8(DB^5OW3+NWO_ ,#^7_/RUU%30[=LNY]GRU8$+HSKMBV^;_#O^Y7E4GQH MN;31GN[O2X6O?+MWBT^V:5YKCS5W[E39NV*F_P"?^\M>M[8O^>G_ (Y1\O\ MS\?^.4 >8_\ "VKE/"^NZY)H+0V5G+_H=Q,[Q1746_;OW_PM_P"A58\3?%)_ M#^MZG9P6MI?6EA+ D\L4_P"]7S5=MJ1?\M9?N?(G]^O1MB?\]?\ QVC8G_/7 M_P =H \ITKXY07,3_:=#NWEW+L?3]KQ-N^XF]MGS??1OX59*=-\:/I]_<6D]S!!O6]C:Q*;>72HM2^9MEQ;^;]Q M)4_VO_'=GS5UUM_K4I^Q/^>O_CM.A1?-3][_ ..T 5T3>U>6:;\:9=2\1V^F M/HDZ)+K;:7]H3P>PO);)OM'_ M "UV_P :5T'_ "[_ / J?L3_ )Z_^.T_8OE?ZW^+^[0!1N9EMK66=MJ>4C/\ M_P!RLKP9XA;Q5X:LM5:!;9Y]_P B?[+NO_LM=!MB_P">G_CE&Q/^>O\ X[0 MR/\ U4O^[3*L(B[)?WO_ ([3=L7_ #T_\);?2HHK*9)=3GL$ M:&=M[K%%O=]NS^!OE;_?^2N^J;8G_/7_ ,=HVQ?\]/\ QR@LW=-_X\HJMU4T MW_CRBJW7%(U"BBB@ HHHH @;_7Q?\"KF?&WP_P!!^)&AMI'B/3;;6+!F67[/ M<+]QU^ZR_P!UJZ9O]?%_P*IZ ,70=!TWPKHMEI&D6,.FZ;9Q+%!:6Z[4B3^Z MM>$_#O\ 9WUKP)\2(O$$OBE;O3UGN)8M/6"7=$LGF_NEE:7YD?S=[;U9MT46 MWY5KZ0HH \[T31[J/XB^*)/[8OBK6]E^ZVQ;%_UO_3*NP_LJX_Z"MW_WS%_\ M17-:)]F_X6AXHQ+_ *1]CL/D\S^'][_#77YA_P">B_\ ?R@"K_95Q_T%;O\ M[YB_^(H_LJX_Z"MW_P!\Q?\ Q%6LP_\ /1?^_E._=_WT_P"^Z *?]E7'_05N M_P#OF+_XBC^RKC_H*W?_ 'S%_P#$5_=_P!__P >IO[O^^G_ 'W0!3_L MJX_Z"MW_ -\Q?_$4?V5']J*]5I9+E_P"Q[+YY=O\ M_W:_9']W_?3 M_ONOQV_X*@[?^&JKO;_T![/_ - >@#Y-KO?@M_R-TW_7J]<%7>_!;_D;IO\ MKU>O5RO_ 'NE_B/,S3_IM?RIB/XS/O:!X_X\_Y&K4/^ _\ H"5SG\:5T?CS_D:M0_X#_P"@)7.? MQI6!_;>0?\BJA_AB?0G[(T4MQJFO[;F6VVQ0?ZK;\WW_ .\E?3VB?\@^W_W* M^9_V0-O]K^(MS?\ +*#^+_?KZ8T3_D'V_P#N5]M@/]VB?@?&/_(WJ_\ ;OY$ ML?\ Q\2_[J5JO703:;! M,[,RMO;_ &J;_8UK_M_]]5T*I$RY3!J:/_52_P"[6Q_8UK_M_P#?5)_95M\W MRM_WU1[2(PW^Z.\EN?*OI?*>^GB2WEM MVBBVNZQ?-\DJR[$VM]_YJJR6/Q$M= T6.6>6YU!+"6+4WANXE1Y?M$3HZ,R+ M\_E)*F[[J[Z]P_L>V_NM_P!]4?V/;?W6_P"^J7/$.4\"U6^^+>@^'Y;I4TO4 MKF)%1(DM][I\[_/\K_-L^3^'^)ZJ>(=6^*FE1PZSIEC]IBO8E673[A%>6R;? M\FV+?_=7YOG;YFKZ&_L:U_V_^^J/[&M?]O\ [ZI<\0Y3R"*Q\8_\)FTD[3S> M'7G2542YBBE3Y%^3;_SR1M_R?>;?_LU%>0_$:\T:R;9;6VKK/=)*EC/$MO\ M9]G^CN^[YMWW?N?=;_9KV;^Q[;^ZW_?5']CVW]UO^^J?/$.4X?P?#J=MX?M8 M]79GU!=^_?*LK[=S;$9U^\VS;\U;UM_K4K8_L:U_V_\ OJD31[9'W;6_[ZI^ MTB'*8%RC/;RK%NW[7V[/O[_^!5Y9=6?Q-?2[)8&E^U_8;/[3]HO(/GG7?YNQ MUV??^3<__?%>Y_V-:_[?_?5']C6O^W_WU1[2( MO^Z_AW;*Z[_EW_X%6W_8UK_M_P#?5)_8]MMV[6_[ZH]I$.4YVYW?99?*5GEV MOM1&V?-63X,AU>V\,V46N-OU5-_F_O=_\;[/G_B^7;7<_P!C6O\ M_\ ?5'] MC6O^W_WU1[2(@O\ >?;]RM[^QK7_ M &_^^J/[&M?]O_OJCVD0Y273?^/**K=0PPK#&L:_=6IJYS4**** "BBB@"!O M]?%_P*IZ@;_7Q?\ JGH **** .(T694^(GBJ+:P;[+8-OVML_Y:_P 5=CYR M_P!Q_P#OFN.T623_ (61XJ7:OE?9;#Y]WS;OWO\ #78[Y/[J_P#?5 #=_P#L MM_WS2>;_ ++?]\T;Y/[J_P#?5?'GQZ_:N\7?##XI:KX:TBTTB;3[6*!E>[BE M>7YHE;^%UKHPV&J8NI[*D<6)Q-/"0YZA]56UW=OX@O;:3R/L,4$4L6Q6\W]M^W'\08-1N)_P"S] WRQ1(W^C2_PN__ $U_VZ]T M_9>_:&\3_&77/$%IKEMI\,5A;12Q?8HGB^9F_BW.]=U;*<5AZS_\ 0'K]B-\G]U?^^J_'?_@J!_R=9>[O^@/9_P#H#T ?)5=[\%O^1NF_ MZ]7K@J[WX+?\C=-_UZO7JY7_ +W2_P 1YF:?[E+_ GMKHK_ 'EWUJ>'O^1A MTG_K\M__ $)*SJT?#W_(PZ3_ -?EO_Z$E?JN,_@3_P ,OR/RNA\9]KS?ZUO] MZFTZ;_6M_O4VOY3J_P 8^]H'C_CS_D:M0_X#_P"@)7.?QI71^//^1JU#_@/_ M * EH&_U\7_ JGH *^?\ X?>%OB99_$F+5M=Z)!J__"Q?%#/?67V?[/9;5^QMO_Y:_P 7 MFUV7D:I_S^6G_@*__P =KC7OFT3Q5XUU7][,EEIUK+]G5E56VI*U?$$/_!8: MT>))?^%4WWSKO_Y#L7_R/0!]^:+OJK]@=+D>)O%OV:2*%_L=ON\V+?_ !O_ +2U\KU]*_L1^*;+ MPMXE\2RW?G;9;.)4\I=_\=?79W*-++ZDI'R.4R_VR,I'V_K= ML?BGI%_>V]I%]K\V>58DWQK7X_\ 6Z'\Q^I>TI_S'7_9]5_Y^[3_ ,!7_P#C MM'V?5?\ G[M/_ 5__CM1W]S+8:==W,2><\43/L=MN[:O^[3K&YEO+"WGD_T?\]6K\>?^"H/_)UE[_V![/\ ]!>@#Y*KO?@M_P C=-_UZO7! M5WOP6_Y&Z;_KU>O5RO\ WNE_B/,S3__Y&'2?^ORW_P#0DK]7QG^[S_PR/RBA\9]KS?ZUO]ZFTZ;_ %K?[U-K^4L1 M_&9^@4#Q_P >?\C5J'_ ?_0$KG/XTKH_'G_(U:A_P'_T!*YS^-*P/[I_ MQ.O$/S?\LH/_ &>OIK1?^0;;?[M?@ HHHH \H\0_9?[7^)>[ROM7]A1?[^WRKC_P =K\#K M/_CUA_W5K]]/$,Q^W_$N/RF_Y 43>;_!_JKCY:_ NS_X]8?]U: +$SJ\KLM> M]?"3_D0]/_WI?_0WKP*O??A)_P B'I_^]+_Z&]?5\.?[W+_"?+<0_P"[1_Q' M85[1^S-_R&-=_P"N$7_H=>+U[1^S-_R&-=_ZX1?^AU]!Q-_R*ZI\7@/]YB>[ M7EG]L:W_ 'K0^5*DOR;/GVU+-JL^B6[ZE;;?M%JOVB+>NY-RT^L_7O\ D :A M_P!<'K^;.<_2WE?\ O=+_ M !'A9I_N4O\ ">X5H^'O^1ATG_K\M_\ T)*SJT?#W_(PZ3_U^6__ *$E?JV, M_P!WG_AD?E%#XS[7F_UK?[U-ITW^M;_>IM?R?5_BS/OZ)X_X]_Y&W4/^ _\ MH"5S(_UJUTWCW_D;=0_X#_Z EOG5_$7R_\ +*#_ -FKZ8T3_D'V_P#N M5]M@/]VB?@/&'_(WJ_\ ;OY$L?\ Q\2_[J55:SK?C7_A./#'ARWT^?Q M+H4TL3.V]/-V?,^[^Y7Z'?:8_P"\G_?5)YT?_/5?^^ZZ*&+JX27-2.3$X:GB MH\M4^$?^&"/&H_YC^B?^1?\ XBNV^$_[)/B?P#?ZA/> [3Q)-YMU+8:?:3O;W"Q+<111(ZJ MC_,R.\O][;$]=&)S/$XVA*A7E[LC@IY3AJ4N:$3J_P#A3NN?\_5I_P!_6_\ MB*HZG\$=2/ M*?'5*LIU)59?%(_*_P#X=*_$3_H<_#?_ 'SX^!_B/\2'TZX7Q M3X'BMWL-*EO9;V*=D^TSK$C+$B[/E;YG5O[NWY=U8EK\?OB?-I*WT7P=O7=[ M-KA4\^5-[[_D^1HMR_[C[7^;=LV?-7JSSG%UH\DY'D1R7#?RG4/\&M>9V;[1 M:<_]-7_^(H_X4UKW_/Q:?]_7_P#B*Q;SXO?%BW\+13Q?#JVN]=EO)[58H9Y= MD2K]H\J5HMF[;\D'S;]K>;\M5M<^-7Q6TO[%M^$\NJI=03NTUO=2IY4L5NCI MNB\IG7?*S*O^[_>KY-X"A.?.XGH+"4T8/B3]F;Q+K>O2WT5[9+'+M^5W;'W? M]VLG_ADKQ5YWR:C8$?WQN_\ B:^@_AUXOU_Q5-K?_"0>&)?#/V.>);/[0_\ MQ]*UNCN__ 79T_X#76,>7X3Q3X M&?"+6OA?=:E+>-:7;WBQ(OE2LFW;O_V*]FTZ*6VLHHI=N]5^;;4L;QIUE7_O MJG^=%_ST7_ONNNG3C2CRQ/FL7C:^/JRKU_BD,C_X^)?]U*N53A=7GEVMO^5: MN5JA\6:9+>7%LT_DS1- ML_>_+O\ O_=_[X:I4\0:5&\NV\@Q$JN_S?<7[M2OH.GOOW0K\[2LW^UN^_56 M;PEIEQ"\+[=!O1MCIYOW:(?$-C-(BI< MQOO^ZV[[WWO_ (BLRP\#Z?9N[,GG;F?;_#\K?>K3_P"$;T]+Q+M8-EPK;MZL MU %9/%MF][Y$BR6CM(\2M<+M5F7;_P#%593Q)I3H[+?0.B+O;YONK23>'[&Y M65&B5UE9G;YOO;G5F_\ 0%J"3PAI7]GO:?9A]G=%1D5OX5H M#Q)I09U_M"V MW*VQAYO1JBN?$.F6S*K7<;.Z[U16^\O^6JI!X0TQ;C7>WW?[G^[\JT 67\1Z>EO+.MRLR1+O;R?F^6HYO$> MFQ1)+YZ2Q;F3?%\ZJRIN_P#0:5/#FGI]Z)W_ ''V?YG;[G]VD?PYILL'D-;* M\6^)]G^U%]S_ -!H 6'Q)IKP>8]S'#\VW;*WS*U5KOQ9IMA?M;2R-N\I)5VK MN5U;=]W_ +XJ5O#.FO<-.L&R;_GJK,KK\V[_ -FI;GPMIEY]G66V7]UM\OYO MN[4=$_\ '7:@"*Y\6:?;-,H\QWBV[D1/]C?_ .@T)XFL9I46))ID^U?8MR)\ MF[_XG_XFI9O"NGW 1YTDF94\I7>5MVW^[3K7P_IMHVZ"TBA^=GV(NU-VS;]W M_=H JWGC+3+"]>.=I$"LZ[]OR,5^_P#]\[:E/B>Q%Q%$%D$LL[6JIY7S;E_] MEJ3_ (1C37\U'@^27[Z;OD_W:1_#.GN=\D'G2^:TJ3.WSJS?W&H 98^)K._O M$MHDD25BR_.OW&7^'_QVNBK#L?#UMITL4L43;HOE7>W_ '_ -!K EX-101.SCH 13 ptix-20241231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Change in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 999014 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 999015 - Disclosure - LIQUIDITY AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 999017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 999018 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 999019 - Disclosure - COLLABORATIVE AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 999020 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 999021 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 999022 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 999023 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 999024 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 999027 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 999028 - Disclosure - STOCKHOLDERS’ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 999029 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 999030 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC (Details) link:presentationLink link:calculationLink link:definitionLink 999031 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 999034 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 999035 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 999036 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details) link:presentationLink link:calculationLink link:definitionLink 999037 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 999038 - Disclosure - SUMMARY OF WARRANT (Details) link:presentationLink link:calculationLink link:definitionLink 999039 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999040 - Disclosure - COLLABORATIVE AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999043 - Disclosure - SEGMENT REPORTING (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999044 - Disclosure - SCHEDULE OF LOSS BEFORE INCOME TAX (Details) link:presentationLink link:calculationLink link:definitionLink 999045 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) link:presentationLink link:calculationLink link:definitionLink 999046 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 999047 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999048 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 14 ptix-20241231_cal.xml XBRL CALCULATION FILE EX-101.DEF 15 ptix-20241231_def.xml XBRL DEFINITION FILE EX-101.LAB 16 ptix-20241231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Common Stock Purchase Warrant [Member] Related and Nonrelated Parties [Axis] Nonrelated Party [Member] Related Party [Member] Class of Stock [Axis] Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Sale of Stock [Axis] Private Placement [Member] Series A Common Stock Warrants [Member] Series B Common Stock Warrants [Member] Placement Agent Warrants [Member] Series A Common Stock Purchase Warrants [Member] Series B Common Stock Purchase Warrants [Member] Plan Name [Axis] 2016 Plan [Member] Award Type [Axis] Statement of Income Location, Balance [Axis] General and Administrative Expense [Member] Research and Development Expense [Member] Title and Position [Axis] Employees [Member] Non-Employees [Member] Employees and Consultants [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Consulting Agreement [Member] Officers, Board of Directors and Consultants [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Research Agreements [Member] Finite-Lived Intangible Assets by Major Class [Axis] Licensing Agreements [Member] Agenus Inc. [Member] CTC North, GmbH [Member] Income Tax Jurisdiction [Axis] Federal [Member] Scenario [Axis] Losses Incurred After 2017 [Member] Losses Incurred Prior To 2018 [Member] State and Local [Member] CANADA 2006 Equity Incentive Plan [Member] Subsequent Event Type [Axis] Subsequent Event [Member] 2016 Equity Incentive Plan [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Entity Listing, Par Value Per Share Auditor Firm ID Auditor Opinion [Text Block] Auditor Name Auditor Location ASSETS CURRENT ASSETS Cash Marketable securities Prepaid expenses TOTAL CURRENT ASSETS Equipment - net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued expenses TOTAL CURRENT LIABILITIES TOTAL LIABILITIES STOCKHOLDERS’ EQUITY Preferred stock, value Common stock, $.0001 par value, 100,000,000 shares authorized, 7,241,443 and 4,435,132 shares issued and outstanding at December 31, 2024, and December 31, 2023 Additional paid-in-capital Accumulated deficit Accumulated other comprehensive loss TOTAL STOCKHOLDERS’ EQUITY TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING AND ADMINISTRATIVE EXPENSES Research and development Research and development – related party General and administrative TOTAL OPERATING AND ADMINISTRATIVE EXPENSES LOSS FROM OPERATIONS OTHER INCOME Interest income Interest expense Realized loss on marketable securities Gain on settlement of accounts payable and accrued liabilities with Related parties TOTAL OTHER INCOME LOSS BEFORE TAX INCOME TAX EXPENSE NET LOSS COMPREHENSIVE LOSS Other Comprehensive Loss - net of tax Net unrealized gain (loss) on marketable securities Reclassification of realized losses on debt securities Foreign exchange translation income (loss) TOTAL COMPREHENSIVE LOSS Net loss per common share - Basic Net loss per common share - Diluted Weighted average common shares - Basic Weighted average common shares - Diluted Balance Balance, shares Foreign currency translation gain Unrealized gain on marketable securities  Reclassification of realized losses on debt securities Stock compensation - stock options Conversion of notes and interest Conversion of notes and interest, shares Rounding from reverse split Rounding from reverse split, shares Net loss Stock issued for cash Stock issued for cash, shares Stock and warrants issued at offering Stock and warrants issued at offering, shares Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Loss Adjustments to reconcile net loss to net cash used in operating activities Depreciation expense Stock-based compensation Realized (gain) loss on sale of marketable securities Amortization of debt discount Gain on settlement of accounts payable and accrued liabilities   with related parties Changes in operating assets and liabilities Prepaid expenses Accounts payable and accrued expenses Accounts payable and accrued expenses – related party NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from sale of marketable securities Purchase of marketable securities Purchase of fixed assets NET CASH PROVIDED BY INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Issuance of shares and warrants from offering, net of offering costs NET CASH PROVIDED BY FINANCING ACTIVITIES Effect of exchange rate changes on cash NET CHANGE IN CASH CASH, BEGINNING OF THE PERIOD CASH, END OF THE PERIOD SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid for interest expense Cash paid for income taxes NONCASH FINANCING AND INVESTING TRANSACTIONS Shares issued for conversion of notes and interest Unrealized gain or loss on marketable securities Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration No Insider Trading Flag Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] Material Cybersecurity Incident [Abstract] Material Cybersecurity Incident Nature [Text Block] Material Cybersecurity Incident Scope [Text Block] Material Cybersecurity Incident Timing [Text Block] Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block] Material Cybersecurity Incident Information Not Available or Undetermined [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND NATURE OF BUSINESS Liquidity And Going Concern LIQUIDITY AND GOING CONCERN Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Equity [Abstract] STOCKHOLDERS’ EQUITY COLLABORATIVE AGREEMENTS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Segment Reporting [Abstract] SEGMENT REPORTING Income Tax Disclosure [Abstract] INCOME TAXES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of presentation Principles of consolidation Use of estimates Concentrations of Credit Risk Cash and Cash Equivalents Marketable Securities Equipment Fair Value Measurements Stock-Based Compensation Basic and Diluted Net (Loss) per Common Share Research and Development Foreign Currency Translation Recent Accounting Pronouncements SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS SUMMARY OF WARRANT SCHEDULE OF LOSS BEFORE INCOME TAX SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Marketable securities, current Marketable securities, fair value disclosure Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potentially outstanding dilutive common shares Purchase of marketable securities Unrealized gain on marketable securities Marketable securities Estimated useful lives Accounting Research and development Legal Other Total Exercise price Expected dividend yield Risk free interest rate minimum Risk free interest rate maximum Expected life in years Expected volatility minimum Expected volatility maximum Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of Stock Options Outstanding, Beginning Weighted Average Exercise Price, Beginning Weighted Average Remaining Life Number of Stock Options Outstanding, Granted Weighted Average Exercise Price, Granted Weighted Average Remaining Life, Granted Number of Stock Options Outstanding, Expired Weighted Average Exercise Price, Expired Number of Stock Options Outstanding, Exercised Weighted Average Exercise Price, Exercised Number of Stock Options Outstanding, Ending Weighted Average Exercise Price, Ending Nonvested Options, Balance Weighted-Average Exercise Price, Balance Nonvested Options, Granted Weighted-Average Exercise Price, Granted Nonvested Options, Vested Weighted-Average Exercise Price, Vested Nonvested Options, Forfeited Weighted-Average Exercise Price, Forfeited Nonvested Options, Balance Weighted-Average Exercise Price, Balance Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of Warrants Outstanding, Beginning Weighted Average Exercise Price, Outstanding Weighted Average Remaining Life Number of Warrants Outstanding, Granted Weighted Average Exercise Price, Granted Number of Warrants Outstanding, Weighted Average Remaining Life, Granted Number of Warrants Outstanding, Expired Weighted Average Exercise Price, Expired Number of Warrants Outstanding, Exercised Weighted Average Exercise Price, Exercised Number of Warrants Outstanding, Ending Weighted Average Exercise Price, Outstanding Number of shares issued for cash Shares conversion Rounding of shares related to a reverse stock split Purchase of shares Exercise price of warrants Term Exercise price Share price Purchase of shares of common stock Gross proceeds Number of additional shares granted Number of shares available for grant Number of options outstanding Number of options issued Number of options outstanding Share based compensation weighted average exercise price Share based compensation intrinsic value Share based compensation expense Unamortized stock option expense Weighted average period for unamortized stock compensation (in years) Options to purchase common stock Options exercise price Options expire period Options vest period Monthly payment Options exercise price Options vested shares Shares issuable under warrants Warrant exercise price Class of warrant or right, outstanding, intrinsic value Share based compensation expense Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Research and development expense Intangible Asset, Finite-Lived [Table] Finite-Lived Intangible Assets [Line Items] Royalty payment, percentage Up-front sub-license fees, percentage Royalty payment on behalf of sublicensee percentage Sales revenue Interest on amounts owed under license agreement, rate Minimum bid price Closing bid price Related Party Transaction [Table] Related Party Transaction [Line Items] Expenses related to services Other liabilities Commitment agreement, value Gain on settlement of accounts payable and accrued liabilities with related parties Other liabilities Number of operating segments Domestic Foreign Income taxes at Federal statutory rate State income taxes, net of Federal income tax effect Perm difference Foreign tax rate differential Change in valuation allowance Other Income tax provision U.S. net operating loss carryforwards Stock compensation  Deferred tax assets, gross Valuation allowance Net deferred tax assets Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Line Items] Income tax expenses Net operating loss carryforwards Percentage of corporations taxable income Operating loss carry forwards expiration description Research and development investment tax credits Net change in valuation allowance Subsequent Event [Table] Subsequent Event [Line Items] Exercise price Common stock issued, shares Common stock issued, value Common Stock Purchase Warrant [Member] Accrued accounting fees. Accrued research and development. No Insider Trading Flag Series A Common Stock Warrants [Member] Series B Common Stock Warrants [Member] Placement Agent Warrants [Member] Series A Common Stock Purchase Warrants [Member] Series B Common Stock Purchase Warrants [Member] Series B Convertible Preferred Stock [Member] 2016 Plan [Member] Share based compensation arrangement by share based payment award options outstanding. Share based Compensation Arrangement by Share based Payment Award Options Granted Weighted Average Remaining Contractual Term 2 Other comprehensive income loss net unrealized loss on marketable securities. Other Comprehensive Income Loss Reclassication of Realized Losses on Debt Securities. Research and development related party. Realized gain loss on marketable securities. Gain on settlement of accounts payable and accrued liabilities. Other Comprehensive Income Reclassification of Realized Losses on Debt Securities. Stock issued during period value reverse stock splits. Employees [Member] Non-Employees [Member] Realized gain loss on sale of marketable securities. Accounts payable and accrued expenses related party. Unrealized gain or loss on marketable securities Employees And Consultants [Member] Liquidity And Going Concern Disclosure [Text Block] Consulting Agreement [Member] Officers, Board of Directors and Consultants [Member] Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity. Number of warrants outstanding, weighted average exercise price, expired. Number of warrants outstanding, weighted average exercise price, expired Share based payment award non option equity instruments outstanding weighted average remaining contractual term. Share based compensation arrangement by share based payment award non options equity outstanding weighted average remaining contractual term granted. Class of warrant or right, outstanding, weighted average exercise price. Class of warrant or right, outstanding, intrinsic value. Research Agreements [Member] The percentage of royalty payment of net sales. The percentage of royalty payment of net sales made on behalf of a sub-licensee. The interest rate charged per annum on any amounts owed under the license agreement and amendment. Agenus Inc. [Member] CTC North, GmbH [Member] Effective income tax rate reconciliation permanent difference percent. Deferred tax assets depreciation and amortization. Deferred tax assets income tax loss. Federal [Member] Percentage Of Corporations Taxable Income. Losses Incurred After 2017 [Member] Losses Incurred Prior To 2018 [Member] Operating loss carryforwards expiration description. State And Local [Member] 2006 Equity Incentive Plan [Member] 2016 Equity Incentive Plan [Member] Deferred tax assets deferred state benefit. Up front sub license fees percentage. Shares issuable under warrants. Schedule of Share-Based Payment Award, Warrants, Valuation Assumptions [Table Text Block] Net change in valuation allowance. Bid price requirement. Closing bid price. Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Nonoperating RealizedGainLossOnMarketableSecurities Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Productive Assets Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Equity [Text Block] Marketable Security, Unrealized Gain (Loss) Marketable Securities [Default Label] AccruedResearchAndDevelopment Accounts Payable and Other Accrued Liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm Number of Warrants Outstanding, Weighted Average Exercise Price, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations Number of warrants outstanding, weighted average exercise price, expired Number of warrants outstanding, weighted average exercise price, expired [Default Label] Shares Issued, Price Per Share Issuance of Stock and Warrants for Services or Claims Other Liabilities, Current Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Effective Income Tax Rate Reconciliation, Percent Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance EX-101.PRE 17 ptix-20241231_pre.xml XBRL PRESENTATION FILE XML 19 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 31, 2025
Jun. 30, 2024
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-12555    
Entity Registrant Name Protagenic Therapeutics, Inc.\new    
Entity Central Index Key 0001022899    
Entity Tax Identification Number 06-1390025    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 149 Fifth Avenue    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10010    
City Area Code (212)    
Local Phone Number 994-8200    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 4,042,876
Entity Common Stock, Shares Outstanding   7,525,681  
Documents Incorporated by Reference None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.0001    
Auditor Firm ID 206    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Protagenic Therapeutics, Inc. and its subsidiary (collectively, the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name MaloneBailey, LLP    
Auditor Location Houston, Texas    
Common Stock [Member]      
Title of 12(b) Security Common Stock, par value $0.0001    
Trading Symbol PTIX    
Security Exchange Name NASDAQ    
Common Stock Purchase Warrant [Member]      
Title of 12(b) Security Common Stock Purchase Warrant    
Trading Symbol PTIXW    
Security Exchange Name NASDAQ    

XML 20 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
CURRENT ASSETS    
Cash $ 1,838,469 $ 1,287,893
Marketable securities 2,768,119
Prepaid expenses 44,398 144,025
TOTAL CURRENT ASSETS 1,882,867 4,200,037
Equipment - net 73,046 123,332
TOTAL ASSETS 1,955,913 4,323,369
CURRENT LIABILITIES    
TOTAL CURRENT LIABILITIES 942,759 655,252
TOTAL LIABILITIES 942,759 655,252
STOCKHOLDERS’ EQUITY    
Preferred stock, value
Common stock, $.0001 par value, 100,000,000 shares authorized, 7,241,443 and 4,435,132 shares issued and outstanding at December 31, 2024, and December 31, 2023 725 444
Additional paid-in-capital 37,445,495 34,559,091
Accumulated deficit (36,303,216) (30,777,872)
Accumulated other comprehensive loss (129,850) (113,546)
TOTAL STOCKHOLDERS’ EQUITY 1,013,154 3,668,117
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 1,955,913 4,323,369
Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY    
Preferred stock, value
Series B Convertible Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY    
Preferred stock, value
Nonrelated Party [Member]    
CURRENT LIABILITIES    
Accounts payable and accrued expenses 902,884 439,757
Related Party [Member]    
CURRENT LIABILITIES    
Accounts payable and accrued expenses $ 39,875 $ 215,495
XML 21 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2024
Dec. 31, 2023
Preferred stock, par value $ 0.000001 $ 0.000001
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 7,241,443 4,435,132
Common stock, shares outstanding 7,241,443 4,435,132
Series B Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.000001 $ 0.000001
Preferred stock, shares authorized 18,000,000 18,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Preferred Stock [Member]    
Preferred stock, par value $ 0.000001 $ 0.000001
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
OPERATING AND ADMINISTRATIVE EXPENSES    
Research and development $ 3,844,984 $ 3,063,603
Research and development – related party 97,357 256,264
General and administrative 1,758,609 1,207,107
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES 5,700,950 4,526,974
LOSS FROM OPERATIONS (5,700,950) (4,526,974)
OTHER INCOME    
Interest income 43,465 264,476
Interest expense (107,682)
Realized loss on marketable securities 51,732 (630,317)
Gain on settlement of accounts payable and accrued liabilities with Related parties 80,409
TOTAL OTHER INCOME 175,606 (473,523)
LOSS BEFORE TAX (5,525,344) (5,000,497)
INCOME TAX EXPENSE
NET LOSS (5,525,344) (5,000,497)
Other Comprehensive Loss - net of tax    
Net unrealized gain (loss) on marketable securities 26,587 16,848
Reclassification of realized losses on debt securities (43,434) 489,120
Foreign exchange translation income (loss) 543 57,393
TOTAL COMPREHENSIVE LOSS $ (5,541,648) $ (4,437,136)
Net loss per common share - Basic $ (1.13) $ (1.15)
Net loss per common share - Diluted $ (1.13) $ (1.15)
Weighted average common shares - Basic 4,899,953 4,344,580
Weighted average common shares - Diluted 4,899,953 4,344,580
XML 23 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Change in Stockholders' Equity - USD ($)
Series B Convertible Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balance at Dec. 31, 2022 $ 434 $ 33,371,406 $ (25,777,375) $ (676,907) $ 6,917,558
Balance, shares at Dec. 31, 2022 4,321,315        
Foreign currency translation gain 57,393 57,393
Unrealized gain on marketable securities 16,848 16,848
 Reclassification of realized losses on debt securities 489,120 489,120
Stock compensation - stock options 666,828 666,828
Conversion of notes and interest $ 10 520,857 520,867
Conversion of notes and interest, shares   104,173        
Rounding from reverse split
Rounding from reverse split, shares   9,644        
Net loss (5,000,497) (5,000,497)
Balance at Dec. 31, 2023 $ 444 34,559,091 (30,777,872) (113,546) 3,668,117
Balance, shares at Dec. 31, 2023 4,435,132        
Foreign currency translation gain 543 543
Unrealized gain on marketable securities 26,587 26,587
 Reclassification of realized losses on debt securities (43,434) (43,434)
Stock compensation - stock options 923,139 923,139
Net loss (5,525,344) (5,525,344)
Stock issued for cash $ 86 1,963,460 $ 1,963,546
Stock issued for cash, shares   858,016       2,806,311
Stock and warrants issued at offering $ 195 (195)
Stock and warrants issued at offering, shares   1,948,295        
Balance at Dec. 31, 2024 $ 725 $ 37,445,495 $ (36,303,216) $ (129,850) $ 1,013,154
Balance, shares at Dec. 31, 2024 7,241,443        
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES    
Net Loss $ (5,525,344) $ (5,000,497)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation expense 50,286 28,218
Stock-based compensation 923,139 666,828
Realized (gain) loss on sale of marketable securities (51,732) 630,317
Amortization of debt discount 85,770
Gain on settlement of accounts payable and accrued liabilities   with related parties (80,409)
Changes in operating assets and liabilities    
Prepaid expenses 99,627 (87,086)
Accounts payable and accrued expenses 463,127 (183,832)
Accounts payable and accrued expenses – related party (95,211) 156,506
NET CASH USED IN OPERATING ACTIVITIES (4,216,517) (3,703,776)
CASH FLOWS FROM INVESTING ACTIVITIES    
Proceeds from sale of marketable securities 3,100,000 7,689,507
Purchase of marketable securities (297,120) (2,764,250)
Purchase of fixed assets (149,775)
NET CASH PROVIDED BY INVESTING ACTIVITIES 2,802,880 4,775,482
CASH FLOWS FROM FINANCING ACTIVITIES    
Issuance of shares and warrants from offering, net of offering costs 1,963,546
NET CASH PROVIDED BY FINANCING ACTIVITIES 1,963,546
Effect of exchange rate changes on cash 667 998
NET CHANGE IN CASH 550,576 1,072,704
CASH, BEGINNING OF THE PERIOD 1,287,893 215,189
CASH, END OF THE PERIOD 1,838,469 1,287,893
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION    
Cash paid for interest expense
Cash paid for income taxes
NONCASH FINANCING AND INVESTING TRANSACTIONS    
Shares issued for conversion of notes and interest 520,867
Unrealized gain or loss on marketable securities $ 26,587 $ 16,848
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Pay vs Performance Disclosure [Table]    
Net Income (Loss) $ (5,525,344) $ (5,000,497)
XML 26 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
 12 Months Ended
Dec. 31, 2024
Insider Trading Arrangements [Line Items]  
No Insider Trading Flag true
XML 27 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Abstract]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Risk Management and Strategy 

We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. We design and assess our program based on ISO 27002 standards. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the ISO 27002 as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business. We engage external resources that contribute to, and provide independent evaluation of, our existing cybersecurity practices and organizational risk assessment systems. We use established processes designed to identify, assess, and manage third-party service provider risks when third parties handle, possess, process, and store the Company’s material information. Our cybersecurity risk management program includes (i) a policy designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment; (ii) the use of external service providers to manage, assess, test and otherwise assist with aspects of our security controls; and (iii) a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents. We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. However, there can be no assurance that our cybersecurity prevention and mitigation efforts will always be successful, and it is possible that cybersecurity threats could have a material adverse effect on our business, operations, or financial condition in the future.

 
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. However, there can be no assurance that our cybersecurity prevention and mitigation efforts will always be successful, and it is possible that cybersecurity threats could have a material adverse effect on our business, operations, or financial condition in the future
Cybersecurity Risk Board of Directors Oversight [Text Block] Governance 

Our board of directors administers its cybersecurity risk oversight function through its audit committee. The audit committee is responsible for overseeing our policies, practices and assessments with respect to cybersecurity, and provides periodic updates to our board of directors. The audit committee receives periodic updates from management and our external third party information technology consultant regarding the effectiveness of the systems and processes we have implemented designed to safeguard our information assets and operational integrity from cyber threats, protect employee information from unauthorized access or attack, as well as secure our networks and systems, and regarding other cybersecurity matters, including the results from cybersecurity systems testing and any recent cybersecurity incidents and related responses. Our audit committee is also notified between such updates as soon as practicable regarding significant new cybersecurity threats or incidents. The audit committee also receives a report on cybersecurity matters and related risk exposures periodically from our Chief Financial Officer.

 
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] The audit committee is responsible for overseeing our policies, practices and assessments with respect to cybersecurity, and provides periodic updates to our board of directors
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
XML 28 R10.htm IDEA: XBRL DOCUMENT v3.25.1
ORGANIZATION AND NATURE OF BUSINESS
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND NATURE OF BUSINESS

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

 

Company Background

 

Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), formerly known as Atrinsic, Inc., is a Delaware corporation with one subsidiary named Protagenic Therapeutics Canada (2006) Inc. (“PTI Canada”), a corporation formed in 2006 under the laws of the Province of Ontario, Canada.

 

We are a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.

 
XML 29 R11.htm IDEA: XBRL DOCUMENT v3.25.1
LIQUIDITY AND GOING CONCERN
 12 Months Ended
Dec. 31, 2024
Liquidity And Going Concern  
LIQUIDITY AND GOING CONCERN

NOTE 2 – LIQUIDITY AND GOING CONCERN

 

As shown in the accompanying consolidated financial statements, the Company has incurred significant recurring losses resulting in an accumulated deficit. The Company anticipates further losses in the development of its business. The Company also had negative cash flows used in operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

Based on its cash resources and positive working capital as of December 31 2024, the Company does not have sufficient resources to fund its operations past twelve months from the date these consolidated financial statements are available to be issued. The positive working capital as of December 31, 2024 was due to funds raised by the Company from its equity offering during the year ended December 31, 2021. Absent generation of sufficient revenue from the execution of the Company’s business plan, the Company will need to obtain debt or equity financing by the third quarter of 2025   . Because the Company has insufficient resources on hand to fund operations through the next twelve months from the date these consolidated financial statements are available to be issued, the Company believes that there is substantial doubt in its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued..   These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 
XML 30 R12.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”).

Reclassification

 

Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation. These reclassifications relate to presenting “Research and development with related parties” as a separate line item in the Company’s Consolidated Statements of Operations and Comprehensive Loss.

 

 

Principles of consolidation

 

The consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated.

 

Use of estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the consolidated financial statements include valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.

 

Concentrations of Credit Risk

 

The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. As of December 31, 2024, the Company has bank balances that exceed the federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2024 and December 31, 2023 the Company did not have any cash equivalents. As of December 31, 2024 and December 31, 2023, the Company had cash of $1,838,469 and $1,287,893, respectively.  

 

Marketable Securities

 

The Company accounts for marketable debt securities, the only type of securities it owns, in accordance with the FASB Accounting Standards Codification 320, Investments – Debt and Equity Securities (“ASC 320”).

 

Pursuant to ASC 320-10-35-1, investments in debt securities that are classified as available for sale shall be measured subsequently at fair value in the consolidated balance sheets at each balance sheet date. Unrealized holding gains and losses for available-for-sale securities (including those classified as current assets) shall be excluded from earnings and reported in other comprehensive income until realized.

 

During the year ended December 31, 2024 the Company purchased $297,120 and sold $3,100,000 in marketable securities with a realized gain of $51,732 and an unrealized gain of $26,587. As of December 31, 2024 and December 31, 2023, the Company owned marketable securities with a total fair value of $0 and $2,768,119, respectively.

 

Equipment

 

Equipment is stated at cost less accumulated depreciation. Cost includes expenditures for computer equipment and lab equipment. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of equipment is depreciated using the straight-line method over the estimated useful lives of the related assets which is three years. Depreciation expense was $50,286 and $28,218 for the years ended December 31, 2024 and 2023, respectively.

 

Fair Value Measurements

 

ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

 

 

The three levels are described below:

 

Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;

 

Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;

 

Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.

 

The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short-term maturity of those instruments.

 

Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.

 

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2024.

 

   Carrying      Fair Value Measurement Using 
   Value       Level 1     Level 2     Level 3   Total 
Marketable securities  $—   $—   $—   $—   $— 

 

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2023.

 

   Carrying      Fair Value Measurement Using 
   Value       Level 1     Level 2     Level 3   Total 
Marketable securities  $2,768,119   $2,768,119   $—   $—   $2,768,119 

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported.

 

If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.

 

 

Basic and Diluted Net (Loss) per Common Share

 

Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the consolidated statements of operations and comprehensive loss.

 

  

Potentially Outstanding

Dilutive Common Shares

 
  

For the

Year Ended

December 31, 2024

  

For the

Year Ended

December 31, 2023

 
           
Conversion Feature Shares          
           
Stock Options   1,953,491    1,357,466 
           
Warrants   4,968,645    942,566 
           
Total potentially outstanding dilutive common shares   6,922,136    2,300,032 

 

Research and Development

 

Research and development expenses are charged to operations as incurred.

 

Foreign Currency Translation

 

The Company follows ASC 830, Foreign Currency Matters (“ASC 830”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. ASC 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to ASC 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.

 

The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the consolidated statements of operations and comprehensive loss.

 

Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.

 

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The adoption of this ASU did not have a material effect on the Company’s financial statements.

 

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The purpose of the amendment is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is to be applied retrospectively to all prior periods presented in the financial statements. The Company adopted this ASU and has updated its disclosure with segment reporting information.

 

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” to improve disclosures about the nature of expenses in commonly presented financial statement captions. ASU 2024-03 is effective for all public business entities for annual reporting periods beginning after December 15, 2026, on either a prospective or retrospective basis. Early adoption permitted. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements and related disclosures.

 
XML 31 R13.htm IDEA: XBRL DOCUMENT v3.25.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
 12 Months Ended
Dec. 31, 2024
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 4 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses, including related party balances, consist of the following at:

 

   December 31, 2024   December 31, 2023 
         
Accounting  $55,340   $36,750 
Research and development   666,002    498,366 
Legal   118,455    6,334 
Other   102,962    113,802 
Total  $942,759   $655,252 

 
XML 32 R14.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS’ EQUITY
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 5 - STOCKHOLDERS’ EQUITY

 

Common Stock

 

During the year ended December 31, 2024, the Company issued 2,806,311 shares of common stock for cash.

 

During the year ended December 31, 2023, the Company issued 104,173 shares of common stock for the conversion of notes and interest and 9,644 shares of common stock for rounding of shares related to the Reverse Split.

 

Securities Purchase Agreement

 

On October 29, 2024, Protagenic Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue to the Purchasers in a private placement, 1,948,295 shares of the Company’s common stock (the “Shares”), par value $0.0001 per share (“Common Stock”), series A common stock purchase warrants (the “Series A Common Stock Warrants”) to purchase an aggregate of 1,948,295 shares of Common Stock (the “Series A Common Stock Warrant Shares”) with an exercise price of $0.64 per share (subject to adjustment as described therein), which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date (as defined in the Purchase Agreement), and series B common stock purchase warrants (the “Series B Common Stock Warrants”) to purchase an aggregate of 1,948,295 shares of Common Stock (the “Series B Common Stock Warrant Shares”) with an exercise price of $0.64 per share (subject to adjustment as described therein), which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. As used herein, the Series A Common Stock Warrants and the Series B Common Stock Warrants are sometimes referred to collectively as the “Common Stock Warrants”. Such private placement is referred to herein as the “Transaction.” The purchase price of each Share and associated Common Stock Warrants was $0.64 ($0.89 in the case of insiders).

 

 

Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”), acted as sole placement agent for the Transaction. The Company issued to Brookline or its designees warrants (the “Placement Agent Warrants”) to purchase up to 129,489 shares of Common Stock at an exercise price equal to $0.64 per share. The Placement Agent Warrants are exercisable immediately upon issuance and on or before the Termination Date (as defined in the Placement Agent Warrants).

 

The Purchase Agreement closed on November 4, 2024. The Company sold (a) 1,948,295 shares of Common Stock, (b) series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of Common Stock, (c) series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of Common Stock and (d) placement agent warrants to purchase an aggregate of 129,489 shares of Common Stock. The gross proceeds from the Transaction were approximately $1.9 million, before deducting fees and other offering expenses payable by the Company.

 

Stock-Based Compensation

 

The Company adopted an Employee, Director and Consultant Stock Plan on June 17, 2016 (the “2016 Plan”). Pursuant to the 2016 Plan, the Company’s Compensation Committee may grant awards to any employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary. Due to an annual “evergreen” provision in the 2016 Plan, the number of shares reserved for future grants was increased by 196,857, 186,594 and 184,260 in 2024, 2023 and 2022, respectively. As a result of these increases, as of December 31, 2024 and December 31, 2023, the aggregate number of shares of common stock available for awards under the 2016 Plan was 873,763 shares and 1,279,181 shares, respectively. Options issued under the 2016 Plan are exercisable for up to ten years from the date of issuance.

 

There were 1,953,491options outstanding as of December 31, 2024. During the year ended December 31, 2024, the Company issued 742,150 options, respectively. During the year ended December 31, 2023, the Company issued no options.

 

There were 1,357,466 options outstanding as of December 31, 2023.

 

The fair value of each stock option granted during the year ended December 31, 2024 was estimated using the Black-Scholes assumptions and or factors as follows:

 

Exercise price  $0.84-$5.00 
Expected dividend yield   0%
Risk free interest rate   4.01%-4.25%
Expected life in years   10 
Expected volatility   213-215%

 

The following is an analysis of the stock option grant activity under the Plan:

 

   Number  

Weighted Average

Exercise Price

  

Weighted Average

Remaining Life

 
Stock Options               
Outstanding December 31, 2023   1,357,466   $7.39    4.49 
Granted   742,150    1.73    9.23 
Expired   (146,125)   5.85    - 
Exercised   -    -    - 
Outstanding December 31, 2024   1,953,491   $5.36    5.77 

 

 

A summary of the status of the Company’s nonvested options as of December 31, 2024, and changes during the year ended December 31, 2024 is presented below:

 

Nonvested Options  Options  

Weighted-Average

Exercise Price

 
Nonvested at December 31, 2023   49,832   $14.72 
Granted   742,150    1.73 
Vested   (233,324)   4.14 
Forfeited   -    - 
Nonvested at December 31, 2024   558,658   $1.89 

 

As of December 31, 2024, the Company had 1,953,491 shares issuable under options outstanding at a weighted average exercise price of $5.36 and an intrinsic value of $0.

 

The Company recognized compensation expense related to options issued of $923,139 and $666,828 for the years ended December 31, 2024 and 2023, respectively, in which $431,884 and $206,104 is included in general and administrative expenses and $491,255 and $460,724 in research and development expenses, respectively. For the year ended December 31, 2024 and 2023, $186,031 and $6,852 of the stock compensation was related to employees and $737,108   and $659,976 was related to non-employees, respectively.

 

As of December 31, 2024, the unamortized stock option expense was $1,012,825 with $530,456 being related to employees and $482,369 being related to non-employees. As of December 31, 2024, the weighted average remaining vesting period for the unamortized stock compensation to be recognized is 2.83 years.

 

On January 8, 2024, the Company issued 20,750 options to purchase the Company’s common stock to consultants and employees. These options have an exercise price of $0.84 and expire in 10 years from issuance. These options vest over 48 months.

 

On February 12, 2024, the Company entered into a consulting agreement. As part of this agreement the Company agrees to pay $5,000 per month and issue 4,400 options to purchase the Company’s common stock. These options have an exercise price of $5.00 and expire in 10 years from issuance. These options vest over three months.

 

On March 25, 2024, the Company issued 717,000 options to purchase the Company’s common stock to officers, board of directors and consultants. These options have an exercise price of $1.74 and expire in 10 years from issuance. These options vest between 24 and 48 months with 160,000 options to vest upon achievement of certain performance conditions.

 

Warrants:

 

The fair value of each warrant granted during the year ended December 31, 2024 was estimated using the Black-Scholes assumptions and or factors as follows:

 

Exercise price  $0.64 
Expected dividend yield   0%
Risk free interest rate   4.31%-4.45%
Expected life in years   5-1.50 
Expected volatility   242-271%

 

 

A summary of warrant issuances are as follows:

 

   Number  

Weighted Average

Exercise Price

  

Weighted Average

Remaining Life

 
Warrants               
                
Outstanding December 31, 2023   942,566   $19.47    2.31 
Granted   4,206,079    0.64    3.30 
Expired   -    -    - 
Exercised   -    -    - 
Outstanding December 31, 2024   4,986,645   $4.21    2.92 

 

As of December 31, 2024, the Company had 4,968,645 shares issuable under warrants outstanding at a weighted average exercise price of $4.21 and an intrinsic value of $0.

 

The Company recognized compensation expense related to warrants issued of $0 and $0 during the year ended December 31, 2024 and 2023, respectively.

 
XML 33 R15.htm IDEA: XBRL DOCUMENT v3.25.1
COLLABORATIVE AGREEMENTS
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
COLLABORATIVE AGREEMENTS

NOTE 6 - COLLABORATIVE AGREEMENTS

 

The Company and the University of Toronto (the “University”) entered into an agreement effective April 1, 2014 (the “New Research Agreement”) for the performance of a research project titled “Teneurin C-terminal Associated Peptide (“TCAP”) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “New Project”). The New Project is to perform research related to work done by Dr. David A. Lovejoy, a professor at the University and stockholder of the Company, in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, Dr. Lovejoy entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 30, 2016. In February 2017, the New Research Agreement was extended to December 31, 2017. The extension allowed for further development of the technologies and use of their applications. On April 10, 2018, the agreement was amended and the research agreement has been further extended to September 30, 2024. On December 20, 2024, the agreement was amended and the research agreement has been further extended to the entire lifetime of the last issued patent covered by the license.

 

The sponsorship research and development expenses pertaining to the Research Agreements were $0 and $0 for the year ended December 31, 2024 and 2023, respectively.

 
XML 34 R16.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 7 - COMMITMENTS AND CONTINGENCIES

 

Licensing Agreements

 

On July 31, 2005, the Company had entered into a Technology License Agreement (“License Agreement”) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the “Technologies”). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date.

 

Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University 10% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. The Company had no sales revenue for the year ended December 31, 2024 and 2023 and therefore was not subject to paying any royalties.

 

 

In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at 3% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or Dr. Lovejoy, and/or the University, as the case may be. The Company has agreed to pay all out-of-pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to the University under the License Agreement and amendment.

 

The patent applications were made in the name of Dr. Lovejoy and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the five intellectual patent properties.

 

Legal Proceedings

 

From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

 

Notice of Delisting

 

On July 24, 2024, the Company received a deficiency letter (the “Notification Letter”) from the Nasdaq Listing Qualifications (“Nasdaq”) stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notification Letter states that the Company has 180 calendar days, or until January 20, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s closing bid price of the Company’s common stock must have a closing bid price of at least $1.00 for a minimum of ten consecutive business days.

  

On January 22, 2025, Nasdaq provided a notice to the Company that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as the Company does not comply with the requirements for initial listing on The Nasdaq Capital Market. This notification is part of the ongoing discussions with the Nasdaq Hearings Panel (the “Panel”) regarding the Company’s listing status, and the Company included this matter in its presentation to the Panel on January 30, 2025.   

 

On February 19, 2025, the Company received a hearing panel decision from Nasdaq (Nasdaq Listing Qualifications Hearings Docket No. NQ 7072C-25) indicating that its provisional plan for regaining compliance with the Nasdaq listing requirements had been accepted. For continued listing on the Nasdaq Capital Market, the Company has until April 28, 2025 to: (1) demonstrate compliance with Nasdaq Rules 5550(a)(2) and 5550(b)(2), (2) file a public disclosure describing any transactions undertaken by the Company to increase its equity and provide and indication of its equity following those transactions, and (3) provide the Panel with an update on its fundraising plans and updated income projections for the next 12 months.

 

 
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED PARTY TRANSACTIONS
 12 Months Ended
Dec. 31, 2024
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 8 – RELATED PARTY TRANSACTIONS

 

The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen. The Company does not pay any rent for the use of this space. This space is used for quarterly board meetings and our annual shareholder meeting.

 

During the year ended December 31, 2021, the Company engaged Agenus Inc., a related party, to perform research and development services. Agenus Inc. is a related party due to the Company’s Director and Chairman of the Board being the CEO and Chairman of the Board for Agenus Inc. The Company incurred $97,357 and $149,509 in expenses related to these services during the year ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and December 31, 2023, the outstanding balance owed to Agenus Inc. is $39,875 and $150,296, respectively.

 

During the year ended December 31, 2022, the Company engaged CTC North, GmbH (“CTC”) to perform research and development services. CTC is a related party due to the Company’s Director and Chairman of the Board being the CEO and Chairman of the Board for Agenus Inc, CTC’s parent company. The total commitment for this agreement is $1.3 million. The Company incurred $0 and $106,755 in expenses related to these services during the year ended December 31, 2024 and 2023, respectively. During the year ended December 31, 2024, the Company wrote off the remaining accounts payable balance of $80,409 as CTC is no longer in business. As of December 31, 2024 and December 31, 2023, there is $0 and $80,409 owed to CTC in connection with this agreement, respectively.

 
XML 36 R18.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
SEGMENT REPORTING

NOTE 9 – SEGMENT REPORTING

 

The Company operates in one operating segment, and therefore one reportable segment, and is focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The Company’s business activities are managed on a consolidated basis through the development and potential commercialization of pharmaceutical products, which are aimed at the global market in the event that products are successful in receiving regulatory approvals. Our determination that we operate as a single operating segment is consistent with the financial information regularly reviewed by the chief operating decision makers for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. Our chief operating decision makers is the Chief Executive Officer and Chief Financial Officer.

 

The accounting policies for our single operating segment are the same as those described in the summary of significant accounting policies. Our single operating segment incurs expenses from the development of therapeutics. The Company has not yet generated revenue in its operating history.

For the segment, the chief operating decision makers use net loss, that also is reported on the consolidated statements of operations as consolidated net loss, to allocate resources. The chief operating decision maker also uses consolidated net loss, along with non-financial inputs and qualitative information, to evaluate our performance, establish compensation, monitor budget versus actual results, and decide the allocation of funds in our various research activities.

 
XML 37 R19.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 10 – INCOME TAXES

 

The components of loss before income taxes are as follows:

 

   2024   2023 
Domestic   (5,526,365)   (4,998,066)
Foreign   1,021    (2,431)
Loss before income taxes   (5,525,344)   (5,000,497)

 

 

The Company had no income tax expense due to operating losses incurred for the years ended December 31, 2024 and 2023.

 

For the years ended December 31, 2024 and 2023, a reconciliation of the Company’s effective tax rate to the statutory U.S. Federal rate is as follows:

 

   2024   2023 
Income taxes at Federal statutory rate   (21.0)%   (21.0)%
State income taxes, net of Federal income tax effect   (8.9)%   (8.9)%
Perm difference   0.0%   0.0%
Foreign tax rate differential   0.0)%   (0.1)%
Change in valuation allowance   29.9%   30.0%
Other   0.0%   0.0%
Income tax provision   0.0%   0.0%

 

The tax effects of temporary differences that give rise to the Company’s deferred tax assets and liabilities are as follows:

 

   2024   2023 
U.S. net operating loss carryforwards   6,305,000    4,940,000 
Stock compensation   2,408,000    2,131,000 
 Deferred tax assets, gross   8,713,000    7,071,000 
Valuation allowance   (8,713,000)   (7,071,000)
Net deferred tax assets   -    - 

 

As of December 31, 2024 the Company had federal net operating loss carryforwards (“NOL”) of approximately $19.7 million. The 2017 Tax Cuts and Jobs Act (“TCJA”) will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss carryover or 80% of a corporation’s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended). Also, there will be no carryback for losses incurred after 2017. Losses incurred prior to 2018 will generally be deductible to the extent of the lesser of a corporation’s net operating loss carryover or 100% of a corporation’s taxable income and be available for twenty years from the period the loss was generated. The federal net operating losses generated prior to 2018 of $0.1 million will expire at various dates through 2037. As of December 31, 2024 and 2023, the Company had state and local net operating loss carryforwards of approximately $18.5 million and $14.0 million, respectively, to reduce future state tax liabilities also through 2035.

 

As of December 31, 2024 and 2023, the Company had Canadian NOL of approximately $1.4 million and $1.4 million respectively. The Canadian losses expire in stages beginning in 2026. As of December 31, 2024 and 2023, the Company also has unclaimed Canadian federal scientific research and development investment tax credits, which are available to reduce future federal taxes payable of approximately $0 and $0 respectively.

 

As a result of losses and uncertainty of future profit, the net deferred tax asset has been fully reserved. The net change in the valuation allowance during the years ended December 31, 2024 and 2023 was an increase of $0.5 million and $1.5 million, respectively.

 

Foreign earnings are assumed to be permanently reinvested. U.S. Federal income taxes have not been provided on undistributed earnings of our foreign subsidiary.

 

The Company recognizes interest and penalties related to uncertain tax positions in selling, general and administrative expenses. The Company has not identified any uncertain tax positions requiring a reserve as of December 31, 2024 and 2023.

 

The Company is required to file U.S. federal and state income tax returns. These returns are subject to audit by tax authorities beginning with the year ended December 31, 2018.

 
XML 38 R20.htm IDEA: XBRL DOCUMENT v3.25.1
SUBSEQUENT EVENTS
 12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 11 – SUBSEQUENT EVENTS

 

On February 21, 2025, the Company held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on February 21, 2025. At the Company’s Annual Meeting, the Company’s stockholders approved the proposal to approve the repricing of certain outstanding stock options granted (the “Option Grants”) under the Company’s 2006 and 2016 Equity Incentive Plans (the “Plans”) to allow the Board of Directors (the “Board”) to reprice the exercise price of outstanding stock options under the Plans. Pursuant to that authority, on February 21, 2025, the Board repriced the Option Grants. The repriced Option Grants under the 2006 Equity Incentive Plan had original exercise prices ranging from $4.00 to $5.00 per share, and the repriced Option Grants under the 2016 Equity Incentive Plan had original exercise prices ranging from $1.74 to $19.92 per share. All of the Option Grants under the Plans were repriced to have an exercise price of $0.2655 per share, which was the closing price of the Company’s common stock on February 21, 2025.

 

On March 5, 2025, the Company issued 284,238 shares of its common stock for proceeds of $102,534.
XML 39 R21.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Basis of presentation

Basis of presentation

 

The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”).

Reclassification

 

Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation. These reclassifications relate to presenting “Research and development with related parties” as a separate line item in the Company’s Consolidated Statements of Operations and Comprehensive Loss.

 

 
Principles of consolidation

Principles of consolidation

 

The consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated.

 
Use of estimates

Use of estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the consolidated financial statements include valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.

 
Concentrations of Credit Risk

Concentrations of Credit Risk

 

The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. As of December 31, 2024, the Company has bank balances that exceed the federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2024 and December 31, 2023 the Company did not have any cash equivalents. As of December 31, 2024 and December 31, 2023, the Company had cash of $1,838,469 and $1,287,893, respectively.  

 
Marketable Securities

Marketable Securities

 

The Company accounts for marketable debt securities, the only type of securities it owns, in accordance with the FASB Accounting Standards Codification 320, Investments – Debt and Equity Securities (“ASC 320”).

 

Pursuant to ASC 320-10-35-1, investments in debt securities that are classified as available for sale shall be measured subsequently at fair value in the consolidated balance sheets at each balance sheet date. Unrealized holding gains and losses for available-for-sale securities (including those classified as current assets) shall be excluded from earnings and reported in other comprehensive income until realized.

 

During the year ended December 31, 2024 the Company purchased $297,120 and sold $3,100,000 in marketable securities with a realized gain of $51,732 and an unrealized gain of $26,587. As of December 31, 2024 and December 31, 2023, the Company owned marketable securities with a total fair value of $0 and $2,768,119, respectively.

 
Equipment

Equipment

 

Equipment is stated at cost less accumulated depreciation. Cost includes expenditures for computer equipment and lab equipment. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of equipment is depreciated using the straight-line method over the estimated useful lives of the related assets which is three years. Depreciation expense was $50,286 and $28,218 for the years ended December 31, 2024 and 2023, respectively.

 
Fair Value Measurements

Fair Value Measurements

 

ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

 

 

The three levels are described below:

 

Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;

 

Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;

 

Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.

 

The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short-term maturity of those instruments.

 

Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.

 

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2024.

 

   Carrying      Fair Value Measurement Using 
   Value       Level 1     Level 2     Level 3   Total 
Marketable securities  $—   $—   $—   $—   $— 

 

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2023.

 

   Carrying      Fair Value Measurement Using 
   Value       Level 1     Level 2     Level 3   Total 
Marketable securities  $2,768,119   $2,768,119   $—   $—   $2,768,119 

 
Stock-Based Compensation

Stock-Based Compensation

 

The Company accounts for stock-based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported.

 

If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.

 

 
Basic and Diluted Net (Loss) per Common Share

Basic and Diluted Net (Loss) per Common Share

 

Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the consolidated statements of operations and comprehensive loss.

 

  

Potentially Outstanding

Dilutive Common Shares

 
  

For the

Year Ended

December 31, 2024

  

For the

Year Ended

December 31, 2023

 
           
Conversion Feature Shares          
           
Stock Options   1,953,491    1,357,466 
           
Warrants   4,968,645    942,566 
           
Total potentially outstanding dilutive common shares   6,922,136    2,300,032 

 
Research and Development

Research and Development

 

Research and development expenses are charged to operations as incurred.

 
Foreign Currency Translation

Foreign Currency Translation

 

The Company follows ASC 830, Foreign Currency Matters (“ASC 830”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. ASC 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to ASC 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.

 

The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the consolidated statements of operations and comprehensive loss.

 

Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.

 

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The adoption of this ASU did not have a material effect on the Company’s financial statements.

 

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The purpose of the amendment is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is to be applied retrospectively to all prior periods presented in the financial statements. The Company adopted this ASU and has updated its disclosure with segment reporting information.

 

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” to improve disclosures about the nature of expenses in commonly presented financial statement captions. ASU 2024-03 is effective for all public business entities for annual reporting periods beginning after December 15, 2026, on either a prospective or retrospective basis. Early adoption permitted. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements and related disclosures.

 
XML 40 R22.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2024.

 

   Carrying      Fair Value Measurement Using 
   Value       Level 1     Level 2     Level 3   Total 
Marketable securities  $—   $—   $—   $—   $— 

 

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2023.

 

   Carrying      Fair Value Measurement Using 
   Value       Level 1     Level 2     Level 3   Total 
Marketable securities  $2,768,119   $2,768,119   $—   $—   $2,768,119 
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

 

  

Potentially Outstanding

Dilutive Common Shares

 
  

For the

Year Ended

December 31, 2024

  

For the

Year Ended

December 31, 2023

 
           
Conversion Feature Shares          
           
Stock Options   1,953,491    1,357,466 
           
Warrants   4,968,645    942,566 
           
Total potentially outstanding dilutive common shares   6,922,136    2,300,032 
XML 41 R23.htm IDEA: XBRL DOCUMENT v3.25.1
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)
 12 Months Ended
Dec. 31, 2024
Payables and Accruals [Abstract]  
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses, including related party balances, consist of the following at:

 

   December 31, 2024   December 31, 2023 
         
Accounting  $55,340   $36,750 
Research and development   666,002    498,366 
Legal   118,455    6,334 
Other   102,962    113,802 
Total  $942,759   $655,252 
XML 42 R24.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS’ EQUITY (Tables)
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS

The fair value of each stock option granted during the year ended December 31, 2024 was estimated using the Black-Scholes assumptions and or factors as follows:

 

Exercise price  $0.84-$5.00 
Expected dividend yield   0%
Risk free interest rate   4.01%-4.25%
Expected life in years   10 
Expected volatility   213-215%
SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY

The following is an analysis of the stock option grant activity under the Plan:

 

   Number  

Weighted Average

Exercise Price

  

Weighted Average

Remaining Life

 
Stock Options               
Outstanding December 31, 2023   1,357,466   $7.39    4.49 
Granted   742,150    1.73    9.23 
Expired   (146,125)   5.85    - 
Exercised   -    -    - 
Outstanding December 31, 2024   1,953,491   $5.36    5.77 
SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES

A summary of the status of the Company’s nonvested options as of December 31, 2024, and changes during the year ended December 31, 2024 is presented below:

 

Nonvested Options  Options  

Weighted-Average

Exercise Price

 
Nonvested at December 31, 2023   49,832   $14.72 
Granted   742,150    1.73 
Vested   (233,324)   4.14 
Forfeited   -    - 
Nonvested at December 31, 2024   558,658   $1.89 
SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS

The fair value of each warrant granted during the year ended December 31, 2024 was estimated using the Black-Scholes assumptions and or factors as follows:

 

Exercise price  $0.64 
Expected dividend yield   0%
Risk free interest rate   4.31%-4.45%
Expected life in years   5-1.50 
Expected volatility   242-271%
SUMMARY OF WARRANT

A summary of warrant issuances are as follows:

 

   Number  

Weighted Average

Exercise Price

  

Weighted Average

Remaining Life

 
Warrants               
                
Outstanding December 31, 2023   942,566   $19.47    2.31 
Granted   4,206,079    0.64    3.30 
Expired   -    -    - 
Exercised   -    -    - 
Outstanding December 31, 2024   4,986,645   $4.21    2.92 
XML 43 R25.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
SCHEDULE OF LOSS BEFORE INCOME TAX

The components of loss before income taxes are as follows:

 

   2024   2023 
Domestic   (5,526,365)   (4,998,066)
Foreign   1,021    (2,431)
Loss before income taxes   (5,525,344)   (5,000,497)
SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION

For the years ended December 31, 2024 and 2023, a reconciliation of the Company’s effective tax rate to the statutory U.S. Federal rate is as follows:

 

   2024   2023 
Income taxes at Federal statutory rate   (21.0)%   (21.0)%
State income taxes, net of Federal income tax effect   (8.9)%   (8.9)%
Perm difference   0.0%   0.0%
Foreign tax rate differential   0.0)%   (0.1)%
Change in valuation allowance   29.9%   30.0%
Other   0.0%   0.0%
Income tax provision   0.0%   0.0%
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES

The tax effects of temporary differences that give rise to the Company’s deferred tax assets and liabilities are as follows:

 

   2024   2023 
U.S. net operating loss carryforwards   6,305,000    4,940,000 
Stock compensation   2,408,000    2,131,000 
 Deferred tax assets, gross   8,713,000    7,071,000 
Valuation allowance   (8,713,000)   (7,071,000)
Net deferred tax assets   -    - 
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.25.1
SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities, current $ 2,768,119
Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities, fair value disclosure 2,768,119
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities, fair value disclosure 2,768,119
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities, fair value disclosure
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities, fair value disclosure
XML 45 R27.htm IDEA: XBRL DOCUMENT v3.25.1
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially outstanding dilutive common shares 6,922,136 2,300,032
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially outstanding dilutive common shares 1,953,491 1,357,466
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially outstanding dilutive common shares 4,968,645 942,566
XML 46 R28.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Accounting Policies [Abstract]    
Cash $ 1,838,469 $ 1,287,893
Purchase of marketable securities 297,120 2,764,250
Proceeds from sale of marketable securities 3,100,000 7,689,507
Realized loss on marketable securities 51,732 (630,317)
Unrealized gain on marketable securities 26,587  
Marketable securities $ 0 2,768,119
Estimated useful lives 3 years  
Depreciation expense $ 50,286 $ 28,218
XML 47 R29.htm IDEA: XBRL DOCUMENT v3.25.1
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Accounting $ 55,340 $ 36,750
Research and development 666,002 498,366
Legal 118,455 6,334
Other 102,962 113,802
Total $ 942,759 $ 655,252
XML 48 R30.htm IDEA: XBRL DOCUMENT v3.25.1
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)
 12 Months Ended
Dec. 31, 2024
$ / shares
Expected dividend yield 0.00%
Risk free interest rate minimum 4.01%
Risk free interest rate maximum 4.25%
Expected life in years 10 years
Expected volatility minimum 213.00%
Expected volatility maximum 215.00%
Minimum [Member]  
Exercise price $ 0.84
Maximum [Member]  
Exercise price $ 5.00
XML 49 R31.htm IDEA: XBRL DOCUMENT v3.25.1
SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details) - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Stock Options Outstanding, Beginning 1,357,466  
Number of Stock Options Outstanding, Granted 742,150  
Number of Stock Options Outstanding, Ending 1,953,491 1,357,466
Weighted Average Exercise Price, Ending $ 5.36  
Share-Based Payment Arrangement, Option [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Stock Options Outstanding, Beginning 1,357,466  
Weighted Average Exercise Price, Beginning $ 7.39  
Weighted Average Remaining Life 5 years 9 months 7 days 4 years 5 months 26 days
Number of Stock Options Outstanding, Granted 742,150  
Weighted Average Exercise Price, Granted $ 1.73  
Weighted Average Remaining Life, Granted 9 years 2 months 23 days  
Number of Stock Options Outstanding, Expired (146,125)  
Weighted Average Exercise Price, Expired $ 5.85  
Number of Stock Options Outstanding, Exercised  
Weighted Average Exercise Price, Exercised  
Number of Stock Options Outstanding, Ending 1,953,491 1,357,466
Weighted Average Exercise Price, Ending $ 5.36 $ 7.39
XML 50 R32.htm IDEA: XBRL DOCUMENT v3.25.1
SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details)
 12 Months Ended
Dec. 31, 2024
$ / shares
shares
Equity [Abstract]  
Nonvested Options, Balance | shares 49,832
Weighted-Average Exercise Price, Balance | $ / shares $ 14.72
Nonvested Options, Granted | shares 742,150
Weighted-Average Exercise Price, Granted | $ / shares $ 1.73
Nonvested Options, Vested | shares (233,324)
Weighted-Average Exercise Price, Vested | $ / shares $ 4.14
Nonvested Options, Forfeited | shares
Weighted-Average Exercise Price, Forfeited | $ / shares
Nonvested Options, Balance | shares 558,658
Weighted-Average Exercise Price, Balance | $ / shares $ 1.89
XML 51 R33.htm IDEA: XBRL DOCUMENT v3.25.1
SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS (Details)
 12 Months Ended
Dec. 31, 2024
$ / shares
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Expected dividend yield 0.00%
Risk free interest rate minimum 4.01%
Risk free interest rate maximum 4.25%
Expected life in years 10 years
Expected volatility minimum 213.00%
Expected volatility maximum 215.00%
Minimum [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Exercise price $ 0.84
Maximum [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Exercise price 5.00
Warrant [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Exercise price $ 0.64
Expected dividend yield 0.00%
Risk free interest rate minimum 4.31%
Risk free interest rate maximum 4.45%
Expected volatility minimum 242.00%
Expected volatility maximum 271.00%
Warrant [Member] | Minimum [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Expected life in years 5 years
Warrant [Member] | Maximum [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Expected life in years 1 year 6 months
XML 52 R34.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF WARRANT (Details) - Warrant [Member] - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Number of Warrants Outstanding, Beginning 942,566  
Weighted Average Exercise Price, Outstanding $ 19.47  
Weighted Average Remaining Life 2 years 11 months 1 day 2 years 3 months 21 days
Number of Warrants Outstanding, Granted 4,206,079  
Weighted Average Exercise Price, Granted $ 0.64  
Number of Warrants Outstanding, Weighted Average Remaining Life, Granted 3 years 3 months 18 days  
Number of Warrants Outstanding, Expired  
Weighted Average Exercise Price, Expired  
Number of Warrants Outstanding, Exercised  
Weighted Average Exercise Price, Exercised  
Number of Warrants Outstanding, Ending 4,986,645 942,566
Weighted Average Exercise Price, Outstanding $ 4.21 $ 19.47
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
 12 Months Ended
Oct. 29, 2024
Mar. 25, 2024
Feb. 12, 2024
Jan. 08, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Number of shares issued for cash         2,806,311    
Purchase of shares 1,948,295            
Common stock, par value         $ 0.0001 $ 0.0001  
Gross proceeds $ 1,900,000            
Number of options outstanding         1,953,491    
Number of options outstanding         1,953,491 1,357,466  
Share based compensation weighted average exercise price         $ 5.36    
Share based compensation intrinsic value         $ 0    
Options to purchase common stock         742,150    
Options vested shares         233,324    
Share based compensation expense         $ 0 $ 0  
Employees [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Share based compensation expense         186,031 6,852  
Non-Employees [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Share based compensation expense         737,108 $ 659,976  
Unamortized stock option expense         $ 482,369    
Share-Based Payment Arrangement, Option [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Number of options issued         742,150 0  
Number of options outstanding         1,953,491 1,357,466  
Share based compensation weighted average exercise price         $ 5.36 $ 7.39  
Share based compensation expense         $ 923,139 $ 666,828  
Unamortized stock option expense         $ 1,012,825    
Weighted average period for unamortized stock compensation (in years)         2 years 9 months 29 days    
Options to purchase common stock         742,150    
Options exercise price         $ 1.73    
Share-Based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Share based compensation expense         $ 431,884 206,104  
Share-Based Payment Arrangement, Option [Member] | Research and Development Expense [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Share based compensation expense         491,255 $ 460,724  
Employees [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Unamortized stock option expense         $ 530,456    
2016 Plan [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Number of additional shares granted         196,857 186,594 184,260
Number of shares available for grant         873,763 1,279,181  
Series A Common Stock Warrants [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Purchase of shares 1,948,295            
Exercise price of warrants $ 0.64            
Series B Common Stock Warrants [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Purchase of shares 1,948,295            
Exercise price of warrants $ 0.64            
Term 5 years            
Exercise price $ 0.64            
Share price $ 0.89            
Series A Common Stock Purchase Warrants [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Purchase of shares 1,948,295            
Series B Common Stock Purchase Warrants [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Purchase of shares 1,948,295            
Private Placement [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Purchase of shares 1,948,295            
Common Stock [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Number of shares issued for cash         858,016    
Shares conversion           104,173  
Rounding of shares related to a reverse stock split           9,644  
Common Stock [Member] | Consulting Agreement [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Options to purchase common stock     4,400        
Options expire period     10 years        
Options vest period     3 months        
Monthly payment     $ 5,000        
Options exercise price     $ 5.00        
Common Stock [Member] | Employees and Consultants [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Options to purchase common stock       20,750      
Options exercise price       $ 0.84      
Options expire period       10 years      
Options vest period       48 months      
Common Stock [Member] | Officers, Board of Directors and Consultants [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Options to purchase common stock   717,000          
Options exercise price   $ 1.74          
Options expire period   10 years          
Options vested shares   160,000          
Common Stock [Member] | Officers, Board of Directors and Consultants [Member] | Minimum [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Options vest period   24 months          
Common Stock [Member] | Officers, Board of Directors and Consultants [Member] | Maximum [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Options vest period   48 months          
Common Stock [Member] | Private Placement [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Common stock, par value $ 0.0001            
Placement Agent Warrants [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Purchase of shares 129,489            
Exercise price of warrants $ 0.64            
Purchase of shares of common stock 129,489            
Warrant [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Shares issuable under warrants         4,968,645    
Warrant exercise price         $ 4.21    
Class of warrant or right, outstanding, intrinsic value         $ 0    
XML 54 R36.htm IDEA: XBRL DOCUMENT v3.25.1
COLLABORATIVE AGREEMENTS (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Research and development expense $ 3,844,984 $ 3,063,603
Research Agreements [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Research and development expense $ 0 $ 0
XML 55 R37.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Jul. 24, 2024
Finite-Lived Intangible Assets [Line Items]      
Royalty payment on behalf of sublicensee percentage 2.50%    
Sales revenue $ 0 $ 0  
Interest on amounts owed under license agreement, rate 3.00%    
Minimum bid price     $ 1.00
Closing bid price     $ 1.00
Licensing Agreements [Member]      
Finite-Lived Intangible Assets [Line Items]      
Royalty payment, percentage 2.50%    
Up-front sub-license fees, percentage 10.00%    
XML 56 R38.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]      
Gain on settlement of accounts payable and accrued liabilities with related parties $ 80,409  
Agenus Inc. [Member]      
Related Party Transaction [Line Items]      
Expenses related to services 97,357 149,509  
Other liabilities 39,875 150,296  
CTC North, GmbH [Member]      
Related Party Transaction [Line Items]      
Expenses related to services 0 106,755  
Commitment agreement, value     $ 1,300,000
Gain on settlement of accounts payable and accrued liabilities with related parties 80,409    
Other liabilities $ 0 $ 80,409  
XML 57 R39.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING (Details Narrative)
 12 Months Ended
Dec. 31, 2024
Segment
Segment Reporting [Abstract]  
Number of operating segments 1
XML 58 R40.htm IDEA: XBRL DOCUMENT v3.25.1
SCHEDULE OF LOSS BEFORE INCOME TAX (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Domestic $ (5,526,365) $ (4,998,066)
Foreign 1,021 (2,431)
LOSS BEFORE TAX $ (5,525,344) $ (5,000,497)
XML 59 R41.htm IDEA: XBRL DOCUMENT v3.25.1
SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Income taxes at Federal statutory rate (21.00%) (21.00%)
State income taxes, net of Federal income tax effect (8.90%) (8.90%)
Perm difference 0.00% 0.00%
Foreign tax rate differential 0.00% (0.10%)
Change in valuation allowance 29.90% 30.00%
Other 0.00% 0.00%
Income tax provision 0.00% 0.00%
XML 60 R42.htm IDEA: XBRL DOCUMENT v3.25.1
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
U.S. net operating loss carryforwards $ 6,305,000 $ 4,940,000
Stock compensation 2,408,000 2,131,000
 Deferred tax assets, gross 8,713,000 7,071,000
Valuation allowance (8,713,000) (7,071,000)
Net deferred tax assets
XML 61 R43.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAXES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Effective Income Tax Rate Reconciliation [Line Items]    
Income tax expenses
Operating loss carry forwards expiration description The federal net operating losses generated prior to 2018 of $0.1 million will expire at various dates through 2037.  
Research and development investment tax credits $ 0 0
Net change in valuation allowance $ 500,000 1,500,000
Losses Incurred After 2017 [Member]    
Effective Income Tax Rate Reconciliation [Line Items]    
Percentage of corporations taxable income 80.00%  
Losses Incurred Prior To 2018 [Member]    
Effective Income Tax Rate Reconciliation [Line Items]    
Percentage of corporations taxable income 100.00%  
Federal [Member]    
Effective Income Tax Rate Reconciliation [Line Items]    
Net operating loss carryforwards $ 19,700,000  
State and Local [Member]    
Effective Income Tax Rate Reconciliation [Line Items]    
Net operating loss carryforwards 18,500,000 14,000,000.0
CANADA    
Effective Income Tax Rate Reconciliation [Line Items]    
Net operating loss carryforwards $ 1,400,000 $ 1,400,000
XML 62 R44.htm IDEA: XBRL DOCUMENT v3.25.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
 12 Months Ended
Mar. 05, 2025
Feb. 21, 2025
Dec. 31, 2024
Subsequent Event [Line Items]      
Common stock issued, shares     2,806,311
Common stock issued, value     $ 1,963,546
Common Stock [Member]      
Subsequent Event [Line Items]      
Common stock issued, shares     858,016
Common stock issued, value     $ 86
Subsequent Event [Member]      
Subsequent Event [Line Items]      
Exercise price   $ 0.2655  
Subsequent Event [Member] | Common Stock [Member]      
Subsequent Event [Line Items]      
Common stock issued, shares 284,238    
Common stock issued, value $ 102,534    
2006 Equity Incentive Plan [Member] | Minimum [Member] | Subsequent Event [Member]      
Subsequent Event [Line Items]      
Exercise price   4.00  
2006 Equity Incentive Plan [Member] | Maximum [Member] | Subsequent Event [Member]      
Subsequent Event [Line Items]      
Exercise price   5.00  
2016 Equity Incentive Plan [Member] | Minimum [Member] | Subsequent Event [Member]      
Subsequent Event [Line Items]      
Exercise price   1.74  
2016 Equity Incentive Plan [Member] | Maximum [Member] | Subsequent Event [Member]      
Subsequent Event [Line Items]      
Exercise price   $ 19.92  
EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 72 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001022899 2024-01-01 2024-12-31 0001022899 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001022899 PTIX:CommonStockPurchaseWarrantMember 2024-01-01 2024-12-31 0001022899 2024-06-30 0001022899 2025-03-31 0001022899 2024-12-31 0001022899 2023-12-31 0001022899 us-gaap:NonrelatedPartyMember 2024-12-31 0001022899 us-gaap:NonrelatedPartyMember 2023-12-31 0001022899 us-gaap:RelatedPartyMember 2024-12-31 0001022899 us-gaap:RelatedPartyMember 2023-12-31 0001022899 us-gaap:PreferredStockMember 2024-12-31 0001022899 us-gaap:PreferredStockMember 2023-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2024-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2023-12-31 0001022899 us-gaap:PreferredStockMember 2024-12-31 0001022899 us-gaap:PreferredStockMember 2023-12-31 0001022899 2023-01-01 2023-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001022899 us-gaap:CommonStockMember 2022-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001022899 us-gaap:RetainedEarningsMember 2022-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001022899 2022-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001022899 us-gaap:CommonStockMember 2023-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001022899 us-gaap:RetainedEarningsMember 2023-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001022899 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001022899 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001022899 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001022899 us-gaap:CommonStockMember 2024-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001022899 us-gaap:RetainedEarningsMember 2024-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001022899 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001022899 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001022899 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001022899 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001022899 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001022899 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001022899 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001022899 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001022899 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001022899 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001022899 us-gaap:PrivatePlacementMember 2024-10-29 2024-10-29 0001022899 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-10-29 0001022899 PTIX:SeriesACommonStockWarrantsMember 2024-10-29 2024-10-29 0001022899 PTIX:SeriesACommonStockWarrantsMember 2024-10-29 0001022899 PTIX:SeriesBCommonStockWarrantsMember 2024-10-29 2024-10-29 0001022899 PTIX:SeriesBCommonStockWarrantsMember 2024-10-29 0001022899 PTIX:PlacementAgentWarrantsMember 2024-10-29 0001022899 2024-10-29 2024-10-29 0001022899 PTIX:SeriesACommonStockPurchaseWarrantsMember 2024-10-29 2024-10-29 0001022899 PTIX:SeriesBCommonStockPurchaseWarrantsMember 2024-10-29 2024-10-29 0001022899 PTIX:PlacementAgentWarrantsMember 2024-10-29 2024-10-29 0001022899 PTIX:TwoThousandSixteenPlanMember 2024-01-01 2024-12-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2023-01-01 2023-12-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2022-01-01 2022-12-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2024-12-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2023-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001022899 PTIX:EmployeesMember 2024-01-01 2024-12-31 0001022899 PTIX:EmployeesMember 2023-01-01 2023-12-31 0001022899 PTIX:NonEmployeesMember 2024-01-01 2024-12-31 0001022899 PTIX:NonEmployeesMember 2023-01-01 2023-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2024-12-31 0001022899 PTIX:EmployeesMember 2024-12-31 0001022899 PTIX:NonEmployeesMember 2024-12-31 0001022899 PTIX:EmployeesAndConsultantsMember us-gaap:CommonStockMember 2024-01-08 2024-01-08 0001022899 us-gaap:CommonStockMember PTIX:ConsultingAgreementMember 2024-02-12 2024-02-12 0001022899 us-gaap:CommonStockMember PTIX:ConsultingAgreementMember 2024-02-12 0001022899 PTIX:OfficersBoardOfDirectorsAndConsultantsMember us-gaap:CommonStockMember 2024-03-25 2024-03-25 0001022899 srt:MinimumMember PTIX:OfficersBoardOfDirectorsAndConsultantsMember us-gaap:CommonStockMember 2024-03-25 2024-03-25 0001022899 srt:MaximumMember PTIX:OfficersBoardOfDirectorsAndConsultantsMember us-gaap:CommonStockMember 2024-03-25 2024-03-25 0001022899 us-gaap:WarrantMember 2024-12-31 0001022899 srt:MinimumMember 2024-12-31 0001022899 srt:MaximumMember 2024-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2023-12-31 0001022899 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001022899 srt:MinimumMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001022899 srt:MaximumMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001022899 us-gaap:WarrantMember 2023-12-31 0001022899 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001022899 PTIX:ResearchAgreementsMember 2024-01-01 2024-12-31 0001022899 PTIX:ResearchAgreementsMember 2023-01-01 2023-12-31 0001022899 us-gaap:LicensingAgreementsMember 2024-12-31 0001022899 2024-07-24 0001022899 PTIX:AgenusIncMember 2024-01-01 2024-12-31 0001022899 PTIX:AgenusIncMember 2023-01-01 2023-12-31 0001022899 PTIX:AgenusIncMember 2024-12-31 0001022899 PTIX:AgenusIncMember 2023-12-31 0001022899 PTIX:CTCNorthGmbHMember 2022-12-31 0001022899 PTIX:CTCNorthGmbHMember 2024-01-01 2024-12-31 0001022899 PTIX:CTCNorthGmbHMember 2023-01-01 2023-12-31 0001022899 PTIX:CTCNorthGmbHMember 2024-12-31 0001022899 PTIX:CTCNorthGmbHMember 2023-12-31 0001022899 PTIX:FederalMember 2024-12-31 0001022899 PTIX:LossesIncurredAfter2017Member 2024-12-31 0001022899 PTIX:LossesIncurredPriorTo2018Member 2024-12-31 0001022899 PTIX:StateAndLocalMember 2024-12-31 0001022899 PTIX:StateAndLocalMember 2023-12-31 0001022899 country:CA 2024-12-31 0001022899 country:CA 2023-12-31 0001022899 srt:MinimumMember PTIX:TwoThousandSixEquityIncentivePlanMember us-gaap:SubsequentEventMember 2025-02-21 2025-02-21 0001022899 srt:MaximumMember PTIX:TwoThousandSixEquityIncentivePlanMember us-gaap:SubsequentEventMember 2025-02-21 2025-02-21 0001022899 srt:MinimumMember PTIX:TwoThousandSixteenEquityIncentivePlanMember us-gaap:SubsequentEventMember 2025-02-21 2025-02-21 0001022899 srt:MaximumMember PTIX:TwoThousandSixteenEquityIncentivePlanMember us-gaap:SubsequentEventMember 2025-02-21 2025-02-21 0001022899 us-gaap:SubsequentEventMember 2025-02-21 2025-02-21 0001022899 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-03-05 2025-03-05 iso4217:USD shares iso4217:USD shares pure PTIX:Segment false FY 0001022899 Protagenic Therapeutics, Inc.\new 10-K true 2024-12-31 --12-31 2024 false 001-12555 DE 06-1390025 149 Fifth Avenue New York NY 10010 (212) 994-8200 Common Stock, par value $0.0001 PTIX NASDAQ Common Stock Purchase Warrant PTIXW NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 4042876 7525681 0.0001 None <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk Management and Strategy</i></span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. We design and assess our program based on ISO 27002 standards. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the ISO 27002 as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business. We engage external resources that contribute to, and provide independent evaluation of, our existing cybersecurity practices and organizational risk assessment systems. We use established processes designed to identify, assess, and manage <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zAgyQ8dXRhU9">third-party</span> service provider risks when third parties handle, possess, process, and store the Company’s material information. Our cybersecurity risk management program includes (i) a policy designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment; (ii) the use of external service providers to manage, assess, test and otherwise assist with aspects of our security controls; and (iii) a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240101__20241231_zy3lnyOtRi1d">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zmbxqKgGqB4g">materially affected</span> or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. However, there can be no assurance that our cybersecurity prevention and mitigation efforts will always be successful, and it is possible that cybersecurity threats could have a material adverse effect on our business, operations, or financial condition in the future</span>.</span></p>   true We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zmbxqKgGqB4g">materially affected</span> or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. However, there can be no assurance that our cybersecurity prevention and mitigation efforts will always be successful, and it is possible that cybersecurity threats could have a material adverse effect on our business, operations, or financial condition in the future true <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Governance</i></span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our board of directors administers its cybersecurity risk oversight function through its audit committee. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_z7sEsPmwHAdc">The audit committee is responsible for overseeing our policies, practices and assessments with respect to cybersecurity, and provides periodic updates to our board of directors</span>. The audit committee receives periodic updates from management and our external third party information technology consultant regarding the effectiveness of the systems and processes we have implemented designed to safeguard our information assets and operational integrity from cyber threats, protect employee information from unauthorized access or attack, as well as secure our networks and systems, and regarding other cybersecurity matters, including the results from cybersecurity systems testing and any recent cybersecurity incidents and related responses. Our audit committee is also notified between such updates as soon as practicable regarding significant new cybersecurity threats or incidents. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_i01_dbT_c20240101__20241231_zUzCIfFcTzDc">The audit committee also receives a report on cybersecurity matters and related risk exposures periodically from our Chief Financial Officer</span>.</span></p>   The audit committee is responsible for overseeing our policies, practices and assessments with respect to cybersecurity, and provides periodic updates to our board of directors true true 206 We have audited the accompanying consolidated balance sheets of Protagenic Therapeutics, Inc. and its subsidiary (collectively, the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. MaloneBailey, LLP Houston, Texas 1838469 1287893 2768119 44398 144025 1882867 4200037 73046 123332 1955913 4323369 902884 439757 39875 215495 39875 215495 942759 655252 942759 655252 0.000001 0.000001 20000000 20000000 0 0 0 0 0.000001 0.000001 2000000 2000000 0 0 0 0 0.000001 0.000001 18000000 18000000 0 0 0 0 0.0001 0.0001 100000000 100000000 7241443 7241443 4435132 4435132 725 444 37445495 34559091 -36303216 -30777872 -129850 -113546 1013154 3668117 1955913 4323369 3844984 3063603 97357 256264 1758609 1207107 5700950 4526974 -5700950 -4526974 43465 264476 107682 -51732 630317 80409 175606 -473523 -5525344 -5000497 -5525344 -5000497 26587 16848 -43434 489120 543 57393 -5541648 -4437136 -1.13 -1.13 -1.15 -1.15 4899953 4899953 4344580 4344580 4321315 434 33371406 -25777375 -676907 6917558 57393 57393 16848 16848 489120 489120 666828 666828 104173 10 520857 520867 9644 -5000497 -5000497 4435132 444 34559091 -30777872 -113546 3668117 4435132 444 34559091 -30777872 -113546 3668117 543 543 26587 26587 -43434 -43434 923139 923139 858016 86 1963460 1963546 1948295 195 -195 -5525344 -5525344 7241443 725 37445495 -36303216 -129850 1013154 7241443 725 37445495 -36303216 -129850 1013154 -5525344 -5000497 50286 28218 923139 666828 -51732 630317 85770 80409 -99627 87086 463127 -183832 -95211 156506 -4216517 -3703776 3100000 7689507 297120 2764250 149775 2802880 4775482 1963546 1963546 667 998 550576 1072704 1287893 215189 1838469 1287893 520867 26587 16848 <p id="xdx_80D_eus-gaap--NatureOfOperations_zGVrFVq8Bxq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82D_z0ODh9UWa8fb">ORGANIZATION AND NATURE OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Company Background</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), formerly known as Atrinsic, Inc., is a Delaware corporation with one subsidiary named Protagenic Therapeutics Canada (2006) Inc. (“PTI Canada”), a corporation formed in 2006 under the laws of the Province of Ontario, Canada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_803_ecustom--LiquidityAndGoingConcernDisclosureTextBlock_zFp6nSYSZeEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_826_zM6tbi28SRUe">LIQUIDITY AND GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As shown in the accompanying consolidated financial statements, the Company has incurred significant recurring losses resulting in an accumulated deficit. The Company anticipates further losses in the development of its business. The Company also had negative cash flows used in operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on its cash resources and positive working capital as of December 31 2024, the Company does not have sufficient resources to fund its operations past twelve months from the date these consolidated financial statements are available to be issued. The positive working capital as of December 31, 2024 was due to funds raised by the Company from its equity offering during the year ended December 31, 2021. Absent generation of sufficient revenue from the execution of the Company’s business plan, the Company will need to obtain debt or equity financing by the third quarter of 2025   . Because the Company has insufficient resources on hand to fund operations through the next twelve months from the date these consolidated financial statements are available to be issued, the Company believes that there is substantial doubt in its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued..   These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z21BqOIyX9i5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 - <span id="xdx_82B_zidTNkxdZDPc">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zp52jxiTisk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassification</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation. These reclassifications relate to presenting “Research and development with related parties” as a separate line item in the Company’s Consolidated Statements of Operations and Comprehensive Loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zAtD1MvkhTfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Principles of consolidation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--UseOfEstimates_z8l7pcQPkI97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the consolidated financial statements include valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zwborjsAs45f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations of Credit Risk</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. As of December 31, 2024, the Company has bank balances that exceed the federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zFIvfZ82waTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2024 and December 31, 2023 the Company did not have any cash equivalents. As of December 31, 2024 and December 31, 2023, the Company had cash of $<span id="xdx_904_eus-gaap--Cash_iI_c20241231_z3TZNxmU1TPi" title="Cash">1,838,469</span> and $<span id="xdx_90A_eus-gaap--Cash_iI_c20231231_z7JnO54PvM8a" title="Cash">1,287,893</span>, respectively.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--MarketableSecuritiesPolicy_zLVDgkU6zPHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable Securities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for marketable debt securities, the only type of securities it owns, in accordance with the FASB Accounting Standards Codification 320, Investments – Debt and Equity Securities (“ASC 320”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC 320-10-35-1, investments in debt securities that are classified as available for sale shall be measured subsequently at fair value in the consolidated balance sheets at each balance sheet date. Unrealized holding gains and losses for available-for-sale securities (including those classified as current assets) shall be excluded from earnings and reported in other comprehensive income until realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2024 the Company purchased $<span id="xdx_90F_eus-gaap--PaymentsToAcquireMarketableSecurities_c20240101__20241231_z90INyaNSwSd" title="Purchase of marketable securities">297,120</span> and sold $<span id="xdx_90A_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_c20240101__20241231_ze8jgoVTHPfe" title="Proceeds from sale of marketable securities">3,100,000</span> in marketable securities with a realized gain of $<span id="xdx_906_ecustom--RealizedGainLossOnMarketableSecurities_iN_pp0p0_di_c20240101__20241231_zjPcXLUHoic3" title="Realized loss on marketable securities">51,732</span> and an unrealized gain of $<span id="xdx_90D_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20240101__20241231_zsydOubQX9tg" title="Unrealized gain on marketable securities">26,587</span>. As of December 31, 2024 and December 31, 2023, the Company owned marketable securities with a total fair value of $<span id="xdx_903_eus-gaap--MarketableSecurities_iI_pp0p0_c20241231_zebWe0TWWfi1" title="Marketable securities">0</span> and $<span id="xdx_90A_eus-gaap--MarketableSecurities_iI_pp0p0_c20231231_zYqwVhUPzYBf" title="Marketable securities">2,768,119</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zzkDgXAqky8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equipment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment is stated at cost less accumulated depreciation. Cost includes expenditures for computer equipment and lab equipment. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of equipment is depreciated using the straight-line method over the estimated useful lives of the related assets which is <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dt_c20241231_z0GaUEq2dDcg" title="Estimated useful lives">three years</span>. Depreciation expense was $<span id="xdx_906_eus-gaap--Depreciation_c20240101__20241231_zgHwLxd6MxC9" title="Depreciation expense">50,286</span> and $<span id="xdx_906_eus-gaap--Depreciation_c20230101__20231231_zpKWJpOn9Uh9" title="Depreciation expense">28,218</span> for the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zNitukV6Yi96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair Value Measurements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The three levels are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short-term maturity of those instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z4t3JzAXUQZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_z6kO8JdWWGw7" style="display: none">SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying   </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurement Using</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value    </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20241231_z9U367nUnEZ1" style="width: 9%; text-align: right" title="Marketable securities, current"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0590">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zdRRnw39whXj" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0592">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zohd6IYrjCT4" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0594">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2brquSymVx7" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0596">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ze1Qio3U3ne5" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0598">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying   </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurement Using</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value    </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20231231_zaPPx48iRoXk" style="width: 9%; text-align: right" title="Marketable securities, current"><span style="font-family: Times New Roman, Times, Serif">2,768,119</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpWmXzRn2ROk" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,768,119</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSa52kZ0XHna" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0604">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zv1glDe9Jrok" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0606">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9IjpbsK9He9" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,768,119</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A7_zq6XXYnN21Wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zM8irebtrCXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based Compensation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zzQYr7ONfxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basic and Diluted Net (Loss) per Common Share</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the consolidated statements of operations and comprehensive loss.</span></p> <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zYSiTOisN8l2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_z7XlTTWRMs3e" style="display: none">SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Potentially Outstanding</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Dilutive Common Shares</span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Year Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Year Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Conversion Feature Shares</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zbxzj7tyJPC5" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">1,953,491</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zLCkKyYd94ga" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">1,357,466</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zo2YmQejko0f" style="border-bottom: Black 1pt solid; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">4,968,645</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zwkh2ROmAWbi" style="border-bottom: Black 1pt solid; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">942,566</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total potentially outstanding dilutive common shares</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_zJ4O1j8HvnWj" style="text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">6,922,136</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z22QPwITOBle" style="text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">2,300,032</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A3_zwqF9ckOANdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zmxZ16yriGue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research and Development</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses are charged to operations as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zhQBcpbCNFk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign Currency Translation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows ASC 830, <i>Foreign Currency Matters</i> (“ASC 830”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. ASC 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to ASC 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the consolidated statements of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcqc4eJ9n9S" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent Accounting Pronouncements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The adoption of this ASU did not have a material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The purpose of the amendment is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is to be applied retrospectively to all prior periods presented in the financial statements. The Company adopted this ASU and has updated its disclosure with segment reporting information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” to improve disclosures about the nature of expenses in commonly presented financial statement captions. ASU 2024-03 is effective for all public business entities for annual reporting periods beginning after December 15, 2026, on either a prospective or retrospective basis. Early adoption permitted. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements and related disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zp52jxiTisk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassification</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation. These reclassifications relate to presenting “Research and development with related parties” as a separate line item in the Company’s Consolidated Statements of Operations and Comprehensive Loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zAtD1MvkhTfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Principles of consolidation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--UseOfEstimates_z8l7pcQPkI97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the consolidated financial statements include valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zwborjsAs45f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations of Credit Risk</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. As of December 31, 2024, the Company has bank balances that exceed the federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zFIvfZ82waTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2024 and December 31, 2023 the Company did not have any cash equivalents. As of December 31, 2024 and December 31, 2023, the Company had cash of $<span id="xdx_904_eus-gaap--Cash_iI_c20241231_z3TZNxmU1TPi" title="Cash">1,838,469</span> and $<span id="xdx_90A_eus-gaap--Cash_iI_c20231231_z7JnO54PvM8a" title="Cash">1,287,893</span>, respectively.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1838469 1287893 <p id="xdx_840_eus-gaap--MarketableSecuritiesPolicy_zLVDgkU6zPHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable Securities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for marketable debt securities, the only type of securities it owns, in accordance with the FASB Accounting Standards Codification 320, Investments – Debt and Equity Securities (“ASC 320”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC 320-10-35-1, investments in debt securities that are classified as available for sale shall be measured subsequently at fair value in the consolidated balance sheets at each balance sheet date. Unrealized holding gains and losses for available-for-sale securities (including those classified as current assets) shall be excluded from earnings and reported in other comprehensive income until realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2024 the Company purchased $<span id="xdx_90F_eus-gaap--PaymentsToAcquireMarketableSecurities_c20240101__20241231_z90INyaNSwSd" title="Purchase of marketable securities">297,120</span> and sold $<span id="xdx_90A_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_c20240101__20241231_ze8jgoVTHPfe" title="Proceeds from sale of marketable securities">3,100,000</span> in marketable securities with a realized gain of $<span id="xdx_906_ecustom--RealizedGainLossOnMarketableSecurities_iN_pp0p0_di_c20240101__20241231_zjPcXLUHoic3" title="Realized loss on marketable securities">51,732</span> and an unrealized gain of $<span id="xdx_90D_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20240101__20241231_zsydOubQX9tg" title="Unrealized gain on marketable securities">26,587</span>. As of December 31, 2024 and December 31, 2023, the Company owned marketable securities with a total fair value of $<span id="xdx_903_eus-gaap--MarketableSecurities_iI_pp0p0_c20241231_zebWe0TWWfi1" title="Marketable securities">0</span> and $<span id="xdx_90A_eus-gaap--MarketableSecurities_iI_pp0p0_c20231231_zYqwVhUPzYBf" title="Marketable securities">2,768,119</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 297120 3100000 -51732 26587 0 2768119 <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zzkDgXAqky8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equipment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment is stated at cost less accumulated depreciation. Cost includes expenditures for computer equipment and lab equipment. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of equipment is depreciated using the straight-line method over the estimated useful lives of the related assets which is <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dt_c20241231_z0GaUEq2dDcg" title="Estimated useful lives">three years</span>. Depreciation expense was $<span id="xdx_906_eus-gaap--Depreciation_c20240101__20241231_zgHwLxd6MxC9" title="Depreciation expense">50,286</span> and $<span id="xdx_906_eus-gaap--Depreciation_c20230101__20231231_zpKWJpOn9Uh9" title="Depreciation expense">28,218</span> for the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P3Y 50286 28218 <p id="xdx_843_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zNitukV6Yi96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair Value Measurements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The three levels are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short-term maturity of those instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z4t3JzAXUQZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_z6kO8JdWWGw7" style="display: none">SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying   </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurement Using</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value    </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20241231_z9U367nUnEZ1" style="width: 9%; text-align: right" title="Marketable securities, current"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0590">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zdRRnw39whXj" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0592">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zohd6IYrjCT4" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0594">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2brquSymVx7" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0596">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ze1Qio3U3ne5" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0598">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying   </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurement Using</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value    </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20231231_zaPPx48iRoXk" style="width: 9%; text-align: right" title="Marketable securities, current"><span style="font-family: Times New Roman, Times, Serif">2,768,119</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpWmXzRn2ROk" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,768,119</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSa52kZ0XHna" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0604">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zv1glDe9Jrok" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0606">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9IjpbsK9He9" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,768,119</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A7_zq6XXYnN21Wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p id="xdx_892_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z4t3JzAXUQZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_z6kO8JdWWGw7" style="display: none">SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying   </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurement Using</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value    </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20241231_z9U367nUnEZ1" style="width: 9%; text-align: right" title="Marketable securities, current"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0590">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zdRRnw39whXj" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0592">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zohd6IYrjCT4" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0594">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2brquSymVx7" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0596">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ze1Qio3U3ne5" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0598">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying   </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurement Using</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value    </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2  </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20231231_zaPPx48iRoXk" style="width: 9%; text-align: right" title="Marketable securities, current"><span style="font-family: Times New Roman, Times, Serif">2,768,119</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpWmXzRn2ROk" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,768,119</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSa52kZ0XHna" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0604">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zv1glDe9Jrok" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0606">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--InvestmentsFairValueDisclosure_iI_pp0p0_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9IjpbsK9He9" style="width: 9%; text-align: right" title="Marketable securities, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,768,119</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 2768119 2768119 2768119 <p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zM8irebtrCXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based Compensation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zzQYr7ONfxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basic and Diluted Net (Loss) per Common Share</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the consolidated statements of operations and comprehensive loss.</span></p> <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zYSiTOisN8l2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_z7XlTTWRMs3e" style="display: none">SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Potentially Outstanding</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Dilutive Common Shares</span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Year Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Year Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Conversion Feature Shares</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zbxzj7tyJPC5" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">1,953,491</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zLCkKyYd94ga" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">1,357,466</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zo2YmQejko0f" style="border-bottom: Black 1pt solid; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">4,968,645</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zwkh2ROmAWbi" style="border-bottom: Black 1pt solid; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">942,566</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total potentially outstanding dilutive common shares</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_zJ4O1j8HvnWj" style="text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">6,922,136</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z22QPwITOBle" style="text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">2,300,032</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A3_zwqF9ckOANdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zYSiTOisN8l2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_z7XlTTWRMs3e" style="display: none">SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Potentially Outstanding</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Dilutive Common Shares</span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Year Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Year Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Conversion Feature Shares</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zbxzj7tyJPC5" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">1,953,491</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zLCkKyYd94ga" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">1,357,466</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zo2YmQejko0f" style="border-bottom: Black 1pt solid; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">4,968,645</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zwkh2ROmAWbi" style="border-bottom: Black 1pt solid; text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">942,566</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total potentially outstanding dilutive common shares</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_zJ4O1j8HvnWj" style="text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">6,922,136</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z22QPwITOBle" style="text-align: right" title="Total potentially outstanding dilutive common shares"><span style="font-family: Times New Roman, Times, Serif">2,300,032</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1953491 1357466 4968645 942566 6922136 2300032 <p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zmxZ16yriGue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research and Development</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses are charged to operations as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zhQBcpbCNFk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign Currency Translation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows ASC 830, <i>Foreign Currency Matters</i> (“ASC 830”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. ASC 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to ASC 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the consolidated statements of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcqc4eJ9n9S" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent Accounting Pronouncements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature and convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The adoption of this ASU did not have a material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The purpose of the amendment is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is to be applied retrospectively to all prior periods presented in the financial statements. The Company adopted this ASU and has updated its disclosure with segment reporting information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” to improve disclosures about the nature of expenses in commonly presented financial statement captions. ASU 2024-03 is effective for all public business entities for annual reporting periods beginning after December 15, 2026, on either a prospective or retrospective basis. Early adoption permitted. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements and related disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zD2bcDo3Mt2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 - <span id="xdx_822_zmU7jW3hg3ui">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zQjHVtY4Tca6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued expenses, including related party balances, consist of the following at:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zYoEm1JDY5B8" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20241231_zVcodhk0seo3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20231231_zGK1ljMMMCV7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_ecustom--AccruedAccountingFees_iI_pp0p0_maAPAALzt0f_zDEwAxm7JcO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Accounting</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,340</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,750</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--AccruedResearchAndDevelopment_iI_pp0p0_maAPAALzt0f_zWamWXxYgqXi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">666,002</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">498,366</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maAPAALzt0f_zOx52YL04ZW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Legal</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">118,455</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAALzt0f_z8AePAtvcT79" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">102,962</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">113,802</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pp0p0_mtAPAALzt0f_ztPYgUuurET6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">942,759</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">655,252</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zpVu8T8cZMgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zQjHVtY4Tca6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued expenses, including related party balances, consist of the following at:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zYoEm1JDY5B8" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20241231_zVcodhk0seo3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20231231_zGK1ljMMMCV7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_ecustom--AccruedAccountingFees_iI_pp0p0_maAPAALzt0f_zDEwAxm7JcO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Accounting</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,340</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,750</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--AccruedResearchAndDevelopment_iI_pp0p0_maAPAALzt0f_zWamWXxYgqXi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">666,002</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">498,366</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maAPAALzt0f_zOx52YL04ZW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Legal</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">118,455</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAALzt0f_z8AePAtvcT79" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">102,962</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">113,802</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pp0p0_mtAPAALzt0f_ztPYgUuurET6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">942,759</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">655,252</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 55340 36750 666002 498366 118455 6334 102962 113802 942759 655252 <p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z9syV07GVDEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 - <span id="xdx_828_zkquuppnNF38">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2024, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231_zUksR3Uan2E5" title="Number of shares issued for cash">2,806,311</span> shares of common stock for cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk9FiR9WM0Hl" title="Shares conversion">104,173</span> shares of common stock for the conversion of notes and interest and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFbkPaSP7gd3" title="Rounding of shares related to a reverse stock split">9,644</span> shares of common stock for rounding of shares related to the Reverse Split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Securities Purchase Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On October 29, 2024, Protagenic Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue to the Purchasers in a private placement, <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241029__20241029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zjblV9Siwnz2" title="Issuance of shares">1,948,295</span> shares of the Company’s common stock (the “Shares”), par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241029__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zc0Vk8FCOdP8" title="Common stock, par value">0.0001</span> per share (“Common Stock”), series A common stock purchase warrants (the “Series A Common Stock Warrants”) to purchase an aggregate of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241029__20241029__us-gaap--StatementClassOfStockAxis__custom--SeriesACommonStockWarrantsMember_zLkJUNUpEABl" title="Purchase of shares">1,948,295</span> shares of Common Stock (the “Series A Common Stock Warrant Shares”) with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241029__us-gaap--StatementClassOfStockAxis__custom--SeriesACommonStockWarrantsMember_zsZhy3T2pVA9" title="Exercise price">0.64</span> per share (subject to adjustment as described therein), which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date (as defined in the Purchase Agreement), and series B common stock purchase warrants (the “Series B Common Stock Warrants”) to purchase an aggregate of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241029__20241029__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonStockWarrantsMember_zGpkM7R1CI42" title="Purchase of shares">1,948,295</span> shares of Common Stock (the “Series B Common Stock Warrant Shares”) with an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241029__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonStockWarrantsMember_zZowJ3I1yV95" title="Exercise price">0.64</span> per share (subject to adjustment as described therein), which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241029__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonStockWarrantsMember_zQhW6RdbKZV9" title="Term">5</span>) years from the Stockholder Approval Date. As used herein, the Series A Common Stock Warrants and the Series B Common Stock Warrants are sometimes referred to collectively as the “Common Stock Warrants”. Such private placement is referred to herein as the “Transaction.” The purchase price of each Share and associated Common Stock Warrants was $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20241029__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonStockWarrantsMember_zZB8HZuaIQkd" title="Exercise price">0.64</span> ($<span id="xdx_90C_eus-gaap--SharePrice_iI_c20241029__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonStockWarrantsMember_z8rWaC5igEW4" title="Share price">0.89</span> in the case of insiders).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”), acted as sole placement agent for the Transaction. The Company issued to Brookline or its designees warrants (the “Placement Agent Warrants”) to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241029__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zdRZXiaAPsW5" title="Purchase of shares of common stock">129,489</span> shares of Common Stock at an exercise price equal to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241029__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_z5H40irrl7Hc" title="Exercise price of warrants">0.64</span> per share. The Placement Agent Warrants are exercisable immediately upon issuance and on or before the Termination Date (as defined in the Placement Agent Warrants). </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Purchase Agreement closed on November 4, 2024. The Company sold (a) <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241029__20241029_zTOx66n41Zyh" title="Purchase of shares">1,948,295</span> shares of Common Stock, (b) series A common stock purchase warrants to purchase an aggregate of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241029__20241029__us-gaap--StatementClassOfStockAxis__custom--SeriesACommonStockPurchaseWarrantsMember_zANzeQk6vPli" title="Purchase of shares">1,948,295</span> shares of Common Stock, (c) series B common stock purchase warrants to purchase an aggregate of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241029__20241029__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonStockPurchaseWarrantsMember_zuTLoEHjO9z3" title="Purchase of shares">1,948,295</span> shares of Common Stock and (d) placement agent warrants to purchase an aggregate of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241029__20241029__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zbipeSg2FIn6" title="Purchase of shares">129,489</span> shares of Common Stock. The gross proceeds from the Transaction were approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241029__20241029_zZH5raZmdVjc" title="Gross proceeds">1.9</span> million, before deducting fees and other offering expenses payable by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based Compensation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted an Employee, Director and Consultant Stock Plan on June 17, 2016 (the “2016 Plan”). Pursuant to the 2016 Plan, the Company’s Compensation Committee may grant awards to any employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary. Due to an annual “evergreen” provision in the 2016 Plan, the number of shares reserved for future grants was increased by <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenPlanMember_zGo7cqXxs10a" title="Number of additional shares granted">196,857</span>, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenPlanMember_znq8JidXLaZ1" title="Number of additional shares granted">186,594</span> and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenPlanMember_zbj8vkevNPRa" title="Number of additional shares granted">184,260</span> in 2024, 2023 and 2022, respectively. As a result of these increases, as of December 31, 2024 and December 31, 2023, the aggregate number of shares of common stock available for awards under the 2016 Plan was <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenPlanMember_zBH4XIIlVMb4" title="Number of shares available for grant">873,763</span> shares and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenPlanMember_zafYBBxbU2q" title="Number of shares available for grant">1,279,181</span> shares, respectively. Options issued under the 2016 Plan are exercisable for up to ten years from the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were <span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding_iI_c20241231_zp4hXsjwbZPb" title="Number of options outstanding">1,953,491</span>options outstanding as of December 31, 2024. During the year ended December 31, 2024, the Company issued <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUc6DhMMmf57" title="Number of options issued">742,150</span> options, respectively. During the year ended December 31, 2023, the Company issued <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUCZleVaw18a" title="Number of options issued">no</span> options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231_zdqAyVrFKOi2" title="Number of options outstanding">1,357,466</span> options outstanding as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zOwNXJEIND98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each stock option granted during the year ended December 31, 2024 was estimated using the Black-Scholes assumptions and or factors as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zAK4WXiXa6oi" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__srt--RangeAxis__srt--MinimumMember_zNvYKityiQN8" title="Exercise price">0.84</span>-$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__srt--RangeAxis__srt--MaximumMember_zkNpbz7fy4cf" title="Exercise price">5.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20241231_zUNc4CnAuDN8" style="width: 16%; text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zZjSc53Jmclk" title="Risk free interest rate minimum">4.01</span>%-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zinqAkRwNM97" title="Risk free interest rate maximum">4.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life in years</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zgFGV6Alzt4h" title="Expected life in years">10</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z4YY7YlOCuQk" title="Expected volatility minimum">213</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zu02se7HrUKh" title="Expected volatility maximum">215</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8AC_zlOXf644xmxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXeiIUuE3QA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is an analysis of the stock option grant activity under the Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zYUvK0dJPuxf" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Life</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif">Outstanding December 31, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7LB8bqs7DX4" style="width: 14%; text-align: right" title="Number of Stock Options Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">1,357,466</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxm1MYgeFfmk" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Beginning"><span style="font-family: Times New Roman, Times, Serif">7.39</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyhMXOYPv0Pg" title="Weighted Average Remaining Life">4.49</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRNUYx7Rgpe5" style="text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif">742,150</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUNI0nVFxA3" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">1.73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDqXRCwiPJPe" title="Weighted Average Remaining Life, Granted">9.23</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpWOnD4TYY5h" style="text-align: right" title="Number of Stock Options Outstanding, Expired"><span style="font-family: Times New Roman, Times, Serif">(146,125</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3cBDTWtZCyf" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif">5.85</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zznpBJPlcr5k" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbBA95T3CtQh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPMyU8iLLOcd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif">1,953,491</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOK6qtSYsUTj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending"><span style="font-family: Times New Roman, Times, Serif">5.36</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrNPxddrf12i" title="Weighted Average Remaining Life">5.77</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AA_zMeetlnCgqK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zNJhrLWMkita" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the status of the Company’s nonvested options as of December 31, 2024, and changes during the year ended December 31, 2024 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zGjlbYDf6xsa" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Nonvested Options</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Nonvested at December 31, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20241231_zoCobPKG9hn5" style="width: 16%; text-align: right" title="Nonvested Options, Balance"><span style="font-family: Times New Roman, Times, Serif">49,832</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20241231_zu5488rRsoK8" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif">14.72</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zFuI9mUds8eh" style="text-align: right" title="Nonvested Options, Granted"><span style="font-family: Times New Roman, Times, Serif">742,150</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zyXUt0ookXga" style="text-align: right" title="Weighted-Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">1.73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20240101__20241231_zrHkGwwXBxGi" style="text-align: right" title="Nonvested Options, Vested"><span style="font-family: Times New Roman, Times, Serif">(233,324</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20240101__20241231_zuOaM7LzrkMe" style="text-align: right" title="Weighted-Average Exercise Price, Vested"><span style="font-family: Times New Roman, Times, Serif">4.14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20241231_zXMGScu63Jjl" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Options, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0771">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20240101__20241231_zTlsZeJ1tcMi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0773">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Nonvested at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20241231_z9Fxw6uKsqeb" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Options, Balance"><span style="font-family: Times New Roman, Times, Serif">558,658</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231_zqHoPVUC7iwb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif">1.89</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A4_zDWJBRgYZ5J9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024, the Company had <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231_zlguBXEOkxVe" title="Number of options outstanding">1,953,491</span> shares issuable under options outstanding at a weighted average exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20241231_zkGMcvdps7md" title="Share based compensation weighted average exercise price">5.36</span> and an intrinsic value of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231_zSPKnHeOoBB9" title="Share based compensation intrinsic value">0</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized compensation expense related to options issued of $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUnD7LT7yYY6" title="Share based compensation expense">923,139</span> and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbyHGiXsH5yk" title="Share based compensation expense">666,828</span> for the years ended December 31, 2024 and 2023, respectively, in which $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zUKiplOeUQh8" title="Share based compensation expense">431,884</span> and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwThXGDGXauk" title="Share based compensation expense">206,104</span> is included in general and administrative expenses and $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zzwMHcFcooBi" title="Share based compensation expense">491,255</span> and $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zPoI9EP24gAj" title="Share based compensation expense">460,724</span> in research and development expenses, respectively. For the year ended December 31, 2024 and 2023, $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFz00qv2cwQ5" title="Share based compensation expense">186,031</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_z7m4cIb46cd3" title="Share based compensation expense">6,852</span> of the stock compensation was related to employees and $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember_zESXyAux5dG3" title="Share based compensation expense">737,108</span>   and $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember_zCFm9pfXAwMf" title="Share based compensation expense">659,976</span> was related to non-employees, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024, the unamortized stock option expense was $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFTTYLl35d5e" title="Unamortized stock option expense">1,012,825</span> with $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20241231__us-gaap--AwardTypeAxis__custom--EmployeesMember_zWsgG6RMQlS8" title="Unamortized stock option expense">530,456</span> being related to employees and $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20241231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember_zVZVkc14oT6a" title="Unamortized stock option expense">482,369</span> being related to non-employees. As of December 31, 2024, the weighted average remaining vesting period for the unamortized stock compensation to be recognized is <span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv8mcUrGdGw6" title="Weighted average period for unamortized stock compensation (in years)">2.83</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 8, 2024, the Company issued <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240108__20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantsMember_znDnQtrOpfe6" title="Options to purchase common stock">20,750</span> options to purchase the Company’s common stock to consultants and employees. These options have an exercise price of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240108__20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantsMember_zNsq6LL9is8l" title="Options exercise price">0.84</span> and expire in <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20240108__20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantsMember_z0uRd9CM01S3" title="Options expire period">10</span> years from issuance. These options vest over <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_pp0d_dtM_c20240108__20240108__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantsMember_zF8gGzhHVTdc" title="Options vest period">48</span> months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 12, 2024, the Company entered into a consulting agreement. As part of this agreement the Company agrees to pay $<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20240212__20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zAJ9yNxwKdQ5" title="Monthly payment">5,000</span> per month and issue <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240212__20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z5ZeNKzie39" title="Options to purchase common stock">4,400</span> options to purchase the Company’s common stock. These options have an exercise price of $<span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zDLbAS4L9M4d" title="Options exercise price">5.00</span> and expire in <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20240212__20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zR358nVajb98" title="Options expire period">10</span> years from issuance. These options vest over <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20240212__20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zop7LBFIt02" title="Options vest period">three months</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 25, 2024, the Company issued <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240325__20240325__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OfficersBoardOfDirectorsAndConsultantsMember_zYAsnx0dJJ6j" title="Options to purchase common stock">717,000</span> options to purchase the Company’s common stock to officers, board of directors and consultants. These options have an exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240325__20240325__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OfficersBoardOfDirectorsAndConsultantsMember_zOfU9dDbSL3e" title="Options exercise price">1.74</span> and expire in <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20240325__20240325__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OfficersBoardOfDirectorsAndConsultantsMember_zLMGY4yeWJO8" title="Options expire period">10 </span>years from issuance. These options vest between <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20240325__20240325__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OfficersBoardOfDirectorsAndConsultantsMember__srt--RangeAxis__srt--MinimumMember_zaRU01WcFW5f" title="Options vest period">24</span> and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20240325__20240325__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OfficersBoardOfDirectorsAndConsultantsMember__srt--RangeAxis__srt--MaximumMember_zTMGpiCscPd6" title="Options vest period">48</span> months with <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240325__20240325__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--OfficersBoardOfDirectorsAndConsultantsMember_zkCqpgH9WF7e" title="Options vested shares">160,000</span> options to vest upon achievement of certain performance conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants:</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfShareBasedPaymentAwardWarrantssValuationAssumptionsTableTextBlock_zyXI49PhtJJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each warrant granted during the year ended December 31, 2024 was estimated using the Black-Scholes assumptions and or factors as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zNgDSSvYoRre" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%"><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBF7SSH2BvNi" title="Exercise price">0.64</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfkvbk7vC44" style="text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDMUrVFrrHXf" title="Risk free interest rate minimum">4.31</span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhA0DFetYVZb" title="Risk free interest rate maximum">4.45</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life in years</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pp0d_dtYp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zyoAktBPLeWg" title="Expected life in years">5</span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pp0d_dtYp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z4HTYd8JjDNd" title="Expected life in years">1.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDHcx3jCNhCd" title="Expected volatility minimum">242</span>-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPhhAEgV9M44" title="Expected volatility maximum">271</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8AE_zmHbgMlvPuW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zFiIsg3MzbS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of warrant issuances are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zYTmpS8w9lUc" style="display: none">SUMMARY OF WARRANT</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Life</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Outstanding December 31, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG5yge0Bnydk" style="width: 14%; text-align: right" title="Number of Warrants Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">942,566</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgCWazJHK3Sa" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding"><span style="font-family: Times New Roman, Times, Serif">19.47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmInPHqfDla1" title="Weighted Average Remaining Life">2.31</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znnzWdVqdoFb" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif">4,206,079</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvOG4oPEtXud" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">0.64</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkPO2zZdNZf3" title="Number of Warrants Outstanding, Weighted Average Remaining Life, Granted">3.30</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLi1S8YMsIei" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0875">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znLiFuM0N8C6" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0877">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm4bVwq6j1Nc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0879">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZFXsnJ11Gqf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBKbOlu9llxf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif">4,986,645</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqD8YbSgYlvl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding"><span style="font-family: Times New Roman, Times, Serif">4.21</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVqN74tCK6zd" title="Weighted Average Remaining Life">2.92</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A1_zzuqUIbEJBTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024, the Company had <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitySharesIssued_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB7J1x5fONcf" title="Shares issuable under warrants">4,968,645</span> shares issuable under warrants outstanding at a weighted average exercise price of $<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIus5QqRsz7g" title="Warrant exercise price">4.21</span> and an intrinsic value of $<span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2luOMxH5P05" title="Class of warrant or right, outstanding, intrinsic value">0</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized compensation expense related to warrants issued of $<span id="xdx_909_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20240101__20241231_ztPxSNcVq1Lf" title="Share based compensation expense">0</span> and $<span id="xdx_90E_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20230101__20231231_zfyFCYrTD517" title="Share based compensation expense">0</span> during the year ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2806311 104173 9644 1948295 0.0001 1948295 0.64 1948295 0.64 P5Y 0.64 0.89 129489 0.64 1948295 1948295 1948295 129489 1900000 196857 186594 184260 873763 1279181 1953491 742150 0 1357466 <p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zOwNXJEIND98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each stock option granted during the year ended December 31, 2024 was estimated using the Black-Scholes assumptions and or factors as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zAK4WXiXa6oi" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__srt--RangeAxis__srt--MinimumMember_zNvYKityiQN8" title="Exercise price">0.84</span>-$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__srt--RangeAxis__srt--MaximumMember_zkNpbz7fy4cf" title="Exercise price">5.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20241231_zUNc4CnAuDN8" style="width: 16%; text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zZjSc53Jmclk" title="Risk free interest rate minimum">4.01</span>%-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zinqAkRwNM97" title="Risk free interest rate maximum">4.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life in years</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zgFGV6Alzt4h" title="Expected life in years">10</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z4YY7YlOCuQk" title="Expected volatility minimum">213</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zu02se7HrUKh" title="Expected volatility maximum">215</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> 0.84 5.00 0 0.0401 0.0425 P10Y 2.13 2.15 <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXeiIUuE3QA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is an analysis of the stock option grant activity under the Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zYUvK0dJPuxf" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Life</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock Options</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif">Outstanding December 31, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7LB8bqs7DX4" style="width: 14%; text-align: right" title="Number of Stock Options Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">1,357,466</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxm1MYgeFfmk" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Beginning"><span style="font-family: Times New Roman, Times, Serif">7.39</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyhMXOYPv0Pg" title="Weighted Average Remaining Life">4.49</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRNUYx7Rgpe5" style="text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif">742,150</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUNI0nVFxA3" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">1.73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDqXRCwiPJPe" title="Weighted Average Remaining Life, Granted">9.23</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpWOnD4TYY5h" style="text-align: right" title="Number of Stock Options Outstanding, Expired"><span style="font-family: Times New Roman, Times, Serif">(146,125</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3cBDTWtZCyf" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif">5.85</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zznpBJPlcr5k" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbBA95T3CtQh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPMyU8iLLOcd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif">1,953,491</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOK6qtSYsUTj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending"><span style="font-family: Times New Roman, Times, Serif">5.36</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrNPxddrf12i" title="Weighted Average Remaining Life">5.77</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1357466 7.39 P4Y5M26D 742150 1.73 P9Y2M23D 146125 5.85 1953491 5.36 P5Y9M7D <p id="xdx_894_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zNJhrLWMkita" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the status of the Company’s nonvested options as of December 31, 2024, and changes during the year ended December 31, 2024 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zGjlbYDf6xsa" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Nonvested Options</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Nonvested at December 31, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240101__20241231_zoCobPKG9hn5" style="width: 16%; text-align: right" title="Nonvested Options, Balance"><span style="font-family: Times New Roman, Times, Serif">49,832</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20241231_zu5488rRsoK8" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif">14.72</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zFuI9mUds8eh" style="text-align: right" title="Nonvested Options, Granted"><span style="font-family: Times New Roman, Times, Serif">742,150</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zyXUt0ookXga" style="text-align: right" title="Weighted-Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">1.73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20240101__20241231_zrHkGwwXBxGi" style="text-align: right" title="Nonvested Options, Vested"><span style="font-family: Times New Roman, Times, Serif">(233,324</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20240101__20241231_zuOaM7LzrkMe" style="text-align: right" title="Weighted-Average Exercise Price, Vested"><span style="font-family: Times New Roman, Times, Serif">4.14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20240101__20241231_zXMGScu63Jjl" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Options, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0771">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20240101__20241231_zTlsZeJ1tcMi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0773">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Nonvested at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240101__20241231_z9Fxw6uKsqeb" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Options, Balance"><span style="font-family: Times New Roman, Times, Serif">558,658</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231_zqHoPVUC7iwb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif">1.89</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 49832 14.72 742150 1.73 233324 4.14 558658 1.89 1953491 5.36 0 923139 666828 431884 206104 491255 460724 186031 6852 737108 659976 1012825 530456 482369 P2Y9M29D 20750 0.84 P10Y P48M 5000 4400 5.00 P10Y P3M 717000 1.74 P10Y P24M P48M 160000 <p id="xdx_893_ecustom--ScheduleOfShareBasedPaymentAwardWarrantssValuationAssumptionsTableTextBlock_zyXI49PhtJJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each warrant granted during the year ended December 31, 2024 was estimated using the Black-Scholes assumptions and or factors as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zNgDSSvYoRre" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%"><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBF7SSH2BvNi" title="Exercise price">0.64</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfkvbk7vC44" style="text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDMUrVFrrHXf" title="Risk free interest rate minimum">4.31</span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhA0DFetYVZb" title="Risk free interest rate maximum">4.45</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life in years</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pp0d_dtYp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zyoAktBPLeWg" title="Expected life in years">5</span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pp0d_dtYp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z4HTYd8JjDNd" title="Expected life in years">1.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDHcx3jCNhCd" title="Expected volatility minimum">242</span>-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPhhAEgV9M44" title="Expected volatility maximum">271</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> 0.64 0 0.0431 0.0445 P5Y P1Y6M 2.42 2.71 <p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zFiIsg3MzbS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of warrant issuances are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zYTmpS8w9lUc" style="display: none">SUMMARY OF WARRANT</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Life</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Outstanding December 31, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG5yge0Bnydk" style="width: 14%; text-align: right" title="Number of Warrants Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">942,566</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgCWazJHK3Sa" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding"><span style="font-family: Times New Roman, Times, Serif">19.47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmInPHqfDla1" title="Weighted Average Remaining Life">2.31</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znnzWdVqdoFb" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif">4,206,079</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvOG4oPEtXud" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">0.64</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkPO2zZdNZf3" title="Number of Warrants Outstanding, Weighted Average Remaining Life, Granted">3.30</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLi1S8YMsIei" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0875">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znLiFuM0N8C6" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0877">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm4bVwq6j1Nc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0879">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZFXsnJ11Gqf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBKbOlu9llxf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif">4,986,645</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqD8YbSgYlvl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding"><span style="font-family: Times New Roman, Times, Serif">4.21</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVqN74tCK6zd" title="Weighted Average Remaining Life">2.92</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 942566 19.47 P2Y3M21D 4206079 0.64 P3Y3M18D 4986645 4.21 P2Y11M1D 4968645 4.21 0 0 0 <p id="xdx_800_eus-gaap--CollaborativeArrangementDisclosureTextBlock_zHvt2RVV384f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 - <span id="xdx_820_zrRn5ys16MFd">COLLABORATIVE AGREEMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and the University of Toronto (the “University”) entered into an agreement effective April 1, 2014 (the “New Research Agreement”) for the performance of a research project titled “Teneurin C-terminal Associated Peptide (“TCAP”) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “New Project”). The New Project is to perform research related to work done by Dr. David A. Lovejoy, a professor at the University and stockholder of the Company, in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, Dr. Lovejoy entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 30, 2016. In February 2017, the New Research Agreement was extended to December 31, 2017. The extension allowed for further development of the technologies and use of their applications. On April 10, 2018, the agreement was amended and the research agreement has been further extended to September 30, 2024. On December 20, 2024, the agreement was amended and the research agreement has been further extended to the entire lifetime of the last issued patent covered by the license.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The sponsorship research and development expenses pertaining to the Research Agreements were $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementsMember_zFoub8giS2rf" title="Research and development expense">0</span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementsMember_zSvBOODAiEw8" title="Research and development expense">0</span> for the year ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zeJs4IfjsnA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 - <span id="xdx_827_zKe8C3KfGz5c">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Licensing Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2005, the Company had entered into a Technology License Agreement (“License Agreement”) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the “Technologies”). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of <span id="xdx_904_ecustom--RoyaltyPaymentPercentage_iI_pid_dp_uPure_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zkWTW5U3b2ch" title="Royalty payment, percentage">2.5</span>% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University <span id="xdx_90D_ecustom--UpFrontSubLicenseFeesPercentage_iI_pid_dp_uPure_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zpXVwzC4fXLl" title="Up-front sub-license fees, percentage">10</span>% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, <span id="xdx_90A_ecustom--RoyaltyPaymentOnBehalfOfSublicenseePercentage_iI_dp_uPure_c20241231_zQ7gkPX3PSsd" title="Royalty payment on behalf of sublicensee percentage">2.5</span>% of net sales by the sub-licensee of all products based on the Technologies. The Company had <span id="xdx_904_eus-gaap--Revenues_pp0p0_do_c20240101__20241231_zCnaL8thYCZ5" title="Sales revenue"><span id="xdx_904_eus-gaap--Revenues_pp0p0_do_c20230101__20231231_z1dV8t1asQi4" title="Sales revenue">no</span></span> sales revenue for the year ended December 31, 2024 and 2023 and therefore was not subject to paying any royalties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at <span id="xdx_902_ecustom--InterestOnAmountsOwedUnderLicenseAgreementRate_iI_pid_dp_uPure_c20241231_zrX4n0MOjqui" title="Interest on amounts owed under license agreement, rate">3</span>% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or Dr. Lovejoy, and/or the University, as the case may be. The Company has agreed to pay all out-of-pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the <span id="xdx_905_ecustom--RoyaltyPaymentPercentage_iI_pid_dp_uPure_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zZ8tDR53F6mg" title="Royalty payment, percentage">2.5</span>% royalty payment owed to the University under the License Agreement and amendment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The patent applications were made in the name of Dr. Lovejoy and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the five intellectual patent properties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal Proceedings</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Notice of Delisting</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 24, 2024, the Company received a deficiency letter (the “Notification Letter”) from the Nasdaq Listing Qualifications (“Nasdaq”) stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $<span id="xdx_90A_ecustom--BidPriceRequirement_iI_c20240724_z69M7CQoHmKi" title="Minimum bid price">1.00</span> per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notification Letter states that the Company has 180 calendar days, or until January 20, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s closing bid price of the Company’s common stock must have a closing bid price of at least $<span id="xdx_901_ecustom--ClosingBidPrice_iI_c20240724_zgrWooMMo9oh" title="Closing bid price">1.00</span> for a <i>minimum </i>of ten consecutive business days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 22, 2025, Nasdaq provided a notice to the Company that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as the Company does not comply with the requirements for initial listing on The Nasdaq Capital Market. This notification is part of the ongoing discussions with the Nasdaq Hearings Panel (the “Panel”) regarding the Company’s listing status, and the Company included this matter in its presentation to the Panel on January 30, 2025.   </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 19, 2025, the Company received a hearing panel decision from Nasdaq (Nasdaq Listing Qualifications Hearings Docket No. NQ 7072C-25) indicating that its provisional plan for regaining compliance with the Nasdaq listing requirements had been accepted. For continued listing on the Nasdaq Capital Market, the Company has until April 28, 2025 to: (1) demonstrate compliance with Nasdaq Rules 5550(a)(2) and 5550(b)(2), (2) file a public disclosure describing any transactions undertaken by the Company to increase its equity and provide and indication of its equity following those transactions, and (3) provide the Panel with an update on its fundraising plans and updated income projections for the next 12 months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.025 0.10 0.025 0 0 0.03 0.025 1.00 1.00 <p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zDN3ypznFsBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_82D_zwNYNE8D2Rl6">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen. The Company does not pay any rent for the use of this space. This space is used for quarterly board meetings and our annual shareholder meeting.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company engaged Agenus Inc., a related party, to perform research and development services. Agenus Inc. is a related party due to the Company’s Director and Chairman of the Board being the CEO and Chairman of the Board for Agenus Inc. The Company incurred $<span id="xdx_90B_eus-gaap--OperatingCostsAndExpenses_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgenusIncMember_zGIYxiYR94ge" title="Operating costs and expenses">97,357</span> and $<span id="xdx_902_eus-gaap--OperatingCostsAndExpenses_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgenusIncMember_z9WyiGX0KV67" title="Operating costs and expenses">149,509</span> in expenses related to these services during the year ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and December 31, 2023, the outstanding balance owed to Agenus Inc. is $<span id="xdx_901_eus-gaap--OtherLiabilities_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgenusIncMember_zJ6LoLGyzT97" title="Other liabilities">39,875</span> and $<span id="xdx_901_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgenusIncMember_zmXAOVWj9lAi" title="Other liabilities">150,296</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company engaged CTC North, GmbH (“CTC”) to perform research and development services. CTC is a related party due to the Company’s Director and Chairman of the Board being the CEO and Chairman of the Board for Agenus Inc, CTC’s parent company. The total commitment for this agreement is $<span id="xdx_902_eus-gaap--OtherCommitment_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTCNorthGmbHMember_zO7vliHmQLSe" title="Commitment agreement, value">1.3</span> million. The Company incurred $<span id="xdx_90A_eus-gaap--OperatingCostsAndExpenses_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTCNorthGmbHMember_zc3AbW9enDI2" title="Expenses related to services">0</span> and $<span id="xdx_900_eus-gaap--OperatingCostsAndExpenses_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTCNorthGmbHMember_ziRH7VnW3D06" title="Expenses related to services">106,755</span> in expenses related to these services during the year ended December 31, 2024 and 2023, respectively. During the year ended December 31, 2024, the Company wrote off the remaining accounts payable balance of $<span id="xdx_90B_ecustom--GainOnSettlementOfAccountsPayableAndAccruedLiabilities_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTCNorthGmbHMember_zefef8uXV4X6" title="Gain on settlement of accounts payable and accrued liabilities with related parties">80,409</span> as CTC is no longer in business. As of December 31, 2024 and December 31, 2023, there is $<span id="xdx_90D_eus-gaap--OtherLiabilitiesCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTCNorthGmbHMember_zrDRzvjcWM83" title="Other liabilities">0</span> and $<span id="xdx_903_eus-gaap--OtherLiabilitiesCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTCNorthGmbHMember_zD8IhGMFyLK2" title="Other liabilities">80,409</span> owed to CTC in connection with this agreement, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 97357 149509 39875 150296 1300000 0 106755 80409 0 80409 <p id="xdx_802_eus-gaap--SegmentReportingDisclosureTextBlock_zP4I62XvHH4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_82B_zBML0LcdNtha">SEGMENT REPORTING</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_ziZqmPlVoddj" title="Number of operating segments">one</span> operating segment, and therefore one reportable segment, and is focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The Company’s business activities are managed on a consolidated basis through the development and potential commercialization of pharmaceutical products, which are aimed at the global market in the event that products are successful in receiving regulatory approvals. Our determination that we operate as a single operating segment is consistent with the financial information regularly reviewed by the chief operating decision makers for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. Our chief operating decision makers is the Chief Executive Officer and Chief Financial Officer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting policies for our single operating segment are the same as those described in the summary of significant accounting policies. Our single operating segment incurs expenses from the development of therapeutics. The Company has not yet generated revenue in its operating history.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the segment, the chief operating decision makers use net loss, that also is reported on the consolidated statements of operations as consolidated net loss, to allocate resources. The chief operating decision maker also uses consolidated net loss, along with non-financial inputs and qualitative information, to evaluate our performance, establish compensation, monitor budget versus actual results, and decide the allocation of funds in our various research activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 <p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zlJBUklnWIPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_824_zbzN2yKNVb2d">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zueWiPvlEoxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of loss before income taxes are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_z1Lc4xlNSsPl" style="display: none">SCHEDULE OF LOSS BEFORE INCOME TAX</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20240101__20241231_zqX7LMQ7CzYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20230101__20231231_zhVIL3Z5ZOob" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOz0xd_z2xrYxMBLIri" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Domestic</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,526,365</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,998,066</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOz0xd_z2MeZkTSqYbc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,021</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,431</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOz0xd_zktuhFNijBr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss before income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,525,344</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,000,497</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> <p id="xdx_8A6_zQ7QDHS8MGZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had <span id="xdx_903_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20240101__20241231_zj15gXJzagq" title="Income tax expenses::XDX::-"><span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20230101__20231231_zQ9bt5cJrOme" title="Income tax expenses::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0964"><span style="-sec-ix-hidden: xdx2ixbrl0966">no</span></span></span></span> income tax expense due to operating losses incurred for the years ended December 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zx61FLhjV7Xe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2024 and 2023, a reconciliation of the Company’s effective tax rate to the statutory U.S. Federal rate is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zXEbvQMzqbQ3" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20240101__20241231_zNV9kukAP3Qa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230101__20231231_z6ANm1nkjVbi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_uPure_maABC_zVMUMPD61M3h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income taxes at Federal statutory rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21.0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21.0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maABC_zChWT9Bu0W27" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State income taxes, net of Federal income tax effect</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr> <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent_dp_uPure_maABC_zfO4K9ix0B4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Perm difference</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_uPure_maABC_zMwF0wvgl7U4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign tax rate differential</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maABC_zD4AUrT3vZpf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPure_maABC_zmx4bgHwCIW5" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mtABC_zAzrpxwwMlYf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax provision</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8A4_z8QKe6eiJE64" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFmcum6jSCj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax effects of temporary differences that give rise to the Company’s deferred tax assets and liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zq8UC9RqEuE5" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20241231_zuXRCMNmpaDl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20231231_zY0wXsObr9Aj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_maDTAGzHVe_zTBThsYkbrih" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. net operating loss carryforwards</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,305,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,940,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzHVe_z3buiT8YmEg6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock compensation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,408,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,131,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_maDTANzUGv_mtDTAGzHVe_zsklnkgCZYlc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif"> <span style="font-size: 10pt">Deferred tax assets, gross</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,713,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,071,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzUGv_z6jxwOHdIxU6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,713,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,071,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzUGv_zRYRdfAvF2A7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A2_zgpM96LOeXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024 the Company had federal net operating loss carryforwards (“NOL”) of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zKpMAhdm4mmd" title="Net operating loss carryforwards">19.7</span> million. The 2017 Tax Cuts and Jobs Act (“TCJA”) will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss carryover or <span id="xdx_90B_ecustom--PercentageOfCorporationsTaxableIncome_iI_pid_dp_uPure_c20241231__srt--StatementScenarioAxis__custom--LossesIncurredAfter2017Member_zHxCEh6OOfc4" title="Percentage of corporations taxable income">80</span>% of a corporation’s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended). Also, there will be no carryback for losses incurred after 2017. Losses incurred prior to 2018 will generally be deductible to the extent of the lesser of a corporation’s net operating loss carryover or <span id="xdx_90B_ecustom--PercentageOfCorporationsTaxableIncome_iI_pid_dp_uPure_c20241231__srt--StatementScenarioAxis__custom--LossesIncurredPriorTo2018Member_zymjgPxbCs0e" title="Percentage of corporations taxable income">100</span>% of a corporation’s taxable income and be available for twenty years from the period the loss was generated. <span id="xdx_90A_ecustom--OperatingLossCarryforwardsExpirationDescription_c20240101__20241231_zuH0u8xTusbi" title="Operating loss carry forwards expiration description">The federal net operating losses generated prior to 2018 of $0.1 million will expire at various dates through 2037.</span> As of December 31, 2024 and 2023, the Company had state and local net operating loss carryforwards of approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--StateAndLocalMember_zQUGwnF1bALa" title="Net operating loss carryforwards">18.5</span> million and $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--StateAndLocalMember_zmPhEMkEYFWf" title="Net operating loss carryforwards">14.0</span> million, respectively, to reduce future state tax liabilities also through 2035.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024 and 2023, the Company had Canadian NOL of approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__country--CA_zieEyHDkMzRd" title="Net operating loss carryforwards">1.4</span> million and $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__country--CA_zLcoReaiqVfj" title="Net operating loss carryforwards">1.4</span> million respectively. The Canadian losses expire in stages beginning in 2026. As of December 31, 2024 and 2023, the Company also has unclaimed Canadian federal scientific research and development investment tax credits, which are available to reduce future federal taxes payable of approximately $<span id="xdx_90D_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20240101__20241231_z0yxrzKKLZ9a" title="Research and development investment tax credits">0</span> and $<span id="xdx_90C_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231_zuDHnxisXsA" title="Research and development investment tax credits">0</span> respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of losses and uncertainty of future profit, the net deferred tax asset has been fully reserved. The net change in the valuation allowance during the years ended December 31, 2024 and 2023 was an increase of $<span id="xdx_904_ecustom--IncreaseDecreaseInValuationAllowance_pn5n6_c20240101__20241231_zGT4umtX3zb7" title="Net change in valuation allowance">0.5</span> million and $<span id="xdx_904_ecustom--IncreaseDecreaseInValuationAllowance_pn5n6_c20230101__20231231_z1R2u5t8rQu1" title="Net change in valuation allowance">1.5</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign earnings are assumed to be permanently reinvested. U.S. Federal income taxes have not been provided on undistributed earnings of our foreign subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes interest and penalties related to uncertain tax positions in selling, general and administrative expenses. The Company has not identified any uncertain tax positions requiring a reserve as of December 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is required to file U.S. federal and state income tax returns. These returns are subject to audit by tax authorities beginning with the year ended December 31, 2018.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zueWiPvlEoxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of loss before income taxes are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_z1Lc4xlNSsPl" style="display: none">SCHEDULE OF LOSS BEFORE INCOME TAX</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20240101__20241231_zqX7LMQ7CzYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20230101__20231231_zhVIL3Z5ZOob" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOz0xd_z2xrYxMBLIri" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Domestic</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,526,365</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,998,066</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOz0xd_z2MeZkTSqYbc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,021</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,431</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOz0xd_zktuhFNijBr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss before income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,525,344</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,000,497</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> -5526365 -4998066 1021 -2431 -5525344 -5000497 <p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zx61FLhjV7Xe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2024 and 2023, a reconciliation of the Company’s effective tax rate to the statutory U.S. Federal rate is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zXEbvQMzqbQ3" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20240101__20241231_zNV9kukAP3Qa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230101__20231231_z6ANm1nkjVbi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_uPure_maABC_zVMUMPD61M3h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income taxes at Federal statutory rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21.0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21.0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maABC_zChWT9Bu0W27" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State income taxes, net of Federal income tax effect</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr> <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent_dp_uPure_maABC_zfO4K9ix0B4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Perm difference</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_uPure_maABC_zMwF0wvgl7U4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign tax rate differential</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_maABC_zD4AUrT3vZpf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPure_maABC_zmx4bgHwCIW5" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mtABC_zAzrpxwwMlYf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax provision</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> 0.210 0.210 -0.089 -0.089 0.000 0.000 0.000 -0.001 0.299 0.300 0.000 0.000 0.000 0.000 <p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFmcum6jSCj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax effects of temporary differences that give rise to the Company’s deferred tax assets and liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zq8UC9RqEuE5" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20241231_zuXRCMNmpaDl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20231231_zY0wXsObr9Aj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_maDTAGzHVe_zTBThsYkbrih" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. net operating loss carryforwards</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,305,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,940,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzHVe_z3buiT8YmEg6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock compensation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,408,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,131,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_maDTANzUGv_mtDTAGzHVe_zsklnkgCZYlc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif"> <span style="font-size: 10pt">Deferred tax assets, gross</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,713,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,071,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzUGv_z6jxwOHdIxU6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,713,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,071,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzUGv_zRYRdfAvF2A7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 6305000 4940000 2408000 2131000 8713000 7071000 8713000 7071000 19700000 0.80 1 The federal net operating losses generated prior to 2018 of $0.1 million will expire at various dates through 2037. 18500000 14000000.0 1400000 1400000 0 0 500000 1500000 <p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zTVbmb8EpGOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 – <span id="xdx_823_zD5p6ZLL7D8d">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 21, 2025, the Company held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on February 21, 2025. At the Company’s Annual Meeting, the Company’s stockholders approved the proposal to approve the repricing of certain outstanding stock options granted (the “Option Grants”) under the Company’s 2006 and 2016 Equity Incentive Plans (the “Plans”) to allow the Board of Directors (the “Board”) to reprice the exercise price of outstanding stock options under the Plans. Pursuant to that authority, on February 21, 2025, the Board repriced the Option Grants. The repriced Option Grants under the 2006 Equity Incentive Plan had original exercise prices ranging from $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250221__20250221__us-gaap--PlanNameAxis__custom--TwoThousandSixEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9gERhND4jSi" title="Exercise price">4.00</span> to $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250221__20250221__us-gaap--PlanNameAxis__custom--TwoThousandSixEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHGYu0sA1UNe" title="Exercise price">5.00</span> per share, and the repriced Option Grants under the 2016 Equity Incentive Plan had original exercise prices ranging from $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250221__20250221__us-gaap--PlanNameAxis__custom--TwoThousandSixteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zM6gLYpKm8Wb" title="Exercise price">1.74</span> to $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250221__20250221__us-gaap--PlanNameAxis__custom--TwoThousandSixteenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrt38VglVkL" title="Exercise price">19.92</span> per share. All of the Option Grants under the Plans were repriced to have an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250221__20250221__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYJm0nSQjh3l" title="Exercise price">0.2655</span> per share, which was the closing price of the Company’s common stock on February 21, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 5, 2025, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0d_c20250305__20250305__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0JkZ19hk4f1" title="Common stock issued, shares">284,238</span> shares of its common stock for proceeds of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20250305__20250305__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2f5S12VNUp8" title="Common stock issued, value">102,534</span>.<br/></span></p> 4.00 5.00 1.74 19.92 0.2655 284238 102534

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end XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 125 260 1 false 47 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://protagenic.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://protagenic.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://protagenic.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Change in Stockholders' Equity Sheet http://protagenic.com/role/StatementsOfChangeInStockholdersEquity Consolidated Statements of Change in Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://protagenic.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 9 false false R10.htm 999014 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS Sheet http://protagenic.com/role/OrganizationAndNatureOfBusiness ORGANIZATION AND NATURE OF BUSINESS Notes 10 false false R11.htm 999015 - Disclosure - LIQUIDITY AND GOING CONCERN Sheet http://protagenic.com/role/LiquidityAndGoingConcern LIQUIDITY AND GOING CONCERN Notes 11 false false R12.htm 999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 12 false false R13.htm 999017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://protagenic.com/role/AccountsPayableAndAccruedExpenses ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 13 false false R14.htm 999018 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://protagenic.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 14 false false R15.htm 999019 - Disclosure - COLLABORATIVE AGREEMENTS Sheet http://protagenic.com/role/CollaborativeAgreements COLLABORATIVE AGREEMENTS Notes 15 false false R16.htm 999020 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://protagenic.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 16 false false R17.htm 999021 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://protagenic.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 17 false false R18.htm 999022 - Disclosure - SEGMENT REPORTING Sheet http://protagenic.com/role/SegmentReporting SEGMENT REPORTING Notes 18 false false R19.htm 999023 - Disclosure - INCOME TAXES Sheet http://protagenic.com/role/IncomeTaxes INCOME TAXES Notes 19 false false R20.htm 999024 - Disclosure - SUBSEQUENT EVENTS Sheet http://protagenic.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 20 false false R21.htm 999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 21 false false R22.htm 999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://protagenic.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 999027 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://protagenic.com/role/AccountsPayableAndAccruedExpensesTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://protagenic.com/role/AccountsPayableAndAccruedExpenses 23 false false R24.htm 999028 - Disclosure - STOCKHOLDERS??? EQUITY (Tables) Sheet http://protagenic.com/role/StockholdersEquityTables STOCKHOLDERS??? EQUITY (Tables) Tables http://protagenic.com/role/StockholdersEquity 24 false false R25.htm 999029 - Disclosure - INCOME TAXES (Tables) Sheet http://protagenic.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://protagenic.com/role/IncomeTaxes 25 false false R26.htm 999030 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC (Details) Sheet http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC (Details) Details 26 false false R27.htm 999031 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Sheet http://protagenic.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Details 27 false false R28.htm 999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 999033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) Sheet http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) Details 29 false false R30.htm 999034 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) Sheet http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) Details 30 false false R31.htm 999035 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details) Sheet http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details) Details 31 false false R32.htm 999036 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details) Sheet http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details) Details 32 false false R33.htm 999037 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS (Details) Sheet http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS (Details) Details 33 false false R34.htm 999038 - Disclosure - SUMMARY OF WARRANT (Details) Sheet http://protagenic.com/role/SummaryOfWarrantDetails SUMMARY OF WARRANT (Details) Details 34 false false R35.htm 999039 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://protagenic.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://protagenic.com/role/StockholdersEquityTables 35 false false R36.htm 999040 - Disclosure - COLLABORATIVE AGREEMENTS (Details Narrative) Sheet http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative COLLABORATIVE AGREEMENTS (Details Narrative) Details http://protagenic.com/role/CollaborativeAgreements 36 false false R37.htm 999041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://protagenic.com/role/CommitmentsAndContingencies 37 false false R38.htm 999042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://protagenic.com/role/RelatedPartyTransactions 38 false false R39.htm 999043 - Disclosure - SEGMENT REPORTING (Details Narrative) Sheet http://protagenic.com/role/SegmentReportingDetailsNarrative SEGMENT REPORTING (Details Narrative) Details http://protagenic.com/role/SegmentReporting 39 false false R40.htm 999044 - Disclosure - SCHEDULE OF LOSS BEFORE INCOME TAX (Details) Sheet http://protagenic.com/role/ScheduleOfLossBeforeIncomeTaxDetails SCHEDULE OF LOSS BEFORE INCOME TAX (Details) Details 40 false false R41.htm 999045 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) Sheet http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) Details 41 false false R42.htm 999046 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) Sheet http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) Details 42 false false R43.htm 999047 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://protagenic.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://protagenic.com/role/IncomeTaxesTables 43 false false R44.htm 999048 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://protagenic.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://protagenic.com/role/SubsequentEvents 44 false false All Reports Book All Reports form10-k.htm ptix-20241231.xsd ptix-20241231_cal.xml ptix-20241231_def.xml ptix-20241231_lab.xml ptix-20241231_pre.xml form10-k_001.jpg form10-k_002.jpg form10-k_003.jpg form10-k_004.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-k.htm": { "nsprefix": "PTIX", "nsuri": "http://protagenic.com/20241231", "dts": { "inline": { "local": [ "form10-k.htm" ] }, "schema": { "local": [ "ptix-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "ptix-20241231_cal.xml" ] }, "definitionLink": { "local": [ "ptix-20241231_def.xml" ] }, "labelLink": { "local": [ "ptix-20241231_lab.xml" ] }, "presentationLink": { "local": [ "ptix-20241231_pre.xml" ] } }, "keyStandard": 224, "keyCustom": 36, "axisStandard": 17, "axisCustom": 0, "memberStandard": 21, "memberCustom": 22, "hidden": { "total": 112, "http://fasb.org/us-gaap/2024": 90, "http://protagenic.com/20241231": 18, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 125, "entityCount": 1, "segmentCount": 47, "elementCount": 510, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 483, "http://xbrl.sec.gov/dei/2024": 43, "http://xbrl.sec.gov/cyd/2024": 7 }, "report": { "R1": { "role": "http://protagenic.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://protagenic.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R3": { "role": "http://protagenic.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R4": { "role": "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss", "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "PTIX:ResearchAndDevelopmentRelatedParty", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R5": { "role": "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity", "longName": "00000005 - Statement - Consolidated Statements of Change in Stockholders' Equity", "shortName": "Consolidated Statements of Change in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://protagenic.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "PTIX:NoInsiderTradingFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "PTIX:NoInsiderTradingFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R9": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://protagenic.com/role/OrganizationAndNatureOfBusiness", "longName": "999014 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS", "shortName": "ORGANIZATION AND NATURE OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://protagenic.com/role/LiquidityAndGoingConcern", "longName": "999015 - Disclosure - LIQUIDITY AND GOING CONCERN", "shortName": "LIQUIDITY AND GOING CONCERN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "PTIX:LiquidityAndGoingConcernDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "PTIX:LiquidityAndGoingConcernDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://protagenic.com/role/SummaryOfSignificantAccountingPolicies", "longName": "999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://protagenic.com/role/AccountsPayableAndAccruedExpenses", "longName": "999017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES", "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://protagenic.com/role/StockholdersEquity", "longName": "999018 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "shortName": "STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://protagenic.com/role/CollaborativeAgreements", "longName": "999019 - Disclosure - COLLABORATIVE AGREEMENTS", "shortName": "COLLABORATIVE AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://protagenic.com/role/CommitmentsAndContingencies", "longName": "999020 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://protagenic.com/role/RelatedPartyTransactions", "longName": "999021 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://protagenic.com/role/SegmentReporting", "longName": "999022 - Disclosure - SEGMENT REPORTING", "shortName": "SEGMENT REPORTING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://protagenic.com/role/IncomeTaxes", "longName": "999023 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://protagenic.com/role/SubsequentEvents", "longName": "999024 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://protagenic.com/role/AccountsPayableAndAccruedExpensesTables", "longName": "999027 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)", "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R24": { "role": "http://protagenic.com/role/StockholdersEquityTables", "longName": "999028 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)", "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R25": { "role": "http://protagenic.com/role/IncomeTaxesTables", "longName": "999029 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails", "longName": "999030 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC (Details)", "shortName": "SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R27": { "role": "http://protagenic.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "longName": "999031 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "shortName": "SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R28": { "role": "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:MarketableSecuritiesUnrealizedGainLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:MarketableSecuritiesPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R29": { "role": "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails", "longName": "999033 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)", "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "PTIX:AccruedAccountingFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "PTIX:AccruedAccountingFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R30": { "role": "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "longName": "999034 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)", "shortName": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "longName": "999035 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details)", "shortName": "SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember107462140", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R32": { "role": "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails", "longName": "999036 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details)", "shortName": "SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R33": { "role": "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails", "longName": "999037 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS (Details)", "shortName": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "PTIX:ScheduleOfShareBasedPaymentAwardWarrantssValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R34": { "role": "http://protagenic.com/role/SummaryOfWarrantDetails", "longName": "999038 - Disclosure - SUMMARY OF WARRANT (Details)", "shortName": "SUMMARY OF WARRANT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_WarrantMember107463156", "name": "PTIX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R35": { "role": "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "longName": "999039 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-10-292024-10-29", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R36": { "role": "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "longName": "999040 - Disclosure - COLLABORATIVE AGREEMENTS (Details Narrative)", "shortName": "COLLABORATIVE AGREEMENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_custom_ResearchAgreementsMember", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R37": { "role": "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "999041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "PTIX:RoyaltyPaymentOnBehalfOfSublicenseePercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "PTIX:RoyaltyPaymentOnBehalfOfSublicenseePercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R38": { "role": "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "999042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "PTIX:GainOnSettlementOfAccountsPayableAndAccruedLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_custom_AgenusIncMember", "name": "us-gaap:OperatingCostsAndExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R39": { "role": "http://protagenic.com/role/SegmentReportingDetailsNarrative", "longName": "999043 - Disclosure - SEGMENT REPORTING (Details Narrative)", "shortName": "SEGMENT REPORTING (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R40": { "role": "http://protagenic.com/role/ScheduleOfLossBeforeIncomeTaxDetails", "longName": "999044 - Disclosure - SCHEDULE OF LOSS BEFORE INCOME TAX (Details)", "shortName": "SCHEDULE OF LOSS BEFORE INCOME TAX (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R41": { "role": "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "longName": "999045 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)", "shortName": "SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R42": { "role": "http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "longName": "999046 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)", "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R43": { "role": "http://protagenic.com/role/IncomeTaxesDetailsNarrative", "longName": "999047 - Disclosure - INCOME TAXES (Details Narrative)", "shortName": "INCOME TAXES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "PTIX:OperatingLossCarryforwardsExpirationDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "PTIX:OperatingLossCarryforwardsExpirationDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R44": { "role": "http://protagenic.com/role/SubsequentEventsDetailsNarrative", "longName": "999048 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-02-212025-02-21_us-gaap_SubsequentEventMember", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r43", "r44" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r42", "r44", "r47", "r762" ] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilities", "crdr": "credit", "calculation": { "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Accounts Payable and Other Accrued Liabilities", "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other." } } }, "auth_ref": [ "r456" ] }, "PTIX_AccruedAccountingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "AccruedAccountingFees", "crdr": "credit", "calculation": { "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accounting", "documentation": "Accrued accounting fees." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Legal", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r44" ] }, "PTIX_AccruedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "AccruedResearchAndDevelopment", "crdr": "credit", "calculation": { "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "documentation": "Accrued research and development.", "label": "AccruedResearchAndDevelopment" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r125", "r126", "r365", "r366", "r367", "r368", "r369", "r370" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r14", "r15", "r57", "r116", "r406", "r427", "r428" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r125", "r126", "r365", "r366", "r367", "r368", "r369", "r370" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r7", "r15", "r339", "r342", "r375", "r423", "r424", "r693", "r694", "r695", "r704", "r705", "r706", "r708" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r635" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r52", "r561", "r799" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r440", "r704", "r705", "r706", "r708", "r773", "r800" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r641" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r641" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r641" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r641" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock compensation - stock options", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r33", "r34", "r263" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "auth_ref": [] }, "PTIX_AgenusIncMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "AgenusIncMember", "presentation": [ "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agenus Inc. [Member]", "documentation": "Agenus Inc. [Member]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r602", "r613", "r627", "r653" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r605", "r616", "r630", "r656" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r641" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r648" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r606", "r617", "r631", "r648", "r657", "r661", "r669" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r291", "r293" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r5", "r63", "r235", "r783" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r609" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://protagenic.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Total potentially outstanding dilutive common shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r167" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://protagenic.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r23" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://protagenic.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://protagenic.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r23" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r333" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r81", "r90", "r112", "r139", "r170", "r178", "r188", "r191", "r200", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r334", "r336", "r360", "r400", "r476", "r538", "r539", "r561", "r573", "r732", "r733", "r786" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT ASSETS", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r110", "r118", "r139", "r200", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r334", "r336", "r360", "r561", "r732", "r733", "r786" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r609" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r585", "r587", "r609" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r585", "r587", "r609" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r585", "r587", "r609" ] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": [ "r684" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [ "r664" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r665" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r660" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r660" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": [ "r660" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r660" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r660" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r660" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r663" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r662" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r661" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r661" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "PTIX_BidPriceRequirement": { "xbrltype": "perShareItemType", "nsuri": "http://protagenic.com/20241231", "localname": "BidPriceRequirement", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum bid price", "documentation": "Bid price requirement." } } }, "auth_ref": [] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CA", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "auth_ref": [] }, "PTIX_CTCNorthGmbHMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "CTCNorthGmbHMember", "presentation": [ "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CTC North, GmbH [Member]", "documentation": "CTC North, GmbH [Member]" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r93", "r403", "r451", "r471", "r561", "r573", "r691" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r18" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "CASH, BEGINNING OF THE PERIOD", "periodEndLabel": "CASH, END OF THE PERIOD", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r17", "r64", "r136" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET CHANGE IN CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r64" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "NONCASH FINANCING AND INVESTING TRANSACTIONS" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r639" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r107", "r113", "r114", "r115", "r139", "r161", "r162", "r164", "r166", "r172", "r173", "r200", "r224", "r226", "r227", "r228", "r231", "r232", "r237", "r238", "r240", "r243", "r249", "r360", "r431", "r432", "r433", "r434", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r452", "r463", "r485", "r507", "r520", "r521", "r522", "r523", "r524", "r688", "r698", "r709" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price of warrants", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r250" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase of shares of common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r250" ] }, "PTIX_ClosingBidPrice": { "xbrltype": "perShareItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ClosingBidPrice", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Closing bid price", "documentation": "Closing bid price." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r640" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r640" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://protagenic.com/role/CollaborativeAgreements" ], "lang": { "en-us": { "role": { "label": "COLLABORATIVE AGREEMENTS", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r95", "r97", "r106" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r333" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r69", "r218", "r219", "r526", "r729", "r731" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://protagenic.com/role/Cover", "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r563", "r564", "r565", "r567", "r568", "r569", "r570", "r704", "r705", "r708", "r773", "r797", "r800" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r51" ] }, "PTIX_CommonStockPurchaseWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "CommonStockPurchaseWarrantMember", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Warrant [Member]", "documentation": "Common Stock Purchase Warrant [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r51", "r463" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r51" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r51", "r463", "r482", "r800", "r801" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $.0001 par value, 100,000,000 shares authorized, 7,241,443 and 4,435,132 shares issued and outstanding at December 31, 2024, and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r51", "r405", "r561" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r645" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r644" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r646" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r643" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r72", "r78" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL COMPREHENSIVE LOSS", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r16", "r122", "r124", "r129", "r396", "r415", "r416" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "COMPREHENSIVE LOSS" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r41", "r99" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r36", "r531" ] }, "PTIX_ConsultingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ConsultingAgreementMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consulting Agreement [Member]", "documentation": "Consulting Agreement [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r595", "r679" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r595", "r679" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r597", "r681" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r598", "r682" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r597", "r681" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r590", "r674" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r591", "r675" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r591", "r675" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r589", "r673" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r592", "r676" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r594", "r678" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r594", "r678" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r595", "r679" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r596", "r680" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r593", "r677" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Monthly payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r13", "r40" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets, gross", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r312" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r767" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "calculation": { "http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "U.S. net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": [ "r769" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Stock compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r769" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r313" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows", "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r28" ] }, "PTIX_DisclosureLiquidityAndGoingConcernAbstract": { "xbrltype": "stringItemType", "nsuri": "http://protagenic.com/20241231", "localname": "DisclosureLiquidityAndGoingConcernAbstract", "lang": { "en-us": { "role": { "label": "Liquidity And Going Concern" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r587" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r585", "r587", "r609" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r585", "r587", "r609", "r649" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r586" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r574" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r587" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r587" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r634" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r577" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r130", "r149", "r150", "r151", "r152", "r153", "r154", "r159", "r161", "r164", "r165", "r166", "r169", "r329", "r332", "r346", "r347", "r397", "r417", "r532" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r130", "r149", "r150", "r151", "r152", "r153", "r154", "r161", "r164", "r165", "r166", "r169", "r329", "r332", "r346", "r347", "r397", "r417", "r532" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Net (Loss) per Common Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r23", "r24", "r168" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r782" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income tax provision", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r301", "r554" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Income taxes at Federal statutory rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r141", "r301", "r320", "r554" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r306", "r554", "r701", "r764" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Foreign tax rate differential", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r302", "r305", "r554", "r701", "r764" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationLineItems", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r301", "r302", "r554" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r554", "r701", "r764", "r765" ] }, "PTIX_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent": { "xbrltype": "percentItemType", "nsuri": "http://protagenic.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent", "calculation": { "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Perm difference", "documentation": "Effective income tax rate reconciliation permanent difference percent." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "State income taxes, net of Federal income tax effect", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r304", "r554", "r701", "r764" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTable", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Table]", "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation." } } }, "auth_ref": [ "r301", "r302", "r554" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average period for unamortized stock compensation (in years)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r292" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unamortized stock option expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r761" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://protagenic.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "PTIX_EmployeesAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "EmployeesAndConsultantsMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employees and Consultants [Member]", "documentation": "Employees And Consultants [Member]" } } }, "auth_ref": [] }, "PTIX_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "EmployeesMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employees [Member]", "documentation": "Employees [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r580" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r576" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r576" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r687" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r576" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r683" ] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r609" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r576" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r576" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r576" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r576" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r685" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/Cover", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails", "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative", "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r108", "r125", "r126", "r127", "r144", "r145", "r146", "r148", "r153", "r155", "r157", "r171", "r201", "r202", "r214", "r251", "r318", "r319", "r326", "r327", "r328", "r330", "r331", "r332", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r365", "r366", "r367", "r368", "r369", "r370", "r372", "r373", "r375", "r414", "r423", "r424", "r425", "r440", "r507" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r642" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r602", "r613", "r627", "r653" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r599", "r610", "r624", "r650" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r648" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r349", "r350", "r357", "r555" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r349", "r350", "r357", "r555" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r233", "r253", "r254", "r255", "r256", "r257", "r258", "r348", "r350", "r351", "r352", "r353", "r356", "r357", "r359", "r387", "r388", "r389", "r545", "r546", "r548", "r549", "r550", "r555", "r557" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r349", "r350", "r351", "r353", "r555", "r777", "r780" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r233", "r253", "r258", "r350", "r357", "r387", "r548", "r549", "r550", "r555" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r233", "r253", "r258", "r350", "r351", "r357", "r388", "r545", "r546", "r548", "r549", "r550", "r555" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r233", "r253", "r254", "r255", "r256", "r257", "r258", "r350", "r351", "r352", "r353", "r357", "r389", "r545", "r546", "r548", "r549", "r550", "r555", "r557" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "auth_ref": [ "r349", "r350", "r351", "r353", "r555", "r777", "r780" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r233", "r253", "r254", "r255", "r256", "r257", "r258", "r348", "r350", "r351", "r352", "r353", "r356", "r357", "r359", "r387", "r388", "r389", "r545", "r546", "r548", "r549", "r550", "r555", "r557" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r555", "r774", "r775", "r776", "r777", "r778", "r780" ] }, "PTIX_FederalMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "FederalMember", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Federal [Member]", "documentation": "Federal [Member]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r394", "r395", "r529" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r205", "r210", "r211", "r212", "r213", "r394", "r529", "r544" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r529" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Translation", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r361" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r606", "r617", "r631", "r657" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r606", "r617", "r631", "r657" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r606", "r617", "r631", "r657" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r606", "r617", "r631", "r657" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r606", "r617", "r631", "r657" ] }, "PTIX_GainOnSettlementOfAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "GainOnSettlementOfAccountsPayableAndAccruedLiabilities", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative", "http://protagenic.com/role/StatementsOfCashFlows", "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Gain on settlement of accounts payable and accrued liabilities with Related parties", "negatedLabel": "Gain on settlement of accounts payable and accrued liabilities\u00a0\u00a0 with related parties", "verboseLabel": "Gain on settlement of accounts payable and accrued liabilities with related parties", "documentation": "Gain on settlement of accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r60", "r487" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r60" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r585", "r587", "r609" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://protagenic.com/role/ScheduleOfLossBeforeIncomeTaxDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfLossBeforeIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r140", "r300" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://protagenic.com/role/ScheduleOfLossBeforeIncomeTaxDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://protagenic.com/role/ScheduleOfLossBeforeIncomeTaxDetails", "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "LOSS BEFORE TAX", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r58", "r85", "r89", "r398", "r412", "r534", "r538", "r710", "r712", "r713", "r714", "r715" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://protagenic.com/role/ScheduleOfLossBeforeIncomeTaxDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfLossBeforeIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r140", "r300" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r215", "r216", "r217", "r354", "r355", "r358", "r420", "r422", "r492", "r529", "r556", "r796" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r216", "r217", "r354", "r355", "r358", "r420", "r422", "r492", "r529", "r556", "r796" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r135", "r301", "r302", "r310", "r316", "r554", "r768" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r135", "r301", "r302", "r310", "r316", "r554", "r768" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://protagenic.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "INCOME TAXES", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r141", "r298", "r301", "r307", "r308", "r309", "r311", "r314", "r321", "r323", "r324", "r325", "r436", "r554" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative", "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "INCOME TAX EXPENSE", "verboseLabel": "Income tax expenses", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r92", "r104", "r156", "r157", "r170", "r183", "r191", "r299", "r301", "r322", "r418", "r554" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research and development investment tax credits", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r554", "r764", "r766" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r19", "r135", "r315", "r316" ] }, "PTIX_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses \u2013 related party", "documentation": "Accounts payable and accrued expenses related party." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "PTIX_IncreaseDecreaseInValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "IncreaseDecreaseInValuationAllowance", "crdr": "debit", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net change in valuation allowance", "documentation": "Net change in valuation allowance." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r606", "r617", "r631", "r648", "r657", "r661", "r669" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r667" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r588", "r672" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r588", "r672" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r588", "r672" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r182", "r697" ] }, "PTIX_InterestOnAmountsOwedUnderLicenseAgreementRate": { "xbrltype": "percentItemType", "nsuri": "http://protagenic.com/20241231", "localname": "InterestOnAmountsOwedUnderLicenseAgreementRate", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest on amounts owed under license agreement, rate", "documentation": "The interest rate charged per annum on any amounts owed under the license agreement and amendment." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest expense", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r131", "r133", "r134" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r170", "r181", "r191", "r538", "r696" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "label": "Marketable securities, fair value disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r774", "r775", "r779" ] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Share based compensation expense", "label": "Issuance of Stock and Warrants for Services or Claims", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r5" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r13", "r43", "r44", "r45", "r46", "r47", "r48", "r49", "r139", "r200", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r335", "r336", "r337", "r360", "r462", "r533", "r573", "r732", "r786", "r787" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r56", "r83", "r408", "r561", "r699", "r718", "r781" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT LIABILITIES", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r45", "r111", "r139", "r200", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r335", "r336", "r337", "r360", "r561", "r732", "r786", "r787" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r35", "r297", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r763" ] }, "PTIX_LiquidityAndGoingConcernDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://protagenic.com/20241231", "localname": "LiquidityAndGoingConcernDisclosureTextBlock", "presentation": [ "http://protagenic.com/role/LiquidityAndGoingConcern" ], "lang": { "en-us": { "role": { "label": "LIQUIDITY AND GOING CONCERN", "documentation": "Liquidity And Going Concern Disclosure [Text Block]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "PTIX_LossesIncurredAfter2017Member": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "LossesIncurredAfter2017Member", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Losses Incurred After 2017 [Member]", "documentation": "Losses Incurred After 2017 [Member]" } } }, "auth_ref": [] }, "PTIX_LossesIncurredPriorTo2018Member": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "LossesIncurredPriorTo2018Member", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Losses Incurred Prior To 2018 [Member]", "documentation": "Losses Incurred Prior To 2018 [Member]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Marketable securities", "label": "Marketable Securities [Default Label]", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r84", "r692" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasicDetails" ], "lang": { "en-us": { "role": { "label": "Marketable securities", "verboseLabel": "Marketable securities, current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r692" ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Marketable Securities", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r39" ] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrealized gain on marketable securities", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r61" ] }, "cyd_MaterialCybersecurityIncidentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentAbstract", "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Abstract]" } } }, "auth_ref": [ "r620", "r621" ] }, "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]" } } }, "auth_ref": [ "r620", "r622" ] }, "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]" } } }, "auth_ref": [ "r620", "r623" ] }, "cyd_MaterialCybersecurityIncidentNatureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentNatureTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Nature [Text Block]" } } }, "auth_ref": [ "r620", "r623" ] }, "cyd_MaterialCybersecurityIncidentScopeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentScopeTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Scope [Text Block]" } } }, "auth_ref": [ "r620", "r623" ] }, "cyd_MaterialCybersecurityIncidentTimingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentTimingTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Timing [Text Block]" } } }, "auth_ref": [ "r620", "r623" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r260", "r294", "r353", "r392", "r419", "r421", "r429", "r453", "r454", "r515", "r516", "r517", "r518", "r519", "r527", "r528", "r543", "r547", "r551", "r557", "r558", "r559", "r560", "r562", "r734", "r788", "r789", "r790", "r791", "r792", "r793" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r640" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r640" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r260", "r294", "r353", "r392", "r419", "r421", "r429", "r453", "r454", "r515", "r516", "r517", "r518", "r519", "r527", "r528", "r543", "r547", "r551", "r557", "r558", "r559", "r562", "r734", "r788", "r789", "r790", "r791", "r792", "r793" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r660" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r668" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r641" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://protagenic.com/role/OrganizationAndNatureOfBusiness" ], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND NATURE OF BUSINESS", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r94", "r105" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r132" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET CASH PROVIDED BY INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r132" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r64", "r65", "r66" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows", "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity", "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS", "label": "Net loss", "verboseLabel": "Net Loss", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r59", "r66", "r86", "r109", "r121", "r123", "r127", "r139", "r147", "r149", "r150", "r151", "r152", "r153", "r156", "r157", "r163", "r200", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r329", "r332", "r347", "r360", "r413", "r484", "r505", "r506", "r571", "r732" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "PTIX_NoInsiderTradingFlag": { "xbrltype": "booleanItemType", "nsuri": "http://protagenic.com/20241231", "localname": "NoInsiderTradingFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "No Insider Trading Flag", "documentation": "No Insider Trading Flag" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "PTIX_NonEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "NonEmployeesMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non-Employees [Member]", "documentation": "Non-Employees [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r640" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r638" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r637" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r668" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r668" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL OTHER INCOME", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r62" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "OTHER INCOME" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrelatedPartyMember", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r702", "r703" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://protagenic.com/role/SegmentReportingDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r539", "r711" ] }, "PTIX_OfficersBoardOfDirectorsAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "OfficersBoardOfDirectorsAndConsultantsMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Officers, Board of Directors and Consultants [Member]", "documentation": "Officers, Board of Directors and Consultants [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": [ "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expenses related to services", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL OPERATING AND ADMINISTRATIVE EXPENSES", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "OPERATING AND ADMINISTRATIVE EXPENSES" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "LOSS FROM OPERATIONS", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r89", "r534", "r710", "r712", "r713", "r714", "r715" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r317" ] }, "PTIX_OperatingLossCarryforwardsExpirationDescription": { "xbrltype": "stringItemType", "nsuri": "http://protagenic.com/20241231", "localname": "OperatingLossCarryforwardsExpirationDescription", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carry forwards expiration description", "documentation": "Operating loss carryforwards expiration description." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r44" ] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitment", "crdr": "credit", "presentation": [ "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Commitment agreement, value", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation gain", "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r2", "r57", "r362", "r363", "r364" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Foreign exchange translation income (loss)", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r2", "r414" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Loss - net of tax" } } }, "auth_ref": [] }, "PTIX_OtherComprehensiveIncomeLossNetUnrealizedLossOnMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "OtherComprehensiveIncomeLossNetUnrealizedLossOnMarketableSecurities", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net unrealized gain (loss) on marketable securities", "documentation": "Other comprehensive income loss net unrealized loss on marketable securities." } } }, "auth_ref": [] }, "PTIX_OtherComprehensiveIncomeLossReclassicationOfRealizedLossesOnDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "OtherComprehensiveIncomeLossReclassicationOfRealizedLossesOnDebtSecurities", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Reclassification of realized losses on debt securities", "documentation": "Other Comprehensive Income Loss Reclassication of Realized Losses on Debt Securities." } } }, "auth_ref": [] }, "PTIX_OtherComprehensiveIncomeReclassificationOfRealizedLossesOnDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "OtherComprehensiveIncomeReclassificationOfRealizedLossesOnDebtSecurities", "crdr": "credit", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Reclassification of realized losses on debt securities", "documentation": "Other Comprehensive Income Reclassification of Realized Losses on Debt Securities." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Unrealized gain on marketable securities", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r119", "r120", "r199" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r82", "r401", "r458", "r459", "r573", "r795", "r798" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r44", "r561" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r640" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r587" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r604", "r615", "r629", "r655" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": [ "r607", "r618", "r632", "r658" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r607", "r618", "r632", "r658" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r636" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows", "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of marketable securities", "label": "Purchase of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r717" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of fixed assets", "label": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r91", "r770", "r771", "r772" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r639" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r639" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r638" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r641" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r637" ] }, "PTIX_PercentageOfCorporationsTaxableIncome": { "xbrltype": "percentItemType", "nsuri": "http://protagenic.com/20241231", "localname": "PercentageOfCorporationsTaxableIncome", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of corporations taxable income", "documentation": "Percentage Of Corporations Taxable Income." } } }, "auth_ref": [] }, "PTIX_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Placement Agent Warrants [Member]", "documentation": "Placement Agent Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r638" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r581" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r583" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r563", "r564", "r567", "r568", "r569", "r570", "r797", "r800" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r50", "r237" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r50", "r463" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r50", "r237" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r50", "r463", "r482", "r800", "r801" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r50", "r404", "r561" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r117", "r203", "r204", "r530" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of shares and warrants from offering, net of offering costs", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows", "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equipment - net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r374", "r399", "r411", "r561" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r100", "r103", "r410" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r636" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r636" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r252", "r260", "r287", "r288", "r289", "r294", "r353", "r390", "r391", "r392", "r419", "r421", "r429", "r453", "r454", "r515", "r516", "r517", "r518", "r519", "r527", "r528", "r543", "r547", "r551", "r557", "r558", "r559", "r560", "r562", "r565", "r730", "r734", "r777", "r789", "r790", "r791", "r792", "r793" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "auth_ref": [ "r220", "r221", "r222", "r223", "r252", "r260", "r287", "r288", "r289", "r294", "r353", "r390", "r391", "r392", "r419", "r421", "r429", "r453", "r454", "r515", "r516", "r517", "r518", "r519", "r527", "r528", "r543", "r547", "r551", "r557", "r558", "r559", "r560", "r562", "r565", "r730", "r734", "r777", "r789", "r790", "r791", "r792", "r793" ] }, "PTIX_RealizedGainLossOnMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "RealizedGainLossOnMarketableSecurities", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized loss on marketable securities", "documentation": "Realized gain loss on marketable securities.", "label": "RealizedGainLossOnMarketableSecurities" } } }, "auth_ref": [] }, "PTIX_RealizedGainLossOnSaleOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "RealizedGainLossOnSaleOfMarketableSecurities", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Realized (gain) loss on sale of marketable securities", "documentation": "Realized gain loss on sale of marketable securities." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r599", "r610", "r624", "r650" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r198", "r259", "r379", "r380", "r402", "r409", "r457", "r458", "r459", "r460", "r461", "r481", "r483", "r514" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r142", "r143", "r379", "r380", "r381", "r382", "r402", "r409", "r457", "r458", "r459", "r460", "r461", "r481", "r483", "r514" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r198", "r488", "r489", "r492" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r198", "r259", "r379", "r380", "r402", "r409", "r457", "r458", "r459", "r460", "r461", "r481", "r483", "r514", "r785" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://protagenic.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r376", "r377", "r378", "r380", "r383", "r437", "r438", "r439", "r490", "r491", "r492", "r511", "r513" ] }, "PTIX_ResearchAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ResearchAgreementsMember", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research Agreements [Member]", "documentation": "Research Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and development", "verboseLabel": "Research and development expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r296", "r529", "r538", "r794" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r295" ] }, "PTIX_ResearchAndDevelopmentRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ResearchAndDevelopmentRelatedParty", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and development \u2013 related party", "documentation": "Research and development related party." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r600", "r611", "r625", "r651" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r601", "r612", "r626", "r652" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r608", "r619", "r633", "r659" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r53", "r71", "r407", "r426", "r428", "r435", "r464", "r561" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r108", "r144", "r145", "r146", "r148", "r153", "r155", "r157", "r201", "r202", "r214", "r318", "r319", "r326", "r327", "r328", "r330", "r331", "r332", "r338", "r340", "r341", "r343", "r345", "r372", "r373", "r423", "r425", "r440", "r800" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sales revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r87", "r88", "r128", "r139", "r170", "r179", "r180", "r187", "r191", "r194", "r196", "r197", "r200", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r360", "r398", "r538", "r732" ] }, "PTIX_RoyaltyPaymentOnBehalfOfSublicenseePercentage": { "xbrltype": "percentItemType", "nsuri": "http://protagenic.com/20241231", "localname": "RoyaltyPaymentOnBehalfOfSublicenseePercentage", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty payment on behalf of sublicensee percentage", "documentation": "The percentage of royalty payment of net sales made on behalf of a sub-licensee." } } }, "auth_ref": [] }, "PTIX_RoyaltyPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://protagenic.com/20241231", "localname": "RoyaltyPaymentPercentage", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty payment, percentage", "documentation": "The percentage of royalty payment of net sales." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r668" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r668" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase of shares", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "auth_ref": [ "r158", "r261", "r689", "r707" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://protagenic.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r23" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r23" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r333" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://protagenic.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r767" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://protagenic.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r303", "r554", "r764" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIC", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r774", "r775" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r205", "r210", "r211", "r212", "r213", "r394", "r529", "r544" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://protagenic.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF LOSS BEFORE INCOME TAX", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r700" ] }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": [ "http://protagenic.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares." } } }, "auth_ref": [ "r77" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r37", "r38", "r488", "r489", "r492" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://protagenic.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r11", "r12", "r73" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://protagenic.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r80" ] }, "PTIX_ScheduleOfShareBasedPaymentAwardWarrantssValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ScheduleOfShareBasedPaymentAwardWarrantssValuationAssumptionsTableTextBlock", "presentation": [ "http://protagenic.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS", "documentation": "Schedule of Share-Based Payment Award, Warrants, Valuation Assumptions [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://protagenic.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF WARRANT", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r30" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r575" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r579" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r578" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r584" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://protagenic.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "label": "SEGMENT REPORTING", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r90", "r170", "r174", "r175", "r176", "r177", "r178", "r184", "r185", "r186", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r535", "r536", "r537", "r538", "r540", "r541", "r542" ] }, "PTIX_SeriesACommonStockPurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "SeriesACommonStockPurchaseWarrantsMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Common Stock Purchase Warrants [Member]", "documentation": "Series A Common Stock Purchase Warrants [Member]" } } }, "auth_ref": [] }, "PTIX_SeriesACommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "SeriesACommonStockWarrantsMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Common Stock Warrants [Member]", "documentation": "Series A Common Stock Warrants [Member]" } } }, "auth_ref": [] }, "PTIX_SeriesBCommonStockPurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "SeriesBCommonStockPurchaseWarrantsMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Common Stock Purchase Warrants [Member]", "documentation": "Series B Common Stock Purchase Warrants [Member]" } } }, "auth_ref": [] }, "PTIX_SeriesBCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "SeriesBCommonStockWarrantsMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Common Stock Warrants [Member]", "documentation": "Series B Common Stock Warrants [Member]" } } }, "auth_ref": [] }, "PTIX_SeriesBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "SeriesBConvertiblePreferredStockMember", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock [Member]", "documentation": "Series B Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options vest period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r552" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r288" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "label": "Number of Warrants Outstanding, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r10" ] }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price, Exercised", "documentation": "Number of warrants outstanding, weighted average exercise price, expired", "label": "Number of warrants outstanding, weighted average exercise price, expired [Default Label]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Warrants Outstanding, Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r76" ] }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price, Expired", "documentation": "Number of warrants outstanding, weighted average exercise price, expired.", "label": "Number of warrants outstanding, weighted average exercise price, expired" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "label": "Number of Warrants Outstanding, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r9" ] }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.", "label": "Number of Warrants Outstanding, Weighted Average Exercise Price, Granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Warrants Outstanding, Beginning", "periodEndLabel": "Number of Warrants Outstanding, Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r74", "r75" ] }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Outstanding", "periodEndLabel": "Weighted Average Exercise Price, Outstanding", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.", "label": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan" } } }, "auth_ref": [] }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Remaining Life", "documentation": "Share based payment award non option equity instruments outstanding weighted average remaining contractual term.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" } } }, "auth_ref": [] }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted": { "xbrltype": "durationItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "label": "Number of Warrants Outstanding, Weighted Average Remaining Life, Granted", "documentation": "Share based compensation arrangement by share based payment award non options equity outstanding weighted average remaining contractual term granted." } } }, "auth_ref": [] }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitySharesIssued", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issuable under warrants", "documentation": "Shares issuable under warrants." } } }, "auth_ref": [] }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingWeightedAverageExercisePrice", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant exercise price", "documentation": "Class of warrant or right, outstanding, weighted average exercise price." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of additional shares granted", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Stock Options Outstanding, Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r275" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails", "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of Stock Options Outstanding, Granted", "verboseLabel": "Nonvested Options, Granted", "terseLabel": "Options to purchase common stock", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r272" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r282" ] }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://protagenic.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding", "documentation": "Share based compensation arrangement by share based payment award options outstanding." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based compensation intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Stock Options Outstanding, Beginning", "periodEndLabel": "Number of Stock Options Outstanding, Ending", "verboseLabel": "Number of options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r268", "r269" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Beginning", "periodEndLabel": "Weighted Average Exercise Price, Ending", "label": "Share based compensation weighted average exercise price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r268", "r269" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of options issued", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r273" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r275" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Granted", "verboseLabel": "Options exercise price", "terseLabel": "Exercise price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r272" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "PTIX_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of warrant or right, outstanding, intrinsic value", "documentation": "Class of warrant or right, outstanding, intrinsic value." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options expire period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r553" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected life in years", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r286" ] }, "PTIX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://protagenic.com/20241231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Life, Granted", "documentation": "Share based Compensation Arrangement by Share based Payment Award Options Granted Weighted Average Remaining Contractual Term 2" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested Options, Balance", "periodEndLabel": "Nonvested Options, Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "label": "Nonvested Options, Forfeited", "documentation": "Number of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Forfeited", "documentation": "Weighted average grant-date fair value of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted-Average Exercise Price, Balance", "periodEndLabel": "Weighted-Average Exercise Price, Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Life", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r79" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Nonvested Options, Vested", "label": "Options vested shares", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Vested", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options exercise price", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": [ "r32" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r67", "r137" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r582" ] }, "PTIX_StateAndLocalMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "StateAndLocalMember", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "State and Local [Member]", "documentation": "State And Local [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r107", "r113", "r114", "r115", "r139", "r161", "r162", "r164", "r166", "r172", "r173", "r200", "r224", "r226", "r227", "r228", "r231", "r232", "r237", "r238", "r240", "r243", "r249", "r360", "r431", "r432", "r433", "r434", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r452", "r463", "r485", "r507", "r520", "r521", "r522", "r523", "r524", "r688", "r698", "r709" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/Cover", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails", "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative", "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r51", "r54", "r55", "r108", "r125", "r126", "r127", "r144", "r145", "r146", "r148", "r153", "r155", "r157", "r171", "r201", "r202", "r214", "r251", "r318", "r319", "r326", "r327", "r328", "r330", "r331", "r332", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r365", "r366", "r367", "r368", "r369", "r370", "r372", "r373", "r375", "r414", "r423", "r424", "r425", "r440", "r507" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/Cover", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r144", "r145", "r146", "r171", "r373", "r393", "r430", "r452", "r455", "r457", "r458", "r459", "r460", "r461", "r463", "r466", "r467", "r468", "r469", "r470", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r481", "r483", "r486", "r487", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r507", "r566" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://protagenic.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r158", "r261", "r689", "r690", "r707" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/Cover", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r144", "r145", "r146", "r171", "r198", "r373", "r393", "r430", "r452", "r455", "r457", "r458", "r459", "r460", "r461", "r463", "r466", "r467", "r468", "r469", "r470", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r481", "r483", "r486", "r487", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r507", "r566" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r603", "r614", "r628", "r654" ] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Shares issued for conversion of notes and interest", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r20", "r21", "r22" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of notes and interest, shares", "verboseLabel": "Shares conversion", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r8", "r29", "r51", "r54", "r71", "r234" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock issued for cash, shares", "verboseLabel": "Number of shares issued for cash", "terseLabel": "Common stock issued, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r50", "r51", "r71", "r431", "r507", "r521" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock and warrants issued at offering, shares", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Rounding from reverse split, shares", "verboseLabel": "Rounding of shares related to a reverse stock split", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Stock Options Outstanding, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r50", "r51", "r71", "r273" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Conversion of notes and interest", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r8", "r51", "r54", "r55", "r71" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock issued for cash", "verboseLabel": "Common stock issued, value", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r50", "r51", "r71", "r440", "r507", "r521", "r572" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock and warrants issued at offering", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "PTIX_StockIssuedDuringPeriodValueReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "crdr": "debit", "presentation": [ "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Rounding from reverse split", "documentation": "Stock issued during period value reverse stock splits." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://protagenic.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/StatementsOfChangeInStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r51", "r54", "r55", "r68", "r465", "r482", "r508", "r509", "r561", "r573", "r699", "r718", "r781", "r800" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://protagenic.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "STOCKHOLDERS\u2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r70", "r138", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r251", "r344", "r510", "r512", "r525" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r371", "r385" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r371", "r385" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r371", "r385" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r371", "r385" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r371", "r385" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://protagenic.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r384", "r386" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r647" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r716", "r784" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r639" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r646" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r670" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r671" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r671" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r669" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r669" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r670" ] }, "PTIX_TwoThousandSixEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "TwoThousandSixEquityIncentivePlanMember", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2006 Equity Incentive Plan [Member]", "documentation": "2006 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "PTIX_TwoThousandSixteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "TwoThousandSixteenEquityIncentivePlanMember", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2016 Equity Incentive Plan [Member]", "documentation": "2016 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "PTIX_TwoThousandSixteenPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20241231", "localname": "TwoThousandSixteenPlanMember", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2016 Plan [Member]", "documentation": "2016 Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r333" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r666" ] }, "PTIX_UnrealizedGainOrLossOnMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://protagenic.com/20241231", "localname": "UnrealizedGainOrLossOnMarketableSecurities", "crdr": "credit", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Unrealized gain or loss on marketable securities", "documentation": "Unrealized gain or loss on marketable securities" } } }, "auth_ref": [] }, "PTIX_UpFrontSubLicenseFeesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://protagenic.com/20241231", "localname": "UpFrontSubLicenseFeesPercentage", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Up-front sub-license fees, percentage", "documentation": "Up front sub license fees percentage." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r25", "r26", "r27", "r96", "r98", "r101", "r102" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://protagenic.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardWarrantsValuationAssumptionsDetails", "http://protagenic.com/role/StockholdersEquityDetailsNarrative", "http://protagenic.com/role/SummaryOfWarrantDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r563", "r564", "r567", "r568", "r569", "r570" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://protagenic.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r776", "r777", "r778" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares - Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r160", "r166" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares - Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r159", "r166" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r686" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(10)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 6-K", "Section": "General Instruction", "Subsection": "B" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "Instruction", "Paragraph": "2" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "a" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r688": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r690": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 71 0001641172-25-001600-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001641172-25-001600-xbrl.zip M4$L#!!0 ( ,MP?UIW4.YSP#, -:F 0 * 97@Q.2TQ+FAT;>U]ZW/; M1K;G=U;Q?\!F[TQ)593\F$EFQO9UE2PIB;9B6VLI,YN/3:!)=@RB$30@FO>O MW_/H;C1(4!(42A9E3-6]CDBBT:_S/N=WWOQ\^?Z7M\/!FY]/CT[@WPC_]^;R M[/*7T[=OGO&_\.TS^_6;=Q]/?HLN+G_[Y?2_OYOHK'P5O7B>E]&EFDL3?9"+ MZ).>BVS$'XRB"UFHR7?P(#QZWO6YU]%<%%.5O8KPI\^_>_OFQX\?+L-1#B9B MKM+EJYO&H=\:]3^27_O=V[]F8Y._?O,,!X1UGF]GAJ^C4GXI#T2JIO!1H::S MF7F1JKO7N[[24\^":/=9ITFV9SEV.9E;+8WK3M M!U>B4 +G9^8B30]BD9OOWKX_??_QT]&'DU_?W[ H5<+LXOM;VZVW[9:'<.?Y MKM]Z/V?WJLNC=[^<1L>GO_QR?G1REGK^BFWWYJ3MU7,FB5+%(W?I@>.1G;RY/NH_E M5J>R+;.%RX^O&LS@\N3MG288'N3OE2G59+GEF9X7NA13F:G8RII;_N]R)@N1 MRPK. EYPEL6'T8DJ9%SJ O[^.)FH6!8F$ED2G<[S5"^E-&M;\NSRT]>^!+0) MCB;?;?VHUL?&-7?;ZJW\[^MO\S9O[8^?/KZ_3PI[]_8G4>CHJ)A+>.)\=GAR M.(I.O\@8[ON5C(YG0A4P6'^J/?'L'O&<'%V>WB_QO!?+;J?T\H=1]/+YRQ?] M2?<$]5#;_,D1P;;W^"PS*I%%1WVJ$(G*IM&Y!L5_^50/:*P+V!EO [Q+1?PY M>@$C&UAVXBR,+F94\_"V-?Z&PPU?^K4.YAG9;_?A'[D' ^,AW#KW,.W3+$ZU MDBW6:@ED%:F>Z' T'S?<G-)>G%0L3!2++"JDJ=(2 M!S P506&L\C**%97*J4K 2^8JTRD4:K$6*6J7!Y&1W$,G Z&H3N1IU(8&97B MLZ17E3!Q8+XPLDCH@[DH81$B-5%>Z"N81C*BH>$[?BO]5FK[O8[NZK)$6_57%0-1&Y@0NZ_OB.5=)O*.QL#=_>M?_^7;6[Y M"0BR5Z';8FV"V[, [ +^_O>MKF#ETK0MP;[XY5\:!L>?/XI_;G4A%W!+!"@, M?_(\W"Z_^$N[>?4([O(#'_\CF]96[N!7F&M_@Q[+M![=#?H@YG^*:_6]VHK2F]A7Z;=D>;Y[!3K1LRAA,ML\'8SG1H'=%.>UD MF&;S TWOO+F'=!KAX39&#T[F&1X-G\8N9JX]1@].F%ZS[O+=4;?4K7UJ]Y'& MMMVT0E,N4_@DT\5//Y^].[L$CA&=?;@X.SG]%%U^ M.D*.\I3/Z_'Y6"YGR@P'=PZZZ,GU,9?1;8(NT8TQ%_3!LV/=1-,*_DE5QBXT MD:914N?%Z3 O3KJ\.!,- 8G"3\T53R[82V' MP-?+2"'G*666,%>3&6T$!2N0=_K7.8;6"$K@+T2>P\!B#+.@D"I',J>5"[_& M&JR,(L/U!FNQ6S#"X>8Z2X%G?L[T8H6?KL1L V9ZZ(,?;C/QO:;48)"4*L]I M;(YZQ!5L3!*-9:H7\!FLSD=T01S @B5)G]^9*0\'1H)1$?R(8L 4#8:E&&LV MFLEA7H'.Y8==W$;8:IZ9@[S)1+".6 M%X&=X!$&M53E*, M.'^<5GS+9($SHS.,CG*0?&"APE$#Y233.2@PD9G1Z\W?B:'T04(* Q[1K!60ZO9K'+UZI-LAW/E)R Z9.) M+,9+:G/6;Q)2VU!F'Y3EWU/5SU=>U46LWL9 M:([#P1&P,:*T-\_.WNZD7L&KRHXMH:!G$%FL;)*^*>":,U>*-2-<$?IO& M/UZNBXY1( E8>++8 ^,F9XD+$GXX"+_BM +4*>!]18/E!PK'7"Q!&S"5C":% MGOLD)OR71.E"HK1']:=05X+J,(*1"HF"$,5#*[='L>I_NYA)F@A(CTR7_-)D M5?:Q"@/ODU]@Y[*I/$#Y!+^SRSR,+@-!)%*CPSV/6T##(O)[C/$_KU%V7HA$0,VDE6#@=C 3^+47N$ M 6#JNBJ;2N;*2]??.M9%H1<1W#0)9S!%M1KTQ@CWS+TF4GS-4RTR7F2=<">B M5/T!]CKI,B1,T-8FK2)--TTELM-FW\%>LC:IO) '.5QF.P]ZL9V$_8J4I-6Y M\+Z[B=!3H%K%4B9FTU$>3D#>S1X-=W'M8'AOL@8C\DP(^7?MJV>)U&0[HU6N.%V<5?8U\W"W' M;C9)JUL$=%Z^CCXRCWR%+[M@RG@=_5NDU;<7[VD+/#9B0.%6NDU\'5TNOT5F:1@2*^LRKLCA[#49JV M",ZYR+6Q"SL\P MML+AC$!Q"IU_UL%'VW=H]R\Z,E%EO.^50T/H#PN>XTL4;+HUF$C]6D;Q3*7) M".R14N;\W[ 'L![[WSE,/2O!^H"OW7_3]_Z+'))J*:S,OCQN&@^C*GCH,,'G]2F MH$C0+H(+SH88L*.9RO&DP P @L.=YEQP&-&088(LBVAB.)AK]OEFT41-RJ4S M6YR%RL81.>G05PP:7XD#3T"]9]5]T^A[UHEMCW(_(KM'I[8H)@,1-;?O$<;( MTF#N>L-6A6]5N;SU^.A!OF$Q5[IDWSLOQ.Q:4.R&Z-+.QIIO6-=%"1P(+TO# MY[ASJ]Q9$7M64C$F&='6]]^,5Z$+(<^U=7Q4F:A #A4P0K(28<,?WV26QG]4 MJJBK^A:Z^)R#\2%M" VYAS*5D3[4I8*GFV$U%]78N1W?T8OB'=2XZT"LV0V' MW>O*#SOM#[K.YS$S]+/);(JV(OK D([KT )\=*73*U(OO!.+M!"1RENXKZ\/ M80\'3GM.X&N*X"ZMBY0^^BU!%72EBLX&O6'D.VOS@>' TV'M5F:L M5I7T )6C-WQWP?PVL%1P= 90L&P #?6#*3 M&"^9K]C1T+.NB&&CT947&F-AXV68J;3.R6^?K>19_2&LS6T)&&ANCRAX54CF M^HE-'((?RB]Y0&>)Y21$S\0>E(D=ZVP" MUR0KX:!5N20#L-@2"B)82-*!DJ5*K,@+L9Z+[Z]J/#?^@#P%@/ +_L M<"_Y;JSTT"5K+>1(FA!_%NXLYM<-1"*=S^L,9 M#E"VGGFY:G96MUQ)L-VQV1/ 5EB P:&$Q*99 FF1TH"'M8KT9R/I7-=Q&/V* M>%MAV<*OAQ>'D0VG^F.FY '*.(VT"\$W7744?%3YJE9'</3KW;N4!Z0:=L/X80D#OK\\/OM-HW84_N$FT:LF>\3F1Y<@%/. M"FE3*IQQ@AX23'C%C.0B FT?%-4KC=B.3V-#GM39VL-U0ACK]Z*]#+.F2] ' MHYE>L.P.#G>_/OW_^CZ"%Z>41 DLYTGLR=,Z7C[?WP70+H4Z_-&]?!XMI2@> M*,OC"1W:O:M4JSZ=BRJ7Q94RN@A3^'96V]K1H_H1:X>$3[W?"^I^,-:JQNF2 MHA F."V.(>RS+C,!&F2O.Q6D!-6IF%%G;'W&%29DK>AIHT"- Y6)M3UE,''K M832CW:1>_O\XUWN_')MT)"3E:2'1"8Q_[HG]Z+]>.)%IRW3&^]V4*%<.9@-4 MS5(3CN/XXNM>*C_"I;0K7;5.]=(K5;UL?HQV]?4V=9L$Y\\PR'TSX@X#3#1R MX9FH@P P4FH#%9=*),H:S'KJB1;''],ECN:UU1Q%]CXO^F*1K?!G"1 TYY4 M:8BIO?X^#)8L&R_%ISD79FG'M;,^C,XF]!F7%L!C'C'!E]:MOX+7GN-D8&!X M'"0?=Q# ]&@1TU,^+6D%+V'2%2_A\5VY':44%XRV8:P6;^T.^P:?0OV][W-) M0=>0.Z$SCK4%V:@WH1)@SSOJ,IE;0+-8AD!%\^R^"W%9D(DRL\-0Z\C!IZ24 MS#+Q!? XH..)GLXSG1T0KU(4UV2EQW"Y= -O!IC)MQ?&_'L?QMQB&/-O?1BS MEVTWA3%/$.],>62$FU*O=DYRW+#\W1>,O(@Z2>LI9,H]B8,AX^OB])B,(S9F M=%4@&JI8KA4'8!);G3SL\OX;=:X3F\U&7?.:F6*?9:IF6B?6^K Y7Q21=+E5 MPP&7$)/?+9$NHRR8P#S7!0Z)RLAJOJ]D['#_7\K3LA]S3Y M-&@2?FFZD:/39^;B=UUXHB.8-@JKQ>A'2FN_48@%Z'[=4UY/>=\ZY=U1&@;R MBU"!9"RP:@4(;UPE4UGV4JVGK6^>MM[+8BH+-.R[D-;O6F5EA,E"58&CYVS@ M6F@KUDMMH*6\Q$ZAKC.D90\\8>L: ZFYG<9M4,0M8C--BA:X'(-_<;:*4\2S3 MJ9XN>ZKKJ>Y;I[I/[*+I1GD;'-1M1?S^2RP/%P4"^6=)E,@KF>J<1*7U![&S MOQO]RSA56,^-N?YLQ:*1ZS]#QW O6GLB_^:)_)CUS:Z^78S0*%TT\%F=.LLN MIKQN!L:OZ*FMI[:>VNY&;51Q+#'AVN+U)2#?1%%[:RWFGLE353J *K)C2?)- M/)2-")NY]1394^2W3I%W].=R2R(,58*I.4[EO">FGIB^>6*ZJWC#W"9KHI&W M!CN"D:3KA51/5SU=O;VH P0=Q12A%)A4E\(FX)/"_W.)7D[Y(I;E8 M8PL:I)J29MF37D]ZWSKIW56DM3E!104:HRZL-S33)=$TV7#4K0FA-/UO* 5[ MI?5JMUG4^.\%ME&RL,CN!796_#>"=.JB3_#I"?Z;)_CWZ+WL1FB$5&+:VT>T MI.CW5-93V;=.97?6:!= 0_) 3R8]&?5D],V3T=G>317IR>QGL0>E,0^ M:#@1V3F33!E3$;X-]L9#]V1;.O0;"SVRE8)=/!_ZKQ<;H!)7$.(.>H@XGO8[ M7XYE$-_)5LSC?XIS7Q=F$:/"C3*BT&Q_C3(8YMP=DV #T1Z-/ MC*"83%Q4I10W[E!-/9YG<'[ MV=E M#XSV4% <*Q.^!KWI^QZ]:8OH37_OT9MZ H1I_Z:KX: &_,#"7]LI%P%/4IE, M;<%24[^&)D(@FV-)#66KC"H] G $1 M1MAVJK0=RX8#%!2,/AJK(J[FB(EC84ZEB&<@M0PU!8'WE%4&@Z7+L"G<'.,S M?LXTH[I'B)\'3:W*4K%@>%$25PEB!*;V/ B@!"&F<)&XIEOTK^PEV --^V@X M<)"U'K&6^H]:;$8')%.YW.=&\SVX_'5'ZG&U--C&+DT-E0%B:U/C.P#:VXTM MMJD0,4#/F*I)R1 _"8QORQ:I6G_IXX0!\(_KF>TZ9B]FDF_^]0M!LB?V<./E M&PYJ!-MCAY1T1HRC1@Q"3M("]CL*W[G6*W:\C*X4$)N#/%)%Y"HUB4Y%'&-1 M)4+V\K8-!ZWP0W@J(Z Z+.QT/7S@U6.$%)$&& J1)K+ =60@%G@$@$2E8Y*8 M1Z,IX\[=XEL1GRH%'O18@ZQX?$OP-W$%I&Z[)]%SO+L_LHDZ,%[$VK63DIRQW+. M,3:N%YEUN$] HP*MQOMU+DZ/1ZCC4!=X.U%.L0(UON3B-,JO$JYJS2D] M!STH#Y(9DDPWHBMA2&)&DKQPQ(:X^;@%8O7@LM9OC%G.8Z.+,;<4N1)IQ;C^ M#6_T8;=9'*VCD(::22N::N;-IBHKL?/<0D=[+_>C2]LCY40LNR*YH7_;,>"Z MB?P]!T:^+KSVSK8*OF%=/U4H@1 ?:#@@>?9)HE.*[J^[(2KS\O7"F_8[N!4[ M:P9=HI\/+(Z"8$ACF2#.U$:W!C$N2YYC#Z2-ZHYD+0 &/.5_=@:^]$].-J)Z)@D9TFA6X?8ODBLV #H-GE MNA %Z&]C810<@50TU[&,167:'$=>970$I5M^#<)$IU>L-M(#PJ'W\=R#7BNA MYWPXN-Y5%JUYREI!47IW[@/V!OCU[65]B2XJ8+V989?ZK[O9*V!'S^)'L,Z& M U+RT+Z$?T>KI2] =L ?YC)+NG)>0^>:^*YT <$'6$.&G5,PBP8TF&OA1+$; M=&8M0;DDB]AJ7JLF,86SR)-,50$C_F\."# ?%LF5,J09DIAGQDYX?]F2O?[< M3 I9+'*BZ_HC7%]HX/S_;@H8 J ,"U94<0)N%4%3>I\X8<'RAP/C*8/>Z:3. M>UU(!%8;^595,#-:57!TJ+3[HT-1%K6.AL;Q4F>2P@9@Q^.TU_EIP_MX2X8: MKI831#949X4-$ZYMH3 8X'7MO=HYH M'Y;7W")OY(<^;V2+>2/?]WDCNTPOV]:3F*T-!_]160(VS#E)$]-K2@\\[3/J M/!O)"6:BK%B2A3*?;>>F-1LQ: I)MJ6.0;2-R,X[O%\_/W!BRA/<7O]8MM69XC(ENI8>M]^(-U0?;R5,\F;#DKG6D=ZHPWR99FP,+8FCP^!YE>HF@?9K3 MY9CG!='N?6L5C.44]7960C5HM>Y26R^TS3,K9ZI(J*?TOA2RF* S1[**D-MD1E%;Z)5%;.CF;% M?VW&[PF*]6\O1M'_J4 A?_$][FQ>ROD81G[Q/0UX(F/W]PAGA3Y+!;;41"# MJ5FXFAAB+J'8-=$4_BP[>V5[Z_,AFWG>UE6.?@(4!X5TF4^)Y/[A-G0 ZE@Y M\TG*37'E/%?! ' ]Y!=9Q.A^HD "QBE!H(C:.6X1?(FYDXJVAO/;R-&Z<0G4 M-QW7P5FGX5K,#%18F5$V*Z]$HH]_=1562B&(#4E8'*CY&Q*'@3"L%=K #4C9 MIJ4.QJ/1_/N\9:/:O6J;%NA/A/)T[[2C(^O1U#0-V"_*-O6=5U'6H\O0MF&E MV36RU'OB?2@W-=8M3 DH#;'D!2CW2^I-FDBXV&I<5RI0O8-5.5LN+/MBV?QJ MMZ ,,G!_D>>P%BK:P+RJ*TN\<"E(#G3D]-&OJR94U,F"TLUX(&H>MK2A3LF^ M*1*6)2TNXV50NX%@QR7KZ;"]9VL^_5AD^)3WG8.$W&2*3TL:PG6WFET6GRSMXS7UP9Q\UC[[U MV(>#EG,_:M$A[JPPC**EKIQK';%8+F)"EP;VK&1?47 M)5P3&'0J*(4A2K'^E@+G-&(&;+BE^(+6)I9\Q\C+):GFUUKP\C#ZT49K@''E MWJ"% <\M5#HIR2"C \,^O'&!68_U<4B"F&M*-R/Q'=8YDUU$%Z*LB@1+2BY@ M36+9]%S1!YES#HCL\TKF!?ZX*D'O :%"%)>*A:U0L[%$V)?"(SM-+Y1Q_BV6*(YX<^Q-/KM3#MTZ8R MYQQ(3OT<684-S$]-7W32]D9^O +8=J'BH/]:JUH,LYAPB^*[.^.O">[S:NQ* M,LF3F>I&*G]#F T'5IH=P@)+M.G0[O(XCWCQIYI2&$"]L7NVJB;7S7$X$X1$ M6C/S8U,D9>)UUQ&9RK4N(IS-RIM.DMUT?,G!HJ^P;RKO+ M JJ F$E3]L7+3@U-9*P,EQK7E@Q#<(C#Z&RRHLM:A9R,)3!+P28--.[/4N9K&5/T,XMF MPW,4E/U%@ &6MTW8Q!5I3P$/10%EB'\![ OD!NGAG)%<9]O_J>0PGW;&D!?K M'DU+=\,!4D^S5B2,/1HQ05NO '43+921J[.EVO!5BT07Z1/ZN3 -NYV[>C1(/9/V=U]L\Y,'*T@9&' MXI7^M,)]+TZ/0Y?AFV=GNYD=!&MV!W:V>[/_%;TMPT%P$*,FOV@X4B-0 P40 MF,'^JXCWHXC(@$03.9$9YP9C1E'*W41L9M&!XYB@?Q=3Z;%%E/6U&8N,@RDZ M39\RBE?Y17%75L1S+O')0%4 ?5%ZR"&9VNME9(G*=HEI%Z ]-+$"!&92F&NY M(J5VUVMM>[%Q^H%[^:IVL7*_:0Y8IT+/TAQ(-<#J1%S'I,*>]&X_]M! 8?06 M9[:8?6+)[+ND'<3'K7%B&>)MO.D4.R.SK)Q1-C>_45)=$/9TP2$:80E.MS?U M2Y$5W_:-JPD#(U('[6:9VDTZ%Z (HKLOTY2#4N@TPHQQ-S]-YA4.M!IGB$J" MQ&$O[F'TLU[(*^=U9M&#GE%2,]L/TN- T",;L MDCL((B0^S,(?11RRQ()86.X#Z4ECJA@ 4978GD M A%_U5 ZQN4Z&^.C#8U]J_/6Z6@+L31;3U1\C+"J M/;A*#VRP383%CHUC6-E9">YW2C]I0)0IA%9!(I=)<[,>!@W@ZR3S]23G WE$GL(,$=&("PE"O-OR7NK&A MYMR]Z1RKRX^']A\B<+R!Z]PBF/S//IB\Q6#R/_I@Q&X\R+PB-LG=)$\ M*.=:_7@^5\WKMAVS##LB8R'^@ZD%81"G6P@0JW][CAE:)DPM(_\G>\FL=6V3 MU6PL%%>QQT6'';N7H/-QH0P,.RULED&WQ>^S5PUG2?8\QXNZS2(,?7JWE?.^ M.4< ^R^#]$-RXO*N*)T]'G6BYZ,]']T9/GKB &JZ46P-Y?71P=H0 ^,&S5SH M$[(I[Z(%ZY^ 1[$W@75=LU=@3HG/77O:"I_#&\3, ^ME@2YG8&C$)L>%_DQM MIG&.86D!Y8>MY1UWF<<&YM@SI9XI]4SI ?P;+O7>Y8[9O##9%D?058F1+>_M M: 8K4#OS^IB-LW;7,Z_)][+U=YF,Z^J[@!6%V6LS<>6!L?C;CHY;ITO=H7 & M]P&3P.J,2I^(V;6/*Z,DUIR6XN4!DV[/KWV-K/T*WIV,HID+K%+,UH>ENUX2 M//3Z\+U*B;<'U58-;Z9H(P+HS@@PDG1%Q6L$-42@$<0^6BE$$LLLM4 MPM4W]=N13\=K+U7AF!G=$$QIPENV9%3*##,BNAX,["8NE%+*N'B$(%2_Y!+]AZP=8+ML[3I+KZ+A3J$H<*B0DJQ@(H844:@2J1D+%PX< 2 M7%9B( 6)AQI.M"BHR\%4FJAK)^$U.8E"C)S"'/HG'!B73V/]$823BVF6C$Z+ M789C*@Y/Q6)$N.2FL[IO\Z$YR]O5YEH_"?+E26E9:8)\G(H=54DYSN390>X] M"6R1=IFX'9!I$!Y4.UFJ+,9WK2J MUYUT.O9.HHJO,&N]F?9I]&86#LI@E.BX8F.A3@E580.[+C.A7#^J.0_<'@1= M"Y)A#BP1]'@L*B&6.;4Y68T\29=&;P+5D@;K-I&V[;^V$@8T[X6$0Q2F_?PP M?%U+DFZ3(32_%MNK88UP^0$>04;5]4][:0FME[\J"_728#\AIWV5Y":WKH:#4;TY90KKX9=T]7 M5N2;:FPHF%I2J0C\VS$04=0P];O=(V1WYY4Q@MB'/!W%/630.T"JLP)K;'2!NS:"2U'P%7':VQB#!%.]&2C5JPI6E1 M1L\EPG<3AQPC]7+C45HG%A9AQU*N^;&/\);X7EDD)$2Z-+97%_N2.?=Y2:6] MI&=[#X7-!/\LF;C(L\#PB*XQKS)V-V"HBG.B$4(105(G+,;P29Z&ER?&Z%B1 M^X&WRAZ#=R6X9/\^'_JKU*V2MZBE0J4&DK='A=>I OT5?A:OV%<6RL/WCZ1( M1JB=V!QJ:KI24F$>9^8C'(HHPCQKS)R/9Y+;%L@K EZIS;$5P%NLMPLAP=A0 MJYU4*S\?^:H]8PLNA*V]J\TI*NZ;"!+@*%JOJ,]FJW:0RJDR(0+PF(MSJ,4, ME?$T&E^#.)^!J6-0G=J]N_[0H/1/'G?E7WVJW!93Y?[9I\KULLU%XVQTGR$R M7KDF,%0=UXRH-*031]X=^A0_[$UOG@]^Z7$V6#NT.-#28DYQW";##JAM2&/< M3@>M%""]IC2QI>"!"[1A;^Z>Q'@";='//9H]H8Q[Q)RG!1)V+TB\8:OQ$LMH M"HQ86@((FQE/+,&Y[E.^^52-CU C)C3;*31:/1'V[0&ATJ&G'O'3R?U^UC4=C:3Y0"(YOOT_9 S@'RZSIG#0>K*!(N>MN$>7"@]#5V?3#AI]+=H'>[ M]V[W;6)H7'AZ[^:\LPD*L7V%W'5,2;8&$YO8([U4DVIP>2PK2V MHY.+E7!O,U-*D6Q85D?WM\ZF_+JQ@Q75X]^Y(8;Q\*3&PT 1S$ZK %D1'7>, MUR)8MC]SIJA@P>M#]9TP(A&W4%PPDE3.S MUOV$IWS/+NJ^"+T7-M^$L.E&LQ?H7VYG(&-NF4Z,Q=$SY[#[6A2."6D^=!&(V=X<4OF J M&(3)M(?NBU?[B!+88-D0/V W4&ET7U;:KE$UH/YT"U$D'1D= MPC<32AB,9T863DUX5=E&B;V2#$PN1?5>(81*/'/,A\0!35E1Q'C6M9HUX%;H M.855DYU5,IRG_,*IGNP*2BEKW44%2>+IDG%=Z0=53AY<="%)C"MWSCBR,F;% MX6-6W$2\592>&6Q6N%.AYU#8(9 VEJ>Z7!7R"54I!]@YV:J0 M> GH^L K96%F*C^,_L,X@<(FQ)N.XG#C(ME;1=8826LK^\@,J>VQ2+0[R"RH M=9>9F!D(,[PAL+*&&PYOQ:;V] %J]C7M53O?$;+7;#%+3E5DO]LR[, M3=>QF7Q.C@BKI6:V5X%/'(9C<3O!7>ALDEE'BF&P=3CHF76H,PVU^76;DT9@ MDT3.L?L8E5[6VG -2=M1 Q2YB&WFJBX7E!YD(6/ MQW2$B2HP9;4:P\WMBD[@\OOI<%P-DG7W_"0SVH-CN!A&IK621[<6*3:5 FM/ M%SI:2/G9>.R3.Y!OH7/JW.7Q4I" ZZH#ZR#S;F[W\_PA$K(?HXJVVVM:7O>O-JF^;5Q^Y>E\NF@^/=VX9*9OL"VZZE M2_9:D4.F]LLU798.&Z1KP70)S(I<6R#1L4^=[7K@LB#DE4QUS@T]V35&G2 " MS!1.R7IMTRM!/TBY5^E=R]B-+-"_51=!TNY\V7>V/4 MR.)?U'7N'7>EN;>K>S1R^2FQ]2^[G%91%.A4M=4.)C0B*FYFTFD604@I.N'D M [MPETOK2E7;'&=D2O",1Z[;$[;WZFI$X!XWBBK ?"Q )4W6E,'@Y1:)19E& MSUP3^ICO"%43HIV,&I%+O+2^CWT=^&S,JK$A=S O;=5-G4M9X[&$TRCDI.*. M,PQ5N'8V7+$92WG/& "/4?SN5#KR&=QSL'TJ9"&?I,F1VW#IZQ/)$7WTTSX% MV;<<#K0#GO)A$\YK9N:_*5UY9@,ERA\CRIC@%#FJ-,:NM:W4LL MFQ]AKT5L(YY2DIP##&D4M:'L5LT:BZ&+6_8S M;@ &%0)=PA-0'IK! M;25V"+. G^ 9K=7D"FS=98.]5$(_KC_GZ?\[/CV_//OX M83CX\>.GZ/CTT^71V8?H\M/1AXNC8_SB8C=[<+[SA[*#L[\$ZA\.K$+BX3*X MK3I"OZ3I:J57V-;^AH*O('?>AYV8#:FL1.9$U TV*VIJI.P8><5A(3V?HQ7E M+/-[+=[B_X^VT2-"5-OU1;%S#Q9R]O8_Y#8I$3.Z=_87ZT]['+8Y_3VU M/QP<650=,L,PD\U$#7P33CHY$,8H@RJ-[4R.5P.M-]>.O/T2[:E#>/AMM$I!P2U).F.M430A-)U7 MM) 4BG6.'W2NNKP_]4C9M7]S$1_3Z"/"2 \QFK?49 M,#(SK PT?C_0VK3:S3[OS56]-T6]-_9-E"2*O2Q<[)!CBNAL"Q<6.-Y<]F*6 M(82.3]L<+ZV/LEXM8C262TH+31BQE/M\-]1R"X];%:9"U0OV;#%3L4-Y;$Z7 M0.VF*'-ETDO=75A40+:G[II?$*K!N2V8)Q_U;4@4U/ZP?LJ;4@KTJB]'/21FDY#,FY"?_.W9KCUH-14^8?/ESH6,1QP*Q,5<\&8&E>E@Z'"\C3/.M9H@XP)NV!NC16Y:#?Z\^%YF16@ M*A"A!1.@K8 9AU/&T-JZNAO.,TJK>0Z<<;XRS6!V(]^,I0Z\^]V%.=!DG3%4 M'PXP.!S[ ,:&S1!+AE?FQ\<2[F_H?@]92KTZWL+#Z&;['<,9]91JIQ1H_#=Q M$3,'=@L\-S?;C%.ODMU7X"2[N+!S;&H!EU08?MG 50D&-EO?L2@*+"/#ZGXN#&7W$JSB__JETX9P1L_?Q MY#>L@GKV\^7[7][^?U!+ P04 " #+<']:ENX!.R8# "D$0 "@ &5X M,C,M,2YH=&WM6&UOTS 0_AXI_^&(! *I:?HR$&NS2FV3;A'IB]( XA-R4Z?C.=\^,6'#5@68C4Q"RE.8PH5L(1$IX;==1@SF5 M+#90$55GOZO7!44OE4D2MN(=B"A75'8A)7+%N*E$U@$T<=VQ$$J)M.PS>O9H M.@EOSF?&)&7)5>=G,Y:R.?M"=P"-WA.^R+.N;14&T2.S@W"1;+56?YV*/>BY MEVNV8$K76NUZT[8&O0,0^P46=T7R7@;IM[E\V.2*Q5<'#9,W/H=Y,#PSZ&6K M;3;?-QK-^H=L94#?#\\,XW_,[AT7W%G#Z63N3D)=FX[ FSCNS,4'F@_< MNH'KP.SUP/>&T!\.IZ\GH3CEA"82+JT&ZWS=;+]NG)Z3,@?%F)M&^)-%HG)\]T3<0@-A)G10P*EFA] M"6,BHS6TFS5H-5K/88?.1L?BN-UNZVG);U'R MJT7R[_&M]5_X=$]O] MSJ;'JGM^8/'(-&'$:++LP P/T2XJ?MH4]0$J=&&:%65!W@&?Y I,<_^GVW:\ M-Q6:G^%_4?0MA%Q2>=TW2$CT$9KHL/)T1U1A?^"[,'0QJ_<=!\O-,Z-AE.WY MK#^LVOLI]]8BD20DRQ%I]=7%8F*IU@77QN.[R(=!9>,SE5@DD*0*!^+_/CX) MC4L-I]*X8?K;D@B=XN8A*!X% WRC:RHOW?"M53AWY\!_=NGJGT<[#%,8WO8&1M"?WW/ MG;'!$'8W:=-E4Y&'@.WY.'?NN?>>&=R^\'Z][%0K[8M^MX=/1G]M;^!=]COM MAOO$TT;^N'UZW?N#W7E_7/9_W@M5DIZPYN$D99Z,A6%78L9N5_Q2([0[,_,I#*< M[W7:Y]=77GFZ>LAC&5H MG+XDZ/9II_\PED.95BM'S8-FNW':>64F?(UU?Z5T\4%_H5\2]5G_UAN<#\ZZ MWN#ZJEJY^7![]Z&+L;UK=OOALL^:1[S>?+?/W[#K<^9=]%^;?:_3*W?]LP^W M V_0OZM6^K^?772OWO=9]\PC)S1_.GKWVNS9A?37A#VH52OON5;LXH!U=2S0 MXV;J_,!6R&ZU2/A*)])DW%II/1)9*'_,,$O_@8.?0[3GT M+1QZR@W<")_%O0YK@H6R@1D(&(MG5\# M4=$>2HPC$S_* HP)@I4<70,[I8[F; )^$+>)\U&T(&^UDO/& MK,V- DDC5PC9F41&H"Q"JRR\QD+R.=FS,)(S4Q!9RU&TJ2:8R9.-QUPP'2V M.5*: LT2+N'8$7/+Q'P'8GHK3OQ!FX^9:IF<>KE^H9RCPE#BTKIWP+@6-@&! M&'(8"7(X$Z#O,))F3,VI68R$2TF7K@-I_$B9#/TH%6L5.49-M/)%@-M@Q#X8 M% A0TM&D_^"/>3(2K(LL=YM%,,WNC8[WQ1O;MWD%56TN_S+D: MU7F?9^;I7:C>#@7HD\_D*KC*- 9 MIM*0SG4B@*1V(%(_"_%0SF':Q%Q2TA7 MPTN1:D@72*0U;51(:*3-4_&T (ZA(*]B< MJXP HA0YGGI-.$+!SR).M0*&612+A$U1X41)64SAVU!00V1S]!?!+GEOD_## M1X1_<@9\Q/NGY\Y-]*]6UOE/S1 S4QD0J[E1":BD)+4,L]%S\K39?BJ5JQY>@A-VF2Z0G(;ZP4\GVE XO BFCL M[2!P(L0 GH@)11H!SNF;Y/I/IC>G_(HL^F/6"#"$!I63N$^ MLT&++F3,$_*YNUR3IXL# ? :'9&*B=9@%A^J+/TTA*>4'+YH+4CCA^6\NWGW MQH;%[L$&JW!+ 4 M $J"'3>WR,V LK#S^F/ZT&E#KBWMDXT3]B3DF3U MT.R-@S7F9B%R*)W:Z! !E!!RL5V1O K,623O!3[LL8.,0VZG29B$T[ V, M&<AY( +2#[(/T2.F&#D[P29(?\V-70%G_8R9A@(W++/'M MZCH@\*4 AW*1L-C"S02_IZ+O)*4M^U8.VT/C MXL#L"BMBZ(5'R #V-6.3)3[(X%]'H BI"ZM:<]#"PWF0QEAIF M6VOR"K7Q<'$G*[;.2-K<=:$>0HT\5 ,_A,V=8)C]+2"G8LW57IE,53055( 3 M/LI_T]!YNA7Q)%)S@:>SL7(YEJ\0'<3\C#RI5I[,XO_+#V)>]_2RS\[ZEY=W M-]VSP=7[G_<.]^SU3;?7*ZZ?;=I,!NF8FAY^WT+-T-@XUWT517QB *CXMF?? M"VM[M\^?8$J%%B^!]T7AKE%D$\+L";SVR,Z-^2P+WKVL">U!IV$: M#O;*6PKMQJ!3M@S_;K\5^GUE'VX#UA6/2[\9?"NHB"$.2/EEEH/>P8XI6X/E MR33Z!JG2?Q!^1D=@#LW9F$LHR&0S41JVK'9>K2P \._J=78N112VOEY'2U MG,#.I3XIZY%UO;):G!X+C35!\KAJ+"-[0[RN^B 2H>VQ8&-IZ.5R%G0HJ-!N M8&F*52JM;8,6URW@?RDC"UB%>^G->WKCWKV"3V_J_PU02P,$% @ RW!_ M6@2XT<^L!P 4RX H !E>#,Q+3(N:'1M[5KO;^*X%OV.Q/_@5VE7'0E* MF4Y7VL(BT4)WT';:JLT\O?UH$@?\FL2,G4#9O_Z=:R<0?LQ,NZ\S3%?T0R&) M?7VN[_&]QR;M]]Z'JTZUTG[?[_;PR>BO[0V\JWZGW7"?>-K('[?/;WI_LGOO MSZO^;P>A2M(SUCR>I,R3L3#L6LS8G8IY4G,W:NQ>:!D>H".ZWCZW7XO%7(]D M(QK?-(CG#KOYE)93@_Z+0O;ZZ]LNEZR&,9S<^^9MRV-?(OX; < M='Y.AF;2:C?(()R__1:PM1R-TY<$W3[O]!_'?2VW3COO#(7OL>\ M^R))A7Y)U!?].V]P.;CH>H.;ZVKE]N/=_<Z0OV$W ME\Q[WW]M_KW.J-SW+S[>#;Q!_[Y:Z?_GXGWW^O<^ZUYX%(3FKR?OOJT_KS0I M?0/8@UJUTHW$(T\"H=D?1ZRKM9K5V(=>#5'7-!Q+QSP]>W6>?<> Y#52L#-N93P;282C$3 8(B#>-)DO$(-R=*ITPE[%+I&)WJ?S 5 MLENM4CX2B?29-Q::3T262A_C#!+_Z/51]1\4T+<(Z#DW""-B%L_90Z)FD0A& MHN;BF@!1I#E\0H*6X$+(?=S23,4R M9:ER[38:),(7QG ]KU;0)N8/ @.7C!K<"X &8T8D(V@0:N!+[6C?LO],:)$;(0]B:2+! YF,V$RF8WAH)L*W"&&W6ID G K@Z!3] M C:1S,V9AI&:FH+,6(VE2S3$2IYL..& ZWQPI38%F"9=P[(FY8V*^ S&]E2#^ MK,VG3+5,3KU!-'ZD3(9^E(JUBARC)EKY(L!M,.(0# H$*.EHTG_TQSP9"=9%EKO+(KAF M=QJGA^*-[=L\#=R5NY2DL!-'91J 428L,=P1CL!\8:!J966D<&6D$".1I^O$ M1PN2%GN%MT,N8_M9K?2$P9B(JJVE7^=J\SS/S]"Y4;X<"],E'"CG<"TB;@GI:GB)4[4\O]-#B50,,$9%,N"I13HT M,I!<2_) .J5AJTI"EC)#Q=\N8"PJT@HVYRHC@"A%CJ=>$XZEX&<1IUH!QRR* M1<*F5>%$25E,X=M04$-D<_07P3YY[Y+PPPW"/SD#;O#^Z;ES&_VKE77^4S.L MF:D,B-7 &*X*4+U&=ZZ!@'1:"Y$,9R71.PF+;N+0*+4$M]]SZ66FZ M%$_5BBU'C[E+DTQ/0'YCI9#O*QU8!%9$8V\'@1-A#>")F-#JHB;8(3B>8Q7* M">K!GNF[9+H/IO>G/,IL^B,6B#"$AI53A,]LT:(+&?.$?.XNU^3IXD O$9' MI&*B-9C%ARI+/P_A*26'+UH+TOAA.>]NW[VQ8;%[L(M5N*D H!8 )<&>FSOD M9D!9V$5]DSYTVI!K2_MD*T>?D7M)22C?SS1QI%2U-ZU6*[$R*1[0P3.,&1^6 M/F6H^K!]^!DD(>B.I+C6.D>.O9^P)R7)ZJ'9&P=KS,U"Y% ZM:M#!%!"R,5V M1O(J,&>1?!#XL,QT19S^[4VE/9X-BK546V8]RL)E.B\3 M(!'R*]0H3AJL[-D0V@ML'&([5=HLA(:] 9MQ+--4B"\4F:&"E*'G@01 :^00 MI$=*-W1P@D^2_!@?NP+*^I\R"0?LNLP2WYZNO-GO'7>]=^Q&T) 858*2M*NG M P)?"G H%PF++=Q,\ 7_791?_JZOZV>S&X_OVW@^,#>WW;[?6*ZV>[ M-I-!.J:FQS^U4#,T-LYU7T41GQ@ *KX=V%>3VM[=\P>84F&%LDY_\"U/W:H3IHU]O;X[>DB %[O)?"^*-PUBFQ#F,=RJ-)4 MQ6=L&''_@36!UQ[9.9O/\N#=R[K0'G0:IN%@;[ZIT&X,.F7W\._N1^'@=P[D M+F!=\[CTP\&/@FI!$X>F_%;+GBL[@^7)-/H!R7(QEB)T2"X7JN#&;>VVLZ5A M2VSGM:JSK;(!SORK7L<,B"@X8[?082T8^)1A!T$=6^QF8K=Z9^R*8RM;KQ?! MZPW^7:!RKM6Q$*Q[A:^+TO(+W5LK-^>KY09^+O5+6:^LZYG5XK4I1-8$RV95 M62[Y+0MY-2Z1"&V/!4U+II?365"DH$>[@:DI9JDTMPV:7#>!WU)F%K"*\-++ MX?12N'M+G%XF_Q]02P,$% @ RW!_6H0*^_[^! B"< H !E>#,R M+3$N:'1M[5IM;^)&$/Z.Q'^8(MTID68\.[9^;=T,6L6"?FT:73R"^M&M MOC4P6WHU.>)H-1W6V\/N/4RL^X'YN>3X7#:@7@LD6&Q.0[BE"QC[<\*UY((& M$RJ84\*%N'3TVG5-F!/QP'@#U-1:$R1=RC+QV ->^CT*)7-6I9;>&]Y:VZ++ M#IDS;]7XD?!X;LB^T01+J?6>3\.@J5>50%1^= S8@CVX\I"@]7;+7+ILRF2Q M<'E1J>O5=NNX*IRHY6W*)14'-GW''%O]7K]C6/WA;;$PNAM/[@P4;PVA_@O< M52:53@4F9D<-0_WRJJ8=WS]'4=28% M&=SBRS"YL:YGI]JGV\40U&_:*!>O: MA(DQ;ANWY@2&OPW,>S Z%@Q[<%&K7>0A]>_![O-BP?8YI[9D/H<%DRY(EP+A M/"(>C&G@"PF^ R/A2_) .;/!;\["4,''7S5S1B0%!$D1]S:R1)L,F 8+ MJL$7(GRXKH AYA3-92[Q+I(]T6*AXQ(F8ANJVQD>7>*1"OBJ)@M_H4''9=2! M'N.$VPRM-70<9E.A8> (Y2@-@DB$$>$2I+^=H%)KQPE*:4IF?B!1U^WIZ:1B M 4-=.2 V 1%3PM$ PZ5'5V#8L6M4S&@X3F3CY/AWHF%S5C_'+(8>20/$B3QO M!38RWU/\7'-6T,>("8K4DJ%RU<;S9P0C0T#]ZFQVOG;OAN%K=J<^KG^Z3(*" MS..8:2I2GIS93M7;%ZFW&Q"S%K2L(X1BU+LDY&!=/5#@C,6B5;[!69&7D,;'9!G?,RP64J:D.;9R M$K,L3',]LQ-6N!BB4THY^M]_8NKAAJE\RV.Q M;Q<,^3!5V2%ET'2U-\>)!&>ANQ&P20[%PHO//P$,.1-*XC@0!7A%)2 :RK=" M%,MH#TSHF(/!9&1T^K=?/I=JI?A\9'2[V?FK55NPF735U-J[)DQ]@8_YLNU[ M'@E"!)3]5XKWZ[HU?OT-GA1);.)E!I-^4$IW_[K5_=N KVKO#FGS&R)L-T&5 M%F)7:P=8W0/@O3PHW/:J\9?P4D=.?2G]>0.F'K'_@#J"#7V/S1*!KX+_X>># MXM?[K6I836#OE*%ZM=_:U@S_C/\KW#MBC/\3BOT/8"F*)$ VVY61V\V)DL/: MA;6UAU5HLGUL3I0_>[JGGMF\/Z3O\EXTF"9M."O^EJT.D9.6-R6+NPXGJ$\KL9=RM;)=ED1^$_E,JI+O5D#1N2!-E' 8T2YK18V81C$ M;R,:,""AA'(Y\V&W_VN&*E&CC/$0JY+IM:Y$/JIKSZJ3]FYU@GINVKW;[=WG M[=_=6F>_;_NLO[M?D&PB_SOQO.L#CSKQBC5;MT1OS)G1(:."7D739%;:LFU5 M&3SWWLJ"2$A"AR+5!"E;_>'^]EM5 #AH<&1'LB69O?9V;(D$ M"D"AYN'=_[[O>?: AU($_L__4ZM4_\?FOA.XPN_\_#_-F^/S\__YWT?6NVX$ MC\&COOQYHQM%_3?;VW=W=Y6[1B4(.]NUP\/#[7M\9D,]].9^XG/U:K6V_Q0_,9,TML>&AF_=](7LPWO; MZLO#3Y^?31 M[2ADOFP'88]%<(0XTFZY6B_7]S*#E"5W<@/!WY5.,/CN. ?E1LV,,W8X^97B MURTFDQUW^C&6YPU@_>;C-9(N&U5^,/AP-^UQ.?)J^R3WN M1N'(\SG X>MM_!K?J9>KC-.!A^^R$WA!+$?A%4G*!' ];JL'B\Z9RY M1Y:-_[V+1.3QHW?;ZE_K78]'S,8AROSO6 Q^WC@._(C[4?D6-G'#=M1?/V]$ M_#[:)G*P#6]MJR'?_:]RV3X3W'/?V#<\>FM?L!Y_8]^[]V_M\Q/ZY6NU?OCU MR\U/]9,/S>85_(. P3^;=R+JPK^GQR?PD_DN_#S^\V3++I=G'+?1^(H;\#6_ M\*]FX;,/M'-,+U5KU=H3WMX]_,H!_P%\^%^SQWT7_A^=>:SSMS#[N]]_>/DCZ](6FI5&/E;!3Z>_?6]]X 1)U]K7S4I5>#!1X\8 MHO[UILM"+K_6OQ+C4&-(^NP1PYP@)%=ZJ,880#\T]N'7JSCD7W>R@_3ADT<, MVSXQO8#G^-WXOX-7FL> JV@/X3KF7*W!_Z* ?J_5B>P*('AGS(FJ^%]CP_9AB3 O M%V]R]V3CB"[*N^W<+/.:=R<[[]1;M7%T]N>" -C- C#Q#FX_15O_EM_L'X7\Q=)G/_N_OK/;^[\\=?\X!4I"HHM/[/OF!N4J%N\^<"$?^F#? ;*$LH-E^VF0PJ@O&)#Y&I-WX5/8&CW MDV MX1&#FPA]0T$_G7[7=^KSWV'0B/@MN]=;_)[[O"VB)^_N;O4E(?S^#N[6 MY@T?W8ANX(%4+$]!08Z&$Z]8_2E7[%'\IWXX][U76L]E'*%=S1V[=<^XM"QK M55#]^.HN(Y!@CX->/^1=P"PQX K7SH*0BXZOA%!G>(LV,C4 W&7ZRR-S&5[] M3X&4[SFHN?R:.QZ34K2%P\RS['XV-%W@UC6J<\?X)=HWLQ, 32_P']R&N9/. M)=R&INL*?!D45R;<<_^8]47$O&E;TG@%6W(-NJ7PN7O*0A\(F)RV%W.7O:;M MQ1<_Y,P3_W#W(S - ,DL&J4(HP W0R'AJQ/XT^\H(X3:D^4@*7-7(U]ZLQY! M1P[7=>V/(QZUN0L;R[(/,U*,VMSX*ND1TU8_2@0OV]=Z-W +0#CS3W@K2C?B MY:E#;;X*UC-OS.R4H#8W<\-+KO.1MWYN)JZ77/.L-WSN;*[I_@7W#LT$\C:8 MLO.DW:!/W<6-@5VA';A&WZL4$8<;.Q .5R0.]BGH^#3*!./.2US^^MS%["79 ML]GI0GWN8O62;<&,UZ<^=W/@DNU#TW'B7@R:"W>G$;)I6S-W2S4AY+F4,7>S M,A M2UUP270T<]F726:HSUVJ?HX->>2%:,R=-C[G(I^.[8VY$402&AY:]#7' M-7-ZY*;OB6@)<+LQ-S%B<_LADISLY\==3% M'M:3Z,H"9Z=K.W-7]GX$WD=2 MKKE+3S\$^Y,O\HLY9Y_A/NS.W<$PFW/V&9:V5UN +9XC.?:K-GIR,&*QU_,BW@SEV3/'D$7UB,:XT>O MSTYU[H%W2[8/3[8?[LP_U/TA7\ %OZ-O7EXVV)E_]/(\%_Y8!)\[K5O$8GX M2^=.R!Y:'P'W\AA:FSO3G]>B'XF=\XOZ7-1"GHZ9\T]8_Z&U/91HN#/_X,SO M^[R>]<;,/Y+R*0N<63[;F7_8XX_ ^RC]:Z<^=_[Y0[ _^0(O**[P^VZXY[@/ M\P\1G,D-]PQ+R]6Y>&8'ZC,L;WZ!54MW6/ M;MK\0^)G!&Z&?5NDQEI[^H[-7>^94P&VW?F7'SD'3JT-DV=,A*0U(BOT AF' ML]492][[S!F^1(-=XSI1&QUA^YOQ -B\9Y M/^K-:J(PW5$']'Z8/J/UA.8="]V1#9#GOMJCW[GH="/N-D&W9!UNOK\*A?-8 M_]=3-FE$]KR:ZT:-N?TR&Z7WJ35EGRX"ND#<_'T6A&TNX.^+&%=TV3: /DT: MVM]?2.CYHA8]@B0?4'<[81%/;OW3]Z&Q2 1XZ*9,NRBP"6KYRO9T[DL @:[6 MZ7U?A#3,8PVC6MW-W(8&%?W,;\9!K@[ECVZ$2@E;Z"XL@(;,NE/[JX0V3^,Y MLV[%X4H@C=Z#ET.9@]J"4&;.E4@/]Q8@#,ZQ$NGAWMS%MQ-ML 8(E?URS/CQ MH 9?HT+T+P32Y%T"D)ZR2_A9TIH 213/O<=+NE[[%KS1E([(AC7IAY#;[HA M3@'W[KYB9XB#H[O-$K M5F7_I^.P;L%BWN)4@M]\F'PL7/RB+7AHTR+XQ"X_Q^>_Y+L&C+Z<3+8]:38] M5Y_(S!@(,F(AB2Y'Z4K,..EWHV]QWTW?H16G<[O9-\S'V=G-9WHK9]S>F5S9 M+[+MZ5ZJKAWIY_H;%R"Y[WO"$9HHVZ[HH1,X\+,J&VP;OJYX!7*:P$=6T;P7 M7%GXB8\)Z]Z M@>M18,"R8L"STX#K5W_\XSOP6FY_M.37]G LT=DOA2!0G/V:W?NI@04K8Q;-.7 :3W#@-!;MP%E )]-UN'V+9<#K M31#JBV8&]2*\X67#&U[RL!\N<[#^!__@^E\+$DRI7+/^IS]YX:_EV&W]A71-Y^220HY.5E"$!X_KM?R+O++>^^)'+,K9_."N-.LJSWP\PNG(7\ M[YC[SD@UFEDV;*ZB; :ZY->/L 5BY]]E2 0BY]#4C] MLG+IZB%U(9>N %*_K%RZE$A=(.S+RZ4+3]AZ0EO75<:+)HSJ"B^.Q"#3/?[T MWO%BE[NX)V@QCR-J?7C9-@Z5*QZJUH?#R0/D\6GJSA5!)K.%HQ>HMSZHMR+! MZ@;UUJ9;VK.@6]%;[0G4K4"QU4.Q):5BM6JY?IC^EHG % .8Z\IC#DFSJX]K M-W%+ JZP<'C#/#ZEU\*D1;\@5:(S>2Q5RKZSD,#>'**,!0RN,PHM*H9R[? X M[QC)8N0B%-!1(I8+.F]FCD.S@G6*ZWLPHGSZV@NB-HFH%8BS5(BS1%3D_2M& MANEK+ZC(=ZE(@3@OC3C/0D4FHT B@34[\&,-CW^R($PH\-#:U^[XIS&1U:E. MO<3D]?%R_E4<.ETF^1K>N)G%MLE[4'#L)PI]KQ6EOK\'!4K-A%*%+/#RLL J MH,^4(EBW=\%M-X@E\]T;<1]Q[L.FKH%3&U=QP7H\@RT/+;5P$[:^_5:SO5 M53[^YAT+W=MAGR][S..*2)L%UBP5UBREU/D$6I,\\8'[/&1>TW>;;D_X0D8A MPU"_T_L^'-(:%.69.VH]9G)5S2>QWWP*'(JSS(,RTQ$4=/('Z62!\07&OU(: M?\TEQSQ+V.\3S*,,^F1,+O#]N?!]A@,HZ/N\Z'N![06V3\7V%:'MVD9D#G6% M?9@RC-[MMO"X:%\'X @?=D^$2%WHB L1(CG M%"$>+$ZHB]ANUT+\6*9&.F+ M'>*JLZYE(M(OV>^K\(.^W&&_8$)>CNM0.E6CMKNWRF>^[.QV^2-H9L26]6#B M"T6;59,BU@PW5UTV64K<7!8-=HEP$2V/-Z7DD7P__,S^"D(J,)MG25-W8EW->4#.]LOUG=4I")X/ M#T+8G]/\I8>$!?W"NC2\!9(JF0.VC7ACF2_R9#8D;47 MC'@F1EQ@S,MCS%+SX@)/7A)/7K"F97'B+WWBB[/]Z!,?J6M\?'M\$811]T.O M]?$5'OKX\E_HW.O/[SXM,.#E,6"%I<@";Y8%;U9!EBRP93GXS'-+E,6Y+\>Y M+URN'+GO9]S%"J&K?^2J8MXMNV_&43<(1>YX1^U+6T7:XC4:^EODWN)J4A%V"9RB0'%W7K&N_6HC(SB;BWEW<+&D 7OFK6%9L&_BCNVD#M6\+ 7O&,%'UNI M.[:VUZ- E[F@2Z-Z!LVOHBTC(4BET];$9T>2PV9]_Y06R.?:%0^ 53/'Q*??CUJ4B@+L^T\97/13TSTPSOML7]&]BB( X=+N$3^J#+F8M7 M]]TV+/W(LJQW?5M&0P]H9!OP_XU=J_8C^Q9(A[0O^)U]'?287U(?E.P;N#;M MMW:/A1WAO['QT>3_&T?O9)_YV='*;=83WO#-]\:C9Z7XAZOI-X[^^[]J>]6W M[[9QP*-WV_VC.<+YUL9;7F:>Z,!7?X%R(-K##3/+_RJ7[3/!/?>-?1U[O'S% M.MPNEX_>P789 .Z$&W41@NI/&[DO6D$(FUN.@OX;^[W'G&_V#LPH T^X^47V MH[>V?K@51*"=F.=KYODG[^;8YN$YZY^9Q6WG5O<,V[N"N(':#@H=WIBW=PV;T]OWFVWCE9V)3>GQU^NSV_/3V^LYL6)??K'\ND6]>__UL%K]RETNRN63P(E[6J#]ZJ K&<3ZVM>O^%NMWJA]_>=# MP_OSK];]\-^_[,!PP C]P"=A1#BV%ORN>7LTRR,*4K?TAE)IF!-546NH;]@^ M0]4" 'B3G7_CJ%8M_T+,-ITCQ9EU0I^(M3P.?.H(O_/S1G6#_NXSUS5_ M/WI]&?Z:L$DG\#S6EP".^8T$I7=1^/CQ!SR,A,,\LUG K[74]2YRGPQNM5+? M%?X\MQRP?A3A=T80ONG[,?.N>3\(H\F([_WVOG:Y=W'E_/9TQ&\'88]%/V^( M^^A-*P@\SOPHC/G(C6A,NA%9 !&)#O=W]M[..9,$B"!Q,\^+B2_,3 M07A]>G5Y?6M_N3@YO;:!*=X"Y[-K#?ORVJ[M;KI;]N69??OQU$[Y9W M^'7ML+$SNGKX$2HYGJ[9T6J3BE6!'3E-$%IM(8% V$/.0IO[+@>)>?0J[HU< MQ2LR*9PJ>\,4)G3_T:W]4C_^T&9SN8LNFI3@O:[+A@@J]T>NY,ZD*YD#=&., MQ+S7ZSK&>%T_.J.=^!-&?W!IMU>?KIP_K_[#?OTV]Z6-+6LWNZQI<&XJH1)$.>P:?R,F+/[F ^WW6/W=O&O,1+O8FG=L(*!L4,C>5 ME+X"\6-58 >:GO]&+O[.9VG]W<[LY3 M^FLS3XZ*?_L3%:(1*+4(N+,.(N#M=?/BYAREO4(,7#>2C3)@U.5VE."OK5Q& M=AMNBOTU_Q_0D=&/5G/9JWQDZ#D5$OV=(+T#<_)CE/W&Y?8334A/R2MY!H]> MT).3">C9_5[OMT^W=W^\GX]D=Y"EDJ,@H#^Z!J_M[NY.I8^K>#2O38(8<>VT M\JX=M4%/6,[";:RC5^4L=U6N>4=()(@1QHM]=>\_3;XRP<=X[\.GSEYP!FI, MA$W8?MYX\^:/DS_>O+D*@XAUN"^RL++D3EG7H/A(B@0RID!VT[3$[59M*6?>Y@\(MK"T"$2-I.EX4 Q-;ZBB0%(7K$ M-^]YK]O2;.YYY;IR4R'P M=*^]\'6BFUG4/:Z3/1CKIV M<\#]>&V%S65$H7&H%\_[YB=T/_OUVIMTO8[AU\OP-KCS)U^N?^[V@OC7^-\# M-J?+U9AZN5)0-HY@H;3S?P;AMYE##28ND$31R_ *]$J0%Z:HLW\>M,(;]OZ; MXW6?29W=F;H-(P#37CRT#_,B+:NJO#[[/:I.0K.K ,[;^X_H3[>9?/J/SWX[ M[%(O'T708L)-@0%==8?UB9=)_4Z_3?_W50K^V_E5;$/=[O!K[Q\99L MN E>C%J/S4+.@#RY\'Y""S48!*C+':V!O[%C'VBZ!\+Q>!#DO@F"1"(%0TXG MD_5?_OGSM^;?N[(_G]B_>B[V+SL_(&>]5M^:0AC'Q(N:7@+59[S"[7K(-KD3 M[KK?=D_[?W3G)#CEPH%&8=@X.CS<*1_4J]/)_+/&*ZYTFMH"@+\!AA**2'!I M*?\@#[FK[@N\HXRBM?IF:PL9$<;)G-X[7:S@83>=Z,V*+OJUF5E6T2%SB^$$ M1@+BS.G:#C;\7&E;Q2J> T: ),=@[CX0A;NN@#-):<;K%-6G21.:K YK]18A M\D16;$J@P.,/E0S)/#=>1>6?C^RR/G"]O]__]1CE+5/J>&J%EA$VGXMG&UV? M"LK3]G@:HV3W66@/F!=S^U_5"D;$S6PO.="[>!LRI+PWPUXK\!:WA3O\M__< M]GK1Y_/:8K?P,+N%N<6I>ES?$Y$*'>\'KV=UY'H:88;"W!:&7V=[)YU^?-]M M_KDW=_P:->XAB9YDUVM4)UW?[/J1U$N7_3T%"96JS/HB8I[]F87?>%20_&RB M[GQ)OBIEF$.GJSB$TY+\=Q:BDFRPB[6;>Y_>'_[[KV^/T> 4"[[59POC M%+,CWZ#[VTGS\K#7>Y3_^"G(-S,7:3P3%UFPY;6P CW)"M1Y.2O0*MO*%^+\ MTPQ6ZUI:PTIUKM5-0MY4EA] -#+X;*WF*E::')S[+L;7<:LUM)TN!^D-X/AF M"W7W,WDD0MK,ON.>5_[F!W)T+7\@8W35,VBYO"U^EF6 E.GNGNFNH M2$IVD(Y4[#_A%YTU/"8&-G/.[=]ASE]PRAL]XSE-.,5Q\_=?XNSRR_!V\/0@ MBAP7G! C,04@8(?!-#=.4B)G)7'DU2"X'T3P"8ARR!*CP*:4TY!RW*7=CT,9 MXX/P1<(H&QCNJS+!)[#+A]$\'VKX6^#%?L1"RAP-I]0DX>UX__W9X2]5_Z_Y MH/>$\(T10 JT7DK@IZ#U79=3IL,(;F_6MFS0!0BA79MY7H+5671O T?BNO5E7"VJ!W@+?M_X"<"UXGAZ%EQ */0ZJ9Y* (""9C.S# MJNVRH:R,7!G=3H6$E\?T67%?$:4+HGH@@N ?< MXNIV/T TG_: Z&%R4KGUWS3NQ1^(Q]4[ZU-W&O]]_: M]4:]DDAP@K*&^Y@UK.^\/:<[;XW>>04W77,$/+G37&Z-W]B]D2S29%]P6_2% MF7QC?PGV_?T_?W5/O?D4#VWL3\H.G01/<6.7'OC'W5C2C3P E-O,<>#&A@SO M&^(L*D;^Q$]!VO3+HU^4;-F#>PY3A(;* S+V8%G#D@5W"L8"AH8[TK$[87 7 M=FL>F/X#W43^D8;3&8#3/&@6P M5F^5ZQ,EXQ7%B]<63O1H<'>7/B=H;ZX0?L)K14"-W9PQ^CVGE*9Y@M],@2;0 MI@*^/$[?Y<2O13JH&F/%K<)C.+%.$ ZGE(?>ZQS_>5SOM\\>$^7R<"J1ZO=# M^.'HR<=<1E/J8"70HBTAQ_-2G!L5AVQ]**,FAB4YHAO- 1&4,2XX)J3NY Z0 MWGT?2^%S.46;O&@>L%!V_W,J#^99X7&\OG?C4G51@% MY0WG\H9X/>X$3(V7P@?P U3V!D*2W.@SWQ',0VD2ZT@AI#("U8N%KK0QDU>X M&4M.WA>QR:9X(0I#PHH8$C(V>BU6D-K-HHAC*C<>,YPXEO"#N5F';-LF@\YF M4@+#QH\,%O!VFY/Q"3DY?&CAFP)M4CZ@&-+*,/#L %AO!O-2<28?%+)3W'Y K8K.W:7RHWV%5IO[Z'B41;>)G2)5*D23]N><*Q,OC= M%F%/&0;[,#?#A^!*D%O9I;6RV!61ABOO4KL(ILI:YTX[;.*+0=A,M^_,8YVO M;NML,FDI3E2!-&*\T8&?>02@-75T6] MIKV[;13"Z",G"$-NJOJ1C3P,T=\;($<9B""6WM PE$FS?O>*[8XUD/%OHEYT MBM,<)Y,_S%SNP\[=Q]\^#EL_T*QNQBLWL6G7=)B+*[A\P'^'R2 ;H:L2@.JA ML#V]!.;*9JX5B5>)DQ6%2R<@3S*(D=Y0"KIX6.K'1W&QW&*HC2"_XKXD8<1" M1R]\1<$AR>S9BYK(H:.52T*9]1B'H#L-D'PD(&@-*4M7E <:[E"E5CTIUX"X MT!6U1J_HF'EP)<]ZI1'UMLLMUND 'B"U[U&" MFFU.B1,V" 2$6>03;2.)A]$F< -,1_YW['.[42W92!E+ML)5P%!F.UX@<>P^ M$"]N4U@!Z@ST-0VD$A9&LA)PEG]5*T#E*?R(]4'-OA= 9SEPC7\];+:Z(FWF MS M8]%6<:\*_UZA^_2<>?/H8_:?UZS 2";D_HU@ @&54(,H,LY%C!DUYV5;, M8*^,>7TY,K^39PA^W'.#R.4.P.YMV/H72=Y'[!]. U++^YT2B&6E@_T]0_ - M8.8&K9-[=F6 ;TJ,A ><=+IVHT;HO5M"M 5B?H<_'N[DD$G]N>D" Y"7<42F M([@1B)M]X1)^[E8;*([T^U^^-/Z]\\NO'P^_CY\/C3T187?+U<98A,S.[HP( M>WYQED%9->/&T7YI%S9D[Z V#6M!S<(G'V!-FNC(L:SUA\.*/L$XL-(K%OZ& MCU_QD&!*MG0\#+W6BO[ST6O(G=;W-W?*Z!M/BD+:V7O2'@-9N#+[G,_@']WD MDA&DD9X'*1H\"\E8Y>2-A:0&G5P>?_E\>G%[8YU?'%]>7UU>-V]/3^SW?]K7 MIV>GUZ<7QZ>KFQZTTFY;)\)$)W?D!&Q?,4ZW"Z7C]ZY8F#FSX21;>2^T"%E4=!_8[^? M5)[(K+$?)?%GIIR1>G['//_DS1S;.X#/_,PL;CNWNM7&C-RIX9+>PMM_QWA) MX"U:'SGRQT\JO_F9PU)+2[[?(_J31B5FHQ!'HQ3S,XR'%XZ$(8Z3N3348T( M1WY[/=ZF-]R)J&FVRGC(C7M<8Q;<%H-I:$)Q5N7<@&5U=7]XV/YQ>G!];MQ]/KYM7IU]NSX]O2C8( M2I75E8E@9W*+.O[FK6* R^!X?+?9>>+Z;_]CMG= M$+62__IW\+5:K6T<736O;VD9Y^^VV5BI^/DM4(E/F=/9$_ZB[]'>W,)GQ]'X M]ZZ(^)QQ=ZX>KHCW"+C:"B-L'EOK&T[PVN+N[<70\;/%01[P-"UQ=!^):7QO\W ,5* SZ" @O".FZ M$=+&VN#I_L;1)]YA'BT",-;A5!BF0-FUH*<[:X.G!QM'GT%%5U(J:_-H:)\( MB:&#<5@0V'4AL*MN"ETD_,^#B7/NC+QZM'/547#<&G^8M<8_DSE^P>2R7I#+ M')_?76%\S2%KK0I\GN+[59&9(+3'NX[:*K#95NT;2O"$1[%S%.G<#3S,?_Z, MV=>AI'A75>DY:7!"H<;J73LM<+WR(L0B[\2R$^WD(NRMS46H;1S]O]=<\G# MW?^_0,XU(]C[:X.G=238HU4M:$6HG\528O($4N%F)F?Q+$GG/0Y\5Y50^6!OHOF9T^W!]A)(];.E*I>%D(I"0/\]="P=)$7.+Z+HVL6>U_8VC2RR2H*S2 MODI^!VUOY1%UOR"Q>9Q=FYBSVL'&42H+T$JN>8>%U$CG+ @Y@&'_.PZ%=(6N MZ$0%G*Y"/L#RGN>^[.M23P66KS Y7G4/8>&D7B="N^K8..:OKN7]U>OAL#YX MQ?0R#3^OKC":YG"T7D51 LW!J$LT4I.D_J)EZ9^(JI@QZ:NBOT!ZR:B36'U MS0B+Q.85(KTI8J]%,F3[3L4#)YA,"SG.E!-==<3=;11D&+!U+;(L"%M!(],1 M/$-:Q^6=#X2W*_KH03X&^)CP[??=Y:@S1RF-]8?4= MN0!KD;Y!%P!D98WFVAZA.@+C%9 YO+[%WC:J)J0L:8^(DE_L<]_E?>R LP:B MR5[AS$,$7XN\#T1PC >]"H7OB+[V1Z=>._N,<^V4YN$ 1.Z5I]1[A?%X+6P: MA85MY6GIJJ-@SJQ&E#17E.FW=;"J[15VB!&^OQ9Y((2M=;1#=$5+1&DX0QJ2 MDP2EV3=.E[NQMP:\_S6;B%>>VN:1M[%Q='/^X:)Y^^7Z]&;5$7._.A$Q%]P' M=R&U/ V:C13P?+"X<_VM?=DGM?D-3J9[I[VUJ>L#?/VJ:C^/GU!NNHU<_6^S MAV_MVV$?YF^&K"6=;5WH=-GB6@MN+KXG] M''5OTWK?*U1B%XC,S=7I\7GSDW5Q>7MJ7Y]^:%Z?G%]\P'+/O\.OY4^7E[_@ MWS>WS=O3S^M74'AE&C?==H6T=+OFP,< KIZ-Y;BIRP83OL3LXSL6NF4O"+[I MEMXF%:+'7)[K?8>MBR1K<[O+0B =JNFWI" PW=CH*A0#] .G*;[1*&'K-""MV,J\I,UB^M7:Z817 ML^UJ]1@[)2L=HX);,FW]NKUG]B.*J0\YQ;CAC@1Q:+>X)W@;#J'O,;0[!ZV_ M5&MK^+T3, _^X??X DL,TT P15__"=#(N-?7WW% >SO)DO4#=O731-AH>TX MBD..+0DICA2XA]H X0^PMJ']S0_N5!I [*O?0R&_P3@Q/$K6<]4R%7LC4:/& MMBJP6;+ONL+I6CTVA*7 _X8!M4\*31=N-0T]9.-##L.F\O@ #!!36VY*:"QE M8<,^V4[NNJ&KW39,GU>+;@UL#7(U6B7J&GE:,M*)XBQ,2!_ M<,(_@QCV"[OMX%&VJ>6X?.@5> "4FDX7]]>B?6[;=\"EI5H&QDO)%CGP6"J-G8YV'PUP0P -,PTG5\ M.9FE6\D^P8T=VY (*#\?'S>@V\T\\WEZ,:4 8L]"?>[XN4;X+*55]Z5BWW;I M5J$/UW)5,G+2D/AA3".DCHE8X>V=;KGJ"JNW6I%P M@Z"YRVP:*C]TER4UB\492_80[IG"7=L/(J3$#K> M\34U54H*N)3=]B'Q@1V MP?L)J_/@'! N8-'87HP6-QW MD2G"^K#G,VS PW"4TEZZZ1KQW'W@^R)-(R@9GD"AUQ+'I[.Z@RF*-IDO #P( MQE2^6I>NMF_B'@ R?"[9=QV.0W\HT%,?8:N#.?>A>">.WG,ON+,$7BVI#@CO MEJ%4>4+7P_N,_-L'<2XB8RR0)B1YF2[T* W&&),P4'<<4&!8L<][*'4#??.& MV"I5R&0V-X"7D$R!@HYDW0+ZF'0&12JLI;@L(29H@,H =$#TFZZJ)P'@NFD! MBN\,H::'O=#D%2#"1_6"+0T=2=AW'"!B1D":!:82B3DD#<7T((KUFM7AG3#E MW VW PBN&"@EYR4;+?MV30O^H*XT?1^9R?6XUJ*X70O/+]E,6,7?6)*@K=F& M0/D0X NQ>F)KJ(\Q "J)/<,]#G0XOV4D5TU98L7Z,V4L(&1(@/;\&C0\1(C@UCB3&,8(*4@2.(PY+Z\AUT M!LXA"G+U_N':V-)X<9/RDEE\[N<(9_:O+!LC,N _Z$ =*CAH0 MW&R[$Z Z -P&N FP5":%#F9T Y(:C%F*N;B"C$6B)SK="'FPSQT0*X [JN(0 MBAEHF)!AQC[=*Z O1G%6FD9NYLK<7+5SO0[+B?_+"=4+Q( 5B/*<4*T.93QO M$VAW/"4Y0'Z E(& $Z@J>$!ZO$!*;75J,^&1A;U%^0U(P1PM\"3D#;]OQ]I: M'22U],@<\(G M*W"$JB':]D.[%2*D\((;.\JNW:.B9_2E-J*W@]!1 AQ0]5A9L!W.T%J60$EP M*$W%0W711W50*+L.TFFS6K4!RNP42S-#\BFP#%!<>YH%H$TO]MML$(1FV3&" M#6M1,C\9_'$5H-H5%'[EH2HH_-(=R6NE\%]\2>H: :A(HO)= ,$/>L)!PJ_H MFR)B)/Y*&"P J@:T&=MRD5Z35"7'PSQ:A317/.+YFH4T5RK%LWU#"&6JV-K MFV1J/#:R[DE&+E;9E1WT;@0@;S?[&/+#O!5>>F%F+,R,JRYJ7<9*O-'Q%GA[ M*<" XO%<"D @LR&U%M$!+*BT)F$%/KD\42[2>BQZ[UR!@\A$T<5IU(^T2A7@IK523Y,XHH,JY#>6PN=R MBBY9(/$*0550NZ4[DM=*[5(?"49$AX)L"F3"HMA.#*D5#@A\2-6T2X3[(:@1 MI*I1*!-%\TJ3F3#NOHBU -?7\:3&D9)*[S4.OB)%H2 MK8PS:G4B5&HJ"325:1>V$2M)X)4Q9E"\B+=B'2(S)U6(N%,5(A8?LGF=R3FY M[8K0I?A>:L"Z.,/I,ZRW,)X6QM-5YQ?:ID#N9S_(BMH@4TOFX;N*D9@N62ZV M9A:M.(F\3MS7<-W)XX6YNH$]VGLKHIO?5SCX^F.Y+423>R!2;A#0W4C%?$\"575A(CS.4,<@U)7QC""Z(W\I#51"_I3N2UTK\ MM,1(!"SPQ\4Z-&S&VMSI!WYYH@MJ@CVV8I^W=9F&_)@ZT2!!"U2 @:E7HP/E2RJY*8*MAM6H\ 1\,K*9ITO,3#$7/V Y6=]8 MSC4UCAQGD(F95&6TF%QI/#I.\*@PE12FDL)4L@R,;X*IA-)%'9-1ZH_9)/!C M3?F)RU&5B%Q"5_J&&C<2DI>4RF!XBN%$!$0K[Z3L !B":Y>F><%CL8]%LH"7 M)&;W40=FH1JL/%2%:K!T1_+**>2$ +4.$CF3!N5@63'E$)H6=FL,P'<3#< M M#O12YYVV!:@*0K9T1U(0LE%"!F_'6"(,E?DI,;,HSAG31LYB@*6Y M_(CB,!ZF;R/R8Y*C7_BUE@B;"[)7(,J:D;T3(?LQ4!4"4-7I^X;17:DGG^B9 MW_:$0Z6AJ2IWR&6D7/Q4.@\442SN+!RT4 J)SK @8^Q5A3>P'"Q^H_11G9B> MQ-)FBY$HXI1Y7YONK$"L41 NM%5M8/0NK M9V'U_"%16%#7#*+"_-[Q8HFIL'=!Z+EWF'@+7(+[4I==4KEIFK#;5[?5:JVV M,T/&A(D"5O$6'IN2+U%0]Z6F[N]-+/=E4GF&\.'<=P&ZQ18%+PA]0>@+0C]K MYL@=IW0/*LBN"7W($S)O ATD]P45^/-91W7EC#CK)7$+TY2 ("UVR"(*UM#N M*9H@J5Q.@*1CE&!PIZO4!WP\20P!6B(#W^=>*9\P0B$2#V6,O/C%6,Z;L)Q0 M%0:2I3N2UTHC,\(P]T%JI6R'T4QD(HHF%0$$C[NH6YI<2"$KYWZO)%^!B2L$ M54&RENY(7BO)^LB9%W6Q28L.VZ6*UL](NM/T MT#L+2#:4V!<-0XB1AY=L9]@"M&11!&Q)%4?BH)$(%11L>IJIAW1GLV%.(R% MA.^$JEHXF?/[:+J'L8$, 8I201'LJ^IG7:\9\P]"C[[BQ"1CLSNFVYSF;#-! MW@ \*GDDL2ZFFB=.5:A&ZP-5H1HMW9&\5A)\I@BH*IBDZ"O0(8IDZ9+6I%R6 M+&(89!)QJDV!'8ZEMEI3 @:1,J5&8?HU13L'@#4^T47N4_<;12-5<0M[,VL, MTOW+5!JA& @5,QB*GL!^ID"%&1F6MDH @QA@+25/1+J;,J4,ZEX1_;CE T[3CJ!JJ',Q:\Z/4I;(P2 M3"3FHIB"9$"^ M/:&JVU'X=I=AY2)56+05DB2;]4RZ0H9QORCON190%?1TZ8[DU=-34Q4C*[22 M9&JD4A#O4&?/"*ZZ#3KW!R(,_$1KSXBZW;B'<+(V1P-!3FU/$HZ%Q\=L[/19$:+W R%Z32D#1Y@H/6+/0:\'B'(3!9.V[Y@TF5_IP)T[OMV M)C[/!5E7(@LI&@&'F8&X(XAF.HB+TK"FQY'(<45>S M4WQ)I/G?N3=,#.%(*6DCU&K6^6\JU@*$)_SL1E4$%(]OF^< M]VT!P.AW]9LT_1EOA31_[7#2_+J'%.P-\F+53QDG@?D=(9%SDQ5=#4PP;.I) M/FGP?E6!DXXV1GU4HTC[!/:31_9%4+$O?K7WJ_OUXW)]=PLK#=+#)".PB."F M4H8X&UJ=/%A;F]I;8>(^/D>8IZHX(_8IFQDL(K_ Y?"W5LY:$JU+&E.Y+7RJ&-$S?'P 16@_KO_SJHUZMOK[@/!(X$:OJD M]M:TI4'B)OM X3%(/HP]F%>Y#9",$NUBIK>7[E2O"*?V&A![H^<\ 83-+4C; M.D!5D+:E.Y+72MINN[G>]=/E=2WA#P*T.GD\'^IN/**@E4B8OC7,D#/EIY18 M[%I;_3%:)?5N%O1LY:$JZ-G2'1D:3L2[(+$K#U5! M8I?N2%XMB37$*TV2S'1N%5Z<<4.*T [N?![*KN@G5:0D5O9D*F:#*)>NFB^D MC$V]4/341,I,2=8].4DH+>C:RD-5T+6E.Y+72M>F6?FT7.BI_D_"ER"DA44 M[>I#5=">I3N2UTI[=,4)'>V%@I)/!K4^*GD"F\_YKG+>D[P4@$#$.2FF6G8R M'3I]/J!F=)G7"DJU\E 5E&KICN2U4JI$2L(CIF 4KJQH3A#V Y7 B=W-@KNT M"WTK8"&1,[1611C K.!])68 MM%2TAU212P]6W4&"&8I.5P5'X5_ZW=DURJ+S_'3@DWC<9ZP"\&"1C]VBR,?\ MBGSL%D4^BB(?"Z AZB:O3!7?=RT]F'!_WOAW\+5:K6V8L/FKYO4MG>VL_YTO M,N9^S5(E%GN(]>00SR/>LVJ5I(!QY;G.:*5Y_V(.Z1)(\T#PN^(('I-21!\* M:BN/"15SSJ>X"H,(VT\*Q[H%F9SU>1QAQ=YSWZG8FU'0X22JFWAMC'Z4PA4L M'):2&,EDB)*)D41A7'^K@\23K_3'=WST$Y#8]2<6:!?ZPUCJS[:HH ZS6R+H M8^XN8;1,#L: M=@Q#"_2[*D05GG59K\]]&S>/Z< *VA@+?O0QY"%9-D]:P_0"EWM2-5C-Q/V[ M&)T!#SA#W'73.8#B-D0O?0V^VNA M+$EID2HGX>KVYJ22NY:O3_1Z&?JACM/RT#P)5,!TTO4XQ=/X@$!PPMSIPF%+ M"LM1550J=DHVT),LTPX4I4P+"JW?P^TT>!-UPR#N='7HM&I0D30XLI+,JB\^ MUKV25(F@;=\&(0 >J"19[/;K9QI>T!P4Y&B&2UW4(MO5IJ^[VM@ -5>8W1K: M)V'%/F$#X=J?8+%_!4.\<[7]M]+R6 L[PD\$I6(WDUDP<$AE@^D.Q+ 9?@?V MQC5T#*W"+'2Z"OE'"5D[0*M,.? 3BB+-BT@#+'6V%?OT'J@2+5D5FV$JW0@> M[7/0ND*.S!FM-6GU][^ *@.$4G63@HNN(I)0 TQ>BGP#&' I*-A,B]2")6> M#)OFB;8N &8!M&,4-2&D< #?^".(@#V)"-C QB8A'.T][ 8,U>E@K(*E4Z=L M70>ZQ3R<0)KU(.ES0]PMG>Z$.FOLL=!&7/>()>K5$C4UQV[>-X02R*ETF,LK M:GK [6^$T'#NL.& 11:9KH"GM6//;G$@GR* S2TAKW.ZO(>T52VPWQW"OGA! MA\BMBGDSQB_)TXVD&%X\&=&+/=@V#B2?@MLPNH.R"XG\J\QQW#$AK73+\()0 MVI<3A&'0"D*36)>E]6.TFY("IYRJRAQLP8Y6[-]Y0A]L-,U4/#AJO#[N@ARI*GMP&Q M./]&>70!9= 1>ELJ@YZV? +K*MF88XT)<;T6B$;UO5(Z'_.!O=)\YD+C0K/% M\/!SS/#T>-G%X$ *_TNS^Z^Z&/5WKL&SX(O/;&C7ZS3'CI[#I#LJ=GW'5<.$ M;$2C!N-!*! W1'\6."R]R9([ >S)WS$+L8ZAVNC=1P.5'@42"=Q8-=FYO6FV M>RL!-GN^5G[FO& 7P'H,PT%L2"YR6>)#AOM1D"X3O21= M&C$7?1)(L;!"I1(J.UH4CY"ZD_ )! _(F\\5Y3:8C^U7H[O '@+_E.NTO46! MA.^ 6Q1(6'J7XS7K"]=4HG$'S# 'TH['^H)FU&2C!.1E <4L4(LGR1@XB$"A M,<,B:V@8I2@Y%8ZE9(!$7LB[]CKO("(B&Y*66# M:4M&@2PP>]6A*DC@TAW):R6!I_=]+] UOA-;#-J!,FE$.8_-N'UQW&-CM_@0 M#1D@/$:J87$$>AU79B[7&$8+]%QUJ HZMG1'\EKIV!ESL!P>FOL11"_P.^3$ MU0TFT9%$LAIE@MN^Z*$EYYK<'">EM(,*FJPS-GA7&;A#2B7'#KX%*JXZ5 7- M6KHC>:TTZPH41D?5XU0J*-8 DAD#/%;>-#G@01\]2+$O=!M=4W(49#71PZ_0 M$*=+JPJP*M%!)&X0-Y"!%2=SO1%WNF_;)YU=H M+R5)77GRA,R@@XH.:6/4M#T6&3 L0@27X\S?M8[.+TZLF[C5$V1$+^(WE^=P M?N>6$X..O0F'NX6Y6"8B2*G7 M U.P0RG)24,"XZMGV8@!- ^BBP7=+HEX*J/8Q#>=54\*1&"D9 # M>MZ4H\- @]B)TA"H+P &_'6#(K1443X:E&T$1DUFP61\P+Q8Q2'PI!="%'C8 MB)$J4JM8&LY"W#'D;SHRZ^JVID+,-M&(BE66=83,$(OC88P0UU7O8(<%Q:@0 M%*I(-W!.//.4B:J*VVGT M36()H18[23@:K Q@XIZ'_^(['SY=P9;<"ZS2WQF:$Z%N-[:,>STL:CT2\#$2 M7H.EI-$EC\&WO4"#0F%FOBE+3F>IVU8$,*!,"$41G['$"P*R?FSBKD[2@,)G M)N[%L3UR05C7,[FCV4#0?AAT0M9+PJZ\-#SU,XM#\8\([#,V8"7[\TD)KCO\ M8"K2MHS^=B!)&.(W*8)/1:=>)5^I0/;CKN!M2U./SZ ;,*<;2QX!4?B@?.GV MQT"J2O](<6[0/!L"".2; MVB#80R($*8##W$6,N/+!Q@6O%G[M(B;YQN$'@5 M6@DNP+YC6+NEW ^!0 *WP_ TP]O4>#>WS>O_YT2![:%E5T9I"*UB,U1-(<=D MLD$"79I!M2?#Y@SP$\/:?/N@6K5[&BX=&YL+IBU95+H>Z**?%,$"C1B(.Q:: MH4C[=*WJ& 7SDRBW+S?9N.@DHC1E="/V=G]V[-Z?6#V<5[17;Q_+*+]XKLXB*[>%THR>]H[0!"ZK'8=Y31(Z'" M*=/%%FQVBTDLMJU$YX0NJUCGR:I)DI9 L>VRQSS,:.M2$=KV!/VC9(D>,B!5 MKE9E?BC23[WAU 1:J3+*CTZ82Q('R&^0.!&,!B1\/;&JW9%3<;[C8K52SVJB MLY3L5AQ1T2-/](1N4I;+[<@F;^@T#\KBP/BZVR2^[D;%UYWH&>Q-S/+8HIAS MP]Y4B JJ(9;BBI@Q (2X:V<"^6%BCYHR ^--U">*^AB)!A"WU-G(6.R@-K,0M0Z0=6ZF5&J-R].FENF[[0@JQFE0=U2 MV:*? M+.65RH$N4@QCY%SM$U(]LMDF24^HKNAT[=COP0WP>:+W2FYI9 *%OV\Z;B=E MYJEPC,PU:M4EZU.+\I".NP4'R%6&1OZBJ9ZP6"PKP!@FI?KV (W4,FAJD$Q1 M5C6MIP T,@#HV//LZ>)J"+,ZF/L32RH,2%EH%+>NP$X/"\/599>0H1TX,4I^ M&0.*.QJB6K$^CML4LG*:(A::!" L&+"J"DRCO1VSAKSDHM*+N@-Y_LJ^62,# M71'67H2UKY+?[#/[*U#ADB>:WP$A21G8YY.3+1O5,TJ4ANL=]".BL$G&(+;S MQ$#S(*0H3D\GFV(>"[$K^^;F^ES:V_;-!?Q;N')7':K"Y[]T1_)::=>'D328 MIDZ#26IS5E7[5)(3O2QM]/7V5(8GIHSZ 5:D,]$$+&(5 M+ -HG,N"(HDHZ)>F!@SK*).S2K_'1'H77?5DI\SX+J1QB%!CY'*+22P A.6^ MF=,EBS:.5TH\%,;ROH*=*EQ#!(P$UIZ#%!@*&J*^VX_ M@'M7L7_A0UT8)_MYWH:?BX'+VM;1CCP0;JRZ%+JZ0(I.[.BCL$(Q>KI=-'/" M0$KTMJ E."(;/'8)E+!>6*;^*V\=;J%W@.&FJ$I*-SI&5\UR(A 8]"X ;OP: M(W8$OL\$3+QY<_+KEC'34UW" =P*5Y4]PU1B2W*O75:Z71!' ' RE7*18!0% M?-'G(=8Q-#613-"#?O,S7(8.O!JJNFFUMW"[#_??RA8/.XG]#'#YFE$(XHV# M;;4W/S=/KF^V;+P*W%*EJ08""QMJ*[M]E1K#$8D]&5 I(D)FO1/:%Y)BF_U. M' T$>[JMR#$1=5>TFXE@X&+\K 4]7 ),5]R&_D1*.@$B3&%?L4 M\3U_+O9FXN[*NL.0V&ODTWZQK0SLJJ:B'B=I.ZZ60^6RGC-THZ#E#R5ZJ>8& M&#)4LM#30Y1R@@?,N,U$F+!SJ@MW?'%C8_P/X"X6XFPIOYHWA.L'N(V>$$2R M;!@0!8MBU:0(4+-/GN:>ZL+,E5>TI:LFP?*-Q]!P!9 5=+<&0S6PKSW'DH=T M210IHCY9]#>A/79]YB'J2PKYR;?MJSI?5 X/J /&7-W!+@=WVI^(?5-5^U1= M_I&/+B)Q7F:*A]JZ2A_F[/HC[ 9W%JQOH$\!?=W :7MLRM)@=F1?)$VI:!0%8T(2*F0C0]I#_6'[>MK$ M&T=75TV([L#<))::I$2UYX2K0[4SCD_<6?3*XM&E0U(\&A9+U$4>:&>B43^_ MIQW?0:3$!V^8H U6@\2J?T1<+#4Y1Q(/H@=6(:1J70I/L3U'*-P.KCZZP[* M69]Q6J[0^(=)@R;^.G:\%'9-:"+MML?OA8K')F>L#ESP.Q:(%I'"!>;V8(3$ M55Y0N.6@<.]:1Y_)0V\9>4+*\K4.#;D8S;XWZHQ\D^'F):I^JJ,_FKGH#V"# M10CRL?^BJ@&,-35 ".#JS@;K8 -[ZED@!A$J3A M+8X?D?"NXH28BGB),*P!" $6D-4$/:#P#B#*^!Y%7RG_JC>T(O9-94^#,NRA MD8_ @BT $I26.L48&@S#LX\O?SL_*=<.24SE]\S!$K DW"+@/F>A2M!&P#/I MVE[0PO@1$LBE27J#"R!0ZN-N)A0*(-";@B6Z.4:QW.3CJ!1P)56=@C2?E)R. MAE1Q%5"%R\X'5;V95/+,2D5+>_/V^B0OR,NXU0$RVT?P>^BL3B3101K7HQS5 MF2*[R-\F5T\#7>$+/8KBJ[G-2822E2FM-E963?N3,I+VE,)J2>#7[6CT$=6% MQQ!VTH)-^V%X0.?[I.6D24@G>9KI=9-H(V!C58U9&8. @:5Z_^11R3RDTX-4 MU%/"@W%:X8.<\W>LX[^4Z &RED[(RA:8M]%RDX8]62C9D6!@SC'5@+.14-B1 M-*GS2YP50ZS2\V[%L ?^:'24-)9CC0:\H?"FMR]3NO,V6R=? MA?ZI:O%:KR<--:U%]9J#R/>+(/+Y!9'O%T'D11#YNE 2%1,VE*0DEU0$HI@IN0IN!#(TM&T>F\BD6OUGXS]M<] .\;:QYD7, YV MOW+PDU*QLD6V+J==!4L- MY?DJBKTH5[".3[*M*K68@%VQX?"I%3FH[B!0 O)@X W( M$$G$MQSV^L ,T$:04>33\._4XH!29 E$52E5VC:,AGN H3B>,LN6BC;L:]U.M( @UZ JI-D>[2H=&A0.(NAZLA/85 MGN3WCKXJG5AXD9D._55FB 8E]01[.R6=ZL_Y1,=N@&I M!CBCL8ZE Z!X!(-;*'L#HH.HA9OO448TZ@4AUSG/225A:KB@^Y^2_=^^34:[ M3DH3GXS(Z1G+M;H!. V!#-\J63>R.A0T#YLIY#=*$]%YEN:&:5E.A)-RTQ7. MDN4L9T52C350F-./>&@1](S G;=G@< =W/'02A4C$(,]+2F3NF9F0>N=CU'^ MB*(&8&VII&QW(W+KHU/F;G5^H[KLI]DY9F/C) M3O6GA&P(;63=W_T)[FVDG^=](,9H -,]/=J( S3(F@NSJ[V@Y#Y90"%<,M%B M(0)5>"'IP-$2/C,94<9"JC0SX+5>+#6MTA\I+7OT.>:9X*#1Q/V+?D")U M14M$:/[8I/!)U1 M62U.^1&NY KE4MJQN19Y$+6MM3\;.IJ#ICP4$K,IA,E MQUEDR!'/[;3$&2]<;&;7$=)/IRKAD0]N%_=3-\=Y G$Z7C.DF&\#>3J3&^7 MDFP8NF'<@ (2]$#*/9DBIPK^10.(JF/-K:R4-DXZZ8!4'**7'MD)%<-!.9%92N!F8=CE#,>00<\73*$?B4CP MIO IN 8(%-5!4!N*2FAT/AGQAX]9YC W3X]OMS([J%H(3;(,(1Z2I*\B&X&EP1\,?E9$@:;30:88KC-E[H@9RQR)"3$RO*>M6,K MTSI^KYR;N41D+!V"RD#%/I^@C1+66ZGX-TD1!B )@1IM[+_4XGZEQ$Y=;7F M6CM(E5:8.E5ATS H)B078X$]&=.U@5NUF9XD&FB5Q MJ%^%6LE!/X((52,_7VV?2ZJGJB+2Q> J:H1$'OB*?4G5LXQ.2&9DD_Z)-@#> M50W^D(_!)0Q#-/3JHE>I%&YT.E*$8^E04SMJ#8@40B]8F 8L4B!*9\:=:\16[1#\][1VQ)$7MDD=2"/*N:^"@?JK%:/%![X22>&"9 M5MO#5&!EJU#Z " )4&R[5B^3'22)^B(BG'748V2 "5-+;"E[(UIB%ZBIV7ZB M_MX@\S"<[VD?@$&G53LXY$>2!1=:9IY:&F+ZB_A:#J2&##= M'T%T59*B9X2*A(C0-3-2J95<^]%;4K;WX:88)Q*YA'#2'?UAWV,.;P4/B8'V MK&*@M6 QT)Y1#+1NNS'J"DH'P3U!48@X8AOH%EKF.&$H)9QT$Q-*VBAT7!VA MS22C[ 5[U A^X0T@6:%!NRI56I M;A"'6<$8EA5"QO&&/ =KLPVJB:6=I<:-[U+H4#:+@IB'BJ_ &X,PA\% M4>%+4@#:LC!7=:,ULB $"2>E9K?:2)0! .DK]>TEB-18S'&*RW52<&HW&'4)!7#H B7_K53:9@!4'>H5QL- M.T?AB 3"_@<-*-2?Q&NW@, &%A8P9"BH]MZ919 3DF?H^6 M27P>2Y#"6BKVC1%T=/P\*8?D_"05TLKYU9-"5!E5&D3",%:6.@K?1SNVCWP3 M$$W',;<])KLMH.NZ6AH6>,LO&VW?@T"X)BL//82^"@QLZV=+5A=(8S@0'4&] MYY5V/.Z%Q5[QY",E2*D[*@:K9>3EP''B/LL)?10IG]H70%$P-DF=;"*DT8&M MM(YUZMK0W4[SJE#)GO2H$K0ROH@D38JD=-P-,BU\"K#R&5J]C=%8K$QC=,A"H%XC_)@5^P/J8>H/;ZL%':+DL3* M)-2.)(E/3:M\I.MF:X*31!K1-%0=Z ,?H_?[9"EULSX(@AZ/+V\/QJ ]WWB\ MB;@P,F*1A49=!U4"/-?3'C! QQ_JA4?W)RAH^$J^#,NV;"M\4 MZS%)D1F5MC.GEXNJ, HEX#MJ%\*/=7" ROE#VQ3&]G;--4Z,WH8LF) 8U < MU_30ZOU8O=OHZYC-5=8%UE&6QZ/3V$EX'%+$)+:O:)=!B>#>&)E4UJ'LGH,N M'3(X47W=,9+2+ JI4 _A47N'(KT4H3*D^$H@T:"?II9DSJ@]!* M32DQVF>Z1DGF\12KE.6/.!)ZC/B],FK"_4&#@/8\_&-.UTH,=!@E3.B,D*9) M3IHYZ5#E\7#8K N2)@_P8[T][9VR)M0.!,V1Z[P1 MMS1 #M#? ?77T'Y$3M"SJZ!A:$9X$P/O M(7Y WF(L"8+(H(/2-B]N3KY\W"K9.U70M8TKH-G#J\*HE#?Z[6IUDD4\,EZC M]9<]& 1O!*DD\$Y1R*P1 A>D92)NHFQ&1JHE<7%;)2M;Y!4_=$2D#&SY=Q+? MQE;%/A]]#)<-%]J4+M=!WEF^HD(9R/HT[M?54)(- MH;R&;0&"9DJZFJ0"F-Y,HMD%"M4T"QI6!+4[4H5/S0ZC3%(!S"J/>1"R<6:P M'"#Y(<_Z](VC@X+E4.6D*+\DA3@.)2\(V1(O"(LY8'']I)9N0$6)1FXK%20B M7Q@(-51< 0,:N]I 3T9$1.D^#(/9YNFU@CMR.6% D8TY80:)2E:*0HGC;/0" M9]BGBBP==?&I^)BQT-G)@&B=RV2>4"ZRU-5WM=1-G!S50'H=( +^'@C86:/T MF6\2&:^-OF1_J%0;01$/0*\Z,5?>8J#ZM9+=J#1^LA.O6X9NI\JM14494BTZ MTIGU),(I*#!@45^FCX\M,LM)+UNI)5.L%@&VMP M; -]Y'+;Y6W49[>)+B7&VK ?-0YW=AK;N&CB8&=GU]=\4*U5&_5&I>^VM_1E MJI2LWXW]NI2W'NQ51P'G?H?8':P7!3]#QC*XJZS8M2R[CWM2W\KR=7N +0BZ>^>N>&\&9]^_,-O5S_^CX(OGD\ M^DIKMY/%V\=9[S\JO:,W+3%+).B6&D&26V!1 'IN\_:KI6K]4.]'%7'HH%HZ MJ.V9'<(( MT,2^4CUG9_2@8L8EN6A$Q_079M(9M6VE)6W50"!!PG4.F*?3;) M(D!5V2G:RO!UH,"I/%7&VCWDTH$NB1\2QHW%HEK&QJ>O'.L$F/M.ABT@ M?OJO2<)9SEB22E!&F\K%B(P-OPF[ %*MEOU:,2 NJ,C]+JQVR](VH,Q;*22; MO-*IV$"&88%8.F]KS,:"SNJ)S$_&'6K),]W40F'E6.7![P O_0L$-%(LT]GT M]+]AZX(P\+:26@%<]>OQHZXW;O6A=%R*90N,->$A^$Q,IN9>NRGYT?YJO>V53%H 'A5#83_%*K)I17&(-80LIGWE9&E" MFR]=A,0[BB\"QR0CFF+>QB_<0@DSPEA,;ZC%8>1Q)K8_]6;JF,UT?B7?4G 2 M0V.>3RK:R'&-HQ7M-AKI5"B^LF\-U46C*%F24U(/>=S7/O*,2H)1.W"H2F_2 M;0$CUJ<3#MIM2\7O,S1:J6FTA$_=CO YE!2X!P*!2@S74=$FSC4*BA#_I5\0 M"M,3G?! F4><\.0Z=U%\^U>CLIOXSHWS?7-FN24K>\ 4+2RO!E?*-!"C\'1_ MF/&@;ROD+P.=2/WF0>R653*;=IR7U8X1?-36 S*M0TGL:&W<-G"#KX M!>!3TQ"$\"MI(?"O A G@*W':1G"@YWI??@7]]@% 6KSN/GA&A\/VO"C5@-Q MN[Y;L73R?AC\-1H#<5#9>:X0ADDG,!JY8.N-WRIN_!(O2-5"S)MN$COY5"=# M2@I4WH2Q1V$L4I9K8R0OU55L"Z05E..)FG;L84_;K,,:#=O*Y0E^3B3)- -3MX6=TL87/7LHA(GH.P=#ALR*?8DN+D\X(+W M 6F1(T46W8Q+!5;[)E?'T% ;8\ZUK,]#[(RL>U()6)^/86NW.H!=I5T=!XZ1%K"#70;XA =A]Y(^JRR MR^2<[3G_FQ9>DSJ5.C R#7=T6 C'Y-@8Q#B,NCW!T,R"SF;F@6QKT,;(I&M. M$1\,YCHL@KGF%\QU6 1S%<%D>G"/WCN*(6D'H4[:;+>,HU9]@.\7-B_-FL[FE09%V795-^7*CC]/" M-##:+5#,X!U7&9K0]#/,G2I*#'&OGV'OM<.?;/6VJC5V*[,.X,?U&:F';'$T* M"SE/+D(2&;REO*8MK ;,HEQ&4.9^$)7;S;AD3=UR9?N-0<\/D#XIXHR1=H$J MK$YAH=D$V\R@DRM5R;Q/M\7M?]5W#O,VP%KUG8S[1S7 :OC'=$P^/CFFE@=) M@%G:OU872\R@"*(,$E13C28IV8\0I!5 8 P=6%NQK\@Y8Z)Q,YPZB4Y.\NTH MS3!K^D"S.!6K4<>;25).?0(CO%'5'AJ4LP(F;F.R]3>? [CJ5I!9CBE2Z*8,TZQ]2297"Y]@LJD]R"\UG>&*MF- M0P6TG0<:':[CH!#,&"6KX,4%CZ\L ZAY>\V5X]5>D*YG865#V?3%BG4Q814Y M!ORE4.F4:"R.C8^;_U$K[C8-M&N>)'AF5$8NV?QJW3/NW M/=#S:-%(,'+;?-\N>\YVCIK55OW7;%W&M5, M00S@Z?B'-MER'(M!(*$\& K-IAO5ZOE1.P M.R'F%HZQ#[LLA^:H ZK \@J-;&+[,L!B.!% M=9N/\0/FD8$AFT^C M$NL#)0 !E^QE[ZK0B=E,UW/&= X3.:=>TAYP$^<4A-IO[Z .W.5(PB(!*J2> MWM[,0+:5O^):;CH[:>K;OD-7S40L]CG[-G;E,)_Y8/^S?N$@M_!\M21DS]:D MA.PT-DOE4Z";)T)TEH%'_@*3VF"6P._+7VZR>0L!,0IO)$6.V(+R(5'((E5] MP4@*2X'NQ[V6*EZCMI:&&J"](QO2G0HPN*TD(NHZ[:;*B,+)D:RD->+#:R=8 MO&L=W7(L<2I\N!9A*[@?4J%+*A313$-HKU0M='L3N\)L*<^5TB>&11^+Y5[0 M91Q:25,Z(RB2>RU?/=\?[6FB# 1!MJY^M@2AB12AOHQ(F#!CD6/I72%[TC0( MXZXN4-3E%M62J^V:PJ6*8 $)1,84A*9TA:U#3]("(HZ@UD 4CL@WE6R3\** M?<) 3[0_P?!_!:#M)-8^T)K18:B)UFT0PHX$%=7/"(B\13EX PJP0BLTTMZ@ MQ\N*DJLE4?)D&$1<^#(;Y*W[&@%_ZY,NAKP=MU)58;0WCZ_/E(0*_"S <6.I M=T8W$["_^4HD,YWVT&5"X5IFYS#YH>^I=&.XB3YU%@IS&:.Z\U$ITTA#NUEA M5D=G_.E>6Q7:*KU)NH2>),\09QA9GMT-BJ/+5@"S#6VP9Z<-;[6=LZTZA)&% MQD9#$3 :;6^GDQ"Z8"<=KL4'@1>3>1;Q ,0)H<(A3(EJLTVF/#6%Z>F4%.-" M4!L-FQ63@*@2F+6S.=''F9-DI/N\0YPP<2PG;4ZPT:!N:4:E5@A@?8*ZY6&Z M;265DXK/E&O*96)J5>.=3JKCM*F:8MB!/4FV5>.8*81&R88ZI[@=.#%M$0*@ ML]-)0=J\NJU6:[6=9PWP66D*NV%FR;@9KV./EXVK,>N8S3IA8<@QSS=]IAV< M]5UT((][T>GE,1=Z=B.(]SYM1\K*!*(+AF+NBB;]J:* !M;UN8X/1I+4JD4HR?Q"26K5(I:D MB"59%UT#A2 +A;V0.A!@Q6_5TSD1K4R5P(_#?H )(S"14[X2$3;K"H?EIAMR M%"\W/UXU0F79MQ5W*J M!N"J%A;:"$N[E>3/,+L+NAAP6]CF5#75DY +-53E%LDKBX4MJ3>C;@)CPA/R M";C8LQ">'*J:H=S!KKVH@6FA>K2SFP(>SA.XUB0U@= "M@ X?Z;!!X78:O>V M\4O\HX2'['Z5[*ZJ9Y-4A+9,R1@< 4UORH9&$1:YG4Z]'3+CF,8*3WU*XB6_ MZ'NN'/$3L8 YIF*!@1\]LF0,L"37S=;-?*B@P_$S5\7:Z*71MN!ZLZ"IOLRF M-9\*<\X4-LD:'[!8/V#2+/:'M,?D6Z-$&FA1Y5M4R\'STP:B>"<8Z:V##&V-PT!I! MO=&&QSJ:75$5]!%2[XG$.MY$]@"TL_P;DX%JQ./;F\W?KK8J]HE*Z#.E=!V> M&&92BP2JKBIDVS*J>[86:"M7I37?MUM7.U?V?*1O&)LAN"I0+71)U.EX3JJV M'T0CO1^%M'R@(=XD&$VQ7>SU3-%86*9;Y1)F*^QD*]'F'//&I-V.56\C%4HS MH%U*+?B)\=Y*K5K^]K5:K57^ZG\0#+>$OZD+-?\'K)]3?!=8W/LS*/\0&,$X[+96-]!$S MCT9$225CJ!:$MM(,R$<;FNC!C"2@FTN/](>.3$48Z]Q/&4JJ4*B6VVGK1"/I M#+0#P,3CD8"!&H,(G5A$20"-*TC2[:J"<2 %Z7@:]$TDXGPZ8$MU0,8 LKSA M&:1T&6,3!I6PK>7G4">R*8$,^SQIQ4@I#.K5%@M#9(JJ7J2OC-VZ.:42,F1> MRDB+VUA),KA.0M,22=YQ U!EY7D%3"8^R$1+T(S9$Z,0_,1>#@*:G^X@!AQ@ MJR7RQ>-^9$\AIYBTAOD9<#3@PDDG/YB@X\5.(*E G@0N&W10%D7FC$PG 4D% M4:*WY?^R]Z;-;6-9MNAW_ J\O'UOV.]"LB3/E74S0N4A2UWIX5G*SNCWY05( M'DHH@P +@V36KW][[;W/ !"4Y4RE3G-AT:%$;4:O]<\R)&9$JU<,)WZ,J*\"D& M'@_3HDS;)BT,3&,&QK!+@#*ER+)8\=7N1#5JC02&HHY^%I=.>S$LK1D<*(;@ MR[1*V+7DDB7+4Z'13,4;[3CV.B!OUJ/+HA"X?GLZE[3NB[1#IR!]!*& &XL\ MMGA"J !@20_]QO0][* _.D2Y609(%YN=ICM.6P[_2#QN&Y6Z,C;#X+35R%PKKM$H_P-U'A=EA@2)F5$$$M3"$H MM*6*60AJ,W#>0\Z5EA&V6_'$*X;53O>*M,8O]%*FA#L-RE5W:61MTM"88>AW9ZE7H3H2T$],#6[.VJP3]"$/@>^!"LLW. M@.V1]7P MB.#^U60X \ D$GW+_20P<6=5>I6Z%)T;D.4%19'X@OS8MA*W-G69NIG0;"_2 M?QOM43&%\,0JSDFC*0;QG6K)!I"+A$L!#A4>G3ID>[:@6C\,P!L[W[4QH+& MK!#&=[%(\'1>,.SZ*ENLS25P:YIV8F $*G)/)-NM<7?N+&+3Z8KD\YX]KS,Y M#=)9VD[VI+S>%LZ]98>#R3?D8&"T7+:IJ8*U5&.LT7FIW>,U2: MN,\B$^G65#]_QRVBW9[021%9^>MK@R7]0T<"IN\'U.W&O]B"X$S.Z#]:7,^$ MU&F1T]'V)TO[\86IFSM//2=O2RYJX4WPRE+K74(H.7Q=PQF-T"QA9L7N'KM^= MDR=ZGJ).I-D3T.#<7J95II$\.9(V1$GL8"H8K]Z(561.D9IFO/G#]V[K;>R5UEC!0);WHX]P0+P?." M:P> N=>DS/-=@(6-BR%FY\:G(\I/^_&Q1(.%[@&?M5NCP6#T^G9*H@)(@06W MV^E+N8'-+;1]'O(:;S+)OQA!%X M;3FXI.D>_^K$=L)I6&HE%I'=7(LH;(4D$X8@@%29>2YU$Q9>/P57&-7)/5OV6:>6TM7H=]TU]#'FQY MBO4SI?[?)CO^\)KL^*YOU?6!O:,QL'>+@;VC,; W!O:^GMC8:5$\)(7P M[JN<.^<(:(G#IE91%/67Z%OYTI(FB7/L0'?L,-DS$K^' M?R4U(X[MRM<9(+H LU."R/%03T;B(.%HK L\9PZ<$77_$:OU>^+C"#"%:[7< M>6P:U/6N#4>CU=]I2C%^NW4+\6OM4UY?9C*@[3)[#NA7;UX=AVA&ZPT82 XC MU'!5=(.@L,EU\2X-AYUY\:PWXKH1_#%1M\0FYZ6 R;JR8_W%SDS(NL.(-;"; MV#DTR\KL^BVZI4+!-0M\:1#4 9W'M2\MI/W V%Z1VGUIZFAJFRH[/S=5 MC>('20T$I9P#N1@.2-)",Q60M@D%<=I^8,-51/*L_]DNEDQ5^16E6"4;%TX.XX:WEQ3\ZV).8BH9:).7%/2VSL)XR"'C$'/! 79;MIVCX MB<*R5X<0JA*,97&KR%21F-@2N-1EW9M5C.SC5P.@#^YC,IC@9#CAS"R#,N6P M4"SXK@UX!X?)#J03^_U,-@_).5D9%$:&.1DGA 4X2=ZFNP%>B(".,9&SFJF0 MG H"2$;'E%-LJ]A<>J))2QXAU*&:G@OJ0U'&)OP9Z7*I2",=&(;@)-L4E]N_ M!8GULM(VL*P.5F=/3RT-RAXI/7BAMED/M ?KRR5UC'#<87I<*&/%*,.W>$)_ MG?STWN?%HU.?KS\K/V6.6EKS\2# MJ"[NKYB]PC:]=]$NN.5,L+:9K;[;/T=RI"VR?[72O&QK;5,F8T0=1 _ !A66 M.9.K!%V5SI($&IR66#HE(P7=0]1!-GD.Z<3224UH]P;C;U-BN-"'"([]QX&\#J*C3X:=F(Z 3;>0W% MS++TQP@IO)0-'.I$NVT3L:3-I:Q5*OL\IZ>&MS[5DCM(J_%GGV$3O9917BMZ+& M7\KLG5KCT2)I7#%"*?J4/12PE,=*T;@>LS2W ^Y,:G EH(S0>M!YF?VE>B!: M7:.O')72%D_H-Q.Q*+"'4.31S[^\CU_"3ON B,?>:VV6OO<26 6-TU9A-9RS M?T*+/RR8!APN,S) 5C+S!*,%9Q(!B#:)0L1/8#**'P)KD]-HGKD,Y3^3\E); M$^#Q@V\*23#K$W228]R9X&HT6E5B]3WW MUVW4^4'[E+N)'JO"_HE6/-@^9XB$AT/Q-'0,C#M=MCG33BY(R*2TW#1M1\+! M/'#.?0^[VT5$@1./$>>T0XN!^U+:,&[_4JX7[KNR?>V1E"Q@%F0]S.ZX\+\^ M$?EP3$3>8B+RX9B(_&X3D>0[VQG=*0>98P(E,D#1RP"@$P+YC0.JIQ-WQZ9] M%\UHC^PR*]G&@$F"R.,BW$@T.2-YEJE%6AD&?M%G666A[ ^)&K/FZ11* 65U=J;-^ 9B\C(#L*,)^1HU9Y[3%[QGO!JFQ M>UK>.OWYS7LM;;WO:^_JT'_M64"N5)OK("] I' 8B]'CS%JR65+I_N;P/+/( MY%V@>Q[K>2GMU?]JLSIK7*^\AL_2*;]7]0 VX_L"GBR75*O+:/F \LX M%5JV@C.Q>2[\N-K%7*V"!R*PHC67'+(^#WB-ZB3(&=AYB"4DG>#,6>2\A9'W M;-LN,%FWT5 /L#H*G.7('="L5"8U M=V:7HE($.!O07.KM2*,6YJ6^FFTAM^0\,RO#]*(04?R+4(''Q^>5X?+OKVQ/C%MU';9"$?UG"_K;PR0^.CAX M+/A#+X3"@ N[C0)V<+XYC?W&QFL;ZQ3VVE^<]G:*:I#E(+H7-+7X3]B^())$ M]F]G[HG+MJK;5,I^)*C4>WR*07!QCY+2VVB+G:62$ D)$*<31% "?R%'/7S+ M[;$DB"NT9 ISHWP$^?!S,E2"8;L%(HED!RD!C&N7CNE[E$>(9/%K,ZE:$J?1 MX3-LS.%CCL,SB(HB$"J5 ?,(?JFN,9?1H::1>]EG31^,W"M[\RMN'/7_+U>DDB/_OKYD!R1GD%I#@KO2#EI MN,56R.G(3N"J04\A%5RM1?K1)!(X7*0S^B7XNEC2*F."*:_I1H.//.^TW. M><3N0N /*K'$H[K!1 >F56^<5J1\M?AHN]R;0T!SP[0=P=PHN L^$?Q!4X/E ME/THGB(^Q"'M4[-L#$-./6=]\X1M0%"0-5OYY)HG6%]-V!P4?BY4N MMW>RAE:8Q7&HY(I2G\NIR=8HE9MAN(.8I7+TTDQEZ*(KCQ[9T'4E54DV\D]C M@E6N"RL)ZY4>D=%*W1Z9>*+@R [ S!Z(.9@.P_+GWGT7/ 2SR/;2HFBY!4?^6?94ELK80$%U]=LFL6,8-@95O ^5%->94"<4GDK@0@&!\11%-" M\Y?FEN?I,\<]Z4] D2\1^65Z'B?0(WNWU=A#JLA+^[3B&G06F?&)!2TO)=!$ M5E%;<"[,Q7AN()&\8]O$#_\GDV9C31?[T7&>#QM@5NI)E1]'M2S46T<*)Z M9H;"RL;*WMR<2_+;JJ?NJ+*"-%4B:LPT32[GE.,8X!>W1S20ZW@"ZR15_)%3 M_%<>?36X<#>^#W<\8[G;$T*83GU%1E.U3-9<$P%3U[I&12JHLWWJNIYHD5[G MX#0ZRD GE5"6KZY>TQ5\Q^RC M:UMJYD/HVB@NMT[*UT.A+I-0&7RWK*/KT_./QO3\+:;G'XWI^3$]O\-Q99H# M^I^D$O%-6GUD1-D=GM"=4_Z=)#L'MVS, &A9NF%P.F9<#3=IE%H( MT10S\G*LHS%:?N?'/P.-DK;T5B*NN$'71=:R:L;U 4"'!-V,9/Q3B_SKG]2= M^3%&+G,NIF%%JB3A[5SD^?]JZ06"2BYDEE=&"7LX!H9NVE0O27P\Y?H5;EG2 M,1?P"\D?6@EB'S#4Q0!'T:Y]=98J06^ZPIZM"A"Y!>/PM8@I''4, <85L]JR MEYV0(N9 %[MWW.E )S4*\Y.:EDSLEY$1E00GFA^,@;<;N/X>EXG1TM(*O9$Y M4P<)8B<2HTQH@$J"/:ZI157^] *KS@^>HZ036BCJ! -LL07PYVK:&'&N.(B@ M-KB,1@I%I,S*<6>3:^8-%_<)?MN=P9/ MV@6&/.T5A-*H5;9'J[!+V:7[8S;&#+U#-EFH!(!9=YO/) M*L8UGN4K82WD$(U_)+MIB!L)"AA#[4;"1.,+ 346R1+(RU]YKRH$V^G:@:*0 MO@)5-DKIT9ND^U['+Z8E;UH!^E5PN\M^M\4Y \M67 Q>0&PF'BJX-_Y0+TN? M!;14J)>T!FO32R+7",N>/>N0)OVH!2].A7FE GVFE?%(Y,,?7*U%]O%P<>RE0GSJ9PG?JV!:59:1XY6[AA3$O1 M%4/#3ASVO]%(85O+280.&ANOMGE"+TV]S!H3I=)?81D$XV6YM!Q,?*K5;G#0 M*IK:RPTG=Q&%JLIRP99"$&N7R2 4IL'GV@B1I)BQ*]TW(K)B ;YHF]8>RSW*$?,,:=?8\3DFI^/K$T'\T7)M!P$_V_@K_M8E%8K1 _O$Z'P$[X(>5U9&3(F6M'8N.2!274:],;[4O8)O M;I:79FE!EK)5\'LIR0+4BW"?G**'H,G1]ZKY^4:]^8ZF]#=Q:#H/X]?-S%2Q M7/XBMAKTS0\_O6.HE,CQ\R[(:&%;IG:3'_VA;1'&FS=+;G07"DX8&<)@#:1O M;>4KI]<4:P).4PP<@SR[* 5S*)U8@Y6)] (;EQDE+)A=U*%N3J5B8E!6.3 ) MA[/' 9(ZA+KP/-'UJF[,(J@?\@@-/$X.7^GHG>QA\(ATJ4R* @(TL%BCP;$E M%_1+!-6Q$@9$QR&826W+-SJ8)]:@O3U]B[VQ]9 O9YOB>@MG= M#T*Z-6/PHULLG?V324!(CD DBK!<[<3_\J,3$:'XJ9$,\*C7C[TI]9C M\D5N%MQJ.+W(_ETN+TAV9JG&QI8EWF+#T3U'T0I_,8T79TZN8CW!Y;R,VHFVJAFZ"6MHZ^&!Z.@ M(2N+HI2X$B:K1W+\S9!&LIUA8I]W4918EXZ:9$LDX9=HDG^8AB\:1W1?U1_U MQV]C[]ZY7?VS)[1A]^)[IR1IF_2RC+D1$S3_][_LQZD/IE"PV D82 Y2B]#<4/V_?O#P>$M=) MEX$V#@R2=MF@T#DKF,"EK/;CXQQ0762)NS<#6X[#U?/Y7IZ2 (Q[LT95/5[+ M\"X=U< 1%$9*LM5OEGZ^XE(X1F9E!G!\)G:CL8C:P&AS\<[/RE]OYD=6_G*T MO"=K,2%OOD\06"31/Z==$UE[=:$H.\S9'C*?W*% PO65;X_'RK=;K'Q[/%:^ MC95O.^SA?8E=\_/QWXZW)Y W&C9?.*'.]M6)Z,()J^G)RIL)*\FFD4=6U*2X M&T&=$7ZU"M9#J57SC#>;L/$BF.H5%#R9006 $@-0[5-EZ!ONS1( ?I/^N^5M'%/T8AI&+J+XV!O M;BJKHFMD5;S%LNK.*>)O);]T[VP;6O0BV.5CEY$?I=G6G=!W;16%)8E"+ M2ZJJE"K^66#&^/[: $!;:6/10LS$6*Y0)*U]U (R0ZM=7$#&E8W_Y4]=UJ]Z MQ[W'&WJX?0_XB^?7<8 W.LH_P!T-O.&;/W_ ;_Y!?5OO*G_Q< _VC_[<)2>? M?"L'^?S)T^>W-,H_6:Q9GBZ,CR$%I 0\!J5"$]QWSN1Q#5/(%J[992&U9J:[ M\,Y+P0%7$B.-R+FA<%$XG+(5)W8[C^AVCNIK:]KQH'SE4>V<\'*V)\;IRK;) M8\G+XGP/:'2V.4'\G_@>$ A(31_N'1[$!?RR!Q_/F2"#L>MJ99%#[QPXY-A' M.<_;*7W@08960&PU8KSCUNYHVHRFS0Y*!QY?5KO6 MMFENV#JY!V]%HRM D=L#-XI%#:7//R;AL!!"D7,FI&1 8_J'4 /=._FO^X!T MVWMX$ MG9NT_VJ,1NG?Z8E@P?//SO)T'>#M'-1H^6[K%T?U2B!MFY+1@D4:[GV+WL9@$8 BAC(I$4YR^89*-^% MIBX)FE=RX,:%=(7:S,#EA'4Y%8K7((H4(HMXS!&RYD00@D'/,QB.IWC71S6* MNZW;DE'QI@#O!.C&H7 E,&' S/.IKV+/XNYJN[MDA\."ZVXD M]W9F\'^=_'02H,%'[Y6*8RPMW)[2PM],U&F+5.*/)*:+1/ES6=:9:P\% M\G DM$ -P##QX6LI:KBN^S*MN,8*$'(F!>NI1\KTP)!N6>U0>&[A_!5:T:UI ML!QTPG'LK&7[1+CNM8!?%$@7[Y:Q.I+D'QP2/\@L8Z1.U MS$TI+: ^3ALI?B_8LS=TA:10OAHQO+9'V!S7$6A3^D1KB4-TF_-)4>XAH:6T M5' _ QNI$)1*;7+O;'T2OTB+=);*=7G5XJ[2L.DS0.]@WDNV,^C8_&PJ&NTJ MB5Y7S*N$+_P,#,SX;U6&RWD_UM->TA'/&-\V3QOF;/8@NXFP.,W5[^+Q,]TF M [0 C,015Z$ZZ9S>U7C:EL[8]R. F7PQ]XSP51UW26C^&/T,@V3^,?H93@+\ M>N:!S05A9MY6 @,LNVHWF2\LBV(@?_J+WGDQO8N)J$P@!U==B]'R;*ETRYB4 ML+PJ[M#=O[[M_LG8=G^+;?=/QK;[[[;M_LZI7;0/D5!'Q$^"B^))*PU%8Y6= MX*:OA,$R,)@'+3?MU=8:7A;@HC&F>9HM:MN=E(%=E6[ 5/@%4^",U5WP%> 9 M>N28 [7VP)=-61I.]-A_!;IJ+3,8SK>VN+\,BI]! @7/%]T&C-:<"Z[!;I, M8['02)66^:7HE]Q\4IY!UEBI> 0D%FJ!D82VFY4C\^.Q"G:76FUU[9PB M;\67&U#0P)@I9R7$*!9JUHRN05H%I@!3[S!TWK2EO[ ]&6Y&-N\]10+L%AUM M9FKX"_#D=%OT1CA@=.N8<&^<6QTYQK95CDE]7$E#]SKLQZ_%_ &P0-(9C#!4 MVM@6V(?49&@:.8M?@#A0 YEW#>H@K%[]IWL:X,\C[+D,^9SP./V M99;T-;%9$4L7IA,+&8[4,G%>I,1\ /=E8$5GK%IC<\A\Y*_NX:N>U5N(!%7_ MPT+#_)[+$<\G('F!O(V0& M0&E[H9PK84^WPX)AI@PPB8OFEU775H@P8#5XW;CQ%$567X#HB=GW9B ^YO0$ MD%-HY6$@O2M8JC+"%X F4B_D7C7(&\T34!"@S:Z:>/EQV B1Y#- M/0,/[')4L05B-+Q%0V?.&ME12Q1M'0"VORW"RW 8<>-03N9=TD=D = 1KG&Y M?/AQ@Z%W@19N[_#K$[OE@OU?J@G/!G2<*9\EX^I/C>5K!\N5>__I M^[-W8L#3!QE.E.Y.R5*]G$<2"852&"7I=DA2LLKDZGC>T:[/&A208^OX1):% M8UQ*.DC@8DOT;/B.$'J9U4ON]L-;R;N#+0 NFL@%R2^RI3Z'O+B:!#);/SZ( MW#'_W(&JU67'9UV0_Y]E!M<$+J,ZMNIZ#><0)ZNH58.&1!@N?S;+D$MDX]0N M$,?Q<2T*@W^)]"RK-[I!(B_7G_[#:+F-Y_?S>+K_?[V?D1=4BA!T1H]!8/_ M/S\<'78&M2?D"_A&/KO=2_+#3V>OWK[Z]G+P]_B4^/CU] M]^+D^.S5R_C]J_=G)R]?G<;WSEX_?KV[,-_=T;>K8OK[8 >)C>Z0\Z= M_-[77U.:YT]$/[=S\X6YU7OWPT^O3WYY]7+#4@VLR^WNU$ -Z;A1&T9[^NK# MR?$O_V/%.+;L_%2[O[X] M@0F(Q7RU:3'UU4?_\\\Y6]VW'-[N_*Z]4?K*Y[U7LC=UFZ[+X>&#@\,'1P<' MCZX?R#>8^[BI-WSGX<&#QX<'R?/'SW_''CX85_X6KQ/=I8.'=)T.C\;KM)N; M^L-/SY*#9\^29\]^SVT:MW +MG#@7E[KYGRU>?>;_'8\!'PWPYY_T'GXXV'1 M8QZ>1#GCU^\^Q!]>_?SK+\=G)V]_CCE@>O8J_OG#N]_._CY&/.^X(SE&/'=D MH\:(Y\YLU1CQW)6=&B.>.[-58\1SC'CNB"MX\.3!X7,.T?"D;_I_]UY((7N* M*J3[W]J3',_#[PZ6/GSP^.AI\NCP]P2\QV#IK=[$9Y)[.'PZ7J?=W-0??GJ> M/#U\ECQ[/&[ACF[A&"P=@Z5W*5CZYMU+&RP]>7OZZR\G;_=.WKY\]?X5_<_; ML_CG7WY]\>[T57SVX?CMZ?MW'\[B7T_Q65N+>GT=JI:ACG'7.^[.CG'7'=FH M,>ZZ,ULUQEUW9:?&N.O.;-5W&W?](Y;0\=OCE\>C\_@G!76>/CCBH,[C;^U MCIOZ>]]YE#Q__#AY='@P;N%N;N'0O3RB2_D +;KCIN[FIH[WW<.N#K;_' M;/OM(FO,NJUVBP/^^<.KX[/X;Q].SHY/WO:6ZL\\=E_KK'U;@^S/GN6X0[T, M]-.#HR-'#Y\_'^_+-NS&EYHPVVNW M?#[<])5*^\8#=F,3YLM*]MZ_.+O_(#XX?'#XE,N,[CU\>CC=5+LWBI&O; 8] M?O#PZ$GR].&-[=('XS+>Y+(\>G#X:+1>MF6'T)Z?/#E\2@=]-&"V84.VTX"Y M_2JW/[EX[7JJIZ;K["(]73EXQS+$2]I4+4%^_>O']W>G)V M\N[M:1(4I08XI2A/??7V[\=O7Z#B],VOIR]^>16__O7M"WQIK"F]3>MD"TMU MQIK2'=FHL:9T9[9JK"G=E9T::TIW9JO&FM+?$=X?V_7_K'#F\P='3R1ZCW#^ M%R4 'L0 8WR,;S^_-O8_%DYM^<'XX:?#)P\>/GR2/'PX]NUOPY7D4M(1Y'1' M-Q6XS\FC1W2='H]E^CNZA]]#+>D?:?(9DV"_U] :TY1;L$,__/0P.2"GY?#) M)ASJ<3^^[G[<^$7C9HR;\1UMQH N =K*R=N?[UA%Q8@;]-VE:\_0>81L+7WX M;._LP_&O;^CG%_$I_>'T-'YYWO'@^)C]G9'-FK,WN[,5HW9 MVUW9J3%[NS-;]=UF;T/#@$*LGAL]^1VD6;"R>A#L;,[BZ?"TE% M'3U)'CT:D6EV= ^'L=T?CCGB7=[4\6+N_AZ..>+K<\0#0)!C;/]SDGWL+]ZF M'>(\\=/GR=.-P'[C?HRIR7$SQLWXUIOQ?>>)QYSP7<@)OWL=']^0*V;O4-AB M]@[O=U/)[]Z?O#MY&1^_?'G"G;]CZOAN1^3'U/&.;-28.MZ9K1I3Q[NR4V/J M>&>VZKM-'?\12V@DD_D3_<.'#PX?.^S?NW[A_7TDM7A\VW<4D[I\0\AT1UV_#\/H]H"O/'QPR6OM!/ *N;\TF M,X+*\V<'R>'3&^-0CX#K8T9QW(QQ,W8YO;OUS#"O?OWP[OVK>[^^?Q'_[_CT M*FO^;:H\+6;T@66:T<=_KDS:Q'^KLH9^Y('07^.3RN!3?>4ZGLD_&%(:A<97 MMDJ>/ST\>O3\T?Y8OK8-&S+('+QW\&SOZ.#HX;A#6[!#),*>/GE\\'ADD]F& MW=A.-IGMC,C\_=W;G^-_X'_NO?K4F&)F9O&K]_'Q;Q,R>1KXM1;>S59H369=&41+ZMR666F2:L5++Y%F^LG M$.HJRDN3Q]-RL82]6L=9$>-U**Z/9%;25XNRB:=M5='K\E5<7A4Q_E09 M7%C9Q=5^3-^*[;=R0W>VCLOY/)N:F 9&_PL?+6MJ^D963+,E?==\,M.VR2Z- M_6!>TIVGNYXV\>&CY_'K;-Y<1,>7IF@-C;8EUS-^?'"0\%3^NZP^^G^AP>CP M8+SA6W(EY(;_8L[3/*)[/C4&9<'C1=^R,_:Z*A=10Y^)FS+F_ZI:GIBX2!=T M$TF+3O,T6Y".K;*:]M#JU;*B'84BGI9M5>,&QY.6/F#J>C]^865%0J*#A,&Y M" I[#)+XG)1U52Q8U4]9AR=1.EMDA89U2"38W],++PVMQKGJ>I(B;D0F7IH" MCXS3\S0KZB9N^0/TE3*G9]!/S47:)&[02WH#&1(T6!HUS;1(SPU&D6 :^0PB MK28[9)*O(EH"\VEIII!'M#H7*<9$7R$S+Z/II#.: *)= K9( MYK1 ).E26"6%6#A?4T#M],F_96%TVD[J;);1>1W%S_:(G_=G)]$+NH.S-+Y* M8;%/RVI95FP"T(T].CAX8F\N*9'+#'36=-'>%>0!9&42RW?W8WJ._CO.Z.K% M5Q=EGJ_VR$ZA!]5NZW'MZ3D-W?DBF^[')PV$TF4V,W4$(R95'Z1NES2*AN]P M6MK4[,AI"&E>EW') MPH3&@0?H^VN21K5)J^D%/W9FR+\IETYFKCV6O!Y3Q6E;+\F4@NT5_WK669N+ M%.*P,B:>914)K;*J_Q+_G%9E_/?]^+BB)\?W7ERD645[=S^)CG/S*>5G_@-_ MKLHK'L=_9;1\\=OTW[0':=%Y 4\%;RD+DLQIU>RQ3J$AUFU.BTAB]D,Y(6LQ M_G^SJEP-?7MB"C.'E4@#+=OSBZA)/^%@T*RA%&B_SJMT4=N-F\63%6^*5R@\ M<_M(&F_W],SMZ=F/?Z-UH(-Y20^95J28Z)MSTH?R79I:9_FCBK0@\4D* A9DU]Z%MIF2&4J2C@Q:^U*>SL3D&3T[X@'@M;HX9/Y69*\6 M)F=C>)HN&=^#A,S"&'X,/JP*B7ZJS+]:$OTB)E6S%C1^6I-JP6\2DU=F"D$> MVK3GI (PE0@>P@4]IQ.XS4)!V#):FC MG!9CBF6A=? _N%6\0^(Q^NO_M;<7O\Y,/OM+_)Z.Z(_T[7^UAA04?>O9C_%_ MI7E+_SR*]_8T(S#++NUH/M?_*]-T?W_"8NZ+<%]NAN8R)$TW5Q0TY7*PT60X M#R#1]!YX3+AJ=KU^C,]62WK_<95.LNF/9)8LC*SIVQ*K=_@L_-8#^S7\R><' M;'+@KP]HF0<6G,[OQ[V)H;M+SU[R?NDBTZSNT@K;LWK=PH3+B77F,WI[]_&6 ME;N=TZO&NKR(>X); ML:JA MZ'9LH]L;0]HQ/9"4[@3*MH(:)A?WK]E/5U=7^TOOS$[+!8*K8P!\BR?T&RRG MCV0UV2NT _+MJI;E-K1AT\-1VGCPX?WTON8"$P^^F5;B>G[ZA/-K*"9'2-& M.H\/GS]\E,"PY'>:61+1O^N2GI#60?"5#$)8?E.6<^F<)H? M,GI;57)EF&N MJ6,_LKANR0RW\5F=2F[)-$=19M$J_*ED/A M-*J9&*7E_4"UQN!@??M),^F\0ODB/CIX_.AYPG8RI <"R,X&GZ4K M^A^:$5GS>.$%HN^\L@=_H>>F"\S[(?ZY)(/^OW4.Y01=(62+.XV!ITM$7*UP MNWDR[*@W[,DJQJ+;M^HT#_>>'1SLT0][!P\?'D@&$']:T,OP0BPY+2JM5F'( M/N73K**K-M/]\_(RAM!B9X.\-/F*GCPX!>6G%>N\<-QU0ZO/AS61:!N-I^I\ M@A]G=Z9W9L*-VH^/R2GSSZ-AS^"O\!YKAJ!VIR>BQTGN@D1[WDK2@;Y/[[U* MJ]E>7I8?V6_SSRL[XTI8!_ [TMJN]@RNI/UW.6W9=:0A7%UD4QFH>Q[DOKR: MKPU-_0K?X=QL6M?T5;R0@X -2QG,@O;R7%>EC-OE3&*4*WDE[GEWN'8(-3TG MQW&C5V#4ZC=R(H1>B3C=*L[3JSODE.W.X)%;Y8=EL__SPW^6_]_!P<,?K/5W M0IL9'1[OQQ^R^F/\.N4@[_YH'OXQ(V"H$/Y*"N%O<5NSGXZ+2)*=5@QPJ(<4 M%L,\2#=N2TJ@@REGG MSDP]K;() O4FUPP"ZYTUL:T*0/(CS45F-4$DGC?,#E+=G(*NR5J2#$=_@40' MR6!JTCGT31+X^FIZ"(0EO[Y '4N!R!\[YW%;DSKPT:P-T^'(E_F4U1HADZ0Q M!QLU'TR/334C'(3.DB#:Q4\EW<:1?WKKR=Q+9"29J*@6$C R.#GF=6LH3X]C+E>K[UW91ZD;M_][^! ME/L:$FWR$]103<9DGFH9!9S9U^Z\OK#GE2_%BW29-?3;#T&4^BNKKG&W_V#) M5U Z^+_^Q[.CPZ<_UH%\"JQ-3NI,C$%5KUFFE53XIO%Y">%'@HS$;H'2WTP- M?35UU00F>8O)J=<*0;) V3H7+IDIB<6T6D692!M;E)C!K&67D@XBU$U6M&R, M]]ZZ_PW*U.[JP?M& G7H&,)>08J$1=$?/Y/BHN$8(8U(SZC%$#+0T=:ECL@S M,S;O"&^._E#/I;0-RC#/T@GYE6PJV7P<+*)\L*SNF&V>M>J"I'/*+U)84!SS M(1U/NY'-R?DMFLBG 6'NT0MK+HG _RS50>4HA]P+#J!(JK(Q]AN<)@T3=_@& M"CYHV](I^8ZM"/J90=R"(S[_\?!)\O#Q07+TZ.E^_#2);W)Y&JV6^CI$M&RWZ;!SEL8P'!DO:6#9&K.3S"(%8@\(..RFD4:-<,O MZ3V/Q7+\_!FQ+GC/2ET33S384$1QUI@-[U*/R105*[+[$N68YB@VFFO; QOF M.#QQND!.F/US?'/]8^$AVB *K?4>KB7]?5T<1H/BEL MDO//CH7>7ARR,+^OOX9/X[2A"B%ITAD5XK"2?Q0C%=A3 %73>.;TO M%.P^4O ?CY/'1X^3AX^DBHU^/#@X2!X]?_H%I6_VMY'^]F&O]&VS9J/!77#\ M_5K]4>B+WA=^!6%$;_*:>K@'9TYT2^@GR:H4>!X!D\OLL_QWP^U*W]]XRBD MTHH$!U*=*(G2P#L_T$F4<'!K)@@W[IESCF9%;!#,$:KIV1D2Z _*GOB3R[(6 MWS'KV 36$@@_[](G9*@5@5' ED#P=[HH"0?ZY_;'6>+R'_WE M.IEKS9BLJ]13H= JKFG6],1*E[% E56PLO("?'?P.)(<^BCE7D'],?V$YQYBYM=&\/+IGX1#!_H*_KU M1ZX$E_J*SD/YTDY*6UU1D9M.UZJ69L7*2#@ATH($F"&H9<^TX+M7_$YV*J=H M_!05<\&.+]"X!2R9B*\[F:NP]&@M>N_:CU_1 M]V"!H @'62))2;D#I,^MD\Y3<=:L 81:)\Y/SG57ALW:R'Z_>U)KND!87RZH M4).Z\T4)T_DZJ-)53'&P[GLP&^[ K%P$PSHU>JW4MI3>8^<8>?.PTTR@59!C MS&)W]=6[(DI=_AINL8VXJ_.EU4A *;Q 8!,M0*9:!.=DWLUW0_+D) OE8U-- M,X:.HNOTAD_67+A(0D22E_/]>.HD+3[&R'NS_R,-@"ZJ('JFAJR3,DD&SS T MIHSG8 /5&%K0-N/&W"D_\#-1:8AN=%1UJ#* U_9.E)F%&J\QJD-%TM'@BZK_-.VZ=&C&3IRMXBZ12V7LU M>;:@.07&1M@KQ2W]O0B*U#W3=U3"(V[.96TP#*#?(_9!$7MOBTX"A0XL'> * M@YJFK>10[)XCOM]4<,\E[OD[NOK5"M+RC>B$-=H\S?) 8G&<7E_I8_#A@0MC M;?9<=[Q?-8#XP^%:N0B3;*)86^RE]PRN4>GMK \(0'HZI"O[3)T$1XIP GB M/#;T%<9[D./*[&?+*7V$Q=%"P7SJ;N3W+W_64G^CL^)]\-#G[OOD7SS)CDN^ MT77O'! MP6) 4=U&#YRU#R/UJ 8HJTZ*HF[H0FNT72NZZ=Y/15>S#QLV\JX]_W/HT=_H M+&_GX=W.47WM.NWQH'SE4>V.6",9QF,;D&/6L5N@WML _+V&Z[1)K#5&_#)- MF 5!,S%ZQN.X\Z,:Y=;6;NQ!BS?CG+J,TF&8$5FD\WDUJ28AW%U7:=PE%-3I<.CM4E!XV2NZ3**A M#>."'[MA*(=B M&35AW#S7$4@/E=8I_J/>!9\9]^5K4RXY#BH*!2,I7^U'';&)0AH[2YFX,!2T M3FJZW[IB/(':YEL\3R])E(45?EP"!QPF$F\R Q)P8UONSAL!+^7\TFF,4C;V M9E5[[NHRZ7!R__UZ!X5B![CFB:M\=2Y_^IT3X M%(+!P^U$MNG!H<)[]L4TODS!OKA2:()VL=3K.FF;OK@7;>8_) "XV4>HGP8T M'\+V AH2"U"%7\C]3:(E"9)L$L!>T3\9F=%5: J%";.!HU!4<+)D0B@?EPM' M8B*#N10\19#^&?M0UT'F(+"@7$0J,B&HD(V<83$71#U^N&M%8&G37TF^K5VE M[QMEN(L"KZI2(=7"D@O.@U2KTL,Z"6T=:F2EHE/8:_O%V]QI#<8[.E#]5D)U M>OU_[(UAX/-X(#T2#X\N(;X9*T):0@5'KFBY?9O^K0L5&@0PV$HZ*2@%5NZ< M#N+9GU9ON$WB;"Q"'(L0=RFT(?URT%,8(?<%>N]4RFY4%EW/N[PK+:#7=E\? M'8S=U[?7?7UT,'9?C]W77TOC_S!JX%$#[Z(&!HZSD9+9;GD&>W42PRA:V-MH M\1X.LXU9K)T?U9CNW+HM&272H$2:#Y?ICT=KYT#('(),8'TW DY0Z9.,'7$N& /.GK'$$/V-)Z[:1LVQQ@#9<:#F*QLLEP06D9Q MM_NC&L7=UFW)]RKN/N,7IG5=3C/&W>;:O;0!637V,:E*.J9OMC5'#I/V ?Q&"1JVM8XF:FBAE=F!*M MY++DBEL).IPN(> X:-^-:MDA6-ZL""AG0"57-()!&S14_3; :;*Q%A=),X7@ M]-Y.,ACAZ31+" '1@[**/ ,+_8UIE6F&B6L?@!DPSV9&*/_0D6#+R2=9N;Q( MZ?-3T[*<=19$XD".!?57D'BY@AI8R(J'*X71]NU15M#A:%HMJ[84]JU@)BLH MJ98SU\DZHJY@-[,S*(0VJZ!?9,@[W(_?DX200G?7*Z&DCY$O=;9DU@'N;WV1 MS9665B;1A1-F)Y76D@D#@ QM&+FG,DU;%8Y668E[0*7-YVRRDKX1+N"7MT=K MR,TA;+,]+]]#]?/=%$<=N%XA?AQ"\F92QCXLM]P H_P*P:\',;Q=TU"O4R@6 M\NP(D-Q[#J_Y8!+D^:&A<2@M@YBXGY)+\U%-LU5Z@;OV(_/ MF&4S8@S!QHGYC=)W G)@\8ITSJP!G$B7%_O?B1#>L-K*$ ;G*X.XC:13%ITJ MTK(YM/B]A>56+X:;+U-MB!-=,D6;3=U._NGX3$A09P*3#T;1(I7>$[3$"/6L M?"]:YF9V#ECZ6G:J0>.K:Q_!ZQ.G$; #>+!KV-TX4^ZBY=:6"5.&69IO^TS? M^2OSJ7L-?CSN+HWK7!S6'35;YZGS57KQLYZ#SN9(WH MU^<57JMH!'6W S%2@/^^9 G;C/'GKB&C'4&V(X#^P[1XW:9E;Q-YS@"^(JR$ M?9^EQ3)/(K\B.$?:"X;^2V6MF]LF90Z-A'3$=,9F92&_#G1Y$NQ8B8N9454PO,R-93V. 9:SD[&VAA*LBMW$IZL3K!F' MR.!Z(S1N@/7%C4,,^UQ,T;Z*Y\*DFS+1N6>&R:H0S;!+8DJ&R1N8[F2$0\TQ M!UWG^Q)'TLAZ*O$H046DQX0ZP5Y?MM3\_17[!LQU4[4,H)&AOWGJEF(FDEZF M+JE>4"(24M6Q]6))V.H^^QP=M$K(ZU,UD0V'(>H>*^UW($^N;^H[')OZ;K&I M[W!LZAN;^NZ\*C^NHVOXZB^-&("5^1QS_='3Y\GSAT<=UOF VM!;D@&:1]^2 M[!')U] _]#%6^L[!'W9?YAVJ*(;M$:90=1)GFC">7J3U(!?K]Z ][N@1)FLP M\G ?=M\]@!.YO05'JG&>0DBF-<.F"JPV/LG*NBN6JC=8%.N(?VW-%N9)M&R\ M];#MHD9?G\IWC7[68KN8_A,P03<&VRD P!29M9OE?L10,CX(U7^%&'%#U+6R M.#-#9BK EZ+1PI%;+W\7#'7PG !]]6RJFH8"L$(*7- (IOC$\=CMQ*PD\OAKP6<+(*D, M2\;Y0I)(Y8(.6<#BZ]/:]+@2^7U%2D.P1=VPVC+:!CHNR$;9DX9'"76NP*$J M_&$E72-1%ZUQ#$SNO"Q[3:9"U-!G.'5'_TWB\[R<2&T)&5X+='!/0\9KKQOE M5-9R]'S2$URT#<1-/,OJJK5(@0$\+ PNZ,(9F*%%EZ[D4@8YB+BMP39^55@7J2)+XLR1S+R%AU;-.F MN,RJLF"+4*$AV2W$$)=8G*F/++8J)=;!"]DF@AVHF>U@:>W>,7!YQFG\Q/*' M+YALVV57Y2X+35A(! C*Q#C M-8'X347&3LO 6]:?'Y ^B#Z8W!8FO+!QD)=!' 3;_,'[0\?J0WUEI3;N6\?N M(0$;64^+-@[N+QSB2Q+T*.)D#'.+-0)1R 44%X;-9TB4S=Q\5D;7Z9RM&A$0 M))PX8R^(AR'*;I2Z Y']M#^>BNT13XAAO1#O2BL^.;NU!$PQ=$E0&CZ75&A! MSRY,BT(:LDGH*%V0L"]A+\ S(XT#C&-8SSY'2(?0I!4J@8M9!]A&LYXH=]/* MJ:QR6?RYJCDZI,CNDQ9NM#C$EK-P<3L?78ZU<>O./#RZP^/DTXOS:/S!Y:(6 M.LW(IEZT"Q1" 7T8GUP_SBY&9(D1H+A+#JS8HL.9H7>)@L2:+&F2'.'AV-J% M6?#T>3FD<)AKCZ:^0BDSY!W7TRJ;N'*P!1[DN!J0@V5.U8U9!"5Y@,U68P[9HMIPS+)P"P,=C2$B!G25KNIAU@0R4:<< M1,]34.J=VO.P;/8L0MO(^4^A!H=)GQJZSM,5H(6R(076W/ #5'AM(Q M7 Q I59(+S_>H3E SVL]KE4Y ZJ'_:QQ:SLNPE1:**.ZF;+SCH."BI8.C)B M^)QX]O);.#%:$W(E32PJT:-!B?[^AF^ST6H9(^=[(+,:>'W=#&+@V6GP7Z[* M"CEI;Z%!-M8M%UW&\[:29M4--9-VBD$/QXL!V@,[?JQ,H!:9*B%8'?JSL]!L M=N?7@JN:3IN05YX^*B6CM(@G;U]*CL$@G8/?6>8=F\:0Q EYC2%A:E.2KI/< M $)F5:S9#4P.CU:UG#70-!SB9RKP\;E.;]!4QXW_(5QL-_#-))D6W+/ G:'JFF,R4KK@"*QF'1*N MR0!EUH"[5Z_9@SZO3",/I?5=/UO75] =C15TMUA!=S16T'VW%73BD-A)??6\ MVNU/!1$:-BIFO7BKL]B4NPK!$9=Y23CLOR<)'IL9=^;JM\@XCKK[,V$XNXTP MTH/N;?@+66%_'BY4LGRWY#*D2^Y!#ZJU:A(*Q7ESL4IZ_DI0NEAQ\>GPT\A_54$*ZT MRIU)MQ]XC8:<^! MC#K$C.X-EB:R572&#DO2N^%3 K(S0T&O((-7X+^COL2"W16ADV.X'IFBV\ZDX>AG#B\IT+Q)13 MX9A#1/YMJ;VYJ(4DC^5MHLMNV>&V_5B< =KV8_A7R>HH?J->6P4W33@/-'3?- M=T?O>8M@X#*$=@#7#TAB7H7_-13*'0?-\A_G#KMQ-JATQM#JEAUL,2',4,0P M6:?R[94F!_7(.#+IQ&A[=]P%MA&-BL,1E&#Z2*T>%.3S)BN$M$R%3. Y4D-< MA0,5X36\F+%:.ST<>/0%G=R86'&)LK4I-B.>LA9':&]S(;@U OS4@[YV#98B MZV;SCK@T0YG'B_**E;Q$UWIWT5CA'W$H5*.PDF%?+G-:4CQM;F:L[05H89-) MQ-J 5VO5#^@Z3>-#T,A>!KE\ 6*RES>"FD*93^[KK1C;@ $>/F.AV?V24LF@ MK09)P,HHZ()4Y#,G;V]-Q&RAI)2"8'N5!'"&>TB>,+05NU'/ULN^V2SU>F&%?1#P,3A-5]@I<5DD\BX5#QQ MZ1@,P%DF#%/SSK+1 M >3C63&_&ZP7)R1-ZK_4ZM(*>S:0;VIE13XG(BE?UQS<:J(7ZHAM.(/)E -/ ]B[Q?H:!;0YTN=G#:\2(7BKNPUP"A7FZY+Y?GVC M:V01#(8[L@AN/="F"A$+[;O!J+ M(^F:RO3U51WD]+GS(A,$*.AH3<56_U>; M0K2,(+ [/ZH1+7CKMN1[%6(>%TWD6&'K(VB_896TM5:+2$ N=2).D[YB$9G9 M>-AV?E2C5-JZ+?E>I9(O/>8ABCD4:U =]A$21Y*]&1D4[L:H1NFS=5ORO4J? M,#HM5E$5.F\:W^(HX 6@.CC6M8D("Q\[;TE><0OM2(RP!8.7I-FK2](NF:!' M;V[H$>,WB/L->OD,=T,/LJER3LZO)*3G@Y:;SD@"X@6).N9E+1G]8=(V&V5T M';<.+7J].7K,QVU9S/-,DSZVY[P6H&:N/G=Q9,[/I_-&X,=6[FA*-78>]T/P M]N\N:"RG+RBI#>$M@Q,;23S[FJ2?A7F21(/T:[D^3Y_L6S_?#$/N2V&DZ)R3 M,'PA-(YE.\\B_RU:O/.RG'6'18-'B;JD0VS_N68F0D07:24L+[*)HG>47$VS M*&5";@UPG]O"5?? P=V/7\'@G!K!!9C*]WO%&[AW0=X@O.)>86B:9U@5V+9W MF_B8XPZC5:#F6B#!K?*WG;=/P0)!3) PE_4)OLWC4_2N3,9@@>S M<<#VO-+3"B@1DF9 \X1LVS2[S-"Q3W^P"=E(TY/3M921P'+'-SY)+#P=L\AU MN9.I]*YTA-W7+#KYIK7?#\?:[UNL_7XXUGZ/M=]WI?8[,%JY[F93PTW/?KT6 MO(&-5S8VS"?6GJZ].PRSJ%%BGYM$FZQ4U0U2]9D(W\[&NZ=-- M>LPF9,&8F<,^* NH/Y,^B6E75*Q%;1.%X4:_;Y%F,]L/ M+Y@U$QWJDGOXQ)RCQ*44LAT_^H0K[[6\ \9/<(FB?KU'IU9+4RH6.@&E5\=U M[%OXAJOB^6MRU10OPUW%'X?9OU@!]-&-\(2P [LV7^ \%B[FPB MKV7P#+;R1$YA@7SIF=U]:P9RZVQF'.-&DQ66-57ETA8U>2/646R%4\_F#NYWLTSF M CS7MHTJ,"WO2J)@#!#%EI.H,LO6<1CU9\%T4&M<5GEZ5;<9W*/ '^."7FV]HXE<30S@NT6EH-Q[6 X:7=%@HWO-HM8B#C%$;8%:Y: @BOX I?5 M=[GH38R"M1TKS[=$5XD]_)>@8@]"V,JN-2YS6)! PVUH:22:UHQ+BR8N:<=_N8$NX M^G2\8*Q:435_O] 1WV3&(K$3A:_GGH)%M MP6)Q^5IM;6CKFMT&OK HF;K,9FU@2T>=,;AR=,'1=<)*28_I=G1$E_)CD6U7 MH.2_?T/[L62_D%I$[UY%FW.IZ*^;?*R@8E^[&5A9V^[8PC8A#PM*;K1T388! M_4)OS%&:-^4Y=Z",]WF+)_1>CF 47%SU(1WNC,6\L>6%FM,1931(KR$O2LU\^K@2\&IHF;CAQ7J4Z\JP M;@#VKQI9KU@P"^MQKD4+-JP)>XSAPDQL,Y?T18=^U]B^,;9O;$59SVZT;]SF ML*:E,FG;,F.HQEK# MK5G]W9!"4BO"_K0-B;$^4T#G6BG& IA+>#J!H\&>Q7C,QE&-HF=K5G\K10_^ M;?M4.7\E[DR\+)=:>F?+Y[CA'/Y3Y@.MSO$:C]4XJE'4;,WJ;Z6H0:+BO B% M32\D:R&_QX,SCFH4)ENS^ELI3"2B*R5^UF,RGQC1$2P"5<9I_/'4C*,:)>8A60?RFTQH'C/\ZGBJQE&-DF9K5G\K)4U( MKFS=($TQ2S.D%KJB]E ^FAL%:K>%)A;?U'[)9LXWI*?'$SB.:I1*6[/Z6RF5 M&OJSE48 I$7QBU1$,X.#9["SM%]-(B.\USBJ4<1LT>IOI8AABI+ Z&'< MZJQ&5:IUHGPR.RN+\?R,HQIERM:L_E;*E-"/\GWN(0>6ZW8$L]F8I!Y'-8J5 MK5K]71 K09EO4YFTZ73A]-KGQJ,TCFH4+UNS^ELI7I!>$MD"K#21+F;F^]T9 MT(3Q),JVL;13V@8;],^-T=UQ5*/ V;+5WTJ!LZS*3R!R\%4R81:J0Y$6]"1S MG2_0'Y?*@GM]G>^MHQ1_4Y#%1R/(XBV"+#X:01:_6Y#%/[,!_H>QNWA@N&-W M\38IWUXP85$6P!+PUGXZ(W$HU*J6.!P*6C"^$6Y \]_(8C*.:K3TMVKUMU+8 MJ(DN5:QF;JJ*6VH4(5_XN5=U-LW2XIN2C8RH.U\XH7=M%65%@+1F@]*?08N# M#[<&M],#AQI@9Q8\*_F8D%*WC'B13N@O91&5!:-^,N1M__$!CE/\:@W=2Z > MZ_6O"4[M.F!5P$NOZ*"*WQ,-X@'_3AC'KWA0)N0JGE=E6\Q@2Y;57S#HQNSX M\?\*LQ),4?I\-#72>"[KOZ%O0Z=_5HK4O6KS)3$/(L M*ZLW:T G"\L-ZB#E& $B3(NQVX+DF&'^$X>__"N9^B3!3AMN%)D81A3$PP)& M&']T U1C+YKJ?7H*'?9HVE85/D]'/NF<;7J<#"LK2$"OOS:KE6H>!(Q3X1QEI__LTXTB&*\0[_0TH\=Q+P*H' M=YV4$JUXBCBF&]/Z11^<\WY\4L0>PA)_?_/FV"K&FIF23@&%W0![F+;C[X;> M=L';^?>63AI.V"6?(QG;HLW/T\9TI!9T&HNMRNR%<^4IODB+=)9NVF"NG8OX M?$ZS:MHN@*W-?$@>U)NQQKO[7)>096 >EV7BH[[Y^'YK3,91N-WJ3$_F?&Z' M%"@.AZ#R7W\)/R-VBNYI5/F 9XLD$VD4.6F4".1]JN]69JW*)+ M=#=!_<5'#IZXNQP_J^?EV$O+*"*:[ M&$/JB$J$UI$FU@QJ34+0%"PNU8"S'#00C*]:LG,,#8LDI)IYB@([=/38W.!4 M QXW*TFS"VXVK8<]U[59IE5@0G3I0QQJNO(/%BV=6=A;^,,E&2G7D(T*_+LS MXQCR:89+1=_C_L-%R6V*UMKB=[')<%GF$-6>,T;!HAV@?(=DQM7JVC?)O>$H M *@AL#H5D[&DCLEQ%MQL,&5ZLDN\P2[F$(.01:["T\4HHI'FN:VDT7[O/OD. MOPEK%;Z,*0^#60Y_MX,_+@#X-*A*+$\ W0]+'3+32"%93J/:F(^#TQ&9$SG% MQ40W0C9@U^>:U6 7V94M3M(Z4Z\55C(MYK%]S63%JX/9STK::SS>%'5;!0=D MLHHV0**O^T9"C!!\-488:6BD^IC5=>_= ,4>N??:!_O#"@X<-R=>-4LJU 56 MM&L9$#?,,P6.WGCC[)>4R2KR="3^DG,".T,-FJ?DYZG M@$]G&U[I]ORSYW1Q9GR30#;H#'2<+]*N2TG>@R' ,0&):?XMZ'5&*^I69_K" MDETX%&VU%"3L9 DEF+[I2CU*.A<7'#>A#Y+H-B2TXF5;U2T2%#B?FS#C]N-3 MN)#VH>Y-*6MIQ(W\4>;B-GHR*_&L(#W,:17FTDFA_3M$@;@7B1H_JM40RZL] MYW3(X\R<^6;Y#[KIDN7AOS>K*SVXQ=RE9A-H *1 5M% M=F1)?R7\BB4<@H/E1__T2;\D)O-CF37,( TC,2TR"171FC6MDC_;S>(O6WY. M$BTULS>3"LGY']"G[:I''8(UH;NO+#\\7!_NA.8N9UD_J!:MBQK1/,($HS86 MPJ[91^BO@!HFQK/9F,$D0ENK79:%&TT)+ 15RF+PK#%Z%DB+;6&5^<-VY*PS4D$%R5,5'T$BVXL#)WG5DG)ZRD= M06%=XSMJ/\M4D^FYB9PPAWU!CC2S.>&+/OUH6=P<$:#J 3ZXB;SV*E Y:EJ! M7;SJ> [VI7%]P6XXEJEIS&+91.P2Q7")K ["['F\.*&2VH09AC4U=2/!K3GB M[AB1/B:6/69S+,\UH-2;^;+,,2_:KM=MA<5$LE.7-=JXK*!3Y(E=IW3OZ?J[ MRULWF*U2_?CC*K^_+RN&"64%2R)>/:M&H[)0W1DJTU+/L!CU;K78T'=,DA+4 M6]OK^ 9[S4N'F\=7Q_)=6LU/;[/SSK[?T/'U%<:/QPKC6ZPP?CQ6&'^W%<;? MF,;]:WIXDK6Q$8(ETC%M(?$6QVJEB6(.>#LB8LUU<(HQ "_D1"#XL9FWAL9Z MA31LGIE+(YSO*71>C^11S)/&.*O-%C\$WF0WTJ ,V9V4#4Q:*!2F>[N;F_;] MN'DH3^,\-+)],[6J<52#DC13+DER@IQ-MEU\ S*3Z33L65,_X'L+\M<)'9N& MS;H#A'1W\>/;A)?_K\,?[MI GJ[EP M;H)566)PB_2?[/G)ER\9F49B\/8I;UZZI_S(MNI4R@$J,\W N%(ODH#:>FHB MF)QK3SG]-7Q*\2DSS2K,TZOE3RL[LW]>?\C/Q\&$Y)K7S1YY$.0TDZK0)77? MB^SWWI^=NB]B"29<7\=N$CSF11J08;I?\#WEBA U/&FP)4D8<+OCW7!E 7YJ MJ>9GAIQD]G>-K,?Y.>QK'%79T6J_0,"'-$'3WQ+\C2F'S/VR^A^GEUDU8SL70Y(C*IR M5V8E5MMO)AK(* V!%7%(E+<:L:>5!,"@"R^R95!!XU-+/@B5]#)+\MRB!=-H MR^5>"Q,A()#GO9J%P!X9CQ,@G/4Q5"$?LCJP68=YODJTIO[O8;'[NA,?^/H,(3]>9M6*;(Q MFT/?P7$@J7Y>-A)K/:^,UHZP5U]Y#='5"$)4N^%J1T-7N\,7>=,;C3KD])+> MX/*TG8*1D[E-9+1%3[N5510JMSJKK6^QTM[IV;:T9KX%V<[V)7G\!D](SWG8RN5;,PT MQ.I,>O%<2G#@?G;O$GV3+T]/&<@S(GX&)Z(Z#[*Z#'%8N4:=/_J_Y.GC1=#+Z]*N@X?UGF84ZQY)RL!H+H M9?1R;J3A6BO)=CI)I8!7YK*4^A/IIQ(3A%WDL 60+N]YE4("#>AG1!))(4W)-0B)RH,J-9^9JLR#HH ^B:@KZ_:R4]#5VQ$6C\ M 9DA71C0@7K4YFTA%:-)%'8FVBKU5NLN.@(FU(.]DHW1 [QCNLRWV-BSNG8Z MUVI4TJ5/V,=GUQ2J=NTF+4PW&=N-*JFY/+F\NLFE"-_;,<-(,;&VXG \^UI0 MO%+49*MLN*.W(W?7;T^T=GMJVXX'"[&MK0$[0R3?!#7\<-[Z[1W:>$1S2YQ! M;^\S5BQK.NWT3O-%/E+#R]!;$EXGC&=J*RW8@<:?K]FE_KA#@3*\*)$5*5K^ MAE5)7=0]7!QGG<\S;OD4_;B2^!/ISDX9YW#]2>(+4$(G 5U?]D/DB] _L_JB M#]IM!=?G=E=JT+)\9K=%E]+WTDHEX+Q*:1E;=1MD:E'?\;C!B?^"^/Q61.6_ M'\_AJUD +],FC;3%>(9*LF[S@'>B[1'E#)NK'ZR,%\N-]#QC?V"7B\@&3<8\ MTY2Y*/9>,HL.U91$/-SA:)'5N4EG5B(B.\= L6/Q].[?(M+D?%JXCI6$WIYD M!1CW? 9\6=9U-F$\=6EE),%C)/D:7H_XNNMQ]P_0%Q^8C(21'9CK-I6@>>0V%$AU@=EL9<#&/8N\DS:=&DWP8]&SZX#UW@5 !R M?N*7: ]IL>*6ZZIJEZRQ)-4 -R0K7*>-?@4F&NL(]]I>(AS+'6V+KCSYUNO5L<;P@F,^VA_:5K!Y\>B&A_]^ZU9%CF MN,EY.97^CQ!#Q;Z&K3AZTXJ+]*[K-T*PA$(-)2H6/*SVCQLN8HL#/-QH4YU;(&%NN@ V,;!^2Q7_IB-NM*.8-/^5B=R( M(0+,)S-M0[OSQ@-80JFGW>Q#Z2$-G/,)JEOPB=<$*X\DR+:S-.53:_L_ M@I-[\^H#G\7H%AO8FH+O-29T1V=JV^RC*R^;?I\IL1;WY"9'$/B_+8 T\6+UK=WKQOO;]3BHPL#H+^'B_S]B*R3(NHB M#7?L@9O+IT%-OEAF =*TJ'(I=W='7LP7,TLB"V],W^,[I5]D!)Q+B]\L8C1 M+-3(25BBI#E+>%-(:B*+*3 Y9-?E*UM)*; 2.9HA&PC ;"%08Y$I:E,)!T)&#:R8*AV?RNA3S8J!\DY\2!?T"1OL$$NU#L#U[ M>!(6V=A1M!:\.W;QT2X^\Z;Q!#4)-NC#]GI61?U"L5;3R_4%:E%IRB0ZK9?; M>[*7FD.NL76!@U*933YOU+',@BJXJ[+Z2.>R7")/07_21VYTD7N36ZN"$P@3 M&T:>8'M(S^%X8A293)*$J; 85BJ$IRM[I-T4^6RSX:<>.*M8X"XM,N:8$%B5 MIHNKE\XXI*5&X@;,J1I-55!1G%^X1)&P7IN M3ECN-S&^K11@3G6C0;*%)E%-LBD08H\923GX?+2@'!3$_?2!1ODI'+EL@<&? M^)!IA52C\)L,0436EBX:=F-3D;_LPV="%=?$2=;*=0) =^]\11/#^I],)3&E MV$L,A60:9I)_5UCD;H5#_CIQVO;NQ7J&.FU?#"5\T'[[7@_3BZ V]NXMR1V/ M( ^4:O.-%^2[E:"I=>NB@Y8]6[4(G1"$;T-; ,]M&-Z,U;"50,,XM:2]:0@L MQ\-849Z2K72A[H8BJ7@)+W)YC+_NO&U_7$?NX/F 5H'HF8-DVZ3RDK7?AP4KHK \5[WA:LP%$J&\$&QY>E5+8#ACA48-SM[',ENSHF'[Q, MO&$_6(7;*?6&V90-/?X+FB)N5+"[WKS(B):,M1R)A1;\R9H>PU9+Z+A8%"3W M3G=W2RZHWM!!'#+LS,.EWX]N+&QXX3MU\RQ\&-S)GIJ-(B9P"3=*&PX2 8O0 M#J;B0);U"=R(7,#BSME!7UPY]W2LG+O%RKFG8^7<6#EWYROGAH%A@*3N6I"D MP$4[=#[3O#[8 \A@5%Q8795SP:8=>_QVWI;T(!,(K6IT4?"!UIK6.MU+B&1L M.& 2VPVAPCW,^ 53VDUAO2S)0!!,\;1:I%/3LCCS6.(>+WP_?NG X&P:ID[G MI@FBOAJMNP9OQ=.P#*(\\(PZS=R1UL.H=;,?GXJ9.W>%":Z;+Z>=9N)UAY,C MJ:)L,6FK6OK] \0Y9*$.2=';YTA_HF'ZL8#2T2]69#/+EG[J$@:C_-V!5N_' M/[OO=C_H8*VG>Y:'WZ(_)/O1P5R)N7.2U<.E]6S]9QPK>4J\M]SO#^)EI)02..[V7^T"Y#XMW8V(T*>S0)!TO)HKP#^7K%G=[+E?A1=ZB=0VB6+'(!,H!N=OS]G933C2IX-1\ES50?G3K*+0%(/D02% M9D2*,;Q)U 5=FPO\<;^N@\.!UQOS0+&VH<2 J\_:WT/:7,NG//9AFAL/9&'3 MO"%J8L9-(VPH5^'4%$G)$U^VG5*&H5D.7KI]3K9M_J)>]V@3:I[C 9*&G;"% M!2'2J>5Z^LQ2!FEHV)V.YX2>6)A*D2RBC7!WOV](ZR-)U $9X'P,UR_2>"[G MWL4*[C['YO?#K+Z#QL922L$( D%:'VQ[;.;#F739)EL<(8^+W(^RKILWL5<_ MJ"=5C26M .PNE"\#5)C-95ICFZ2GAPNYY^OK2R.::DS\QC="[-;:<$D30S-4 MBV\(]3>"==WB'-\%+*F=? Y'/30#TW/W63XL316ZJ"I??:^@>+5C4G;WE3V) ML: =<;#]MP_BN\C.+QH'=:6^3!\R4LK-@U ,NUMK88Z0YR[RC@JKE^#XI4W8 MZ\@1FG[4*2C=3GJA)G;3K/.5]'MH.DJUAG2D9]7^!+%?5I*F[JRI MUAVFTPLFLG'.=_!. MS?1817L4GOFN01>:??X$E]W<@D,>Y "T5;#=TT;*69DU.L28E1%T-N[_U.;6 M14"':B]I"&+<\]MZ^,TAKY%X;V@K4)5"0P=-=J*&3+\)_2?-+P: 7:4[B9*W_[V4B98W]5A( A-8C&,MM2 M-X6A[\:>F%SAMD5J2&6V>S1B#IEIU_$W WM]() O-$\P1;[7BWY]E=*SL4KI M%JN4GHU52F.5TIT/HM#GH[F9@9>0MOT\J[6)$$*\$^ID\D3MG2++L9W:G+QX M5F&Y2. >@7P 81C216\XS\H O4&;D[.#HP!EUY:N"JA^L1KS+CNOS!"*L2<@ M?A_6+[Q$8?/)@E,=KF+E34E'TD8CXF.!MC@Z.'C(P?HW;XZY-3%%=YL[6)[B M'">.ZZ67+1E):>T#QB1]$/R+%*D<,@HU"K1ZA;9@TTN>*"DE32Z\$FTM*19P MU50:B-%F=WE;#K!6*SL<3W<+WBQ?-H:?NOU(@@#\)?EKY9M-1+7RX7S;R70BCT1C4! M*L@QF%!FK*->8)7=9AP>2*D$ZDZDO\'6"7'10,V!?)<2\.WO\.WDKH]'"G"7C*+5Z='D:UQK,#:X;F%%E)S3M7@G1Q,[7[&=\9V'6O7F MQ$,YCT0Z.,_ERL26(4@+;JJ STM]-U9L7@GJL=<8+U]$#@);DEVN7N$_*,Q? MQL!VET$UE:C72.+'.C@M$0R0]3![>%QK)5;J2FI%I <4OR[=%?]VD4F0!U*4 MJ_V$!(R$(NH,L2XNE(4W.NDJOYUF3O9U',YR3M>;OL!!FW6)O"0/8RJ5H3;P MPW)0HLV<7C<-XFB6C.>JZ(FT>E4W9E%[B%#^OD S57Z=^5D#M8WT35OT$EH]4AW+4:9M;/VF'( 9/6R;4PMI.?Q1Q!C^&XUZ8N; MTWF68"^#>8(%6P EZ)1Y*!F8MR#J[B"3=6GZ^GBUMC(IB"A%O?9 E[L:JY3N MZ.TZ+E8=,!#M^%3 AJ"+/YU\B>/#Z?0BFO>*JEW;PN!]Y4R1.9?:>E]992'*W#M=5P&;ZXP>HBOB M'( 4=D-"2KV1? RINC8+T/]*YA=JBZSQ-3!>O7GIY8SS+J6)@*5TZ#R!9^C+ MCAS3$4-W.;I".%MNF$KX[&&:< MEW6]\6S:\\S'R^\:(\"@_DGNR6AFW*F9HNG+"6R+=-4VR.@.&A3KE#!<1I+. MS (?"ZA?/$ZK-I'5=59SZ7-6=.@XN>@^O /*Z2WE@8.#&(( [5(A^E:/3*M? M>! N"I*YW+.[5JW6Q[J+WC&S)J:Y,E+;0=]E5"JA>K/>7_A;Q0D36"_PFV4A MAP$:K_0;EAGM:]ZJ';\H7[70SQ=4:!>="R>%?\&F6LN@2^5NIA<%#?*<]9N$ MXJ26IR:Y##ZWAI$N,K&RRDE=@D=H-*5W7JZ^D68\[5]-8K**D''04CI% 1W" MD@[,'-]MM*ECX!S%?5R#;.&()0SLX)KS560_TV66=9!DR35F9\\X=[ BB>7@ M#'DD$W_BV3X/3-0%'7.:?,3]<^I5].H3T+S8N5.=^14IX[Y.R_,B\[2W7!F MP?0[Y=70IZLUS\9=,;5!+"'Q"CP,N,L2)];ZHH$^^6O8XI7* M#&'^P([Q>UP>6R*<+2"=U8'B7)_ M80^(\-3@7$RRTNEKC1EW\\NT VTMCZ$"6@366[/2^65H0C<-FR+_:K/E4L#:=;JAL6$"C+? A)9>;7>O M.M@'/4/"A:369Q?:1G9V46 ;!0.GF\VA^";]*'?;K)D&&*@LPAJ&-K"UZ81L MJE%A@(QB$(DD"D)Z#)?Y6 MG-7M/)S;.:JOG7L9#\I7'M5.BZW0VPY:$BUF(:/]V4@TRMH#L?7_L_>FS6U; MV=KH=_P*5-Z<6W85K*/!\M!YNZMD.4["9;WZDQ6U79PA0.77I],@+DNVCP[JS1K5J .OW9;<=AWHDZU2<2^\:3P^NJG41U][5'MGCI"I"W-&K;Y4CIXFFZR1+H ZFNOI&=R*K!S MRS0SBOGWRUG\##EH\!,$-GB2P3-R1FX'C7;GV=.3NT'OQ :/S"BMNSZJT6N MJOM,-@KBKH]JU%C7;DMNN\9:54V38Z,N&$IUM_)+Y!$Y5/15UA%64VOJNL*J M+!]VE<#3ZR5R-0BVHH^S3WQ^(3Q_\"8:A'V3OAIQ2O*,<>$YC(8Z%%:A6A(C MJ6(,-QY,&7FJ4_@@_SZ$#$-_MJ3?BZTHS[68Q#@,1AUN\M;'@/+/D#3FWZ8N M[ILYTU<$&W9N$)$)KEI3*.*31=\W&Y@O5+.=(LUS"%-MR3(-$>8*)!F#/O:> MC21U<*W?:XA(W/,9AM#@$EY"4G.!O-@+*PN.[WD.:E3YR&J$0-8OJPHW+ MGQQRUP=SBG2LPKZ0YH4.&R\0?]PR_;WX:=JF$F]"RZ>_@$&/M(_7C(2)#59) MY8(%AT3 S)D#;X-'")=#$OGT3H2WG##::^+#VP_!]-U6L)L;.M.W)B*D)]I\ MD+40]](#!R?^D]XQK1&:2AEJMR([$I;Z($XA@ZKW3RVQ-3H#H^8^&>H>"S3=D[DG3EQ2$D280@G1F:O$67A($[SIS^G/GMD=U@F&Z/ M2D"U&J%+FWFJ"AH,E0IME89>RVJ&!B//$KI7^!@VTW@CJ!POEP4=XP5DI&E& M&4,94JX=(@XWN(/4S3.(*7HA%$$]V;,0E7H_***@Q5_C+TR1G^MK\8=_&7A' MU74]R,1+P;V.]D=PKZL#]SK:'\&];BVXU_83>#/4RVL$\XI>(\ T&PIXZ3WW M&35>":/&35R FPP*_'80?=HFDZ@C[;U8 DCV4&07R),AX0+FD# ^C'K\ZLW^ M_L'!_8![%J.V-:.K>N2S2I47KXJT' D =MX->5E&?^]@BP\/$B1W/6:V1V(3 MR9A$"XV]%R(Z)TK8PPPLORA; -7"OJEJ>'I%QNXO;Y*8B)=2MIY9L'YYPY0_ MI(X"<8P$^L+GO!*"ED$*(*?51'03Q 2R5$KM JY4!IR/WSBP[(%I8%!O:8@I MMRJC9V92=VC3'CS"Y3@XWH,Y$@,&AA9RX_D3&=-=X<\<#!#G9KOH)9Y8I$T;Y4V#:9=7O"*"^FV'?!N$\O8ZB3%MN-NQ?(9O?&(8.@< M$W+@Q#[?/T["4Y82MC,U!UK"-)1[V^N\,25"PJ;30+$NF!^%YM"#1V;DS$2@ M)^A9C5GF]]*R[,CMQ9$WB@;A2,IJ^W5-6>HZQ,B55C'-@T>0)KQ-\*F+M,Z: M06QKZ\D2C5UON>0PAXL%8\9+&<: IG?O$M8%)(6:(BG%/??'JF26$68FC*7J-%7?>&+(IR#"/NK%5BK3\ZWG0T M&XLL->MJNOHF75YDTI>RG3UO9&O8>1E_/HL\U?GG12$)&I%L^%*\BA;UJ%,W MDM3\$">>3Q"QR3KBL_"@$Z/O$F@SU>\6+LC1G8#-56/O0H/DX*V4\[XKJXM[ MB^HBB?I=5:B0.R&FQ,!UV6H_Q&6# [<8YUKF4[A'&W?YNOO6Z6['K:HN%*Z( M-4^=Z=(@06A^@/LZ M+6%UGS%K/*[J#WB%Q$_J'&?/#2 G2"L#WTOU$JY@^CDQO\-\*?;N;Q5:P# H M,OU999'YBS,GWD:IT:8+4.^Q8/1LORLH'J;)IY+$OS UVS?Z/6+>PF6L,8<' M1D1\LA>_@-7YK5H+AP5N/^8L(B2&Q>^<$K_)^O_Y/X\.#QY^U[A=3;RM=AM, MU_/08%",!2$]T_%L4$X&%R,R^&3=3]W>.[I?P?+K]L5W?GAURE4*-GX/ MOENPEV?PHC],#=YYMO&4YRB8)??ZG*UP7R.MAP\6GK4()5@-UWX-S9N23L." M3CDK7EXZ0[**G/RI+D9VUILUTQ^K"]!J-2M@'_IM0&P2,OLQKS4'94-^M :S M5/\C6:G0K_4T.F?NY*E*F&:[.I@2+A*\N9#0ABCN N8LC],-3S GIO X6>X# M51Q5<6XD2_D^+LP<*85\OE<\+"G?K;]WF!V%,>U%J+N0H2@C)X,#()LG[96# M_'R#5QO"KL0O,?&("3M#FH<62M?5M;#T'XX%0[#N'3N"MO @G.*G$$++#5/))\+'A)66<"I1AR&@#I4[K8] M4*V@_#"9TA;,)1X5^"?!:Q;\4JT33>1R%,M#G$ 'AJ4W']L,;6N6*XHI*7PJ M/'YI5X6K3J<8?C$P:)"NO'$[NA<%)$SDJZZ%X]QU!(E\38LT7S;AX$1=4\Q* M=;V060?OH=RTCMS29\FW0=XCW ?T5U',_!>M,&342JZV:9V)0@8-79D8@9W' M30YG-:T]U3LJU1LUT^=EI))*91[V*+"Y[!E:>"R*!@G7\00C&QA_,+B8!TUG M+'-D6!4J[; X!G[E2.1Y SY#IF^M.RN)XJ">EJWJ\+DO63D+UB>^ E<6S0Q2 M%M8P#^G=L((!K!SX2.2C+3@F5]2[9%O@XR^0C'Z>TMU*L#SS8B_^&IQ85[;Z9= M:X2U6Y><\%.MA>CL)F)[U5@.QOSH_1P.E $0O6U0&)I@!:"^EB-FCEN6S<\. M+E"]JX5YSKZ^\:_A<_)R=+,',*>W[C ,(E'%R/$]^$972F7?'QAL;(RW&Z Y M$];;_==;5.P:QH=EBZ-^NU$S1=[RGB6'=^@'[+ F-,2V&%_QQC5?I!?D(C=8 M5X2U&K &:#&51)0:28&3ZK0!L&()T#?H:(JID#;!HS>];R^/M<7V9 \?CCN. M!'-ND5^$!<, Q;LD2T//H+ Y9F8FKIDE9.Z/&.FS9:*_=77>H)''J_-V86A0 ML[QP+FLP=-0EZ:2NTBSQ;I[0_Y-".6=KQ40CN[8Q*<<\&WJYO>U!)U%L*+68 M;,[#3W2[>CP0#AH;!XU$S>",;,TS5M]-J6G)5U8Y7Q+T&8_ G/2F0Y,>Y#0' M@_X9A]60SSO1UVV_P'H/-=9@PY4M8*]+KMSK#RZKNSGG7C*#L@"&(QY#WQ3> MBUYZ=O'&-B2:6"37W,N/J&;M&KX.?"[S(*O0!)6C'&TF0[<$9R,]A\>A01#U M0W8R(+V&O4OB.XF>N'LD;ZCPT/,RG+1H_!+N1RPTQ8]C=2RX%+?V#KB\*/!@ M+ J\PJ+ @[$H\-86!=X>\XO31V+W2 \!:&Y)RW3E1EE9GZ4&JP,\C])7[AO8 M+$,F1I!WBJ0AIF/[@H,Z=$M5'=:(KTQJFR'(^FKX[FSDMVEK"\XG)FB/4&IL MX_5*V)XDL=ITG)'K4=J+7Q.4'Q7_5-S/K-:J%\&BI[/;)NT$X+6V'940S&K0 M+!=5_<[V/>5$W[/()[0,\#(P'=D:X1&Q<;>.R ;.IS$55['3Y5&A!XQG[0+\ MMWAM4@01G&%G4]Y2R)V?:#+_*WOQ+ZN!2J29#3WER,^.#AW_*L+F"_D]#I[L M%JU\P@GQKLFKP+D=&+CW>E@M6DY-;&VLI]]'@I.C*%@T*:KI.QYB[_E@IHB$ M>%\Q5XW& MG3-Q$WT/UA&< 1?1L,$=;9CS^B TT<\'@ *IVL,7R'PI-74ZMJ%^%4_0J5\M MG4G!O0,G&1ED+>?AK]E$HS3PIQ _@%.+6@@8ILVJT$LVC M%1I+E7=>^L."E\\A)!1*G]JR.UNVIR$@R>-$7$69.MVM5?$LRGNQ5E>]96LJ MC1F$[@/5U&_$G)#>/1/TV]$8V(NGX(:AU#T&4[W1V,E88T7*O=2?)Q->RA!= M"Z!=DB"CQ@@D!MWF6 MPR;AW0)+#4( YAO6?JQ2B6W7U1I,C'5"S9>N%(6O&7^#,1'!P MV_N*1 %I=!*FLG$-N[1ALZB%XH)5X2VQ!:M+^L9& P8Q9I"E*/WL4E?;GB%&&P-]URRT/-J#EY:\IU(?1W(\HU?/02+P$LY^5 MIE.1>I88IX5FHCB^;$SEP6WV'!F:VE!$V9P8E #P..GL)+X>PZH?%H5!:D^L/OQ ML,Z[E&I.3.0ZN#=Q)M2+G*%G5KVFT M#O,1#H;D/:090"T04GE=Y%DNRK0K0#VQ(Z+*N+=U!;@)YJ6T7R?;<%C\W M^F [&-MGN'P3TU,M+/2;" A>@0%#(/C*E;&=O- J/V4!QZYH@.L*X,!-%59 M&H*C@+6=P2+QKM9=P;K,6YUM%JF]%MCXA+'])H5P&$;P,H)%SF"BF+/D:@O? M>@WG.35I8[P\%Q;:E1TE2VM)>V%?D,Z7FSRI'DS<;8K #/V91<*^+^+W^5U" M6=ZL.ORT;(W#8W:CK6HOYY-*+\XLV)@L76(ZRI8#=J.I=+-F^@8.M8GDX)85 MWGYB^-OX%IT(S/(*?A/>$A_6+X2_@K&_?D.#5<9>TQP^DH0S8M]I^/%T//4F MH4HAVUU&:CD)86WT L)F+QD9*3B7^R4_QB+<3-(FIU,1Z<@N^:;%V"3W+/G@ MV+@@T=<2H/KJD'' M<3S1NQM[XG '&]^1=XM9.\#['=?$E6)(V;#-I1!% &JC=;+L#S%:*%W4FUIJ[@<<&"\,"F^ .-5E==LX*S1.E]Z+BH53GD- M<=8=6SQ'0F?U2# .0RY,8UEABE& 3EW0TXMN.QR6?MTY524-1L3%3O %,NK;_&C&T NI^[LV\=;@ M0.#NAW!*(MP6@-3',F/A#E#-(I7M!$R>$M[ 0<%2NJ]LH(I'9['D^S5B8HL) MHA.7A4E(0/_,T7T)*O(H7=(YDLBDYZ4[<-8@'.FX9,/. )M*\L^_?8T'[G;Y MD8]Z1_Y3EV5[\3A_1\9N*\G[6:1! ;FM%N,-T*Q\43T?//82*=:P41C";K"O M@K.#%,NO2D.1*+"R"/R)LB3V"1R7HNH-!-4>07!N_GF!*R*:Y%6OV1_&@5 E MC#TQ,89:V#$[9K@%<;+VBHB]&)5C[_9!##Z<>:*80-1OZN*FT>S#21]\R2]G MK]Z\Q$:X]IZT^[N8 F$ <-!ZL%W'*ER&S8XT?42Y+N^.E%NQ"N)R:9TWW"CE M];Y+B%8O$K_K:Y.\G#(Y7C61G[V/_&E@)"+URF!XSA18YLH;(T6J.9% > @2 M&H2&ESL<'X:'H?M.X$PQIHQ]MG)+#ML939?CCLF"N^$EPM+.B":NNS#U^)#/ M3; O!#7@NIA03]US50P4M*R;SEAP@KR.8)D)VCQ$"WCA]D/"4RY5[%>*H$(+ M6NF2_M49-'F'\$B"YV<7FX)F\FA98,2U@&7B ??!*8=,/6>LG936B- WV,!O M&!KNBWK$[9V#)1^- P^]\&7Q+(]=*IS')>$: B%?1A[W8<=$^&! *V9M OX["V(08S07::&773KQ5< MLK8T$+2V%^0KJ,NQ!$4/'Z::0Z?U1%5(+2 O#\XB/'S]/:8S+#%FK$S?>!S. M^+^EIM"B!]CKQ5G.K%*E7, S@ZV>B+>](6R8C7*J*;1T5T%8&[\RY7D1()>4 MPFIW"L/#!;VVY$NI\:7I>#:=@MP?5:BI^X: N1$/="\$%=\T[/2&L7A?*4;3 MEJS%#;=OZS7"=ZW]#4[*\]TV,HDWCA;B)MO_P[#EP=UV63)0M%\EZ&T$T39: M\#?"@K\"$/\R2 ,EX[),PBV #*@(4L6 M9]2LF]8LW6IXS54!_)8'7^!]1%:*BM!BS[Q3+)F/=&LBOWG.8)D&ZU_NS>*V M-S9PBWQF& MMRGB-N3KR!, ,-U668QDN7BNVHX]QK?@J\4-XLQZ, !FHR[RA M]C P/=. TOAG8'$B[]#Y%O! J?EL/"!?9"^C-=$5366.$&AY08*@C0TC; M;,ET=5'"NY=P<@2;S5HP_9J\'M3%DB$7]-TJT^BG7:UBG.+ M 1HC:NE4<"2\7WM81-KCU_0DRT%)*$B$\I+!HTHL,2W-+&_'&-R-FNDKKVZA M=Q6'? S;-!<&E1E*AL2D]2K@D@V; M'5#4CMZ^HV#5 XQ%G+O$JNX4GL]]_KK9- M7L*YIT[5VO71J\.F4,D8UX&O!>OJ6H[8ZXTN\F;A>HPLV+ 0::I%;R&,3PB4 M'_85X1>]I?W4M2!GT:$D66H\;0ONJ3<&BG0U+^D%;3''4C*X11J:W&2M6)6* M"X#7,;DF&^J92D\<_8PHR,@KY,069A%MAE*\O#KE:*Q. MN<+JE*.Q.F6L3KGQU2FG?"4HOXU69<+-T-?]?,6'UZ"@PN04@5^$Q8Y>OYE@ M!DJ%YX3*V-.\ULBL"V-%JY!BH-?Q-(83=OY2.VFBG/U]Y-&1.G-%8.RE"3T$ M\*JSI,086UV8]#PG+UN _6)*9 P8%3VWW"'T65(A9Z#XB461_DMREQ;P$N[+ MA=?GJ6CF;%4)&B9QIE.]S(SA"?7U4?CZS?>Y'F))927];EQ.S^"S">#02UMM MH&S282; ?S/E3YLR)4.:'M)H'+J@(UIP$!A>P50+*?>YJ.MA*("-/;9-(973 M;_0=9]T*0\CQ*=J1_,:NX JC!N%M74\BBH%P%>"0(H)*2F*3DU"4:5U7%]KC M1LFOX>R7MR$P9F]_M<(AD;)CH:6$-^'+O_ Z\CQTN#: MA@JN""U(>%+VXJ=&,\=H:4L?L&AT3?UR *XD#J^$ CTSD]&^B6LP3$QQ&5S^ M'63R.-S_CO*+].^#[^XF&/Z[(/JS9O"*$7A-A%:BD+('%\OY8$(IHH]R2,4_ MQ7P_L=N#B]V5#DP?E ^B[+-O2)]CZ=BR90BF+X^-.%'KN^,6A6.37<%!03$J MA3POA/*X#:K_)N=.7@;Z7&,)-O6\H:[XXFJD+W!5Y(Z@3[%8*,F>=60W917H M,4*OZR;+O&E(H<^,2_DZ TTRG)3KC1C?A0HZ7+S1Z5Z-1TK/S.!(IPYH#:PQ M#C@:##X2R28YZM@'V9\%QS#]P8S&V\Z?8,P%<74(UY^PH&I0Z#()LXGWOIRD M<=D1KQ;CR&U(?%JOMTAZ1)%PCEAEW#'O>3#2!:]%RE@)Y.YR%[X#T?5&%,(< MIQ-X5U5J^3)YV=2]YE6'* ""J\!*Y D66Z"F@"K#7(!)U1K$KO*M#A?.X]ZV MPF#=6' ->OR3)5L$/2P_?$1 !$$X4I2?X8BDY<>%NU"N.\?%0#D6JL-3PWQ, MW._$K*1P]Z.!UQB_#$/2#M/$<53XG<&#SM0]K;YSK!2)J_N*?%C7%78V*CJ$ MJ_NMFFW!7Q_#;:/&;N:Z-H58(X2#E^)"[;/Q*VH04(E-W"$D]Q!.I0ZU=:AI0V( 8E4NI8515?IJH&@0BC#P,1\B6] MREO;ZSV!9=747N)#1 =B82]PC.EH-:?7G^4*[")>+ &-5A@23SS(^>!!:JQI M>*R!!M>H+!CJC'']L;@BT7!Z+C=]1,5FZ,6,>3(PBU#(E3^# VDABY,S 2/- MAO8(DZAPMD&HK5QA(-$X6Q7&,?"E7I4/EGT6MD*=RT&X.J/W>:R?=-Q0>FU% M6$RIEP@'KT!C\69.P&TRC+3=0 MY\\%)4XU]F*D"^5'<\K<(>;9FH,U*P/[S)3QX"WH$H;2\6:AIJ(^3!3V 4CM M>A!!SV>7ZG"G:/OO#[1M\ >O$2/ZB!IOTL,^3ASWU6";0P^%G5M?AE%M0W(X M?JWA%4@CYU:ZMB;+TK?E,:S)[?4M(>N/5!)!NQ)U\ C;6')YV^^EJL-;-;@P M217"^LQR[50:-%V/?MU2]>($ M399$Q"3G)L>LSARDQG_+U#*O:IJ)YU*QG1G/M*%7:7R7S5NRBDPS5/7W?%A1 M1A[?&8_QM6)V)#[K'/.YW;/^%,;EJL:G@>]C=[LH74AS'?DFM(=GMBW2 M[4)P058Q<>;;Y1!\0P0Q51WU@Q"*2,[8!-PU1Z";[M*PH)TV-'\)?((,?# C MFOAN1!:%X4B*F+I&589QRY>3KF[417!7'S/=.-3?#9_0.TA<6WI;%?#E%7SW MQPJ^*ZS@NS]6\-W:"K[;8_O\!**)AKY_HRF_4W51QLHZ715;P@ETY6!]"1L< MINQ'U$"!4YE&*A:W[WMY5X3@V$1U'W0'K@5J^$T"U'R'G)OTFHBX<=JEI\[S M2CN:O- <5I 8!/32)9:L:TQ'PWTN.2"!SR FXI6&Z,3%!60[ M0$",J 7VCHA:3EOLS$*/)*<+22ZBO&2E(H084L5'+_@=U"%\!_NZ[/<3C\P!/VI! MRBU40Q*"EY/SBWR3IAZA$'=>G;XU$4IC4.A-92T&JX9LT.%3Y%![RZS$R+5( M&#F.K,T4?MMSQ%2=<'_G' G%]FF+\.0!4YNTIG1FYN=?J6$13';'K*/GR!MX MRKV0X#33+8S/Z\H^QRZ]I:8AY3SXZ MWME4HEMKJWOE2'61 $[>:C\>ZM3<>JDLO< 7]+NC$UD)1)7X2_Y#6 M%7AN,* D?K78>[J7Q*>+-*^7::F+^:0",Y+#N4_KO?AI>IYG\_ *LW=^J M-=N[IV!SS.(S]_X37H_-]M8TQ!W"*4IJ 1&8"I/-A6\5%YL:YM7Z8N,7+>EY M6MKT.>*[@-1$KKJ%B8G\MV1P6ZX%.:5K.4J$T2_*9,C;?3%A^!>*96YF[+=S M+XV&U8V:Z9LJ@C=<)+9EF1(J'<7WE+1ND1-OI2]LKI#2WJ.>$"6!TAC 37-$ M23]*BBUBY**<7:RR,2Y-(RVZBV[))9,,E>3#'GB*+?=\(+K'9QA#")NH.8%C M62L]J*G(^A>7& P><%-8->9AO(+;LW'8/N6012_["3D=$?8&")P@.Y7.9K*- M >[O?0A,W.N6KXRO#*!T>T[VEP95LN U#F\EY[8G.B<:46=1"*& AP"1O7SG M:./NO/R#7HD\K<*:L[?-I!Y$4UA&>-L!V<3=2@QC<;%2(O>MP50*L'NDPI[! M%M'21?STE7AEV+1[(ED M#EYMV/.1%,Y7*URFKA2(2K:!3<^!8-] ZHJQ&Z]B6SXH:\!6.J)KX=.-MV)7 M,Z9A4U07_EV ^$#X'2PFBZC74)>,EL$+3-K*+PK^DDDZWADW:J9R@Z13;J#Q M@'Q[066ND)2F&2N S\"0NL6FTBYF1KVH,\26^V^==1-%E0(\?2;&"SZT>3%NUBFM;8E4)]ZDO0DJ1]+[&J1@J5&R/1,X)YG5VCS&J5^D:8UE2'4:1[EJ*@$(DXH65*L:]ZLL0%47Y))K6 M?HH\6HY9O WG0M'_>DWUG#$<1G@3=&';P6<=:(9(LU5C-8<2(C\"/T%WVPL; M6"@'H6:6WGI$7<0<9=6D!0PF1_YLA"1>"!X$#MA;&;;+>N".6)T?P&5&7(). M[8@;,\9"M9SP,*@KU#33.E]QT7W=S0D+P\L[]Y$4JZ*_"&[T@64J2&^16H\6 M\B98?1$+7#2.CG(D>DK%LY2U/L>B>JG1DJ;[F"W_9X4H]$T%8D# )!99M4<%D$NMN@ CZY^NIXK+ZZPNJK MX['ZZM967]T>_+27'CM9',1/N(3VO"L0^TRB#(1CC%J;+TGU;^ MTS5@"X,^)-RTZR!,& 6! +SWF$E!X%O)R[$^UV;2E(A(D%C6AM'3 M"[!P&-LU\)C"B%3?!(JX3GB(=>RFRL'ML:F?&NINI598:T79K(F*I?6T$@MA M6Y=BY7JRWRCK3M5(^MSKAL LOTT-U09!SU(. W#E'@GF7R+[R/.\[D#<<16+ M"_CD=W&9M@@D0EV:\+JZP56KZPI,YR7HWK3&GPODJEEVI30%,+CGNBN;:$Q\&S^(CAF6X058W" MO%YB^3MJ6)#/,$2*;;_2D.>6K^Y%U,&:-^\8IL3NB/18HU;)F[I;20+;!\93 M[IKAF<9VIGZ@AW""90<6\'F#P&WBI43.*I>=Y@?I)N!OL>94H"$1<$X46*:$ M .R8)))\5,*IIEHM, (\M8*'>FVYHD9Y&;:46.K>D!9S.&),3:'>F;:K1- ::H0X6I?I!J2HPQHZ\,/X7-ST5KEK0F7E>H/5V MU+.F#7$I:&\7/88C2H9R,)_\:IXNJQ$<-'A5W%DH?!#]U??5 #:9,9BK6#4\K\1' M2.P]), 7:YC7/C,8KB4T%Q?BMO9(Y$.\8*HKB/ZNTC6/Q(KJ#,T5B6* >T:P M!AO[X8NV N8CUKL-?&_F6**O9EK%GFD5]4VKT:2Z_K-BA^$9&Q51#ZF) VBB M%D!9>:(^B'4I120FS7HAL*!+56*$=_QZ F6,F^;G>8$]\-.:>ASQL)7,!G>7 M G#GV,H>4@-J\_:*(&'T2A:T"S-/)2F]6:A AY.] K^(=W0*=MXIP )=*;;U M2>PV@1)U>@++II"Z/SY_=7(20.JF2^8 %.P'^W W MCCXR%281 M?^A#RT&;OK'8#'5MZ@T1D-4[D]\=:^7P,WD$01 CCYA@ID8PC[O2A<8J4_([ MU(M%MER'7>6>'=@S.VP2R(%S6>15ON )(MQ-3[*-JQ5C=*$%X=WSDG_V?Z/T MO=YAZ<&02/F*8)T,+.DFND!\QS?7N$8]0MJJO.WXO?0=5XW)SQ[P,.XZ>!'O M[/I'RAIY/OBKX N1G/;EDP7*HY?<>D!IUWOXU60FIXI!U>MOO_#L7[]3<>/& MDP8YK 0G5AY9 9$'=IRG@EX(=E^><34NNP>SG.)[ SOA,!;0PDUY_O<4EP6_ MVZY]F(5(V_^I^\8!F'%(8)FW+3^)GG-;DS@W=*8<.)+2NVCHRO.=KM?VWHD/ M]P\>_/>#AX\3$M]2PR<_<&0E?HI/>N6>Y'U35?H/3U^]5H7.F>VBJ5AIH9WZ M:1I/<>:QXX'#5!ZG(P:H\&UPV!C>K/* @'Z"-Q\>)SBA1]Y',9)#$8,LPD+K M_LH$:D8RN-__$N#*KZI6W'AV"_N@U:U+P>-HNY5B'X MCW")!8'SU_']_^(V&:JWG!?5)$7BX'-C<\7./!!XQL99%3B98/!:K[YQ'S5P M"Z32GA+&*'0'HB @X57A8V$5\F.7<\+V\%_G\T3B%6M[D)CXT6XH8]LAF2)J MT04QQ)//PKJ9U2JHWPEL>+2H+A0)9$@XD%:],0+B[SJ*<0AD-*R=3RY>L*"8 M>'JW\2?NVQU$A.U7;$0ZAZ#;HX_*V5%0;U6DTZ#H<6FP\"1OEAQ49X*_ ?1Y>8$[ M"FGCDA9TBT9N)UU=BN4J3/Q2D/^!!V35TI8OGE=$8B=$KLC2\3ZW 6H?*H9 MB"%2I)A:Y@.O?U+CQY)M7!Y1CSID4]$Y75(.C(X$Q>^Q8QYR>$,!!A\"Y_6D M@8:%%K<2?_/S(GF>A9&2%YOLMEH-/!C+1JZP;.3!6#9R:\M&;I.Q'[DK M_12;&*NZS-,-7BY2R][?3S44\DH,&C\R6_'#E.PE,VB*C)I3<VQH6C7>VH#FN2B4)DI!4/5JZ"XJV,')(@$.KEZ MSX;OEP K6II-4TUSL@G=NO(J]EJE>8%#U''T,-9^L[6,C: \^4(R_0I UAX? MTA-!LB*8@99DRC2MYQ5&E_L7[Y >64MRF8L%)-#./VRK1[B;V#(#^?PEF>F[ MR8#9T*_>P&CS7>;!N,)UC/[T.O:B]'1:4CXC&U0<8FAMUJ'Z31V!*5=2Z2EZ MN$W;92I5-LU6V-K='B. 8(50>A'+^CF![SIQO7N,4C"-8Q!#).!(DPQD)LI* M6+^',A&8OFNH$%VKD'0[)@+;:]_QGVP0&I<;^T*/WRS^(&4@O:8.H9]3;AS= M9,_9<:)A=86#)AD:H[1@I+@Y\N(/WO9A.038"95 /'LV)Z',^+W2>7D.=[T' M_.M5$FKU8>IV/O)JMO56'VW/73=1?&Q8@=;Q/2O2A>HN*0UO4#-%,0TO?D%8 M9Z[BE6'DFG1FL#0^"(A8>;7ET)$EMA@MPET_+M@]N=7R&S!4!"!3ZDD5NL_C MPV+DP;6%M2$056XP6Z1_I'6& 0R] /EQ0I<9@8I\G+-)G&_=R=\ M"DR?PJM-. ([3KVIP_?VBOFT$#=RA;A%-56;IQ\:X=M"CSV5JWA/M[4KB0OX M2_"'8!(<:=C ]N!&1%1XXFP%$Q8V6FO' IO158HO)=39@9<*K 2_U8D"9S?R M&MU6\4X=FW)DJPHL.^*\RS-34#F1*+B&\2(LJB7\;FW#51I5=7UBD[MU> M%U7]CKTZ7NYHZ)R$6V65"7X7CJ"*,>'%E8T6>6@E.,DA]L]UO('<,Z5@Q41P M:+FQL ,MZP0U#B.CQJ)_6$"LA',A[@4*X*=)IC0#RY1+K^&U5'J&3(!P$ETI MG1?&@U"P6R9'E!: M#CW1Y02:_RDN Z2J6@G!QEP S-DK8\EZ61QIY%4=[.=MN)X_N13FX5@*6..F5,K#/$Q+J)4[^A 8(KF\\GST%" M$WAY*Z]HWV97^#;P>\"X7G;+&(-VA&"1VXPWU\3#E?]SVF3I[Q@N/%G5\,## M1U2WIS#>.3;*J7=L5Y M/[&P6G9GQC5AL'Q[L+>_C^D [MV@\1[M<_A9V%]< M+SN3T66/0I>4^T%D%!\UZ$2/(#,Y(51%ZN"PR%')D8^9F&\X\)"VD5?'MZ8* M>V(R3#%[B.5E:2Q%DEZK ";*JTPJ)G&I#A[!9-+"H(_+$R" $2)!'VHQ"!Q? MMWO490&&UZPE^!K%E;&CR[ :#]VM2QZ]966H%Q+!Q6&H][)T'6],QSI.YZ - M<6A))%Y=%M_)[V*U&\*B-SW-.""%)"F"@B[HE#.I1$$(:#"C6**D40=Q,TA& MMZQ*-"-7/Q?GD5]G#XS?J?%!C6G[5#=@W/6TW3'OIV;5VI8JNYR1]R1)[-W) M>5EDF1JM]1-!P\>*0&+W3RML*)KBF%*J#]UI3T0SCD12R(3W:V.?,'!BK/.; M4ML8IH7X@#7P82YPM'0FMCF=LT&\?1\G4*\[6)WCX^/].^G=.X=W<24X_=4B M2N[[51Z&FW23^L=!1B[I4%P+W&N3UK9N\:R% Z>/>2%[_ \F:=&R3!?'P@]B M+2BO;D0V7_P3"]R+%Z?Q'7R*'%O9 7J!;5742)=="-(8/28"V2#C[0]7F\V" MKTK3KUPQ MBH3)11*=*(@OW&Y)\#9*I>(&%#(__7YF6NP6+FW+5HKQ*A3)!GQ Y/BY)M>J MWO5?;C!PE9="FQ&C.P"JR4\^ MV;!&2&UU,(!"B_@>X2^ +[(E)H9-;Z\#0A@YED4)ON@34$V 6LJO3EE)YW%:L4Y&C9=!;G@M&_6]--0&P[X M@%EYBCQC$W.9MHSY3J8$(N-;!%;94!Z-U]YS)!IB M+_YZHOF5CL,S,ZFYQ>FQU9+#5[U81VP<(4Y_WE@@'=GO.Y??Y58.SR^2\UW4ZV/$5N0CF7#@!\(SDFRS">.0!,'KGL9Q5#0 M@,XL>[U3='XP4?ILZ$K73/K@\2#6Q^ >XANG%PQKJ[_$=P[NPEJ!HF?^JVT7 M#VJ*IJ\JZ,<)_IC$9'OD!=X/[%YZ=7511NP/$TY7K[E;3OLLJ.X3>U3*6'"N MK#ZK'&HCKK2XD7XC'==T9AZ0K/?!6544! 44$T!QY+]6O,:CNX$+P >/>_+* MN%MA=AP7&A\Z@X$B@P.)&.PS>\S\&0+DPW)&>-AOQFNDPX>6(-CQP6$,:]PN M/N<==XTL]$L&0V'>* SSQO]9F/?/!77]$$7T58.Z$J!IH@\$=6'_;D">8 M[,1\+#-"(,]@O]@H["M3@I:FB(_&7[U(2+."&QAYBFNZ.ER)&0504F&8I,ID M*A7'^U3 3;F4'3]7Y' >,S@X8YWHSA>B@#$?G7U_2N:(5@21 W)P/+_W6.+! M( TI6 _-0CJM";? M^NNII!NFR9GZ2E?4$&([TA6T04 MORV\)SFD(6K8W"KW@M4V+,>WQV$Z!MZL1H-YC_6LC?F(KR5Z7*C+5?I@.>8M M3;#H>H7VDA3%2MT>G3SM!I9 RJ2NWC&*>V;@%"K]E8E2 M:3=Q_(Z,5:K),6>R80>4>W7SG;T'-YXMYKD+INF!AX%HB#6=UX8C-H(JY;TK MP=@7AU,I_D6/R 1S$=_Z>Y?R#^+U>>-B=C04A^F"V %NPR&[/>KD.8+W87:I MK52$XS\MPLFP^%+42W!4+0U@T!T$,ABQ3$O,T3;N5G2T0?@;)YLXMN^D>!NI MBF-T;BI.?/7B_1K+N6S4DGS(J4@J8OT'7^/W...4?T2=UG26M!EA)@N3"2"A M-^Y@JARK:.0H@;E*0T6L-$PFNDX1(IU%PN7+ACL>P!LU4[S/AT\,U5^CDW2. MN7.;J-R\ROIW6.HWXS73A]F ;7OPLT+T\_W^LLXGJH;-=,?E$LID<-EJ^C)O,.LM<"]*HM]7^5ZZ3G/'?-" MV]Y)4=N9+$4)JN/KZ'K"*I,*HWG79&D3FE>J1@=C'*)@W:J9/ M73B7]/LB5;. -",#L?FV@+8=H\O?LUO@YTD%NE$"5@83IVLJTX1!!#_BRH' M:YN 73-KI/I%&KP;2:YV]A1\E*100?4[PS0I(#)D=:^MY'C 9R&7QP4FX&9% M-VV[U-HQRF"''Y#^;B()J;!+5,%#V&!'/WABUI5R&%7$!?\EI6T4JL\F5 1# M)K)A_ [0@D. 5,B9$9T,WEJI@#W1? L'U:1TL\<9EO@:I_R0Y;DNX9ETFA^TU.T@IO@ M9?2UP80@$7&%=1RYY! M-JPA@:!(U 2LR?F_W 9!'SK2KF'3;]#L-W!^\FH$_9M;^SR_P6Y*KYGSXY\_ MT/;YC;1FND[/3Q[N_MXA[<675:UMMD,C?_S@X>,K&OIG'BLW:>#H")NE*KKE MYO5.-7KG%.L(HG82^H(W4-@"_AM,FOJ"KXGL[I"PCM)IQRK6:-ZN:8@#-YQX M^A)Z8/EE.$=$.DVGIB,I8I33O&H=":,D1$>!O>Y"L$L"BUQ)<].HM Y:HL*T MZ:E12= I'R75QWU0?AW_PMS&H9G@DFD3R43E<60P42)1]^B*1L&_]L*T2X)/ M]!HT.L3'W)IHP*Q@9V&TO:K.41%?_SW>)7F4'C0KD7YF("W6 EIE&^(L[A;A MV2:QZ/&PP@(S)$O*&$_6@T^\6%3B+*O@8W%\PH-@D1_HC0-M[9XLGC\6>4Q; M=R?83-YX3*Z]Z.W2,<%F0AR;$W*_+4(Z_FW;125%FY@)9,@V[YRPW>%_?:O( M]SXXRO2UEY-=DFE$L$2:3T;!P%$&1@=A/K8Y!52K&8&JKXCON*6/-*8^1[]R M%,IKO]&[))2J:%EYVJ)7A(KWP=NQU(&KX5.BQ!!?D&LO L%F:&8BU?":9<^^ M/QT%]]H+PRX);MTM05/:"+%$++!CR)$C:YM#YS$9JO*!OLV:;#3&WP^7ZF8_"#@Q(;70>1#?):UU58/^,@;X*8 M>JCH5@05:B7I6ZP*7*X?[UE-G;*J2.F$@2 M!^YB3X(['(4.*WB%1M2G+$)GR[+H"@ER#VK>)BE<@%CE>UA,!5KZ>B)'?S)H M^Z,1M/T*0=L?C:#MMQ:T_7-67WXSUGZ-EN9GN,2O[ID9+<;=MQ@_1U@]4TDC/"A# MV$K3W[N\R6VVLN>=^&RXVT+QH[2-TN8/JS07-(P!*BC\$;,V1!"\JHV7)B<< M6=1X0U_S<-)[5*FC\(W"=TD5G_1="FPH$_(E\0J\L2EQ1#IJPF13* D-H)SF MH"I'.1OEK'>E!0'@*N&!HX!$6S2@_H_QXPY+H+@T%V_"K93XE MMOC<4=XV5(U66YC*>%Y7%^U"8V\"9[GW9>)N8S_FE1FE0@*::&/$*FW: MQ,/299AOLHQ<)T6_H40>2T2!L$]*+TL,=V MCS@4U0S1;$/8(H6@:^1S6;V!@9>42T&S2E M*5,;(=91(S"%H9)U8&2M4LXPE75F^C> MV)/,U+I^K2\Y%G!1$T,RD0&#-(V(ISLO]&]-1'346FOEA,(2%K':_*6DWN@S M@@YC? WT#XAQ #MP>CA./0#"2X0-/_W]>S;_HI,I:V0.SFV10WZ[HI%Z:/ 5 M3$'3I."AW'OYOC#K&)[/)"FL&+%?KD:>*,7OX<*R*"W+3IJ/?N_@ M&C!UL98I--[X_$GZI6C\J*XN\V9!3^XR6CQ] G;&>RT@2M"D6GO4MCNK.%C; MGMB(2V13PGW@=H?QSCEA8JLG!I2\%)*3!D'AB7M@BRBC_![N[Q\F 2!:B(76 MH;A%Z)BC:U7C#5\C=/7OS"MAD%0(/DYB"&_-8(2,7R)(% R[D&;$&H=P%L0E M)R:3V@_*:F"I%8JR)*GM\ M(9 0L/!O"F/B))'K+PT"IG"4O4KKC/'5P%HU%CV:<%"T9P-%7V@/SW$D5E(G MAB%$Y'Y@_&D>D N9$N (P\'WF"BMB1Y0IR*B"**)^ @B>#]YQ"V3=20!,>RH M>J_D4CI?OI5,"A5"+0='$Q,%9-6U?5] YX(,Z,GRG/ MH-,>&;G^917 ?1/X4>56R00A&)8.H?O@;9;/6^]=5*%2^(AR1ZBGGEPA PL( M!OS<,'H#<]?0)"N:9!.%$C>P1[?AW-X>#?6LJ]&*+%#I0Y!J'"Q#XFZ$451W6](UP !(BB,AZ+K0L6-MB,SHXN M,/7-9W03#MM8LUS"]H*-S2S1Z9K1&:U]L%:%K-8OZV0T@-U1",G0&M@#/56B MV8C'^<*0$7NIJO^PQ1$:%9$8!H%1T2.J$>#SK4:%Z\@.NK%I,15J4K5/? ?4 M2K?$;\-T3,&[%37&,$<.6^G$C#/K"HI43V2]F'E9WGW7XV M[9_/(I .Y89RS**E,S?B9MVT9LG]RW#^2@K$$8(;FM7&AW"SYV4*+BY<:-;/ MY!92VY[JU>[CU39M(P)JW8M/$7\0B_]:],(=\K$'? GOGN69JHK^<]4O9VL@ MU^M32,T$R9LW\ &TS(GX>W+DFAU$M)8 MA!2N'[IZF#40"V0:OSX+7Q+Y+V'^E-D:=6XJYGAI#/$N(8L&F<@66%$9U.A M5F7.D,8#8Y=OHU O$5W0]F?G6-%#=TYH TB]Q.;#A/6&PD!-;!F4>=B$C= X M1O4_I2B$: W1<+:T\5 0C'P9CZ*JVG;D>7-,-DP2LA>?X'U(MUC5R(6ICX@N M9"A$7V(3:CP-16&^5$G<_&-T>Q3&3\Y 0U<4RRV5.39MP6WO:F5<69NTOH<6 M;18_A;- B*='!\J&/GRPA#ES:N Y!GU+P>ET9X88[%N-08$PK[B&$R[/2$J= MU /]9>]L+_[AY.357NQ&[4YI%J)\HK4,\X9;:1IBP!8T=7]C0&VG;^B4'H&@R-_DI;&\8ST M"&B4282B.&DSDE:,GN=(6G&C<$JV@^D@^53Z)]"!7$W!5$11MM\*84?SY]^C_;2?X/H_?ST)*8$P7E:)!8OK#!:3_/? M5#DBJ74QRXJ\).J)%G,!H[1>?PG8)6EU]> ,+2J0X1A&IE8*0<-E7.91]J[] M?NZ2['T:0+C?G.T#G218RPM&YSR?4IECR36/\/O?JAP^>PY/I]PM%D>FJ[RE MX#462=)[1YF^]G*R4S(M!>=J@5+1^0!NA11@NJJC$91YE,;/((T"06!1R;"Y M4-3A+'YGUM+(4)IB%+UKOYV[)'HYIH?1:NPI0\OQ,;KCHQQ^@;$&A'@;:0Z+ MN^AENQ278V5*0>&XQB4THUCNIEB2U#%@T#DC#]2:,,/N::SEGDG6%OM\)F9= M2;>1%-Z,Y34W.I&(6=J FS9O?$@+WQGF).X6VO"]^/F?P"3RP88CTVFF=#$$)>!VO65YT6G4+4IF#6%Y( M'(HK)@U*7:_5?]:A(Q;VRHN_AA@S6[E[QQJ>^P MXM>' [+=VFG15)N#O(1D>LBZIMXT-&E +9(EC*@TS$Y2(\9!/P%57KRKF JQY;#0SJ_/U[PSV&'3PZPEOI#8OQA60:_N.F[7A7S5WN;6' M)$3N]E9,P4O6&NP#&']-?;?Q[UV%EZNTPOU\#UU-JJQZS\KO@%?=G6T(7;L MD!2HI="";'+4&N,EM>N7%.[U,#(&**C2P!_ N@5E R>?:QK>$WA@[JU=8O[XU45:10XNF6@\\#.#_7";,)IJADTEL7&(%W8=EP9;LH*OC3[#SHL]B ;IIE5*K7N>2%3E MIBK#KG1J'B7@0[RF4:C\$ETVQ$M?M@B]8B*O@"6,>&K.\!V.(O)D;9>T$B'$JV*%%$K&D;3XNLFB==5!]<>J?$6 MX3!A$YS_GY)6)V> VOHHT&;7"L&-9PP)MGD%Q.?8-!C 6A *K:!T>.'!\(ZT M7V,D71PF3FF\-W96 =J6L-I$@H<-R@&1PVJ2:Q*P"\.RSQ>#(.84.9A!F0*7 M=;4/V[* 0<\Q((LNLHK9J01GQ[MDUX\":>BH3Q>VPDAV.C4=I2<]YGCL!$,) M8&1HO$BZDB\#I-^A$#G!]]@N0@SOI!1S4CWLRZ0%;I^#>8UFM>AI:D2'<2Q- M/3O^PY">7=D,4 ?(VF6Z+GDB6" M++1Y0M"$QU_/\M8&INQ\]^)_.S7/MAO^13M?W% %N1 #QU.Y1H+C*?AK$29X M$,04/VP#3 0K2-C+U2VWM_?'UOOKZ[U_O[^V'H_MM[?^-9[BG]: M(&W#2'D!)B[FUQNK@AF6%S2VA,FQ JXQ"H>]JLW,U(@4SCX5WA!5USJS7SJ% M-*+D9V7"'/1@0(SY8]7=&'3FQHSB#;G]4# % WKF!6H7BH/.F42V]3F%%^:2 M>J*8L+5">2 ";6=8()(GAL3#CQLRYN05^G8/J]D"GR_!A$DVQ-L39ROJ[$)+ M""#QSE P+1%Z38]N8LY'VP\96UST@'F-]3->H ,AL7,A6NE*,*YTTCX_ADZ# MP/7%JDR]U] WQ*>*$$4)UJQ;43T,6FOV&_9S,"N$E_?").E:6E;I+O0B-"G] MA.#UDXZ!_?MG.X@"":)^9%\E2=>8$Z[]H)&7ER20_%EZ#GJ-$($7 CS>2TAB M?$/"Z=E W/V-MR^11!WZ^\%[&0#\VBC%>G.(5(4;QH55U@(=!P MJ5 M 6D:/)*I6U:!(-E]&Y3%[5&+ 3N?@,(SCP9G*UFDP9EJU D^D]J"P_TCO3F? M@KQ=X#=_8)Y'\.CD3IN8>FO\W&YAD/:W1-\ MU:8T/2S/_OK-WZM?]_?O?Z.FY_/6+*.#)WOQ+R666Q;GS/$VFV$8A2[%O2]L MJ.[TM@T)Z%5.Z.>JC1R?^]?6!CN]59_WA!WW3MCI7GRZ1GH8KGI;W[Q3A5-_ MG[W_]?&CQ[^:Z3J[=R^8\.N\>?>3+>9XA1#?"(?WK*I/E _@N:#^PS]/RHP^ M#/]\LT!7OGD#O7L MY/G)3V_NG9Q\_^;'7_]XM'CU^L>?VW?+_. ;+I;G0:X69?OKZQ^*/_Y]^/Y\ M>O3/]?^>G;3/O__Y^-_+?ZZGA__\+?O7WU?9C^_FORR+/]+UDY___?9X\;^' M_VS_]^WQ_O,?GG7_>_KD3?;CWQ?9#_\LS=F3[]-__?S;Y(?'?\#WBI.37W_] M$P!CG[29^?N_E%7Y<[>$[Q+W-7[LM9G]]9MG8'C@HMS;/X#_;ROZ]\'AO2-< M@8J9$K*3]J_?G%;E+_OP?\>'\+EO8K XTA4&T^K.?$.[^2R=MOR!;^(R7<+? M8%O_\GEV]4I/8_XW'%?D!D9NS!G#%JPY^"+"&ZSCSIU$IW10J$_W'PV?@I_/ MWKW*3O^8'+]\R*(C$=PO=W9O.TP$1 L[ YI\Q)4'GZ M3"$O\5,?.2ZBAF@V)H(\B!F1 2I^)9=S8#F6P6(*'AZI$$7$H2?:"I;G9R_C MPX?[^X>QA7@0TO2L,EQ\@RNYM@F_I3&AP7E7-2Q(J8*(53@S*8CF6NC0W&?;2Z)@EC-.&0 M5L02!\\GSLBJGJ=E_D*$ M.N[Q_NF'K0N0@SI[!?N\_IX6*GM6I/-?L\F;0RP2 )O-6;-^1R=]OH>+2?+1ZB@ MZ#(5=">_BX$5+HCSA8].J"6?59CX$EK:OUL*U6V7$4;.:RPVUG=XB.H;CZ&>=B=E86-) M8JVM6+#NUDD $^H^2=V) ZWG\8_5!59_$N@HE>=M*16M-JXR;#OE+GBRMI:N M,]_,9D2P2,5K:7&1KC%E&?3BN_ISO&ESSB6B23ATSFQ#/1'[V:M/BAND)2>2 M](8M O^(Z=MJ=2KPWK)AO>CE@$.)Q3F[X\_UG?&386_WQ]\.\OKO;ZN+%T/. M>-^C/?I$A]N/PQUM4W=/,,/_?+RZAPC*YMBZX]_E!T[?&E:O3#>W7%H;,?*%V+"NH&!\H> M; IS]N_TZ?ZS/WX[>#C]Z"C4X\T@V>/_-$CV;'-H)Y-_U_/IWW^:/_SX -GC MS0#9XQT+D&VIL4JS95Z"D8#>3HZ7V&8LJM)# C=0.97";VZQP&^D<.FW DK; M&K/I:SS9ICDEPOVLJI^3VP:V QW04WW6R_JLF]@GOV:O"*]A^,I'JMD_'C;? M-Z^6%S^>9-,=L1>W:[<'^Y=JMRM>3\)QZF\O&D.U^R*A39" &&,!MS$L0& > M-M+E12"Y-HQ\97R.0$(%8A<$V1HIVH %[%;8%6@C!YO2O,TVBH8F(H5K \\G MCVH9YCLXGB>! A>-66^+.%!C1H' 30Z.G'JP;6LV6<12 N.'AUU4[T+)^%5U MX%A07;!X#FX&]ANZBABB(6\7A0Y<7-SILF^U6Q\WLE5Y)K.1EX;#8@/"3S@R MX(BS"SZ!R2$F&-6:JOS@_"O:!3T!5(;HINL#H&%1=3"R2/T)(JS<&L'Y_B/R MPI7T1[VLK0IHO%/_FM@NWU2D),CKSD%W;O6\?_GC]/GLV?3-'T]W19-^E.?] MX.!C$[*?NIS#"I0$R"J?5#A',0TS*/]Q()YX'YOWX(U2 % U%[GB5"-'+5N+ MW,SB9]:1?,DP&+?4<7R\:0&^/%BOQF:'Z[L08%,[,VV*U@$)$*@-77QP_%>\A6LN:-=O%5BO MCO8'ZH88F\\8M PM^E6-]\X*OFO>@S:B:G7Y(-B%C'S9Q@?W'X.2F;6+Z 2, MF<[ :+N\-?'Q_GY"4_DWW/KN7]@\=K#_)8OL=EJ"/N]!?Q@>]*.]^ 48)T5, M'H1!&V4\[]?IO*.1$V').O7,X'\%=1&CX&"[9%037Z0Y^A U8_XI$CB:G&F- M'DE7<\+353^8#M(4B"_.D 82: MNUKL[[E_6X+MS%^CXS,Q%DV0A6XQ<=G:/<>::?P)P^R) S.'-PQ!W2:1HN7: M+,5$.]0E'WUI-#[>B,8/A-\3A<_=3%B,)VSOOU_?D_XZ E\ M@L-_9Q[FP$]>>/ Y8B+4\:NNGB[$K9?O8D>P (./#MW7$P?>[>BY2ZB,FW%] M[+!!7'"'RLE]'0+JKXCPZIK"57L/_G&/2#(=%#)5CC5]*/NTR=+?>U#V<5<2 M+AIE 9>3JHA0"QSN?_?JS?-_[=&_P>PCB$0"1"$*&GCKFB$\3*:O'*0<( P- M&;(0[-B'E&8.RXR9BSUY/@&MQIA2!&5DC(+;D5-_[M#PY854."?]-@H7MXF@ MX4A[V RBQ"16WBT2BTZJ=#ZPP[G$%RE?++D1DT67K2!3D2]RA'R$K\';XDF> M"1_!X+((:C?N3JJ4T;," P+$*7$O,VE!6)-<;RZ8*1$AKQ8T_7O=*J%_('4 M!3,IP#.3A;*NV8%+95W)V^UL8&>X7&WS=_^Q&>O&6E!I9E8#SC/GV1?7I175RC;=HDL;Q& M)_USB\0U'NXMG_W'BN40T$X]G]PYW+^?'!X]2@Z/C^]NBNZ'5(#<@P]L@&B[ M.K"V]=6JM,/]PZ,[!W>W* H9W^%_?4%-&K[ZX+\&(V&?Y?[05S[HO9.0KC[W M2X>7^(M/?MSJF[K5_XFF>\N08I_S9A[*HN=UT\;_ /<6/?7_._D;*2HO#O,9 MKZ^!&?Z'6_+M%JFX2O$[W#MZ\!&O^1PG:]P%^XZ#O:-'7V47/J\Q\YE/^YG! M$H[QN'_2<3\\&(_[U]Z%@[T'#W?NN'^=&YW 5L8C_DE'_.#Q>,2_]BX<[#V\ MOW-'_*O?Z,\JQ-X?C_NG"=IXW+_Z+NSOXG'_ C?Z;DO.I;&9+Q8$&H_QK=F, MKYM;^&KYA/O;\PE?.K+\H37Z4@+]*>/XK +_55,,X^[?OMV_YA;-F'6X$J?E MT>%H[7SM70"GY>OD?G8Z1C%F'?[,<=\?C_O7WH7]O<=?9Q=V[T8?LPZ??L3W MC\8C_K5W87_O^.OLPD[?Z&/6X4\(VGBC7X==N/]UZPBD1?SFM#,U7OM2O[WI MDR<8=/-O[6WJMS-]_/,'0 V=>W3LS.#AXO]1R:P'GNSKT]O]DF#1#4G M<,:*F-')CI4%!('$TM6JKM[GB.]5K..C9']_'[%509O&PD:NJ&$;;=%_F+KJ M?PA' <-[$K^JSES\G$A0'H,((#4>@0F2+3?")&(+7UEW%:%#[60X>/501Q_EYL MTKI$)$3\%GZ GB\("!8IWKR'Y40@ "4!]> 6W:,R R;",B]3!HZO<&[>? A; M86(09Y7>D3=3&*8'@CA$Y8#+QI@,B*\8=RL$(XC*CK =X:.SE#[8IVK:PL4T M"(4HHP>ERSQW"1/;": !/*D%8T@>X/\4Y=- DS8F<&#^GUM"$$SHGLQ/H.M;$<5?'U4\,LR I]BNH@/#\E:.DI\ M)E#!/>T88R4^(*?E?ESSGHIQU.">QG?P:P)%(WO.NRV0-'<#/&F+7,6/F)AY M6D:*%X-JB)]Z+\UP'5 /I VX2I8,HP>1P\(E #GPIW!*"E=SD1)>S721EG-& MQH4G.'7GN"JB9I$B7KZP;?3''$+#G( &I<\S&P<\BW_RV3#X:H$5<4JR:6%1 MF=R$OJL3I0N&P&6(_B-8RM&LO"9J@/0: F1$9VG!@O)+61,NFR$GP**HC;KN M/Q.YH1#_!6?QKFZF/U>E&3?I.@ ?'GRCIX6 #Q_LQ?_O:]";];G)_K_Q*%V7 M73H,=^DAPE,JQKJ])1$SNW,(9R=E6JSQ#J]\KIE32UJ*GWGM/(N7/FCZN._7 MY=;^O_G?_EUU8!\ICGXF/K."]F7AKJ?>KJ.;-D17NQ4N'VRAN2%/C^C?PN\[ M^XD(N9CJBV%/RPI9M80!/5.?&%U<,NARQ0E$NQ!^Z V9?4LD:VMZGR??%5U_ M,.PNP-V\5U35.^+G!O?I3@[04\JCNO/2['>S\<\=ZO$._]<,1[O[5X M[S?NXL9L])7>S1BTF*0-HQ6_JJL6-K3,I];\&[JI$W3=IHO(?9S0A5=PJ5# M'Z/J4TS&(0$V7_J_[)WMQ?!1>"^2%B*)Z*IE-E%$4$;-+_1C!9)P8HB)'Y>Z M:VM;X"6JX4SG&.CQ!M16L&OOP%R ;5DR/2=ST7;+E5@EA'+,A$!\K4G*/EWB MD&BA/$+5(@?]4E P(%9+);-\,O#AB#D"YY00V/(]">MC4D."4L/KZU&J!D/# MB%W9R0C0HD#.TCCK:D>3BI]$TED!5]Z+7^+VP^[.*_P0!> 2?Z7,.=PUM$)D MSX0+]EN7S65,?3,DN/[GR%UJ,.E#6,D3 ]?YGO>6"&6,J:;="V!CP18!,P65 M&$VGSDDWD_U6QNV;-WYX5VZ(4Y/J+H02RG@ V].\GG9+6-\2 M<9TCWX:!72!9)LY0^C!'*#% "O*#L[5+$*>3JN,=G*9U33DI7#MSB:2PD,' M,*6%=G9>4"8D191Q-JEX=@TE7#" MIQ85,))67><)O341^P=$BETQ%SW^&PX=J'2?.-B>>L(;STN0@R)>$4,#;G.\7 MU)]_N4$",A8H?O$"Q0\7!O_)07X!A_/Q@X>/KVCHGWFLJNQH@'C U5 !\V]: M@'J;DFD$A@<^Q?ZFQ:"$,-UCO*6N,M $85$&1E[X%E8RB%6^ F.AI M;OP** M*&@S?U%1M%X+0AU\RL0[MG6BW!@09SJ*>K;\GN MJ+; ND,_D@JZJ,#*,^_ZI;3P:_#C-K681C@EM3<:<-=Z[W=ZJ*/T?/4MV1TM M9PVXMJ*4 +)#DB)3ED0,QV!4#2-UFV:$K3*:75+M0FKI9Y"NI MG&"]MTCK93HU'K[XENZ/]TBQ=M39\Y_FPY(SF ME ,V,RQ4:B2C4=6KJD;[3A*WDEUS_4&4O,4F ).IPAS5V[7:])T>ZB@]7WU+ M=D>]+;':$_Z7T BIRS,3#[9J,6.+6@]MMZ(PG+J'/ZQ 2-8QEF+,JB*OOL,O MC!)XC79UIXU& M7W(J*IV?:PY7W5B6_^UG:N&.?C1I35@9K]+2%-RUL3N3T&7_G*/^6O@ ?^^* M=7QXGWKI[X?P #4JLW\+_*&;HY_@$ULO]1$=_11]"G[;:Q^YMIB;+R"_V^H9!;N("^,0%%0 M? 75/79+A\,6AA*"SJC><%YWA8F.CX_W[Z1W[QS>I?RZIJFP=I<_!=-[LQ6V M;>B1L?=(6X^.3X.'-K:-G",;[%!$Z< TJEG\[<'>_KX#(.!JR\$W/CK8OS.] M>^?H[IV3N^AU((J,EAS'LS0OL# =WVA,^^%EB\Q[>#I<^S/!M[&"H,LCQ0@Q MEY;C6(_V\8\X/RHI5DR" MT7 T4HKX[VG9I34(\;Y%!$.4A7DZ("67;Q&,;>";P:'0#H@(*_RI 38.Z%2>%#O-^\LJ""=(]0">&+3.DO<10N\5?64%^DJY]U M\N#H9-)B,.?&ROYYZ.LHRK.3 MCHT,S#NG\FZ2P8:I#/H'T7^B* #I3M$Q9)5AI4V?7#MM'>CF&26W,,%?>-HV MND3;4G=OZ>L1^!F38WH0M634-48U[N7RT- N"2XU^HU>1!&N8)UI/TW_C.N( M485U36([@70-;+5A2/1;7O1#97[ M&S!R M;5K*&VVY[%''-7TE1S].\,A]TG>_<4.._EM4+V'?V M44YET+QA([L5=Q.RBD%TPCK-R=H@# )&+:#/9)1Z6Q**WV]&\/FTRZ>$(Q(? M',:PQNTBM"NN>R#G2X1PKK7V^Y((,@+M$@70+B.RR_5I%'MK(L*A"XHJ&^R5 MU;!M#,XHMHJ"A08[B'VO= 7T2BU!KU430DEY5E6<\'I:=_/X)$,'A?0P7ESJ MS3][>F)=>:U=)T 7=(I,C0W.^1^ICV0J>?VQ+?4:3^@I-993PS0V92+V#EPC M3\&<(;#%HP,-)ET8[E0EN%_J ]UL/9W%WQXG#_?WD\?'^^@ZD#C6#)7X[?WD M^/!!\OCA?=MW.O#"2%[(2)#>O-'E\[#6SA.)@<#%90$ M_I-WVLZ];MMJ%GU[?'R0'.\?RE@/DL/]A\G!_L./>3&/]2!Y>/P(IO?XH\8* M[YQA7 V1?-%PI?%&'[&P(@J*ZH2.6VY8'@[@_8]QR#2%P^,'R>&#CUHYGL#C MA\G1,4WX@R*Z*3$?E =/DESB;%HUK9U*Z)2[@)$U@[>_@^NA-D?U,9N/^*>9 M;0^GKV82=<(S!1]B0]-.A(^'J'U:IE'K7A/[ TRJ%SEX B!@:[HOU4<"0XL1 M(4;CZOJ(VAF<-Q-QP0\ZOH2-#GBC-;@$.H,C$ 8]@^57>!3;P$ 2 ML/S00O)+Q2U$?H1?=Y 1K#:HHI( 8EBC-@IJNZ5_$!5M@\#$(&^H%6#F.06F MTZ*@"#E^S$T0_'+8"@0P8= :D]%2^$!_B[KJYAP_$ >[0F 2BO'QI,3M]5(B M&D*#QY\3VG^13BG.X"@\2BI:P1"E^]X-5V&7(\0=C0AQ5X@0=S0BQ(T(<3=% MESS'3']IO"S_V?>GCHS%0>^G<;,PQ2QFO'/QYRT(&<5)"5 M&L ZD F._^4N^3B=SS&JW1I-,47V_K&)UV[%WL_^_MY^#&M"/CDN6E:P6![\>+4OHLA MZT_F_!?& 6,L,Q@]8C#1+M!+&M PT>:BV95P"S%(FZ77.KZX&G@WU@82[%U5 M*XI?6C#M#9H@^$S+Q!!M/-WAM.E39?TL&\XRS13.#;]]J1Q6&+"JE_'9O:.] MV*+Z]U\:;7\I1L_HA6 '<1.*,OVAYPM36IIV46626V%Z&O8%D;>GU*2BY&?E M"2J%"L>+'IR98:(6/6C*S=X_.,:LQ?V[_H(X*^ED2O;0P>.C(U[P)7FZ 1L' M)5'@AL]Z_&B/]O>)(4TVP3T_$->]Z*1HJD2SNO:\T)+33BUHV!@I-!FK%@M_ MIX*2DH&)2T'C"%\U@SNN0.O/?Q"!'\,3^D$>#(X$L_AV?^_P4C&MS9)SWQZ= M$UJX:0 &V-OOO<^79AV^!OA2':^PRS*JZC1%'H93AU&.;^\GAP MXN;E\3WG,V%HILX):)4BH<>'Q\G1_?L$PX>^81)_^Q@&='#T&-^Z&<[1^$\2 MN? ;=0DC3&J>A4A\7,FM$1_!IL3W/GZ^&OR7^=<,=O]V>$%LKO=-BRYF^/4P>[/'\*IV]? [*JKIPLY?(./&27^&D](2%"V2?Q!\AAT[/']!RSQ^Y]+ MTO&YLZ&A_#E)=\.VDIZKV^/,>0I'BGO&A=0PI%%:K_&$WAI-3Q'0B)0">4B[ M&8N57^Y%3GI6(6NIP_#UZRZQZFBC1DPL]-)TV Z[:K%\*<,* B\/%L'[YW6Z M9'E>IK]5-;H'%NW=VC2<<1.^5'P5+!*!I<3G(,]$AB)<+*<5\Y)B H5S;R_K M>5I*\4$3WSE]_;*Y*QQ_-*JH69?X.EBEVJ&IT)#60H8"%DNEIHXK5KD;]V?9/DOL/ M'O-9#!_*%M_]?;BU'HVG\AI/"(MV>EC7@J5-(1 +"+X=DWLO?I(*B0/YQ6+Y MN_23,!*!_ A>OH/4E@,O^<9(HRY--^,.D-;R'F/LS4OW<+UFZ*4'%$WXDKS. M%/ ;?TFUS1AMH^AV '<>)I.BB5E7 N^+\X51$@-"5UZD:YP'C;,TPK69@FL5 M).KY"%A6:M)!6.?0+EG,A $!VY%/ M&^J3237;V*1<+;GP,3$-A>C1R*I"UDCG6&WLR)FD7H X1AG^W*>32N,-,FB7 MAQ3R#TS-^<0,&TP9RW2-ZOK<2*CKH@;UGU@$YM[X_$^&"/"+?+Z@4 RE[5=$HP/$RURHHO MTS7XK)($"*-97N+S.0H$J&,\B_Y[F!I$GN]+! MLZ*Y3[$?%@^ZRQS 5ZH!*3:D9EU-/K!_96Q-"R=(&";K%6'D5T\%+"[1<>3$ MUK51?L*W("@&#)I5/E/?C=&LNUX<\@IV9RRVO0Z#YP;A)V+\12]!UY[GYN+S M] K?W"WY$@19MAFKT=8K3_DQT]+<2';.E'!AU>F<^C.[5OK7T-1O*.B(SC4Z MO;:5ID"R3#+GK0).XE=O]O?W#^XGE'>;&)=EC? J+NENNY>6[W/#O2'_3>E* M^%UFL"N,LG[X3+A\6K8FIIV86R;$_E+2HZ"J$N;GR M;JJ/5-AY1)(V'@IWV:+#O9GD*$! M:Y):T2>CIB>W[H2@#NX$M^D83 S,55:]04UB10GY0JUF0 M7\HQ(UYPH&[(+LBK2.YQP"@>#.XI@X=XME5"5SWZO[A3)[I3R$TZ M8<+GA,N7V85V(2^W\C$W3&]4,:_J'-L\*@P@/212RY]2BYS @5'P8RL,J2B+ MN&5X5&$H\-6-(5Q&QRH:OZ+DV_,86:;69&N(A-]PBV%WO!3VO9YZB8.?Y4PL3 E'ZV[ ^[&>[,9'KT;61V^X7XQ0<:2"_/Q(I1BZP;$Y+!TI1*W0 M&L7;NC:S7,S&)G[^\U/%C*?;W+NX,6Q/7K\$,< _:UCC4)Z(BB4L4'TSC&-Z M#81\AZ1Z'.KVH8XB=3V'NCN:T1FV-,1_'%(:'17ED@)/2S"7\M6 >[/5M1GE M\[KO^4X/=12IZSG4G5=YK[BK7*HON)N(#$,.]E# :-2&-U%T=WBHHTA=SZ'N MKC8\8FWXE_@Y4^6&"NYY^I$J[HJX.FYR8/3JP]@_8IU$9/%]XCM:K$M-S+B- M9KDJJK4QS=TQC'V] K)^=1$V,;<77,5Y#\//;M_^$O^0UE7\XUY\4H.'EL#! M?,H-T]^_5ZS\TT6:U_1.3+N=%.9]2CW*_X-?JJN+)/Y)OG.ZR,TL?F;3AB^Q M!,C4">%%5266@!=%.((D?I%V(%3Q3QWRDM4R@A0F5N:@%&QSQ!D5>.=-&S:2 M4\,#=9/G[V-J+_5Z-/\2GY19#6MV5L";(GHRC]$V[MHQPKI.X *+S_;BL];D M)<_*^\I/)J/XO?W"4]C1-'Z2ULV:*JOPHS)*^$1\DIWG346?.X=AO:C.S6_5 M6D8Q]#EFDC;)[3E !$M[DUD]QK:O=3;/2$AJ4U">:]JRK1Q4 MOS_4RG73TXH[<[I (&JP&8E*3C53I91BUP?J7O9U9%CZ!#D MV[18-SF=T(%S39\9/,2D6KASJ5MISQO\'HM5J7K*/X_X3LJ*:)"X(OJ#PZ=&.0:XH5?"LIV4V,<+UAP5=0F! 3?2#1T-*BFW M656<>JJ,!!\U@KW8!\N)?T;;D[[+<38]@,2EX($B3>6X#HZI1'T[<)[M$6;# MU!NN:P\>7"5+OM4)V]8[XW6VD=3U6]M2OH"X:@R7TF01=]]Q=R##I^!7P32E MH*,J&H\^ KL"*QJ[![FR\1U^2R:.'O5R#DU"6@$C'4[L#=:3IM.W.:_/G M+]$J&^3IP7YB;BG4L\3%F5F.A?3:SHU[Z"WZ6Q-[C>*10:0G&G577[ZA@?X= M;\UK4'1L]!X.NM@\^AG!$IXFK;I>+RN MT?$Z,R;"GK0[]'(5\/]N_] MSWA2K\5)/0Y/ZN,]3'=@!(\\;>22RAL/\8(<;K%'"4L,MM0S3_$+[J2[2W0\ MTM?H2/__[+WY<]M&MB_^._X*?/TRKZ0JB%>D+"]Q)E7REC@3+\]R)G?NJV]- M@4131 P"'"R2F;_^G:T7@" EQ5HHN:?NG9$E$NCN<_KLYW/04KVKMP\86-.C MPU";NZH/?5?U%795'_JNZF^VJWK]#;Q34J2C!A]UU"#XAX1/6 @PQ@=L;4DD MO71G]WW7;9FS#/,FT0TC\YB?#Q%J M&C'>9LZ\:L(]Q+Q#<+S 5 \E#-KHJ+*>3Z!&$T3]H6]QOF[GQ?OC][MHOW);W<3C$Z(IO-4CLG7@W>&OX10_> M=*C69=%M$=?7?CBW3^YKJ!IP1$-:$1 Z8I7K^2ZJ0LL71(T.%> 4&$R4T[\U MD.?%!8@#1H8S,8JZ@=[63[@8+1A_6%2AT;U2N,?Y+A=Q6:?1B]S(DBF!E@=F:DF&?D?S3 M."TS;*R?9KJ:O46!L(;1T<_C]+;^7U Y%C-OR2A$B)E7JXEF:.RG:'+-,L2F_VG22BJ7:=I8ZUWAM%.Q=X](<^]X[66C$- N)?DV4U05GZ5S*A:A0O6+ MVZP$^E[4FAN)HX@'0W3?G0).'O$H8U]$"=.@UG90HAV0H/$/5*HO!84D*ZMF M_(>,'R=#.*WT $@=(V,PY$DQ1_/;6.()0Q%.;$+0%/Q644 3+G29I,(4(5=6 MSA=@9[>$L#$]:>JHL3SQI;AWQ O$60+WB&'NW0TXJH+^,3>./L4N-"*_(A6/ MI 8N=,-'S'JQB>*R$UB LU/HR?,.3J:)%G1O%ZQEW?4:Z\ 5/@=C6:UP6K@V MG"8QLZD.BK4&6[2C7)%4\ :]P2DN>^ %1;T!L14/[$S)I H;"(-;)U*!YGGE M!*4*EA)A?3I(6B 2L%B]M5J$0.#Y',.8*5(X,0%@\]+LC*4L6PWQ.7.>!N$Q M#:'C,\ IB783M!RS$4*H7BZHAP)W+6/GEFS#3DOZ-['1A80U34!/*ZLZM-N.TY$BUE,31&*N M:1XZ>DU:@^$\OY2'P^)"JF4%[]Q2\,5M%3T>OF7]4CWWW#))1G=#4_W*\I75 M%6**T^!E#1K&\E'[I;G$<8S7V6>L"D)MORB[&8P=[WI>D5%2GX>!4'9/3'0)>Q Y8HC!ZCI,3-.PZ M06N]3IH"*Y,Y:X>Y;-GK_!15/B>&AZ0-EDRM1<'+>GH;_ZPH$?M[2$'$3.!@3&+U3B%"WO77VN["1:OMZ@V6),$< \ MU@72=V*<'SHEX!4^PM735>M.=[==?1JLJSYE.X;+$G6A+"';D&WDDJ%O%^MK M9S?O.;A<\D#E=%!2$&3GF^OAUX+W(L^W89_.0 \VTRJS0(.HB 8KI?/ &)UC M6G0=QU(NA*M*(NU]X8]5,X?[R$EV@@YB]!3F77D[INA-'K-:J DG-=*<,B_' MKUY8(Y/,6*IL@JVZA205QOG<$T@I9-C,<:*(O-R..N*#.8=N:'=C2B4P)003 M*E>O'-?!G+/#M9)-;>5D[GOAG4^5^%3)/4B5R!A$JNK!H<8IH9?VISZT!'/= M[B:?2*$(X9J1$,)4-7CGW2##('S)<@*=>5P*BBA:1!YC84?4?2OF.G#R-+CZ M]#)9A:XSB;.S>%FAL%\4%9=B<^4U_QDG8,.WBSFR.PBSJ8KI0X/0#)(4F85U MSF"RX$KTDR+)%;O UFY1(?]] F0IDF4'GXO5"VH&G?AWJQ&K&>4UQDI/QF85 M57'](1,%!%EZFB9-G%6M_+<&P.)WZ#F?D@V*TXP4HX!<]E-0,E1.G8(>ZKEJ M@]!2.CJ9TE-4#+&BX75]$)HIR$23)?_-#-(K:0HV>FV)6T"F4_8^";--XN%. M+]5SCT_"7%T2)IX7Y#4B.&$=5Y^5M&YRS;CV*#=7OOJ!!UMET+^T96[_:6)P MSTITC(&P/66 KO-(6+':LTL*<+9(G;402=?A45HMBJU..!V2JZ];G65S 8R" M5TRD,69==].X67&T^\K@X#RSC(L>.KZC];N[96Z.SXO%@V[MX"<"/>U[$9>' ML[;G@A+S*;?^5QM=DBXII(HPG;>@7X/>LA">FT[O$0M/:HTQ6*2KC55RSY,O M=WM#/Z0_?D1<7K:K@P]9G/. D7NSPWM'LD]%(+-LI46O<_D-Z#/(Q7%QJ@AM M@)P0E9^ :$-QV4I5@Q=9)A3"77)(;\;]?N@7]M;<1ZHDE]MJU(@K1$KN#DZ MEXAJ9A"^OWIL%5.S@ZV'@VL3!=MD>Y8G&V"F N]5J_K%]B!&''H; M@Z76X&BDGN;;@HIXX+'4U^6&AG@I5$PT5_4@?-V46%$42:-5!]H;A<\?\#=AK24&J M+-:I)OA>BB,=*FQ:>ZXF,?5)3B4TN-HL1U(HRSJKK^CH;?8L<%?@GK0^U.Z9 MNH],$3:=B9W"+O%#/+@"J0[,3)V>)M5$'&TFA>F!$[=A)M\O.78=U1"3W<"! M)[TSV#'>.MJ\H?P)0)Y%7/R<0=S\CG8750[_,;I5/(HA=O# M?Y9^7Y(O_WZZ__3?BI*;\[V]=\4;MHX^E3':R:^S^.3?R?C3ORT1N@)?OL^+_%U#8%(D.N"\/JKIWQ^\+HLYKF]O M?PC_5Q?T\W"T=S!\$#(S_OU!^J7^?EP4F8I!Y#3J 9W$:S R]^$_CPX>A'D\ MAXU\^/3FO[_O.P\](Z6U"LO<]X9-[IF8>M(14R\&;@WJ1U/S]+HH%?HFOX!B MK))TXHSM^B">&/#$0M LO&"[I<7_W_; E/___J!E;NZW>.S[+:ZPW^*Q[[?P M_18W)<*O7GJL:KFG1LM]./KX*7CSYLW=W=V=UD\KI!GMMPV0X?[ ;4!8"4-S MX.^%@;+X"5UCPLKT-L?MT=3"?;3(9 CI2;,]#LRGF0HL;!25[#)"OA];S+U3!V3&*QUVC M^-+;.2"+\RH%"YJF+>%Q%5T0HRM=Y?DUJ5=^SD/DFFNWH8Y._-&O;.#PT56S M^ ?!F]VI=KO'?3^+N'^*RX+6\?, 7-"YRJ^"P^Y"E?G5W]+'H_M[=E>YJGXX M.EW(L-KY?/\OX5&FOL0TEPD7\P^\B65QMFUTNSLW\?#A_3V[JUP559#10E:J MR.[_I?M8C&%IM)+G@_"X5JG7?7]=]_D;=[%&'U%JD>@^K.!\JQ("/?UF;MY1 MGI3JC%9RG"FU;32Z0[?N\/Z>W?7HN?=44TR@]-_*;?O'#%:4L9Z+RS(^\1?N M+Z_TT?[]/;OK4'/W_W;!GXMZMJ2E_%ZF)[-ZVVAQAV[7X_M[=OYV_96=/B_3 MF,<$O"C*4U5YU>4OE[]<5[337U2>IU,).CYO5)9M&RWNSNTZ](;AU]\N#T1S MZ_4H/XPY(ZBS@5'X8?8RZIFF$V%Z%-'UBEP9R+>"<%JX N6/@L%AJ7OL&&?1 M4J?6:'__X2!\6[P2:CT;/GT*+\2FBW">)GOP_E%8STH:'(2+B? K<5858:7*4Y[( MV\E)!28G9Y(NRF*8XC=0.10P3"@$+ M*"ZVG:? ];$,]!HW\#S<"-\@167Q E!V91 -GDASB\_RUMC(](Y MH]PP*F4%\B1.>8ROZ46G":2R>/S0LFCJV2#\6?&$Z%/9X*L,F"]\4V7XF;01T0I#C2';B//(X'L,W?W8_?'2& MEVZ*%]=^XI_Q9 (\@^TM=5ICAL];[WJ5UP0Q MF:NFU!C7_X*W=+8? ^?F)Q4?X4+)OGE;A[S_3_#-MPJ.&V0X,+@P_FOD.>8? MO?DB/REP6Q.:Q.G"6\WEZX% ,-=+=ZO.8D#>X\L7LV7%$)9X8^P%7TPL-DI7DLC]Q"V"[B5+K>YPU.%)9!XS9Z7 M1?$9^W?S\!WM#9;P:SQ&(5J4-"4N#W]%_#MFORA\]R^/&[ ]QH.M9-!5#%'X M=O 2%/:+UT?1.L@2M"4T.\)7<#YR/%<. ,K*-Y -7JMQV> LQ='^\)'[];2R M6/C!*G8*0;"4""%'=S\R%H46!HDB=0-;;A#8 Y0R\B_"+>KA/&E+LO)= 9E5 MV7D =8']\;E2I!6*8!Y_5J'@=:#R(1@2X/HFBTMW[N,,=#<0J41 $7WATC+$ MN0(\K/IGUHR(N)(6394)FOSK][0OT)_5'!O=]9ZJ18I7"'&%< Q":T^\?I07 M!WLOX5\I =9+>:*PN1 71)93I6:N M@-X*AE%\4N3IE_"3%LQDTI X"N2=@C=3@=E 7\\4-P5362(K:L9,QD9_K;") M1;1E1-/K2S8X75MW]!"QE']2F'$"R?Z+GASKNCXY='_^?[\/F;][_N M,N?"M=QW3.WA0T3G8: ?-B:Q694-.L?T-QDZ;?H/.J\22]10J<72:*,S!^$W M2L+)P:XW^PRQ+.VP#)U^QR6 20AZ[22=:&&!1_(B+2<-',@GY] UE300%[:3 MD1NTJ LPVA5^1KP.4../W6,818ZH:B]E5465? M.\+KBJ^G7<_@O(!#M9!S#!6_QG_B_7X1+] 0 M1?7S6>%%_O77%ZX0!H<#K8^S(ES"4RLT\)^B]S5DCEN[7>*+& '0Q=KZ%?Z2 M5Q8_A*\,'*A2\FC-$.D41!%!?:O*V8VV[.OP=Y6 SS$+W_*=ME/8VC8N6E*@ MKL0M>6ID;HR6&:,'HDXC+@]^CLM3/ _-1L>3&HB)R GOXU".PO3-\XF/2 M-8@6D^:$JU?![BD =I2.^XX"L1<)S.ND;(4G'^X=P7&/BV2) MK%-4'*YD<_F_,>#R(M !F8)^*W#Q*2T4 S23SPM@9#QB M>0&%N.(Y',-[!"M#@^;@D*TEM&@1%[0D.TD;L*MQ;+BV#85]<#(;@MJB';-( M3PLT^LHBHZ^.$9B-L-DDRD3&8'B, N T_J%J%BAZ'C]$Q0\_1^%KQ%S+5_\0 M_#,]!0>Z[OG*ASC_B Y4SY\^@2Q:][!0 M-N#6]/TB$QJL?-MQZ\38%](W5N'M_C4]H3&1K0.%)[QL/L#-1FDR^4SW=5FK MU4]]+"9D F=%<)3A!#1XU#^ P]]B:@!O(]_!L4(3U@EKQ^;)Q_#(!?=\%[.Y MXDN%,7&R7%^*32J!O@]HCS*OL;TM"^)?D8G[LOFL'$O4705.IR/&D*!!>%ID M#?A?P#?H+)3-HIX .P*-B+$9QQ_\S07&!!^3[&M.$/44N!)](S.PR/GVF0 5 MSG#*RA 5_)D=/O \L [@<^:Q550QY\5[ RG M>J'N G%?L5^'V.0+EO$2$9!@(,;X2K5G]!W> W@;Z [S*QQ 3B/07UH\S$4, M=^?@,8MVEE$88^$8.ZI'1QN'+SZ^A\^PVM@S63B3Z*-WYCCZ+$9$YR)I)K7S MUVDQ:=@HRDG1 #7%9*H(H9F@IU^\.X[@LL9C5?,#X;I.LWB.02F0"7"-55RA MOWT,N^7X#9XM?H@]DK%:%B2>\%69T:>T-4HLZC&6(OS HF%,6@R8FM3(>S>Y MM@/[WB4-4QPS(K.;4-!:' ^K!J)Q2$$"6/L''$(9'NA@+Z:/[(G"+S'H,V7D M:F#_"6&(LD)$/PNN!Y)L,G\D9VK C$S6&F:J868)U1X$;/ >*'AC6* MPYHX5C.:$Q84:/H.TQ4Y)9!C(:?U4W!Y ML:40,0\J0);6CT26P(SDF_P4'O@3B+$%1?_PRL+EPEL3H99FA6UB>E0@$+[" M6".*$_J>P/5B!J$.X9_=4I&#@;R%32T!'/[NX#G=.8Y RD"'&!,8P7N3GLF4F<5,7HLR5XQW!!U#4'\W"O4KS7B^6"A9+X>@)158>1^A9 M9-K**1:@F,>45@0%7Z//3X8 YM9*=8*6Q<^#\-7G]$]X'VA.DD,8NF=-*F\/ M4++1Q('5W--K+EU#5OHGV"$@Y'1^8P?Y>[3_C']-_Q@^VXU8WKBRAT!_XV31)0[J]B*4+"X B($[!SL+@)=LGQ$5,;AC8> M%075LN+67L4$Q'/M>==O@^,!&6>2XI$=2"IGG=BG 07FN%;CXNRJ*BPR9EE MPY(M0R%1H6!/3BBZ8T#@85E9HA-,=8K.*6:K I1-N"O,F70V0JMQWON"AC-E MF4,C^WY#+OLIEV3?C0Z-P.FMDQL$O\]2'-SKOJ=O01^,:.:7EQ:="X=WP$N( M)VB9QPW$0&$E.(A8Q06P&(Q4 1!?*D9@_T:LVC.M#0-F![)P9LKZW6 MG!RKKDKC,<0YC;[21K.EC20,@01#)L&3)^U[@SNFW;TLU1<%ED)3YK-X#F;T MG.*"^LSYS_J\I;!.>$MGX2S8&47+L+A(NSNR7?BP^;4]H4!S7SI)%W3Y>;23 MK94+\X;,!AR9R?%:BG/8@)U6HI3O,V3F1?>1>*[T\[B@8V'6%:Q9KLDYUBJ> M$R5*K!\D0:4KUCCT^<:H:_>]-.^ JO[:%17COOK3P TBZ[")J9GZM"J#6L6H MP(%\AB_BM 3U_.IDN:C;JX&MH'1.<$(6%U[QT ,EH4C@<#H,2;G:4K6V:OXX M*X#II5J0_K^N>7R#*9YSOF!JRSB/.L"RSAF;?0?[XBKU13"= 8TZ!407(+YL0]#"M=I4&ANRVYTW*C.?$.>(;=B .: M#3*ZL$GQ2U'-FABLB RX;HX&!?(1O[)=L-%?7/8V!=W]W]JRUD4;.D)LXLAT M7222^=2$@UK50Z.!?EC*1.PD5"TY[4N$*!)SLS 8 Q174QI>/6 M3*%'8*1,39X7Y9=BSB_I0/[O6*Z&,/-5[=3:XFU66-Y2LI-C$CBXB+CE(#Y_ M\_[C3R%NG'(?7$55I$DKD6,6YAPP5=Q>2A"VR^1-H:GCQ\*WC6_Z:/5M\@[6 MZXZ! \P-LN%G'' FZ3%GLKV9*WHY\4]UFP$GS1E/$78/+N"QSE-PB.*A+R MOV)&T.:)G8V*LC@8]6J<0B2'#&_3 =(4A0YBMXJ/"LMN2I S47A4I3&M[I<8 M/NO5RK:I%=,)25V0DC[HU2W(-BR$4NVQ[H_V.2-&7];%QQM+&\.5KB:M)VB4 M:%")4%DM<&W%YO ]/R,/PV-^8D].5P?P[$1V&?1';(K>+NG%JIOZZ@O/NPJ. MIE.02Y7)FX3',PXYZ9Z(A5O=T"X'^,OU!W00D:E""*0*@:S D6, K@;7]=;M M18TT\*RF'I/XLHZYN#U<5Z,*B3H4T=ZM4X< 9ZJ M*SM?Z&R/22]9BVCG>9S.=]'JT"?*@=+3(CNUH^]ZBU?LB%/:'"XJ[A1XZ!(, M_"B[^_P(W$F!Q^TFHKC@([ '68RQPPL)#&<@V?X7TG(0H3;5?BNSW5M0W1-J M1]!_HG=S<#T/WQY+ 6N%)? 5U0JQQ]=,ZZI=J!H\AT\5-Z+H[J1*,\GV306P M3WT![!46P#[U!;!WH@#V7EWRJ[117X#,;S(,77$L5'ND5U_4>W](< .NP\L8 M_-S@:!#^"OKYCV(ISL,QQD1KC$QK0K$;\5.A[ATBM)<5R&IT M!! _$#?UC%\YE[HC6-]PGQNHF',YFQ]KXUN[+LPM8R"022AR_QL'^,,CV,N$ M@ 9>)2E&G=BTM0\._@#FSR7K0]5?.+(2%X/3[??L/WE\O5P6+-W.P$2M&[9W M,6)_(R5'/N-_&7$(KA16(55<,;8#SU'EM#;Y2KKV*L1<>*VFPM-93G"[I46 M4T&OH(BPY932OK"8GU1>S-&O>D'^79TV<]=7-^4+:K[("BS(-T'MIQ*!DH/D M;(%[CZS@"] _!Y&##=;HOR^HUU+:)XQ,H(3;X29I8&%1)-5(=C17P.:IW 6$I64-VDR:5J"K>[G:7J$8N>4E%+.G.R$&T$&ZCF*#>$ M=9PL,TB-,9>4%E2W):ER!*/(8 \VWWJ/]_9$S_^ _QL(:)7MX]8B)T29\]8 G@C"A G44)3#N178 MZH4\--H?/N'K+2F!=N*Y,N]Q4N-!NQ$9+R&.;^8HG],LH_O[-0.;W,E/8.EA M.N@XGLQ@SSC0FR)A'X#=%947(^3*\_<=3 .J8+2614!-.L#:;O;'SFILM6;5 M&&HH,%*3MVN'-B/HO,U^;S M7^)<4%0PW_RSK930W0L*;6^2A=CEL^":_Z TT\A9,63+/7@=EG7T ;,!@^K4 M #Q$RM$KS+:;X+>7G3<32-#B('@#'+O 2AP04SZ*<'L7_!6(>>S*? M.("9\ M3+&LKG)!P:[KH;'D0\KM4D._6FKNI&2MTBY33[D$Z(.5KT^4?#\ [9&H*?FV M&&*@'%SXELI"%UD,ZNTCVE.'C_8/=^+=G=&NO[,W#CXI[I]$:\(&_ MVQW;6R(6I@*_(>2'@/?J$ >4<'V&OAJ&/N:%%)TE=I9VS]Q>^"BWT:(W,@=[ M$N-3&!)!Z+$<=27>:="5D\\ZGPQ2O"%0KC$6>RJW+*IO-/" 4NU*1R%[%F[6 MO6)!AVA?B_5,J4M8BX5I-;"P(<+'RL=VG)_AE?8!MCL^1M_N1L3(6HO3WYW+ M)RT5F^?$P,!$"3TW1BFJ,F93HG^-:%N8%()E$G]441R<@S#X:5@3A3YFZM%Y&>.K (?Q&PC"9 MXRF7Z-FI7,ILL=^OI,2!7HHT:D:[2BK_(2Z6F6-58. KX*5X$70S6L@JFA"L1&?R]:LHH!2&5%, MA (WI1V_>A$*0,X+X:=E^)I9#$$$B7T)CYKQV(%)<&: :"8<+[!Z92RW%.E<3(D:C!. Q6,1 MB8,5'@#BIM3P2QV/8+*DE",C5=*5[%JLH_A-26"NBOB@AR\HZ4[J,2]\ Q^#B<*$&E\ FZQ,L^MR-)%#'">28:J,4RCYCC@6B4"['^O@K MZ4810/KEZJ^U!8%O=SNM34][U1+B@=L5)[L'#=#4=(*D:F@L G92:H6UE H M*S/XWA^""AHQ;:08XZ0HI46#%F@6$,E),JP#D );\P-'(7:>/\&JCCVX]7N) MJK!,1QB GCHO3OG\@"ZS=)R*>-(?Z#\B\UD"I4\S-C1*%4S+N"&VX!\01J?( M<\5"3_HKG&E(6"8#VLN8ZA=@]"K.C0B595Z258TU4JELNF>ZDY;M.44[<2M! M="Q[.*!LT*-=;0AJJ/;P:%+O\@H1P 0+J4 V\_[6/6M(SWIJGF7E?^>I0@?$ MEP!B(4F518BW)F4DY\E'8_<2,/248$NF"S -D4>,8<4E4(BE:Y)J-C[?-4%#G!%5(#(]CV$Q]JNL7TV/L\L,-Y'FI$IS,PXY-B M00B.X5F)HT2P?L%D".XW&W_1;O.E-&?14F5"WM0-L.$4+&W%W$CN=#DGW/?4+T+@A M0T^T"?OG#N%?WG%F7(]#-/6,@2,)6E\X%G0B\TN!OW[A(NU^M/:.^1Q.HV11 M &9(I9Q5@\S M@3JW56":1T3-")VG1B[@HRW>$%=VXE.WZ\>EA<;MP@:C:P7 M."1'6?+)C,"R/,,49PA+AE,KW/P[=*2;WG'VM"A4_NE03?CR:1 Z'5=S,]KJ72U,4]E MXR"90& A3"DI36Y$&VKM9YV8-NT(@X Z=M,&0-J MA$"@%3U$%E' ) 7E> J;=[EA><[!R@5DG&T/D$KY@H/$%*2+.@??% IM#D 7<5PRZ18WACETGU0RQ1[7;7^RH M#[MOFU%@+36<[:P0N7+C?CM03,X!(Z )1@%.N.:*8$O-BMGRDZ))OIE&%=BK M'S"$7*0K,0F>!5,)JIR'3EFE4/;=\1&>^:\I=P1@6675=]Q>.7Q-E=+05RE= M8972T%@/HRQI+NX7&N*C95-:R3=)N:0;CHSGQ6+ MRV"5Z9DIMJ[WO4ZPVT(/4Z^\=K^TQ1BAI[!%J+U]RNF#QL[4QK6OVEL!MWHJ M92RNZ[.R-JPLF..T(DHVPC85P!=HK*EX#FMFHC6 M1#*S&TP#"#Y+$ E;IE _T[*Y6[*IZ[SK/O3(7^,,P]O:CXUD!*U(1M@7R; " M:5T I/=K+ -T-P$R10H2JT% 3*ZK0)1H3L61XXG3ZN2B]K0;\+WX"PM(%)K! M"!1+N:Q,YLH8D6;J!L$N"&A)DM0WUS/"?Y&, N*(>RM"IX755Q#(+R6UP"S' M>/$$VV%QL;JS06*VSL;(>2#8=98.*"P#?<_<87Z(>3W1DY*,=!991[N"[\\1 MW[H4;%!]-FU<^,C)"8M?*XXX@OJ9\/9$!7(&LI!0CW?\6JJ<[\ZVA&MPI<*U MQX6]U.J#>4S9//P?S')^O:?;ZWD9N2P2>)WG2K>WA>+NBNI+[>P^2.K;,@Y' M3P97W$$.,EJ"QX%+H?&/Q$NK<642=<2,S$8XO*UN&5^V(9NO%TJY,8W$X8%Q M<&<<",I.Y:8&(-5EW%WAY !LZ$$Z1P3&J:>KZLNVNO*4)*?"Z@TE80M'Z.!? M"74#596&PT!5HE-H-.4";AF--6TAI^*3T$(DO4)PHMAXKA?2^;QI$"^P6"S5 MDYW$8$9SBM!:ZBIPHH:,3LIC0.+3.,W(=VR+3920:65"LBFC.(C>T]-V29;E M"C^14M%,DJ*AVV0U-N"EB.1 0]Y*@HN9%6<@AG(ST_T$.!X_70ZT9XRP(EJG$GOIO@<'*^O:K\D 3GHDNO'U4 1@9H;JQAWQ3M8@U<5/98*XK*,N4P>?UZEJ MTI+I0@L!MUE/OW2!Q^D;6-&O$MXAH$+\&3/<,PTD_2>>.,S@A_C<]TB>2?9!&9/Y'I0Y6] MU**3I1QSB%S?<")]H6 U\,:&><8#2+ M7&F:U'8GFKLX.8<&#E BGV01!57,\<+_>-FT11OY'0=$GMK(!YO:,JC#TMPV M*A%7GCI_I'A3BQ^<1U2D/(&I",ITI0)58M!\^&^N M.B*CU!;W'TWJ\UF9T>R6P'XRRD.G,E6\ M* ;]=F83XL0?X%^$NL4:L($,W%[W$+G".#>4NHQ$PIJ]UYLQHL$U1GB M')V,.D_P;%@9MQM?-[QZ![\4.24RYJ-P;7&:VM(,!+V =G3JB+#!AN!]*2HA M+<@8ET(22&;Y!,U9+@C&>Q%BR@)8N,(G5+Z^!^'6\!AKPK@UU70]Y.[OL9MD<3KO]E&:HZ!=J5/I>:=K MCA '6-$+5R:NN(Y/(0OA9#1)0^(FZ9NT1REJ13FE(T%I.6GF*-@G?"=*-LT)J'$T5XI5%TKFF@'OG#P:PH'1[YP\ H+!T>^ M<- 7#MXKS^--7A73N"2=T%&7J/W<@,!Y#CM9G6/E6#\R@MR!XK( 7#P?DKI( M",M&&I*#1<<\PGMR4D@CRFE:I1JBR]@MD3%PN$\)43ZU>R,6!.::W;RQ73?/ M"95V;(O#$9#^Z9X(.E!BODNQ"]71H$F,MB)F3:S5TCDC"S6IX5<#%D/IYT69,EJ' Q>#GR*'@XP=B?7T\AN"RM<7X[I@ M/=?I/#W/W;2VYI0 TN*$H$1,&2TO!&NX?(1HBS;RB7":4P3R,2!WC*BBT3(< MX!4.-FJ&;^;[HBTC'?841@I$!\PT3 D).P'X>^,Z8Y95MTJ\!SXE>KLIT6F! PJY3@\]#*RN$Y#%%&V1>2P827HD"@52E85Y M:I5PZ7 LF1 H0.#:)];NRV,,,*P&HRD\-"4TJ@H+'ABXD'%\7H):I8*.@R&B M;8P>D@J#'PZN];ZS W.WV.;JUXQUHLT<7KD,6CTCGY!7KOOJW@P)+N587WQ? M%W/!'Z#7N\'IYBC+ _&-K:N].4CSEX_LP8_O:+P2P[S@X\@VT5 M@W$=[658Y@BM2\^3GB>OC3CO:9BC9TK/E%O$E.^*?._5?QHL);X,W[S)<9'H M=G_(" /(^G.>6SVW7B>WWG'^^C\-G!M6X-SQ?;Q44X5)OCN^C7LDN5[%U'/K MS04O@*^-.$=9=BF>>D_IYWMTR3QW;C%W?BKJ.+OC#.;ORE7=%:P*O%Q&Y(JO MZG5F+JXT5'[MJ[^NPW!DTQ8OU^_>[][OWN_>[][O_AO9_45MKV?A&'R'DQ+G M*F!]2U%^'Y8GXYW1_L-H=/ D&AT>[JY6K$C1R^CIWWJ[2/[J/GZ*RR+\>2!( M.FO\+OWNOUUK88J\Y>'?KK@H FO>-F]L>+5GNM&'O=&SO(6-==)YY7===/N>KS^K\BE M(30N_/ZNYF6P,6T-3:_[$M[4&5VG +D)N>CIX.G@Z>#I<$'][TG@KX*G@Z># MI\,W2X?[JQJ^QOW[?9;6RE?B7?B2?L,7Z,8$F2>&)X8GAB>&)X8GAB>&)X8G MAB>&)\9V)@FO8>U'F?H2$QKY/[ FN"S.NC7!=\:MW%#VZV_>C45EAH?[T?Z^ M#X_=.B$\"3P)/ D.1M&C_4-/A]NF@[\*G@3;30*?.MP..MR(D?KD]M3"G7$- M7\Q2-0U?IWF<3](X"]_S[($[[![Z.M/;OWG>/=P.0G@2>!)X$G@2>!)X$G@2 M>,_P#M#AOMNGVC.4(<]^LM\U+?J'\8^O:&@G3N0+CLH2)Q?/:7 GC<051Y%:4G^G7386CMG'@[X>B0 MG@(_R_N2L,GK- M_:;)ER.,7X;_5EXF"L\.'P8.&3_;FL,$9OCPMDI">]UJ- MRR8NE_"-X5.<]UHT)[/PJ#F! \:G[(=)4^(T29XK.\,1LO+&/U59A).XFH45 M30,CML6)L2H\ =8&KJX1,AB__.1)=/AP&!8TI(7&U&:I:F@HI?W^('R-*X*% M/#(+P=QZ%$Z:>9/%.!$C6T8A$05)83\_#+ M[QX/A-C5+"[5(/P$#ZA5.:?/P4:8I_[W_WHR&CY^5LGK]3IA65F3J'#:9%EX MBE.G<2SP9*(R53)+-8LBQU'C/ .=9GS2G.N;&+![)P7& _WT_V]O#ZZORI+O MPP_QB7H&C_A/HX /O@\/#YZ%_XRS!GXT'D(W1V4YTA3B7DL_T M78&G=WC@?NN_]-?P3];ZT*;'#_\%Q]QSX" /^^-%0@R>/:"Z.4B:]^?$]87 M8=/!N,>)YTP\ZB_YM=EL+T A-!D*W^ (U %;;-XJNSVK#&ARE">E.@N.,Z6B M\,/L9206V?L%J4;0DV*1T=CR\$UNIU.C41/AZ&NZ?V \I'E=X,AZ0V90^T)F MMLM13^.;<#AV/*G#N')L0//&0+\Q_%T,()R)K;^ZD^YVK130WT=@-&3A\# B MJP+,O1H-M;9)01;%H;8C^,L1/ \>.'P2/3YL/? ]N RPR0 ?!H]\O.&1CWL> MV?M,MBF?1')R%WY@L).>[H8'CZ/#]J:-R3D\N/0SPQUXY'"T]I&C0VW[MA\9 MV$>.1H.'^_@@V.P*07Z)_'P)DRVZ[Z8]TG"O(0WQL'SN*R68/Z3B#F>I.@FP"T/CY+3M"I$ MNKP'85 UXRI-4N =D$=DEV<\C>( M+B*$ B.$:$VAK&E O](+!!>R5!6X U6*5A"Z? 78)Y52^"S@ST15<(+$L(D" M1ZI8D( #]GOUZYOC(Q!J5;RLZ(MS<#?9Z?OTXNA#%")[JU.PB,GI". K^'M@ MY$4!GU/A.(5#+3_#+:6'X!?HA:VW+-*% J<+V!Y1W\& M5BI!KN,_YZJ>%4DU"'^&W?1J!#AH-9VJ";F+XJ8&CG(9/@:)/R."&.\?Z MR M!!=7HB\)2V@6J$R^.R"1L4.,D<;Y+HDZ\ M)-=8X62DF>I;:4 'K^9QBA/UBJ=SE6=$GIX;]5D8#7O63][;%K2^:QSP25Y^_G6 MM-M'Y- Z> ZRJ@8-(3;T6_A_'7?6%O5;E:! ME58XQ_)PKV<]8PO<>2F-K/@ M>AR"' =1$\,7$I23\#/P54U"LYZ1%.V3PAV#GDSSQ:* U3@O;!GJG8T,G,^U ME6> &F91%J-4'HGWLD)W\5YR@8+T3=+CRP%4!?%DG:+W3$ES :>E9YU_S M6L*.U]+RKMCUV T?KS@QJW['FH=2G-H^T[L@?R62?">/"53 +RK/TZDJ@^<- M68L<11'[FZ361W6"9C)*N9>. &OY/I?5!/0R1Q.8>\7\;\4N)<;0."K"I)"T M$NB#_*3Z/MP9[K( 5J[E:[(H$W<3I=V$*X4Q@8//KAK0&F7=]YP +.X$5Y0T MDSJA*^+ M@M7;R[(Y@4.*KJ)5UTNR4\MK1>XKM!(X#$79 6 M,!^HRS3.@/([(^-< 5%@7XH\)'#:0/&S!BG5 @5W;+^\">3-T M(.%SP11\(= T[07']>PLIJ?+M_&0IJ@./RL\L$3(4J%AD*@I/"P)QTN7]B [ M\YB3\BLZC%E7U$V.I(KK!ADK8+-72^ =T:"MVTK7.5&3@H_R>TXHHD/\X,=W MQ^_U7&FM9GO5PT6T@S@G!X^BT88H7G!!$YV/_VYIF#NI36Y W@/-/@?/57D" MGT(AHTYL'.OR5OU;O!#PL%ZC?C1:D>3IG$4._E(%E5F \P9C28O49/&PC/"N M$3=Q"4*:GQ895E@DY*E0RANC\K0L^".(A:*L6K?7+%9LL!NXO.8PR 8=C38% M-IX\]$[Q32?UM)L;M$="^Z3>;4FHGPK,H8&L.(O+)'+]0C);8KCYT[1",P(] M87*4M0U'UYP_ C=[3U&-'9B+B= 8+Y[$L3IE/!_D"<:99N\T6!L<="+.>5]L M;$AJ5[Z.@H]6A0])ZQJ6Q"(,WK_$HIT4Y-([D+-)DK)]9<00/"'+@K$58?@L M$I @*-%>=)\)@J]HZG#,H7XP[N311YE]X%D*_W">!^)H"A\**7!?AVB[J3M)PT<_A2/D$^JAJ,K51A3_53 M)R+.:VQR"=BV3H1M2BKP6LC^X.FV8(_J[Q*P6A-8NW$,1%,AY9N*%Z%YS?O0 M7[^1\RNT'OH*K2NLT'KH*[3N;H76?1<&5[:1=XYI$&AQ7<'"EJ@72Y7.QTU9 MB:H%19!B##^N"HYP8-PDKQ15!L>@=G-R;9X78*QPD,.HX[E2J,HJ;\G?$J%_ M5T';C7R+ODK%G8DS5CNY*MNS-,_E>-2H+AUQ4_=?(( M@_!E[^*&YRPNZ%W-V\$%U Q_YWP^6#L_+$W@26?_WM]_\D#O MX4VMYL%P!$R@)L M]3)\?Y:KLIJE"Z3;"S:FP^RT"^^KXO9\@\NA$^TBCUTGK='.S]3V*&+#\F2KVB? M);)/,'A=E,LUW;HK[WL6RFF:-0X75]O#:XX$#A9_^_<'HZXC=?'C6<-XAI]= MQVY_Q9G>_XJ-[<2[+C^&U_Z?F]C4NV)PJ9U@]I25=ZJJZSR.F]A\75QJV6-C MGE(\SAB>5-948_"/_"XQ6J/P+"ZY5Y(L>V1A]\2Z%[/G%EZM=-B(V.#%PE\6 M"^-K%0LWL87?Z2!5LA>#5@,C^U*;6/6__&7X=B_#Q.O(MHYTBOOCTSC-8MT! M,VUJ[$]!C8)9(XG2*++FV]@,F$JLPAWU!3ON,1%YF<6T5C+-U 3N^5V75VE^ MJ67#E6KF>=BVW[9!XEPOZJDX+P\?_:TWK?!7]_%J+8?&"RRA40DM9+S4K+<, M.3Q3K9&VLL[1WZY'H+;?,KS:P]BH1O0K'W;>^=5P3-'3PX/HX=/A.>^]^:W> M21JN0]"Z+O(=#@X>>Z\J(W1[1K7^ DQC#V[?%40UU_?C<'9&PK(>BK<]*W8'%SULR;N2=TPPDP&KZ3C MQ0)[476(8!ICWRQ5=U,YJZ_IOKVFE?=Y\$N3JQ#1JA@&"W%+*EMY7X5Q4BRH M@;4IN7M9HE:K9(HL*\Z0 1)536,%!FU:N9S/4,$?H&MXNDTY3YT;&E'X-T2$84$KX=F M8N#6W.<%GA5N%V/FA_3'-K#5#_^5_C@(4+$@;&!L_P9ZR$4;1$AW]X_X#0NG MTL,Q^ ONOL1!*KJ;TXR\$0@9V"\QGOYPX'X8F#6CX2X5<5C&$L.X9/]\Z P\EL$4;8>;^A!(L M$ .*03M(H D.)G$[0X)+5Z6&V^C3B-)YK%)2L\)1=A11"Y=(&(NAUQ"T+Q4EM WGA&>,*X=SSE2%8B-FE(\5\!,' M!K4/T[@/_"3<@?T,A_M_(U!Q^\" 'R@(*G3GX0-K*&OV2(!;B/0*"\%/NL;? MKE=JMW3OWTR#7M(+0)EE$-!)6'3\V@- M-](U.5&Y*F.$U1TSBODD*RJ"2HLSYA5X$G3,>1$0%)&,?R- 35V$ONZ$C,XWK&@S5*<:'QJK2&IV_9.P6$!L&OA%/2R:\KC6>R3N9IF6% M)CXH]-;*T#K 2";<4B!*+!-WZ9=A/$=+@<(%K-^_DP%>WM*^+0!0;3%&0;]3 M:!$WY1XM8C A=^)=0HG$.<+ 86 X(6 D.[3C./\<3F8*H3MWQKN:YY(4F%"Y M,DI3E7YAH,L*YQ118V*/&<+@6?&,-=(3Q1@M*JZF 1+^FZHP]A?>DXSQLR\V&MLCF><=5V2PPU M:79*C:^RST#MI]?MF-BO58(,0<]SH4GQ6NN PW#T^.%.LNL&'2).(E"H@8%1 MZ7@SE3!(*,DJH69JO\441?@ "J#$/$7=L##[B M3"7ZPT[GZ+@L/E-G.(JS.6.6NH7'/63'Y:K=X*)4P43A)%SC>T$@,L%T4:6YX+.7T).K;!@R^UTSRM%/>0IMWTLE-/7U" 'KIFC6>I;=I(Y@PO"[F""_! M',$-,H=GA+4IE5=4!A XV(0OBG)1D!'Q"84=3^9TE PL4"PAGB?& M8*C$0=L \80R%0EK/Y:8Z$GP!)T8E%YYHD Y8D05%Q&S$,5QKE@=D[)MDW4Q MQ8V4C*M*80[$BN*89;0,%*7T3(FA1(FQXD,(@%1R K)9_.Q.W,HKRBD$SBFX M.<:HQ[^2<.=8)T8MS"W9STN]=5AU,]=1S0*,DI/8Y++#5",Y+YP'-X\_*S9TP/#%8Z$9(17?8!T)IJJ1 M6$^?)0M.>X#8DX7$2NNFUN#X.6-\D!4YCJNT,H\Z9KL/?LSQ:W]@!0I-@;)/ M?$9V%4Z!(PBJLQ+SM#F:O0+YCB8Y5Z2D"RQWT;-.E&3G,HNZ/V_(,74TYHYL M?25!G;=\:K37+FJ&NB_D&0#S.-'S^-#I9@L_6[IOV&4SF>Y M0#530Y3WM!$ M1>0<' 8L[]-&/)T2GX-9GM;_=%^'":2XI0=\$CKJS+, M"AHQ%W]1E5XR:59P-@)6PBA4,![BF?.FBGR'CX)UA:"^H/=VW9S-=9'@>:,% MD77K(H=77!SJEN=FV=E""T7UUD&*2)FR3LJ6& MG-+S80KKQ%R*G:6J<9V OI=R4F5.0/"1:T;)I*9V=5C%91@TFZ_-X!PGM.P:U&,"RS=2'GQC(49&:V7XC\PJ WF%#J+K<<%[<>!34L8 MWQCBY<^U?R=/LPFJ<9'C4"BJFH_$,40;=@\\$1Q!P>7T-%B5_D;O:?V1#B98 M<_QQ5A5@0%# .$[:5:OM& J+%1Y.XA8K.C8&ZG1>Q>>4#?F8QZ_QB'/X$!BO M.#M#3\Z8X,?*)E.5.UR7GJQ=K+@]V;8KU@;AL>48)]H/)D2T@>V827FS?R(3 MDCU"F=-2X01>E+*U7HY>!Z@PS/>* X5^TJSU.@[-848<5K\L MFXS0#0\*:ID?K ME4]';="4K:7H7U2"9,CFII8GTAHR,B'I2,_?XBFB/(?::E0[==-,VQ23MNP& MJ:FEE:/ :9*"WHGTK]KK<8IM-YO5',F(\86HJ]&J"ZYB)^&E=^)]MEN]%9PM M"!R#M<7V-B6%CDQ\)N#/TE"X8+Q[&!N22^ M I.XZHGE8(J@J9#D8Y459[L2",9SYA+$<(C3^!Q2M3SK.$&^IPR(^#/P]ISV MIKU><*1X\D-0I<#S8/@[:-ANC$"\Y#-*X.NL4&7*MW3N MQV9.Z$WIVNN%/1@Z#HW<.J%$RIF-U4L$N\CM]$,MK;7?CF=R[CWF#"?SGY-# M(CE.YXQ=)?:H@L).8726&)FJVM[I!3T]]4/?]'Z[36%YH&>V1YW;@[GJ."41 MO4Y0.!GN6,>'ISREGJLIC>S1E[V/$;N1JDM(8&3\7V)X$XXA-1$A"A9(/1C% MISF9.U9PV#1;PWR%$"H>IL31OHMNT'1(F80O MU@I0\?NB2/-:?I0Z]IW#P>'?=@.1NC5"8YU_>5N%"7GX4DT4?>-@6)G@N6W_ M:M601Z9$P%6,).;88NB^JT]%]1+&!IX<#0;/7:/!(LD_@^8JR3G5#78[7W8# MGC@$_S#'-'SR-U,J>Q.GA-IH9[E[F??![\!(7G<\/0N0YKO>%0"--#\&FK&L M4G6WIL6^T,95^6)GX07M$\\2K2-UA$N1QH(4+3,5UYJ<%':C/P7MIC_D:[?C MD&IQU]M(-CJGH_84A-.V";="4)OCM*?W 6/H_.! 6URETXZ8%_9FTF96N=X8 M:O:#^MLQE73#AL\E,IW(6=& >K::OYA,FG(0OL]7!0W\]U,6-SPQV?AP%#T\?/R5+PW7OC18 M>>D(7OKD831ZM!]JQ8/NY'KSYQ+*P,$)XM9[59I**[$TNRO\GKHNZ.P?:WM5 M'D'*#'N7S'/"]<]!_F?:.F91CA_$&WV:%DV5+0/P W0Z#%D &SD>'D3#I\.O M?O-HU$/@ S[KPZL-ZVTO;O@*W?W$';W]%'T!-CW:S@IN)[=78YV MWOR]\U@HPV\,"V5-Q/&K05&&?: H@?GJ7P5%B7KA):)SL%)(2*#$P +:P)WA MZI3GK\%."<_!3KD_J"DW6W-V?O+PL4\>7F'R\+%/'M[=Y*'7^EN$A,3^I<$3 M"@1/J <**:Y,0""A@FN.$K.3R[Y%P2 _%34ZEX*#Y'R#ROPI#U& 'XU1A9SK M59P0 WX\2*3)F1T7>2B]0S^90NX7/C&-/43=*VO@C%9.*.B'6I(1TUKAZI/2 M@$L.V)*MVEH?X>X>:63/-*8C#;[F!6N.O[.%"SQY)>967(B089N0'/78M)^6 M3]0+M!4(T)9["0S+.QW?%X'=*O\:8_#5"?IPIC:GOKDG+LYS+%H$.PNW =' M84YCV.X_/6I;MN^*&C]AHFFT&M!:)P7\*PK22]R#S9*#*J"+U5/M"!+^Y,:3 M"YR3R]&$P=@;N_$*PK5MU4"LFY M6JG_MKU'$;]I58#*V6<$3('2DDT*O3X*&0;T!UL]Z "\Z=O0@IMS =7:CVM! MK4V[#XN!]V=S6.^$ >'D$S/8,T6+L^),7[2O>)/447 T':.4P"1H)3'"0=C0 M?N))3:D%)TLJCPFZ(I!+/^WE<5E2CMJJ@K7"'9/O83MOI!G,A#Q6F]BHWE?< M8^H:D]6;_%:Y"C@HW(49LB M/.MD-E_;#K[!VD@4ACOZ@#!$,,*#L,#$K/#JG_[U/8>]/:V.G9SGZ5/!X=+J,/:WP7>:H-NN5!;A)^ MU3"BGW".ZL;;+;E,1&X?8/NLVS,4F#[6&/, 5 FDJW6(QR]JVYKKA\9>ZP[& MM6V=T %.J3F"KV!'72!-VB8K<3XX&>EJ 2<3>WB^.25:7)UQ_K$F<&8M? 4J-9F0&4QFG;%WG4.-V'1,M*Q==2V*-I!6T0_W M]8RK) BCH2PQ2,_E)19@G^I=U[B&AL0LR[GM/@^=@++#H<\$5@!Q/C: <*6@ M(XB)+N(*V?)+,YC$K6,$@_6_J!#D=#>@+3H\3S99;(JGNTA>ZYJ[P-ML-:,E% MQ^ZIKG20,_$)"K2 M'%[0S)6M[G6DK3DL4Y\3,O.L:S"D/NM=QII<>7C,Z+!E>)J>%B1N:T0$Q#]C M>AX^6?%$ 1>D:->::^0^TQ8,XM$BKBIK1_6L/ "6@SM"B$ACT.M3^#NXX(I[ M%Q%B$I9YDDZY?7>&WKF8OP*H0Z7#ETU<=J"[@BN'[O(R\';;(BC*>>3>UX_4 M8=UNB-A@E+!ONK93&WMFU$+1+L@M*?NTL1&&@^!R'"J-T;;W& LWUZV%V;\3 MQ%O[\4#[NQ>W2K'I0H]?:Z?D75S4GK >K6-=$C[H5J:NA@:,";=F+[QSW9"! MV]$!S..CC^?UG9C 1- ?F!B$UL_@>CY\Z+JE\ &12,RH,\N*.D;ILE*D<-&= MI7CX^ZN]>MX/ M1B#$;EI$]\QZW=Z5/WWT^.D5+?V:UXK!=5S;6N2V7MFV:1!3M[IHK00Q8&HH MRFD1MCIJDQ2,PCD6*'+$:KP\9RCXK=V6.W0]_%+7+]6SU'8N]>Z)V)4FC)5F MQ;6B,K5Q,P?'KV]ZMW>]KF71'SCZ'+BAY%8[[BKJE43C(PTGFBW996IC1;I_ MHD]C?4A\'C2"A>7RCO?75-@^\16V5UAA^\17V/H*VWL87?MH8M[!L9';_--O MB#6H<89_H%A;>FZLC6/&3B2]JQ0PA^4@(W8B.HP=&G[LC<17NDBPG=ET4IKH MPKF)$BHI<<,W3M6 7J.MS^!"#NP0PV$[@J2 7;?8;6M0RQUX0ZY(K05N(L6B MJV-G:_#)J>S-@5[F0I%-VE6KUB#NCL_1QA6B++)&Q6(.Z0TF)Y7B4]@O;(/: M&,FO$29@+@%.C9SI[,1N;[-&OF1TOG7&'6S(=D24@G(&07HE$P.'T8+3M"WN MW'.MW"2-9&#LNP;A2P1%4GE2K?30K[S*K3J02*9)*01. 4OL &\GYO'($OJK M3OT2=W3;4B*BO*Y9,5D870<@T87^?-0@L#RV!K&1]JC71-,)3K&TJ#;0I"V$ M@'@R:>98M"'8JK-]K(!>0J +-W^9;C &)3(D9M$P70I#LRI94W4UA M<#F-)J>PNBTI."_+#K)6 O%K3\T<;^463ACN\'?3XO:+<3RM9A; MM!'6R1^L* N.K<1W?OTUNGD58EBKY16@8:N< Z?I\T/O WJ^'1O "IV$](VHU3JFW=>$:ZP@,73<1_2WU*]YK.LE .V;,C(6[7K M[%7*U*G*2"LX8(\6Z+'%>5@V1L7[?%L6I=IS+A#8H70%!0#)R"5]X5RUOW9 MS;K;MV:O.JO=+?QL6\EQ%?CBM6V^.N_13&%C=>\YUT0A? ."T_,_VW?II MYM6<:RPV&OI&Y0)5*(OEFVPRD?WEJ9Z5;[<&26!1AX]&._-=XLXL13EH%<$; M@WO1.X#! 0YQ 2JY?\L8$!K.M&4!,[P\*!U$$Q+<@BO1YP/86 M11961/6:3D;L5BI3Q.=42P/<:GHL):0@_F-@JXUU@P7>!ZUQ")_G#!P4'-_6 MPAG6'7/HEU72NRA0// JPJ@LTJY?[;_"@@HR%! :$GC)<[ MHE?QL#C!3L.B; ,HQ"6/]AD\:$ZJ$"8%A[ F\2*MXPR6,MTENQ@66EFT$_C] MR:[S=I9Q\-N9^UN44!5CH9ZJO%'5LP!!WKJ+1F[@U]'ITQQ)>-0?NQ)(FC8Y MP\Z9=;2AF-P*8OC>Y]UV*B]=@71I3\5S91E\/7-)H[X@DRI3U3#YS"A1]%0;Z-0:)?.WF2!P!I- M>S>PHM-=&19:43TPF97CBK(;>-S\)]-8XF#QE YLLM33F"*7'IJ?[4J6F+HY M;&-Z!2M\AA"2]HAMYRVWR9 !Z\Q@T94\)L8)$FQ>?6^FQT<,N1N!+'5X%!\W MQZ$J?[) #*C7=BK"3O;7)T\.-R)6%;T4?VW;&E;DRGY)0_^/K >C68P!=S+(C8*3Q1V MV2QF[J) F,1YQ3PK_A$L7JHF@56CUHL9/ RK6CV[(["P9_KZ, ##5AC("_"67+HUU+5-:'IEG9OIFMIT.:^ MIP]TI3Q(M2)#GI/("%CG&A9;G11U:C[6VE? 7>V6EGC2A13R6YZ@]T:A/77X M6/OH(LL>9('9)U)"=5P8K1[GB19NHI10G,G<+3-*>O7T=Z:@XZG)MY718?0 MQW,W:@.KT.?4QB7.1-0^8,&[\([!U]1(//4U$E=8(_'4UTCX&HE[Y?T?U:1B M9.QXUW.6)(6;;NAM'%KJ1L(-Z;WS6]N"[NM1K:&:8)O!787IV^98F6WTYGBQ MDI&+G (U+Q7XS;CF*?;=J11N]%<'J?IR1I*0I[-P%M%I.9V5)1'3O3 ML0@L1MP49.<.*"QH &Z@[D7T*@R 4KLW4 KG(BUP1>_V+EBEV7==[I!ZW1] M&F>+-H)#TP.GWD,"+P6U\4S@4EBQ#KSZTS*KHC>>8Q0HMKD!CC MT4[3"GUX'A] ;J#4'.@BJ;Y^1=<]L. \H];LI?[*(AJ1@%[DQM&T%QQ#:^M6 M5H?*VG(L(&O!,W826U6\ I_W5[>DW783B6BW$2:HZDMQN/6H(3T^K@-T$;>( MX62N\,,KDS?< ^P]F?X1O9O.+#!%:!2$Y<;R;A*!IGF!N%NVYL:Z1[*+%?7? MF0%/WD&XW5&'-.8+^?V%5-V],%[B)\=+O&@S<]0%I'(25U.3 S43N4VT2IEU MQ!+3$UNE+HOLO!'&N6O$6(!-2H MR]_0M:7X-=#G3_P%1CXE^6!?2] N*DNY09]?-B\2(*0S0LA<0W-=VL.H[?DP M? N?$@YLT>=$EXTOGXXHF,2RC$URZNGHTX)=?HD2.)GH<[K;0G'!S8"3P3&% MTIW")FW&G-T^ITI,<;.Y >"A.<\IC8GBT$I9U"3$=$T81UQTZ)2.R1&-5;!: M4=K#07\!C8RK)V7J&D=ZQ'25I%AESI]4I\88<:E(<(4UCK'>&![6@(L,(7:B M=!\W@4#@()A2A[M[ML8YJ$G<5"K08S,1<,4=5>0,2EROMLG2H"R4.X%G%2T- M :,8@P#IP.DN>KV%80SLH'!Y9%[D>U*QO.E1&!.F"7K\+ ,=NKX[*[?XDZPE M,8]'NQ:\MXH_5Z<[-'L;(&B7)R_:?.-TA^2]*P4\DZ3C S5-CH M'*]88?*&T:KRY<:%]JRS;YDD04@>2#6=J'ES6APE3_3$$?8-Q30Q<\?6-RCG M/34(O5 ,G99E.IDN3W/*\>LX8=->@_9>^RL=5FRYBZP<5&I$52)< W^A#00: MU8%E#1M_4J,Q):G405ACM,7J"I;+.5Q>)TD/IWBYAXD,$EN[:R$FY6VURJH" M_PKB7(816Y,X+GT8K/9FN_#,SRI8H_HP7FXT'Y?-PT^) #KVS5&[D$K,%8H! M77Q@]:,WCV_5/#[2M(V"3Q9\J6T,=^!=2X7V#'$\C]!%:,$L?$O9&YS]:&#C MP8_+4L04HQX-818;@M+=$C2PE=@I@SMJJAY$(_5.!NR!H.D9*FON*XW08Q/) MF::'6W<0@E#(Z]@$B0H!1L<&(ZQ>:<.C=PK9=!$*^]UY82^-1/GB!#99T<@_ M&3QL[3^R>UQYLS* .5^]=BW3K0_&3"RX#@ZUG2@(;WTI,\VYO#5FT4P^ RT? MLZ@5 C/1+%MSK)OWCDX)[%^F(VKNDB?I:B,7Z(O/9QY3RAGG&E!,LN>X N>X MVO$#81+20QO/R;%J&5?3%?*8)42G1*2O1"^MX.+$=966R)X\:7B^R)9.E-E6 M)&3Q&09V-!9W9!6C41-EDZGN/%E!SP6N9UD[)K?!+2\P5#VVOPP8;Q(GK5;Z M$=I;6E(NUV%'(I(==]V.,:^;"W&1F7>!OIJZFD5\PDKB:9,,JYXJ"673;\&= M/$DE)*2#Q#J.DOM92)CS43O+XHSNGR)[7'B&DJD MNI[#+2$&XLV.M"/B$ZAD"RB6[D: \Q@PD@B7&FRG J\AHWTY19Q3A<94%M&' M%.=6L@)#B;H,"3RT"J<0D!M=*CC0R%X44!)P77E]^L)JS$4]M?O.I11NGR7/ MS?[#ZGSV_\JR_X_V??;_[F;_?3KQDJ@)DZ*A K'@ ]:M+IQ->NV7ZE4!:JB="80"!H YX MT3+WK5/(H+[,8B3"J:)*[J10_#'0E%0++;YNC: !IOEJ2\(\(X3U)V#\+GB[!%<1^QMP0!O MBV[4QW4*-(M<]P=#("D^'CG&30@2>#L*_XS$6&C__ MV8&@@[\6*6 =\?:$K8VYUZ@;I=2AY$EQDL/>X=5P?4BJ.JLU6:'V*"XW19*D MV"I,CLY8U6=*K1EM;O9KT1\XQM>>[-./-CP(CW".8YQ274!65)5=N8 !X(7% M5C1JU .QD+KM]_)2.[E5&Z"QR9E2R84\W-^\6[IYGQ#BQ+;[. '1-CMNG*9G M+B$CF>EBP\YM7!WB00I3+3#=#3R0CG$B5W="*9G(&7 9AL[AQ3HX!@]G!>>R MD*0JLRPWV6NEVF%@FG\LQ\"X_#Q2!6<7%/G)'K7Z]+$Q/;%]K:DA M4,J3Z$C/9DHT=WMQ&#&LW+L#)T'JB8;79,L]$[R3&O"=^JS8/!H1KSP6J5!U MXLXM)2KB7*$("*H_"80CE'N 4;A-LZS/1^H2>U M4)M?R4W.,G>[\YA 'J-_/XZS.+==J,@2E VDD*Z1?-,I#^1N<4Z-+9D>.>06 M1>#KPM0V&61'NC_K5/BYY@;E=1;MN$&XTUB\-?>1A'R %B[-?8^_6% ;M]S2 M3-K5YFL96_N?*DS4W7]UR3 MH[T/_5AS#&+=$.:.Z7"0[^ZD4\Q(W\C<7G\M>FURETO%>12 1C=WN:KH7;*; M&M(^A$TIM3-,/0A_1TX6[(@5<$'^^ X/EUN%5]02=Y<4F"YF;XVB4U^GKP)A M6,+1L,5.:Z^"L+(<57(.XZ\YGAW9E;\(MW01WC $:^V60U)WW#'8JZM>),:X9#[QK318=>4HJZ%&=X M94@3)!JYH2WS>4_4@-Y9^D;;NU.2TPIQ26\35NPA_@B'^A#0@N)FV&-3FNK^ M=J@K6CTPV7 MIO_"M'.M% IUV[($9K07%%F3-5<6ST-02#N=>-LMWK<,0^'1T%=17&$5Q=!7 M4=S=*HH[:;)=<6+V/4^,_HE]7#M-0H-]CG^\8WNZ-[;S$;5=OP0'B+3HP3#" M/ATZ@05T+.%ZX^WJ9C2F MW&P!^IO;W;X['!P\"DP?"6$ MTHP&-%L_5K.%#B4^YU?]E7;[.O:_!RW>4"L MN-\:$QZ<_Y!AYR&"<;EBIMX&=/?#)X.GAW3K/*^O\#JV1KC%QT ,Z79Q!ZXA;28Q.O8#1=E M(X,<['& V2BH@WX,' )[.(P-*JD& KZ+YQ3-0&[%M*DV>8/$]%RDV+ ,&T_' MK56TVJA:31J56.]T4U.J(_LB)1L\Q:)=:,,6!M>#D(O-[A35ZEO:T +CN>M= MF4O%$^-6?V\<9MK9BLNH]VI&SF B#-71M5Y2ME#NUFW45A66RR&^:)Z@C5>4 MWZ,G5:NK-@VL4 ]>,<-*M20P]&OVO_Z%Z;%7>7+=AL)=I):1G3= +LQ%;[[* M6N88;SM1Y]UG#KR0!F_U2=6K5LF57]4;.+/-T]4OX&9=?',7<\BZT]6[+AC[ MW*M3>\]SV6GG9PI+:_ AB-][A7?KP8_H%;?GN%YUWG?7PF8['_-01<#VLE%_P/FP+%!;G89_3(/N=_[8:O+)"'9NWADBOE7W^C_(W: M^AME?N_OU#=]IY@G[OKE>*7KU2ZSL \81?.L[UG_CK/^(F6TH4LM_V5 MQ\S31?RL/A^T/!GOC/8?1J.#)]'H\'!WU1<3=^Y@]+?>;-E?W<=/<5F$/P_" MHW*N\G!GN+OF.LOK1W^[GMO9?LOP:O>X44[I5QYTWDD-(U_QTN'H$$LNSGGK MS6_44_"B+]WSM+N*C7UWPV0['/A;=V=O75\*;U&FV:7LA>$AQ8X?W387?(U! M\#L'I36AKYB(U\F+-\6 5RDS+ORBZ]B0)X8GAB>&)\96$^-ZG=OK94D>+S>??14N,G;T.,*OI_4!0Z.OI0S M^(B ]P&ZAP>Q[@:S4NF[A<7LX%/$ 7\.!VB.I=P+O!;-[0]<3PQ/#$\,2X?R[@ M0^\";GZ13P)N$3&&3QY[:FR#(S@&)X8GABW ,O\"A37V+",_L'NH)E<1;N''I7;< (WM!-Z*MS);.!H8W?@]NI.[P=^(P:6)X8GAB>&)\:6$^-.^X&/ MO!^X^44'W@_<'F)X/]#[@5M/A=OS Z\<(F9[%:=W K\1Z\H3PQ/#$\,38\N) M<:>=P,?>"=S\HN&3Z/&A-WNW@QC>";QU)]"W!F[);?#@,-X-_";L*T\,3PQ/ M#$^,+2?&G78#GW@W\!PW<#]Z.+P=(\D3P[N!6^<&/O1NX';#?Q&["M/#$\,3PQ/C"TGQIUV Y]Z-W#SBP[V?4GHUA##NX&W[@;Z;."6 MW 8/%.K]P&_#P/+$\,3PQ/#$V')BW&D_<+CO'<%S\A^/HB<>&G%+B.$=0>\( M;CT5O"/H'<'[QFS>W/7$\,3PQ/#$N*^.X- [@IM?=# $RGC3=SN(X1U![PAN M/15NSQ'\I5+"WXXSI< -//!NH'<#[PPQ?"[PUCU /S!B2VZ#'QCA/&L8SVSVTKCPQ M/#$\,3PQMIP8=]<)?.2=P,TO\HG +2*&=P*]$[CU5+@])]##PGA&NV>6E2>& M)X8GAB?&EA/C[L#"M+R_Q][[.\?[&T9/']_.+&5/C.Z+#D=#3XG;]O]&H\%# M[P!NPX6XJBR@ ,+&)X8GABW#LG\(EW L]Q OU@B*VA MQ8'/QFZ#%[@_>.(A0;?A1O1E >/\TC[@$X\)ZEEMFVTK3PQ/#$\,3XPM)\8= M=0&?>A?P'!?05X%N#S&>>(=\*YQ /Q=B2ZZ$GPOA?E[;9@/+$\,3PQ/#$V/+B7&W_<"A]P//R7YX/W![B.']0.\';CT5 M;L\/]#,"/:?=-_/*$\,3PQ/#$V/+B7&WO<"1]P+/L7J]%[@]Q/!>X*U[@1X> M=$MN@Y\3Z/W ;\+ \L3PQ/#$\,38$;?;^O+$\,3PQ/#$V')BW&TG\:%W$C>_R$^3V")B^&D2 M6^ F^FD2VW(A_#0)[R=N!2-Z:]@3PQ/#$\,3X[[ZB8?>3SS'3_1HH]M#C,-' M'FUT&US%X>#QH:?"%ER)^X,V^E]U/,[4CT'PP\)],N_JO$.8Q^5)"LO#C^Y? MY6%V%KRXHO7!@WZ@_883E67P\$F:G_S]P?X#^O%'!KO1/8&@X!LO%G]XU;>IB\<#EE4NOM;Y\O^Q]^;-:3/9H_#_? K=W'GNF_Q*=K2P)L^D"F/LD#BV MXR7;K5LN(35&B9"(%MOXT[_G=$L@0(!8+=D]-3/!+.K3??;39W'W*6QUMT=L MX5[SA%M7LWUB")H@ TM*DB1X7GG!D M$LMX)YQKM^0]?/MO0&P=5B\K[X5OFA7 2T78VPMIPC#OHK5#1<0\X7?"@06N ML"##XSW',HUHQ>'G9=Q,3$/&->*DQAQ?85K53:C$J3.;X[@#RXU3:6C^)-M& M.@'B6@^_&3BTZK_?"U: /Z]==K6WJ[X53K4?8F9XZ>'IE)?ZKM]'/\*,1 M"484^.];..:$ W>)]F>O33J."\_N4WR%APR[>DXG'-'\O(.)'R>>,Z71[+/N M4YN(8U&M)])YG^*R5-I,89$/47C^6.6,ECF4O"[G MG]'4]/%%KLVRA-07PV25_#,92QU8/:'TYC):S/)"E%1H/@606IR^'R7*6!Y+$9$HJ;18&063.:%G"Z\MA MM)QE@B0PVMP8R"?-IFQ6Y3GZV4/JR^&RG"6")*FS>$!_FL]X*4QVL?IBV$S) M61H(Z\8VH91,3BC*+$+F6HX\LL\Y+>LHF>SQ MGEF$S..TRMS8?IJ88]2P<>VF;[LFS(TT<4P$.FDBP3V;O+.YW1PY;N'0]?;# MKDJ:;; T<1&^:EG.O6G? G[_!@!:QP1<-[J:?4L$IR,TX%&N8XGP,2 = -!#@3P0/?#-.^+]G_]=5>3*>WS7W@ML> >ICU&;A\1G64*;Z$Z/ M"&:O1PQ3\XDU$-CW]G.)L8R0V^(.HRKO,+K!#J,J[S":BPZC3R>W=R86-@GT MO^T/ER#,7=,?%,[N;>)Z7;-/=0E0A096Q0&Q2:GR_"PH>_NTQI>Z2 M6\TUZ-= @;='2'7B2,?/&DZO!S^X]!U0!V!2PMO,6E1I0Q"T&0/;(I['#(5[ MTR,%V"%($%#IHM >"*_E-P+1X!=]>#(\ZH\-B^ 'X>-A^_#: 2@2@<$5>R B MJ0DBE(96AQ/XG@_$AYN(S-H."#P*KH?@BH772KBT8;I$]QTWMBM<5A1>JV_B M;X0&C"< #[B I9%M [\$J& '(J7XU\4W EHST?>B!1@_3/^J,+XPGJ0FH 3J M[PN M_!LPE_;ONF;L!\;M(X!>*._9/CL:O!0T,A$N'-\:OK9^ VTH)#]A+YS M#T=V;P*^X43Z !,>+4+J!7JW$!T4'*P1HJ WC4!AB,!\VF1+=X=.H5K3[SB= M$I[L#IT\\VS: UYDIM&=WQ,M"4#H&V6Z(>/W:3.KO> >7RZ M\[3_0>R=:G[@D@F5+>1APTYGJ$U(FRWR]0"BN MB;57'\Z)B\^@(**Q;&F>EU[\)<"W6;REG; YTC9YF#D7HX,,@_O"=[_=X:ZA M/57&F,;&INPE".%CS76$CV$(]E\OZ(=#TH+^AQEL'D*F_+,=&3B^BKS)[2^0 M_-&2Y8DUUYZ(*4HU0+,L+UAWLUMEN%0X+C>+RUF3,+>SQW\V)G&^,[QE%JK41*4RZY)[X^JZS)&2 MZBZ"JVM.&IG3$!P9&4)&3M3UJP^'VIUI"/5]X<2Y([^= 2>I^:*_"'BI[,Q_ MKG"%S"/>7 ?D4P=P9&0(&3E1R G^\R=BVV:'N,+EOG 0$,OB#O0R"ELNB45Y M9WEC58Z55-<07&%STLBEB6>+*.,U" M.[A?V)HR3H)U_3927#=D6S=P9&0(&=M5U,P1QM?O!-.'!^H;;<]0MZQ9[1'# MADFL16*L)Z+PNAIU1'S#J7*^FR?*M@\$QORLP:YFNL/!,ND7?/#MJ]:V[F+FK^:GJ"_=81SU_&U M6V*;.K:.=;4^ 6&JPU(M6]\7!;E8$X[,CM\5ZG?$#@B $ #L0DF21 K?3\?] M Z]^8A]26=I-B]%YF2[8=2R;X&J(K7+<9SK';Y6WA2 MZW M@)]5P(XK5FLS>E[O"W7+4102S6QHB@SGB!H/HX# M 1O-U;$7=-\%BL(O_4?>KQ3%PG]*^Y*$,T/^4\$78*:Q!^T+APX\S7;\:/7$ MQ>62(E8JU6AQOXO+N83^+ER3RCIL80TBL"P)AC;PHK[=AN8C+ 7XS!-PTY!J]&K0.E59-1*9]W\1U'VBU.$6UA$N,62 M6%75]>A6X'3[7';XNAB3R7))$JM5:2:%VD8B296JHJR45B-K)&2YN%^6"LM* MX)JH5DJ@899QWP=3E&WDGTPNHQER;956BS(%=%1:EQTD-4W1!5>S;W&84,=U>D)<#HM)@O@YX^0%4%UU M@40,$^Q7=;P>QV/"D7']M2?K5%RH_ELF\WUHC:JS#/B85GJ0I7@JMU=G:'^;6+!!/HER51:E4W07ZLW4XSQWYF]S9*SHV,J0? MO%TST11CXR,W]?@('^L\,^FH%R'HU8# !!Z_==YXX8!?PFO.P['OP>QS:S#^@3W B+E.7#:>QC M,["I;1 )C5M7LS&+*+XY1A#",7[D#?<6T-Z["4 6%$DJT\B3(LEEH?DW,/T! M7@#@?&J ZMS28*'X O2=X8/9W&GGGC[[P-%< T$_'&:"QG])/X[_DFV7;KTP M;6[-WO=H-Q28?>$\<+T -HP/9893X'<='' O)J)5C($; F%0*,9.CPWM'GX^ M]ED,!GJ"B0!R"3ZW+T74?&T3NIX-C%@*7@0-M M7 J'7-NO*?%[1TSQ#:W-62 P:KDG;@Q<>!:=9YYL4DO[2KE4$F+[!9FK=X5[ MS:-/U"W' ^ *PU\DSG&/&\Z);$RE%]45[2&2"O,1MHY3=*-HXZC9SE?<9,;.0.A[X+A!(\#40\< MXU&T"3C[Q[XE/9I4A@G63N *MM8CL>J36.4)X'=8H@)ZA@C@@.FNV29"FZ ) M0].S_1'.,;;C 4C, _-, %X#,,;X&903Z*5/FDWU#54WX-$OO]LFJC8_M#Z)O$:1XGAD>#)RO/2^Q@+',P/,KR;* MI](_/R'>G%Q!M12X8-MLF!'^S_^NE2NUN54T2_IEVY,^:$XC;%H/["#@3].^ M H=$\ M=AVGA\*B?@L/"4L8A>]$ '*P *0"TMV-<_4!4\WZ9XL#>Q0#6A^0']+RS8=VPCT6%EGV)Q=.-':" Z^=6T# M![@>QNC@0*X<%_#BL+ AK+[P$>6::-V+! \!TU/>CX\K'%QYNT+'RDL\:BX M$>5?49&+G]AH7.%I:GACO.<[>_"/T.\./%PF.FZ*=>KTH+/%U(,&= H8LF\+ M6EC%&A[=&&([8.A;N"%<(\+0OG#DN"P6ZQ(-#IZ=*:. J4=X 6Z>'D#@]AT/ MMH#7W$[@@]+ITP@@ZB.\3G=LH$2* D\(^@ O>^2^<.CB9#D06B*EC)BXZ6JF M2UG"1%Q[#CNO\%VZI4;7))W83\[""LLAS5*2?09-CV=&YX_0@O?_*!)U M\NB7HC]$D!%>'RP(X#V+!4282)N!:HSQXQ<\L$E@9VZ/M17!^PD:*6K1U< < MH3R(=Y^-=-WV M1@X#9#-Z56UI/G 8#54BLX @K@ZO)#NFZ_F1D19^6A,%Q&NDBBF;HE71F:F5 M47@('X?*^[R[?[@/%I'GT189A<"+Y(%!0#PX??1+:$#6,@U\$Q8+*XM9,)^" MYP4].$83-WD'7W,$\%S933U^BMZJKGG,3H2_X:M_B"_@$>#=_&^BAUDY:+^@ MT*"6!U@FKL;,.TS7&5O3=T(9%[4_HI+(HV8NM<3"3$!ZO,QVW)U3W/A>&(>6.:<&3:)T''LPE'*H+VR-LZ>:#WD4' M#FW"G@GG"&Z6<&8+GP*;"')%#-$468VC<#K\MA[ .;$? M[),+^0W96'U^J/ M81H#/#O0J 'J"%_ _!HA'G]6%I62-//FGMY6T\MITZ;6.&#)97"@'8EIC!YQ M[] KF93BH2HQ;03"= 6\Z78)6M3V$"0Q"CGXQ-X;$,VE>H)N$7V<>$(EI@O, M*?I*2$21)G9;N-="RQ*71\4"AVD@P3EXX2XK8DF:/ E*6K@3 9P$5RA6A1YP M8==;$<1/@37 TK,D\(3YX%4V"EUA_@&6*(3)Q[@ SJ6.L9#B&*?2=@'2+YH+ M+!:"65P20&;9C %86 ?/-!=CIR59N=2&J4I/2KST9(.E)R5>>I+?TI.\,ODF M?8]SX&H=#":J)\Y=1R=&@*G6:'OP)) L^B3?28&9= :H5M2]0A]Q.& F #H7 MTY<38OQ>S'9ZIDU"'!.+V?BL'VGT+5%H$YO ;_%"RKFW$R[,L',$QEEU"SR4 MX>U9+ %1C-V<>?.NSO!KX<=3MV?,.H O@(O5 ]@CYX/:/(Y;8$%:-'RIU1]E MD,Q_)IC4I->WG &[>\=H*/7K;'3>QB+P+@OAARDO D9@HX28X5)>H'<+[-%@ M:^.S\#;1%6Y!KJ,[.'627;,_O.031^DQ+L$I:;Y#A744 T*TN"$;(HC4D8NJ MH6!1ZIW0W%(J< O4(]/&DG>H=Q2, LDL[]IT7.IMA#XD(B\A:QD? 0?G=UTG MN&4^ED8=(SURC 0D%O1 PPO(&!)1F+NB'BQI\BW#N!9VA$\L00:]CQK'9O$-)JF'0OS@0U%42FQXB5P4)_,[S#[@"JACP? MPYT8NO\8@"BT Y^2L07A)!^(UP7785A(='-^3!&>K#$B98F$(&J,";+"K*(B]_ M&%4:7VJ,4(=W<4."#$-#L3/C;M)N+*A(6A;B6$+;Q1%)%$$,;0$;,9P>P;1+(+7\@Z+7 K>P,/\#FJ",2, %1I0 M!@W2TK>'TAE=*)WHH%,8>:?@P,,68!A-D(7AAK[ICV\'%A 5,5J_/*Q_9;5J&'S",#3NZ;+9$-S M0MP.50>3A_@FDXKT+6?ZB(:+,"MSRG2)SLQV[+W0("2%R 2>V/D%+"?(Y?:> MBD*[%UBW5!J/=,P7*,P:)DEA@#8EH(,HKCQ19A.4"6;Z+]!'()90Q; M"C@'/!>?F:J1^Q+:F.%-!$U$261PZM*Y6%&(NV?&:9M$@HG^B>"$>P@O=81; M#,_:]#8C)L(\EG\2\O-<64EO*5P:SJ+%!6PW+/Z+B32_:3WB5+[FL!P@)@UC MG\+70\\.#$:B81C9)L//V8__!D!M'>HS 3V%LFJ"Z0O U+ YD];_P8GZ8B3 MPGX2U(XEFAT6G]*TO:)4>6V\>5UZ0R4!N0U8N8QPN?<9+^C&)$)[P*ZBF@V> M)Y.AC8 !T":626@N&-#0%_ @\%HR3,P0A8;CWH$7)PK?Z2R,L$+-#8>6LQL* MC486IK6@']'0D!YG:\/"#&T79@.R/_J6!OQW055F1\WLE1! MKS3Z2$UN5,.!YI?K8/8,31G$/^FOHD(*P:>Q>68>CC2JQWJJT"2[<$NA\K)# MUS!P/1IOPK7Z+F@R=T 7\L0"=7X([HE%JF/*DJ[PQ3S]/#VW*ZSSH,J1>8HL M,CS^T1SD[9&@C0"R%2Y^8-AI&XT62EV%]$+5Y(@K\/UJO_S[R9+!D M:)1@*4;&&":C!VY8B@*6(/UA6(BRD' *LPDG;\?]]&2R.)FLS)/)-IA,5N;) M9/E-)N,Z8PF=$98X;%IG)%55O!R%\9R)YME7:3NTRA@SXNF]#'V!A=8>RX6G M.7OP4[RQ(K3&M\!K?+-"_%MMMB=+$\WVBOO"^9#ZZKJ.F6Y(04@!\:4R7'Q; #[Q9JCY^( M1IX+W2[BF!8Y?>!A#ST^F MLF]SJP_;5<&YX+O_?:5,.C0SG=($<#?80/#5AR/*!Q3"GUB0B70_X^02CBD! MOHV>',?;$GA3,X2WZ4YTR>R>) K=V_9K12J*BEH5E5+IS70;NE"JE-'33W#< M5]T'*[-&_3+C),-UE7^V0V;CJ\B;W=Q_YN])+D\L1V_@UUA/+I?$JE);L.IF M]SA7@'#D+8$\5IGRU,A;1XI\9P;5)'XV+2[VHE*(!+&Q33K; 7%MDJ#V4JRQ M#>;G*'AB%&S7$-@@[%?: XU:< +*%@%Q%#PY"G:@AC?MS-6ML.WIV^:RU";I)_5"+]C0> G(V(+) M,2F"E/W26K+_RO$U*Z6X6W>M%?4,758PG*!MD:=3-;.AV&Z,,1$)3V=I"9AZF3RF*/2+, MFV'T'))7$D5QQ.\&\5?:PT9DE1L.MK0!O]H#I93Q,0X46[Q2LV*8]"^-'A7*%>2[W!9,C8;"OBL:3X6%8]S8=G;9$ _6%#EN'GA0Z=T16:9':4 M;3_\%<,3:ZUHWVILL%^4XCHYY S[.R&V(]N22_$GRN+'M.A) L%*Z5BQ<+QI M*$V(]L)67&/&'54+L%QXZ1R2R=BE%=81C88V:FV'RD=N,6X8=>R9/LQ^X."O$1QZA;>Z4/4F>ZG3U8T:ONT(H MEX8-T7#2'3Z%SH@8=O[;*O_L9J;WEF!>7&5;X56V&ZRRK? JVQQ6V>::Q3=I M#D]4A\G#ZK#S^L55H?5MVT5?>43$3NKTE(DZO=(^Z,FNV38Q2G@T="XNHTB/ M<*EWP5NQ=E>HQY'6_O!:>U/ 7H6T0>Q$_!6;V83C_7RPS:YFSTSX-4IEO[K&7>)S]]".]N3AE)"C/46*%90RAX$*0MHEE(TT M"7L0@TN";1R%5DMDK7:K4>NG)-2S\N8 G KZ-U:H'FJ^%O9K*$1\2^=$RM+> M9U[%_H2\K+PI9$+K/1L$;7LC0\S040E..%JH370M\+!K,AFP+L@FC9?@-5?$ MQB+]:^3L#X?(F#9&/K7A"!?\Y;WIC:; \K#:CKA1?5.(K%'.=]G:".K/J)T" MQ@C'D@%,+[P 8"-(8L.7VP,V,HQ&+_#"*C:%BX2H1EV+(4.S8U)6!I4\'>Z3 ME?:>JK#P7F%JE 6 /=+?..+F84*WLV;C 4@&#(2P:XH1U/3"G$8I+>*S^1]H M7\](?1C^+M-R83NT%_UO_FC7W:PR"EW%0U63H:RE(1F+9,V,>$UVK4C__(0 MV'12:IHV NF62PR+#!&4%%N+!PFEJ<"LM 9%@HP/F712O L;_<\3[N_4F309 M$U,RT^-OLX4I &$D%F) KE"?LCJ]1PG:&VU[@2/.Z)T8'>0]N;F$M/$-\^MJ M_#C4W:',D?8KV[4_UJ+$(9!R=F'W]_O>T3?OW7NWM9=O6O>$>\M,6XU]ZVA^=I;65*4:JWV5I(D MN:A6*L4:[%4M2J726_*@[LG[7;\W-&_VX$E[L %7TV&[H66-5KOI&O1(ZCV6 M48;!J0M",SD-H8'TUS&Q-R4=(V7')A?C&^>NXX.Y;)OZ='OT?>%U:Z:E#_9U M9(T#U>"?$ZDK%*9&.'_E(O0=;!84JX8#JZ;SC?$KGP*;"(J$Z7!R^0TH6RU/ MHCZ;Q)]-J+@TWZXT5SCII#8OUQ+>2K%:+<+6X'6M\C84SBDE^#3(\1.+"7!Z M5'A?& Y6PYD6BAILHE1:Y* M4E6J5=.["I=$=^PYOL+!P-+NO?DN@?A$ ISZ!+1"1JYREX!+;2ZU5]I\D0=X MGE9J*T5)5E15!:E=3">U8T'OD>D]G':>3AH7F31.*C"JL^JDB0 -9BW-D,:1 MT*[W7=,2PJ+%-UPB<[;B$GDEBBUN5[BZYQ6'M(.";?\Q'4[/9;:(U$):VWHO<>N?2/7C;.A"L7SB,2S*)P=' V0_)/&??SQ#\%9E(%).J M%R#_7RA7Y!K4YTD]Q?U23O&1#5#7%?7%HB)ALGNM6)4K;^^*:D51U1M,:"FM MG^\>OU4]MS2==6NIW^+_1[>L:0WVTEJ2FDG_D;0.$UZJH[JDC&>0OP1:?FZ@ M/D_JD:7-Y!URVMFVN2Y+LI)&B#=[?2W+B&L13OI=%AO:.&39C/K MEDK,HM F_CTA]BS;7FAHMF9HPFM%DLIOF*&/^>F'[CX<21MH6_AENLX SB^] MR8Z4IVS38/^?_^$*(&.RRJW[5\4*^0:U.=)/<"&17YKGQTSOIA&J(<- %C9 MT%C#L*&TWXYM'T9R#O:%2Y^8]H1]3^&9%=!'0GL:^SX:Y_VLFNMN:I5M-]-^ MZB; 3R^MM]@]%'AJ>Y>IO*'H-HWW9U;FYBXM\)=)D42I7]EF3&:F MF?Z\V#9'W)!K4)\C[0 /5C94Z<2)9P=2OY8J0?Z*Z%W;L9S; 3VA$U,GMD=F M9-Y@?9-"\VZDTBA ]:_<&W#%US/] >H/ZX<%[;I@"=@.W<:Z_-[Y("NH*^I M2IB5B4^A6**G#6J&6G(%U7K*@=T%+,B@'X9PD\<4_,F3F M&S&3I7HQ0P:M@&,'J-W&>ZH&&"RZ:;%YZ3,LG.%%UR;:\X6FS-*VS#-JTO=" M62K7H#Y/Z@%FK')O-S?*0Y%2Z8[+/KBB8$JSC( +XA%Z7Y^H*&*=J.7B.DIB MGH)@UU;Q)+9H(,*&-(HBI7*.6>27EY<_$S;+-:C/DWJ80N$:)4<:)95*&3HA MT9T5%961GEE"QZSEB$SHF*FLC*WKF)?U /,6,LI0C(+ZF;G M+\M2NOD\:3+LY++0_!N@(D"Y2VR/7:\M2JZ8C#FE"C=1*):=LLQK73)(S[D& M]7E2#W*AE%.,9!;4CFV^)KRSJ$_+H-M>V M9$+4\TKV[/% KD%]GM2#LIYWK0YD-)3B'ATOQY$'2N07U!)(72?"-M MJ%XL16U!>*<*SJ2?!W$<:!BB&:27X^HZ<:U!=$4L"C&PFPOU#:V;A43Q6.62S5X1LZFND=QP78]<#%Q)>/ MCH79,@VGUPO@MQKK)47E;=1A< G1KG+1'N^SLSKC;. AB\'+_%'*M7WY?S)[ MDD,^!R:MA4[UA_DI9RW;,Y'=KEP-NQ$)YXYEZ@-&XIE"R L5W;D&-3O4L_7- M*S(/,V;+;&$#38J2K*BJ"F:+(J<+,UX&;1")IN::A%4SI[LC0@*8=4>TTER1 M6*&X4GPQ=_S9)=!\0?9\Z4-1LRAI=T$=(^M.42/K;F5PL4$[WFHX'>&+9CDV M$0XTD$,#43@Y.1<%TS9('R<[P5=<%OV@#?:AH.FZ$]ATME/'='MC M%]?/F/CRK4YS#>H+(BE5ICYF+M&465!CPE.-#,$/#:2+3AAC&J9]=DW2$8Y, MO$HPP6H[Z\ WP$/N!ZX7:*SSZ$5@$4%6M3VY^%I[(SAN^$[)8.^\%&LMWS21 M:U!?$$F!0%2X0-RJ0%06"L3F ]$#VME@D4!L3PG$]HL1B-DE@7Q!]GSI0U4R M:=UEF3SBHDJ9:[O1X-L,<46GDJ6P[2ZQ4:-C"S6I'#WR4G/;F@T@GCV ARS4 M=>HV*Y*D<+G&(>-R#?=:J^0# UF!;+.7&[7:QG(RZ 4P7D!<$!U3ZFC/V:;K M.C9Q L\:L(&0=,![K$-)NDN26F7&%0F%AE^3O!#?(]>@OB"2JM6R>-62;X+: MN-Q/=:E=#PR3Y;YA7IWI^P0-9J]2([(-:@OB*2 6WF]3=:U0:IZF[CEGD6E M,+-I"E<*+X4Q<@WJ"R(IX%;>^BKK2B%5:&A4/\F*VFU#.'5ZIJWY;"+1KC4$ MA2(YBE2;W8YE0S&D_1?*SCGBDER#^H)("KB5M]/*H(: EQ6%%G2F#2)=ZN9P MPL1H B=\CY((-<@WJ"R*I_RM+TK[\_W** MJ,R"^G]_'%R<[+G$&LZ#,!P]P&[CWO][H926(^SE&M071%(@O&0NO#9_K"T; MK$:-#D6F0!Z"G2H<@7'&A5?VL9=K4%\02:'LNFQ\S"FB,@MJR\9>=!0\M,&$ M*^W!L9W> 'Q4G]@>)L1=ZEW2TX3#T")[H?27(YSF&M071%(HTAKUDYPB*K.@ MIA!I#3^D%.$9594%/(MQ.M32PNVO*'VUR#^H)("D7;^44S MIXC*+*@I1-NY2["='7=.='0G M*KS&69&&$6:NF3;-76-RDFK!U_.KP M?[M&8/]#87W@9P&=AZ<_XP?-/SA*N8).+ M(03?MV_^^DE[1O_N:841_+PW! MO6GX7?RJ],][H>VX!G'W=,>RM+X'-!B]>I45L1Z"*^TK)=/>))]MI!?5)@$Z M&DX^[Q*7H+3+IJK=*!(RV!$L R$E&.9=!$^H<-J.[SN]=\*!I>E_ M!!F6]!S+-"(HAI^7:=''2!/&-=^D9AQ?85JE3:B^J7.,L64"LXV?B$4Z]!=# M$I\^KK'EX+NQ4XO.Z[UP->C#^G57:YOZ>^%4ZQ%VIJ<.GEZY%O_5V^AG^-&( M6"-*_?.D3@?2Z-;8 M)8\LOKE2K7;X,-. )]W?2++Z*BHMNFP=G]:OKB^:E_^^;7_(U[YVYI^%;YIT M%@5:P!LV@,_#WI^%L*+8!?%BNM2LH25K43]06<6VQG+IM?%FV!>4S2PT8;WF M@][5;."DL#FH7%.+8O@\G)[A8G?1KN8)1F -!%T+/'#EP9'WX'-:IP:KMXF M]A6H95C.A-7;I*M9G:BB+H 3<-D7Z)-=$MCP*_I +?"[C@N[,O8WBY)MDPSW M[K(ZVNY%0P44@N_^]Y6R-/%M6'F<7YQ=U8^;IZT&!>[J8_.B?MZ\OFHU+D6A M==K8'U,=F7*OAFQ8^B>;Q#0$L*AF'4(EZP!F_@2+E2U#F!W&VVC,1_/)NWF( MF'!EVY.N[%, 33O+4$!5UM6EE"/=\X10'0QRA^I_S0]OO;<4TF/-=82/^T+= M!>/]W[=F1M7B\RH4)6HG",V(FS$H>*0[5">D=7,UWX(H7E];EKVKK9 MUZP9$VH.,9I3'T9SHL^2LSHX_W&H.%3<4>..VDLCZGP[:G6+/&AXFR%\1O/2 M=>ZYM\:AXE"M"M60GR@P(Y[B_,2AXE"MXK*9I$,!F1X5&O/@IC[<8.#J[0+X0?C;K M%Y="\_2P>$L MEO^-V?V2_.H#FSQ" 78Z0LLV2)_0['7A@N:"$Y<8PGG0MDQ=J.LZ[)N.V#HR MW1[.'0$7LU$_.Q!:A\*H+BI2>H-,8BYMT?'^3HN_J)EW.@HAR19DF]N M\)6LJ/+-8ZE?/_(&IZ3VNXNQUX=WMF.?!CW8A$ZK]>!0+A#J(]?IX:_V)!G^ MZSOTM:SLJ?(KNO"1IOL2_*=98S>L*1Y9SGR-%6N9LF0,\<;:,I]>"1?-X];E5?.B>2B<7Q^"T>M MBR_/XQ8T\_+\RBG0!D0Q;Y0&D@XJ% MJRYQM3X)0(3"#UJVON'N1L] [V[#K&MCL<99W[1!+6,O*B2U9/L-JS:VR_ < M*2%2)JZ"C\:O@D-L70$0!Q8(A>1+X<.@5[D[;/\N_[16OA0FG@XL"7:*&Y") M*^)2PA7Q)&"O/GPGA:YV1P0-OT"[H,%K'7O&:O8 +\+UN-_0#B^Q/'J)A:)M M)!^$:?E I2#V3O."MF<:IN8.A-=HMQ':4=T:L*9LM%NK]+[!%J5_R>_?%#2Z MP"'1L=NZ*PQS?/"AF.,CTE>LJYM%P1N#U1N+03CC,7Y]+,9O.1Y K(\"B]YT M8+% :&"1+:IC1*.#$0V@#9?"," :R'=X90N87V!,0V>C.S:^?_BL0US,0 / M3?/BI]$9LOAH(]'1[!=:MN $+NR*XI,=8](OA#X;Q2%T--/%\X;-:98%[ ** M&[\*'_^Y1&PU2-/JL!L,#7!4*$-2SLP:?KI(^G'G;GO[8I>5-Q26&J4T;3 M]F>D2N1,(.53BE+5=NP $@L-!^2*:PM?-!\HD^NR'5JO75(8D_B)%_3P!WY7\\>$Q+T)(@95F&D'!$6&)MPZH3)!+.\+=4\P3$\/ M/(^Q*(:J"HH0=OU,@D <6P&;=WI!IT.SMUSL_.GB\U&0P^8[H#$GQ0W^PB:W M&FWR$)0FD$(,_=Z9=A M7_90D7BL"3ONV@5X7"/7 !)9;G" ;H=]=LC\Y(4/91SR;CR'!0 MQ\!7=2LP !H4UP92#/N8[JQGWG;]4#:SO>.QPJ: B3U:8G! B\KYFV/^!& M_LXDX8'FF5X!U6!HIW$QN%,QZ)%"(E\!.T8631]$A!ER_KAE-.3NWI#A]X4S ML-$F?@7TOS$("QK&*+P>LZ#>"*]#.Y6F MQT:&*96T"$38M]D(.RF;L;1;NG9H=D8"/UH?K5, P36HES&$\GK_PY')+N)?2)QF\,>T4###W3H_/K MHD?2O7$!N .@P0T%C6D$.I+8B*AG$01J90.H0WXH@+! C1[G)C3$1'C7A?W M6K I8M^"P*$?AMM")XQM"\%@YPB@V!JSRES'$G#,66P'K.\Y\#TUS<"^H[\< M(:)P3Z;XFIT6+L6:H>.IH^3 )=,N)[3A4'&+D?/7#]P^XA >$LI(_-9(3$81 M, *V'W6B;12C,T3Q,KNF5 8OT4G&0PT%M.V %:AWH^6Y,-@!T* U"T/^I[;L MD&&9O^_HQ @ /2QJXB&>J'XVO3_>3,:+B"39N4ABRD+$E&)<9DR"0/T%JN-# M2Q[)EX*R+UPBZ<2^/-P.>8"SL>%1(FIQ#4[4\U&KFP *N3,->AW(W /TCJF8 MZJ%J9DH+?2?P=<)GSMP6,T#"HZ0.Q0B .\T*-)^Y;R0YG"+0N0BX'@XZ,#N@ M76V_ )":/1I%Z6G@9;0',8M'1!?HGH#W!_].+(&\AZ&G?GPX[!R<4(.F32R3 MW(4"/":.X$SQE.#D8L*:GA^5)+'8&.?8G?DO#32K=##1:+0Y#.7P>XD= CW$ M %/^L7A"[+5)5>K0]\?8"8I'$&^F8XS,AIDF3FA,P3-U,)D#&Q:D5IL[8?47 MQCX.+7WV>/S$!'A(:&IK<)JOY3=AJ)R*=2:0/'QL7-K1QT'[-[,I1%P5(V(6>0 T&;CA\0MCQ[]5"<0+D><\/U6OK$6Y3$MOIR1M=+9!K%7? MY+5C9?S:$;.,DJ\:_S:U'\6_OYR?O\S-U)^6$RX7<7EL(FDY-CG03(N )7UR M#JZ88A"0XQ*&/FTW9P\5+:EXX]B8H;@X!_1&VV=\S=PV'7KS[< MW]_O]RC&VQ3C^R U)V_0,M)'[*7@[CMA@T3QPL8C[AV]J4ETCS7&MV#=H[>A M2')EGR/M*1EN)-F+XY+]Q-$I[R5+]]N*8O_\\?GGP?GM9J1[)4&Z1R"\^O#1 M :K:_P;/V<)WUO M(5M_/%5?&:;JSVV7*$[V2VR[;S\4XLW\A(/Z2?VTT10N/S:;V,8O3X3=*>1;VQJO:QENLK!"/ M2">U)N,1DW**\>_(%-A84V!\U+CNWKLG>$6/:UI&HB>\,GI33V2-4%>LU6,V M:7!R$%1..\ZM/ZD3Y@9:)C:TT1;+PZ15W$64N#KCZ[IG^K?MJOJQ9O7)Y4UNN7U[&M14[\*W09X*I%]J!6V'%^#HN M'M4N%MK&AC@R,H.,Z:!#>K:>Z!W!B>2Y$@E'1H:0D:B^I2GUW6!7Z2,M+LF@ MQZ\^GFF=]A?9&^Q(CR=&258]C<;UQ046FW,-GVT2Y-=^A,8>9C.S M2_.09-[A(;\:NX"O>V>=69?NE=(K3%WN:?Y_7YD/_CL[Z!F.;Q#=[&G6*R%\ MX=%H>6";[('7EX>O/LAB%2BH6*Y%U_ 1/!\6',=F#W\N\W*JVCI5J8E455Z= MJI1J1:S6U,Q15:*HKL=$]1?-_4/HO=.HUB]TS28E>*MB7U_56Z4!N5U!@L]H MY)DDMC=X)*/M":-:2&Y9S.>I^ _WX-CVS(>]KFD8!!X.%*28#VW7 GZIOOJP MEY"^Q(W"IT/=7'$XA]>7D)*U5:6D(E;*55&64^O>)[9BS[%YAVDT'_K$]L@, MH?CKSKT^&IS=5C[6=F;63I[+IF\\PXU34 C;_:3,G',_N%6K9='=Z:Z8=ADX MMLO4B52:WI2NRJNR<[$HJK5J6EY.O$C>%;8XE>:'2A.53E59V30',J6)O9DE M4Q[_S(MUQ>.?'!FIG.JQ&TZT&*_ 9/1#DQ%LQ\=3NPS^]-&W3W]_5$[O_RH[ M,!T5*3%U:Z/2[>KLJGY"P> WH1M3G6/$M(1A5UPC1EI5Q&JYD@T_C=/+INDE MV<1:.:8.,DB21$G-"+UP>RHO=,SM*8Z,F?;4T5@D#IO.^H-S2[/]NFW@W,(^ M5K6<$IHXUAH959[Q]\_=W?WGAK2=:^9MQ]Z&6Q/V!)OX/*"1V8#&;))1*Q)J\?Q:J626)-39Z4ETL?3V8F&*R>50F\< 7CD^B;=*QA;'&$CFL M03UIU0]:)ZVK5O.2-5"Z.FM\_GAV7XU=!X8"DTVP:+X6)&_%1^N&X_D MR6H%USCYZ!2%/CM&-L"6'>2\6L&<<,JL\/P.8^_IR73>_5%$AS>)9#@1OE^Y MFK81;4F5DK92RR?T=APQVKF(D''G/^] ME[Y,,M8VP%XY"-.@LY@'/0LQH%N*FU=LT M^4^(G96+AD'J5"M9KAGF9/U\R'I2H2XD:W7E!BQR22S6LDS7>5"Q/>T$'+AB M\>;1^:E7#A].W8/O(UUKF%[?TF#S<,!D>N[9\U*]7"8]4YFTM*I=N7B4JUI. MUME5M2MWA,R)JEWIDF-V(/)EQG1>0HB=(R-#R%@AMV'8A":T7<&(?:R?VS>/ M/ZM2Z_"^_E&]-3<7+UJI"&8]=3K=>F9VY@-7Z%E1Z,N9HQ/*>>5RU%I1$2NE ME>L.N-'):31==8PLK7R]5BZ5P+AZKB73W(1\>58+1T:&D+$PT!J3>L,2:F8R M@NE8OVP^?NR!]=CXJ_9*ER>'5]]7R6C)HO7(K<9<:>3TYJ*\2=4J:9U\_ MMZ7B3OJWKK'QX2;@Q[ +4?@/>U2TY9I4F[GE<\T]2S*W[W>7_*[6(,3\4T?P9Q:NJ^YPAT^*-K/" AU+2!4 M!H3^:%S(]ZVOMGJ;#HA%TV!2@)'>MU/2)IBW3H_&#>ASNI*W18 3[7TEK;T_ M&V!I'^LW)#G!\I_E"M!_1EAZ+Z2G5[9J/?"[CFL^$B.!3C5%[?SX=*<]#LAL M$O'HCU<"8B03BN&>G?I-8\NU=_+ ;$$^B?!6().T\YD&$?[*C2: M"LADVDR;])(,I"*)DD3_MRQE4E$]A9MI*JTL()"6YP6,. P[3J"WY/=%[6C0 M[STL) V3/F)YVCP+?,_7;'2QI]<_Z?D]Y]:K?KIM+P3 &3UH&HKZL@<0,L?A M[V_7WUJM5L_55SX!>:43" 'P?GR]/VY99R>.M>0)+$WY[ R68,WQVV0<>XJ4 M?^^XAD?L;?!F[*32@ZE*NP9SSD$FB@]5R=I!)H-97 ],3.].(^"6$X$3JGJ, M%VD&=HPK!-,6_"Z!75B6<1[]P(=HXFT^_3KAM_U0-6P]/J)!\^> M?RS+E>GYQSETUCB!;(U $@9DYY! 5O?FN[$P(7A+.'&@@3+JK$._.5%K,_Z8 MJ*"U]EO_?$V^DK/?VN;BA]N+ KP?^5?3\8#B!N(!-]-GRN*N#:?7!]JV?2_5 MN3[*[:#8;E:_ULHKA176BVVH&]V+(ZEW#PW%.SM+N9&!09)X,I2I5BJ ME972A$&2-E7LZ6(8JVRKF/;:??.1CFG/45DCOK$I6NW\,KN_OMS_[I'%3MB\ M,$EUC3#)IO9R>'M]\;7<#&KM4B:B+2L1:-IRVMW&9%;:2MHJO!F1F_2!FT+D MH:!:92]3!&X6L=^,P,VFJ+5TW+":I'1:5 MSGIQI$71K!EQI$WMXZ[H_.H[I>M*??5PU&R+:G$X:E/[J!5__3)//I7_>HMC MSEN/:JTD-RI9"]FLLYE:]B)DJ^RC)&<-*>ML1LU!M"TYS/8"8R5+)4.FC(6H MY>E8" ]SY0-U"7'.IP] S8X_+!N T@/0T3WX"@! O(.&8]/X4MLB,_3]CQ_2 M8_?,[I9+64]185L2#E"<1YL2^@OS5F8']]:*4ZU_]-^]X];WB]_?FL=S3*TY M02MI.T&K]3=6/K3<7Z<_OYR=_LE&!(MMX"8=_!/*/FUA[A-&LM;87GG]9*-5 M(UIA0Z8H?V>2N@\V&]Y:GZK-YNWA-^.V?WN_V..>%^M:E/"P9*QK_8W=??WY MT^C]ZEK5;*09K47/J^6B;3T MLZ6ULNSDJNKIC"E25]*'P7;,G<2Y=A^:%T= M:/KJ\;#F_HQX'5NG-^M31_CA;=621F'0)>+P=O>P&9=?:TFEDPU)E+ M\R(Z\JN'/+>L08C>//]EEL[KO[LK,U]Y>>;;XH[:VJ?:V;>O?^]OYZ2(;YWY M-J ]*JL9>-L/O*VSI_64_,J*<$;JFN8+AT2G< JJ+ HH843ZK\HNZI0Z=;3@!;4M'TM,OF8^]>7C?!+IS[$GI=Q((E7/&M5[__JV\K&=R615 M!O_,N+^2O-4EBE7/C4_E>^WSR8].;>@$C"\Z)SI?67WYL,#HZK3Q1_=.&M5N M,<7RZ\*4F(!3%5)!]+^>D6FXI0+7DW&"!N1RY.6B*B]EIZ>56IK-H:L**DGC_" M_>'<$4NBE*FLW!._6,S(*-_$8&/<,:T;AHG@:=:Y9AHMNZ'U35^S)EWQDOW8 M^_GG^%C^I&<]2V^T(_";3&//M/=TMBG.1FNPT0Q"6<)47'G\DUH!$W&I"5!< M N>5=)+-O96UMEH42Z6:*-62@BY9DCX[+2:1)83R$B-5 M/-C'=69WR4NEKFZI$MLS[PC+5MW>N3$\;Q3XI]UKK2'2:GM_#@K%3\. MOK2#SDX,ZBU,-1Y*=0?W#W02.P *C@7[YY,5GFRRP@+>7Y* 4^L4>'MM02 K M-;%:2KJ?2$M-&T7II);A5/RLJ#A9G:7M9#*'BF55+!53FT6[I>)U!HE,. W< MN=ZJ#<>[&7)DS#1)XW>>-,8]-CUD.*@X-#OCT^9.];/@3_^';-ZK6[% GW3P M7.JA(UR59V74US3U+F%RINW5-14@E$4)M+1<2GU?PP?2<2I=3*7))N7J-R!B MN5P59;F282KE!B6W83@R\H2,1(,R/I(B-GVS;AN)YF4XRWAH5:K2^9>F>W%N M&-M)%%C)JE3V2YL?:"S43P_7MS/7!6U%'4Z7%0PG:%MDHXKA/\MH\-E0[&RJ M;")=+V%XKIPB)(NU4DFLR4FIK^DIY^E,3TZX>2'<9%MTB8O?B=PV455442VO M/,)[)X0;Z;:WO@8X^E H_-N//YD-GYC_W/="3W-O30 /ORJ-0ZP3.&=W99@3 MYF!,;**?!Y@O"2EH.M[\:?8 ,Z!MQX<'^ Z=I0.T2/TS>DG8,6W-UDW-@H7# MXF4O7YO=(8+8P__7WIYP9!++>"><:[<@:"[)WX#8.D!44=\+-)L5UA3V]D+9 M:9AW:3UF!L6>[_0I),,WHA^4J7"GS -@65;(Q%0>X-]P"'KT]_B28,I96M\# MR*)7[X5[T_"[>#S2/TD38&:[C !?HJ1(-I'9^8TM]^K#T5[\(*,C?"]<#?H M0=T%B:J_%TY!SK)C/G7P0-7XC]Y&O\)/1O(E$B[_OH6#3T"!2[0_>VT"8A8> MW:<8C!][.>'8V7D,J2I&*R/ZZX\M& <3P:?4P)EI&S"/"G\Z]S>2I+Z*--[Y M!3@(Q\W35J-P];%Y43]O7E^U&I>BT#IM[(O,4;@^N&P=MNH7/_]MNV\_%!IG MIY=G)ZW#^E43O0CXYTOS].I2.#L2SL[A$5/LR_E%\V/S]++UK2F< MG%U>;O_4DGRS>Q:CV2X)I!,XD;>J2N4;659O'DOW]MUC^:?=^P)FC1?T8(,# M^A5@^$C;"'M"(ZZ0AA]X@M,1SOK$U="*\6B]SM@ULH WR*^6/^9T O'51-0L M5<^-K<7*YOC9.PL^PS'AN_]]I8Q07:S5;] )DV1)OKD9%6Z>>E?DL=GR+K3B MI"*:J?L6Q!#6%!PXM%4I+A.7G8)G6SY<]I J(2K5(5+#LLB>UOSDU"Q)^IXE MG$[6[#TE3H>=->:&V%Z&E"AGADB.')>"A\[/@&BN)Q#;(./5GUDCHA0W-B^# MC)3,D!'7'[G!4^9TPN1USE'L.B>T<>W;YD,?+%OBU=N>C\&[&_/@YO'[]]/C M@U^?S*.?M:>ZN5GC/$*GZ?28^DSUPR^MT];E%;[UK4DA:?XX!Q>J>3F!,'X= MF9GK2(Z,#"%C8?W+!?' PM&[==LX)'?$A46A0LV MN]595U[1:N5_=GFW-9>@QB^VCERG1V]D)1G^ZSNS;F?EM&UB$A*NJL6B6*NF M3@O<#H;F"@!.>D]'>BHCO5FWJ_+*^:BJ*)55L2RE3@O8&>$E:@3IAD0-AY,/ M\8+0VIQSS67I0C&M\%']]/7BZ,='WZIDO:?(+*4@T)P?^;W@LFUBIT9_P*V: M%7CQ_*KU8P8CQFEH146P<@.)6D542ZG3;KF!G'=26B385\[W4DIE42EGN2U4 M?)K+,;&)JUEP>'6C9]HFQ@E\\XXDV_>N?E@V;U7/+6O;:T&RZ5A3N$4JTK6Q M3?+BBXP67RR@RM5T@[)$WXK)%,Y*J0JVVLJ9<+QVB)/O O)=H(\4>77B5:2* M*$O/M:1HMG_ ;;+G&K3DR,@0,A96%TU=1]%RHIN>'YJ5/>^L=?+X.RC=/'J& MKK4?;W\19950P0P#,Q)HN/5W@B(E7M'MLFA]WAW6K/LKKMVSHMVGR'E%^8BF*):4LUBI9[KS #5!N\W!DY!09 M"WLM#P7@J$_.C PA8^&%\JEC.^-"+_0ZQW+0C[^4Y+N?S<'1 MKV)>;*PSK/C%0M^S+TU.GUFE3XZ,#"&#:WI.+QP9.45&HJ:/C\!MV7?$\S'9 MCNGY%E;9P3MASMAIJ_EX>&#?//YQ'[\?:$>M7V25>K-4=WJRM.$0<;07P:1; MXU2ZQO7#+#I9+9ZB+C%T9,(#5L5BF4\6?/XTM""8HJY\\:J4BV*Q\A3CS]+* MY\:8?&9G%/I?<<<,1?3IC6'>]+RAF-9^_WQ\K![V/_]<);=W<97&KB0V8=OE M[#:?W>(_W/.(OF<^['5-PR#P<* EQ7QHNQ8P2^G5A[TA/%Q29@!U"T+.<]A^ M)6FY^=:P,\0"S7T'4W($:L^_9D,$,9] \?CG_+>ME\,BMY MXP5R<#(4#B V;W@^V"Q3"T\(%J1'Q&KHV"$)UNB4A'O3[PH7L=KH:?TQN4.> M#[KK?% J0E9C@]5T57'EHJ6J)!9YN1VGYR6]U:*RT%M]VN3BD692T]R9AX4R ML>S$GC]41=U/=;_S^>+D\:?UG&ME9E^[F/E6@.Y4A++ M4F8F,7/%\<1DNR!6MAS=+G"ABDOT@IJ5I%E1Q9*R\J2H[ X2Y]D<+R^!@",C M0\B8U=0M=EL8):BCM&O :J8=@' 9SNM ?B-1]\5P-A;MJ:.VCY MI.>!/$6YZ3J6125JE!""M38Q&U8[;9T\MFJEF\>+?JU]),L_OS9O=YH'NFE[ M%0MP*!@'S:.SBZ9P5?_!M7Y6M?X627U%>W?]\HX2V TE42UFILAVLG"(T_^+ MI?]%=O,&;K1$>)!8K&6FQQ&WG+FQQI'Q+)"Q,'H[%)-A[." V*1C^C11)#1S M!U???IS\;#^VK TFBFRWW(E%7-&0C3H2<1+=R!U%2>(9=7E%G?S$J..&1 ZI MBQL2'!DS#8GXI)U3XD\VJ(DLB)[6:)V>73TJ@73SJ/\V/ITT=+?S-]]!L]/F M%85B;-3QBXD6S)J,DJ% P1A!KA;:*BU1;,-#6YQ8MTFL"^)0I26R#G@O?]SJ_C4EX"6(VS+^<7S8_-TTOLJIU@8W+: MS@QM)FV JH-<4F0OG\'C'@/==HGGDD+!_ M1P:!)(-)H-6O;K\4W9,!*>?%)*![%\8V+^"^*11[@DUHT9NO/7#ZSBI]]JY]/@P F\SO$J94]/WJ<&]BT$PXT+ MMYII"Z^Q%\.;J 1WU)"!-V/80,'K!HAPM=!W>>5.94I9+%7Y+&).:RDCU^65 M.YK)9;%:K&:#TF8E6J71)A=$MS3/ QV \)]U+F+G3."D#TG;GZ=4BLVK7Y># MXL.WSQOL1[WU3CYLSYUPUVB[1O1%0;'HYE&E&+!]KDPVT8%EEN0XIE V2W2+^LW .N6*V)\-@,*YABRMC(D>,2@*L1N"ZQ]<&5 MJ]D>VTS=-NA?%CW_NO$[8)U*HVC*M+9YD,Y^2K?R;^='Y]DT$0K/AX)"'O2N M9M\2P1^=2]A).?1U7EX&16:*@Q8,+-H*"ZRHZY8H#)K(PRAFIH:>MX#@])Y. MR:[<@:]4$=5:E@E^G1O%"=^*QS:>:S"9(R-#R%C8+F).LE'8M,R/&;S6P>#Z M\>+C_7UME?#*8H-WI>1U9;^TH1YE"U.-9LG>=4%84>/3907#"=H6>;HTX=E0 M;#E3> [MKF:H5I;HXWYZAW.3@T7@F^Z2,8"90P3@6@M/$6ARW=[]K^ MS;5ZT36.O_F_OI>D5D.Z_:K4 EVI>=IW^OZ?UM&I]//'A=7^_BTP/GZY;2L_ M;Z_4 TOO'4G:=_CNX*#;[GW%W_GZQT^6=OP-?F\IORX/OK35T\=Z_>9FN3V' M1)J\Z^!L4#OL7/0'I7*J78ZI]+S"O$M&]HG>0MJZP=7HTP[@ZIS!XBX*9 M,_"U(MAI+_U2@"WORTGQR5EFXO@_W._A0GBA$%:'XDAEXJBM7"E_I"OG]&,W M?T*XD5((3^WZL^;\TKY]"LJV]:*$\"+O-NU-XDY%\ *@J])&!7#2Y-L\"&#N MM7-'D2,C3\C8KM>^:3/L.[TV(H:@ 93:+1E3D5YD&5 HN*.^?%;'[@S%9LQH MBI!:9S@]#7IMXIYUF#H\"WS/!UP"HN9X\5^ENT;S6U7^'#,@T]%*%JW(&0<2 M4O/4N20?R57KHBPYA[_O_[33'\D3FYCSS;6EZ&0U/[J:]F:%FG%#ZRV=N;DD M6E?+=_N(A/Z:^4@8C%.[ZV]K,YN$^9*0 LZ:[L$#!X!\P79\>(#O"'X7Q8U-\\+I M<.F.:6NV;FH6+ QO8-:UE^'-[A0?[.'_:V]/.#*)9;P3SD%DO(#!"WM[H:5AF'=I$_,9%'N^TZ>0#-^(?E"FIA!K7J 3RPJ9F:8- MX=]P"'KT]_B2P Z6UO< LNC5>^'>-/PN'H_T3P+1S(DO 'R)$B,Y A(Q9VRY M5Q^.]N('&1WA>^%JT <(ZJ[6-O7WPBD(:W;,IPX>:#'^H[?1K_"3D9R)A,R_ M;^'@$U#@$NW/7IM.X'DG]"D&X\=>3CAV=AY#JHK1RHC^^F,+QL%$\"DU9(QW MGHEP&]ELG?L;22J^BC3?^<795?VX>=IJ%'#(7W5:ER*..UX7Q3JIX?" MY?7!9>NP5;_X^6_;??NAT#@[O3P[:1W6KYKPX17\\Z5Y>G4IG!T)C8_UT^,F M_!;>/VM\_GAVOJ9[X.[LAQ"RC_?Q+-%9JV =+_ MD.@$+2!!E44!_54:DT/+)E];2Z+C=%(SLOU52;J1Y>+-X\%WLU=6-?_G+?;# M"7JPCP']"DBM2$."C=Z(*]'A!QXV#6BP8DW3AO<=_4_7L4 @>_^?T/P;F/[@ MU?)'F4ZDOYH($ANFU[&;R3'CK5WFS"DEV%F5'AP3OOO?5\JD=IRI MD!=4/JQMO3 K?YE2LBF(MA6+R JFA@4R!]+-T!D?YZYTV2IGAK3J/?"#?$Y:7 @\ TR-A,#ATBS;H.&T,7[5B]6J5]&N*]=& M9JB \^L25%!>F@KJ "]&R33K7#.-EMW0^J:O61%%'%Q?#?[4]%+GKYX9B@A! MY"2Q)9*X(+YFVL2(DLHB6OAVU*G_+AN'U]YM9FCA]2'IF+KI+]':Y4530W%Y M :'K02^PT(&;U;4B(I ?K6KSI]KKJY=:9@@$.VIPVDA%&XV;Q\O^T=?F+^7G ME_-J9C#(R#-#.*2W-@O3S%Y&R" [?AUS;"F$!S1J*<1\7/;&T$EE$:<,D13' MZBQ;;U2]R'&6TF]/=QB;=M.&?@2[,D#XT*/8,^T]CK2L(FUDVW$*9ZBL MM)-$;VGSW1:4,J0IL5BVQN+QO%W],Z@V/DG6J&/O@69IMD[$L,W!?!US0, @\'S"CF0]NU)*56>?5A=-4_CZ[E672]NXXB M+Y/#UNBU^M3$)7'BRCAQ+1+?Y=V([X2R%M7_>_SIZLO@LMK-LIR=VY%E0<^5 M.F@B-"A8IY7H-&ZF#F.\!TLM[?"_F3U8%%E4$WN\:I!YAS4N>DO@-2GUN^-T'V2\S:&B=[5175BBP6I=0SMCCU<^J? MN'?>"ODGERI.T+VZ]HPYI216*A5@@FQ:.K/N\CGM/V?:3UV8.<$.:=OJSF:' MW M#?J7I>%?QYII8_'% >V'?D'HA!&S QY6]%WMX>:Q_'#ZUZH>W!W]KFPE52WR M+?$ 60ODC3J6X6$(>G@:@C\Z K*+9P"9X*Y"\WJ;<*%T6[QD#*/2)7DA7E$ M''6H,>WB3&1\?"Z$!TSF?V M)0%/WO1-XM5=TX./#N%/^_8<@' ,A@8:MOA9T_^VW--BX%=7"%M,W!_O*%8Q MVC:-2@A KCW-_4/H]"H*BS?P\H6'U*9>B9MZ&4,=9Z%LX"$U M"Y4Y"^45=8L[GW'4911U/+B>.=0ENGOG5ZT?,WV]91V/'<4CTG;7FNXS5*V) M $@VO$%.H9FET'%Z4Z1G06^)T8=XX^"Z\3OP?&P%Z%TY,QH@T19U;HP3[,JRAE\3Y!9U/#R=.=3E M0$U,*(#*LU B1&*P\G11BW/"X@13RVAY\:FPG@T!A2;$!//BFA*K6OE:UD- M^JN$'YX\*V*T0\R'L!T?OJS9+"'"Q$F;Q)NC6YLE\K'B'NM]X_-.Z'RPH=IK.*-DR&*U^5R1FY)>/$EUWB6R(D MIJX\BZBD2&*UE+H)/Z?&;%J.*K_!RBWJ^,U)YE#WU#I@0KJO?.%!I7LY(](] M,=Y5&]4#S3O7"X+'2NA7+ON6Z7LWCW>-LU[_V_'U8?'/YM)K-EG6@\O!-H0. M8%EPV0X$#Z'G_,?C5CG 0VH5QM.?-Q2W4M/&K1($XM8"53\._3MR=_[U\8$, M U5SA%M68U331[;9:$ Q;8.[Y*!432P74\^%Y>R444G((_AY15V1MXC)+>IX MBYC@NGKJU25^J%.*MS9'!D<&1P9'!D<&1P9'!D M<&1P9*Q:2W!*?-9" AM%W#S^<+4?'S\-FE:ON/G6!.R'[P1YPQ4!L ?:"G'& M"2TI+E/EXL&&@YZE$7!$>)!9KJ5-QMTW3;S@Y M9U[TE1:G-7#1]\QI9?.B;T*V+3'M)I^R;9TL@8E %X^?/M?X*4<&1P9'!D<& M1P9'!D<&1P9'!D?&,T%&4FJ 6J/5@L5AM6"15@M.U!YV'0O\7(\5#-Z8ES>/ M[EWKTGTX_^J>ZEMI*4BW>D_PL/%!%CC3D\ZBLE]:*\QP4#^IGS::PMXAT6FL M3U!ED<*!+G)*CW5=(%:,==!E!<,)VA;90;AC5)9:CI,&K5<\"WS/UV@)*%)& M$C4M7WMZ[I(.<5UBQ,M/$Q[3P"$H9QWZ+?:(80\!V _Q#F*M%Q*?^7AV6;[W MZ[+6P(FA84GK@69IMDZFRE>71,6NHH/EY:.#%.BGBP\^-Z[YSS+QP:) M'I>EM#U_ITA9+8JE4DV4:C*G:$[1J>_65R3I5!E%2TRPF''KKDIBI5(1JY4, M61EIDXHX/>>(GE<<6URJKDWBLJR*I6*9TS>G[XU;(!/$NO*,;54LEZNB+*^< M_+03TR+Q#D!>[0[@]E#Z9)]\MK^9UC D8)A>W]( -#@ 0'K>K@18H..%,O>B MH%3IN<7^KR[;=Y6?UJ%\;F8NUI4RE%M9W#6+NS O0B6FO2Q:/#*3$\R3BEGU MR6+__<[QH/+K3'WX+F=.'NX^]E])VVR?Q_[SP'99D=-/$/LOKQPPY;%_3KZ9 MBOV75Y[XRV/_G**S%?LOKQ\8Y;%_3L]9COV7EPBG\M@_I^\GC?U75A[BFJ/8 M_WACP/AT[%E\?>2X!"!J!*Y+;'UPY6JVQW97MPWZ%X@%^.L8%!X6GQ\0.$1R M072,SYH=4]>B[VH/-X^&9TOEVD69?"6;[S>(9_9.D*4-GV5X H(>'H'@CW9- M0;F%K?.ZE[D+\4ENV)\$,/&F;Q*O[IH>?!0?#\RP0.,4 MWG7@W+>:OTO'VVEPL.60Q>@$:'!" ,+M:>X?XFMMBU!8O.%!< ' W:X8"">U?YPD-:.Z\F<3LO8ZCC+)0-/*1FH<4M3SGJ,HJZQ17K''4911V/K&<- M=3.J/GK+.AV[B4;4TI9;SRX5*:IB44U=L+K%DA!.I=FBTMGAA]H2 M;5&S376)(8AX%Z>Z\3OP?.P,X5TY,TIN:?."MN81 S$"Z*!'?T'^!J9G^@06 MOC-UP@(_@"#GUJ9/^:99 ;EY))_N?M0N^[]__:CE,6>"U@X!%8TV+NS!<^!- M%JKHXUL\&,$]J3S@(;5-QY/4LX8ZSD+9P$-J%N+% IE#W=PKL&U;0LLZ3.G; MG]16;D]:4U115FO9N"[C!+NBK"E*_.X@MZCC,>O,H2ZS:F)FQ*(H*<]"!22& M*PXGFTZW/"\@1CS=A)X<+$0_\6X>S_]\Z5^I[M5A1\ M+F=5[A3E ^IM1U/(5\+=:-^P >+A2+K.3N2BEOK$/RK>W)W?O>]^?/(&'8( M3I1F4_V"=]P":N$9+>FCS>^P6I33%ELF]PJNEJJB)*?N<<89)TMF8BI#9;/D M)JT\S*_*B8P3V=)QIZ*T<@=I6:R55;%8ECC=993NTAIT_*(HMZCC%Q290]UV MI?V<\-'*-PA,DB_1BO<) DC-E $DFG1T\WC/E_\SF_"BF8;PKWF MNAIX<*$;1N'0?,'I= CNG#,CCRWE ]I]9G,\Y#_?_:^M#EQ9%G[.[]"U^\Y M-WHBL(=]F9[;$1BP3;<--."MOQ "%:"VD+ 6V_#KW\HJ[4@@0&)Q:^*<&=N@ M4E5E5FZ5^61(L:5RT-@2%9B1Q95XM,2:LOG-83Y7SQZ&^3_P('0NW6=9,R '-#;+Q769BS&''RF%!6H.$ MR&(;Q)?2NZ?A'X;OXLJ/D$RZ&/OF9$D7!P9/EG2'#@S:@CB[YN[$+!4I2P5^ M47R^8V+$Q(B)$1,C)D9,C)@8,3%B8L3$V+8*HHE4"H>63\THL)/Y0P@<6$NM3<&)>B7F%\LKZ M4L"85SXYKZQ)/7"X.1NF&720RO(BXNJL+&(R*IZY4[OG%^23^4P^F0)Q,#4F1DR,F!@Q M,6)BQ,2(B1$3(R9&3(P_A1A>>0+92\]Z3%=!YT02L*>KT)+,/E_O+Q[E]%OU M2I'8ZVB*WLE2WQ%L-@PD<,M)!)F+_$Z!ALO*;:59K3/G-30DT3XFFTZ2>< V M!/18=YW$EM$.\EJ&D[2!@/80\+!J?:MVUJ!%JIJJJ*P(NP*<$4YU;UM&(R3+ MB+,7^'H,4X7N+JT1^18=PFB6"NM!RF55$@E;XGWR'',Q_#E]R_R:?T]Q+V;1 M\"4KL.(0+94%;TB*?<4'LYO'!\FD#QM-O$%')P]7%QZ[M\D9!J]@-;%Y!7LV:&-Q;[B$8A*3)IG+ M9;<-B,?'[E/*Z?45] Z+.Q1.#@K\L83%4,P$KHF/V3=FWRW9=P.#0W]$S M=="THIB?3XB?M^O)G,MF=X?ER923I7Q@].>8OS\Y?X?)WBYFW1ZR+)E*9Y/I M_-;)3WLQ+3SO /+;W0'<=.?IUUGQ1^4]9X8$.%Z9"2R>&MX 3/13NQ*@@8X_ M]'!OA//Y&6+_U>OZN+MX2/V:CXXNUA4PE)M;CYL5NS!_A$H,RC#K>W_&#'-0 M,5L[6.R_^C)Z9>L_\[4R>W3R_,/B[M++=ZU*_,E)7'/)XLNE?&7(=Q5^@>@ !58K"L M!OXGB 0@O)D1+[+BD&<%_&(]4*3L92=/E_K_M60 M.,0S*N:_,J2U#7XG=_;MZMR^D<86?F5Z\QF>045F!_SP*]/$TIQN H^ ML62:(=+^_1MOO <)9,2^G \0%NUXZ!FAH'W;"Q[;3O?#Y"H;KUC\-W.\T#Y- MF#[AAO@P13%G.A)H[M%[/Y7*GQE:MMUI]2K7]6:CFNC=U#N5=OV^UZAVDTRC M6;U(,I5FC>G>7W8;M4:E\_SO0/[[6Z+::G9;MXU:I5?''_;P?^[JS5Z7:5TQ MU4KWAKFZ;3UV3VM[O$@:3( 8=Q#95+Z?3F?Z"RW7$C@)_93N>2Q>M"E>QYQ\ M!1]@0WLPYTS5KF#,#Q1&&C%55IDP5X+T;MT6QMA!9^NS; M!O67!#%H:3Y1A>2.CZ@U(&76)&J6$G64T3CM0;LOMWX?$U&S1T14Z@RM@X+Z M,\1$X6B8Y$J2R?3 ;9DC5F:0R&&=8J_0/C8>"@ H]F=P4>9HN"C6'R=#IZ-3 M"8<\SE'3_8BG^X>OWK.%2\;9P@5 MDVE4JKW&0Z/7J'?WP4<>4:X8<>A0ASHF1F@RYLJW312/7+RH474K7^+*/VMF?]&>CUKQ*C" M79K?-:SQML)_]YI/$ +R='[W)(&-D:>CH8U?:D#,;WODMZS9Y"'KR6UA='' M R5SY>(Q<9NG>+^TB?<*]UM35!*9[TD=A'=NR O(L9\]:6,C,Y7&9B;;$XH# M;9BY_. BL3,-;Q VC%X=K'5.=]Q;VV;1@)3$R,:6,:+>@!#^"C\/X9)#PWO% M\"(C&;O%L.9VQ4;1L1I%,3&.B!AK+=0:FN%3R+,@:['HR3@-U$%ER-__GMY< ML[GP#%2GZ,FD0D[3LJ^(01\S)"KN\N.809TO6FT?V#=T.W.TL#525CZ5S)0" M9V+'@NVD^&:-65G8NL8J@ZV>=.DXN&9M'))4-UZRV-:!#' LK7QD\:]IMW/Y MZ[?\U"[MP2(,72R3-.+S :R3&=H6&A^Q'8Z8-^]L*:0WJ)UQ'K=R)IM,9\O' M<=YB%HJ,A=;)ZZV!?@J%0K*4.6:!7>HC PJE@_"K%XB[9GD1//R6V&4%U!K= ML?(+(EF!7?Q=F7BIRU+\Y8[+3WGI5=S&K3^,06TLF/DRQDO^B_KIDDAFH>"E M0U+BU%P\HYBKC\_E-F&Y=J_Q],\F3+:EN"_L'K1+)XO9S %.K3LH''-6$(D? M#F.M4P(;]+QT*8%L*IE-!PX 'T )V '<*E,)2^T%49:M40T-U!JO#+&P5MLR MFO+:=%GT\QJ_>!@+OXJOVP13#F[ VU<,(I_#:V8X?='Q@5Q](.T/KH"2*JQO M(Q%;S\<@2PWK>:T8V$:&%K<.EY7RR6(Q<&'W80(?AAT-&@AK'Z2J BEN:8TJ M0[)S2IN=@R*JB!S^BZPA[I9G![Q@6M3-/L?WIXI-M/;X._%E-"R5 0#B1,QJ M6#\VH[&];.P 2%56WP,RF1G="(85.?@ MH(1K+V@FT[_S;SSZH21$<$3P _* ML0&^DP&^'7=N9XH7MT;@*:62N=0A B^Q!1Z.PB]F#ZSP/:5TQ6;H-L2AC%@% MU1#]KRUY00>5LF4N9"[[BT+^0?T8#^X?7M$GR5RH3EAQC*A(=J8C*%AX*T0\ MV\1R?#2.]38\)L81$<-3\N172AYL4\]8GJO32WTL;[++IN!+\U;*3KY7L_+@ M9$Q!?5U&MD(L079QR=:QS98V6M"V=?[ATG(Y6<@<27PK9JH-DV2WXJIU?GY0 M..1EN[^83!TD+29 @NS52A$>T,?/.D.GVNWCK^&L7KSY7CS)T*F^:"^'GDPE M%OR1"/[H7/;2UKE)N4(VF8[5P+&RV,9J8&L>6Z,<2KNWL4N7LLG2$5S0^L48 MC$CP!INJ:UNE0P.=;5:&SDEN=9'^N+\LW[]W2C>C_?H 88,/5-9%@PW%P?SO M_RMETNFOC@CP/#@2P/Y!56V@"/N2$YO,(\K8\H[\OJ7&VKTDL)Q/8A[;%I U M?2#0X)B[P^?N/3/W.E6Y/@^;I7= 4-G,[XF-R,\:58V)<43$ M\#1\LUMAT$!9<*\_52TK=\I6J_5.=5%O_NPO=^LUIM&,P6BBJNX/R&);VI4;)'SZV)4YZ+:2S!\D]S-.9#@D=ZTS[':_ M=,DFBRG\_^)1!&"'$*N#M0 M9UD1N3M6A?+*N6_!N(41.KV_Z2_R[?3STW"NI6LA8H1&GL](E\V,\+H]:L1I MZ7A<)QY&ULO&++9=F*>\-3I(-IE.I0#>,4YY^7/Y:TV@I[PU=$@Q62B5D_G4 MD214>6J$E%TCL',=+[0R?-5X&?EI 4=F.]$$I<'XZ;*:_O[]Q^04DR#;FCR< ML$JL"J*+Q@9BKBWE_P9P(2XPMG(QB0_^P>.O,3?MC9O62?NM,4(RR6(!B[#@ MO;6X3*W[ ^N*$PNKTOVUHV]0Y M'C:-K]UI/31J]1IS^1Q?"D<1B0O.95NY^/G4UC!$F60IA?]?BD.\?R)CK;/H MMKXYR($]E\R5#E'!N+>K>E\I'9^)3VM0Q,0X(F)X6G>%]=;=%2^RXM _M4_X MJ2!QI-WG^/&IV'+NW+ZK1K/2K,9FW.DP]972)#]I-,)/B.,D:=^*OVW\ 7N,2GSC=\@;O\#I79H9X.^(3 ML8-5=7B>W-):VZ')^I'42,:L^BE8=4W:5WIK4-YRN70K=E%-Q7>?A_B?S0B]$3OUH?*#OYJ=5JK_3:5Y M70>X7HC^Q>R_@U[?+P-N:6YN7:J=SZ>2^8/ KL:2^3.PYCKS8*G)S8R8V+X&IF781F9FP8Y^6Y_T>F6RE..[U1))*9 M4C%9*F?C#,28_T^!_S.>_+]U3D6-S.4=WW[EJ8">2W#2=I 0*'J MB?]L8BCXS^*3VPJ>(=[,UO@[%5NF5JC6[UM=>\[]2Z9!;9^3=@:IM&\:G7N M*KU&JQFS\[&R\@0TH&=MC;9;GFD@EN!:+GW?UQYN6>O/"ONRA M%4DZ(&#]SBXU%IUD)C.\5C '&5Y?/(,^9DA44.Q8'-2QL#^XHIPMLSD60.R) M_LD,DTT=)\-X"N>T0S@/I2GJL1](<@1,W[",O.,1RK!H1H55 MQ^?K),[7^OKB6"#'#&-CF.QQ,DP<1HN]JY@8)TJ,0,F:$#IK2B+45UOX]R+G M@;8"5PZ"I&@R?G]43Z5^%JSU:0A- .^AZDT:ZX>'KU.I=D% M1)]6,X;S.5H6CXEQ1,18VPNXJTK#%P#=1%R:^FWHM?>K):X<4,)RU=9@1MB:<2(DHH(MJP9E!%^^0)QURPOMN1;25%: MHE_G^/Y"SI;>,])D]M )$6K\,+K#6CJ9SQBOG\'* QO>! ?):B3OWT0^%@1' M( C:O<;3/\'Y>+MJ]=SV90^%9+YTW$(B9N1/P\AKE%UNZT:,Z4*RE N,GG10 M7?>O#/FN@FE+I[*T MB-DIS+F+4((=#J4I'G .73BH?Z5*C#I!P)*D4(Y5P1>CH2U6P"_&?R MO4]K ML7LD$!W\?\[/F2L>"=P_3)L=8['31:\:$H=X1L7"5^:!%328''-^KDM2CG]; M*<1LI8MT%N>J-",S,?]@/% @HIZ:/$,D"/HA)L( ?L>;,#1^=[X2FW<".U/P MS(R?OC+O/*=.8'M2__78V!7W''A^GI+".[A"]\_QNK-O5^?VC32V\"O3F\_P M#"HR.^"'7YDFEKITFYL2;&C!_M#?QE/PB25?#.'R[]]XXSU(@(7WR_D 81F+ MAYX1"MJWO>"Q[70_3*ZR\8K%?S/'"^W3A.D3;H@/4Q1S_G?PK=UI]2K7]6:C MFNC=U#N5=OV^UZAVDTRC6;U@_I>=8G;MWE]V&[5&I?/\[]^#;R>W1#H8& JC M]WXJ53@SEM!L]>K=1*]%RL"JK6:W==NH57KUFA'1K]PRW1[^ Z30=D]R[34T M1-,!DA/9=)(!\__T5K%W+46-P*8VQ0\. _M32!FR,Q#?LH9<9FGNS-V:@%4U M&;5&MHH;D)%&#*.4JMF[92Q]N;^X?I"O'EY+EQ^O5IY2*%OQ6U-4?C0/F0OA MH"72S/_^OU(FG?[*6 >2K#93ZR]2K=JD?/_(ED:#LV^MSG6EV?A%TM')E5JS MTKOOU"%E_?*^VVC6N]956K3<',%V1,_.T=#P7_Y;E9K%B4LS](4]II@&*R:M M_Y$7.02#IB[RO!CF0MJRI&(32>2'B=X$BX<9TK"UB1]HB,,+Y@L!GTBA&;]G8$E56YJ6D/N[%)V"53\/SC]A#Q^S$,@->FDU8>Q9XO\H MRKF,.1@ M:<:&U,$/7$5)*!-0H;JD"7ZK-M6(I$MP"#_%JQ>@@LVA\2CXCS,6XJ$C M30:1:8QEB%BG4.55A1EH"B]B(>H:2E D/%40J6.LH=\0Z86:#BI,"F\'7&.H##N0-)5Q&2OIXE=LA@QX 4L" M$.T&W $8+"PSEO1-!LGP6:7W22[DDL5\D,"V(K 180_,L=AN'>KI3C-)X0GK MO$OR"R$B.^-5S LLL>B,P >339.XA_.81914S(1OP$DCX'=$CHGQ#LPJ M(PW2JE3%QHK,C%4PB[TC 3\WQ7.>Z'V\"?]#LR&5L.K:8\L0&^:-Y042D<9O M&R ]RXN>%??Z$K[KHX$=YAU_P&G(F+A^3#AF,'D[Y(5 8*;!4VTO5=(4W.[7OXAN" F?N"/K#P,;[H=3P- M*<',!. ,^W3?>4' 8@+/!*]+&JB0Q\"A@9K WHF^@I&18VPL59WP,L>\:JRL MXHGC=^)YY^G!L/_[@KE$0Q:+&P\)ZLD2> $38#V#-2RV2*@3[ ^/)V0D$9^+ MB%G$N4<#)/!XSV$6+)%_,GS/0T#R]#0%DX;$28.L$5%G"':DZFZ3O@KZ,I^% M)%P+T7G[PDX!0ZY[+9Z3R 'E"7(-GA^H#0YD#_U8OY'#:@V,>F-%0)VAP"H* M47O$]\/DAR_)P,SX X35Q%32R*R6O@R\(O!T,!YD "QQ"M?AL/4B/@J* JXJ M5M>:P+EH@-U*@TX>NYK8HXXY>6^@Y Z8=BU+IH*M(PVV=]S&3(>/J.+G"^3M M*<.!!N@O,NG+UU9C_E3F\R?C!V29\R4/X+*_X+E>\^6#^U5K#P$*Y.ZNTGF& M$&JW<=UL7#6JE6:/J52KK?LF%"LP[=9MHVKO.?PI'(*P63.?>$.W7C7&/C75W$%.Z^7$ MIO]I3E05R>"6)&07/>RG9LIRQ#+$QP([+MAOX"7.-$2IQ0B7%&:B&01PL.^A M?]'C2#IDJA$@69I!@L:NZ9O)]^%LZJS?P7]@Y>%D*2!.SK(1]<:''0Z2<2E$ M+%H%1 ",*V"W#;L4:&J$@-R2I6J3+(FN)4_@CL5RJF$"\*2,)DA4P.F%Q-!3 M.X_[O-DUK1OT0?RC;RMSZXIQ;EVDN77%4\ZM(^ZLZB=DGS&;?=;TDV M+,)66_N.6OD5C_47%;66OGM[F?1&Z$1L_+9IYX&A/[2O+K;T#V_IK[?LC0"; MK9)Q&#II8D:<4Q_N;[1 ++7GH7\0M(M@0/TS?3.I),N]=(Z&D43$40 M'+=2I&;9N+4?L *X$M0<4&565&@9AMV.0@(_Q:O J_D,UD'D4FLI\_!>0:U1 M'2]N"B[7BJB$\XO]14DHSH8_VR^- 8@D9*PA%D>'%T,#:[X*" M2"C#/8(0/W%.S+@ =E->-1Z[-GB!(A97Q'_!WLZ4?4$6Z8E$P8Z1-IT9US6L MRK"DB:I^C3"39)B X9+AR9'+ OJH_4Z .$MF"@E#E1ZX5?!FOV=4Z]K$8]D) M[]L?(]+A,3?CB@V^HT.LVN_OZ",D#$,<2"QXAZJ&AZ>7_A#P@?L+CH>[/^-R M2L+GQ=RQ"\86,;=M)$F=$^;&BX*KES?L?UB7A5#5SD@SR_M[9V4L\.FJ$["+ MBF*D$7 (3Q("3BK[H=_@6(.Q@B"]@]:(U4$ =5#P,&+!#:(GLL,K+U6\T;P* M/[ET0\UIP_H]U5^\8\_NMU)1*UAW+%.66PO MXO\K5DZ(:;%B$6O)'_P5E5)SS$N. *6@21;69$7"$.XM),#9%<"VS8 MXH]),+MJY0YCT8F%-YECPG[?.V7GU"SEZ--$36$O&K(8, >-Z-C8,C9>"H:K MBN5JQ3M]8SF-:\"*+Y9-3#06C(_5!7S3_P4]USAPBPXZ0N8A*,$9.5N2J.6][TI8?0$^3C$^3$5HCL@=W_YE4$*=S.YM<_W%U>-M]&O4N:=[0U/ M1=0#*#*)-H/PL*TM%O/'(^;!J.0AFQZL.V;"CR=8R@DDFQN+&,"6I*8EO7($ M6!L>SQ[+GRE4RM&<-BQ99&2F7P'P#0CF]PE<8&KR<$(D&LVH(GH$6:QPD? 1 MT41 NO^:=>85XBF::85D+>[!_>3_TN )&-RM%3@Z(![@/\Z,CW(JYSJ_?;[1 M'\+(Z4PVW5]D>[^:']/[=*_-GV%]I@+%X&OK *C(=P+WQ"OLT#]Z34\\LD%+ MJZ[XK#I+5UW\+K;RN?;;78D-9]6>N".%[7%'UC5!2X++-D, GHJ$N2-Y[A.< M^D-HR\)23,P+?H;JNA7Q,?^'^HO;A]KXY;ZP:-^9SO$Q"?"BA9Y4XPHRZ2XP'0H@Z M_HC%#K[CSR34>L%8<&/,1!(@)8$ (>H!6NH'P\3,:9[CW\[I-,VU);[P1O=4 M&B5UK='(U:&QW[^L!>IWZAP-L")6%O$01LZ:'M.%_'I2235TI+_HK5K@'$+0 MEJXA/BQ'M) :B;8GUE3+Y!SVN^5Y+-FQ]JZ4;79.SEE/J@S)Y88G8"FQ[5/I M5+K?MZS\L)_KC.% \]D.>+)0V!IXLEQ,IC.I ME=X"EAEK7(:V+$%$38'Y=O&QKXCY$MD;!MQV5?H^EA]Y-&](VC&W7AZ:G MG\B4K0FPZ2RW)$9I6V)DD^E4*HG'\"4'[P,YJSOQIHS3@6I'B26R%:S*[HX- M0W(5I&^S/YNE9JD^QWN3[7=[^'1[?R/QPZQ)-F/LU4BY*T$N@TUO.QH5-W"P ML0L$*X*?L&3\O[/S)8CG=+*8S:P\0I@$FN@FSO*9JJWQC)RXG[ IWA11YEQ+ M&_Q\*JMCDR+W[O=O2)-5;M[RO+8DR]81@-4 NL'#1M!L\28T>$2IWN/CB$^;E+P+BVS! U+%#?K36^?%2:+5 M2F:E?EF_77J@ZOGU_6%RWUX\7X[VM%V>D:SB!OK8;[LRR6*AE$RG?2-YKIC6 M)P@O1!VS*B[=\&"38(9D==X6H*)1Y,#C)LG[JR]YKIRV3Z A^HO%2VW\5'E] MF9=.))QE+B4.81W62S()D8!Z=)7X[]AA'TJ*2F]D;*@C< TL VX3O7:OPG?T M["&%)CEQ/" A*GH7G.E,@WIT9+R".O7LP/K+!7,'&0-()($!R"R"]#->I@7I MV"F2Q_06R$BALH&G7#"/<%ED)'3A[X,W :)+Q1X0_@'/@7CN[X!%PO'*3 +' M3AHE]8B%0B?DMT""826CJ?1F! @<";C4]IK;4%H<'1QXP&\9"5B&ZC$$)U8* M?3TD/YJ;@Y\P7P^7^8J>PI6 %FQ0X7Y.:GFF2)U(>!EO>J6_D?D%3Z"1)C " M%MIFG9U1(Z3O$LVTP&_RL-W7BYU[\H);?H1 0W*JW9I(7;/W]=<,5QM:=F'= M0$!Y0EE2$8=_5 M;#QA\B% >7@Y0.8FVI_RMJ3'-^^W'USA[J-:-G?,ZUWK[ G[,]O9QJ6M;>-\ M*IDI%5997YYNHO\N9&3YI.EK0.TD['Y!"9<2_4>-+08) .A(:K@+"R8H*)*BS9C+]7 >K(\6C<,EI50GA8=5W6FH-'C"M6P:\.CT[%*8RM19" M;HB2)%F'P@KIW15M(R; BH*,G6Z5P3M#4>NP082=:UZ90%J_?;43'IM@\G R MITLEA=[8^UX@N@N\B,U54NIM):^K:#@1^5<-Z:!W4+= 9^B\ R.)DF!*#&2) MQ38NE&HKS)A_,]+P(4<*3\QX*4%V>M4D4KX-NZ_0&U\")T:WAQK1// 204[5 M+3BP+VUU"U]NX55,^J^$48P@2._N%VFB-%"0_$8"%?HR]0>S)X>I<+PUW*6X MACO2&NY27,/]2<]9J DY5!#K(AA\> X;AS(_@,0$A*7C/R>VID]COQ"-DT@S M#:J!C)RD>]%4[V%H1*+;>1*W0HK"@[!TXFM^AJW\9#R1&S]0JH3L)MH_'9J MLO"3\4AV66XL6[5&,,7P5!QNB9$B9F<$6\FQ"_J6N%$T\\O#7XFMYD-"9K"R M3 J<:;VU'V:Q)12\B[Z3C**!;*"%BDDKM#]CYX2I]-L!64-F#3<>9#:3I0\2 MUX;<,NP$VES,@0Y7K,](F4BR>H[MWZFK\@5R%&V2*N:F0W&3#<,$N_%ODD \ M=A>R&N8/$?3- !&,-FUJJTR294@R!51[B8+TRU.# <\%)(Y5R'M5>#P'/=A" MX! 47B4YLQQOBAZX+D,J 11/)D;8A#W7Q0X'^2^0E@H%K;14E%?4"Z:#[ !S MBH&M;T=E\8*)2S+\B(#=)?4\6(+A/)T)5'\D 8_,74,BF6;[:E-ZM4.B M)/)4L=50T;I124%&H 5!]BZQYY9WQS&Z)I([1W(N9>?Z\*F'")(-,_N30,R$ M'O!>QF8>3A"G":@U,L/6%2(1*R)W:\E#/8C(M<2.T8J"X,/V0!CZ!,7+&3N$ M0DNBCBG!I'A#"7L)H\.8.G]=GHY/9( M(/$+HDBG$'C+8[$4\FYEXD: M\S:Z30O=K![0"P82>OZ:2)))C5XG1#CZ=4SX?/GTCKO0TF6NORB\M$K?NUYE*MUOO=4G#H-M& MY;)QV^@UZEWFKE[IWG?J-:;59#KUZGVG ^#AEY5NHWJX[:1OW"AV&7Q6P:*< M9Z0YNW]+>2/V:>>)]"SDKO/; MSN<=04X)+%O@0IV1N4UX]^"O_W=F=4#UG.+2=/;0=;>JNQ!DLGJK"\?=9H"M MC7;>ITKL=,Y]^^![X7$(PI.[;9CTTL4IST;K4\C\-QIV=+XE'>XZ M_^->DYE]7RJNJ7VL4JP,SXK1\GVV4!3OQ?JO-16C20-RX\RUSK)KG3*P[ X+ M=3P(!2+G_,?YA.#%@9REZ\UE_.M+^@YL_ MWAB1=J)Y_<:GR0CD*VE]V 77Z8COV?+[Y.GWNO-AB[Y;4.5'Y=_57NZT3TLN/BVQ;HGHM&2-TY(9R*]:=SY]^"B>]FDI MQ*=ESZ>E<+RG98'2/WDI>Y\54?ZTV;IT;&QM..AZ01A-L[DR1YUHMXAB@KC5)@__$HY3H7Y],2.4V&.YLHAEEN?^=(L3H7Y8TD? MI\+\V52/4V'^1*K'J3!_ +GC5)@X%2;*N'A^FU08'9:2;;<_J:?.XMJJ5V!#0NI4NPO7@M/ M3\]B,Y-^G!P7V/\A-*-L$ M8, 1^HN[$B^C@2I7GTZE07U7Q1,_OP1DJH1]F7'7B,-G 7KVJ%<(P2B4V-!& M,-*:"J#X.+W#%,D95 R<0NBU4$R7S"X4=EKKIA5A!<;]02;]-9F@<+P$ Q'Z MA+E;/M#.VT-I+!)@1!,7T9B:T7[)P#1*B/"$KT@J&+\!C%F@.9YX+T]]*;H-'&8JZ]I W,!<$QL9G>LCDQEEE1 M?S&:S@1ICH":TFC$#Y&L0/\+\=SV >P012269 ,(3H>!(R.1KAGV#;'Z@Q$\ M[:$DBLQGR!1W110+X)?]6/^U\FDBYF/67"PHFG)WHJB?0T0-=!?#Q& MB%>!=TS&(6PD(U631;WM"V9I ?JN0#\:_'YE-"<'E<*U$G%"SE/2UO,/<$EY M$?,^14(%>%3]V#$#! ]2&%1)3O CG_F1_&=X>(($POM#TGB/_$42.)I8_8%( M'VK)P)'6^P[JYX2V&\1F,>1#2_XO4A)X>"H?"?XI'0Y&HY2"EG.VK3*QS0DB MJS'%)/X)2YH!8EC 7"6;3W9/@\:,E-IVV6Z2C (_ZK1/F+)-;XV#_SHD.,OZ M!$B3QW=HOX@_GC/2$#L(1WV>C[EO3#GN&T.?\$J)"*%O3#GN&_.Y>_P5TAFW MJU9G91% L]M([H*\7>VBV4$QUCS97RQ^/LO%5G/T)FA;.$$# M;=]$*O/E5E*4O\ L [$/BHBL-_;7#FN=46)]$4SB&%8"$ >L<;VO,@=M;;#L MX#G#P!:!J/0YO>,-S8."PBTLC$&@K+5"L(T$Z.ID3"SL$HC%%@:UW"],[K%- M;B^S2MAG-1,T:I1P,!OH_X)&(T2M$_UQ7E$THNW4B2QIXXGAEEG+M+#J]7;, MUAAT6#"\1#)WTLUY@.TA3+4$X,Z?FR_66^[)1"W )@"4OM7U67?+ "P?%#7Q MP4B';5I>A]]E-84F8\$>R@A;50J,#B]VV52AR\V M.W=*UKI]6 $77FGV&N>UQNU]K_%09[H !TY1PNM/U=O[6KW&7'5:=TRU==>^ M[U5ZC583GJI7.LU&\[K+M.L=IGM3Z=2=?'@"Q8M6(N7^DGHCSM8M!,[6]0BTN7KQ,QU9,P5$^.(B!'KYIA)8F*<$C'V M @E02(6;_DXS'ELTB^D3%JEX\X-W%>2.%U(5TIB>HNBFTJETO^^!I[OC.R[G MW@.X*F'J>NXHH2XEKE'^,OA8_"ZJ\^_MJ@6^2T WF)D5R'=<"9M7G_9+:<5= M!I,N[!7;(!1:G:VX3K4N4\TZ&=]==5VP%@(6QS2:5[:B&&H=GWU+)\OY;#)7 M3A]=7*8&*=$C&B=E'!O+!Y9F90N'/K&<8M;QHAM ME,*G]%IT>IN]HC+/TY_H]XN4&H5CEVQ"P%.U5?R]%\?N.NV33%",-V_[))[TJ#U]:E29W M9'AX1X)N4] I"D:P F NP-/]Q?3C5[HP ME_EK#1T]42B"@;$L"F)@+2P&*SALM;*#+IQ%%P,D32'X24,LS,84.LQ>\:X M;AKTH-@+%-@AV@9'+3VR2Q"55Y*,\*II:X_AO">SHD(5AH)% OE5H/N_&A$E M;9,I6X_97TQ^7@YG@VKSZB5W(I)&7VS"6"UC6U\L;8X'RI(VME8(3&$IFTHR M%NT8DW9WK*HB60&Z,5]TD#K] 1.BCJ"CZ0\.C0=5B^@$8U+_%5&T2:-;=L*) MYD$^TT=2M(&"#4[HKSW"1YM^IHGDU&![V7A1DADC$4M$L)OA*_C4.#[E1?SV M^XON!5,#* 19N3 6?)Y.G>?RC()4!>!1* "DQE-L1P*/20!8)&8BO9,VW0"Z M"'\".UV=8V%-T?%TA#>/N<&26'-!^F-?*-0E#.3Q<0(@)ID)MN3Q>GAQ1'<0 M-@%A82=-YW\!5N2YCOA)WSR0I!>R?8 Y)W/X#2-&1$.D*/BYORC@)2@0+'$P M6Q!$.DL ,6.6U\%3 "X%X?UI:[*BL:(*:'J.O:(X?*P"6Y9D!)X=\((.[@W/ MVS23U\*QYT)Q]ED2B:O&>4R! ^*8^6[H8I'QE1/ ],'LE$Z2=N\\+;.,19,%E/M3? MP9H;0N>$S['.PH"R"/M(-#^G,$-6F7Q6O7Z2"P'IZ<.I!.7)0W1A;C'E!&>! MS>*WL6,B]TQF_JUQ8Q/!EQ??).$-*03ZB.?T/\&'6 M$9!X>:A-(7PP!'8BH$S&*;/F=<%<&U(SZ61GQUFP+<00&7A,//O?DDP.R8CA ML?2TB1,ER5CR#8L' 6( 24/@B^,DX(?*6!)3B4% /BF_4TC,)/,N:0('8L)8 M.N+\9?] @_T"60Q#P-\2VDQ'C9JQLK&=!$6+ELWIQ]5:F4D F_B:8GZBF+V. M>5PP#9!K'L]Z3"Y!2(]I3*SV ?+43BH @,("0 I3L:& 7:](6#L"VI6),6S7 MI[ID])R(H5D92[/"3'1\90/"6)MJ%/Z94L )FX6_*TW1!7,CO6-_1,84'?D* M::]%VK2MM<+$VA5::HT< THH!7DNR3()G#MJPEE[3)4P5F* ''NQ"[P8W2<= MFHWPA@W\%WI#*KGR0+T]>ZV MA(3?$NP6#JM2I#9FP@*:&TP=K IQC(Q]]+6 [&)$6F81>)5MW0GWNO%V$4.! M':DZYBY!Z :(._I^$( M'_]EDX!>)P&\))XV#G 9"4<-^WQ(CMH4![J4BG&@E^\P0L2!3J=B(.A/?IV2 M70*"QO.MT*XGF+7;V,?%/PZI$J71RM5QT)HM#KKI4/W%\'680]_+8KE[(M'/ M#H+SEK"6R3C7&4= #]RZ0TQ4M#'X=_@\I*AY<%7I7A+(8VP%5+KWY)/S5"%I M])+@IS,!^K0HSABA[F>2!V737F MRH/*'Q+D%I4'E<&A 02;%'SJJ&,VF&-; M?BJ]F0XZPDXK-?ZG$H<$Q7L(XC*Q)#ZD?TB0848Z,@RU9:UG;&\T'AU@[W_$ M$Z?*&B"A#W#!5!02\%0T04W2:!4LGO3% (!F?9K0]0<;S(H>0D.TP0G$MZ8# MQ'&(\YH<]#&!WAQD(3!3,JJ^:00PFUVU9Y@D$H1Z685\DF0T4<"6(%9RLDH< M3-V?A7@"->QE"#BJ.D:UP)-V)J83#?ZEOM-D'MC)UTCTES;82?"@.I%BWL;I MP9DAUF&*]36"(US1AWY#!7:P/81@CM&AS7)0A]D_P-!,VEL2D M$10I:>=29RLHTF-H:%\A]M[/]9?B">"MF$BT'0PV*(::'N7F=%QRI&=MV)#) M2?Q$)H[Y/$&QO_5!C#XIHH2-9.R'R5;'E O'#*$!$IV7V4R%AT:&S!R_#YQ) M+!-$R\,S$."8=)ZBNB4IV^(O ^4YVM8E,0/#727;+Y'/>.(=8O[;:/0490UC M6+IKO$(6P/$<87A"0HA[00 =CVQ@G8L)KW8_7@&+V),\HH5@'=#$OB'A LI? M/EH@>YXJFFW:NHC&9SOF1="7GC3#1E>FE/KK'Z8QA39@>G !NX+T:X3CC2>M M3J)*4K\]T]NYD0B="B%,$DCCZ5BZ@-$[J=(QK-:IKJ9-UFV"@=F/Q GH*<[V MC )>L88E.-YNK-&&T.Y,'SEA)!S0\S#39 A?&4($6X0B1R]+R.J0J'>E@@Y2 MX'<3YQ?N"FEK))*_9MUU6$'6-Q)U!OE"RH)+Z.V6B(X;P3TE MG9:I?/$TZ"F$,-8V(H5*,FL@B#RZS+3EZDN7=X30X9YG ?\4K4&S;KI%K+FF4\Y9& M3>F"H=Y.QC,8T]FH34CP'0L[Y;1 .[CDP^L"*+N#LXFQ9#CDO9@P)!)?@--W5LC"AA]TR MSV/Y0,&63(,#-FA9.) 3I0VP"<(,X-899(UII9$OB*+&"C:^-T[>NN./O03H M:,G3=G70"M(XRWK_/=L?!JS"XYG65TH*X_Q"1Q@2.U2%>0)!)TK6O,BSNLF1 MTVUS.8CDB6@?5"MYXA#8B#W4L]6[1 MO7:E39LN5D0._P4_Q]U:N0[6"?&)>*0<]1?;C=A?U#*#84W*WJF9T2E$/IJM M7CV18\X95\.53*:_F-X7?S]F)^.LQI]]JU2KK?MFK\NT*\^5R]LZ4VG6&/S' MSGV]QM2?VO5FM]XU97&T<1(3O3Q251(ZVQ96M!P*P&X]^,2ON="E=W.AC8?M M+W[^OGE0GW.](5LXR39"QIH31@=68J;299N:RI[M8$C/&2NK'#4.(F+RD%2=G & $>*PIU.QTM")8:@P0H MI%^:X)]#VRM;M=OUC[3P^^[NKOI0/&K:9H^(M@=O(!4UKQSQ=/_PU=M8SSS/ MJ:L^&F)#0IH27P:,'^MJ\PHAI<\W^K-9:I;J3]E*NU*Y7:BI$79?ZN^5CVGQ M^[!5/EO-R+L"..^PI=9*/B$RZW_6P%GN!T^TW6L\_>/).,Y2X(K2&OF5S&># M GZ"E8?Y"Y&?S$+@^V[M[%L^G\SF4D<'^1FSVL%8S;/6/%O>G=6RA60Q?WRL MYBG=\TO2W;O\V4?*/[+3QZ>/Y_'K$[^%E'>!.D50?V\LAG$5UWXF#(N] 4'8 MSYL4"@D4ZDC@76(F2A2)O(4UKF@B'DKF"A7+B6SP6'S#B"B M<\[;!-BXMBR-D**0!'/0;[1:UT](MS[RF>?;5.[78RE44WS[I=^B,2O$QV>+ MXV.[J%K!"!O(X:!H5"N.4#I=2N;R@>%J8SE\XHSD+8OS(2CT9#:;.PXV\I3$ M]GO=%MSW+U^"K9;$I0IJ5]2W8:^X35#$QUP.-]Y+UA5C/3O6?3R0Q:NY;@.Q M7PQ![*ET-ED*[C@>%BK;4C_5E6E%/AO< MYWNF*E)MJDAM/X_O-4VN]PJ1Q.?=FY:YR.]TY@A(9D "[?JN+<\W>2W#21HF MR%["JQO.(G)#,AA'!M=2^:"--%:<=8#%+^;+VYYULIN'TU,Q)Y\<)WMJK7P8 MX]!*O=+PU]UX?/19KH>HQLYGEW(]H0)O(@E0 M8U,G%9=-247KDY+S]L3.H&/T%V5E_I J7C_4ZK^/GD!&&G+>(PT9\]K+JZ;- M9F+S*ELZ^];MM:H_;EJWM7JGJQ\YYRCT^YCB7\JODJ[=#Z9F6R3M<' MF]-VG1[R04.B?KCUI50AF4W[=JXVE@PX6'IO %*=;:P]+CD^HH4$.U390(>J M$/1054WXA=:H:N$.6-T;UG2<,XOZJ)$ TY)$J!9S]8RCTIM,Q>@;]U*^XCOE MQ[O4C6 >5CHI&RC$3J=S[>(V;,VVM C7:0X:,O7I.IW*)=/%[#9G60>Q,X T M\%=$R8"*-?$IX!;U/)&R!A7@YE[HL ,=V*=Y?6&S"M!L\A\6ODE"SG?>[#$"DZ15^XC M\)&^[*,A:?,,M\XAC(^#AA?FR.2= =#) DP!WB54U'J+0P/+S&DHU"_K^2@ E" M@.%!FE@@T2;@!+R4PI> W$WH(L<:B& / [#%&U2FSP260J(E5RLN%@I0B:BE MQC[^A8@V*MP;HJV9!O4;TJE,6?<;R$_64";BIFU0E\9JT]FUC)VK5;:8#$^3D^LO,:?8&-S["!#( '*/$?-VO4;:QAT\)M5F[)Q"KA M" "HT74,$C&&7JRPM0$3#CL-4P\OI:MJBVN73':JVK;'M@?K>"K +OA=N3@8 M:'FI&[%6=BO6NN_6V@9[I2[P0/[>KH5(]L62F[!A9,H6\V!) Z*RXF2WF2$Y MWVD'9J>PZQK/V(=D]&;-)F."1#/' 1!B'0F%" WHUY&),,,QJT*K*(XF,Y( MY*>+J=CH:2S$X+[;E^_WS?M9O7)I.6>F:CFD,*-+Z*];@8OU=HNS;"+5'.P1 MF($8IWS3,1A%!GT@>*P!WX2/EUV2>[65F#Y6RR4?&A!BRJ+7":YLUK11GV['0=LZ]4WH5?'TV MN^Q2M,%OP X$TXX#PY7V_ X2V4H\P/:[4)&O/B7@3\*S^F\0I .=-Q1569I MAU!VSO#3*>)X"LEI DR0:)/MKH>IS "'"9M\-1!:7\A+1Q3[7'38:I9]2;L[ ML0R@I!.()B !@/]_29?^8O#>JA-;,P:OER4V>!E%9=,E^.46$OPR1 F>/; $ MOUQQ\JYG+W?%3KK:R&6.6(+[K\!U_':+EX0IP;T9: <)7CZX!%_%1[^D]^_9 M1GK^4,X?IP0/RD+%[5R;TY;@3M$\ HBY+V[^J]CXS]C BLA10K2L1M,]/ JP M&J<^1\=N/R>/A0XW^/'KP3(8X,5GJS(GMF4/&SN<*VCX#Z?)8Y"\=?'2E.B24(PC;&C0IH8Q"KWT\C]FNRH@@"AP4V$FB7I9N?FEL MX^<+MZ5$]9UW!%)S.]-[)2_XIN?W1>R66>B=-R9:+EN+\S.1.FX,]$? M?B"CO^>[E"7I1>!%E*BR,U[%QMP=*[^09L@L@RG,&PD:%7D(K>%L5W=)YO:V M:D:NS8&LL#4T9P:K!PZ\W$<=DOP[B&D M>$=.S+ ^4R&O#=%M>BR"\0G![++2"-PZ)F+FB4;!*?F;7(J79:%X,_2QXH%+ MC/-TL!A)<+XH[2L^0D'L_83*4B3$'O8@G9MY_5(]0?I#DX[!5"-3^4>:=;)D MCWWCRC[O_NN".7GE]"=H6>BR[I'H K4IM'FZV2TC1W-MG'T3L/[D,%O\M:2E M]UD>A(.;2O^:3HXK NX[]=M?RNT;6D\R7P5]K;N(3IC5R2I##3+21Z%\Q3P^_9F8%PO>)L>OF[S,_IIR#[\MI^3: M,A3%ZMPR@*R)*Z#9B'/X^;.$#<-KY)99%'*$()A7QZ.+"W\.R M5,\Z(6;W2#QT?3H3I#E"2:;&RVBHDFYY<"LK0G]HDAU#M"L6ZB*X9]\U$3'I M(OAFZ8(CU$C^ %\S8HL7D 1FEA3 -^$K"?A*TC.%W,XN1&1#XSR$]V[.C$FB M#HMU.4<4.:P"F5/'HH$?(CG)9#G[!U#1$IV#T%=0W *JOP*$U-H".2:+& M>O#"W"*Z?M&H;S;*OJ 9HORF5SCK/5+'UH6XT9J: XFW*A6$*$AR!.U;6@%% M/"::^7)N?:7-SHFRAKTU+($*1SMLLP+5M15-G4@RYB;OZFU;2CQ>'-S>..V9 MWKO4FTB:@CFKBY4(WB+XGIGN)A6'KT\?2CK%>I1^L^94#'U.=@1Q@:YVH]F$ M527C5L&X80^M6KU+V>[HT)<+R5*^Z*=JETMQEA(J(N09_WK3;7A&?"U]Y[FG M6_97^I1Y9KD(=7.>V=%S+Q62^;)_Z->K]+BX1[;)F&R3"8%M!K]+;R_HK=GN MG+2HR9ALD]F:;7;TTDNY9*;@VP<#%!XME 36)DP$DTV"AC.;89,\.:C_!D4- M6A#K1 696@[N78GSM@1.0L;S05>PO'K1C1[B+JIFWUA>( X$2;6DM@7I;YYP M*&NB>]UGX"K,,Z 3W9C/E21? ^-9UZ6[<_[E3>ZIT1 >[@8Y?WP5YXX0YH^< M]7W6O@I(< MNWRW04"IFD\7"6GP'+UE9WB.?A*%8V='SY>7'X#[S>KILLJTN M+:9V+:'-%,O)=&D=J(];#+9HEW,CS8.((*>_L'2S"AM/TS54)"9!NQ$<(B$@2C%#3]P/"[7)W=UT!-!)OFQ$UQF9[NY6\5<)IGV[Q]G;%PRX=00P9@L&,!8/C(FXZ0U MGOXV?%;]): ']CU=\O+8CHW/_$&E-N:SXG*-$^:U=PD[*4A%_J+R(_?XQ#^Q!:%TQ MW9M*IWY^6>G6:TR[\GQ7;_:8RF.E4\,S /!SIH7=LU:SFV0>*K?W%?B9J72[ M]W?TS\X-W:BP+/BF!RM!.S-ZX430IR;$?@C.^H#3[$KHUZ CU.X;*ZJ'MC80 MKK!L(@66-AGLJ+!PEHP0IT.1U?/S#HQ,G0WR^QTO\E-M:C@7S;?G'[PZYW\V M2[N4RI)4!<+R8OF,M+M4:!EY;R?=2\'PI"ZYP7%1F/^Q4?FG.!HOB:)X; MCDZ0RO:UN*B\>WU__B*UHI?]6F$1:6^TL%IHZKJF!-7.H2H$B,^ 002I1-@* M8N90]^NS:_HD,O^-M-^3H5;#7:EW4ROS\)="R3SR/BETBVOZ#G>P*=GG9GVM MK@)_R>9VSR M!8B#]4?05E;1\.Q_0Y,J>[4R.[SRPHQDA"SL?QF3\C3-S3TUP?;*1(XB-]+K MW &]KC"Y&CJUX-SI=AFQ5%8+JU^_N\-\]OMT*+Q8W1*\.8"9TE'W*E56K&Y+ MX;)1F,Y?N.0N_*&$_WN^%I4HTOVA]EH ZO/B:^6E\]Z\*Q?74Y^.>GCJZ_/8 MBOJ9C;(K5E$_XUL<%KW1&IYF\;%7H[!1!7X$+$4A[&)MLE$$8RF#:[#^@ TV M,=H ]B!M03.ZY<3XZOJA4!$6:FZR;-(Z"+L2:''5*0T"IEC,+'>KC&PWH*62 M#P[CR;FE>PY3ZHSQ)@F8&@*OSN/COIOQ&$J1Q"J.?S!)M9GYF'M^+CX+K:KV M\V59,%CT/XCIN')M6YH/&X6[_,V'3-HWD7?)= PE>W>#_0EL/&JIC(**-_+] M#P^E8*?] 0S'E6O;DO8A124RZ:.S'(-UTZ[V%T+K:53(Y3ZF']%TT_X,.050 MO;X^I\#.X_:K_@KDVV%V79E'4%V31[#9X/W%$^(;]UH]^[-2/$FRDMP! ](< M4*-)72PKS!7>[!6UG$@ B(AD.VS9[I#H_NFO^G/]Q?/]VX\4][VM?8S67?4S MKJO^:NNN76]VR7W^TDU_I=IK/-A[G)_*Y;YE$4=D+Y*!WDEW$WBGP'UE],TP MH5[3LW"M5=,TQOL"?_V_LXP;F]<7#MACNLO NCO,EF;7^>R5Q\9XS"@JR_Z8 MR>))@W EU(ZD]0;E>*1M?3BR]J#_5/!19.N+<^=1B[?-I5OZTM*G3'1 M[*Z@%FMJX_:3T+=2\)WR<5XJRK!.\8]I^NYY MC*Y&4^NRTIB(X60Q9E8^F^_;V-@MK]EMP(7C>Q MY4$+Y #D3$ D"UIS?V0Y^U:^R&0_2]&%Z\)AIX(*7OZL-GZ8 4:R4>094YOU M^6:?X\,_Z[/'EEC+]9Z?\Y/-+'V=F)'8"5^B-?4]MC=B@R"W(\INKI!,KRK4 MC$R4_/4Y#^M&]WKKS$X/=MJ_J9\=7M9ZC^JOZGP4W-:/\@Q';.MON.E1G^\P MX(-*ASC@L<$?X$7G)V>SK<_<"S?QT#AL?IA->\O!W2+O-F)=D[;K&I G%/N: MPI!3R45E@+W"R=S/J.R^A3B[_-X6AG+^95.[3Y_95CG.X;C>^H/@_IWS'^<3 MGN,0'ASO=X;_&,@"%LA%^ZD-RI+[NY?\@\_#9;BV%^7& UI>@\M*.=_+5M6? MDTTLKY,X1>7X%!W5*3H K_C9/@<@? 19L^Y59"[R._'0J@3:7,"=W'4.6_(Q M>2W#2=I 0'M5"&'>CGLDV=;#%_GMN_E]B;^];0VY#8TGO3O3=G0X[@OT8(FW M@3UMIX.=WS7Q=DV;JD!G\G"*[;.)A!6)NJ5#).K6HS$-6S\*KVKW6;GO_=[ M-/PS9,3&R;O;2H[=DW?S%]G &?NQX#B +7&@H^)* UAJ8WR@'.!019C<;']P MG#Q*9_@P,,3 M8,[/=5G*\6]!'7LZI7-5FI%IF7\P'B@08;\13%$P\"$O5 1_-QS/SY-?O6]. M*&"#"^OHZMR^D<86?F5 >OW#5&1V +@"T)&;;G-3@@U-9^Q/_6T\!A]9;&[P M^+]_XYWWH(&,V)?S <)"!H\](R2T[WO!8]_IAI@\9N,N+ZP= U)?$-*5@,$[$="'(NYPDY%V2@_J+Y?2+?/MZ]\"I[ MDO!RE82B3?$TYA:6'*MJ)K**Z-"A\*NPM@'=-L M-1_JW1[^,_G*Z76A6X[%;@SEM@MLF\';*Y!D'./&B'=FB'OE9L60=Y\5ZNO\ MA.&[3A?&+MHD(%UJ%U*[%'Z;LI1AU1@UIE\N+:'<[Q!S,#>7WJGHZ,B*'W;, M0JI*@_:/Z_)$M%5NF@32!TTREZS BA!H=6W4 ?JVA;\YP7N=YW?K=9XK)TO9 M3(SKL&\PEZ4N5&'PD"ND1TI^:JR*3%A^WS.GY7.EDMQ1I!^EI1CIN2\>R^TXIH1'%FPL0X7%F![Z%1/<_3_.E>34G2R].8#:Y./\OI MVE"/!CYYNQ>ONF+?:N>+N0 M7^Z6L3Q\E6F$)VH?!RHJ';H[JD_N(GV(0W:86HK=8N%7DCQ"_+)>_6-K?U84 M3(01P-%_-[?=I:8]A91%[L5TW&QVY$R_)*+&@7# M;ZE@>X+R"WU/J\.[Y0197P5[(BXPG8K^P"+LFT*^\'(TK KW/>VT?%ZC> M=8&+\M7'>T'[H;RBP287J,=7IK.G>U5/4[FX7;C)++C)EY*%?"FNN3F*T[KB M(G:II_N>+F)]SN[KC=1^N*\6^??!]A>QG_,D;W<_ZWVXMXLU.6/)I<#M,$Z@ M'";77]0>OU]VQL^_\M_+QU4.$S!M_R23K2M*PCL?W9;.SDQ8CEG;KB-$ >8 %&:KUDC7)4A?JNH[];OM3:,GQ&(=]D>$712 H[ M[6COL4E@3K/,NU&)R.K"'1G"?0;"'3;X/V[:AYDC$+C W,$1+]=WPS=NIA2G M%GP$>0U#Q#BFAC67=4L\@8IM)PN5=L_N656/G8!2%*"WJ,J\J/!#Y@VTFRSU"QEYX!N^X=X@UK2Y65Y/0>XEK)'BCM7L@&-@^9Y M0!$*=MP1^%Y] <7T:#=R;H(2A:&4TE,8B_M#%O^@#?D;XV(Y6!2[0M[$+;4%N<#>8WU_R3:@;5 G;05M"X5"LI3Q# */C,)K$ 4&8( M:FN1,$]BM<:\3_CA9+5>/NC1M[[3$#$GX&_@F8"^O(4Y@59UCG2-1&P:"161 MJW!37N05%2"JWY ^2U.@_.!G0@O=_YR4CH'IMA HYC<"K=C%F4%]B!6>Y.GZ]KU$ZN=JBS;A:W*0?V*%6R52162Z90_6_'88A$) M/ ,'XFM,9TFXC77,T]A>Q9L34Z B>U[DGAG%7MNC(+KOJ5V>NX/NI50(%FLQ6\06J[^+3@.-]-^>)-U)"F]UB+U(6KV: MEF>CI\K[W>@82.I[CM>2- 3SKY O)\M%WPL.QG5D\5?.S6/KTM&?(,#\:2+E M*^^J-@K;S)-PQ/);_P0>?.\F0U"S'JE)ZFL8/^\ M*BEJ4U*?$69'(Y9O[TKD=9>U4_CUJM=[OA6R>2YOW8W?K]F+=>=^+SL1(D)U M*16"@9].8G&5+/GWB&3>>=4CU%H\:A;RM?L>E?%UH7/W4^B6/A'?!# 62ZD0 MK/U\-I7,Y?TUS !!@D5PL_ XY-"VML?#KX>783HG]0KLY^.EM09+&,'X4B:9 M+?A? 1)V2OB9+!=,Q0]5%#3C4OJ+;&*-P^;!?V>D<-Z\C5K6I0Z/![]_@.QW MU;RRE!Y6V =#TWK_*TG6_P3?2T<#XOY6F@[OY6ON^KVP#.)N;*QM&U=O(?.% M%^F=WU_' ?5>2J?=&,'[I=K9M\Q%R:_?.]VJV!8_HH6TQ,1W5M0 ";GDE3*J MIZ6XQ<)2MGM$Z$(E>N[I3[;>H7H@O?ZJ\>H<7BN)T"+1)0?P!U-))&?*",EO M%%NKB'A)HJ()*LS0$"%B3?RIRJW9"%DBQ&AQA47J3).'$[Q4$!3X[51J'!KAS@INX,0I2[69'T@TM(>+K362N]MRFJLMO-TAQWVVC'R9DKK<.7J M72K=S7KP)MDK:O@%-^7"9(]@YMUR"XBPZ'?V+9U::;!(7 MA)'PZ5KBMB6(TFWT'/G7 W5SZ'S3X/<"U]T=-===E<;7B\G-0X\;+G$=V;,C MXSD\CCIQ,5W9D^E"(B-XS7Y\1R:S%X+D'!*&>I(!A M0XLU3"U2E#26$6$%$M68L;)*[UYYQ?K(,13Y*[7NV/FRQ96Q29$:&J@-45%E M#4:A?,0/=3[3I4$FG=&E ?DI#&E@?@8AA];(QNY.B5 U=Z%BK-20!I7OY7GS MX_T'9TNSN ,F%^:P;/CJ.L-HY>+]3)G,>3IC_;1>;O@NP2D9,AO9RZ96\&1VSB? M;A-I _\RM]9"I].N:.I$DB$:=P_EH;;P85M@1<7AYG2 DOI?H*)4)]PJSRA- MKA=,G_.8CD#M=E#IYF[+=SDN#$_S0/OK9P2NI/-E\0']O>@7 K%V0Q19@9R-#,'<303.SF:HSF:W/"H>4V:%6\O MKQIJ*A."AQDMH[U+,J<@T<5K$?N7Z@1/3/0:X]D\EOQV:!N&!51,%U>ZK-O>3DGZ@I+, )8$W@!G+(HV MD[66=9'8VJ'8* @;R87529RFUNB^S-4&W=LL.OW[JSV>K>U<;U=/C6VOLZ+V M,$Z"95UREP)!V1!$7H*.3W.U[DI]K4X%JV9.]L/.G;V[ZQE?589M;CG3ZQBYTS[[ MP-QYX,M=4HV16)M?%7:OI=/AU,5+]74VOBD_7A67;5(=BUO1C:CCZ=&T/]LS MMYM?ERZD@OIUY,AKF!,8=CCAT1N]P\;>%IZXRF+#%(L#,A-L,<"V<"0E.DY? MV,>D_QU@YO_VR,K$:_H'D_.;JU_]*:S":^N#5A4XNS4A9SZ5 PTHV*.@R MMC0,@1?B2Z I9B-7;D_4[]^SD>!+[P,HH: M\FC6XHI /2SHW"FI*=(4XR&"U@X[+PE0K6;M)S$+)9D9L43")O#S(TD0I'(8=94;K,]Q?-<:W;?7N6.K*%<\_QRDQ@\;ZK-WM,Y;'2J249_.].I=GK)IF'RNU]I==H-9E* MMWM_UX8?N\Z]).#I6%$(@@[B3G)BX'?\K:'Q^\;[K2/T#S']V)F"-\'XZ2MC M]/).I?Y[%F&7&/TU)7C+UK#S=4=H;75S\LPN+UK?4"*:%NA+C2.B;G6_HHQO M:_O>;)!@$\Y+X-YFP-=5JQ?4I-95@6'\7EX5N]V;S.5;TT)0J^\']GOM<@-5 MOCO6X]+$810!%%9T45S)_G&9M$ F*O@*F/L)WK?_?8#R_$:7=XY849 M058*3Q+H%961,7$_D_ )_>AY.?U1=+'P.HE KRM,KH9.+3B)^ET ,7BBE7BU MNWOYX4J6;YZL2Q(?#F*F=%9[E5,K=B<*<;51XQU_<96[\$=Y_._YW@QHS\VC M@?P]L-:DDJI=(?7YX==@/6O161V>M?1YA,]:^8U"R:M8*^>+/G5*.G&/5KC MCTAN![E\C_7@;GIP*3URFTN?519I#\E3L_[V.4H)%2B+8"Y57M3+]BUZ'"_[ M! [.V@VEQSFU8 D!RVDM^6QH:2UK:73V+>]S_;JDX>J?GFF8<4@\KD?*'?EQ1> M*)UO-]B\O3EU[C,8WPEO;>TQ?Y()$_M,2#)S;M 'Z6[U[=__.3]GKN ZX1^FS8[15SS< MJX;$(9Y>*?N5(0R.)\" Y8TKGJC0C MTS+_8#Q0( IQH]R!8!D!7GK7W[C"\_.\+/1F]B&"8(TK >'JW+Z1QA9^9:#J M]1^F(K,#?OB5:6+!0[>Y*<&&IK/VI_XV'H./K+-@'(1__\8[[T$#&;$OYP.$ MI0 >>T9(:-_W@L>^TPTQ>L/>@_ M>B&O*TF=.87U&DEP&ZVW33,[':O=-W/&YR ^!R&NMV/TW]AHP;?\Z.#G(-IX MNH=ZI=L''__#\"I^QS!<9^;,+/V)P^WAO"B*!<7$B(D1$V/OF?(1.7\Q QT- M \7$B(D1$V/_EJX>I[T5S.7^?G8Y2Z%.?!H MGKF)D N[;C2:3( --MZSJ#(;O*BRL!L*?#F72>8+O@UA#U9,^3E.^5(9M'7 MKVQH$9&RV4JXRJA._;CZR"Z^W_S(=MGEMJ/Z3!BSKIG,)6F7 0];,SUMY,FE^'EY*P(3W0O'L8$+(CS;0 MW-@J&@R6&/]9X!9V=VFN*;#19_*5+?-E"8,X7%[5]RX:XT04%X_G@S1^^*Q.1RU:I\-JFJ'T^6:?XZ,1*;=\NEMZOE,:B \L4G2R1F.M MV!\$D7'.?YQ/>(Y#>'"\\1G^8R +6&;DS[Z='_('PQ[,(AXTBY+0!CK+W5 >BC;9+[ M'['4+45M/>@['XU G>8&#^^OA=_IYG #JT&?TE:E&'N3N.6U$M>SAFQ?HNP/ M/C+EB T5G3T/9Z;\NGI2Q._I]/7K:!,SY12.52D='ZNC.E8'X!4_R^D A-][ M$&79LLI=1Y;\CIY+<-)VD! >]4B2TB+D>>RUJ/1 M%I<_!BU!*PO"QRBX#>;,9]N0,B=WM1PLOW6#IB&EW?);<\ERJ9 LK,(G#G!8 M#Z<5/YNL6)$1&ZVQ&3@C-B+9\5HK/0^ZXV?A3=@M(_8H),@Q)LIN(E1V3Y3- M7616(.3%,N7@]L>!CHOKPKQP9!?FT=V4/[PVBSFU^J.P6)&%LWFZ;407X*4C M3; 1_\?-6:&:^#J\96##/G2N:VA*_N=K1UD4K38<^E=UK97Q6$9CS!L- M8RX$_=BVSX2K9JE9*DR^R@A:Z^[C)M].Y4V^J@JLHM@13B69VJI)^\E,NG=M M/>/M?*%X_162>OH:.%:QC)U=$SHCD7DDRGML;EIE*2\8G MD)\JGK[30FU_=)O#A]?TK7 M0?@HWV[95*M'U[#7M6]PS,L+QC 6595ZV^9EB.R1(:MH>NJ5MCE.[L MRYV=N[BZRI<+@YUWG__I?6JU.XU423J(.);E7*8[,R_TXM3*ELY.E'>?:NUF MLWK5*J;AU)=OE,5J7HH-8T[=F-,TX!H MP.\ L #[(-NI")$@I)9_'06N.Q!Z0E\%UP7^!,Z&.):V@=O4UG![*)W"3XJB MTC. T18XG*?(-"%(X,6E^=0\S=^K]BC*2[ P.J/ &#.P8LRX)>C](+5 M@ EMP5@V-R< K(A%D3WB4- K%B$.;]> =Y$A!XX)0YM@T8"184QH0-@6G"ZX M$$*V8S%!%BI0T&2BJ7U>N7 HM757+F1HSC*'6 X!"9J98'1%E$?'_FLC>*W' MF.["E0HN[!(X7:PLPVTEFMA;;RX3#)H^>FX/J2E!3? 2;!A=OVF#0'99!)Q] MVW5?)D#N,%0?: NW%GB1W@!S%*S:MV#"O5K]:$V 4 T3)- DL/E #4'*%^Z' MA:+6%F=?8O/G&<^2[F&3Y_VG8+<-]ROP4.K^/ T^33 8E7C AW=0M0!!Y4;F#HQG%YYJ%[F3-_-O5BR\&5^U\+EK%BPSB'O)@$>LN@KF57# MEYO$C^+=W](&VY?<#FGC[;N\.VZWZU6U<5]^P>V;[Y^TWO8]9?C/,R@7>=.I MO3>]H3==R!A/! ' 0DT_M@("QWJ$]"#O4Z W5G[*M5.!W< M6'HU]VI\ZJ,8G_JH._O&RK7\M\'G6;&//O79V6F'W&BIVJI+M7:K<]KZW&C5 M3AM[Q_K9]^T?]5.33#6\-L67;,!I^UUX0?.MK:>^.MI4R/1,<3XI(ARWD#JN MYS*5^'ZR@+ODQ@GFGGB!BCB_;^*8&'*VT1>X'ZG]N1?(CR W15C[KN'HPBE< M SH'Y/Z405X&P S^+J/$(O30T?1$;WUL@/')7['1;;9"L99.P#GSX@8I]/,6 M+C[H"AD!)Q,=-G#;B@17WS%->!DPKABP4;IA(UQW&&1!E2OKW'7E7K@"RWH+ MVO15'_&*)+H.U,,1W;YB:+<_?%F?OY\S$>[WDH9?,$KY7/>(GG("S M:;,F3*Z#4YLZWCZ9E\8YB45!#)1?"TU;S_^ M_Q!>3QK=7 'DPMR#I)6ME!V0"&/$VESUQ&W97>B'B5E3_\$-U)DM6? Q41') M94ZQ@F!CR!7H*!0+E1A*:RM"P73NS64[3\9:@4)CZ-%*I,=4E/3J/NG]F)Q@ M?/_2Z8D93V"DEZ; R?75_:Q6&%PW_2**'Y.# 4**F#MP43=@*!-6I,4E2]TJ M2:Z5Q9=,DME$%_8_+A$Z27@1&G<:? T,I)!&O5)41/-XDL#$(Z!&&F%C*52 M&DDNC>_TV$C6!J[P#(S'TG.T54T2:VW]F(9I#RX]VF=A2HNALMGWH^'M^77^ M_-)2DJ11&$2?L]AF4FH)H(OH)$P%V;4RZ+8AF$34.+A#1">:)D74:YRTHF#_ MHHSA<'SRCND.LT0L2S'B4V9JNMPLVZ-?M=]^DMLEP6KR >9K*9;/,I1+[(@7O MO8E$H/GHL&%DK"OLTS__=7 @G:A,4SY(YR#7/L)P?QP&1O,'J5SX*%%")P @ M'1R(PB]%O5NUNP$'Z< V)@26]X/[08GB)FO=/[_:K?)QX9GD7@0 7VP137S' M 7[;;N02^Y.#(")=%'Z4,'S_0:J:<@\OA6T!,W,TMPQ$:+80_.IO]S-\Y-?> MN(4W__P-F(_9 Y/)MP<]XI /P ^XA4&\EV+PSA'BT5B & M.<53?X ,WD8]L-P824<7, ;/!N!!#I8,Q_1C#BG7Z!4A/%!(!WY 0O;/SS Y M H-]%AF,Y#>-#8>*7C"G867?"W )]E2/87U,U'8)=&!W)VOK53Y-&V;Y@9.( M\;WA+V1[D:,U,Z\+>N:L??/'\3N)AI8ROPS/M_0S5S"?9J$5O![ :YC!6_+/ M\\E&,-CY$M+U^#!5A;V)#8RZ/C8LT='PU$@"OVD\'S\"\E3'2*OBJ)ZL$, 4 M[;I)-9TNQ_!QA5ODQF21-0W3PN/#OV&L0,(0.51_"S/()VWXF6:1^L ,1.<] M%K7%K4C,"2UZP[$/C,'!Q.C?@@,P4#6J# &PP+YSW#RG%,)K,YV"85Z2@DKA M+9UQ&B#9X >:+9X=%LA@"'L)I[H/+:Q=U0>8GXLPO6 M)\@?UX#4V!#%F(N=*%2J#NYRFOO2S ;VHZ4"HONP(Y8G#@+&*8ZPX$:FW8KW M_2[;]8MB_J0T'KZ*>%]V2\&5A6[U7 #WGI@OFONXLM+8NR8OF,$E#M""B8<\ M PN/(R0ASY&*4:@$,SR#9VU"KJ>EGA,RO? ,+7OTT?(MDG3@&$0H': L*D.?MBA5'.Y,0TNC3!1)OZVIZ4A MI@KK7#B0]K+ NE'&8!Y8-B\X\GXG\078& J1 S:H!Q%&R46]_Q"%!1AQW C6 M[PP-QG#XH4': WH",^#!P8#\,$"1/!0N!BQ#4WPG<9KJ<9NS+TH-Z A8AD_ M!$/'4590;C%1(D*G$3"BBP(22P,535=\&6023]'?%^^^J !J&3;H$-YS1 -2 M \K9BZ"7I:;M+6$-\-NZ1+E56#4QUW F9;(^0Q<%V%UA [6O,KV/CI:-WE>H MB@G(:2!L(:E)S_VZ+]=!;\F6(O\!JXC(3?H.1HCWD>7E9?&WO*\M6WB>(_(G ML10*SQ#(]QV#_17.#T&Y.7;&4D]51&<3D_UQ5%.82!:ZV(9IHWL9!>?"T9A4 M+!8S[^6_WN=XN9H;.E,DP2,I6%['7TI-GJ@V2+4SV03O_7#9D (6BT;#PBGP M)4T532\>F^.&'LK6N67$U<4'#FF/587:A5SXJT4WE!_F'>4*W5FIH4QY_]Z7_W+C;"*LW29PJ7@4-)&,&8OIR;0B3"Z):D\RB!T!UJXQK+2:8X.LSP8U_J5+J1$6&)H_#>/LS*@8HT"K MELA<"UD@,OX:Y+]98]R5R9\3&NAUEV11F2/>F;Z XIY3U<2U"K_G-Z]P#>X? M7#VO]N-,(N5R+I,(5A "0DGA800:2]&$WAA^5$@W<481K2V"3!;5!^2QB$*JR.%(IY>Q2V].?<4O#OB6S:7N!<'QHXC*):P(T6C\ZXDXM!OS#9I$SFA87. '<>"%86P$>BR3$ 7)A8&7"=;^Z;8$5SRE$6\0COAF A$@]E""47$Q67MBO]\OMO@\ M)#L1Q K$ESB1KJ8D&B@!IF7,.%4"LR:OJGV MW(,1F$FW1!"!Q[IM^1:6+/+,/'EF(.>@W\\(TXP:A]',[G$T+]%77/L$SXW\ M%P<&UI7SS3(LE@I.2X=F$IA>H9-MSGCBX$IR)EA+@(C&00< J"GS0 ONLRA! MIW<0"$ <[GVW+[U\ZZ*NZSKIXV MZZJXS[IZXZ7'N;G2XPO>ZN8<+,YI)Z!8EM<=UT.)R"N/TIW56_GI9*:?6,?* MJRDZ+I,]G>PH&-Y4'#-!#1='/>,V;L%JQOQ;\>\!,DI&F M =9YQ.YK/+C1@=I(5DV"!8_/JR:8R.&S:/0N4U0/BME+U.E3MSW+R^L/!. 1 M),)MY%#!7QQ+=!WZ RX&J /P3WL&MI3"B!MY G14[_ T,#"O*:(G&E*)=_;G M1CNTD#JUM$PM:<*1#:>(,7T(NE"1JD.F.Y9TJO):+07 MO(>4'02D$XY)\&*MN?#E<4 _M2=4J8J735C4&D/T9HGO9-M=JM>.I\$GX=8S M'%( U,T@^WSZZT']=5$I8**7"(]Z ($0L42.B9MAMZS8)7$QZS4*BL 9,10V M[M-:.4KGBT?KM0;*K;Q5R0V!MK)5E9]3]?-UYMM5Z>@%MBJQ*=#BK5HUX6]N MJ[*%2KJ8J23NE:K[69^!EHC F*"07!FQ?OO=5*AAD%2EBN'X]Z._YKG$"U[# MT),UWO&2IR &I1]*K+A3#9_6,'FMJ8([I-%IH7>N\12T];74-)J?I[-.)4!; ME#VG^1 L):@(Q LS1U>AGOP:C<#"U).OI,M'R3=IQ#+Z*LA_$L8>7U?;5S]O M*EI5?6+DK\.Z^37:>$58MYA)YRJE).R_O:9<;]B,R\6;<;5.36IA3D5:^CSN M??'R..!W[SQG+6,NA2/NB!&7EL0R:!J @W?WI-FY@6<;-J6UN0W-A#>D6H'. MHG'R/1<5,7Y/-"H@T(MZB>1,;@MR!A9!6X0;Y(J:]M&=IGX9?V]>^N:>#T.P MYFCAY20AH>-_'RMSN/!0=&K$"C-2:##Q(HC";A%PU3$%2WU MZ@M9ZG&[U\]7>S\K3*^?YKS=:\0802Y7/9.QOG1+G^!>A5@-GGDA4SUNK]2+ M+T=7^L]\/5-Z@;U*M-:7[M7F!GNFE#XJ)MM< 8,]M46#/6Q,2/75OD\'DY.D M>].P*9PFDB;<&S"Q&1659T[D*9V\>/9\3&+>L9^1]!F^;^N77L%9>U 5(YWS M@6#[X!?384K0QGP>(<(&;%!VKJ\*USYA(L!X!ANHD:,:O _\MKP7 ?LJ'N327=[8CUE3 M^^17WXNG4CKU\NGH\]G)M/DM]SQ[L:9V*6Q\G=42CG,#+,1V\Q728=/\[3F@ M3WTT6SB*'LU>LB&U$Z!6%* KEQ_)!GV?%;[NSLX+IZ7<]=V7+X7>JSF*K20> MQ1YW9\=GS4RSK[3LD?SNTV7C,[: EBX:Y^T+[/_\>CL_P^)=HGP3I\?!0U># MS&[>=R$J\,L!B@9> VG7'GAFNB!QJZOTNX[X1WR?-?7WG_&Y=F4HRHTGM/EP M5*CG1?@M,>(R^9T(RF8=T@J555N01>XUYK.^^V3H+%EN1U>7CK0/P\N->+\; MLD!#;ZF8_]=W FUH,!T22RNG%R61;W&-TX-JN>.N4 M,;&F_9$JVR@\Z<(APU!P;$JH"C?;\\)$?NDCZA5N%\M4IZY3Q R;7= A/>9[ MT50]V5(!D)%I.,.1*"?Q :8,3 .+M541:G)O'?+2,"75:QB%2GK0\T !P89#!-O14TH]2/BA59>:Q_\TG+ZX(]9 T?CMT!A"G!" M7R"\"LC!QASBIBZ>9HTCWC.7@= FEB5,[-38_*[C5HH$!H3&2^+U2TA5G=,@ M#LU!P$0"D]VI[-Z_F/$RU%\U'$5'+/V/U"CH72-7YUD>8-C0%83/$6]U(ZKD])45IAC=Q"DQT ME"IO@5I/#)/.53QMM8ILPD0J; <+=C"U5\("1BKN9 :L=PKS*V MN4#-2:Q4Z,7 X(8KX>A.-"[?^.8MAI)#Y" ]) PM8[B#.UW8S$/5H1@-0XU)_'D.L$E)#(C9@C)9.;>)AB2NFE,^5?Q%*CG*"!^\09"RR$M MS%OE8<D6'9 %AY.>B>#5':LP)F5I]#WKN)R5[&8C;J* MIU2VT9$?EON(P?[!BS[KSK2OQS]N-?WGZ;G\:IS#;";1.RQT9[U9*S?]UKKJ MY91WGTY;M?990^I4K]_:E4!;I[?\7&BB/V**H['V@)/0,7D2/CG!'[#2?E57 M0$XS6'L'78L$DJS4@F&+QXW@U (P M&= \>_?ILO:E4?_1;$CM$ZG9OKR4CALG[8N&Y+-[&$]KU?NLCLO5*H/>84'+ M@EH@7B+S3I2]8 W.9JB>DQ,XE%]01 /=,VS&AG-JRD=)(,,KTLF2E-W>[.Z* M$"_XZ_^]R[WS]KI0J73CPCA_KH^:9]^/:K-?O6@)5F+55\S:YNNG'K$TA"X! MK3$XC(%GJVC=Z4W-=^-N)QA=G3;SOXN_V\9.;6I^AS85"^^$H/"P&JQ+1H\QR-6EW+)\V3VKM6>9!Z M)?N?V&+-)^%H=\I29$[JHOF(2=\O#G8_@K@V"X<7USC"Q C,_[T[B)YE%M/% M7"F=+R7FRB3A=KO;^=>>1%\EB2ZY,J98>C2!%M*52CF=*26F<+\$@<;JF?KC M](QPTR)JYHS]ONU<_OG5ZV^@9G[R]D91%)67F80/1=_KP/' M8WE^ZRPOMG1#I53>.&LSG72A?S.4/<*ZJSZ.'76>+!-V>U,?6JSL=4R=-$0'J\8<:^)Z:J=[M@.J+Q; MVQF=M-2;8[/R))Y5%(OSWG[NL/@H?FXFQ"%7W.O'3K^A.*%I)<5P>AI[88F2 M#,KN"955Z7PS95I:(RU\@8=73.<+A4UE#^W&LWA[>T[XUW+"$OU;RFV!#V"@ M=*&2V'+AI?G U<*B<5C,^7C@++!:PCN-O]>_7);//O^^?94G>"^=2+5>5[W2 MOJO>TW;5*^V[ZOW+&?))LN;C;B#/Q^7VB"+68Z:S@6IWE8=F?([\3;8XO/XZ MDX=_ M=HNE:^EZ3XX<-U_?K#AX/YB\DS:TP^=PCXO=*SB_VO9GO,UIE=(!43 MY@_4AX.1J@#F/T@ 4$Y]Z)D::-C"&N^6^$7>@DYB_@CX/2Y,;OL$/Y\/\S6H MFD'4NP>O]K:65MN^A02X;2<@EYJ=*=73=Z=]_/9G]ZW_.K)#?3G4H!-;V*-:=W9U]N/LO%[*GN5'3YS]M-5XRVDH*=AVU:BO70D. M5*K[=)1GB3)N@3XWBZL?9;9T^7?V,+$SQS,EIOQG3ZNOFE:71+Z/UKJW\!51 M:JSRRJ^IO!#/V)ZI:<#" V<1H++"&JLV^MFI'#N9G]BP>5N)5%M$#BTD=%J< MIDI&\!1=+>4_)#BXLQC9P:=D]>?B[QWCZ202VU#QK'4/8X"=YT^U.%^7#Q,[ M$2U"[+:USI[P7I;PEFF1PELDNU@5TO!['ZZ"Y7.&1=W@&-;5@;BD!'Y"3W%. MAPS:A6\5]2%S7'B6Q*1'X D7)2G>@O:\ND'^++6&?!P%;:@B5DV:7V+Q958W M^+:X:WO%L$O$MDPMK-H-^1606JPRR*SI3X@4X= ;+J:Q^=6<3CB[/\GM=A([I; MHBO*FX9,DUR(S.'*Y1#/[$(4U]0:M9&L#^&%.@,,FTR!EZJ6Q6SKBK?T,_0J M'LYC[Z@Y!5(O5'^8G?S=[\E@U[T*ODSL377GKHN:5]'"]DS]Q+ID#2+;3*V4 M5\VQ7A9IKKQ(;&"O5G:= I^)V2]*#1M*^55[ANRD\[ 7\CM!9ESKX$MTF"5V?FY.'^_DS[M?/F?Z#,@.Y^QU:\>W;<.CO&4=<>GFLG:3>Y6E1EC)2$5T MQ,_4YMAFXXEAXL4*_@F_Q9OT#[%VR%2MQ'N*%8$]TN(RX8_JE((W*/[+NB6# M$?:G_*-6N?C31<7]3.6L K=6V7BDWV%42K;64C4#?T*W-_;;5[9J5Z MLTM;N?-U0TRJ?CMD=73[EBN=ZJ?9U^N6'?6 M.>Z,K%^W/5-]525"5%Y+B=>A,G6I'USSON+B.5R8#8APT1V]$:-UXYMX2^E\ MAGH)O6PUQ2H;MJ?$W:+$6%^ZLFIJ]APE%M*50F8G*7%I+MX<1O'*&O&;:(52 M"]RL!3Z>Z(QB78[ /SF6+:8$7Z@9EAW50/F>HW;*O\:-8>E)>R=O%9F7-KBM MH5O%]BUH=[2Q\E/0\!H*;(W6ZG.-:#/E=<3&OM7RGLZ?@\[CU>.J*>HQ=)[- M9W>6#.'_,\FF!Q=M2-T76OVX_-==VS[:L^ZU?3;8>WW+VV3*P.2':_P MND/A,>&PKH>&.2P&(W;U^3AE6AKBTJ/MQO:'0UO@:"*J-73/&MW0PSQ93A]E M\^OPY%,C?T\X3T0X,<(\"_N^*>$] M$6-/LF^ 9.-5T,:!W[55T YHIK2;5+-> M?F&N.QM.SBJE9IM=/\VM'D^=7O@J,\2J5LH8Q/3P#N30T44" ]&+;5F&@/0> M4^YRF8^M=I/^EOWX%^;NR9.):3R A6$S;2K]3S@7K1+*P4@^8\2#KHE>U$O\ M?@)*>^G.7RE0=>R18:KVM/J@6MVNVQ1)M),[HY5V9]\F9]61,BZ,QXIWH4!K MR>J6A0F205_D6@@(NR$ (\;;JAGM!T4O[;@T=\UDY3#Q#B )R$>#?Q]*F'B9 MRV2/),"D5'-$GN17HV=)U;[M[6^G]K7J;? ]?"P-F8[@P_:2-SQWRX$\L('" M:&C;D'J,4*O" P/L+ DI?* "O$ ?::GGV*G(H)HZ5FVBRQ@:5)CB\ T1^9\: M@\E-M]]\$M72S(8Y=TW&L=]*2S29D8>L/:@9)B:@4O8X8 ?%&B2,7PQ*'4C/#+!,C$1,#@<3G* M8C"XH'E$?,P!LP([:V: M&;/02"P?%I<9B;3%KMF+/%Y*K M"%-BJ]*2R:P)KXA$PQK$A8EV T@9QP9M(7@6PX6A4B@P9H)2HO@6+AU[4PYZ MLA2NR;JLJ# ]N. K2-C"4TI8P]%M8UC7^K+Z*+0L':C\%((+!W1_1: IXHIHQ0;<)IK]CO%L)"? ^2'85\\7N M1RJ^;0;-]SG![T[$+P6:R%-Z;;F\J,?=XAF]]O"AQF&Y$*#'6^Z9Z8,Y^_:M M^;OBVU@7ZRUV&5FN#.$FG2: 3#>N84C4W/&RH;8QUN?N%W/J7W20"==6=3>1 MOK % Z!\X_SO9&,I) 3VELZ+63IX7ZCE:!3"$M(7*1+$)#-M6<78 SP1 @RD MU$"UTUZ =_[LFV1LCS&0J@X&S5"0FG<8D^B(;_I>9T\ONF?+RN23%,5'2 MKW[KJ83A#^1=';A%MDBDQAE=KDMS*MZ#$>G/4STF8RY@>D6%Z.=.P1G;U_E9 M[RBDS/N+FI8NC'ZM M&&XG(;;D]F4P=U=C3W0O3E;FC&!M@I$%5HH;I-32P'C4Q^[#9Q;U(@B<@U/,K$X 7+ MH0NY0(S>X5F&S64I]4!#&0@$[.B*:MFFVG,P(NE-"B+/<,S40/3@MYR>I8)U M:^[IXB7;Z;CN!][)/=3A(1XVV0SXUB:!.6&ZK%'XQV0:A9B!8#S=R_O?&9;* M3U/0'6+ ^?HP[1Y+T2"R,E9UI F9[O-FO$[*$JX5AR"%>AGI256XCX,G80!8 MTEPF^^.HI(9E5X?CV=M"CVM/:3M ::J[=YR6!BIXF"1F7.<3=\N*W (GX!] MIW.2 ?M)_),D6>"X5G; DY!Z4V[NB6B'&G3/4_>J/?(LMWC#+5M^#D)YWCY/ M?"'14YWM=C\#PR(WU_T,Q#SL-BRQ<8<=5!/ZFX4BCHG?=&>=J]ZX5VY,/K?[ M.Y\/]D_O4ZO=::2R68D.5+,?(\>>Y5R^.ZL7)Z7?S>91O:R\^W3YX_BR\?U' MH]61&E?P?[]U5N_3&R!)P(A+E6]B/6T]=<)ZIH/MYW)F*9)J6UP/ M577= 0%WQA@%5$%748>#D:&!Y+.D]_BE2*4*O^IGS>G2W(R'J:H=V]\N/$8Z M]ATK" !%^>X8/[:'OX*VQ6"@X3Z@WTTV 6$AX'=UL^'8(+)U3"A-T9"2,>%Z M>FC*.IH-P<6UZ9GT&1]9WMK ;@01' =D+I,I"26>+4D-4![@](-SA(8"0'6N MR7H8>_2+.W *%T#99_C&L2&;"ID)H('ZMA'!.SWV0*( *2Z7B5P:9O:QH2#_ MB2Q:;]U2>-W^:@B8P]2Y8UJ.K-L\,4>V/?TT3<=N:SH K@"";TP(>]R&\IZ' MG@5@( QRQ*7"B*/C(0 #6$G6(BL$30VN*ZZ-\CH6'L3'E[=731R!$GJLXZG_ MSKD\Q=^J>!C 8;8XS*=XJ9MJ*#^IWQ=3JG=@$PQ90\!UCF!1!A&ZX,4,;!.Y MX.)O'C2XLA8HHO!)<>?>Z(P,QX(-NU0?.#H\;. GXO28IR)=(.1\ /KW&=BP M8V?LOI.DKCK3B?@JZ0WWC+HR;%R,6O7"S:6?I-((;<"RH.HS(CTVSE \R.0. MG%.2+'>?2H<)N=%(:/.D7SV MWT7R\L-V2?[+YU].QJIF?[38OYKD0WA=A^37NDP@EN2+BTA^ OK"PA?3I&_M MU71+]@ET2_55,YK-F/[B^N6L-&S^FGP;EW_VWC:S+<;VXW3,6M<&Q#)<]O H M.>4@3L?4_WVDOVT]8]KY\M50N[IM_NLI?U-54UBK)".>\BN'E=QR78-U$II; MH9"D9;B3=X^5%*Y&0L>.CB& >^9=LSFVRNTL6VU,YK^^CC/ZY?>;45Y[,W2^ M#HFN51P12Z*9PURIF'R0&;"'> (5'N0C.?8UPT+CQ2.WN+A%WQB/#=T-#,2% M;MY $.P)#RE",#]YO+:MI\XHX:D8%\E3+4&Q M3$N8&K-<6:V"DV>EI(WS#K.97+J83_0+#O_IF7]_6GQX%S@^RV+.E]'3KMKG M$[.0W]+1V/.*WY?6(WS&_SHXD$Y4IBD?I',P8#["L$@"?0"S?/116*?6!ZDI M6[9T<"!:DRCJW:JMHCA\![8Q(1B]']P/2G10MM8E.:M=?1-W'I=\$0[ %]L+ M)+YY$;\3)'+3SLE!$)LN'C]**#T^2%53[JG]CQ*ZDQS7+0,1FCT*?O6W^QD^ M\EN(N/U#_OD;,"_V(/@5#D>[\Q(D]/IF=/];PWYTN17F_^?OGJ%,\<^1/=8^ M_3]02P,$% @ RW!_6@&@1U#A=P 8'X ! !F;W)M,3 M:U\P,#$N M:G!GG+II7%/G^^X;ZU2U2F6L6J%%$24,K0JT3/FI( K%" H!8D@+(D((J$%6UK.>=5_/=7^OE65\9WP/^CS@]-G3H T;-H!^!%X@HP!T"K3Q MDT_^?0/;)N"]^=/-FS=MVKQ]Z]8MGWZV_;//=FS?L6/G+M//=^[:O6O'CL\M M/]]M9FYA8?&9B=47EN9?F)I;F/][D T;@>]LVKQM\^9MYCMW[#3_/]Z,?X-V M?[K!?$/FQ@VVH$]V;]BX>X.Q&V0# FW8O.&_-M!_WS9\ ISCEJV?;MN^ ]B! M\CGHDPT;-WZR:>._9PU\F@5\#MJT>[/IU]^>V&(6_--6VVOF1W\M>/KI@9,M MSRU"AN0'CT5?O[5MNZ75%WOVVAVR/WS$X;BKF_MWWWN<\O4[[7_F;,"%BZ%A ML/"(R)C+L5?BKL8GW$A.24U+S[AY^[<[=^_=S\DM?/2XJ!C_9TEI1655=4UM M77U#:UL[A4KKZ*2_>-G=T]OWZG7_\,@H=XSW;IP_)9[^()F9_3@WOZQ865U3 MJM2:]7_GM0&T<QMT@"$C_Z?*]AZ[[]X4B]OFV/=1>2/<9 D^V'70; M8"0P&]DB@:)"+\U7H9QTH=.>1Q4]-RH2G-G'^*Z-5(T1E*+C"8R@C9&WIO9X M71-7%WS[L^I\ %MZ0IDT< >Q#I"'=X: M05?3"PS_:"6&:;819!9Q(U#HW6!^1-%'D%IK*[#G"/!GVA_"!G: CU\0#"J8 MIF3AZ::-TW"*$53\,Z_\(P22JSN_C.MC+803#(Q&),3PW3+L+UVD@3^F.\_S M<"[P-H)TMN?]ZDXX!+38"_;H>!JX'K.T&R\Q@HBYO5[#^.ZTP)TGOYV1^.08 M0;\)5PQ9E4907SUDZCNF$53^K1$TS9U&[O;ZR8<0-S4(AX[:W7TQK6J*P;0X MRW93$Q6T Z16C*9"DX;#?6A.W9-"V-&$"6I9WE6]ZVG*]"8:'GL6S!\/(*AZ M.GT01I!(R[:[E%%M<[_WXK,AO,N158C.W@JW\L)%=S-??<[9")K]#:E>PVJM M03JAV[T4T_W N@=35=H_%^:R.!!4GM / M%#73X:AN")NCVN^V:'!:^_MJN=O8(::\N,29Y)R#4>X\%(&PS15.8GFX]@/D M(A51XNC;0K_FZW!%T IHDP M2M3?CEZA8F^WMZ+041<*6-W/HQ:+>4E"S!(A*,T(BFRQI;U=(BAQ;?Z.[#^]BTP^^.1"]U]B MM#;^S.)TK>CYD"DW%E#+W;AIKM@*5LKE/' ^+O#L7"5EUS!\VTIQ>D(=T?10>,H.U^ MBD.B-4:=BOTG.?:4QB0+T(Y89DCW,X+R@XV@;3TBG3S/"+(F_V738^W0)L?? MI>R0)DBLPLH7I/@;&6'U<33BE<5U*X-9'ELS967P]O\? M&F+]#-VO_O7X6;PV+'#%LLD_+-"VA)QT0CJT!3LY@Y195HCR&>> M.X*-:'S>G.[C?>I27F@@5U$J.CO.@L7'CO^LK= OPMV2QFFH [1EKN*BX4=E M.$:SFMF0OGY6>)6++A-GM59 )HR@F]76WS%M%+T08.B;RX=:&M29W3YVA8/\ M%_TJY"WPX*FT(HF?GF#)$;:?(W5QK;+Y+6@QSM)N]EYRO:Q8@?S\1,)R@N4W MV?,F#C M7#:N2]7Z&$'+LO%_"QG5?^]E?^8HR[MT;+*Z#/TTQT?[1AL:;P3) M"5'_34V:5".HV^? ,N0V-MBR-L.L7WE,WW9:J^#WT[:U78X*02,(!BU55D : M]CHF#EP@W\^V&W$F5W%#7-S"?=XN*#-#8>\* ACN56SY(1B"XUMY6/_D@8,I M_N^;+]7B&?/4]">^R)(RP=*H&_%S^(76W)F11;R;HN:CA(:_"=$V4E9.D\3[ M;W0;/AUS(L)&79R=F9Z9SBWQ2M<\K?-<:B(-^D@-7".&S8VC-?,J)P>.UCZP MG;JR%^-@AUBJ>RA2]=N.!I;N5N?5WGUZ!&L/!V0S.*M;O@?(IM)@1N!HIDT, MWN'F, BE@+NVUZ8_N;@;!;@()=\9%-1<56&T&OSO$,]*:;/WIG MD>A_=7)VV 0W=E*PI1(3M? M"G'OOX)X;7Y6!Z7-7,$4N=<*GS0D2\(NM7A[E!5$652JV:'LCJXLD]Y_%GB6 M9AI8,1ZUJ>4@>^4UW^YT#OMM_RIQ2_I=%\OX/)S$N[H?,KZ$MD-S-M6K_B#J M"6H\VC?V#2KL]SFL/RP78WZD?\S^ONXL>HH!\<&5"22YYEH%3156<_WW X/' M/NTC3+E>+K*]4WJ:GZ>#7GK[='K2>9))R. ;D$O\/J K6&LI8LAN'Y=GS$Q+ MI+0,KD[.S$@5\(T@WDM>6= -LI6DB2*NP-YI\G&J*W75QK$ MWV?-+AE!<_[DNP.2^^HLF?[@^MU9<5,U3=A2 %EH''(Q<$*-H*EKX/$DM;B>6."5[X$&\N\>6BZX=?F3( M7I7R+(ERSS0-WK A2C2%S$TMY78Q!AT/[3&"N F6,I80:3C4]6ET#.3^Q\4O=;@#72V!^P/8"O]=2-HG/1)1\. MT(>T[9SS;P$>847HBO!3<5=^+W 97*&J4C$EDR)UB4"]8#DK/E10HWXA>\F_ M\V$ONCLXRV#@%LV@KHN6$=@_?W.].]6G7LX*W:YVVC?E8NX.637BG&8 M\YJ4F1E!U]A\C77UHSX/O[8)U[=/X]&U/9N9I)NJLRW%65J(K(OHHB+]U27W M:=N%O[:EI*$O:64A+;)QCAY>*#Z29I@K=R%\$!)OR!(%$73("W"9&^<'*OX\ ME;!87PG.GF/A6@8< ?UDR9J^C]'U>G$ACQ=2V#9SZYA?4TS,WG&L2;7\OU5[ M:/@$GS$-#R?GM@,G?8\82+B N-FSJJ[6>M&V05ZU&D$W]/,O1ID;[(R@6SKX M4WWKSG6)A/LB8%Y@NX),[:M+R0?-FZ573$>-N#B92EWW96KAF1V$?@TZBCND M-():M46/ED8D.=>+H!*/KLLR4"Y%EMT1 M2JP=8)08U(7B8OI(2%0YQ-S6+S9MZVZ?)UGL 1' ME!VM: IAJ_V\9Q[$7BW][?.NXKR?:BHKZ <"43\7RC3(5-ZXSL:=X^^(^S-J MN%91UJ>S+[?)A)\U@JAH+])XY&%(IH'"D]7J/FE "8_ASXY=.#.RFM>%";GJ MPW7J8K;XMIQ@)ZDR$%:SF*(+^GO-";B[I<1QJ5T+'CJT=I%9/(\X*9R?CZB8 ME&#> ?C:)2QP: U4Z#E+84M=4UVQ7O\:^=9[SAAGXEA0.TV04F%B\DB1E*? M=NWI>\X7E]3"29G5F!P;"G8CGTXJ6R$WB=RM+ M19(@D6K25(EE?;R@_$NX'._S=7KV55DUXN8 ^JZ(XLFAV$YH?3#*-"QC#NBW M1/7/\3_/H\D1AXB.1E >%JPD MZ<< 0$_% \7RKH9*CJ^2K>%(G2=M.;G%M:LR@B)[W-0%:#L%KJ;A%EO.WCB9NQ$I;NPV!F/2L>7@<@:L M3JJ#JQAD[45-M"FPBHX?4H]OLCR+I5M7N_U)OYZP,G' 3YL75B0^FRK3&&:, MH$=JU+-A2N>:4QR\I?QP@:-=CFUZK*@KTDGDKD(1.]7(*J2:*@IA4*B=(XNK MKXYK/8^$LE,D 4OY>I[VM8K=B?#U""TKX_:\L?SY5,HU ^MR3B@03++8N158 M]F5Z.S8!)#T1"='>:< L5O)I=0)-8\;8QG!QCKPVA M1K;BGC3S;;8IQFN7H\]XA SO>DSY)V-3NIB9P-W;UQ-U>&16XVR84)$,HZ85 MB3C=M1&@20SJ+/K32<_W8G(LOV\.$8,_;LRP&E/\V6R[4T6EJ7#CF.**X)G\ M(T,G::WX;U?8SPGQJZ(]Z6NP%W3\O?;!T^M@DDU[1#43'C9IFZQ!RI+\R8GJ M(/J\4V;PK^.+&,K.L4'=KA8_\W,+AA4 FD7'I^6%.^IT38$([MJ^"ZJF@U]^4WL"BKFI_I.;[WAF+>BT MP'^DFM7IZ20.>H.:8>?9F":MSEDX 85_$53O+/B..!OD8:*9!\+-3,(:-*>4 M[JT+*SS;VMM[J(L.]"6(\@JY,'$-3#:;+R7>GP6:<1X06Y/S=98+"MN+4_7Z MZ,9.UA?_LH+WV:RHOV)L1"]"R<>A>< MDZCRGFBM^?B3]N/")2!6X_O#$ _972*=!6EJH3<0UC;R500Y&OUHD@V0]>?W/;S!KY$T2;S"SF$6,Z;D/;M.Y\GU7:3L#"0]\EI7A>+3PT MHJIH'IQSVE:-3)R\01HP@A*C?7T;-93[C:+^O"@4WC#=G0_ +^SM2&T([C,H MJ3[R+Y\COJE5I5T2MBSTI_8TO93NK$HV@K*;)N9AHH1 U!<'L@H.M+T1V87< M561VKT243&9#VR./ 67Y>ZCNCIT6)W!G,,$N!1NLEP=I\X,BB#'CBIICT4']TV6*7&X&5)MU,7JI;^^^\O. MRS=+UF8$55MKY"_%H4T&0JSDW$@\#'G0=$#U'F_("(SJ,H(VD._IW,GN=[U@ M:8XM#NDW0CJU%K.#"B 8/7?10B9OKC.F5/=CV>WX"_2SFK.-GB*:N>=X.X4ODYA@J+5PINZ&# MLV3:($//M4?JZ8 <]TMZ!I2&T:2S6HJ%-EHI/@&X2@M(V(XFW0DN>0F&4P96 MWRF%Z%KUPX'@6BUT1CJI'R7[R'&_>X5F+,,0PT7K'8D%-XY7/[GE@^3@9O@D(OW.^^'L 57LK8C8 MO%ED"8T.T:M"7B[OZ,9,P9O\#:;[G:3#\##MR:@(?27*5^H(M$K'(I9?LK^& MM<[5;C1IZE;28^@,#QEB057(+.3T\96D:51F((J 0KFX03K$=UV0PGR79W]WA>^3W!4*$;N.2*VY2.D.L :Z8@29] ,5 M#%WUL9*JIIW ;V ^.LA+DN; 6- MH+C@FF^F[@L:'L)W?^O=;6V)[PYAS TE%B/F6IV(+ZU$1A!*3R?&?+7>#;U2 MP;R[TLM7%M5?BH]\V+F9PA8TCB&2X%?QB]>@*$<&A&&@'@Q-,QA!''H])-\K M%%MEFE?@#)]"#U!4&$%-5X %[\S!?R#M-WX*V\F]+R0H5P"2'JB,A.7 MRK0.B@FE!HOW@[M1&==BW]>1(Z7O&5"]:-I?L +S-\GW.I$QK3_9 M$]=&;:&)*N^#7F0P"',I2J![I/=J=H"RK[ZU+.RTC?*(?X M9EE*4X!P70P/K^Z@G&'RSK#',05 3)>SM8\S;?5,W&-E+OAOC,%V?AW=3*R) M7[]3<]N)!V0\C.VFO$'$6;%>1E#!DF8T/FANK7TW^_,@<;YI3US6?H[RY#P\ M&9\KTH-?05>3\PR1;5DS.-WU_!A;'YH9_R-YSP@V5MP$.]>:RXMJP='FJ6$% M";NSRN?#"\.K,]*JD [Z[G'VC$&?G.W0R7BF+IA*K^95M[5VC+C8HM(N^C([ MD. /1E &#S=AF'VMNYAIV\6,M;Y:?O=A,Z&H:$0[YY=^Z/:TR6ZU^]0,P3RM M8!Z0_:>4,MT^:9%/GZ' '&I05$'9LX99%6HDVWJ>_K"E$C%0%Q6)E#*O/NEH M+S^2YM<"&6M'.@,,"*!O79%/R-S8[P_IN8<;'[:. ?;\-0JY_I$R=YO]#ZQD M#J&B_](KFZ^_6K[X8I?MA]N2,L!"^A] M]H_ +OW:-'0"2$.:;J;^HT;VTO)<. !\184Q/:$:QF,?5=FA%I@.3QKWC^2W8M\KZ5DQ,F_9Y>&N/[+ MF'A-C)E;?'60Q])%O@*(QTHP?/BM6 MP&Z-XS*=>9<-@.B3*)C]3/=8QP7'9]W2EL14V814MRW*!^USLZ#:;%YQ,_C. M]Z$%+^;IREIQ4["4;(_:X:OABU*[+P(=N*'*_='@-27:L@=AIBW I/U[-"R\ MLCG'XC&]ZTU;%@FWA+: I"BP1$_]_"RZ<+Y'1I"YF:^TRX#(1ZP,QHCW.X/_9$T?E1JVPHP@ M,>GY:E# #HAYO)+W(.U&_,\"NR)Q1K2O$82)QE(FX.G4S('QQ%5-(L;N#.OM M,#^0_<&PU0B*D9!MK,Z%>Q#9>'=W!?'4W?I31VL'[N:[N*SLOR-Y4S]%Z"AB M+C#J^4,(B(2DGUP;LB^HG*N?Z:_';$(>Z\J04FD?.+&.RY<$6?@/MZ.K6OR, M(% S_K41]!OIC%[ZQBPCI+);3GXE,_!A17NLJ^:N8Y'; N*H3'DV ZBR7=$' M!?-3(P@WHR6JUV[./B=;0E.JU7&A=(S(1%TD2@)<:T+#?@^/9$X=HC([A]/0T#'YBPUS_7Z_L4!4"9 Y3?##^J=5E2 M#.@X!8/UIP2G<8.#9@M/AXO;DDDM#7-N,,B*L!XY3*Y^6*=&Y.]=IG3- MWL5><*M%HYV?UHIZFS(L.B:/]A-M ^IU*%I"JUY6Y+.6D7_[N,W.]+V&)9P) M0ET;VD$OANVF*G\?[E6 RSK@,&TP".M9$?2F_^A/ M1U:&?_\=LG..Y_8Z+:,N \=/4VC:JH*Z;/F$$#N,^!V[1Q?$HE@;WNZK:ZJF M_^I,6#JI:/XW$"3T9,SF&/8&BH,N]*8EC(WQ]K+R,37C(@]9\21>N@^P/J2P M=J(Q9N#[S+[+E8?])SWRB)9SU.&/!M\644UEAO*P77ML<@2V%C^#T5[FHK30 M,^G. FDI;EPJTA_1C8Z;&4&T?\/)3:8J0!U?=Y *\_%7HON4I9,(#"LPORBQ M^E=KIP)?DH$"D>6^^2=[#XJ_Z[;C-0$5>?.'ZX6:LT6M=$8 M=HMDDE).E>2O?&D81O;??#E/C]'GAC';<11L<2NS7BM:E^AEZLT^^[2!A+R\ MJ[6W4'FX-7E5 \=*NZ!SE93:OPS*]#4\+]Z!.C[JA&FV0]&8$3_ECL'9WN)T M)ID@T3834ME:BZ?RA2GN[&^4#\3S89V9H?1G[/ XCM7C!XPEO0I3 MFG,:\N920B!ARG.A+.Z'-I3(;7W(CI(W2(>ZNO>8&D%F39?GHMQ:1IF[@2A[ M\9EK.4$91M>,Q^+ ,MQ&FGX9@+)F!\Y4,4E9]Z2<$Z1HBAM-@E *$;R]^?S" MT#/5"*++^JBHBZ /26P2 #O/6_ELD//N-M7>#@K$M1A!5P>3ZD2.VSJI!VK& M1 [V(L/^U>O=Y?&X(T\,/D-7Y#-%#3T6@[K(M]RV%AI%=,US<6).@FMI42UI M&0[@_!R@V/PL@OI&-_1:-OF#O?)ZC;Y^I?8-@!.7),1?O *G& N9"WND%.I( MBB>)%)XD47BI77;OG?*Y*# [R!C/1C"BZ)WM6;!0'M.N07@B'NUTCU\^+SS" M1[ 2X68QB4% 1$397J(&487BR8HBNR([_4@;+B4[5K R8O->KU)> M^@9N5TS(=(R<@+D# L]BO5M:QBZLN,N3*HLA;ZS_5>=^(^CWY/W@H,"YM)<#]]Y*-[I2ZOAIIF11B7\=C4M#@%"S&OM9)HZU?&B#IP)EGZ MFA)ZJW_?./:L)4GYFQ$4224E%"2*V@ P*GP(8/PWF0'$_N2]HKLZ5S&)5+^4 M%"P\[/,<6ZP:-#T.IV7 /B6KTCQU^?KUODS(I^FPB'_(Q6$*G"8NHZCF_'@N7.V]%S8?KA[D:& MDB:\HA7)'99T-Z:^7P,;03LFYDI/$^KA'WDA$VXEJ0,8,Y+O1T*V?RB:H^>S M4WUDW_JL5@[VIYC@:L*]SO#N2Q>*U-[LG5LLW1;-IM&O M*)J=QNUR4FMF-33<1]?92,@+!-3W64=ZQ? A;K1<,0>PG=],S^8^OK-=LN]E M(RB4>A&JWCI1$X_\+.557(8$?A4K6!A@'YD-2XE(%K76OBVP79K4=]ZWVK.VM MX;>3QW=XNUULUZ1=\I4!&8NO!;"/P81YL>DIPZI*V6;SX//)Q>TXS8Y((XCG M1_YAO^$6D^-O!/U!(>N3(U>?BSZ"J?=>8*GQNO#"78_;;U<[)5O_)]C/''2[ MVE5SZMQ^AX<-$53ZW,2!K*&DT\E/R\?$K.69JT[9#SSKO M+7%L<1U<27 ?]V7OQTXA <#)B-NM8*,^ 92 ER):TW+G(A@P^8A[H=UN,H'_ =^1K1M"[ MXX(C2["W70*6TX.VR\CG;"UWEHOWRG_R(N1\U65A^MFG;,5Q/>S\,S_TP@Z. M\OXCPP8 AO6[6O=[^4]1M4&T=RG@+*WD3(04P<(M81>B[N#<- AL75/YPJS( MG<,&G*N1M$I4,^\!9?W]X7RV$41/$*33H)TY+N3C#TX%Q6D,/"72%2);_/=7 MF?6Y[+VHF]FTN.F(5>T":E %M_BZ:+\A_)$:_!KK78\Z+^J)JV@G7_M98/D% M+"OS#O%ET+=>^S U"4JWR.9:<+92?-5B MLKX8[[^H[1OVV?Z@0MY<2%:Q^JP,O\([7)_#=:Y9UD+(HLENU-[3W?QGKU.4 M[W"R' "1IW^GC,93Z7^Y?6XW]M1B\$6S-;+U\436-4;N>F2P)&?YF*KJ1I0K ML&0:D6L#1M"5QNVB9;+NSE= ",!I77^$64#OKT^8R&TM9CU4^6LNGZ6+$!&) ML:/M8$]OCXC4C(XOSL9]GNU3?*L2 Q[E-+9GH-KD3#I(S^.>JV)'.6.C'^? MT' P7&P@&_HF&OO4C+I#!;%8EAD^:ZS(F0'$I*L]6E(XLT9C@*Z19_0<739] M!W%+>@(G0GMY>9'.+D2!HT6:O"^S>)^[I4T_ M&ADSM[T>LA$T,&2X4G*Q=^7(48E&=D=W+_^S9?-M 0G%J?CK! MV32Y^&(:3A/;8HO'";7$GA\ZU6T>X#[T5/U2RHYT%PF3EMGC2]/NJ^AG*+$" M5;-(7TS? 3#TU9MWC:"C0\-A\-"(IV6%XN][: MY7K::%(Z*'$9B#)QF6J@DYU3]B@5"&G^QW&/OW? ?7N+^,7BE677YA)4+>=& MDH(O&'"6E5FG%U[4CW'HN7-=-"QPM<:;V/?H#]Y6/YWLR0!?FHCG/^#>O@01 MX?N+AFP,FO$+$6K[@&>C%>RV0()[3O3I7*'B8B[RB)M]*4%)'=5DW^R67\FI M?8FJG5<*OT8$#'/)2W8=-'PL4V4VP(I SFKK55;:]DPFZZ,__W34<$ >=%%T8KC4,=G 3%VW3 M.A%C)MZ-/Q2@M8,KC"2,DI0P^W?VKN5[RKM/E7#T6=>SZ"3G9J=982'39IX5 MF\56]0D-#N.$%Y$7>3 K)[1V'",>+=$![HPTM:T$])SS7]\QNT[5A3>54BB]>%._5N'Z11PXLS_/ M :P;8&0";J$DP0+EV065U/*Q5&'@.S^G+K(L0GFP^>$<0":VP4?\'Q_8^]?0 M3,'?"(CYMC9>5-9HE:!R0>!QJP;V2J[%"@$?$"XZ806T,[.KAH]C!6^Z'K2NY< MN0WEA (3.DE!?G@G6AI9PFZH_&'!H>]&W,^/.->4>?M>HR63GK*B-)*>AWE? M67J@R(-XY;2'+CB.Q^JG?PE()2\K[B>GE;<-KYW>G'5$TK4B!=>"S3!,[E4] ME/R#/54_WA-WHSZ@=8[Z+/)@BR]AJ3Q4Q#9L6,$ YP/[C\%D^%!Q1*0@I:5J!FE8 ^50M'I%YV50CYZ%U4!1+6DWIB%N!RYZS^XT@ECL@Y0!)_<#R MESYMRZ?.WPND,]M&^/O/\52 M\I.'?+'3H;=K38>8ONVGBR-@^J1! 0MJL -GZ+8^9=(^&W, C ^BL]TZPVL M]>\ AE)6Q^%>;)@:>)QIN7*EX]:.BR+E7)3X8(X0GB9B7V\]QN*19G*^+(+\ M^6+( $:B^&_O_SC\Y)X_O8W=P2Q98J7O';N8H]2Q/8P@D2?-"-K5G_MR.CFR M^$%:W?.G;^?,+57!B44E7O7(*W/(N*42'VVB2,$+K$UW>7EO,:B6!%$BN,,' M7F: #4J8Z)HY&S+895!XA[?)K4MJYL@Q<3[UZ'A%5;QE[<_E)\D39UBX21?M MXX!@P_D/];K>+(!A78^/84VVE,7$9L0W'VT>-?>K<-&9UY;*B-FNX5K?K MX=7']:,S,S/@=' O4OYGS9,'T6/7Q_OO"^Q6HO'791J;Z"7# BPB@G\H9\OM M)/D)[[5^]K(H*O!G(T@UP@A[$.,3A4E>K!X?*]$$6AN?^BWJ@BC!34'I&Q>/K!UNM$9V,$94 M+%0K;:EH+QT-4W;(#^4T(.9*<^>+>3]#)0ZN^3IL('5K;-Z,AA581]3SZ@J" M/?/*MG[04OK2&]:2/0F9.U"P40IC%-,ZM^S6&VLX@C"")(\#=>=$\OT][ M&^F=)PF10F(\NE;84S-?*(R,6##MF:GEVQ:/'2ZK@(DDG@@7%?R#E@T9>*/& M*!WA@653<)**D!.[KH,!$YD M,10O:K?Y#8NELPJJ)BY52UE%*?6)';<3VH,#G4B+!L-X-*;3P%$UA.V%F#\P M@MKMY$5/@.&[A^HXK M=R0YT?@9#!$S02XQ[-/%+F]]N2_O_NI8[DI0.2P^6@[.9Q(F$50*'/XF1 M*@>F-J_@6'B1O>%71-%1%B[SL>0A.L0B2[/_=,O4W3.'%'N($ER!09\>5$YR MHM8M^'P,WB?Q1Q#VZ>E+1M!43=C,Q3 Y660$E;L3@+__J;]R[Y0:[R!M8PRM MY4_=C84"_VSI0LU^J]X68IA3EOA<^_[&Z<:,2ET?.*.IY\,EQU:2#..N[UK+ MJ4^_4^,?ON<13I1F<%C;87.[=.<@'3H[;P:XV_-.F!$4VTSVE4/O8-U>'[QY M17M'VW;)I73M?4 1DF(&F'_[LW_R75W2)3[;U(>RW-\N[WJZ#YZ4UT\]FPW% MJX5=C_ZFP]-KN^O3+=AMR;0)H&-+&MDO+RVZ\?&_IX0G#[@J?L*4E+ []3/D MY'^2]V%,XG^>4XKF*Y%=^24$+5><!S9'^$&V($30O?V%9QYOKE/ MEUC09#L#=*J[^>;TH%Q<'Y/V WX?82E[C751 YD@GVFV-8+$;H1*];#VQ.CL MPY?]M\;"[=#2F?:EN14L(3C-P5EIT)MK'I 4"NVPY#LI6)M@0&Q/81+AN4XI M=I2S%1TBH$V8:G_#N4IR]J&H'%6:M*%T5Y?XLGSL:5H],@&&MXFEP <.L[@6 M/44C@=KQ-%?V4H6OJ--6I*@=T,^ON:C/)7_;.%"],PI"[9DA-?>-TP\*Y]A) M8Y>A)8]2YY\805;8KXK#5$1!@;XP)?Y'?#]>U>(\J*A]K;IP$Y!X*OW[:EVM MB6.,\J&9/X]YFBC/&\BZT1"%J[T42?TK[YIY6X^RJ>"2%POVIMY*=#9U"4F0 MA?6]W,+PN8P[:^CB=%L@K8V+_FL:3-GZ5B2")%H8ZISO1&7 MEF%)V2<0#)B'+,)$G480-S&(0<3)$R?I%0QUY50>V#.P9*UN6"@^$ING"F$L MYB@'%.@)(#/B)BM"\"_[+\5\H9WH^]3%ZT2#< (>F-9L!,7W\ZLB*?C'K^-1 MJ%9D6Q"OIQXYALKAI(4/V;6J_]^D'J5VC[=HCR0L/(GLOHG*B-D/+ MO,C,_OP6)2X%S"#TTH_OK6;]R?\-B2JJ"/4-NRQR>9/#7B)!Y,VRT@?^?1Z' M)$>9BLDYVTRG]#7 P+ZZI4MW4;3)=)"2J/?N2) MJO&JR)2\C& O:4+^M18+GRLB%AUN\J#X6 )^M]#/T>U!HT]>PC_//?N7ZK1" MY",)\I':'7;1X/7/3_2N6XASQU$'BR/22(NA>?JD/FU3FYJ:Q6\&0LZC@3U9 ME;_P*$Y!9G BE)MR.)F;%U@\)@ZW7\&8768E1B4 &F&_7EG49$-E0S>:U ]G M8:?#>(FN2/>@+/L?TFF"]L\*LDC27?64$LBP.R9%T.(&>_*QW&78Z^SFB?6D M)[0<#2E>SA4>K%O MZ$,P2")@.Q3_X^S'UVMM9HX9]B!/_%3-OWJC\8_YZP-UPB9FBT?VM+15)].+ M6&Q9&.27%"GJ@OIVZJ/F^EV/Q]*@3C45P^P"CPG;VC?+MN1^CL+W#2,UK!MB M>IRW7'O_?1'Z*6583*$5:_N+EIRK\3.^0?4K+AR%+2 %#3C&8.ER[R ^*$\; M&@5?2Z/[] I;TAT[VXSJ%EJ5ZD4'^G4U9RW.QGKN;%1<2 M"J7X78M7WB_<#/_-"/)74+.D#$-Z"[/5^=[N:=@0S;YK"&E/>"ZE5L;M*X*JWKIHO.\<%>F\\7 MZ!=7!N*<'VR"6<&L=A\]6?>:(=/S&=7I;0%CBTLR1YE[SV416V36+<<2#,F7 M)]CV@_[NJH 'WQE!WW)T-I1BP4L/8BF>W35&GLE%G'9Q$(>7PMXM$LQD3FFN M;XCW#=:92(C6C\W3XU]KC[,PA+;!<4FB2.6#8ZCB#0>7FPE3>?KM?"U'1+JD M+]^2NP6/6DS54(V@SHB HW\];+C^^X'E_=;KX!PYN7O2IMM6O&WIQV>C7Q6O M64^.*]&W8+"L14+V3.]EP_ZUSB=JX@_+>P/X61R^5U-Y@A?:K$96LB_&ECIF ML#0XY)P,=G:-JI6M6LS<_)\?N3F!:/J+XI -.U#AYQ.GS>,CU8 SB+>HN8&.%(S6X=UTI1E"UY>J&G4;0"YNM M"6.MIRSSXFLTK 0O>O(V#-BQ+8.V&X.<*GJDJM?A>L[SL6;RE!JR>'\ 8HO0 ML!!%A^?-L![$B2BV?GZ3J@NJ8"QQD5T[$5[O9P",YBS?\'FM^%>6$QQVG .,>WQW;KR#A>###6D9^3QGXHAKY M/J\S^_5[O2O&%K4981:0F9E_1'"C J@$ QDT,>G4CCY@4\SZ1M]H$\5Z9L3DVT490JQ$DQ5EZ1]8T\Z:?M.3\ &F5YQ+O&0F_Y=CKWM,:]-4B$#9MW. MR>1%W)[ .%ILU[JFQ5X5!:#9U!>%,Z$//Z6UX38GZ +;M&[U3R\UZ!; 1M#' M^$B?PW)VGMUH^SC6O>E=O.7A-QA;^K.5+5YS;R_@CS^0(5>@8I8S%RR9H1=#]Z ME'>IG#]FEZ??;*5"NA!4+(PX+8ZR(HSAI%=0+XON2 UI4U.JAQ>ZKX3U8S#<5<3M9"[$CG@^F#9TAG\ M(+#6D-<[&!C3=-++,6HI^-+;P(U/,5^:FQ'0]=PTF,8G#*F[ M27>"BE,I/^E;P/%4%\R6=OKF4K^9 4?:SC958YX.XHG-67%-#OSS_>_U^CH\ MQO#%V_7?(XO*&Y[-6Y)^4B+==@YA*&>C-8]P;YII)@:I)7)')#^05.**])A7 M<()S)6,[ZQ1"CV-T "**+ER9I$1![D>NM7U\T/!QH"("ZBD0(A$]SMT85]L\ MB78HHT%05&UP*6Z,-QSCNGIO[6F9_[RG"K47W=[:5 %VI"Y0D0X(J:*_J>TZ M'TNI1UF$-5'X830D;10MY6/('M!%T46M S.<2/6A:U]>GECTO#5?( M#;6-\?C4L8+TR(608GMF+I+6GX-9T;'39!"108].8$&6K?-OKCO24POB,(0J E8#!3 MB $HSB;]Z1KGV?/:CX8+J* GCJT#@ [<%PV P6O96:E9,N4\'1O)E:T&YBT$ M'0OR'UXMYJ9\T6R/(5YN[9[[]ZZ(;(6M&GX883;HN^BH< (]FW M ^Y$P'$SSCH >[UBJR4W(O$O[!C/Y*.!*9\-SWG E*?L5DV9%WHH/ED% ;\W M:5D[LWP5%Y M[&-IK+Z)]71+)<:\7I%19P3%"8V@C#(W[)QATH;YZZ51R5*O7=F-J4LW&X0: M6,%+EN*MN"XHI'L\F9)I.()F_-/# O^,]3D&*7(U$0C2V>F:$RRJF3AAR_'0NH/I/^3 MW].?45,MSY-ZI-VMR%WBHQ[L.VMX%/06(TNG>F!]_ELR4Y8P<-)L5=NW+S40>@)-\IW0GY/.YS MD?I7_ 4X"A'U=NP0]$!FS[6-2[D7-4JI09%H!/T:2H)NFX_RSTE*2BDK57:9 M=O/XR=8A?&G>Y:B08^PWA!+6E68Z<$#;KM\R.O,=H;=A.=7S/SO7QBH%VC^; M?8:4\ ?*1JH!1D@R@JZNA""G16Q]Z8+NU)2VZX)AMT9*V7Q7=98)KRH5N[C& MZ4>ZM4HZ]DVS2.XP=W@\5'IP]],ORC-NR&O >F<1]%'PH\7[ZRQ] 3HU4.8. MU*H3"%I_DV#/HW9AMO4DK^A_7:H-K\C,.V.7(_$3M67/(;4RPV#*J\<7M6>Q M!WM_BW&^>L<\."3E__1WK!.?'QAFCLEZ(H]B8T=4\\5':*?H.>SA"Q),.UQ' M\>]K&VQ6_Y)^8[#0R6'L8 ?K##SFG*(M(_@8[L:'5(P,2Y3"\%'ICP*,H-]F M!OZ.[/NE6 #E6DXONE_O03EU\?X@$%6!*T J3!'6_BFMOCN;?[PJZX@1M.U< M#@ 731 CZ)-'1E!NLZ=X:R]BXW/D3J\3T^", [QVO:7W2D]M/V!,.)2+UG50 M]YT<=P^= K0BD\F/'G[S_&Y\F+N5V[?'V7%9KR7'%C74HUFR)3HL-D5^^SG> MVH*K.R[\LAUA=0'-&_NYIKM#H\)JLQ,J"ZMBMUU_M3)HKZ3("8&TR!8N$^+" MZ71!P[%G_KATZ7@S216M:(K@&D$/(L"1&/[MYV"Q9]:W+O:=M([8,TM-[],T MM"B9D)#F4/O.V0>C1-4NVSR';DXGA76-4I FS[/JA,X#>3GN2479'$<;8#F5 MA_03Y1Z#]Y3Q:A3:U+?=<6U3#([?Q-3& M1WDWMTHG\E>R^ H2\1,U^.7Y=/R+\^G[(H:2QX>=W#+:LWS@KRC@G3+/;FU! M42A?/ 7I6G$?#,>9L1/0)X4*A,T+_O4Y:H']N' Z^->Q*>22K@"WBZ-RKU9E;*]G=97BD0/Y%35EVPL;S/>,]\!UJ1)7O@ M,AY/M"/;7H ].])L%[ZS;)+D ,4P<$)M8Y.>7_I=>4:F1Z$J'^GV=T"^++YO MP@@2Y/M5Y-;7SY^/#S,57J*^BD;,=!V8>;M5O -W54T.&!%K%VAINFVD$? ; MK 4&CNO]OPGT<6YAS?^J@XUD'J0RF^1 -&DB& ; MY20]+)>]&,TV@OY98#W99=8'4>P&@ *WR.5PD?LFA.G$GJ-S83S3.678MPY" M:)+V2B%,,VR!FT(P(@@R[)P*Q6D'2.;3]'M1C*%D>%F1E!QZ*1A[7J_SVI^W8N+'X E7[S%P>IBJ5M.$6)/ZE'WY3#HW;5 0C>C M;=2++?7L1I?VK M(7>""L?7CXQYM7J[H*RCXG?#L5[R+BH^K<;OR=Q<;/*K%4&5S<%&]@V#VF"S MQ!40=\[!W*Q2C\T5CT1$T0C>C!Y%@,C^K4B*!58B-A0,V3MW87P@ZT:*->'R ML\B)K(JE]$>2,O>*+ -V("0?^'ZJO%3L[R*$2.H?;$0G!?>W$1FC5L5^7H9R:(:CT$.SM3<]7^5YWWCKE%NE/-@DDI3X6<9V6)UFT&PQRQ]A4?Y5'/ M8VK@\%.91I#-$7/D DYD!+'X#>GW>O*>",?CY?&JF[VDFV3',#>XN^9L6V:; M9T.#[B-;YAIDDMO^,B4FSON#Y=ZR#V<=(V,GZO X=SF0H!J\%>R4-Y&&;N#4 MAH!*HMG7-D;VL%PZ-Z)%5EJV+9:]&(IP?[Z^*S_AC_"/8V'7'.>2Z\V1"F[V MM!'$I #>)<;<218,!$:L22%2*Q@RUOCF51VUU!3+(,^(IU% M?A]V<)*&D7/SB&;/T8T?2S-]!6N!$4MC:-'!0-,#6"-(!;#TEY4B\ZZ2-*W5 MN16LZ-ES]G\?5_K?QE7/L_*GT%8O>3 KCRLEZ)\+4]KYF(@E[#;*[NGIOI7PY8QA*%6K9Z#15$ MCB_F4U@ESI7QNVH]9+E#LTA7GK[_4JN;LN7XX<9 C-5']V*:U3>HTL0Q^5$_ MK]?)!-LK6H(HY2)!;'*W<,'WMC9A2!"1$=(S511A%ZL%0,K@:5C[LO4 OT_S ML#1W!N.%JXZL8L=T4KE1=OC!P, _"?U7*S)2(1P5 1TX)?OR*NO@L-/:#G0 M)Z;1.O'(]8=*F4/-*Z*>3$!_V6J"LDZZ\+2B4QK8Y[$KGS2W'ONV&KU3JE,( MGEN5LA="W3W<5?!9I':I/='K5'4"S.KGB/E4_-%QGX&JN\FX P"#+ T-V.H; M@[:#2T:R[=*1H7)=Y(=(26X\U*5(F0<@B$C/(:A)\)#E7465:7_QFT.+-6<>0QG_Z&4-#M -.02&H3M3_^B/'F]7_ MI8TSKF+M!ZX0>W*^FCOQ)/D)[_^J[4VCFCS;=N&TUJ)U0$6@A0JMBBACJPPM M4VH%J41,&0/$D$<%$4)(E7D(>=0J E**"*E0B"(SA,@0HDG(;1E$C(@R"B&) M09E) @EDX,ZPP_.^[_>]?;Z]UK?7VGNOQ?4#R#UPW\=UG,=Q7>=YIX(F_:4&S7E1T:I=GO9EU(]"/?X4?WHGX_J^=;,!#I@J@EU);3V" M?@N[(EIC7Y31&@Z:&T6$9!D[D5,R#>>M: M7'9D7MEXDZFB*+1=J(5$.FLA^Y(.^"L .="<8:$36F/F*J\0Q1NYVVZ=$_3- MTOPZ,K__[IFP.T6A\<^E4*%]KA:R^NEROD;O+&%E+U]H?]M\=?,R4:,'WZCZ MJ'T3?'R:CU/0^=)__5#W&4-I5#?ZGRR/K%#6"/^GZ_X@?IBFO[/0=3+US "@ MD#GBGWU76V8XAK%GAP96F9!VC]SL9F^SNT322W%^!\]W]/6WU.F5S/0MA6)8 M&OOCC1+8U;&GXIO)?/W[PY8CD7E-8B=*H4%<2!%A0G?WB/N3]7HNQ$_8U']6/2'7=%A$2;NMX.+V2V?UZ_M_?DCK[T_Z_U;R&K2$R#6*8:$ MMST$G;$>P_]@9MW0I\Y=T0M^1,=9@J&#FIY) ED]Z&5%8)8'"P%NC!2Z)>58 M]RC)B HUC#&"OEV/H,=S)JMX9'6EE#TC\LX>AU[>HR,:2\WWX6,K>K"VL>W! MM-%F%*<-V>[SYZ=<>98\[#&@^+&MCH4L8@ T. .'Q]MVH^5=K-&--^U6Q3YB M?NIFS9'!?/E)A0]!B(*%C)[70O)-G^58ZX!1WKPA&[@7DSF:%Z/V.9F&;Q6T M;A?9@]JPMSP\S3NG6+QN,9XY'97 3N)5\7YII2I/'I-8D_/=LM_XW0$[YIS&$;WF-F M$"_%-^CF%JSM6FCXV%*[?[>$;L7 )A%$-+ZRGE>Z_$P:OEPTH;ZY8P]R8$=3 M[N8JWFS*OC@+K ATQN+GM!!>$U%C%#%?>V#'SM"V<7%36P/F<4UP<7JM$;KP MA<8P*2MEN[@U CL/&?A@V0MX]L Q>7HT<;A!&1 MFME^>G-&L/IG"W M*(+%_G-?#99HV">N69//O!\(*3](3%ZO' =')W[C=P4Q;>L7$1*%#/RYJ,!& M;$EM]:1+SV?OSU48G!?BIOC2.+ZF_W3J$]_(I6D[?VMX%F(B^*K@K8WFJ7PB MG&K78"?LV[MH/8E3CCC'<2YK(;\%I62:+LB,2S+6\?U55"[K8>(O$]<&K* % MMN(),^[4>'M0@D;#)4LM_-]H[+ES&L,A9+=+8%TM[.%X^-/YA!9U:W]$[NP$ MB8Y]E:]"ZW3]TYA0S8%%EV+* UAU]&F0& @K-7XB>4!Z_M,]BU-AMB\!*%N" MGZV7WU;6%LTHO!M1EPCC>R;GZW#GL/7(M]QJL8N LGM(?6!:F216ML=-LE'. M>2RS@:FW-O=ATZTYMH>T$-\B'0XS5CQOS6]41B;V]KP=Q&_%MLTUG1]Y2$UY M %YD_QH]E("/1M?GEMRA83:KT@+VHBIZLA7CC M^U1FB/Y6=8G[%)!LGE"IA6Q/)+X6S;86#_FNA W@+F,RY(7<0XJ"*:5\_]&F MODA4MB=4S]1WS%;SDIWZ(#7L"I5)&^0P?3%R\_/5XP1 *E321K)9QQS+\]24 M^/L_E>!'RQ+KHG^C^8@3?L?B?RN%)KQJ_ U((T^J8$_>K G-?8?;&F"8W+YW MM&)3O+=PSU,):_@BW%JDYD^A9Y. M:#+[$QK%E:-$.KU@F"MD0MP]*U'5N[+@V="5'_^R(,H0MZ;4PBXQB&I0DYZK MQY9I8:I5<]>ID> MAOW:<1M4'Q8?5P*+D9>*C>RM#A9-)< +9PA<5_N-NJ(WXB+P+!TC?3\*P=SAO&]S\>S )A0S6!W"@-:9&)WTSJ>>6/WUX;@KC>WX"^063 MG"GUQZ2&#LD-NFM!#_1: RU9'E:'R70;%KOY5B&CB[$[\XVS]P\V)>J[)[_B M!3!JBEI%ZA$^H+ ^T:V%[*E9YI'KG]*/A4>O.QC1C,<(,8&).*MR#<@5A PG!<$=119$N=$FLXAK9N!LEL[*S MX1ET]_8'YVJBZ?B2,!L@ZC%HVPEGH0NG^:VX/D:PU919_OG.B_W MDY]/))4D@G\E1R?.,(UW(95 !ZH4H0%Q3Z1OQ#"N/K>7M\/\J=E7K[]:!CF$ M"[RSE_()N+V('59=;@8LL2,+?B<0+/7 $0D#"-+3B=&B=Z0=E](\:LS4KM/T MY"B:=.B"ZM9"TQL[&5SQF9"+*LYV(+J8E;KEL4*QYY,)8J?NAI$!JSLN[T_: M'=*_ZN8.O9%A6'&IE?WEF)'1963;&WPO1STQ"7]RIJ*E8&2+I/?N__]FQDS\ MWS8S-4MR$PP !?)N)N;K%[[X4O",]*3=_F@22QTU9ERFF*E M>)*.K0M)V3,SF"+Z!V%O"#:%E$9[R>\);_AA\_$#C9^]?%F;*SWF" \482N8 M5^^76Y1\88PY8/Q;PM)&#.;KO@B"IX"ILS@KS&2"00%T/&#&6J*P"%TIF7>DLS)DH=BQ%&)R9MO/F@Y MJ.[I\K)R;?!XIAYF$+*FFVA(A684O4OE)5C+/3.$33#MMX<7H\X+!.E@[C1_ M#VE(Q7)M>P:8DQ/.]W!Q+LOEI^E5T7_4AT4POYF=9\[2=L\CXPM%W% M/^8D!)(S9\EE =WF.R/HM.&U'2>ZQHS]K)3&5]K\Z91E80Q$XFLLFUY.5UP9 MG?4;DBWY&$[LW'6 M\\$E4;)K"\X[J-,$Z(L$"4 '[%_QU46)X6:O-2:*PBN7)J)NXF16#18=;3M? M-,@S48!H(^L*=N*UN(HQU(8QW38>Y(_,10;II(2HX2@%;/MH<".[6S<^>JJR MTD*"IBC@YQ2=1G41-_S;&L+/>GI_2YD@:R$F.@CZZZ_/:B&MP9M3USP.+"Y# MG]X*/E0E\#T0A#V#9'N5"E>\#(=$N++]41'_2G##CI$63J7HM$"3!_=3FF-^ M@9X,-J_!C1MJ"&WXASBV>F -Z)(?OCH4?+;9H4V\-0435.9VXH+QA+\6@A\. M\')C!2N'9HL/\JFA(ZQUNX5B\ZPP!^LXEJ!7I MT*C&1)JGY[FB?UUE$?F)41IW'28H);1-N+\$Z'2I'_HBO\2VP%55@)^&BP/I MA[*GL.>MK=U_1&5RX-G4,E:@E,.P%+'Z.L95?/$2#V3YS$UK5KI,"C0!@X[Y M'\UE[A\FM-DW9BSFU=]9*GMCZ86?NU/!&@\R!=<:L!4A$UZU!W^.12HC'].5 MP&BKW5C:,K@#AV"N%/]&GYZIBMI1&OTMZFPJ[;/L7V1UK-&0"B4AW::.@0]_ M'>L6ZI17KX7$+-"Y-ZM'TW%[]KDLH%?SVRQ?Y0,8.^ZB)I\FAVMZ]M38SVP9 MSA_/YEIV4;;,!>M?E.5N[I@=7]H/RZT+)5X0Y1PNXU_!$NXE894-L(>KLQ+MJ'+""7M6*7LBJ9G93.\_.K_F,&R9ZA>%O,6D%+ 6 M8Y-!4E> 71SZ5NT+MTEF]1)OZ_+-_,3J5V]L6WOP*P.@N?DF/Y#R[X#G#7DYXUK?X2C MOSA>Z]X)LQMHH?7/]-AST>]/CDLMU2M^&",S^YNC@[T#H^>&;#F!M&L"HX4I M 5IH/O>;)D!$X.)[\6SU>A-:_(7TBLK/]>$[<[UH.;S:L:1RHJI1MA+F)FG! MD](<.SU+9=T,;G(L)VPL<],;JBTV,76)*\YX:_?%8*J?20@PXGI(W=AW-K_; MUBF52M+CHH\W\<(FQGE5T\^NM52R,%Y&_3S$2\8XX;J.@!OUVE=(X]@Q/U2B MRENVSQD\BCR):[$!)&NR/(#.E)G+4$^G#RB^+?O6S\JQHX&\O)DO8E M+02'CU;H=Q,GN$VDAL4QEQO49U5U/37C;R>D01_M^]C;*IC4C.NO7$^"0"(4>5UK?T2VA*7-LUMK^6K'(<< M\S\/7RRYN3C0YH79,Y':=*O\!$.U0&E'WQMIIVLAFY-2]T8@H&WW.$L75-6> M'I\/DIML9W/Z,Q;3^]:VL"XJHTB$$BUDV5U\5G9CN>:G(3?C&L65V9=/:-?[ MI:I[D338S2*:3U..%G(4D)LG)GM$FD5^*=&/-)_^'J.%9$WLK 2K6E,N@J=I MX8D=P\W04BLL<<8[>&*A08*?P*B^6W[//7MF(CZ.)#0M%!Y5GIJM[DLZI&[H MR%Q+#-T;X=?_E>Q;C;\UYE*C<.J:Q?A>G]HZ]4A828[U@0?6_]\.' M@#DG!!Y(!XW-*3V?L..#Q73]K]YG'E#MBG?OXBT+P]OST4<(V%5LJ:JQ:Z2T5N-M86MH ?PR-)FPY)J#L>EM9 MXM)3_Q;-CP:=*ALZC&?1@B)GO%@^ROI#[_98'YUR>]74W?[T8DKA5\DP^ND9AR=HD"'C4(_7%:GFLTS>_*JO MH110V?=':;+,;Z(5AHG>*GLR9N,;<\47B8&7S6B7WV%V7 C&G@C*,#PLTUEPJVN<)W=IV+U&<;,B:M,@#1_O8)]/84DH"4 M0S4_*NTRP=Y8I*G:J=X(+:37NBN!;'90V408C#,7NXY.(*/!))]FBPRA&]O M/,T_>XUZY:RSO4WJD_Q:TZ?E7P(A3;$.(&S;+=8EN]7GQ4<"-)\"ZSN2@J3. MUU@6,9D&6THY(4-#8B^&_#D .N*WW<>,EA\SIW6V> MH-P>_EFU4?@*Q6LOXGZJX+0W%U[QS^_,;Z 7F$$Z1V&HA6BR4&N_0#\#1E(: M-,^L-\IT& N0_[5X&QSQ7#A5-N:9GK^:=Y/C?W#HQBJ 1D_H0XH>$ M-BJZV\.J>;F;GK:P\W652H@S$"H-BRV+=/:&SMB?!D2=PUS81BYK,^JS(5M7 M,7U*QUF@"N@)9=DN^Y)N5[3E2$*'EB@V#3*"3#BM WX2@HSG7?CM["3 ^Z;P MF1EDN,EV;778 5::519;,>S4P)Y9FKR5UYH\B0-GVKY6/!0@B6TAS./_T$7" M,O([M9A?E(DBR8=T0J5#,AI)ZRP[VA5*'6Y,1/ET^;=("B[>J.!/V]*12Q$1 M8%.SO88=A'Z'R"IC>O3;LEG9QN-3TN C&6^9?.@%$9PXHW&8&*'1XZ7!FH * M+>1&F0!-TEB.EHY.Q]YS5FEP5A*N[]XUK(0RDL0[P;O;5"_*TR%=/ M(G<^P!BPW1G JUMU,X#F>RF!$4)9AG=-$+/:?(TD,"$,/OB/G(J&@AOMK.I- M_#."EC\DMS3$))'.7^,(=]0>7)@'^B7M5NH9)<#PRNHA?+9 ?S]O1!\V"!?2 M./)VV&SU7#O Q8(8HA9R,V5Y..UT6$2RR[6PL.Z"T!ZZ)6A%[IK\>=2";_US>B6&;(@^7R2J#Q9O$.0*W2J6%KUCN$?9]]/V9 M.E5-U3R]J)Q6S>&'3)*GBSI3'YWUDEN@Q60CF5/[Y1.&U+9=77&,_3]5!/X$ M3&J$NMG;GE\]$3+>\V$BK+MXQ5*^.R FJ*/H5;(7X1L_+\-/__+ZCY7&_QJ; MR?^]YQ+EV!LMY(.M;AJAC#J^25[_3/A@F61;0C Z>+W*]JMY&$KO=\/WK,]> M)_3CIG ]^L(='H-:R(MA&YFZ:3,1M[Z?D-:1PV0(B*J[_!Q MINJA0P&WM\Y M[_9MYOMEVY8 +41@JCML[HMH+233B'KX_G9 <7*5M/YIJ Y[-QYJ M=G=8:JX6$^0"C'\.9#8197R:-F0WZ^LTE.#7:B\R!JG+\FQ^!LND79D9E%X- M5WR,X)7\:1[]Z'$^N-(R-IO:S#[:7V;Q,&.F@S)4R6%A(^['@D&8YWU4(XP3Z4U)0QHKXU M?E8SNQR4-EWUXVY%?B8YU"=R$8L+:DTHY@1UM"> 340X^KAF $W%**S]-,]6 M(LQ7#@/$])A1+40BMI=/YX)DU6FJ--%P'"8_.G.U-[OJ2U^[4'-*$F(Y)K@9 MA83OZ_9O4DR?G&P$>&&O]1R7X4N)X ^G!.A=2(5QV!.I@^])%#VAU5F5-NFL M:M%"$H%5J'Q1?'F4E5,$QYA=$%QVL,BJ8W\][.<5&_^G?B=E+5Q'$LTZK:"% MG&A:?_SOA GY)?-O.51_+^$C!4QY )M46V[L]0LUR\X2Y%D'#0KCID;6>L>J MBB6AY^\)_?DOLDD?-[:A9,<.,XBY:(82SKU=(;#^X<,(D3Q-2\M_^2 M]BKH!047E ]1QT#]-] M,\/&N!5]++H!.C[!G2FWD";WV'81XC.0_ OX 9D\6 JV MY]3#S$K0?OU+X!*\!;JY.786"[.KNS"!\\6?H]]:4L("U\/T(EB(5CD/Z/QZRU&7YJQRS"E$#KO M@]O;T]@+42AZ!\RWP'7R ,RZF^ASIT?"6N4V:X+' TD^"E(5GS$?3'[(X<4, M)*;*O)"4TB59/2E5^2J]$V8U^3T:R&G MG?"KX,AB."3_+.'3>?1R@4C#D90.2)/$H+@U"WVN8U3W M?%L=DQ\/^JE6<\;1LPC/8EN.1G(,+U=Z>"M98722\2IB.'Q@B?A<1T=(E(I\ M1UTWY3DN52W2 R?G)6IQ>45EY&'5H;;IC:3\^U.%;(HC4S%_?[RG%F[[6Y4L M?8M)J&B/Q5O2O/_$QDXZ4](-8BC+6=ED9I0 Q)]_95V*295;%B8;]045M=,T MU\_>J3D,#KI>"#M&M(F(T_&QY4__N1+Q7^,CS-\3>EZN LJM&\UA@_Y]HQ#V MDXO_V/$/FU.SNM#*(^B].A %)*OK.10;Q9&,J1]#J';6;ADZG[L-(I;+^Y3:-P8KHCT=/^ZIBCM@.&YNOCA'$ MY[60?XKX6L@FRFOCNR=_&?D ;9/,Y2\CN@W85'#@MY_CG\H#<^AU1\B1=7C;_;ZYP=Z7CN$N541X?NR M]A7)68Z*: MO>R*(E\+V884&-UH.@.NZ5LOT?AK//LB+41,Z=!"/J:\B*ZFM #O_LS\YJ(6 M\BN[:T]?A^']X0JT'$C00M8_1M3\2K1I3/F^RBY%JH4^SW8MXE%'W?VR1 M2/?""^:NBSC28,M;<0G['!/4,/23EE;8]_*)2;1/P4'_%I<,!I![H>-8)\M@ M2&4>E8RI4=>\H#.+9>BV,Q*@U%J,9P!9ZI(>19E@QXEG::B[80%(9$Q2:UL[ M_=1S[)>77_E/*\[$]Z"W9VR=(ML-+8T=O223 M&<_7*.EPOG1,?LIXDG#/C5^@,Y/XM'U9UU?[K19,:QW68(_+0X,%FNAD=FL_ M04XZ'Z>%7&$.V^>P'=!Y*5 MV7+@[NK;3).4F'UA[(#<']INROK.PT+];5G!PV]+H9/>D0T#@HZ=ER@)U:WM M"702Z+,PE#Q@PWC#'(/+WT#%)9+"9?N04N18',ZQB)GKQ\H1E(FJU$O;$@J9 M9W* 241VYL6-%A(!F0/R/D,^\5"I \TD8+[NV("-?S<)FSH5A,V7*$_?TC'2 M)$=J88<6&_;;3[O_*!6(L^SCJ-OJ5FM9;PA:B/F9V_,S6@A- O"4 3J8G6\ M.K60+2YG/7EF+>,V6V/Z:!\DQ(O=:!&^&R1-AHTL/RN-?ZB(]VEF%F]M(F,K M#;0WN>SJM33]W*_V)-147I5-7];S#M3-W\Q[Z?*/X,>=P MG=-_- #[?X?M)9TD,MIH&9;[KY9AJ>4ZH?RU*WI]X3\ZBF'U?U7&#BF:#^X[ M$JWG$S;G]D_*-PH=F5E83Y'4OV()JT760XNS0ECXL)NEGG!SP_RFN(::XS+. ML>E4_ORV&A&\4,&*1!?_T^-J!F_(I6_M.MXA._S7;6W%4<.Q_B'% MH(L<#/\$$DPU@4WXIV*'.[<1!!VA%EMF1.6C' )&E.!@MTL6D&$H* MNU/O)X5Y_5O.*755LI6Z/?0A_QO;/4Q-SXR MI87L8UDNH U4CN2^F9ZFL>B1, [1\&1Y2+*]*E$8?K/ MHTZ$32_$6L@#US% $?6.D,L\T1+$Y"&')4ZJS5 MDT^V-&PT\QZG?W_([.R@O#)#9NPTM=5/%FC!-E\&^8K=$E)VF_G.N1);,K7; M(&2>$(T^^AY^-?*Q3EI&AA(34_>^RK9A9.K02"3(K1=($\GOR+1_9NS8V<2S M0'@]"7G8\OAZ+.T,_VD3167=T?#A7C4E?VK[2=/=_M]VJK[U8-\\/%474!?P MQ8H/VMC9^9N^ZD9E.>G8R)%J2N%M./WN35]'O$YE?B)D7LK\+N:1_23Q!#%9 M]6E(P_1X]3@Z3 OYRW$UU-[CH ((Y6CRHZJ]H@'UDTA=,&IK:,_J,7CYC"W? M _6\5)$CT\__/[J&H-])*^E7EW$PZ]CVHE]H=RIWAYU5/["@<<$Z)-BHA7 ; M]7-9WPR[?50Y7S)"&X@@PG&IN&D<=^9?:>$%*@HHHI/-44,97I^TSM-&QU:0 MKV22#B;CC06(! M]VA"IWAD2>6'J_*Z@)7EP8(E[3'): LFTC:YPF4)7=B?I&,F BW\ZKD53)>Q MC&:<5WL\JMHF6$1+OE)_D*6+ (51O&#X$=8Z00]T+"(O\K>[!=6?#<<@7%#] MH]<3VO,O)S_98XF]4T%()"J [$R?N9E\R9]G6\"CW_DZ3\W>QKH=JVD45BM9 M6')73%I6B2YZMO#9<1K1- M',)[#^!;V""?62=I>LZ*!$?XOBO;=(2'[6C%IL-!U)T7\F^4BRR+W!FB[N&D MY:7WEGC?%*]:8^8CI(GW- .Q*UX=ABQX&4F!F/7BJV=]RN.B,PXQF].S8IBK/(M,94*:%Q$]3_!7I4]P3/7XQS1BC MXM'D=H,>X_7MC6^.PG![Y^7 8A-?L0,QE&F;$JR%@$%1PT('3IY=*E94P2C: M/26IDC!UCG #D2?(GRAR!0A?9]RM!+ZBQ(,#Y5/$&CS)4J4_K86D5:#9+_;B M^6G^+C'6!82&Y&"RV%,+P7R(;$P]F 2F$5XF#"/^G =,58ZIAD22=D1'P3*@G(/*+S1"=U#OV4?\=)9I> HKI+R2'\U]*!/EQW[DTF79Y#JT0& MN..V$3^VK,DNHW8D8QPIUEGU5)T4VU:_3;TII 7%CQJB8AJ0Z'4!<,5>I8=/ MZTB1+_6?DT$_6MCS$S"_9V$L' >^ *&R,,C:PLO11"36^%3'L/W!$&SL5'HV M%[AAF.P8/?;U2D!7H:)+,)"=@/3F7";4P'&[=3 KG+Y?F^$]T_M,?#LLZQG: MN+]^4M0^>)]O5!:IVNVEA?1 5Q!_^#J& *>6[*K:GV23FX3C%<7&Z#)4IK=W M8U\UI8SD4--_0%1W6S4E?1_^2F(RAX(PA7/V7E4>C@1S@C!9R3O]&:XK> MNT:3LE7LSJJI(X2V@PAP\5/N(TOUBI3P=/%]_KBS[#)#\?Z]Y["CZT7XYNC" MA^C3.EDFT1$:43?& 3H@'EMHW-6X^^!EJPHK82":$7[3A,3QP)B':R%TK_K# M%1V;>O]W29#RWTAP3][-H@M5)VR2G'X)K6QI:R$S?4JG<2PMQ'XE&)'K9L:S MPIJ%."++S$#8$S"(VE/IYP.J:G)%+D?58VG-@CS[GU_'-DT-K_6MS4. M1%X]+ZFXJ-RO)-R =H2@]R;D"L_;;GLQ5#.ZFIXN=@X>Q%J$5-%S7R3"F?., M"(;Y17$)_);@&YTZC[+?&1Y6N2T9KU\TC4UEUF4FGO+COBG$B,$3 MHHWUU"GX/TL0V0Z+W.^I93X#<'J9GXBUB)%XS*MWC3L^705UD P$\KT6\BDFK+>[[ QX9K")-R5(^##D^#CNSN%&MSI4D[,*9"42GC33 M_,3Q&5[QWD2!8USFYF@:$7%E] +F1MO]XZ+1MX73L^B&W7 %$[RAKE/N@)%EY9TOFLZS,Q[Y=$F0K#HY#[GWG#H-:$)RF^5(H3>$YE] MXGG),?"MK$Y.C-@"TK209OF<'/B#70*]:'G?^2_W_5@[7@^E27;\@NU-'>!G M3L7=F>>+\,(^FGJB@;#LZ@6L[&NZ/\&Z7XCDP>ILJ^?:<<6":;#4 WV/2YA0 M6EM-#$S%H.?]V![WY_?6Y]J78C[0R4LLC,X!&^"HDO98C4L?YJ '#ER)Y,#\*UX9$3F)Q M1_;SI98K-JAN>O@1X$AD2],"H]=I8WB'Z9 M^..OD>(K]\I-WQAWF>PD5=F.]*^']DS;]DPR9HAJ&=GE<%JWZ':J3GG??_0W M3OZ[R/XW3OZ?]+Q#$#..:B%W2E<0FDXG8-VG:,%QFK\=^%"MTK'%HSR*YDX5 M)"UOK]\/FR^;6&:)W1RG8/Q'M42OX3@S4?+.K4)>9=I2*A?0:AO([20]7W)(_^^BE"[Z?H* M1?7K.]W[0(..\ TEMY;" MU -R8+SI5,#=#^F/8_$N#N^_^++#\#%;@&MA7UF?KD!V\P);\2VV.3KM>5&S M%FMY?6F?7\$'CKQHU(=T[D #>*:@YPT*Q;I>R7=8X9RM8O^@":S;6__LD&:1 MD%1-V!;]J"6UI>68TPC?DA=#.O>U3G@&?+=@W8[[=-R>%PT53]NKOFXG\ HU MZ_6RH\:RHF.W*AA[E\M+1"LV>3.4E^R9#+8.)RT)!T>,>JA;"G^.Y+7G76%A M*/)V]8+[K]=!GWML/Q11M3_)#%C;H67,(+FFQJB3L9]A\G M[?5#-2]C"[60+TER2<63Y79BU#:V6_EIF/S>] 35K/.XNNKT^]HF'0K/+&ON MZ9%2Z[RC=JI+199!J UY9PP&W6?M:(X$!P%U6\/&3;AX&WLE'1&4V45'9EOP M;="+019*X%T@H=-6)UV]2WA)7([; GK_>AWPK\>4'-69UHL1U47*FL?';?D MQD3POA@4WARWB%"&LJ*A-S+7S#I/: :KKS@@+I7O>I0X23G00!CR(?S7PWSX M]B?T1."K_3E"+42PHU6S2I*/?*NR/+>M:3[B)*X@&2;_CT<395U%>!X\IJ'; MIL7(&S_/L(S&N1VMN4<_- DXXG96T^=[?U]9H;Z_=3=R]VK;76K=4\-_G[QI M>2GBJXY<9YBB=.64/74;Q@E[Z0/$2\]-5"-G^T IHEX/4U2M)&+6#:XY*$*O:! MN2LB\Y?'7#+']/430.OWE&[7_!O0'8GV!IS0'H+CG^VUQ:(EQDO:[N,JZ-HH M$]V)INW,.M"GA6S=>6BN0>MZGE$-Y>K-\*7ES,MK%C;5D^[Q:.N#M_D6]? M!,3Q2Q7)3GSY(K3IC3MN[9BS!JZZ9WYJ +R8@@@<3K"%=HTZ)]/6?VLXA[%" M6_W0'#;@R(1=9B3W:R'F?D=K>!K9BZ$58^%7;N938J,YUH%!LW$'TT5W(()O MS0L)MR+?;<:/2,,7,TRA62\N\M'6A*Y(#%)8JMF%^Q1'*VOZ"K0N=]8# 6X;W^M*_9T3ES]IJ:PE/]E-V%VO9-\:Q>/#QJ) MB$ GAU]=+ITJ5/F2>KP2E YS;64GK0^/OL/>&R%C1= 4TE,^P/G7_Z>85;BP2 M$G='XY-N$>J> !)O+>3C['6'X_MV;O[X!Z[+^A3@#@C>\=P/:'Y8-U>O;T" M#-^-#KJ(<_">7]XLO_A8TNPQDZ<#7NXJCO=&$HJB&USB6F()45/!L< ME8U0L+S0X'N0@1EL>,$\_HZP^VQ,6,0Z=G6K(57"9]^0,.7)XZTQ3MPZ(RT$ M8"2)Q:IAS\_HED_7'A7"D1T_(AO2@W,"<8YW<,66J-(Q13+;6B?-J6B]I97T M14Q]>-$E)F5)?$R]+Q/%:$>0."I')G,H827UPX1'4L0/B *Y13Y'5H@<>#[8,# M4;5'&,43!^^(D'4J3C:BGT=6#U\DBBFOJ ^F<%L5+5I(UWJ0SM?M&^&V-:3' M)X$5X.EFG\:"C-]*":OF1%&P?PJF-^^R3B;6.-Z0=O/\W59\[KRH!YV:!N[8 M2EIC0?[^N#0(=J"3&R8*"J6<*^\+YGJ\&".>N5V[XEP@=>;ZWGZAG-]M]!V==Y:]QL;H)>&B>,"8ON[]50GDF# _$15XR+Y;,>D MWU*.:1G@S+;&$>.$_5)/(%UQI)CNG/\[]%Y\VD*!1F DVJ'1V>SR(YGP9MDJ4/%3 MYKL7TJK:FT:36U2_QX+-6!K'0 L9\RPJ [AI#RX+X"9\SL1 ?"T?9N5:,SXZ M$ET:U!%ZE#R9S9J!0?+#O2^II94RBW51YB]4J&J2DFF"]%$<8!-IJ&BFET:9R(*HDI!A]CT4X\$$])B+%X,!& MP/T;IS;@!JU983?TPTAB:).W[!J/ZROK"Y51^ILME%]D)I[<2)]S@6>966HF M1^R0P:?:P-(_N E:B$=*084OZ.RB>K% -IX$7Y+DKS1U F#/@O%Z)+>ZRK%M M-/@PPR(BH3@X09K!)\XH Q1)^(5G0QFN[]G/"X4E_6N_HJV$TJ^B6=$!_1$4TG> OXQ1DFHUT+T1^8:6@E;/)D M$#J0F3:*1/P497M?Q?$4.HI"LFD,8LHOHA5R[HS.PT5RU".IQ:F3M-C$#*,P ']"(B1L5IIUH,9'E\=2*]LL>(EB!C9?CS?/HV ML=1U $BB:R%A#$0\_@6$YMS)(",#BV%Y7@(:ZB3L-^ 2^_K,D[J[(? M7;)SS#NSPYA[40J1]5EF_>A@L.KM\YE4' MLRO[A8=A;V'B)>SFD7T3EB#@X-M*6$;0_8)T)RQ8(&U/;"A(=##[JIRG0?49 M=A][WF#2PGYSC!;OT" EM"(,!.3%N7#3H>EA2,FKT,SA,9NQ3Y&IAO*G&X71 MCP 1.>W&WGB](U-IN$[2YTCV)X6*\F-6*)AKFS^LQ?;-?E6N"OLDE$5@ (KY M6@6!&L-&*YX!!U=J0N_;Q$52*WO:XD]GD[QGW=E)&?D:T8#822B66RU!=U!G.QA@$HTU.B.-5Y=/ M$;ZSY&+)*N@!G;5H52^LK1^>V1E0OOR,>.A&!7("9NWS1KP%O*?Q77I.WI*&(#J,_K$X4W96LB- M;]^AUPW:H"I(KA:276OGL2UEITPOCWG@886+$&?5OULW]:N:9+^_UKN:^=J\ ME6END/EYF +3!42\.334%#S3[T9^9+_]MT9C\(58BNC7TVP5KGQ">)E\0C(FGVS*WJ:ZRSS_SS:>M5UIB8^1.U3H#->Y"<4E1KJJE-X/,(NPISK?2V$ M'Z"%K#@0NIB:K[20U\G'_Y^+>N,/O9_W'J[;IL;T0V?GE7PM9*=4L9%@R]73 M;$30[(>:?8*-:ZWKJ]>@.ON*KC#-K])]F?M7FB^&1VLA4/BK5BWD$XGB&G3& M]<%_7LNQ^1U.83F6DP!\>2FLZ0GETN!\L/%EU&17W$;9"HX1(PH#YU;.O/** M_M+Q6 FP9^:[6^E'7GZ@HF^8&8Q1IEG##J:N["CAS&JZON."S7%PJV[?_V0X7=CKL0^=C7Z&\I'WN[[M!_S<&5#O^ M/P!02P,$% @ RW!_6@;:UK/G/@ (4( ! !F;W)M,3 M:U\P,#(N M:G!GG;MY7%-7VRZ\U5JK5BESE0HMBBACJPQ5@=0*HE!,988(:4%D#%&9(6'7 M6:!*48%*"E$T3"&D0$@D@:0*B(" S$)((E%FDC!F8"<[)[[O>9_G/=_OG.]W MOF\EZQ_67FO=][[7?5_7M=E1OU6_ [[P.'GZ)+!APP;@%\T'4'.!$\"FC1L_ M?C7M$\UW\V>;-W_RR>9M6[9\^MGGVS[_?/NV[=MW[-3Y8L=.[9W;MW]A\(6V MKIZ^OO[G6H9?&NA]J:.GK_=QD0V;-',^V;QU\^:M>CNV[]#[_]S4_P#:GVW0 M!MHV;3 %-FIOV*2]0=T*F # ALT;_J,!_[-MV*BQ\=,MGVW=MEUS0<,7P,8- MFS9M_&331ZLUHWC-./")]F:=;[X[_JGNV5^WF%[2.W0E[_%G>W^L?:[OW;>X M[W#8Y:M;MQD8?KEKM]E^\P,'+>SL'1R_/W+TA*O;2?=3ISU\?/W\ P*#@L// M1UR(C(J.24A,2DY)34N_=OW&S5NWL[+OW7^07U#XY\.BTB=/267E%955=?6T M!CKC62/S14MKV\OV5QV=_0.#0\,C;T?')H3O/TQ.3<_,SBTMKZRN265RQ?I' MOS8 FS;\5_O?^J6M\6OC)Y]L^F3+1[\V;$SY>('V)YN_^>Y3G>-GM_QZ2=?T MT)7/]'[,>US[?.O>P]Z+^F&7^[89[+.;,%OZZ-I_>/9_Y]C5_U^>_)NT 02@\BG-/K#QT(_94_:Y!MQ GOU3X_@GH!IP*=XF-]&&CN#&0M4(XPL M)D +@E:!R']U%LW/FQZFVL0'YGG:-%:![9.KZ;Z(%4GXBJ<:V)C/D?K67,;J MR8^UA!ZJ?6.3=.#QDI\P4VATLP#5>);S3,11Y0IK^ALYNG*KU/O>-";<7_1/ M6SEZ5@W,J(%Y3K^_V8J?&KAQO[.F)!1]_/=VIC<0R)Z;>1HXIL06ZZ#I6HR M]@Y7#33KJ(%_\*4KK5*'W3\%9()<65SV/H9BL@ M!J'$C#/(V_LP6*S$WH@+ M=8>"X)(W:CLYX\+BD(!@(7'/>)5GHKJC!OAJ(*Q&#@JMTH-",=TSK7 MJ]M4:67;X(CHX2RH@7H_+RAPI67"_,\YVS54B(6@=]#^,RMK6=Q*_'3@?7@] MINY^VJL[>JP^."(1,[/6JCPKS[!M#70Z$L< P[-;_%&*J>72?*EU?R:V%G!W[2:34E+8=Y:EXNZFZ 8.0F, (;IT@#N5$M;"N*=2: M*N\11'$;_&+2GOJ&]^"W-ZL!MD VM'\6P1YZ5Z &MCBE?9HCC YHR\%4QPPG M;[=B)GU@Q=M\S0@DRNJ>-&U?5GV ($'R6%)N"\=DWG @NJC\-A93;8U)Y+C$ M>G;=UIE[WYT#G7A5"!+J7UV+D7 A;E;4U$X??LIIE;3,N:?#VQ8AH\AT4WK6 M5C*?+'+>;[YN6$?-0ONB%U[15NFT89M[L3=7,)G@0S"Q,^L2TU>A!C+\3=XA MY(FU'Y0XB""/.N6J4&CAS"PJ;U29$BDG0C^4$1+ZJ([F:TW[.FO@/:!P:-?QS M:FXK?8RW1OE0IQ@Q].Y:=AS-3!PGVL@8*:.R +#C[&OC'H3VZE>A1T*<"YPO M&_:/$F+&\5" &J!S6M3 )FY(NLMD32BFWHZ5'V(DV4OE5Q_5@-8LTX[9M#[Y(#U.JPY%= [29XM[ M98Q#2AH@^"+*,,4Q!T_J,6T.;"KSO*$:K%0-6ZY8@@V^*Y2VY:Y'-($(Q7/M M4@.Y<=7-MM(KBPZD"8)76M-Q3'3X1<*0C=%YSG*7'!31T+*UF&J0AFA9PI-1 MIX51UF*[QM"#PT)')*M^"BFA2LYFHIN&JF,\S*TJ3GI/.1ZF=,AP"%-P)/;5 M?35P7.!=5BPTRE5$E+TUARYW750#D-GY>9,]2ET2CU(4.RP;J6O?W.I/1TY[ M+'GT61P%=R(R=$$FE^P#&_1>W\L:>*<&KN<@K3/G]>NJN4TOS_LCE4GW80@I M\8.BM=<"UX M^@="(:H7&HY6 W4C!:GU/Z+U8G=7IQ0*FAO4P(_9T!ET?2>GW5;&R9E4 [\% MO-%Z$7 #%9_X[ (D23K&4*G25[YKF.SJC/#^*QIGA@_P@C(+I/S8M J6\"&L M!HHXE^:+%J6Y"9%"RN%SM5>G>H3S";W2FZ"%+0^QZ AWA. $CY+T^R?R<=-,[# M"+U"I'NC#49RE&D=W%--9J0\6258A306'N2SJZC,\9A[V8R M"\,7B$AH8[WAITCB.56'/])=&!>_P%R3 .;P41C % MLLZ174OWA>+:1?:T>^/=SEVT*^4Q1V]6]]^,S0E\=(KN447$ZY-4$LCH8:8H M 3IM'!'S7?YI#W<-7'YV1SH.QH=,P\^.:VSU]4[U]$>N[5XE2L=Z]JN!-\DC M^3/$!NOB'FI&^=QN7RFE[/DO6-O6N8+.E>:J8TI!LAD4S&0L6=A?. >_34]T MD!;VI89)IWKF5A;^..>6IJO@F!=QP7=6!$,Y ZSW'#O5.[?:^RMF;^LEL OO MH 94,R0&5K5CSOSH!T3&B17./%^!4@,G1D/1%?# 'ZBY(EKRNMT*N[!B/-H; MI>@#G_8:=U-TL8HPU1Q. R@K/G++D4R3U,JFV E"2$@UZJ>'DR5\E'M^Q#(I MVS_;E\_)F,YBQPQP3^62W1=>/9Z.1:_:G-- F?B1&A#.T-_86\Z3H]<0IF/\ MK?Y^#72L_8QGB4MO%H<>04VK88$@;)JEZM&D>.WGN1 6"$/,F[K.^8_AA!9B3+"EJOI<- M+**0H^%>=4L-[$=%;:]#OZS/MJV3I^]YE7.Q,IX3%9VB[(;O$EN"BPP7%$^C M_0ON]:;A[ .IMC8U\78=DW6H?&9A=^HN/U[34ZY.%58-%)Q>":@_^X,)8ARW M'U$\ UZO:6__:N8W-3#PVF3=WO+6H/*[LMC==XD5H4'5(_0=S+'W M"7N?@/_$3B2,GYOPMFML#$O_T^/27VEW]MT5CS9Q,1Y20S505J>H5 .XADO^ M/_.#&T0UCQ:=Y\YU63HS12=/AXPZ4)7;6(4UA^ EXDLFA0!NIE1KKMZXXJ,& MSE,--^>0C];^3A+?__/-K;HIDX1E5!<\/ZPE15]=.Z ;0&PIX,:7NT,A_+L= M4YT"41U^KEF80:R5)_@08UVZ_!6Z\JK<+&4L64XXPZ 1%_R'%Y'ZK=&?[^0F MJ]IX;,[9CME!HF-=UM3D$,F3\& 5N5E^R-JQ]7Z,=E3?6^>74\QGIPS,B]4 M%U[#S".6]SS3Y/!9<&&M(]536/ XC=(62::4CT[ZCPTO':JK4PH$^*'^\7-X MYGIT$_W&'C\_$XFR8<;WSBE?U>Q\_X.JH>F\OE14\6XM&5%31F,XS@]T'25[ M[W!C;;M5P]!0ESPAF-[0?:-E@>G?^\K%?[RG"Y9H;L[>_L9]:0U/NKQ/HF:. MQJF!Z NUM(1+AO?WSQC*\L D3A,-_&46#G:5.O!]O:LK2H)% 6BF0.*/R(;W MI:;\XQU M2+50$M"U$C^N(7FXP8=[M*1NN7R4$:9KF2HNH+1L^X$0[N<*SU'21(QVK8V\ M^=TG"5MN+TP-VC\(2I3_RA=$^>,YYETJ#?L5"*FG-?!]X'_;/\=CS^0&#)#H M>?1XJ(:89B0/;KJ+,';'IB5A\)]4#]?9LY#Q+"&&T\:06&>3F;FM+,OOBQ\U-#:"^2Y)RWF@ M(*7:VB):H@RHY)^K:VX9:[U3+S;O@735P%?5UK\ZSAJ2U!R5YF;XH+HJ2VDB88WL#_KQ>I2'M[QYP.:;QVNI+[7EYQU? M:GV0^_CDTT6G'.EJ0$SM#K57 ]M#* W%+F/+UBY&GN27=9$9E/N!IEV36"9O MN48--.6+=X];.MRI<.UJWCV,O@]O.)=^0N_-?GF^K"J>SY(%S.*]9% N[-5YO3S[ANLZP$.-UL8Q*B&-"?+S1ZOW;1MMKU7-OU81-)*-B_V7"SK%14R M\D9G)2F9'=/C=D8A&M--H*'A\NNKOSV#.^O5 &<[RDYX.#3H]RH/4'L*/B@/ M*99BUWG-*[4%[6J''< ,Y MK>DHKE T087M6'% MB+B2Z0J]AOSF!?;%!NVM1S$OB94HM[2(HPL%_-"S!=5&IT)-#I;^WJ;JYE@# M. 4E%(=\K,J\--%F2HK4J M[$F_?VNOZN7:$.(E#B'9+&X*E*-)L>'RM^^,.$DF/5S")-3]@XD30F1;$0N; M80S=%U=_#C$;1&'$-8,A3ABKVK0 ;8P:.)D_NLE&)-@;3_X.'I)ZHYI?I__D M/X9]&S'X-<%WT"FK)A_'*_$-]3EL Z7Y">0N)Q6,$4HT9Z?3$5(,SRN@\4U@$I(+7 M$=&LW"_/S6AA)Q#[N\ZF/FIBAGBA%^JZ4I)B6+J1DH DLN8<%4XFUESH5;DK MMZJ!54?JX[);?K7,3[^TMEW@3/^!M@CD\+!,@5R$&R7%&J04>K^MYLS66GI: MLVK:?2/3%3_-N2R HO?SE[>Z%Y6KF"B.&O@CJ5UU.::!BO/LPWW;WX9W8A3] M5=]EB1JSD87T<15/CHA\EC[NA%5;)D1=[IF"$>5&Y&5G,6C MP@;4RR;FL]J"I'K/H,E3CQF^65)+=GL*U*VAJSSJ$3XK!;]:0V%_/;,[\L8" MC1(Z[3U8> 8\*/HFYW(P>S93 AV<]$2C_HBL>^%;V)#[G:(I9K"P9>\,.-KN MC?&S1[OT]$=A HEW;[+I@7\*)T7OC4/#9V82,KY?.554 M<*_@Z!IN] M_QSRY/>W^]4 ([>'8O!RVK>$W^5%N[<^A\S'6!LF-&20II]C/#WZEPE;:\IMG$PN5-T1P5*)E#RKM77&?\SF5L3&0&Y0]P=33VEJO@N& MLS!$B6U)#\@R#5QS=N%Z9SOP*R_IL(>IX([[ X\/>GA//GO8D*M92-5ES$FIQ MR#3) ^OMWEIAS$*JZ=]B%)PQ/[*Q5G.VY&QSE(9<8K+1KGA!HAIH.#=XZ<^B M0 'Y,E3>O'#PY"V[,R5JX&=Z?]QD$[,80_GE#JD@"!5C2N5?*./%#">_:5T> M;]?I[*R5Y 5D,,;1X$Q/E?0WHG3'KO#*"PY-(:]:33G;,OHH.#B:M MF?'<6DNXGZH&MEK*A\$OQJVBHXSY!PST(T:5!X@9'S68.'U]Y7<9E=9>G[RF M82OGS7,2(_%' KSIR1R_#*Y^')#' C0]W+WT/JKDE,C-8*?QK(,I0EMD[C:-"]& M#&C"QTH9/V]I?D*NF<1T>0<4R,,#%]U?\%S>MRS&2G^V,CS4.2RR )](,-QD M*B]X=8^E'VUXP90]( YOHN6GN-LA&XU_LXLJS08._#_[4]*C;0.Y>9QQ:N&O M)V\8[X=FK2H$,N[(H*B?C9/?FE X.0K)60Z,MPV[=@L/@C3[R.O MIQ-)%I?()G5XF^/!=K&=.I"[=278?N.%&DA+#G 7FEPQU'*\D[1GK^N *[-Y M\KH:B+R)KN^N&&NKK:&$^D$YEI9@LS+)\&H3PC:KR1.[T5405I]O8Q/!759R M#K5I^"A6FVF3A=.,E92J-NC.K,S8# KHY.R?FX$_QVUC+NYGI CW M_+AVAI0D?<7NC?S\%-N7@;%PJJ-V7[+I9@7!XFEJ4BG[D>)J W$_Q M_L[#V.>9>^2Y/DCMAI9SM/Z8;SV3+M_'O.VO1G\4EC*-$&.%+FE2^)4I!#]# MP-?0QU(WP2>*0%7J.#A[;/#RUU9RD[:QFP_),8:]A\?'T6/(I,O]I/VS6>T #SKKI 7_*J@S'BNGYD=;=XV0,5D><%J'PBYFM M,0].''+R_'#F"F5UYE[@$&>:+%&H@7<6'+G*]YONO24-R B=%OEP[ ->>;1A M2JSRL!?]$RPT/Z4&VJ.U$-CV7SRT59CS)UQPX.JF:>"P"1BVJ-9F7')_6[345NWMI9D"OB;*AM"-WM*31 MQCVH+#406[[+=5!N0CQ\#IY^N 7.]EAS+/F^='S91B"Q3R6V>&G;;W<.%KLW M+I,:3^5_PRS8AZE@L>7[@Q*_1.K;B?8T:047-.(+2'*XJ_^$W0F 3O+MJ9=:N ;2]OU)5Y-9+8>_M"<60KV?6QZ\X2Y;^'/XUR$T"V5 MB("R?''.LOOPLH'?9YT/V+XWTA$#H,-Q:X<$FTH$B8QT- M%Z\&WVZ3J8'C'I$W$5/.:N"7[;VJ>_6KW*@:],\K*3BFUWQ-1X@+)DLUAK_N MDB)E2")OQ>=JP(-9>$$--"XC(+O+=[H*_V1-2!J%MA 0 LZ<#3B^>-4M]R7C MY$QY(MS;AGY!IR3(33#YXM=/A&4(N^A&V93]$)#T2 M:%AE67^;IHQZN0:&G2KU.W5?7(J[_6!][LZ!$ER5+W',2(,ZH6779.N?0XA9 M_I0Y5K4C9BI7F&$=,ID5>BK^/;JH7VB>[:?!((T\@;K\8O>V^M?$\=<1]^:> MA\YM!9E=2H2X3DEQK71M"'[J++F]FFY1G8!E: Y<$RU >Z[@,^$S2G1FBQ"5 MQH6=)>\A)< ?]@ +:VJ["IP=T[' M+1VJJ&Y&G"VQ+!](['XE3B?%M1 L&6BJR>;L[UPU\ZF=>HDX+^VT;&_:M"0YNQ1Y M.XEG*GE>2!])]Z 2=A(O,I"-!.PXUC)&R<1-G\??,=>'< M7(<_?XF4%7'5[%F^<0@!',2"]^6E7)]>G<;S&=TGTB(WJZKI(]]:=S>1ZP)) M(3.SH?J.(D1"6=<$A EH^2)H;G?^!X-E;EL%C66:;QVRVSSJ?O=Y* :++E3Y M#'L112>JYY/A7:S:OD0NQ@5>LA:7T9HR*!(+%---5W&*'9-64U>^N* (O1M5 MIXC0PJWO?_&"ZU&7W=/SF8AB&I+SN66M077 G1;HAVJ.5KS3&69RT>_,ZP9> MNC$8:8:M(PQ&+',N+N%'?<(Q&/(Y,0GZ*899/%4;_C0*,5HWRSCK)LVY!9U< MB\!R# ;/"Y;MO)31JK$;!]HG=@8A!7FK]OK%$^31),3.*-F "'(;^MU09R&$ M<]BU>NU)\)]_\/TA0D M$>(X=H7RSDU.7]N']Y>=K1UIL-XC&8THL00/]CWTB9<4F\B]ZQZDW7GL@DQ< ML=V*\JP\LX1R'?!@1O0?,E6]C,433%24-=OKCV,5DC"Z_\.1TTQW5_2SUUFU M"#[5;U%V\_WB4G.^Q 8KED0$Q<>+1X,F([S(,C^_S.#7R$].8RXEKX.W[3$. MV[/&9D68,7.T/?M"Q/C=(>/7,_GQX3U-WVV/\9Z+C:-(3M=% M:++ ']\C";PHWX;Z--].H#V_.^E^Y[+JGD%67P@Q8>&"ER ]]T*XQ5_M&R8^ M8#RL4Q9B1H[995Q7]?:N.'1GP;)7:L L#F<#TN1%PE0$7F>TSJY2ICTZ$ :^ M?Y!5'9)Z:%UV$AZE+:Y5Z]+^]JQZVY4L@]@ISU;\^E(.8Q7@S6<"'5P*39[D M+"Y^A,0(52F^3,BONT=0-QI<;V&Q?TC!P!%38"C]!>G4Q/ONO6]:?B6_C\FP MT-8PZ,<5U#]PIZ&3N%-]MMJVMJL9.SJ:O05GQHD9JO(+\&[6.S4PAFK7H.Z] MT<"Y8#R]%IO(=:JL-G[>!W*F5 (QN#W W@IO,>3\X$AC+EJW)? O,T3T$7<- MK7*IK>9H&SRK"W'0D)=3@ZB%'+A3#73Y:\I)S=RTTGKIT$!PPR![!*LJSB@_ MND\Z:SNFSU )#HY(XB,B1E5S"TWVI$[9#G+,=U_&BUU.60O@$"$L@;IE!#50 M2PU]VIBY=W*ONBA7D>I M^P^4X)?E![N]7,83OUVT#*/BX &_@A[S05%8P0&;/9FI]T(( M?0C!VWP[_HY"+^SA'X@+>R7XFQ&\&,W=,E%$<,6@P)X4^S2D([X$_..>2)&7 M>3Z@YF[J5YD]YC."WW!Z+?WU4!OH!JP0/Q=K@9*\F"_T.$- M"R1E&>;2"&+,Y9NEF^0R&VK"TZ#HON/+@:5I]4T5W8W%?71J!R,FX+$:".M5 MS6AFE[%WGY)$L%QOV)"RPM+HN-7 MU<"2GD!^8NT3->#W?D\20@ Y<=;U_'C_:5N81MQ'_=O)7D#JMW,/SE[XV2VQ M$H.OAXO>CC'@+O1A>?G$W$, D_IPC.VV9=HH8B2>FQ(() M4+XT16JE!OAW&UG$&P4IP?EM'U)2'"[WKG@4+(M.:MA:;&OW@2[M+U_FK>VR M<80.-55UB=P?* (F#%^HSJP(':H8ESPQJN*O.*,!Z;=ZI^&U3,D26 5;K(&Z M2A?6DM9MT5A&K[G/E1(4"G]898HFP.D2+[(A3T&$B-;IQH6+;,\=_K$WV$5C M",LPCSKL,ZX2[<#39J M?Y]<^JIQ>']:F>V8VW)[@?F6Q99W@Z%;"][_/"A!-"0U"C(\#,]KTF6AE;-H MKH!EW:'4Y0&6MW'^K&_EP:XB]\U'+Y&, ^^69EMX7?P*%:D:$FI&*R3RGF6:WL_#;.C5 M?,:1,!%T*\ZTV!82$[]NS&DZV_8S_+96,U2A!B15FC%P>@X!S15:M?S):?O* M3TN48Z)8S_VXXL>]GOS'BG\F&,J?9#]6U8:K <19-2#P!>,T1ZYW$)0-?56_ M4Q-RO4N^_UHJ]U]+%/SZ&BV\:W%+VI:K5&E*!_[L?UOB\NLC>6#V]U4F7 /$ MRIJ):LW]WY=U?3ME%VU1*.W^U[SZ?\][53>U^4M]SW][#(_4_J>K549U(<08 M:EL/*2G'VHY.TM(RDT!QP*,8XK(>4PW4-'PX'%540UYBM:8W^6,^#T;?]$'V MQT_FG/?FG9%8+H#"T3J+M5\7O_*1WWWN8BKW4VKL_:Q??LL+_"*>J_KS/I7 M@@B(9K@M< #WZ^/YW6PR*7".7EAT\X_.PN$ESV81*(!%J=06?(;/HN/S9[20 M8__LEBC-#6HSU\2KO3S/2@_(Y![3=LA/4]]/A(QD.Z:FQ<=+ MG(PN&8ZMGHYHAC#KFH+6%$XBO>.=0J1FMZ9FU MES9*"BQ/RYCF,JE_#8$:/+^[C%S.M>X=LVOT/BC[YQ5AU'%_.T15 P#548Y8 M#)Y^7LATH=;$+*+G#'9;!5L7-Y.(H\*&:Q\B>2LL3QO)^QH#[@OVWB7L;2M. M@PAW'$,*G6?R6;@_NJR0TM12R)G$7H/86,%;8OH5DY/C?%00#\5%.EWD\;"G MK'ET)Y9/P@)2^#8_/%Q)M,2I@62V[R*UA1<+H2>:>QH>S3NN%]^Z45-C'?%L M)<1ZS<1^DI$](5,2##\H8*F*&L0V7@3O$/]QL1P< _6[A+W=89&3D&.4D M0JZRK5/CN'[V5):CL*S1\),/6JRNRTE/"6J8N^?LF:'Y9' !D^*2RI5Q"O6 M027SB9J#4@R.528'O*(;;VKZ6XY?G/?H=[(7$AFXPMWT^YU M?M%9O/07K4!)%7VF!];(: MJ/M]EOV;LP=VO'6YCOZJ, '':0ED(GY?O8/U9+"O3G> MY+5B.M*]CKW._GHV=/>2J^%WL8ZY$X$-IVA=N7P%LULUW7FO7";,VB-5 QRX MS9.*.\KNLP=OIWR;FH'BC/RRV%!"*!68]EKYL% *0RU.YC!&(D.\37X4V<\V M&EE0ADRH',\-E+@/)'VI(QPEY<32O&1&$2XMJ($U2]6/+WN6+0F4H[[9RWK8 MDD_/\S6*?W&;QH6K JUXW);W5+W -M73(GW*W<*(30*D)6EP7I=65R:1;U02 M;3O..=-KA5$XPZ4SUH=_6+*_E;V&"BV MTQ.S2:K]P[T_L3)RW:*$:\8%4QJ9+:J:&Y-LBGUAJF\L";*(;V[ M05PH#7%\,7S0B6.E[9IEW7JJ%QI-[K(9P0LN_S;E\L5+G7$RS^X5IF7VQL?I, MLR:DC:JSG\6*$["F']6$SX1DM 6#-VVMK1NTG(V%EEE^_9^FYH5YB<5J("D3 M+5'-42?0QM&AAPO,^MG#,.8.^RG5_J_:O<=MQQ7<2=XROE-1Z>3XGB,/Z NB M%U.:VSC7(AJR^5A[C12G2I(52-54MI9$-39[8='Q=A):FYV=%YN\VWHD.VZ! MW1??W_8A.MD C3>1^P>!N?**0R[WEU&9/ K[(7J_&GAA*0Q8G+ZQVM;OY)6F M!G3)7%*?C<&L-=QE_;)U);[ -ZIH']+>40UDLNO>5BY3QQ_5)[S05(+I.8W:7MBYEOG4R#!JAI8382<'Z#Y:,<,)OAW_H#GNT-YDDRCD6JE7UFS ME##='5/7A65'[3;G4QO@D_ >07MPAE&RX#TUUUYD\O*-W%O@,6CM%)Y6R95? MZ(6,,2Y!_?LXQ;R:R6?Y:(D;YT([;/*.^HM%9B?#@L".1RYQ>_(\+<"1*? VL@(HJ!M1^78MG59&^50KU_C MDOFM:MIH'**^E'9U;M:4$9@W*4B:4J"/2=S3SA8]_+5,>3(#K><6&4ENT:!+ MW'K#\+V5PY(AF_(4R*5;,.]_H)@+L>@_?]4^F*%9^S0=*;;'D1[)#[?IIEJ+ M*/::XGA)N"?N9G?I< B7$DLR6/%XPA[8K[(I+CY8D,:^(*#.+ZH!NXJ@ZJXGK]:PPV5,5[Z MXRB3A25<'EXB-=50N?D7N%UJ8"N.K^.R=P"#0R54F-_$"G[&GQ 9^PT-#8"E M;;&&2Q987O.!30N8.YSXX2I)VL90,P)2)Z3)RX(K5O ").Q>\4BWR^'%,^43 M 0.KNT2X2&J4Y)%3K?[>?SK&'Q-.;N[57-SO-/S/G!$6F&"Z.DF&3CW<-&?M=\5T*A\\%WJV5; M'9Y6$9>6I&F\L4_Y8I;N)"9_GF:@=];M6PM^E-115A!0Z'#Q'._MX:[(2X1B2[2& ?[1T*Y*HIHV+E*S;9V< MA2&'-*' PW^/+&C$Y<$ZF%>CB^>,JX:A1->:(O2&![DGFD9HT):ZH+7/OH'. M.OHL_:)\9O(RWG+A;7L:++NQ^-$,0#J[M M.5V-&=6Q]"_8Y^G%,>^N]9F&.([=/S7*W9QO9I5&2]-M\JK:#!Y:-P\Z]B\@ M&9U9<)$:V*M@N8!2-GBOHG5-<"3E:6B,!,O:N=Y9O^1/!)^PNY\DP0)5+.&]9 ?3B %CZ'<-Y?NHR<;,'^O$#@/4$:(R1*51$R%-)3A M!^.\2"'9"!K%/$KC"9D%PP&IQ+"F4WS_6$B%XI'5FV&HA*>2HL-TGT":.&I9*8CS#WO.# M[LB,S,LPWT"E M!M)\*+#DX,V.B_ MAMX4(UM?R[_;=CKIXX=[.V4A^T7&]4174!AYZIXU4<0"-P/I*Z]O=S#]W O% M$FPS/&GJI2OA6B%KZ8[=,A,H_Y_4^\^/UI"%F/BI'0CD0_.!>P+W0;&98C7+ MWQS*BX-7GF"1JGNU-,'UNO%QE(KL-K"*MT 1M.C1_BN*2BM_LF5\OI1:M-RI M,7L#NN@WY\B>G#CD5%L=>@WMR/_X;X+!M#ZE1@'D?E 834%$R0+8CL?"4R&'%'YX=6S2 ^C?32Z>SUJ0UX M5C W9!\=T13D/^0G>-X=V8SGGWN< M!"X(R^1N.":.!ZO2D+<#5N0%UBXHSQWVC/&H)537Y-%Q3ZR>MQK8(J9; M'*6JDGA*?1]ON4^%6]F8S<-';\])LI>F!^R/O6+WZ@^XYJ'&X[)M#])-$:^R ME!D5F_HX$P[]B(G=C!%28U1B5^X]\R)S@:7D[>TLV4.B7-M"G$7AQ@Y3G>O& M2RT7SK,:"OB^H&R7-OD!9_'"$U(T?QO\ZNIV-2!W-UTN>AD-]TZ)&-[]>8G1,(WBT 4A@UDKWFF3!7W3GD_?]BZ[RCXG$,(6($+4IJK2[(,% M\:EH\;@J0+'[P"*'U[A.7;8+^(IQ=-M1CO*>>"*"IY@O-=EX*(_BV";0.E&.$AR:.XV]M(4+?MAC(Z> MTT)?^$L.-_VTRX'92K :Y56.?D$WS"I_;IO'$JW04%(W.%/2[9\DN45/ESZY M= P=P@T.'6N+P(=CZR.&FLZ(LS@7)B$)*Y(?_*02=Z!^D%009']$#7PPMR%O M],)L?H&B5=;YCG4T%&H2D.4?YJ4&MJ/=$F\NF4?3.GYI2&TB!X5.3!;SPKP( MB+>@E'P"UE4=5!Z)H-B.\?G+Z/KG\075(Y>[FDIY[HJ"^H-.R])>-X(O0X--9VX&1:! AUB'4Z7%]R^C-'*WQ4;PKFQ< M>69QK:18?[5^7%6".I8Q-!HCAGWK%&=Q1'X*O.V&RZY1-LFJ?B[]1O=]GFM;S) MV%R:4PW!H=ZI@FC.&R-$K[>_N&V?<^ 1/,8>"+&*'(C$NWQFK92;X<4$?0?J M.+P-8$6_?T7!.4]D= >/)0XVS!2^JAMX%WOK0E033Q,1CQA<\*+0,YF(5GHQVQS-&&.:PQI3WY%_'F\PS J\!OD,[)-+Q&6>S5T M!>),:_N;$*J\R ID7%[(\:382_K56ZU9KM! QH)*HFK@_;#;=NF8VTUI?T_2 MH)5X.K54([4= QC1Z/.A6%D*0Q-/8>RAE?=GKNV\4RE ':\(Q60T9M M4E(V^J"R'-N\LJ!1-R$:MK1I(7V2WXS!C1QMI;/VB$6/L Y^.6$(0GTBNF79 M+'P6_>DOMU[,EZ%CBVYTC[U]_JL^_RVGS]_\=+(KP8&N\)D2R-@>P,PW\CLD M%W)T>=<>40.OM1;%(,3 OKIU\9YI$1#9%M(W("RYGQ@V'9BLS_$F0&[$A0PK M%&Z&Y=A)7.UP-._]B3#Q5#?&4+>K2N#R<4].V+[32A17'%<]*"]\K 9B@J*75?0Q\5Q@:519?>*R,7KM MM*TL2.I#59JE4>0)/]4/VE<.!-8WHH8&1:;(M7F.?)>#2,%S2<7W&NUK)1 Y:=*]XAA,))Y#.B->#XO,2I<1Z!$,^ M.Z9U%8-SW#P7+3O<8MU&::[J7C[VSQ]NDV[U:N!'A1K(FB<2WO'^*HI!':^> M\]>1-*V(K74.,%259R-=-MO)U-MP*9L:GE-_M?HBV&@]3 $*I3)$-A M-01]N:\:YZS9TUZ<7W9(1?0O&;(UGJ"G^?^]S[-NGZ^"?4H#1__PJT-Q=O5- M2W;,:F:Q;'22#?=COMOETB,SB5QFJ+H%"2I.?L4&-;!(HQV.E3X(.2Z:!"U& MX1>0+2Q;SU7,<2Q=UF?L\&'UK6> M&,QJ@E\JK$+%P\-H"VN"$^6.P;#B;";8'#*WO\T-%BX\NC#]7Q(U=[N*2ZS2 M\$^WRYX)%8^KP5?![V'F2#Y:Z3G\#2KK73^EC,$<-NNW:[W571 4:@UC6BLX M+TI\.:8X@5EZS7]Q[T##$L-^V]4/ ^)$LF>Q,ZH;E?8H("=3Q96"&0D-B=[R MSY]>^D-Y:D1G^ZR$UHWP\MK=C4VJN%!<@GZXI\]:J@8,'Q#8H$0$[QC:06Q% MZWMARZQ@D[I:UI"M*:,>2JQKS:;H=EFR)029!Q&4,T8NPU_V7>#<5-!RS)NS MM>HI+?\0^FW%6%AT?ESYW6+SM!3G/4,GAOV]$FI][!6R7EP8QF*"&1_(WWV? MFFD=ZV/-IGZ(GB6A9CB8QEHO[G0)JORJH#.?/6YRI/K'.FVV76[ ML;$8,"SV-JEPP2,G=EI3O?GCA#X'D!%R0Y-E-,>5>*S&GP_U&?Y%PLT*:W"Z M$.(LG'TTRS1Y:P<5FXYU+7A0I4Z"?_(,U@FFZH6YTQ2U^N4NFV7;<-5F! M:$0E\XT6A:%SX(5^VB#KF4!?=G\C%G2<3OP(PLW!7\Q('=X$'=?_?:O^+65Z MJ=OR\>4X!8*U[-()K'2P+>?HE^<-K1]7CQG+Y83]T'7ZOX=;DEG=$K1^+TML>S\X4F#B7=)U7 ^X? M.2=MP\MSRC.-_53;B%@$C20:$M44Z_9(IGC')UWSS"&;7EO5$K,!9_*^.+8M M>*5JAKSS.L69A<9UK+A"CF62_'R>R0V^S]X)?.)<0 MRZ)MR]E/TLK;+J4X:5C%LYQ$QLYL8I+)Y3BH^V36DONY)3,X_U/BQ&3BLA5I M,&14ZC9=)M/HAJ1DMQ4-;<[('). M7:]ZQJNU>6K!GR)RR,JK$JF1/,KB"V[ M+06D]]'^Z-ALV_IJ_H^24W3,*"SN!";VRY]4GWC$$R#+1X.Z8BM4]]9W^0? M73D75#*C3)D@9SIG4B6>L[?-&3D:7[5L7WQ+:N$)ZIJ>40.8T4C=!DT%2(A? M'6L8+;^*._*Y?Y[-M;*G_G6*O\U'?R8';<(&1%9KVX?.EZP; M!3:-C!/0T^<_OMN4N.$YH@U_N25([^5PY+$I7DOT9^NR6ZLB]"EZGQJ@A:5$)D>N1&B@F)F#Y6$/ZH3D:@Z; MU$)Z;9'5,K8_ZQ()C'P.1E\Z>LZC\*);;;%/#"[[-KG61ZY#IS0YDH+F#E8< M+PL^4;$OU)OW=.O4 CRE!L1OMFRN4KH-Q4G6_/HIE!H0S(36MG([K_)[]O%G M1)['Y MJ>UXM@6G@:!7#5DC1;2FZV9!6-?]MMRI[[,'L1<$^GX9^)_\E\\4ZUUR# MWB9N?[,,UN:=@/%$>#TXCO\EB^D6M.!__J2_;V&XY;\BN6 M-BXJ$E4Q&03,B;;=M--2-V+XV'.K"D&D%V?\BDD*A)IW0>7J':_FC7-M;QN+ M7V3PI'>I4O/Z;'.4+U(Q;T69=/F@8,-STEN+?_7SW!)L2G(O&4@L GPC$=BQ$?^MT5]"!'>)$3<4O&QGSPC,^QX=Y CEMV M+G0I$?L%C:%<30C%&J;C\O%%3VN3MT=SE>L,U2HM(W"+58_A"_1LB=E2?+DN MEE8PM_TS(IQ.T\;D:P1">>+'7R;Z!?RZV,VCG=8S"/W)4^9M?9N,U+#$E)_5 M #%24YX+0<3TJ,8DTI-_1\VY>E/!!;S^X__5 MN<6[I5#0&?']QW8!^@H:$!_(C^ U3]P!Y <]$B M]7_TM1C]OV39DB6+%R]9H:6U=-EG*S[[;.6*E2M7K=;Y?-7J-:M7KOQ\[>=K M=/7T]?4_TS;X8JW>%SIZ^GKJ2C0TT3*+ERQ?LF2YWJJ5J_3^Y9?J-V#-,@U_ MC2%-C0W HC4:FFLT5$V ,0!H+-%X_P(^OC06H6U7KCCWCZG3@<$ M!@6'A)Z/C(J.B8V+OWSEZK7DZRFIMS)_RY:/YW5W;#]XC*] M[V_>JWJ\?...HT+]D^X;Q-L('%6=%XQ?K?46G?C/$7\X9?GKY M?"PMWJF,OJIT4B*I;-U&-J,]IY\))]-E6S1G[,V'"5\D]2$[1::IM5L0XXSE MP;D6[,8LT5P&;S2'"#FQJ3AO=T\FH6$V\5EE$BP1BT@IU(QK7G5>)4/X:UY. M6X0$Q:9,;NQ46VPV2'4E2&+O!*0)I@>AZ==:[]ST1=AF0O^.9OQ2II-LXQ/. M&*DPE+GDX6MK_IZFP6^Z>CSA;70[G?Z*)CSFA59NBI1.I$C)?9B@C+\8LIO# M]_.R:.0E1=_&XIX:Y"Y)ZR<''M_@<3KF#3=A/%_[7 'S:YD5?$2Q7Y83PTOW M4@&^LO-!^1-VN4W+A[.\NWRSSK!HF(4!1I+'@#AQ@'69C/0C#GF/,1H1!2S% MDJ%6BG$(;B&[I#SV_E854,/W7^IW/2_ C2$%=8]H<6MQ;8:89WA=RE/M*TRM M[@C%S@I?&:71;J%!0K[7;-4WFFUQ]QAG)EK99:X"UBZ,$[&BC!'\=4PPX?I= M+1E!Z[)1Z^-H^ZBN?MFUE91:O$WW8=CK..D,_CS\B\9\F_Y;L(;P5)W[2CSF M+[RNT=ZC&@<'T4QD8GEIFHK$)LI[A DJZ/+*TQH\CR M7E2%]X1_$NV&Y*\NYOPXTJE"(B3 .=Y+ZEYK!,A.$7B"%/_OA"6ID6VN/LCS M*A;3J*_=YD%B7GT)WM:+^\AX1@7$;=&9\!1SI8R]_.Z$*N$0Z+-H0 M2SI1187H74O3S%T7ZS+,&IZH@%83-\A)P' V4@$N1+I0(*%UUJJ *W>U6?-\ M+\$SQ$1D,ZIDW@D9=ESDP8!@Z\KJ:>J;:;).RTHHE>#AIDCQ_W)2>> MK=\5%1]9FM08!D(GFRV>#?BU28,UWRV8CX+)&%I/.@^=5(5'%[5!RT.8G3'D MFD(<.+G0XTD7;_ 8[*2U#[@^8AZ'4L)H,@SL*3,?,4CA-N9Z& YF5>3IL<+/ MU.\N;OU1FGVHWXNW2@4DF0%2,W2T.6DC!D\IEYG;.K\6)DHO167(#D2%)5HY M"T<'29$+68W36)O1K !/3_SMVQ+E +5?EBQY+4L8:M?WDX&>==TQ(3E5(?%/ MZ:?NNUIFEN!;58"E>""1%=ZF C00,V#!-E5.?T:BVS5J7V-N9SOL+&LOSQM8 M.K;%QKLBLC3"8GJMA]>!@*PDC[1Q'Y;H&3]=" ]+4P21X?O\_/G6@FI:5=G$ MPFFZ3](M.EXDD)2R1].21O.U$POJP_8K"Q46%(5'M\/*(M\P3L7,G2B)+]^G M]5"VW_86T+Q-7/P0?M"/&;*9K@7<7?3^)X?&9]6&)HUP[,6DHN5TD(PT+KM6OTKIZ9J[-9W,V@>KR+FA+)[K(]H MO?3?H,RA,+]6[!")BI@W>=K)PEBL>U>MP&ZTSC7,X,[B@?J#*T MM<10S=+87/(5-\?]" MR/XM8WH7:?&4(;=1::8"W)A4T8H3K@'GV+N23G/RF'[0-/M-]Q&M%TX8V7I1 MIJ?LHI#-,[Y6(K1(3E78% R&T#E1SSB9AP9VE2@2IMW@:(J(Y4JZR#6*S$CS MWRYZ=C5*L&A"RK3ILF8X?N_[KK(87M) 9Z#D^4M MU%G3Z4S8198QDLB?,S)C"ANRRV@KHY&ONLH%%E&[5G56(])VN1_(P?+R5],E M#V4;*<1X&3X@7W9NUI7&.C.?YNAOQ;]*J'9]Z\3/J/J2&%9-@A6Q M1NU-W\H,&CD9R<3S/_&PIHU;?\Z^U;=;FCF&G8?SE!P6&XS07AI\UXSQ&GNM M'E^*7?HH:OC*PZXYT';Y_ ],0G43C 1%J8!I6D^LLJ9V76FD]IK^$UP?V4&\ M=I@]2W+[?!&]GWZ\Y>;!/"E_WSZN6-$/-3A_16FB]#Y[ZF35E;3=-J\RN(>3 MD49T+Y9ENA@8A:0D/2V%R>FEXIE^Q3HRB[A<&-/<@S>:MTIA;GK4T3-R3)AX M+2TJI*B^DARG1]E6GL=6XMK$*D#_] 2>QKY$M=CE ^4<%&W.4N999E,(#T(& M/:H?/V"VNEYQXT[>@88\77DX?DK(T)USK5BA],H\07>[K,=**W3KF>MW/2H( M8\C4>44;-2>4"$6]TWSFBRQ7 ;PI[63NRI,W!(WVTNN*M9Q:G'W2O:BXL(#$ M):.-!QE!E\]4;2<@@C9?Z'/H%-9 ECQ,NE2_:QA=FD["N^3B\NGZS M^0.N9Q\5U^0(7I5#<2;]C\A]"D?81V;+>[/!T%3\ M5@0[SSBFY$K(TV5;-$<@W:073CM$7H6B6>**1%<7@)@XHGT1;ZC%QY02/5Y;.:RL:%R5.A&_OB3%I '7.80V MMYRL$SX;D B38&JKK%#RG2RO?$(%?.ZP7.NZ@U68L/79X#=HVY.]&-E;^[UJ M0@(.1%CPNX)^F6IPPD7+O9@3*(8YBKC3*3Q0/P13FUY,(Q?]QM4%:ZYEC3M M[Z# E#7,#C%8@ZZF3%'R]$;>2E**_]<](UT*@Q$+@Z:0']G9=SIOZ'4/*%1PW-MM'3YJ26,&Y M3G,)BPOE/I2#XY1!>=B4SY;\1:G_^V-%UR[S#0658\B\,1.9CCR@ HR_!>M8 M@1?,DV"XJ@,6S#SS"LY?P55?5*>PO+-:]H @P=/^>]"20H1G113WGINTRKPJ?WX#8>CG),3:]EUN;MU M^KWE]X]>O[G!5A;MG-N;1?W1(^BN#.J;4>2C"[W^3OS#$7J M)+8;H)28-3Q3)+0B4T>T7B';E!G$G2,K,6OZVRM")>>F[+TR[U>TU9,OF34H*UN;SH65BVKY#Y-X^W,':AD'TVU,H_FF@<. M,% G\ SO)BG.UP:$F.F:^T1;V>T'L27[>P)L+K@("+VS^_6)]V!-\[?@E!^SP'8,F.\X5_W6_LDB( M21IYD'.[TF!4#IW=QL#T%%0S>_"\TDW*!TDH8WRR,Z&LF=)LUQ=03X?U7HR> M.-Q301L)M>7"4S.**6>CQM^G,>X-:;UBZ2V_WP;-.CMY/;'E1?19:=TKF+:9 M!7//,@72=3!U;8U(\)BYCAWEN-&;Q:_UG=KUH#RYOWCO@8&"5'S.&#)=*J6] MUBI"/BTA?\_BI$[,:E3$8! =LN\>9',9 /=?&*8;#R!P/2*S50$W_TY)D MW_$E)LK N+@B'Y>1518S5)>! .T[LZVSV\'?DB*CY%!*:+CQ"/YB_>X'(1(. M+F6N'T[?-\SG%] ?#HJK"Q@*:*::R.672!]H0K^/\2/!5[+J9[_=7=6CV!.? M2$?Q8=VG0UX\0NMWZ7?63 M_H*8M#!S)1]U=Z^U*GX?@A,_R4J&^Y4&GJQ(OWT6";!].U_L.W&CND5$A&U5 M0,.HG7+V!"E9!02K@,]B\YK]OQ(B=W,R$LHGO!::\,&Q&VQ%6%U7'7MK!F>? M!R';!!V#J3_&X#\VR[V6KUY5T%'B=*Z<%:D",E+ (6N-DVI\Z02?O<3/4+W+ M/GWX WZ8)V5I(P+#V%,C]^]GIY?Y!=.,ODQ0[CJ48@([*L4577%X"[*\'-X@ M)_;25,#JR87H5$"^[JBL7W3KB7AP%Q92..C@D][MY47WNIXA M+1@8:S6 W715P,-*MI,-T4](2-<]2%CJ5$=?*#_2&OMUMOF6S&E:90?J.W1F MX@+D)+ -S?Q;$AW%5[]'LO81ON\PB\ED&CY*\_U5M%=R]/B$Y'P1SJO*M]5, M^38F^$Z6;A)+#CWR/JH(D[T(*YVH/B$+M4M=9F.%P59W5J:&VJW\*2PJ3.\H MM'"?NZTJ KR9:XI8W6*JZW<3!363#,(PF@3JVG!1$?"!]6+E]V%;QO96L4T"_G'&^M DC"RF*"S^U=W(.UYC=B%\0ZW+ MI\RK%0]>MM%'*?O>MSFYR63%J#+[Y;%9C-63&15RN/)/VZB7Y4 MSL1QO6/XRAD^=W,+>0CD)/.T4^:-E_9.,I?=>$+0F=*9B*YQ6RR!'2AF<0'! MMY'Q/A\_"+/02YYJ:7K462X@A%N9TJZ%,?P&71J;RD41+NS1&O?V7&.P:/F MM'#7SJ'3?'?YK%V;3V92N[]^ELW5.%3@S7]!-8^^6OFJ=P,S*^#A#Q #[AY M7DDH)]$9B,^46,NB/K,OM_W9OZ^YU-\EP:JOQ#/R=-9H;S5_D%R'(S1 <#FU M6T:2G!=FI,WS8W#=7BJ '_]2IW\@SLXRI?KXAHL2%1#S]J(Y>TN^]F=L3$"[ M5EB,C@WK5=5H:U3"MNR)Q.JM/]:A:\3"=U0%'!'OI=3 W&8OA1OL( .;_;\6 M>9$?X*>JK:[S+EJ5>XET],2VRCL\N=W&O1,-28D,NDT"JOR&)?AJZ-+57UJM M<73Q@*N>]-8;_UV.;ZO\7*.8>$FN-S[*4Y@SG36$7TQ/7N=V2=(WYXJVO2^F)J86LSC<5W5*VX;7 N@"/O=Y)?GGN&US\KC/ M(3?\]QW.1E9#5A=ZC+2[F!OZ74K]OG/6]JXIE4LY:Q,.!43UV#\//5XQ2#J=((+'F;I0W5< MVTE)W1_QNS+441CKH#@2VHS#RF0YB*;SVBT%*#Z:*HC-R)1G[N\? /,6IV]C M&YO]UY">I V3MU*]"03+;QAT-WO?*_V2 SX6XI*%J[.*JX-<+@57<,&!/(2[ M3L3SM!*3/3;K]T-HOY09=E3N&MR*0YJ!^=S7E:?/;SX+GG MM)E(^0Q8!X./_%8%!F/$GQG/#^*5AMT:QOU4<&&)BPJX2%)>-8Y@J8!W^@;( M4E"B3W$!3B>/BF>G M7Y(V*[LUL'P.I%Q4@ YP._(D@QZJ N96I*D 30R\@@3O1VZK@)%N$'5I71A% M_(6O436L IP?0,(=*N#7PC\7+4$Z5,!]4#9OS,',M:-&GK_,:8"L EZ;62D^ M0]?4EG\H6JH":L$)$N*X7Y*A1!.>/5BD_0^_71I'GES[\Y>F7>X;O/Q>T7=! M:4I.YZ>?\!(9*R[,8+AHWCT^0/T?Q#/*'>QI150 TNKU#BB3&HL$5G"%U^\L MBDF$-RFWF01IF XA^:Y!0[EI!1?N0N= $_ M]>AV:K/J\_<<3+-LST0YF4&;L^&-O X6E%JE^#9(_WYFM46_@SP)K@%;O9#Y M.+2(-'&$++@F'"#N3N]JPH<^Y 1ZI.(N@\]?E96A!D!4#E '92=YHW."04X< M!LI!? 1J5>^\?I7^Z@EPG(1@]GTX.>NZ'YG)0= J1^8B/IXU;/Y[F;P"*5(> MF5&,^DI0I@R://Q*%.%'$IH!0I"CRQ.D,[\8G*B*=6UTI;@XEM-U&!-L'+X! M)]>5&L<@6MYX7::=8J\L@1*V)@19Q! Y9EU9$UHF^>O!%,?R!S6K=@L?"=] M5<;^?$+<)+3G.%07SL",_I9>KL#B9 @*/MBF-"6=*TQI#==>.-CR MCEQ2]"#][.CF]CG*@.W;/FAT/XH)R,^3MW,!088BZ+)?N+2!?"YS%K M'K^=U#[OV[:SG,+K.UTS[0:B*,1BH5 $>4)8"L^0E[7Q1=?WJG@DIBU[R MPGG=V?O/LV)V\!%;LHV+I5_'EX6W[4!-?FE2IPJ8?7(0J''Q@E$FT;Y\R\?3 MHC9]7[Z5"G#85/CAE+_2VI-0"RF$MS+>OU_8UN')_%#:Z;]>R8J%PFIK7[_, MB1,"Q69#G.1J@,8<1B MSW$F"V5C;E 8Q>Y0@B,C.S++SV$ ]2&H'[QVP=$L/+IGL'-F;.1(JGD8/C?. M/S'% .8KK-OV^-*[PF=F"#;+*KZIP=J.^:9(BI8KQQ ^L5L%5(7S7](LSHO, M?1_A?WWC';I%> 9MM=WH_M/>[IZW-J5@TI1'E1QJ6=)3J2&UN/F>:*Q82?J9 M8M!G.91P)=6*%,CE*EXQ:&0G08XL6'/"M>V =6^V+Z.9EH),M5HVE76$]=#7 M5@_L+]UM4^0NKSZ42=[@0H^6@#-\.;G)&NR+GFQ\G/LL>5[;:#*7VS^/TKCG M%$)!7&":(&EJ+ N5F=(N DS=1^C;L%AH1!GV-3;PZ^O%O^&TZCC27Q 6>R&X M/DGY@U>D'=L57*OGT/9B(.$W4<2MC;-/:P(WS!ZU4 $A?GEY8WMA;MS4R:"@ M#IM%+U\12]!U:CYV!R=QR?/L]AI'=#&_;O)IKJ0L.C[AJDMV.9U-::CGWAXX MZ35 'PWGFN,ZS[NA&@\=EP'Z0@D,S1Q9PK=#=GN1YA]CY@QO8T9X>-FJ/27@ M0'0?.A7FR M72(#"+=]JA0604NR\L]'8*AZ.ZFKO TO:$9I MJ0B2)'WS(:1EJHX!D_Y!)GT:W\$7180*-X]#G9%86VZH?&>-XI$8!E\8KDE M%YY,$ZR>R"UN:,+%!Q2_Q;F7'RMN6C%A1AG8CTA:>HZ6M!H=AY^ZIQ\..>\Z MX*!U0EE;RU@^#Z\W;;SLSXID3/DN*R^G+@%I#HP.SN8?\D8/G!0S!6T-ZT8I M!SJ<;(]/)9G5OF8??%23/?)]CH\*. R:'<\UW9L]P /SX@4P]QS#E[#B'8T0 MW,.Q))V10)-&YAY8>3[6YB0R(VB@5=LX M8!_CJ=DW>6T17=BZUQ%S>^MN^#ZH-+ECLH^>VLH_6L?'#Z$H,8%P[$0]1!)M MWTV3DS#$ MZTC]NOJ2'_1M(_PH-".-GJ*_(753;RKIC0<9V:@"_KK^&2P"WX4Y&^3\+C'+K!;Z M0*X*Z L= /3]1Q#'4?4*:\8]1)UZ'#@0"I"H%J:A/H#YCC\QM0K[QR*W6ES\ M\0,QT[-#\(TI%6!Q#*[5:'#9=[UJ0YF0?/2(AHO>?W@L5?O3\@6(K)217X0K M3'F^I'63.J$&=E;#,,5Q76#!"^9FK][K9?U9S/&7>4FC'J=>'BINB?=_AO#7 M^3!/T60V(E>7#G[%-IN=\^LD'5ZO=O6WZ_F%=U'6D_BXSR [TB,_6Q5P-G.T MSR=)4[93Y-_?O-:>V3!"J6HM"A&&B/J;SUKP&Y">++_1E-NZXRD%Z33NI5/;\NJ(<.&0TJ]P$WM_7U09S3?,,6A5. MGH&AF-5.UJ9/*G"-$B>3:[.>=)"E/;"6Q6PL(38&"84\.2RXI+)Y:5IA.4^4]4#-NF#E;/R7[Q902/.*=+;"A7@Z*M,'0P2 M=YWWPB9O3@VWDIXK;VS/F6$*Y*'=&O?&W)2]*D!0YO "8A@KY]5!]<'3W($, M9*'P91YP"T1YY M5F5;5->@MGB?W[\.IG@AFXAKA*14XD1[B/W&R0%6?!9!$@J5&A*.:Q M0#N6EI#7?[^!#N5-)WFRLEJ;MZT*%%,9SK"U>2N].>-.T/^]OE'(B*%QZ M>6F)C?2ZEU[G*)U>CZ]ZLZNIJ[!5)]QS0.J.MJP7IK'WA(BT&W,X13Z)M*K% M;)QAD*3^!\9MPW8$Q3%&V*5DB;N,F%LBNZ]LH-5^8! ,X3H^\6^IKG\@ M+E109AGH<$6QO(D;7D>V&_3++A^"#^?8-%Q9B._S=AWUV7:4*4TD<;DUXRK@ M9'G5W2]D?4.4=?B)['BC2D[6J^(UN4NN/2'&X0>C@VE-%"I-T _)[(X%ROA# MQZE3Z6;8S_L3:4L#C/-S8,F3]NXOYP))[4E?R$(H3I3\-U.V[/,U M#>+$1_5DB5P25Y7(S4S@]]&J+*#3T**^]*K66S/' M$06^&>&P;88PFB&DU;5ZG=9/'^4:.U::/&22VK)Y7HFO9E3 8"6Y"11KH@B6 M9*5<%;Q(_ =C9*'BW]<*16/8PC=_T:>(VO%/TM=95U)?!]E\HT-G;4Q2)/C3 MDCLHJVS'*)+2/Y[O%]07]GPS8*6850'/WGT\3X9N6?1KB+83'G$\4=)D]17X M1.O>YJ*>H_CD1ZFLD]=Y!!'NE/\Q>"_*.&Z>!B?-PU!7T_-+X9>LOYP^ MWY-CLO.PB9O6R'1\3VE)+STY@L]DF36/-;Q<1( MM@JX26]4 ?-*+1%((XTK%%SON6-^WW'6%'[WU-1)I[;L6>X>.Y3_.*@ T4+2 M!QUVS/W$_OS3DX=?=D3X91VLM<%"^G$FI#0%-G'DSIX]*15\/J9SPZ6@K@%% M11F\'@'S9!@&(_%0\?/]WTY$XEYFJX!U3EM#?!QKZUBI;67M!17\.^DEUX) M_KH7WNR6P6KZ30DXL(, MZ S[L-<)*L1Q33?W5(=1]0I+>#T/E96A9S7ZJUT MZFTW:QUUH"C?9='.P!0IPGMV-:^>0GD)?4IZ\99>?63M[/*W9SN>$:'.& MT\1T#\\C)3\%2N&)F3$!V-L3"\9/(0-43BV;U]:=-%S54\PSJ4]=^OID9R6* MN-4^^)S3E-E:!"FR7)KA&;SP+ZVE M?K22$M]!1V;&SQEZ.KTNVTJI3!S!L3@MIH5,8];D(,X^).4Y5.,[YZ^LBU%< MK@"G;H'O;+:#SYH@H6$R2D?_ZEFB_!FK7'K__Q DW%+PP'_/N$^KT81N?+4@ M34!!W7Q25?W.SXY,@'4IQZ1B93.*O18^#]LOUV&NUUII^C;S=L%3RE!>W'AD MMZ4.S_=XWYO&B,ZR^_P4:@R8$!659'A+& (V7-)7*J!S7@1YZ/N-HSTN7K.; MD6E0RC+Z@.OOI=)VPLPSU*6Z?X)_M3KZ;V:SN8U2CC+V;3OI*17 +,LN943Z M9JGWA[+B2KU[S\">;]?V,P5WS"H%\&1!?<]$%"M8H M:(0)DLCZG3+-PKB]I!]3C],2<]JX#&1IUN41J"^0^VSP:U80LR>\L)/J"CM^ MGY@;S7=SN'[+JJ8Y"AI%*YEISTE@.]I3 XZZ_SV16Z,<*2BV/UNR_(F_E),A MOCMA6U72OWV_Q7R1Y-KT$.8W5:_/5 C**9&"ZI!7[.@DESI?%/)"HEO-RQ*E*"/X M+JE%MY^X,^])AXS!SP2?_##XS64O9A>[[6*?+?2\\GHG"HYWI%9M4O/\<:>+ MU\2<<;Z1RTO=Q#LTU]&#&:-V4F.8NB(LE]CALF%R;89>^?4;F95/H^4W#90+ M(C*FCWVL*^GS$[%KNYHDV5C)@SLV81;VOMZ$DU@FG:)7UHGZ4]W"XG,WD6=T M4D#J*[QN[_X ?59YVA*8EO81'TVRMN_ 6G/,2>RL/(-=Z MD %RC;I4R6-E?VR=."_YG;=6?0H-7##E MNQ[@9%]8\53D6620B\UR<-T>)R2B&.YW]"&4;F]\7>$R%'*&:/I@<,)GNJ;I M5_^)V7*WI>.<3MK;\);4ES"8%AX5WVVW)OC?GGW5(B[_U=SM9P8]:1[#<%YW M/47'K&S:$R8?\UQLYV+P\I:C"FBF8F"SO-8\N -UQM8:LSE/,^1;[:#Y)X-U ME+YV)>$ZD@TM:.+,17DQBFV^ _UXZ=KY3N15BBF)Y\Z>3K+\'Y-?+QXICMO/1^%U@V.. M\FHX.&<_IP+,P ]ELI'7_=#P\MHW*,*);&H08\F4C_&SE+;KB%[&1B&H2/!U%N:4P9B Z7&TE*O,/7U8!>PXNT$]#@WAXC''>BK>7 M]QMQNT6'9_TCJ,%8.;L_QTY:B-I56)OCR4HUPU?R:R(F&0]F+-:.H2LP+NF> MJ.109]3ZT)Y$6VE+YU#=P^S3P7GG'NON"'>#H:N2[A;WC":/4UN)IH4$@L!F M1V+LZASXJ'^HT08Z.H[#R^Z&X/65UI83] MIDJ9HE]YQ MFC\U1:()DA5V!?C)^.R_]/R0&W"M^-1*KM5"_.'4]BJ$M\WWMN\8_,+CP-PK M"3+KW@#5LX:3;)3WP^MU1]+ S\ ?'4<'%OK!@!-NH-X:?*LE=P31=YMX1!J3 M=XW*R[A-QARLFRSAP<3"?LG>A6SJV2")G,][E&(QE/8\&R^3@5FWF:^Z-?B[ M^N&VHR@S_WK]'N01!KGHOT?(E5SM=#*1P4>%#<5_R1;W3;P.-8JLGIF5;CK\ MG#1=PM$=I_CFQ4@VWZ.B_4&=#](,!/\G1'\7LKL'FG_Q7R#ZZGV@R@9B-%YXB!/F@Q7 =D5SNNL_[27^/N> MHD_8=S/1$6<3"ML;["M5OY%^.+,%,]R8:9JC?*MV= M]51 S4]SH<5_,N":XWQ7_.+[!N4\RS#M M58W40M+XJF 7]%?95N)"I&#%@)*%@$!V]&&LY)>A50I7,04 M19T2U=(_D0=+D5'=)R6(=&/_NX)4(392[20))9WU)9)4E,9LZ$*>]$ +Z^/I M:%*A)!E-,FQ%GM#0I/ ]LJJ=WV*>W!Q!M.4.^&%4]2&740['S)I_H+8L<6P- MRH%B$$P^# E*T!9BK'HN,7:@=C6"VM6F@E3S-L?S.SQAD=>*8/M(.TIL74"! M'XW/7A[*/#^#XIYCM/41+&>A:TS63>5J2O1#I[F(/GF4= M"Z.\4M^::DAH;%\=+#RQIT06=N#7U$F3U-B*N7<%!T[B'V90G:)0*<"8W*)Y MN=MAY3 _,.&1H'YG,;; M(F[MD<1L4T970:OY &2;JN-G$0]0QR]>QD07.HI9^:\7_8>;#?^"OM5L3OHN MMK\)T>ZNUS>X1JG-"^B.PM0,NI2V/!"LY=;G(9)V7O\L[D'LS:@O(]>[1:9L M=/.L*/:URYG9QDARXPK-A,:!N!3(0SBC;N(-81LT8#GMN%=GP^G#-AG:K5Z@K M#]9"3J6(6A68/@5D38I M/()8/SJ#PL'H\0(JBFO0 M !$Q=50J5[%1(J*V%',%WG?XQX MW?_KJYMFM3 7[@_UJT;A!JLX]_<;U075XHJC1[1>0$7;#,66+ MZ56L!_13?]4OB,'Q]E!G8?&0&W%6*XW_OS1C^082*$?!Y M_[WP<-+$7T%M. 1%PM;Y:WT8=;UX4YD=LH^BK4 9?E<^:K2=3.IZ< 7_)92B MFZ8A?![Q3ZWP]Y[Z_)\:JZ?Q[YKZGV;Q7JC?K@).^ZN7R'$,*KYK?%A[<*CK M<)$J?P:52R\8'$:_1%&4Y_[0+?_R%J71-R(&;VGA4+CODVQ[OYDK=(-,%7#? M=Y)]9%/[TCE\EDG6N@@)/#%&XT,;<73V16*D,#E%L6>$M'@P%MSM^]QZ@C5# MB?FMLJ5-:E=?:G:FC_%V@ '"J%!OKLW)=9O^O'433J>I57=OO]\Z@I *A/4$ MHMSIZ\_UCK@HKYCLK!0RAV\H=XZ@A*5[]ZI M4]ZK("X8K[[-\MT[]8Z1.DN&.D6MA?ZGA7I,4Z"W2\XB"OR"H5>. &I8'Q"; MT8XT/1P810GYG,V_R,?]EP^3UD[9L_F:/%=7/_^%\49:E:OF1'K)X9LN9IOP M3T5GX#9S BZ\7\*7JRW]PMYT"$.-A1&P3M3"?IP).[='B!.WS M_A%O8RL@#!8#D=:>>K3(O5ZW@OH5!%HQO .U^;@MFF,JX"^0^(C@41]SF=.X M""0I2;T,KSR[1#F4>[U%@Y*2T#'^T5EH(-SZ4'S>A])"3AQ?[W[_[+9[*#R[B! MH%Q@8OS^'3ALC_LEJ0,OWN@-]GJQ4:)..2+V1>)?^'O#>^ZW+^;8_8TKUD?= MDJ#G(6&D:;P)7+'_9JRC5*:.PMBJ@+FI&+1]:M,.>PLM1^!F?V,_KE@9H0+D M^BAYDC,IG],54J9Q$U\XTRJ (8O-FD'YC>)\70U7X!KF-.8V5=0[DS:EV\05+_H8N]RBN?M?V/C&O21I6^ ]E.4*W_+BOQSA%-]]FAMF MD,K;2B1'BN\@D[1N5 J&^V$>X=TDE+\3EP?8(]V#_Q;V-&M,O+Z3/\VCSWH6 MT/O6SOMUEKN*!5PI_;56Q_Q%7DCQY0.K]%:=&R0:;ZBF**@'@]*(/Q7(C/M<^@H\H<_G,0$860RD16:-<XWH.7Z*,>__44JQF5P']V M=#W)HI/G3V*N;GSN8#PK(W]<\7_2N;@72>J(I/I*@IJ-JX /=-P.I>-JF3O\ M.QW_^<^/R9890HI+5M 4BNWO;)+^GZ>RB!G13(1))WH'))[B):Q;9?1%@5<7 M)9+*B,KR0UNJNR-I @F00[T^